<SEC-DOCUMENT>0001493152-23-002473.txt : 20230125
<SEC-HEADER>0001493152-23-002473.hdr.sgml : 20230125
<ACCEPTANCE-DATETIME>20230125170829
ACCESSION NUMBER:		0001493152-23-002473
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		78
FILED AS OF DATE:		20230125
DATE AS OF CHANGE:		20230125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shuttle Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001757499
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269414
		FILM NUMBER:		23553077

	BUSINESS ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		2404034212

	MAIL ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>forms-1.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:SHPH="http://shuttlepharma.com/20220930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_SHPH_shuttlepharma.com_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220101_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001757499 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_XDX_Y%2D%2D\2023 OPERATIONS\2023 EDGAR\01 January\Shuttle Pharmaceuticals Holdings, Inc\01%2D18%2D2023\Form S%2D1\Draft\Production\form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityCentralIndexKey">0001757499</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0039" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2022-09-30" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2022-09-30" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2022-09-30" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-09-30" id="xdx2ixbrl0086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:CommonStockToBeIssued" contextRef="AsOf2022-09-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0164" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0166" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0467" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfConvertibleDebt" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:CommonStockIssuedForDividendPayable" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0823" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-09-30" id="xdx2ixbrl0990" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-09-30_custom_PromissoryNoteOneMember" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-09-30_custom_PromissoryNoteTwoMember" id="xdx2ixbrl1080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteTwoMember" id="xdx2ixbrl1081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-09-30_custom_PromissoryNoteThreeMember" id="xdx2ixbrl1085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteThreeMember" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-09-30_custom_PromissoryNoteFourMember" id="xdx2ixbrl1090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteFourMember" id="xdx2ixbrl1091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-09-30" id="xdx2ixbrl1095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2022-09-30" id="xdx2ixbrl1098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2022-09-30" id="xdx2ixbrl1101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1265" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1267" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1269" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1271" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1273" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1275" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1283" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1285" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1287" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1289" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1295" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1297" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1299" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1301" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" id="xdx2ixbrl1307" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" id="xdx2ixbrl1309" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1346" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1352" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1354" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1362" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1364" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1366" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1368" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1370" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1372" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommodityContractAssetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesClassifiedCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl1431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl1440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl1463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl1464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl1486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl1487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseCustomerDeposits" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseCustomerDeposits" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1634" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1715" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1783" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1784" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl1870" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl1871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl1874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl1875" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember" id="xdx2ixbrl2089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:LoanForgiveness" contextRef="AsOf2020-12-31" id="xdx2ixbrl2094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2231" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2233" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2235" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2237" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2239" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2241" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2251" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2253" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2255" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2257" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2259" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2261" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl2269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2295" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2305" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2307" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2315" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2321" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2323" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl2354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl2355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl2380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl2381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="shph-20220930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-112016-08-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-11</xbrli:startDate>
        <xbrli:endDate>2016-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-282022-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-28</xbrli:startDate>
        <xbrli:endDate>2022-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-19</xbrli:startDate>
        <xbrli:endDate>2017-09-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-17</xbrli:startDate>
        <xbrli:endDate>2020-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:OneQuarterlyPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:TwoQuarterlyPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-252022-04-26_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-25</xbrli:startDate>
        <xbrli:endDate>2022-04-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-06</xbrli:startDate>
        <xbrli:endDate>2019-12-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-172020-09-16_custom_PhaseIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-17</xbrli:startDate>
        <xbrli:endDate>2020-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-162021-11-16_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-16</xbrli:startDate>
        <xbrli:endDate>2021-11-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-022021-12-03_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-02</xbrli:startDate>
        <xbrli:endDate>2021-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PhaseIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-05</xbrli:startDate>
        <xbrli:endDate>2018-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_SubcontractPhaseIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:SubcontractPhaseIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PhaseIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SubcontractPhaseIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:SubcontractPhaseIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SBIRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:SBIRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SBIRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:SBIRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-292018-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-29</xbrli:startDate>
        <xbrli:endDate>2018-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-21</xbrli:startDate>
        <xbrli:endDate>2021-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-212021-06-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-21</xbrli:startDate>
        <xbrli:endDate>2021-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-24</xbrli:startDate>
        <xbrli:endDate>2018-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-24</xbrli:startDate>
        <xbrli:endDate>2019-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-24</xbrli:startDate>
        <xbrli:endDate>2019-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-242018-01-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-24</xbrli:startDate>
        <xbrli:endDate>2018-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-03</xbrli:startDate>
        <xbrli:endDate>2018-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-30</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-30</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-032018-04-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-03</xbrli:startDate>
        <xbrli:endDate>2018-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-29</xbrli:startDate>
        <xbrli:endDate>2018-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-30</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-30</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-292018-05-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-29</xbrli:startDate>
        <xbrli:endDate>2018-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-23</xbrli:startDate>
        <xbrli:endDate>2019-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-23</xbrli:startDate>
        <xbrli:endDate>2019-08-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-22</xbrli:startDate>
        <xbrli:endDate>2019-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-092021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-09</xbrli:startDate>
        <xbrli:endDate>2021-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-152020-05-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-15</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-282021-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-28</xbrli:startDate>
        <xbrli:endDate>2021-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-282021-12-28_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-28</xbrli:startDate>
        <xbrli:endDate>2021-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_NoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-082022-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-08</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-112022-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-11</xbrli:startDate>
        <xbrli:endDate>2022-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-082022-02-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-08</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-112022-03-11_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-11</xbrli:startDate>
        <xbrli:endDate>2022-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PromissoryNoteThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PromissoryNoteFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PromissoryNoteThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PromissoryNoteFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-04</xbrli:startDate>
        <xbrli:endDate>2018-06-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-04_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:MembershipInterestHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-162019-08-16_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-16</xbrli:startDate>
        <xbrli:endDate>2019-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:NotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_NoteWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:PreferredStockDividendPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember52285984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-212022-01-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-21</xbrli:startDate>
        <xbrli:endDate>2022-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-072022-02-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-07</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-102022-03-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-10</xbrli:startDate>
        <xbrli:endDate>2022-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-292022-03-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-29</xbrli:startDate>
        <xbrli:endDate>2022-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-052022-04-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-05</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001166" toRefs="Footnote001185"></ix:relationship>
  <ix:relationship fromRefs="Fact001168" toRefs="Footnote001185"></ix:relationship>
  <ix:relationship fromRefs="Fact001174" toRefs="Footnote001188"></ix:relationship>
  <ix:relationship fromRefs="Fact001176" toRefs="Footnote001188"></ix:relationship>
  <ix:relationship fromRefs="Fact001182" toRefs="Footnote001195"></ix:relationship>
  <ix:relationship fromRefs="Fact001184" toRefs="Footnote001195"></ix:relationship>
  <ix:relationship fromRefs="Fact001311" toRefs="Footnote001318"></ix:relationship>
  <ix:relationship fromRefs="Fact001313" toRefs="Footnote001318"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on January 25, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20220101__20220930_zRyduELpxtte"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20220101__20220930_zITAhcPQ90q2"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityRegistrantName">SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220101__20220930_zN6Wc85GrYAd"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20220101__20220930_znL2prrxCCNb"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityTaxIdentificationNumber">82-5089826</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction of<br />
    incorporation or organization)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary
    Standard Industrial<br />
    Classification Code Number)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer<br />
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220101__20220930_zVfIuLTfIi1k"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressAddressLine1">One
Research Court</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20220101__20220930_zXuabCyxICfh"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressAddressLine2">Suite 450</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20220101__20220930_zM3UeL7vxgl2"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20220101__20220930_ztDygDBvEcB1"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20220101__20220930_zeLm67v3NT2d"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_905_edei--CityAreaCode_c20220101__20220930_zdlif3QyefB7"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:CityAreaCode">240</ix:nonNumeric></span>)
<span id="xdx_90D_edei--LocalPhoneNumber_c20220101__20220930_z9N6zjg20Heh"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:LocalPhoneNumber">403-4212</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address,
including zip code, and telephone number, including<br />
area code, of registrant&#8217;s principal executive office)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anatoly
Dritschilo, M.D.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>One
Research Court, Suite 450</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rockville,
Maryland 20850</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(240)
403-4212</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name,
address, including zip code, and telephone number,<br />
including area code, of agent for service)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Copies
to:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Megan
    J. Penick, Esq.</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stephen
    A. Weiss, Esq.</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michelman
    &amp; Robinson LLP</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>800
    Third Avenue, 24<sup>th</sup> Floor</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
    York, NY 10020</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(212)
    730-7700</b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. <span>&#9746;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of <b>&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221;</b> and <b>&#8220;emerging growth company&#8221;</b> in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20220101__20220930_zMqCwKFBDKNl"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20220101__20220930_zkuUzDdHFKgj"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20220101__20220930_zt9qygFkucLh"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_90F_edei--EntityExTransitionPeriod_c20220101__20220930_zRFuH3LB5nY8"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b><i>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities nor may we accept offers
to buy these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary
prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>PRELIMINARY
    PROSPECTUS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>SUBJECT
    TO COMPLETION, DATED JANUARY 25, 2023</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt="" style="height: 173.25pt; width: 297pt" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to 9,744,605 Shares of Common Stock Issuable
Upon Conversion of 5% Senior Secured Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to 1,018,079 Shares of Common Stock Issuable
Upon Exercise of Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale from time to time of (i) up to 9,744,605 shares of common stock underlying a $4.3 million
convertible note (the &#8220;Convertible Note&#8221;), which shares represent 300% of the maximum number of shares of common stock
issuable upon conversion of the Convertible Note, and (ii) 1,018,079 shares of common stock issuable upon exercise of a warrant (the
&#8220;Warrant&#8221;), each of which were issued on January 11, 2023, in a private placement to the selling stockholder named in
this prospectus (the aggregate 10,762,684 shares of common stock being registered that underlies the Convertible Note and Warrant,
together, the &#8220;Shares&#8221;). We have obtained majority stockholder approval to permit the issuance of 20% or more of our
outstanding common stock as of January 11, 2023 (the &#8220;Stockholder Approval&#8221;) and will be filing an information statement
on Schedule 14C for distribution to our stockholders. While we have obtained majority Stockholder Approval through written consent,
prior to our mailing of the Schedule 14C, the selling stockholders may only convert up to 2,719,265 of the Shares underlying the
Convertible Note pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the Shares by the
selling stockholder, except with respect to amounts received by us upon the selling stockholder&#8217;s exercise of Warrants to the
extent such Warrants are exercised for cash. We may receive up to an aggregate of approximately $2,392,485 from the exercise of all
Warrants, assuming they are exercised in full of all such Warrants for cash at a price of $2.35 per share of common stock, assuming no
anti-dilution adjustments or other adjustments as set forth in the Warrants. We will pay all expenses associated with the sale of
common stock pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder may sell or otherwise dispose of the common stock described in this prospectus in a number of different ways and
at varying prices. See &#8220;Plan of Distribution&#8221; for more information about how the selling stockholders may sell or otherwise
dispose of the common stock being registered pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock trades on The Nasdaq Capital Market under the symbol &#8220;SHPH.&#8221; On January 24, 2023, the last reported sale
price of our common stock was $2.47 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>An
investment in our common stock involves significant risks. You should carefully consider the risk factors beginning on page 12 of this
prospectus before you make your decision to invest in our common stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, and we have elected
to comply with certain reduced public company reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is ____________, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="margin: 0"><a href="#z_003">ABOUT THIS PROSPECTUS</a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">i</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ka_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ka_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#S1_001">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="margin: 0"><a href="#z_004">PRIVATE PLACEMENT OF CONVERTIBLE NOTE AND WARRANT</a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#S1_002">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#z_001">SELLING STOCKHOLDERS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">44</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#S1_003">DIVIDEND POLICY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#S1_006">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#S1_007">BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_001">MANAGEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_002">EXECUTIVE COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_003">PRINCIPAL STOCKHOLDERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_004">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_001">DESCRIPTION OF CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_002">SHARES ELIGIBLE FOR FUTURE SALE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_004">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_005">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_006">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_007">DISCLOSURE OF SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_008">INDEX TO FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="z_003"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information in this prospectus is accurate only as
of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our
common stock. Our business, financial condition, results of operations and prospects may have changed since that date. You should also
read and consider the information in the documents to which we have referred you under the caption &#8220;Where You Can Find More Information&#8221;
in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States: We have not done anything that would permit a public offering of the securities or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United
States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the securities and the distribution of this prospectus outside of the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of
the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
should rely only on the information contained in or incorporated by reference in this prospectus and in any free writing prospectus prepared
by or on behalf of us. We have not authorized anyone to provide you with information different from, or in addition to, that contained
in or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus is an offer to sell only the
securities offered hereby but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in
or incorporated by reference in this prospectus is current only as of its date. Our business, financial condition, results of operations
and prospects may have changed since that date.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted.
We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where
action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus and any free writing prospectus related to this offering in jurisdictions outside the United States are required to inform
themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free
writing prospectus applicable to that jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, any reference to Shuttle Pharmaceuticals Holdings, Inc., or as &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;
refers to Shuttle Pharmaceuticals Holdings, Inc. and its subsidiary (&#8220;Shuttle&#8221; or the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate or plan to
operate, including our general expectations and market position, market opportunity and market share, is based on information from our
own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted
by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions
based on such information and knowledge which we believe to be reasonable. Our management estimates have not been verified by any independent
source, and we have not independently verified any third-party information. In addition, assumptions and estimates of our company&#8217;s
and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors,
including those described in the section entitled &#8220;Risk Factors&#8221; beginning on page 12. These and other factors could cause
our future performance to differ materially from our assumptions and estimates. See &#8220;Special Note Regarding Forward-Looking Statements&#8221;
on page 39 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_001"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following summary provides an overview of all material information contained in this prospectus. It does not contain all of the information
you should consider before making a decision to purchase our shares of common stock in the offering. Prior to investing in our common
stock, you should carefully and thoroughly read the more detailed information in this prospectus and review our financial statements
and all other information that is included in this prospectus, including the section entitled &#8220;Risk Factors&#8221; beginning at
page 12.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to &#8220;Shuttle Pharma,&#8221; &#8220;Shuttle Pharmaceuticals,&#8221;
&#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refers to Shuttle Pharmaceuticals Holdings, Inc.
and its subsidiary, Shuttle Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Our mission
is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting
the late effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers,
we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination
with surgery, chemotherapy and immunotherapy. We currently have no FDA approved products and we have not yet applied for a new drug application.
Prior to the completion of our initial public offering (&#8220;IPO&#8221;) on September 2, 2022 and listing of our shares on Nasdaq,
we were funded by investments from private investors and government contracts obtained from the National Institutes of Health (&#8220;NIH&#8221;)
for performing research. We have no product revenue and our independent auditors, in their report dated June 3, 2022, expressed doubt
about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the major advances in radiation oncology have focused on improving technology to increase the amount of radiation that can be administered
to a tumor without damaging adjacent, normal tissues. Examples of other such technologies include intensity modulated radiation therapy
(IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and proton therapy &#8211; the backbones of state-of-the-art
RT. All offer improvements in physical radiation dose shaping. The basic principle underlying the effectiveness of RT for curing cancers
lies in the differential cancer cell kill achieved in tumors, as compared to the effects of RT on the normal surrounding tissues, which
is achieved by delivery of highly conformal RT doses &#8211; in other words, delivery of high-dose to volumes that are shaped to conform
to the target cancers while minimizing the dose to surrounding normal tissues. The treated volumes frequently include sensitive normal
tissues, thereby limiting the magnitudes of the prescribed RT doses. We suggest that technological innovations to define tumor volumes
and shape radiation delivery have reached an effectiveness plateau and that further improvements in RT outcomes will require pharmacological
and immunological approaches to sensitize cancers, protect normal tissues and engage the immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, the drugs being used for sensitizing cancers to RT are chemotherapeutic agents possessing radiation sensitizing properties as
secondary effects. With the exception of Cetuximab, a growth factor targeting monoclonal antibody biologic, all other drugs used as radiation
sensitizers are used &#8220;off-label&#8221; to address the clinical need for radiation sensitizers. For example, certain chemotherapeutic
agents, such as 5-fluorouracil, capecitabine and cis-platinum, are approved as single agents for cancer treatment, but are used &#8220;off-label&#8221;
as radiation sensitizers in combination with RT. Treatments with such agents are associated with inherent toxicities associated with
the drug&#8217;s primary, single-agent mechanisms of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma&#8217;s platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current
limitations of using &#8220;off-label&#8221; drugs with potential new sensitizer agents. Our pipeline includes Ropidoxuridine, our lead
clinical sensitizer drug candidate, to sensitize rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors to
sensitize cancer cells and stimulate the immune system. Our novel technologies will be tested in combinations with radiation therapies
(conventional X-ray and proton radiation therapies) and in combinations with immune-therapies. To date, Ropidoxuridine has completed
a Phase I clinical trial. Our HDAC inhibitor platform drug candidates have been tested in preclinical models of solid tumor cancers.
Ropidoxuridine and the selective HDAC6 inhibitor SP-2-225 are the clinical and preclinical candidate drug products we propose to develop
using funding from this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property for Ropidoxuridine includes novel formulations that show improved drug bioavailability (in a preclinical animal
model) and for sensitizing cancers to proton and to conventional radiation therapies. Our HDAC inhibitor intellectual property includes
new patent applications and granted patents for composition of matter and methods of use for treating cancers with HDAC inhibitors in
combinations with radiation therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to completion of our initial public offering, which closed on September 2, 2022 and pursuant to which we closed on the overallotment
option on September 21, 2022, we have obtained funding for our research from private investors and Small Business Innovation Research
(&#8220;SBIR&#8221;) contracts obtained through the National Institutes of Health (&#8220;NIH&#8221;) to support the development of the
radiation sensitizer Ropidoxuridine in a Phase I clinical trial. We have also received awards for Phase I and II SBIR contracts for development
of human cell cultures for health disparities studies and predictive biomarkers of radiation late effects through the NIH&#8217;s National
Cancer Institute. The completed Phase I and II funded discovery work performed to establish &#8220;Cell-based Models for Prostate Cancer
Health Disparity Research&#8221; and to develop &#8220;Predictive Biomarkers of Prostate Cancer Sensitivity for Radiation Late Effects&#8221;
enables Shuttle Pharma to apply for NIH SBIR Phase II funding to develop these products for advancing basic science and clinical research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration (the &#8220;FDA&#8221;) considers new molecular entities as drugs that use new and unique mechanisms
of action for treating medical conditions. Our clinical stage agent, Ropidoxuridine (IPdR), increases DNA double strand breaks following
radiation exposure and our inhibitors of histone deacetylases (HDACs) stimulate the immune system to produce T-lymphocytes targeting
cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to improve the outcomes of cancer treatment through RT while reducing its side effects by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitizing
    growing cancer cells to render them more susceptible to the effects of RT;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the DNA damage response pathway to protect normal cells located near cancers; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the immune response to antigens present on irradiated and un-irradiated cancer cells.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, no drug utilizing the mechanisms of our candidate small molecule drugs has received FDA approval as a radiation sensitizer.
We have developed, to clinical stage, the small molecule strategies to sensitize growing cancer cells in tumors to conventional RT and
to large fraction radiation therapy. The pre-clinical technology, HDAC inhibitor platform, is designed to target cancer cells while protecting
healthy tissue/normal cells, thus enhancing the candidate radiation sensitizer product pipeline. The selective HDAC6 inhibitor (SP-2-225),
discovered and developed by our scientists, has inhibited the growth of melanoma tumors and breast cancers in animal models by an immune
stimulating mechanism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on developing a clinical stage product candidate (Ropidoxuridine) and a pre-clinical product candidate, selective HDAC6 inhibitor
(SP-2-225). We propose to develop these drug candidates as illustrated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview
of Radiation Sensitizer Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_002.jpg" alt="" style="height: 165pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine,
the clinical stage molecule, sensitizes rapidly growing cancers to radiation therapy by increasing reactive free radicals that increase
DNA strand breaks. Ropidoxuridine development for treating glioblastoma will require Phase II clinical testing for use in treating brain
tumors. The selective HDAC6 inhibitor, SP-2-225, a pre-clinical stage molecule, activates the innate immune system to target irradiated
tumor cells by immune mechanisms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ropidoxuridine
(IPdR)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine
(IPdR) is an orally available halogenated pyrimidine (5-iodo-2-pyrimidinone-2-deoxyribose) with strong cancer radiation sensitizing properties.
As a prodrug that does not become an active drug until after it is metabolized, IPdR is absorbed and metabolized to IUdR by enzymes in
the liver and in cancer cells. IUdR, a halogenated pyrimidine, is incorporated into DNA by rapidly growing cancer cells. Cells that incorporate
IUdR into their DNA then become more sensitive to the effects of RT. The Phase I clinical trial of Ropidoxuridine and RT, supported by
an NIH SBIR contract to Shuttle Pharma, was sub-contracted to the Brown University Oncology Group (BrUOG) at the LifeSpan/Rhode Island
Hospital. This Phase I clinical trial has been completed and the results were initially reported by the sub-contractor at the 30th EORTC-NCI-AACR
Symposium in November 2018 and published in the medical journal Clinical Cancer Research in 2019. A maximum tolerated dose (MTD) of 1200
mg/day for 28 days was established for use in combination with radiation therapy to achieve therapeutic blood levels of IUdR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported Phase I clinical trial of Ropidoxuridine in combination with RT provides the foundation for proposed Phase II clinical trials
to establish the data necessary for the FDA to determine efficacy in treating brain tumors, sarcomas and pancreatic cancers, diseases
that offer potential for orphan designations. The FDA granted approval of our application for orphan-drug designation for IPdR for the
treatment of glioblastoma. Orphan designation protects the marketing position of Ropidoxuridine for up to seven years after marketing
approval is received from the FDA. This approval integrates well into the overall intellectual property strategy for Ropidoxuridine which
includes filed patent applications for &#8220;Method and Compositions for Cancer Therapies that Include Delivery of Halogenated Thymidines
and Thymidine Phosphorylase Inhibitors in Combination with Radiation.&#8221; We believe that we are positioned to initiate Phase II clinical
studies with Ropidoxuridine and RT in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Extended
Bio-availability Ropidoxuridine (IPdR/TPI)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine
and Tipiracil (IPdR/TPI) is a new combination drug formulation designed to increase the bio-availability and incorporation of IUdR into
DNA. Shuttle Pharma&#8217;s preclinical studies of the combination of IPdR/TPI have shown up to 10-fold greater bioavailability of the
active metabolite (IUdR) as compared to IPdR administered alone in controls. We have filed an application under the Patent Cooperation
Treaty (or PCT) for the intellectual property. This new formulation will be tested in a Phase I clinical trial as a sensitizer of rectal
cancers. Another nucleoside analogue, Trifluridine has been formulated in combination with Tipiracil (TAS-102) to enhance drug uptake
by colon cancer cells to prolong survival in patients treated for metastatic colorectal cancers, as has been reported in the New England
Journal of Medicine (N Engl J Med. 2015; 372:1909-1919). We anticipate testing for uptake of IPdR by colorectal cancer cells following
administration of the IPdR/TPI drug formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proton
radiation therapy is an advanced form of radiation therapy using charged proton particles (p+). Proton RT differs from conventional RT
in that the radiation is delivered by a beam of protons to precisely target tumors and, due to the favorable physics of energy deposition
by proton particles, there is no exit beam, resulting in less radiation to surrounding healthy tissues. The use of Proton RT is expanding
rapidly in the U.S. and worldwide. According to the National Association of Proton Therapy, more than 30 facilities are currently in
operation in the U.S. and an additional 30 facilities are planned for installation over the next five years. (<i>See </i>www.proton-therapy.org.)
Much attention has been paid to proton therapy in the popular press, promoting its advantages, as well as addressing the increased health
care costs. The role of a sensitizer that offers proton radiation sensitization presents an opportunity to enhance the value of proton
radiation therapy as a cancer treatment modality. We believe the development of a proton therapy targeted radiation sensitizer, such
as IPdR/TPI, is timely and consistent with current market needs to advance protons as a therapeutic modality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to perform clinical studies to support the development of the IPdR/TPI combination to advance this drug candidate with proton
RT. The addressable market includes diseases such as brain tumors, cancers of the head and neck, GI cancers and lung cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selective
HDAC Inhibitors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
roles of acetylation in the epigenetic regulation of chromatin structure and gene expression rests on the balance of activities of histone
acetyltransferases (HATs) and histone deacetylases (HDACs). Increased acetylation of histones leads to changes in chromatin structure
and accessibility for key cellular proteins to specific target sites. Acetylations of non-histone proteins also modulates their enzymatic
activities. We have discovered novel HDAC inhibitor molecules and testing in preclinical models has shown cancer radiation sensitizing
properties, normal tissue protective properties and selective HDAC6 inhibitory properties. Our HDAC inhibitor platform, described below,
will be evaluated in pre-clinical studies of radiation sensitization of solid tumors and activation of the immune response to irradiated
cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
    is our candidate lead pre-clinical, pan-HDAC inhibitor that initiates the mutated in ataxia-telangiectasia (ATM) response pathway.
    ATM is activated by ionizing radiation induced DNA damage. Activated ATM phosphorylates critical factors involved in DNA repair,
    apoptosis, and cell cycle checkpoint. Phosphorylation of the molecules in these pathways, in turn, activates the cellular functions.
    ATM also can be activated by HDAC inhibitors and imparts radiation protective properties. Using rational drug design, we discovered
    HDAC inhibitors and ATM activators capable of radiation sensitizing cancer cells and protecting normal cells. SP-1-161 is our lead
    candidate radiation sensitizing pan-HDAC inhibitor.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
    is our candidate lead selective histone deacetylase inhibitor of HDAC6. HDAC6 is a member of the Class IIb HDAC family. Selective
    HDAC6 inhibitors are an emerging class of pharmaceuticals due to effects on neurodegenerative diseases, cancers and immunology. Specifically,
    the potential to affect regulation of the immune system and enhance the immune response to cancers is of significant interest as
    an adjuvant treatment in combination with radiation therapy. We propose to test our HDAC6 inhibitors for a role in enhancing post-RT
    immune responses to antigens produced in irradiated cancers for their effects on control of local and metastatic disease.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    is a selective Class I HDAC inhibitor that preferentially affects histone deacetylases HDAC1 and HDAC3 and shows direct and selective
    cytotoxicity for ER positive and Her2 negative breast cancer cells. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
Development Projects for Radiation Treatment of Cancers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
advance research that is complementary to our radiation sensitizer discovery and development projects, the NIH has awarded SBIR contracts
to us to develop reagents for health disparities research and to develop biomarkers of radiation sensitivity for patients treated with
radiation therapy. Our scientists have been engaged in developing model human cell systems for testing radiation sensitizers in tissue
cultures. This project provides an efficient and low-cost screening technology to provide data for the FDA&#8217;s determination of drug
efficacy and to identify candidate lead molecules for treating prostate cancers in African-Americans. First developed at Georgetown University,
the conditional cellular reprogramming (CRC) technology offers the ability to establish new cell lines from biopsies of cancers. We have
obtained a sub-license from Propagenix, Inc. to establish 100 normal and cancer cell lines from prostate biopsy samples for use in screening
drug candidates and for health disparities research. A more detailed description of the Propagenix license is set forth on page 68 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to identify patients who may be more sensitive to radiation therapy and are at a higher risk to suffer treatment-related complications,
collaborative research with Georgetown University has led to discovery of metabolite biomarkers, which are predictive of patient responses
to radiation therapy. A patent for the intellectual property has been submitted by Georgetown University with Shuttle Pharma scientist
(Scott Grindrod, PhD) as co-inventor. Developmental work in health disparities and predictive biomarker development has been supported
by NIH SBIR contracts to Shuttle Pharmaceuticals for the following areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell lines from African-American men with the goal of advancing research to address prostate cancer health disparities
    (designated SBIR &#8220;Topic 352: Cell-Based Models for Prostate Cancer Health Disparity Research- Moonshot Project (Phase II)&#8221;);
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    predictive biomarkers of prostate patient outcomes following treatment with SBRT (designated SBIR &#8220;Topic 345: Predictive Biomarkers
    for Prostate Cancer Sensitivity for Radiation Late Effects (Phase I and II).&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH&#8217;s SBIR program is designed to encourage small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;)
that has the potential for commercialization. Shuttle Pharma will apply for additional NIH SBIR grants and contracts to fund advancement
of these projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Cancer Society (Cancer Facts &amp; Figures 2020) estimates 1,806,590 new cancer cases and 606,520 cancer deaths each year in
the United States and, according to the American Society for Radiation Oncology, more than 50% of patients undergo RT at some point in
the treatment of their diseases. RT is used to treat cancers of the lung, breast, brain, esophagus, pancreas, rectum, head and neck,
uterus, lymphomas and sarcomas. At present, we are developing drug candidates to address brain, pancreas, rectum, sarcomas and lymphomas,
although we may test and seek approval for our drug candidates to treat other cancers in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there is only one drug (the monoclonal antibody, Cetuximab) that has received FDA approval for the radiation sensitizer indication. Cetuximab
is a recombinant monoclonal antibody that binds to epidermal growth factor receptor (EGFR) and inhibits the binding of epidermal growth
factor (EGF). Cetuximab is administered via intravenous infusion and is used as monotherapy or in combination with other chemotherapies
or radiation therapy. In clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest
or sudden death, and serious dermatologic toxicities, toxicities that have created deterrents to its use as a radiation sensitizer. Present
treatment utilizes &#8220;off-label&#8221; small molecule drugs, which are cytotoxic chemotherapy agents that also sensitize, but do
not have radiation sensitization as an FDA approved indication. Moreover, since &#8220;off-label&#8221; drugs are cytotoxic, they are
often associated with intrinsic acute and chronic side effects. Nevertheless, these drugs have shown clinically significant improvements
in disease control and survival and are typically included in standard-of-care treatment recommendations for patients with cancers of
the head and neck, brain, lung, esophagus, stomach, pancreas, liver, bladder, lymphomas and sarcomas. As a result, we believe that there
is a significant market opportunity for our product candidates. Based on cancer incidence data published by the American Cancer Society,
we have estimated the numbers of patients presenting with local/regional disease, suitable for treatment with RT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
RT Cases by Disease Site</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer
    Type</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cases
    Diagnosed Annually</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    RT Cases</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brain</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,979</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreas</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,832</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rectum</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,340</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,437</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
cancer cases for each disease site are estimated from American Cancer Society Facts &amp; Figures 2020 publication. The fraction of patients
optimally receiving RT for each disease site were obtained from published estimates of Delaney G, Jacob S, Featherstone C, Barton M.
The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer.
2005 Sep 15;104(6):1129-37. doi: 10.1002/cncr.21324. The Estimated RT cases were obtained by multiplying Cases Diagnosed Annually by
the fraction receiving RT for optimal utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Development Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, to commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in radiation sensitizer and immunotherapy products for cancer
treatment. Key elements of our strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer</b>. To date, there is one drug (Cetuximab) approved
    by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine to obtain FDA approval, a small
    molecule sensitizer will be enabled for clinical applications for radiation sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expand
    our leadership position within radiation sensitizers</b>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop a sensitizer drug for proton therapy sensitization applications.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</b>. We have built our current product
    pipeline through in-house development, partnerships with leading academic institutions and through successful in-licensing deals.
    We will continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other
    biotechnology companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability
    of clinical success, including programs beyond our target franchise areas and current technology footprint.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invest
    in our HDAC platform technology to maximize its utility across cancer therapies</b>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization and normal tissue radiation protection. In addition, these drugs also affect immune regulatory
    properties. We intend to invest to investigate other properties of our platform technology.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enter
    into collaborations to realize the full potential of our platform. </b>The breadth of our HDAC technology platform enables other
    therapeutic applications, in addition to radiation sensitization and immune therapy. We intend to seek collaborations centered on
    our platform to maximize applications for our HDAC inhibitor technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
propose the following clinical development plan to identify, develop and commercialize drugs for use in cancer treatments in combination
with RT:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Develop
Ropidoxuridine (IpdR) for Orphan disease indications to take to market</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture
    25 kg of Ropidoxuridine and formulate for use in clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase III clinical trial in glioblastoma to secure FDA approval to market Ropidoxuridine for the glioblastoma indication using
    orphan disease designation for marketing protection.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Develop
Ropidoxuridine and tipiracil (IPdR/TPI) for colorectal cancer indications to take to market</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulate
    5 kg of IPdR/TPI for use in pre-clinical efficacy studies, IND-enabling studies and a Phase I clinical trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    IND-enabling studies; obtain IND for IPdR/TPI with RT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase I clinical trial of IPdR/TPI with RT in rectal cancers to establish the MTD.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of IPdR/TPI with RT in rectal cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Develop
HDAC Inhibitors for use in breast cancer for immune activation after RT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    pre-clinical studies of HDAC inhibitors in human xenograft tumor models.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
    with RT in breast cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    with RT in ER+, Her2- breast cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
    with immune checkpoint inhibitors in lung cancers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    the lead HDAC6 inhibitor, SP-2-225, for IND-enabling.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase I clinical trials to determine MTD.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase II clinical trials for proof-of-concept efficacy evaluation in lung cancers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management
Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has significant experience in radiation oncology and in progressing products from early-stage research through clinical
trials. Our CEO, Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior academic and management positions
including serving as Department Chairman, Hospital Medical Director and Cancer Center Director at Georgetown University Medical Center.
Prior to co-founding our company, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became public as NeoPharm, Inc. (Nasdaq:
NEOL). He has experience in providing care for patients undergoing treatment for cancers of the prostate, breast, brain, lung, sarcomas
and GI systems. Dr. Dritschilo has directed basic science research supported by grants from the National Cancer Institute (&#8220;NCI&#8221;)
and performed clinical trials using drugs and radiation therapy. In addition, Dr. Dritschilo served as the principal investigator of
pharmaceutical industry sponsored clinical evaluations of human interferon alpha-2 (Bristol-Myers) with radiation therapy and antisense
raf oligonucleotides, LErafAON (NeoPharm) with radiation therapy. He serves as a Radiation Biology and Radiation Oncology expert on committees
of the NIH to review Program Project (P01) grant applications, Specialized Program of Research Excellence (SPORE) grant applications
and investigator-initiated research project (R01) applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Dritschilo is supported in our clinical development effort by Tyvin Rich, MD, our Chief Clinical Officer and Medical Director. Dr. Rich
is the former Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center and proton radiation therapy specialist at the Hampton Proton Therapy Center in Hampton, Virginia. Dr. Rich has served as principal
investigator on multi-modality clinical trials for the treatment of gastrointestinal (GI) cancers and helped to develop treatment with
5-fluorouracil (5-FU) as a radiation sensitizer for use with RT in the treatment of GI cancers. He has extensive cancer clinical trial
experience in developing radiation sensitizer applications through his participation in the Radiation Therapy Oncology Group (RTOG).
Dr. Rich is a co-inventor with scientists at the University of Virginia of the Proton Activated Atomic Medicine technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative services are provided by Peter Dritschilo, MBA, who has served as our President and COO since 2012. Mr. Dritschilo&#8217;s
experience in hospital administration and management of medical oncology clinical services and radiation therapy facilities, including
management of day-to-day operations, human resources and financial oversight. Peter Dritschilo is the son of our Chairman and CEO, Dr.
Anatoly Dritschilo. The addition of Michael Vander Hoek as our CFO and Vice President for Operations and Regulatory expands our capability
to provide the level of management needed for the proposed expansion of clinical trials. Mr. Vander Hoek served as administrative
director of the Lombardi Comprehensive Cancer Center (LCC) for 12 years and has extensive experience in negotiations, management
and supervision of Contract Research Organizations (CROs) and research contracts in general. As the administrative director of the Lombardi
Comprehensive Cancer Center, Mr. Vander Hoek also served as the chief financial officer. Taken together, we believe our leadership team
of highly qualified specialists will help us achieve the proposed milestones for the development of radiation sensitizer products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Initial Public Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 2, 2022, we completed our initial public offering (&#8220;IPO&#8221;) of 1,225,888 units, with each unit consisting of one
share of common stock and one warrant to purchase one share of common stock, exercisable at $0.01 per share, at a per unit purchase price
to the public of $8.125 per unit ($7.557 per unit, net of the underwriting discount). All of the warrants sold in the IPO were simultaneously
exercised at closing, resulting in the issuance of a total of 2,451,776 shares of common stock at the time of the IPO. Following
completion of our IPO, (i) all of our shares of Series A convertible preferred stock were converted into a total of 336,810 shares of
common stock and we issued warrants to purchase a total of 336,810 shares of common stock, exercisable at $4.00 per share, to our Series
A stockholders, (ii) all our convertible notes were converted into units, with the underlying warrants being simultaneously exercised,
resulting in the issuance of 295,00 shares of common stock, and (iii) warrants to purchase 530,000 shares of common stock, exercisable
an average weighted price of $1.08 per share, were exercised, resulting in the issuance of 530,000 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on September 21, 2022, we closed on the over-allotment option, selling an additional 183,883 units to the underwriter
at the per unit purchase price of $8.125 per unit ($7.557 per unit, net of the underwriting discount), resulting in overall net proceeds
to the Company from the IPO of $10,045,513.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) acted as the lead underwriter of
our IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-IPO
Financings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we completed a $500,000 note offering pursuant to which we sold to two accredited investors (the &#8220;Investors&#8221;)
units consisting of (i) a $250,000 promissory note bearing 10% interest, repayable at the time of our IPO offering (the &#8220;Note&#8221;)
and (ii) a warrant to purchase 250,000 shares (the &#8220;Warrant Shares&#8221;) of our common stock at an exercise price of $1.00 per
share (the &#8220;Warrant&#8221;). The Notes were repaid and cancelled in exchange for the exercise of the Warrants and issuance of the
500,000 Warrant Shares to the Investors at the time of the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February and March 2022, we sold a total of $365,000 and $225,000, respectively, in convertible notes (&#8220;Convertible Notes&#8221;)
to certain accredited investors, which notes automatically converted into units, with each unit consisting of one share of common
stock and a warrant to purchase one share of common stock, upon effectiveness of our IPO at a conversion price of $3.00 per unit
(the &#8220;Conversion Units&#8221;). The warrants were exercised immediately following consummation of the IPO, resulting in
the total issuance of 295,000 shares of our common stock to the Convertible Noteholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, we completed a $125,000 note offering pursuant to which we sold to three accredited investors (the &#8220;Investors&#8221;)
units consisting of (i) a total of $125,000 in 10% promissory notes bearing 10% interest, repayable at the time of our IPO (the
&#8220;August Note&#8221;) and (ii) warrants to purchase a total of 50,000 shares of common stock exercisable at $2.50 per share. Warrants
to purchase 30,000 shares of common stock were exercised at the time of our IPO and the notes were repaid upon consummation of
our IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
acted as placement agent in both the Note and Warrant offering and the Convertible Notes offering, pursuant to which Boustead waived
its cash compensation related to the Note and Warrant offerings and received cash compensation of $36,500 and $22,250 in each of the
February and March 2022 closings, respectively, and also received warrants to purchase 10% of the total number of Conversion Shares,
exercisable at the conversion price of the Convertible Notes. For the August 2022 offering, Boustead received a warrant to purchase 5,000
shares of common stock, exercisable at $2.50 per share, and received $12,500 in cash compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Post-IPO Financings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2023, we closed on a $4.0 million private
placement of a $4.3 million senior secured convertible note (the &#8220;Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;)
to purchase 1,018,079 shares of common stock to the selling stockholder named herein. The Convertible Note bears interest at 5% per annum
and is repayable in equal installments over 26 months, subject to the holder&#8217;s right to accelerate conversion of the Convertible
Note subject to certain equity conditions. In the event the Warrant is exercised in full, we could receive up to an additional $2.39
million in funding. The January 2023 Convertible Note and Warrant offering is described in more detail under the section &#8220;Private
Placement of Convertible Note and Warrant&#8221; at page 40.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Boustead acted as placement agent of the January 2023 Convertible Note
and Warrant offering and received cash compensation of $320,000 and a warrant to purchase 71,266 shares or common stock, exercisable
at $2.35 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks you should be aware of before making an investment decision. These risks are discussed more
fully in the &#8220;Risk Factors&#8221; section of this prospectus at page 12 immediately following this prospectus summary. These risks
include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is primarily dependent on achieving the development, regulatory approval and commercialization of our product candidates,
    both of which are in the early stages of development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    approach to the discovery and development of innovative radiation oncology drugs based on our HDAC small molecule delivery platform,
    which is novel, unproven and may not result in marketable products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have no product revenue, have incurred significant losses since inception, may never become profitable and may incur substantial
    and increasing net losses for the foreseeable future as we continue the development of, and seek regulatory approvals for our product
    candidates.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical trials of our product candidates fail to demonstrate safety and efficacy, which are ongoing determinations that are solely
    within the authority of the FDA, we may be unable to obtain regulatory approvals to commercialize our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any revenue and have incurred losses in each year since our founding in December 2012. Our net loss for the year
    ended December 31, 2021 and the nine months ended September 30, 2022 was $1,152,134 and $2,277,539 respectively.
    As of September 30, 2022, we had an accumulated deficit of $8,143,980 and received a &#8220;going concern&#8221; opinion
    from our independent auditors for the fiscal year ended December 31, 2021. As a clinical stage pharmaceutical company, we expect
    to continue to incur significant losses for the foreseeable future. Even if we achieve profitability in the future, we may not be
    able to sustain profitability in subsequent periods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to regulatory approval processes that are lengthy, time-consuming and unpredictable. We may not obtain approval for any
    of our product candidates from the FDA or foreign regulatory authorities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval, the market may not be receptive to our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to establish collaborative partnerships with other pharmaceutical companies, through which we expect to complete
    development of, obtain marketing approval for and, if approved, manufacture and market our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties satisfying the requirements of clinical trial protocols, including patient enrollment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face competition from other companies in our field or claims from third parties alleging infringement of their intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to recruit or retain key employees, including our senior management team.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to continue to obtain significant additional funding on acceptable terms to continue operations following this offering.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and
    prospects. Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
    risk. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant
    research and development and general and administrative expenses in relation to our operations. In addition, we have not yet demonstrated
    an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
    fields, particularly in the specialty pharmaceutical industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not submitted an application or received marketing approval for any of our product candidates. Regulatory approval of our product
    candidates is not guaranteed, and the approval process is expensive and may take several years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is difficult and costly to protect our intellectual property rights.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a smaller reporting company, and as a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an
    &#8220;emerging growth company&#8221; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted
    and intend to rely on exemptions from specified disclosure and other requirements that are applicable to other public companies that
    are not emerging growth companies. These exemptions include:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
    disclosure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional
    information about the audit and the financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the above provisions for up to five years or until such earlier time that we are no longer an emerging growth company.
We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenues, have more than $700 million in
market value of our capital stock held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period.
We may also choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced reporting
requirements in this prospectus. Accordingly, the information contained in this prospectus may be different than the information you
receive from other public companies in which you hold stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards
until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended
transition period for adopting new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation, Shuttle
Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;), in August of 2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma
Acquisition Corp. Inc. (&#8220;Acquisition Corp.&#8221;), pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition
Corp. and we subsequently changed the name of Acquisition Corp. to Shuttle Pharmaceuticals Holdings, Inc. Our executive offices are located
at 1 Research Court, Suite 450, Rockville, Maryland 20850 and our telephone number is (240) 403-4212. Our corporate website is www.shuttlepharma.com.
Information appearing on our corporate website is not incorporated as part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,762,684
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock<sup>(1)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding before this offering:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,603,129
    shares<sup>(2)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding immediately after this offering:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,365,813
    shares<sup>(3)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    policy:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never paid cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future.
    See the section entitled &#8220;Dividend Policy.&#8221;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the shares by the selling stockholder covered by this prospectus. However,
if the selling stockholder exercises its Warrant in full, we will receive an additional $2,392,485, assuming no anti-dilution adjustments
are required.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering to fund IND-enabling and Phase I and II clinical trials of product candidates,
    including radiation sensitizer Ropidoxuridine, IPdR/TPI and the HDAC inhibitor small molecule technology platform, potential acquisition
    or in-licensing activities and working capital and general corporate purposes. We anticipate that the funds raised from this offering
    will allow us to complete Phase II clinical trials, although there is no guarantee that we will not require additional funds. See
    &#8220;Use of Proceeds&#8221; beginning on page 43 below.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    trading symbol:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SHPH&#8221;.
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully read and consider the information set forth under &#8220;Risk Factors&#8221; beginning on page 12 below and all
    other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in shares
    of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    number represents (i) 300% of the total number of shares issuable upon conversion of 105% of the Convertible Note, or $4,515,000,
    converted at the Alternate Conversion Price (as defined in the note), which is equal to $1.39 per share, for a total of 9,744,605 shares and
    (ii) 1,018,079 shares issuable upon exercise of the Warrant.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of our common stock outstanding excludes:</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">(i) warrants to
                                                                              purchase 20,000 shares of common stock, which warrants have an average weighted exercise price of
                                                                              $2.50 per share.</span></p>


</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assumes
                                            exercise in full of the Warrant registered herein, but does not include 20,000 warrants to purchase
                                            common stock set forth in (2) above.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a 2-for-1 reverse stock split of our issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;).
All references to shares of our common stock in this prospectus refers to the number of shares of common stock after giving effect to
the Reverse Stock Split (unless otherwise indicated).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary financial data should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations,&#8221; and the Financial Statements and notes thereto, included elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Years Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Nine Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
    </b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(As
    Restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,742,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,813,490</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">754,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,742,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(509,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,813,490</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(754,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">590,858</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(296,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(464,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,367</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,152,134</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(805,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,277,539</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(693,086</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common shares outstanding &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,301,750</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,291,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,723,510</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,298,332</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.12</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock issued and outstanding actual, pro forma (reflecting the conversions of convertible notes and exercise of the warrants issuable to the investor in this offering). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_002"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other
information in this prospectus before you decide to buy our common stock. If any of the following risks related to our business actually
occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of our common
stock could decline due to any of these risks and uncertainties related to our business, or related to an investment in our common stock,
and you may lose part or all of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we had limited funds prior to our initial public offering, our independent auditing firm issued a going concern opinion related to our
audit for the year ended December 31, 2021.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the closing of our initial public offering (the &#8220;IPO&#8221;) on September 2, 2022, we were funded by investments from private
investors and government contracts obtained from the National Institutes of Health (NIH) for performing research. While this has allowed
us to complete a Phase I clinical trial for Ropidoxuridine and a pre-clinical trial for our HDAC inhibitor platform, we have not yet
completed our clinical trials and do not know if any of our products will ever achieve commercial viability. The closing of our IPO and
the underwriter&#8217;s exercise of the overallotment option resulted in gross proceeds of $11,088,764, which we anticipate will support
our research and development efforts through Phase II clinical trials of Ropidoxuridine and allow us to fund certain drug manufacturing
and perform pre-IND testing and obtain IND in order to initiate Phase I clinical trials for our selective HDAC6 inhibitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all
of which are in the early stages of development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one clinical stage product candidate in the early stages of development. Ropidoxuridine has undergone an SBIR funded Phase
1 clinical trial at Lifespan/Rhode Island Hospital. We also have an HDAC inhibitor small molecule platform. The three lead drug candidate
molecules are in preclinical phases of development. none of our product candidates have gained marketing approval for sale in the United
States or any other country, and we cannot guarantee that we will ever have marketable products. To date, we have invested substantially
all of our efforts and financial resources in the research and development and commercial planning for our current product candidate
and our HDAC small molecule delivery platform. Our near-term prospects, including our ability to finance our Company and generate revenue,
as well as our future growth, will depend heavily on the development, marketing approval and commercialization of our product candidates.
The clinical and commercial success of product candidates will depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    favorable results from our Phase 1 clinical trial for IPdR and proceeding to Phase II and Phase III clinical trials, which may be
    slower or cost more than we currently anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate safety and efficacy of our product candidates, which are ongoing determinations that are solely within the
    authority of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if our clinical trials are completed, there can be no assurance that the FDA will agree that we have satisfactorily demonstrated
    safety or efficacy or that the FDA will not raise new issues regarding the design of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required by the FDA to conduct additional clinical trials to support the approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance by the FDA of our proposed parameters for regulatory approval, including our proposed indication, endpoints and endpoint
    measurement tools relating to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    incidence, duration and severity of adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are able to secure collaborations for completing the development and, if approved, commercialization of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our and our potential collaborators&#8217; marketing, sales and distribution strategy and operations of product
    candidates that are approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    success in educating physicians and patients about the benefits, administration and use of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers and potential collaborators to manufacture clinical trial and commercial supplies of our
    product candidates to remain in good standing with regulatory bodies, and to develop, validate and maintain commercially viable manufacturing
    processes that are compliant with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize our product candidates, if approved for marketing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enforce our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference or patent infringement claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our product candidates as safe and effective by patients and the medical community; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable quality profile of our product candidates following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Many
of the above-listed factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to generate revenue through
the sale of our product candidates. Any one of these factors or other factors discussed in this prospectus could affect our ability to
commercialize product candidates, which could impact our ability to earn sufficient revenues to transition from a developmental stage
company and continue our business. If we do not obtain marketing approval of and commercialization of our product candidates, or are
significantly delayed in doing so, our business will be materially harmed. We have a limited operating history and have incurred significant
losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future and may never achieve
or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We do not
currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant research
and development and general and administrative expenses related to our operations. In addition, we have limited experience and have not
yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and
rapidly evolving fields, particularly in the specialty pharmaceutical industry. We have not generated any revenue and have incurred losses
in each year since our founding in December 2012. Our accumulated deficit as of September 30, 2022 was $8,143,980. We expect
to continue to incur significant losses for the foreseeable future. Even if we achieve profitability in the future, we may not be able
to sustain profitability in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no source of product sales revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenues from commercial sales of our product candidates. Our ability to generate product revenue depends upon
our ability to develop and commercialize products, including any of our current product candidates or other product candidates that we
may develop, in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable
future. Our ability to generate future product revenue from our current or future product candidates also depends on a number of additional
factors, including our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    research and clinical development of current and future product candidates, either directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of
    bulk drug substances and drug products to maintain that supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates, either
    directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch
    and commercialize future product candidates for which we obtain marketing approval, if any, through collaborative partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate product reimbursement from third-party payors, including government payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance for our products, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish,
    maintain and protect our intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates
may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount
of any potential future product sales revenues. Our expenses also could increase beyond expectations if we decide to or are required
by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate.
Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with
launching and commercializing these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any future revenue
from the sale or licensing of product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such
as whether the product can be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing
are based on new delivery platform therapeutic approaches (there currently is no drug which has FDA approval for indications of radiation
sensitization). Market participants with significant influence over acceptance of new treatments, such as physicians and third-party
payors, may not accept our delivery platform, and we may not be able to convince the medical community and third-party payors to accept
and use, or to provide favorable reimbursement for, any product candidates developed by us. Market acceptance of our product candidates
will depend on, among other factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of our receipt of any marketing and commercialization approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
    of any approvals and the countries in which approvals are obtained;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy of our product candidates, which are determinations solely within the authority of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any adverse side effects associated with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warnings
    contained in any labeling approved by the FDA or other regulatory authority;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our physician education programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of adequate government and third-party payor reimbursement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    of our products, particularly as compared to alternative treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative effective products for indications our product candidates are intended to treat.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will continue to require substantial additional financing in order to obtain marketing approval of our product candidates and commercialize
our product candidates. Should we fail to obtain this necessary capital when needed on acceptable terms, or at all, could force us to
delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, substantially all of our resources have been dedicated to the preclinical and clinical development of our HDAC small molecule
delivery platform and our initial product candidate, Ropidoxuridine. Our capital needs to date have been met by contributions from existing
shareholders, as well as through private offerings of our securities and our SBIR contracts. We closed on our initial public offering
on September 2, 2022 and exercise of the overallotment option on September 21, 2022, pursuant to which we received gross proceeds of
$11,088,764, which funds we anticipate will allow us to complete Phase II clinical trials for Ropidoxuridine, fund certain drug manufacturing
and completion of pre-IND testing and obtain IND in preparation for initiating Phase I clinical trials for our selective HDAC6 inhibitor.
We believe that we will continue to expend substantial resources for the foreseeable future on the completion of clinical development
and regulatory preparedness of our product candidates, preparations for a commercial launch of our product candidates, if approved, and
development of any other current or future product candidates we may choose to further develop. These expenditures will include costs
associated with research and development, conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if
we are not able to enter into planned collaborations, manufacturing and supply as well as marketing and selling any products approved
for sale. In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain,
we cannot reasonably estimate the actual amounts necessary to complete the development and commercialization of our current product candidates,
if approved, or future product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our receipt of an additional $4.0 million in gross proceeds from our private placement of the Convertible Note and Warrant,
we</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> believe that such proceeds together with our
existing capital resources, will be sufficient to fund our operations through 2024. In addition, should the Selling Stockholder
choose to exercise the Warrant registered herein in full, we will receive an additional $2.39 million in gross proceeds, which will
further fund our operations through 2025. However, our operating plan may change as a result of factors
currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt
financings or other sources, such as strategic collaborations. Such financing may result in dilution to shareholders, imposition of
debt covenants and repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek
additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our current product candidates, future product candidates and conducting
    preclinical and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including
    securing collaborative ventures for completing development of, securing marketing approval for and ultimately marketing, selling
    and distributing our product candidates, if approved or building a corporate infrastructure if we have to undertake these activities
    directly;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of any additional product candidates we may develop or acquire;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products or commenced against us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
    and the outcome of such litigation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or royalties on, any future approved products, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate preclinical studies, clinical trials or other development activities for our current product candidates
    or future product candidates, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our research and development activities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize
    our current or future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional
funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions caused by the ongoing conflict between the Ukraine and Russia, as well as the ongoing COVID-19 pandemic,
may have serious adverse consequences on our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions as a result of the ongoing
conflict between the Ukraine and Russia, as well as challenges arising from the ongoing COVID-19 pandemic, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases
in inflation rates and uncertainty about economic stability. Any such volatility and disruptions may have adverse consequences on us
or the third parties upon whom we rely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are in the early stages of development and may fail in development or suffer delays that materially adversely affect
their commercial viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market and all of our product candidates are in the early stages of development. Our ability to achieve and sustain
profitability depends on obtaining regulatory approvals, including institutional review board (&#8220;IRB&#8221;) approval, for and commercializing
our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our
product candidates, we or one of our collaborators must conduct extensive preclinical tests and clinical trials to demonstrate the safety
and efficacy in humans of our product candidates, the final determination of which rests solely in the authority of the FDA. Preclinical
testing and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to
outcome. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges,
required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability
or prevalence of use of a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays
or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development
times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of
patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility
criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria
for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity
of patients to clinical sites and the availability of effective treatments for the relevant disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product
candidates is high due to scientific feasibility, lack of quality and effectiveness, changing standards of medical care and other variables.
The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained
in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects participating in such trials are being
exposed to unacceptable health risks or adverse side effects. We may not have the financial resources to continue development of, or
to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize, product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading
    to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug application (&#8220;IND&#8221;) or delays or failure in obtaining the necessary approvals
    from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling research subjects in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of research subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    than anticipated clinical trial costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA or other regulatory agency inspection and review of a clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations
    in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to our technology in particular; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA and similar foreign regulatory agencies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties on which we depend to conduct our preclinical studies, or any future clinical trials, do not perform as contractually required,
fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with materially
adverse effects on our business, financial condition, results of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying on third party collaborators to conduct our efficacy clinical trials for Ropidoxuridine and plan to rely on third party clinical
investigators, contract research organizations (&#8220;CROs&#8221;), clinical data management organizations and consultants to design,
conduct, supervise and monitor preclinical studies of our product candidates and will do the same for any clinical trials. Because we
plan to largely rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we
have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted
them on our own. These investigators, CROs, and consultants are not our employees and we have limited control over the amount of time
and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of
which may be our competitors, which may draw time and resources from our programs. The third parties with whom we contract might not
be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical
trials being delayed or unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or
meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible
for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan
and protocols for the trial. The FDA requires clinical trials to be conducted in accordance with good clinical practices, including for
conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on
third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have a material
adverse effect on our business, financial condition, results of operations and/or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development,
preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials.
There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials
will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at
acceptable prices. In particular, any replacement of any drug product formulation manufacturer we may use could require significant effort
and expertise in the event there are a limited number of qualified replacements for a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers
must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards, such as Current Good Manufacturing Practice (or CGMP). In the event that any of our suppliers
or manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise,
or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third
party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture
our product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty, or there may be contractual
restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist.
These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have
another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required
to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations
and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product
candidates in a timely manner or within budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that
we have existing or future manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms,
we may not be able to fully develop and commercialize our product candidates. Our or a third party&#8217;s failure to execute on our
manufacturing requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or continue clinical trials of product candidates under development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of the cooperation of a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    our product candidates to additional inspections by regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease distribution or to recall batches of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unsuccessful in engaging in strategic transactions which could adversely affect our ability to develop and commercialize product
candidates, impact our cash position, increase our expense and present significant distractions to our management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or
in- licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter
into additional collaborations, including with major biotechnology or pharmaceutical companies to complete development and marketing
of our product candidates, if approved. The competition for collaborators is intense, and the negotiation process is time-consuming and
complex. Any proposed collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing
collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not
meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require
us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation
challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage
a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances
of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs,
write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration
or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or
customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired
business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect
on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or
other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product
candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face competition from entities that have developed or may develop product candidates for our target disease indications, including companies
developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies
or product candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability
to develop and commercialize product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as with universities and other research institutions which are developing new technology.
Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates.
Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments
that enter the market. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of conditions for which we may try to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we obtain approval for any product candidate, we will face competition based on many different factors, including the
quality and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept
relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of
manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present
superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than
any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense
of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact
our level of expertise and our ability to execute our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success largely depends on the continued service of certain key management and other specialized personnel, including Anatoly Dritschilo,
M.D., our Chief Executive Officer, Mira Jung, Ph.D., our Chief Scientific Officer for Biology, Michael Vander Hoek, our Chief Financial
Officer and Vice President Operations and Regulatory, and Peter Dritschilo, our President and Chief Operating Officer. The loss of one
or more members of our management team or other key employees or advisors could delay our research and development programs and materially
harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated
within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service
of our technical personnel because of the highly technical nature of our product candidates and technologies and the specialized nature
of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service,
they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any
of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and
retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing,
manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public
and private research institutions, government entities and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our product candidates advance into Phase II and Phase III clinical trials, we may experience difficulties in managing our growth and
expanding our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience in drug development and have not begun clinical trials for any of our product candidates, other than a Phase
1 clinical trial for Ropidoxuridine. As our product candidates enter and advance through preclinical studies and any clinical trials,
we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these
capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and
other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial
and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information
and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution
capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable
to commercialize any such future products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we plan
to enter into collaborations with third parties to sell, market and distribute our products. In the alternative, we would have to develop
internal sales, marketing and distribution capabilities to commercialize any approved product, which would be expensive and time-consuming,
or, as is more likely, enter into collaborations with third parties to perform these services. If we rely on third parties with sales,
marketing and distribution capabilities to market our products or decide to co-promote products with collaborators, we will need to establish
and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter
into such arrangements on acceptable terms, if, at all. In entering into third-party marketing or distribution arrangements, any revenue
we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate
sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we decide to market our
products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with
technical expertise and supporting distribution, administration and compliance capabilities. If we are not able to commercialize any
product approved in the future, either on our own or through third parties, our business, financial condition, results of operations
and prospects could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization
approvals we may receive and subject us to other penalties that could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive marketing and commercialization approval of a product candidate, there can be no assurance we will not be subject to future
or continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results that are
reported after a product is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval.
The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and
to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of
the product from the market. The FDA also has the authority to require a risk evaluation and mitigation strategies (&#8220;REMS&#8221;)
plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturer
and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA
and other regulatory agencies, including for continued compliance with CGMP requirements. The discovery of any new or previously unknown
problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer
or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over
compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to
regulatory requirements and continuing regulatory review. If we or our collaborators, manufacturers or service providers fail to comply
with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or
they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA to approve pending applications
or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit
the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material
effect on our business, financial condition, results of operations or prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products,
such claims could result in an FDA investigation of the quality and effectiveness of our products, our manufacturing processes and facilities
or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications
for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may
also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s
time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently
have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior
to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential
liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable
to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a
material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and
state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities
to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. While we make an effort to maintain
strict employee work processes and oversight, employee misconduct could expose us to liability through the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Furthermore,
it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity
may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of cyber security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For example, the loss of preclinical data or data from any future
clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly
increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers,
clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of
this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable
to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced
any such material security breach to date, any such breach could compromise our network, or the networks of our CROs or other third party
service providers, and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for our drugs. Although we maintain business interruption insurance coverage, our insurance might not cover all losses from any future
breaches of our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems could significantly disrupt the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business increasingly depends on the use of information technologies, which means that certain key areas such as research and development,
production and sales are to a large extent dependent on our information systems or those of third-party providers. Our ability to execute
our business plan and to comply with regulatory requirements with respect to data control and data integrity, depends, in part, on the
continued and uninterrupted performance of our information technology systems, or IT systems and the IT systems supplied by third-party
service providers. These systems are vulnerable to damage from a variety of sources, including telecommunications or network failures,
malicious human acts and natural disasters. Moreover, despite network security and backup measures, some of our servers are potentially
vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures
we and our third-party service providers have taken to prevent unanticipated problems that could affect our IT systems, sustained or
repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain
data, and in particular to operate our proprietary technology platform, could adversely affect our ability to operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various
flammable and toxic chemicals in our facilities in Gaithersburg, Maryland that are required for our research, development and manufacturing
activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal
of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Gaithersburg facilities
comply with the relevant guidelines of Gaithersburg, the State of Maryland and the Occupational Safety and Health Administration of the
U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the
standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens
and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs
and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may
be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and
local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and
substantial fines or penalties if we violate any of these laws or regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
information technology systems could face serious disruptions that could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection
to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of
our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners
and delays in our research and development work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change
our compensation policies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
methods and policies for pharmaceutical companies, including policies governing revenue recognition, research and development and related
expenses and accounting for stock-based compensation are subject to review, interpretation and guidance from relevant accounting authorities,
including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise
change or revise our financial statements, including those contained in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
of our product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses
of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods
for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from
infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of the date of this
prospectus, we have filed five patent applications with the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) with respect to
various aspects of our HDAC inhibitor small molecule delivery platform and Ropidoxuridine, our lead product candidate. However, we may
not be able to apply for patents on certain aspects of our product candidates or delivery technologies in a timely fashion or at all.
To date, four US patents and two European patents have been granted. There is no guarantee that any of our pending patent applications
will result in issued or granted patents, that any of our issued, granted or licensed patents will not later be found to be invalid or
unenforceable or that any issued, granted or licensed patents will include claims that are sufficiently broad to cover our product candidates
or delivery technologies or to provide meaningful protection from our competitors. Moreover, the patent position of specialty pharmaceutical
companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary
rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates
are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate
our proprietary rights, it may materially and adversely impact our position in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
requirements during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors
might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent
offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding
patentable subject matter or the scope of claims allowable in pharmaceutical patents. As such, we do not know the degree of future protection
that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual
property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may decide for business reasons to no longer pursue or to abandon certain intellectual property rights in the US or elsewhere, including
due to non-cooperation of inventors or owners of such intellectual property, prior art, or scope of protection, or for other reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or
derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which
time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted
period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the
allowed or granted claims altogether. In addition, there can be no assurance that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are
    not covered by the claims of the patents that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to make the inventions covered by each of our issued patents
    and pending patent applications that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to file patent applications covering certain aspects of
    our inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    third party may not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others will not have an adverse effect on our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then
    use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain,
maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive
position and business prospects may be adversely affected. We may not be able to protect our intellectual property rights throughout
the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions
where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared
to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents
or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities
in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce
patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals.
This could make it difficult for us to prevent the infringement of patents or marketing of competing products in violation of our proprietary
rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally file a provisional patent application first (a priority filing) at the USPTO. A U.S. utility application and international
application under the Patent Cooperation Treaty (PCT) are usually filed within twelve months after the priority filing. Based on the
PCT filing, national and regional patent applications may be filed in the European Union, Japan, Australia and Canada and other countries.
We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In
addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national
or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused
by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes
of patent protection may be granted on the same product candidate or technology. The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights
may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with
respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business
and results of operations may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to
resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay
or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors, or any future collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation
of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold
harmless our licensors or collaborator for damages arising from intellectual property infringement by us. If we or our licensors, or
any future collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights, we could
be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our
licensors, collaborators or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which
may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive,
which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a
required license, we or our collaborator, or any future collaborator, may be unable to effectively market product candidates based on
our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce
our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating
to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s
attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because
they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant
could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity
or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution.
The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to
the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose
at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology.
Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights
also will not protect our technology if competitors design around our protected technology without legally infringing our patents or
other intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could
be costly or not available on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products
or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop
or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual
property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially
reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms
acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages,
we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We
might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could
lose intellectual property rights that are necessary for developing and protecting our product candidates and delivery technologies or
we could lose certain rights to grant sublicenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding,
milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach
any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages
and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell
products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our
licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless
of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine
the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we aim to
develop and commercialize, if any. Therefore, even if we are able to develop and commercialize products, we may be unable to achieve
or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade
secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets
and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with
our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not
be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain
foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217;
or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we
may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to
commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to effectively compete and our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation and Product Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development,
manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing,
marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are
required to be completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other
regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product
candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval
by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement
of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign
counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from
preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit
or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example,
from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials
and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular
product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations
on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority
to require a Risk Evaluation and Mitigation Strategy (REMS) plan as part of an NDA or biologics license application (BLA) or after approval,
which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing
to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use
criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market
for the product and affect reimbursement by third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be
subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our collaborators are subject to federal, state, and foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217;
rights. These laws and regulations include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing
    remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing
    or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing
    to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and
    which may apply to us by virtue of statements and representations made to customers or third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical
    Health (HITECH) Act, which prohibit executing a scheme to defraud healthcare programs, impose requirements relating to the privacy,
    security, and transmission of individually identifiable health information, and require notification to affected individuals and
    regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Open Payments regulations under the National Physician Payment Transparency Program have been issued under the Patient Protection
    and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, and will require that manufacturers
    of pharmaceutical and biological drugs covered by Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report all consulting
    fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws applicable to commercial
    insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to
    patient data privacy and security.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties,
monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion
from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid,
any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and
prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected
violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of
our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations
may be costly to us in terms of money, time and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations,
we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and
could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse regulatory inspection
    findings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, marketing our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, importation or exportation of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of review or refusal to approve pending applications or supplements to approved applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from participation in government-funded healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from eligibility for the award of government contracts for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties and fines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives,
thereby harming our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries
require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently
in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result,
we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial
launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products also will depend in part on the extent to which reimbursement for these products and related treatments
will be available from government health administration authorities, private health insurers and other organizations. Even if we succeed
in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any
products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of
development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly,
the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring
that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts
reimbursed for pharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided
for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidates will need to be administered under the supervision of a physician on an outpatient basis. Under currently
applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under
the Medicare Part B program if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are incident to a physician&#8217;s services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to
    accepted standards of medical practice; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    have been approved by the FDA and meet other requirements of the statute.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which
the drug is approved by the FDA. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at
a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if
applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed
for lower- cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary
constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded
and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on
our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory
proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and
biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare
markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have included
prescription drug benefit legislation that was enacted and took effect in January 2006, healthcare reform legislation enacted by certain
states, and Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
(the &#8220;ACA&#8221;), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending and enhance remedies against fraud and abuse. The ACA also contains provisions that will affect companies in the pharmaceutical
industry and other healthcare related industries by imposing additional costs and changes to business practices. Provisions affecting
pharmaceutical companies include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandatory
    rebates for drugs sold into the Medicaid program have been increased, and the rebate requirement has been extended to drugs used
    in risk-based Medicaid managed care plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    340B Drug Pricing Program under the Public Health Services Act has been extended to require mandatory discounts for drug products
    sold to certain critical access hospitals, cancer hospitals and other covered entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly
    referred to as the &#8220;Donut Hole&#8221;; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share
    of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans
    Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal
    health program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory
developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have
an adverse effect on anticipated revenues from product candidates that we may develop and for which we may obtain regulatory approval
and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal government agencies currently face potentially significant spending reductions. Under the Budget Control Act of 2011, the failure
of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to
most federal programs. These cuts would include aggregate reductions to Medicare payments to providers of up to two percent per fiscal
year, starting in 2013. Under the American Taxpayer Relief Act of 2012, which was enacted on January 1, 2013, the imposition of these
automatic cuts was delayed until March 1, 2013. Certain of these automatic cuts have been implemented. The full impact on our business
of these automatic cuts is uncertain. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated
to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely
review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market
and sell any products we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product
candidate, our ability to market and derive revenue from the product candidates could be compromised.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by
one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and
materially and adversely affect our results of operations and business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval of the product or seize the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall the product or change the way the product is administered to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Common Stock and this Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to easily pay off the convertible debt using our common stock is dependent on our common stock maintaining a relatively high
trading volume.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the intent underlying the Convertible Note was that we would repay such note in shares of our common stock, thus preserving capital for
use in our clinical trials, in the event our common stock is not able to maintain a robust trading market, we may not be able to easily
repay the Convertible Note in shares. In such case, we would be reliant on repaying the convertible note in cash, which would negatively
affect our ability to complete our available capital and thus could potentially impact the timing with which we are able to complete
our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
substantial number of shares of our common stock may be issued pursuant to the terms of the Convertible Note, which could cause the price
of our common stock to decline, as well as cause a greater dilution to our existing stockholders<span style="text-decoration: underline">.</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conversion price of the Convertible Note can vary as it is convertible at the lower of (i) $2.35 per share, (ii) 90% of the three lowest
VWAPs in the 15 trading days prior to the payment date or (iii) 90% of the VWAP on the trading day prior to the payment date. As a result,
the conversion price is variable and depends upon market performance. In the event our common stock experiences substantial decline in
per share price, such decline could cause significantly more conversion shares to be issuable upon conversion of the Convertible Note,
cause greater dilution to our shareholders and have a depressive effect on the overall market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of substantial amounts of our common stock by the selling stockholders, or the perception that these sales could occur, could adversely
affect the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale by the selling stockholders of a significant number of shares of common stock could have a material adverse effect on the market
price of our common stock. In addition, the perception in the public markets that the selling stockholders may sell all or a portion
of their shares as a result of the registration of such shares for resale pursuant to this prospectus could also in and of itself have
a material adverse effect on the market price of our common stock. We cannot predict the effect, if any, that market sales of those shares
of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
requirement that we repay the Convertible Note and interest thereon in cash under certain circumstances, and the restrictive covenants
contained in the Convertible Note, could adversely affect our business plan, liquidity, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to repay the Convertible Note and interest thereon in cash, if we do not meet certain customary equity conditions (including
minimum price and volume thresholds) or in certain other circumstances. For example, we will be required to repay the outstanding principal
balance and accrued but unpaid interest, along with a premium, upon the occurrence of a Change of Control (as defined in the Convertible
Note). In addition, the Convertible Note contains restrictive covenants, including financial covenants. These obligations and covenants
could have important consequences on our business. In particular, they could:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to dedicate a substantial portion of our cash flow from operations to payments on the
                                            Convertible Note;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limit,
                                            among other things, our ability to borrow additional funds and otherwise raise additional
                                            capital, and our ability to conduct acquisitions, joint, ventures or similar arrangements,
                                            as a result of our obligations to make such payments and comply with the restrictive covenants
                                            in the Convertible Note;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            our flexibility in planning for, or reacting to, changes in our business or the industry
                                            in which we operate; and</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our vulnerability to general adverse economic and industry conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we are required to repay the Convertible Note in cash, we may seek to refinance the remaining balance, by either refinancing
with the holders of the Convertible Note, by raising sufficient funds through a sale of equity or debt securities or by obtaining a credit
facility. No assurances can be given that we will be successful in making the required payments under the Convertible Note, or in refinancing
our obligations on favorable terms, or at all. Should we determine to refinance, it could be dilutive to shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe we have adequate cash to satisfy our payment obligations in the event we are unable to pay off the Convertible Note with conversion
shares, if we are unable to make the required cash payments, there could be a default under the Convertible Note. In such event, or if
a default otherwise occurs under the Convertible Note, including as a result of our failure to comply with the financial or other covenants
contained therein, the holders of the Convertible Notes could require us to immediately repay in cash 115% of the outstanding principal
and interest on the Convertible Note that would otherwise have then been due. Furthermore, the holders of the Convertible Note could
foreclose on their security interests in our assets, including our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated
to the public.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), internal control over financial reporting is
a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance
    of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with
    authorizations of management and/or directors of the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to include a report of management on the effectiveness of our internal control over financial reporting. We expect to incur
additional expenses and diversion of management&#8217;s time as a result of performing the system and process evaluation, testing and
remediation required in order to comply with the management certification requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging
outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies
that we may not be able to timely remediate. Moreover, effective internal controls, particularly those related to revenue recognition,
are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable
financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported
financial information, and the trading price of our common stock, if a market ever develops, could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Jobs Act has reduced the information that we are required to disclose.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Jobs Act, the information that we are required to disclose has been reduced in a number of ways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company that had gross revenues of less than $1.0 billion during the Company&#8217;s last fiscal year, the Company is an &#8220;emerging
growth company,&#8221; as defined in the Jobs Act (an &#8220;EGC&#8221;). We will retain that status until the earliest of (a) the last
day of the fiscal year which we have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth
in the Jobs Act) or more; (b) the last day of the fiscal year of following the fifth anniversary of the date of the first sale of the
common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;);
(c) the date on which we have, during the previous three year period, issued more than $1,000,000,000 in non-convertible debt; or (d)
the date on which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act or any
successor thereto. As an EGC, the Company is relieved from the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is excluded from Section 404(b) of Sarbanes-Oxley Act (&#8220;Sarbanes-Oxley&#8221;), which otherwise would have required
    the Company&#8217;s auditors to attest to and report on the Company&#8217;s internal control over financial reporting. The JOBS Act
    also amended Section 103(a)(3) of Sarbanes-Oxley to provide that (i) any new rules adopted by the PCAOB requiring mandatory audit
    firm rotation or changes to the auditor&#8217;s report to include auditor discussion and analysis (in the event the PCAOB adopts
    an auditor rotation requirement) will not apply to an audit of an EGC; and (ii) any other future rules adopted by the PCAOB will
    not apply to the Company&#8217;s audits unless the SEC determines otherwise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Jobs Act amended Section 7(a) of the Securities Act to provide that the Company need not present more than two years of audited financial
    statements in an initial public offering registration statement and in any other registration statement, need not present selected
    financial data pursuant to Item 301 of Regulation S-K for any period prior to the earliest audited period presented in connection
    with such initial public offering. In addition, the Company is not required to comply with any new or revised financial accounting
    standard until such date as a private company (i.e., a company that is not an &#8220;issuer&#8221; as defined by Section 2(a) of
    Sarbanes-Oxley) is required to comply with such new or revised accounting standard. Corresponding changes have been made to the Exchange
    Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure
    regarding executive compensation, by disclosing the more limited information required of a &#8220;smaller reporting company.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Jobs Act will also exempt us from the following additional compensation-related disclosure provisions that were imposed on U.S. public
    companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a) of the Exchange
    Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to shareholder advisory votes on &#8220;golden parachute&#8221;
    compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship between executive
    compensation and our financial performance; and (iv) the requirement of Section 953(b)(1)of the Dodd-Frank Act, which requires disclosure
    as to the relationship between the compensation of our chief executive officer and median employee pay.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price is extremely volatile, and purchasers of our common stock could incur substantial losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
commencement of trading on Nasdaq on August 29, 2022, our stock price has been extremely volatile, having traded as high as $126.26 and
as low as $1.67. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public
offering price. The market price for our common stock may be influenced by many factors, including the other risks described in this
section of the prospectus entitled &#8220;Risk Factors&#8221; and the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical and clinical studies of our product candidates, or those of our competitors, our existing collaborator or any future
    collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions
    or announcements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other
    comparable companies or our industry generally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to
    the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    and expectation of additional financing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    concentrated ownership of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terrorist
    acts, acts of war or periods of widespread civil unrest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters and other calamities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, industry and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets in general, and the markets for pharmaceutical stocks, in particular, have experienced extreme volatility
that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.
To the extent that additional capital is raised through the issuance of shares or other securities convertible into shares of our common
stock, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such
sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future
offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the
availability of common stock for future sales will have on the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Following
our IPO on August 29, 2022,</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Holders
of 1% or more of our common stock prior to our IPO are subject to a six month lock-up agreement, and all directors, officers and 10%
shareholders are subject to a one year lock-up post-IPO. At such time as such stock becomes available for sale, it is possible a significant
number of our shares may cause the market price of our common stock to drop significantly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
at the end of February 2023, 6,348,990 shares of our fully diluted common stock outstanding as of the date of this prospectus
will be eligible for sale in the public market from time to time thereafter pursuant to Rule 144 under the Securities Act, and 3,030,108
shares of our fully diluted common stock will be eligible for resale following a one-year lock-up period; some of such shares may be
subject to the volume and other restrictions of Rule 144. Further, we have 2,615,833 shares reserved for issuance under our 2018
Equity Incentive Plan (the &#8220;Plan&#8221;), which shares may be issued from time to time by our management and which will then
be subject to vesting and other requirements, and 21,748 shares which have been issued under the Plan but remain subject to vesting conditions.
At such time as the lock-up periods end, or if it ends earlier pursuant to the discretion of the underwriter for our initial
public offering, it is possible that a significant number of such shares will be sold into the market. At such time, the sale of
a significant number of shares of our common stock in the public market or the perception that such sales may occur could significantly
reduce the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain applicable listing requirements, Nasdaq may delist our common stock from trading, in which case the liquidity and
market price of our common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to maintain the continued listing standards of Nasdaq in the future. If we fail to comply with
the applicable listing standards and Nasdaq delists our common stock, we and our stockholders could face significant material adverse
consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for shares of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is &#8220;penny stock,&#8221; which would require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for shares of
    our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news about us and analyst coverage of us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the
sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because we expect that our common stock will be
listed on Nasdaq, such securities will be deemed covered securities. Although the states will be preempted from regulating the sale of
our securities, the federal statute does allow states to investigate companies if there is a suspicion of fraud and, if there is a finding
of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were
no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state in which
we offer our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use them
and the proceeds may not be invested successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds to us from this offering to fund offering to fund preclinical and clinical trials of product candidates,
Ropidoxuridine and new formulations of Ropidoxuridine with Tipiracil, O-18 containing molecules for proton radiation sensitization, continued
HDAC technology platform development, working capital and general corporate purposes, including the costs of operating as a public company,
as well as potential acquisition or in-licensing activities. Therefore, our management will have broad discretion as to the use of the
offering proceeds. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and
you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion
regarding our stock, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few
securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we
obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding
us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet
the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
board of directors has the authority, without shareholder approval, to issue preferred stock with terms that may not be beneficial to
holders of our common stock and such issuance could potentially affect adversely shareholder voting power and perpetuate their control
over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, allows us to issue shares of preferred stock without any vote or further action by
our shareholders. Our board of directors has the authority to fix and determine the relative rights and preferences of any preferred
stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the
preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders
of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of shares of our common
stock. These rights and preferences could negatively affect the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ability of our executive officers and directors, who are our principal stockholders, to control our business may limit or eliminate the
ability of minority shareholders to influence corporate affairs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers and directors, who are our principal stockholders, own approximately 73% of our issued and outstanding common stock
and, following this offering, will own approximately 63% of our issued and outstanding common stock. Accordingly, they will be able to
effectively control the election of directors, as well as all other matters requiring shareholder approval. The interests of our principal
stockholders may differ from the interests of other shareholders with respect to the issuance of shares, business transactions with or
sales to other companies, selection of other directors and other business decisions. The minority shareholders have no way of overriding
decisions made by our principal stockholders. This level of control may also have an adverse impact on the market value of our shares
because our principal stockholders may institute or undertake transactions, policies or programs that result in losses and may not take
any steps to increase our visibility in the financial community and/or may sell sufficient numbers of shares to significantly decrease
our price per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense
of the Company and limit their liability that may result in a major cost to us and hurt the interests of our shareholders because corporate
resources may be expended for the benefit of officers and/or directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for the indemnification of our officers and directors. We have
been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public
policy as expressed in the Securities Act and is therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation, as amended to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware,
except for cases brought under the Securities Act or Exchange Act.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, provides that the Court of Chancery in the State of Delaware will be the exclusive
forum for dispute resolution for certain enumerated actions, excluding any actions brought under the Securities Act or Exchange Act,
or unless the Company consents in writing to an alternative jurisdiction. This exclusive forum selection clause may cause inconvenience
of our shareholders or other stakeholders, should they need to bring suit against the Company for an action other than one arising under
the Securities Act or Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to pay cash dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable
future. The future payment of dividends directly depends upon our future earnings, capital requirements, financial requirements and other
factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your
investment, if any, will depend solely on an increase, if any, in the market value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage,
delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, and bylaws contain provisions that could depress the market price of
our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the
stockholders of our company may deem advantageous. These provisions, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    the board of directors to establish the number of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that directors may only be removed &#8220;for cause&#8221; and only with the approval of 66 2/3 percent of our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    super-majority voting to amend some provisions in our Certificate of Incorporation and Bylaws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known
    as a &#8220;poison pill&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eliminate
    the ability of our stockholders to call special meetings of stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit
    stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the board of directors is expressly authorized to make, alter or repeal our bylaws; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders
    at annual stockholder meetings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section
203 imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S1_001"></span>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221;
&#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221;
or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements
about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs,
    NDAs other regulatory submissions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt and timing of any milestone payments or royalties under any research collaboration and license agreement we enter into;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    or a collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of any approved products candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercialization of any approved product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain additional collaborations and retain commercial rights for our product candidates subject to collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, technologies and product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of our expenses, ongoing losses, future revenue and capital requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funds for our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our technologies and product candidates and our ability to operate
    our business without infringing the intellectual property rights of others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to conduct our preclinical studies or any future clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research
    and development, preclinical and clinical trial drug supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified key management and technical personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    use of net proceeds to us from this offering;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors or our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially
from current expectations include, among other things, those described in the section entitled &#8220;Risk Factors&#8221; and elsewhere
in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other
risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. Except as required by U.S. federal securities law, we assume
no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="z_004"></span>PRIVATE
PLACEMENT OF THE SENIOR CONVERTIBLE NOTE AND WARRANT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor
(the &#8220;Investor&#8221;) and consummated the sale to such Investor of a senior secured convertible note (the &#8220;Convertible Note&#8221;)
with an initial principal amount of $4,300,000, bearing interest at 5% per annum, and a warrant (the &#8220;Warrant&#8221;) to purchase
1,018,079 shares of our common stock at a fixed exercise price of $2.35 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />
The Convertible Note was sold with an original issue discount of $300,000. As such, the Investor paid for the Convertible Note by delivering
$4,000,000 in cash consideration to the Company. Boustead Securities LLC (&#8220;Boustead&#8221;) served as the sole placement agent
for the private placement (the &#8220;Private Placement&#8221;) of the Convertible Note and Warrant. Boustead received a placement agent
fee of $320,000 at the closing of the Private Placement, representing 7.0% of the gross cash proceeds at the closing plus 1% in non-accountable
expenses. In addition, Boustead received a placement agent warrant to purchase 71,266 shares of common stock, representing 7.0% of the
warrant shares issued in the Private Placement After deducting the placement agent fee and our estimated expenses associated with the
Private Placement, our estimated net cash proceeds at the closing were approximately $[ ].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Purchase
Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement contains certain representations and warranties, covenants and indemnities customary for similar transactions. Under
the Purchase Agreement, we also agreed to the following additional covenants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
    long as the Senior Convertible Note remains outstanding, we will not effect or enter an agreement to effect any variable rate transaction
    other than a bona fide at-the-market offering or equity line of credit.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
    we obtained majority stockholder consent approving the offering and the issuance of common stock upon conversion of the Convertible
    Note and exercise of the Warrant, as is required under the rules of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), we are required
    to file an information statement on Schedule 14C (the &#8220;Information Statement&#8221;) informing all stockholders of the action
    and mail such Information Statement to all stockholders within 70 days of closing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we granted the Investor participation rights in future equity and equity-linked offerings of securities, subject to certain
limited exceptions, during the two years after the later of (a) the closing or (b) the date the Investor Note no longer remains outstanding,
in an amount of up to 30% of the securities being sold in such offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Senior
Convertible Note</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Senior Convertible Notes were issued to the Investor on July 15, 2020 and mature on December 31, 2021 (subject to extension in certain
circumstances, including bankruptcy and outstanding events of default).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
on the earlier of (x) the date this Registration Statement is declared effective by the SEC and (y) February 28, 2023, then on the
first trading day of the month for each month thereafter, and on the maturity date (each, an &#8220;Installment Date&#8221;),
subject to certain exceptions and unless deferred as described below, the Company is required to make monthly amortization payments
equal to 1/26<sup>th</sup> of the unrestricted principal (and related unrestricted original issue discount) and interest of the
Senior Convertible Notes payable (the &#8220;Installment Amount&#8221;), which must be satisfied in cash at a redemption price equal
to 105% of such Installment Amount (each, an &#8220;Installment Redemption&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the noteholder may, at its sole option, elect to defer any Installment Amount until a subsequent Installment Date selected
by the noteholder, provided that any such deferred amounts shall not continue to accrue interest unless the deferral is at the request
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Senior Convertible Notes each bear interest at a rate of 5% per annum and, upon any conversion or redemption, shall include a make-whole
of interest from such date of determination through the maturity date. After the occurrence and during the continuance of an Event of
Default (as defined in the Senior Convertible Notes), the Senior Convertible Notes will accrue interest at the rate of 15% per annum.
See &#8220;<i>Events of Default</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion;
Alternate Conversion upon Event of Default</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Convertible Note is convertible, at the option of the noteholder, into shares of our common stock at the lower of (i) $2.35 per share,
(ii) (i) $2.35 per share, (ii) 90% of the three lowest VWAPs in the 15 trading days prior to the payment date or (iii) 90% of the VWAP
on the trading day prior to the payment date. The conversion price is subject to full ratchet antidilution protection upon any subsequent
transaction at a fixed price lower than the conversion price then in effect and standard adjustments in the event of any stock split,
stock dividend, stock combination, recapitalization or other similar transaction. If we enter into any agreement to issue (or issue)
any variable rate securities, other than a bona fide at-the-market offering or equity line of credit, the noteholder has the additional
right to substitute such variable price (or formula) for the conversion price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default has occurred under the Senior Convertible Notes, the noteholder may elect to alternatively convert the Convertible
Notes at a redemption premium of 115% of the conversion amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion
Limitation and Exchange Cap</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
noteholder will not have the right to convert any portion of the Convertible Note, to the extent that, after giving effect to such conversion,
the noteholder (together with certain related parties) would beneficially own in excess of 4.99% of the shares of our common stock outstanding
immediately after giving effect to such conversion. The noteholder may from time to time increase this limit to 9.99%, provided that
any such increase will not be effective until the 61<sup>st</sup> day after delivery of a notice to us of such increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, until such time as we complete the Information Statement mailing to our stockholders notifying them that we have obtained the
approval of a majority of our stockholders as required by Nasdaq, we are prohibited from issuing any shares of common stock upon conversion
of the Convertible Notes\ or otherwise pursuant to the terms of the Convertible Note, if the issuance of such shares of common stock
would exceed 19.99% of our outstanding shares of common stock as of January 11, 2023 or otherwise exceed the aggregate number of shares
of common stock which we may issue without breaching our obligations under the rules and regulations of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Events
of Default</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Convertible Note includes certain customary and other Events of Default, including, among other things, failure to maintain an effective
registration statement with capacity to issue an offering amount equal to at least 300% of principal, the breach of the financial covenant
described in &#8220;Covenants&#8221; below and maintaining our Nasdaq listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with an Event of Default, the noteholder may require us to redeem in cash any or all of the Senior Convertible Notes. The
redemption price will equal 115% of the outstanding principal of the Senior Convertible Note to be redeemed, and accrued and unpaid interest
and unpaid late charges thereon, or an amount equal to market value of the shares of our common stock underlying the Senior Convertible
Note, as determined in accordance with the Senior Convertible Note, if greater.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
of Control</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a Change of Control (as defined in the Senior Convertible Notes), a noteholder may require us to redeem all or any portion
of the Senior Convertible Notes. The redemption price per share will equal the greatest of (i) 115% of the outstanding principal of the
Senior Convertible Note to be redeemed, and accrued and unpaid interest and unpaid late charges thereon, (ii) 115% of the market value
of the shares of our common stock underlying the Convertible Note, as determined in accordance with the terms of the Convertible Note,
and (iii) 115% of the aggregate cash consideration that would have been payable in respect of the shares of our common stock underlying
the Convertible Note, as determined in accordance with the terms of the Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent
Placement Optional Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time after the earlier of the date a noteholder becomes aware of any placement by us of equity or equity-linked securities or the
date of consummation of such a placement, subject to certain limited exceptions, the noteholder will have the right to have us redeem
a portion of each Senior Convertible Note not in excess of 30% of the net proceeds from such placement at a redemption price of 100%
of the portion of the Convertible Note subject to redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Covenants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be subject to certain customary affirmative and negative covenants regarding the incurrence of certain indebtedness, the existence
of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer
of assets, among other matters. We also will be subject to a financial covenant that requires us to maintain available cash in the amount
of $[ ]at the end of each fiscal quarter, subject to a right to cure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Company
Optional Redemption Rights</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may redeem the Convertible Notes at a price equal to 105% of the outstanding principal of the Senior Convertible Notes (or, if greater,
the market value of the shares underlying the Senior Convertible Notes) to be redeemed and accrued and unpaid interest and unpaid late
charges thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrant</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Convertible Note, we issued a Warrant exercisable for four (4) years for the purchase of an aggregate of up to 1,018,079
shares of common stock (the &#8220;Warrant Shares&#8221;), at an exercise price of $2.35 per share. The number of Warrant Shares and
exercise price are each subject to adjustment as provided under the terms of the Warrant. If, at the time of exercise of the Warrant,
there is no effective registration statement registering, or no current prospectus available for, the issuance of the Warrant Shares
to the Investor, and the registration statement is not subject to SEC review and the Company has otherwise affirmatively failed to maintain
such registration statement&#8217;s effectiveness, then the Warrant may also be exercised, in whole or in part, by means of a &#8220;cashless
exercise.&#8221; The Warrant may not be exercised if, after giving effect to the exercise the Investor, would beneficially own in excess
of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares. At
the Investor&#8217;s option, the ownership limitation blocker may be raised or lowered to any other percentage not in excess of 9.99%,
as applicable, except that any raise will only be effective upon 61-days&#8217; prior notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company issues or sells, or the Company publicly announces the issuance or sale of, any shares of Common Stock, or convertible securities
or options issuable or exchangeable into Common Stock (a &#8220;New Issuance&#8221;), under which such Common Stock is sold for a consideration
per share less than the exercise price then in effect, the exercise price of the Warrant will be adjusted to the New Issuance price in
accordance with the formulas provided in the Warrant. Any such adjustment will not apply with respect to the issuance of Excluded Securities
(as defined in the Warrant). Upon any adjustment to the exercise price, the number of Warrant Shares that may be purchased upon exercise
of the Warrant will be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for
the adjusted number of Warrant Shares will be the same as the aggregate exercise price in effect immediately prior to such adjustment.
In addition, if the Company enters into a Fundamental Transaction (as defined in the Warrants) at any time that a Warrant is outstanding,
then, upon any subsequent exercise of the Warrant, the Investor will have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which the Warrant is exercisable
immediately prior to such Fundamental Transaction, provided, further, that if holders of common stock are not offered or paid any consideration
in such Fundamental Transaction, such holder of common stock will be deemed to have received common stock of the successor entity (which
entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Registration
Rights Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Registration Rights Agreement, dated as of January 11, 2023, between the Investor and us, we have granted certain registration rights
to the noteholders and warrantholder. The Registration Rights Agreement requires us to have the registration statement of which this
prospectus is a part declared effective by the 60<sup>th</sup> day following the date of the Registration Rights Agreement (of March
11, 2023), or the 90<sup>th</sup> day (or April 10, 2023) following the date of the Registration Rights Agreement in the event such registration
statement is subject to SEC review. It also grants the Investor customary &#8220;piggyback&#8221; registration rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional
Information</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing is only a summary of the material terms of the Purchase Agreement, the Convertible Note, the Warrant, the Registration Rights
Agreement and the other ancillary transaction documents (collectively, the &#8220;Transaction Documents&#8221;), and does not purport
to be a complete description of the rights and obligations of the parties thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of the Transaction Documents is qualified in its entirety by reference to the forms of such agreements, which are incorporated
as exhibits to the Registration Statement of which this prospectus forms a part and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summary and the exhibits hereto also are not intended to modify or supplement any disclosures about us in our reports filed
with the Securities and Exchange Commission. In particular, the agreements and the related summary are not intended to be, and should
not be relied upon, as disclosures regarding any facts and circumstances relating to the Company or any of its subsidiaries or affiliates.
The agreements contain representations and warranties by us, which were made only for purposes of that agreements and as of specified
dates. The representations, warranties and covenants in the agreements were made solely for the benefit of the parties to the agreements&#894;
may be subject to limitations agreed upon by the contracting parties, including being subject to confidential disclosures that may modify,
qualify or create exceptions to such representations and warranties&#894; may be made for the purposes of allocating contractual risk
between the parties to the agreements instead of establishing these matters as facts&#894; and may be subject to standards of materiality
applicable to the contracting parties that differ from those applicable to investors. In addition, information concerning the subject
matter of the representations, warranties and covenants may change after the date of the agreements, which subsequent information may
or may not be fully reflected in our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S1_002"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of our securities offered by the selling stockholder under this prospectus. All the shares
sold under this prospectus will be sold or otherwise disposed of for the account of the selling stockholder, or its pledgees, assignees
or successors-in-interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant will not, upon effectiveness (and continued effectiveness) of the registration statement of which this prospectus is a part,
be eligible for cashless exercise. There is no assurance that the Warrant will ever be exercised for cash. However, assuming the exercise
of the Warrant for cash in full, at an exercise price of $2.35 per share, the selling stockholder would pay us aggregate consideration
of $2,392,486, for the issuance of shares of common stock thereunder. The proceeds to us of such Warrant exercise, if any, will not be
subject to any restrictions. We plan to use any cash received from the exercise of the Warrant to support our clinical studies and for
general corporate purposes. We cannot precisely estimate the allocation of the proceeds from any exercise of the Warrant for cash. Accordingly,
in the event the Warrant is exercised for cash, our management will have broad discretion in the application of the proceeds of such
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="z_001"></span>SELLING
STOCKHOLDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock being offered by the selling shareholders are those issuable to the selling shareholders pursuant to the terms
of certain of the Company&#8217;s promissory notes and accompanying warrants. For additional information regarding the issuances of those
notes and accompanying warrants, see &#8220;Private Placement of Notes&#8221; above. We are registering the shares of common stock in
order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the notes and
accompanying warrants, the selling shareholders have not had any material relationship with us within the past three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling shareholders and other information regarding the beneficial ownership of our common stock by each of the
selling shareholders. The second column lists the number of shares of common stock beneficially owned by each selling shareholder, based
on its ownership of the notes and accompanying warrants, as of January [ ], 2023, assuming the conversion of the notes and accompanying
warrants held by the selling shareholders on that date, without regard to any limitations on conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third column lists the shares of common stock being offered by this prospectus by the selling shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale
of 300% of the maximum number of shares of common stock issuable pursuant to the notes and accompanying warrants, determined as if the
notes and accompanying warrants were converted in full as of the trading day immediately preceding the date this registration statement
was initially filed with the Commission, each as of the trading day immediately preceding the applicable date of determination and all
subject to adjustment as provided in the registration rights agreement, without regard to any limitations on conversion in the notes
and accompanying warrants. The fourth column assumes the sale of all of the shares offered by the selling shareholders pursuant to this
prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the notes and accompanying warrants, a selling shareholder may not be issued shares under the notes or accompanying warrants
to the extent such issuance would cause such selling shareholder, together with its affiliates and attribution parties, to beneficially
own a number of shares of common stock which would exceed 4.99% of our then outstanding shares of common stock following such conversion.
The number of shares in the second column does not reflect this limitation. The selling shareholders may sell all, some or none of their
shares in this offering. See &#8220;Plan of Distribution.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Selling Shareholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Owned Prior to
    Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
    Number of Shares to be Offered for the Account of the Selling Stockholder<sup>&#160;(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Owned After the
    Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Owned After the Offering**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Alto Opportunity Master Fund, SPC &#8211; Segregated Master Portfolio B<sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">10,762,682</td><td style="width: 1%; text-align: left"><sup>(3)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">--</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">--</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">* <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage of ownership before the offering is calculated based on 13,603,129 shares outstanding as of January 17, 2023. The percentage
of ownership after the offering assumes the issuance of all of the shares underlying the Convertible Note and Warrant that are offered
for resale hereby, and the sale by such selling stockholder of all of the shares offered for resale hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Ayrton Capital LLC, the investment manager to Alto Opportunity Master Fund,
SPC - Segregated Master Portfolio B, has discretionary authority to vote and dispose of the shares held by Alto Opportunity Master Fund,
SPC - Segregated Master Portfolio B and may be deemed to be the beneficial owner of these shares. Waqas Khatri, in his capacity as Managing
Member of Ayrton Capital LLC, may also be deemed to have investment discretion and voting power over the shares held by Alto Opportunity
Master Fund, SPC - Segregated Master Portfolio B. Ayrton Capital LLC and Mr. Khatri each disclaim any beneficial ownership of these shares.
The address of Ayrton Capital LLC is 55 Post Rd West, 2nd Floor, Westport, CT 06880.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The beneficial ownership of Alto Opportunity Master Fund B consists entirely of shares underlying the Senior Convertible Note and Warrant.
The amounts set forth in the table assume the immediate conversion of the Convertible Senior Note and exercise of the Warrant. Without
giving effect to the 4.99% limitation contained in the Notes, the maximum number of shares into which the Senior Convertible Notes and
Warrant held by Alto Opportunity Master Fund B would be convertible and exercisable, respectively, would be approximately 3,248,201 shares
of common stock, based on an assumed price of $1.39 per share, the alternate conversion price under the Senior Convertible Notes and
exercise of the Warrant for 1,018,079 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
In accordance with the terms of the Purchase Agreement with the Investor, assumes 300% of the shares issuable under the conversion ratios
set forth under item (2) above are required for full conversion of the Convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="z_002"></span>PLAN
OF DISTRUBTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Stockholder (the &#8220;<b>Selling Stockholders</b>&#8221;) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the Principal Market or any other stock exchange, market
or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                                         trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as
                                                         principal to facilitate the transaction;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
                                                         of short sales made in compliance with the securities purchase agreement among the Company and the Selling
                                                         Stockholders;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                                         transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a
                                                         stipulated price per security;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                                         the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933,
as amended (the &#8220;<b>Securities Act</b>&#8221;), if available, rather than under this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or
markdown in compliance with FINRA IM-2440.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short, subject to the terms of the securities purchase agreement between the
Company and the Selling Stockholders, and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Any broker-dealers or agents
that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in
connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of
the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder
has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person
to distribute the securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S1_003"></span>DIVIDEND
POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings
(if any) will be retained for the development of our business and no dividends will be declared or paid. Any future dividends will be
subject to the discretion of our board of directors and will depend upon, among other things, our earnings (if any), operating results,
financial condition and capital requirements, general business conditions and other pertinent facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S1_006"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following Management&#8217;s Discussion and Analysis should be read in conjunction with our financial statements and the related notes
thereto included elsewhere in this prospectus. The Management&#8217;s Discussion and Analysis contains forward-looking statements that
involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221;
&#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; and the like, and/or future-tense or conditional
constructions (&#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; etc.), or similar expressions, identify
certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause
actual results or events to differ materially from those expressed or implied by the forward-looking statements in this form. Our actual
results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several
factors including, but not limited to, those noted under &#8220;Risk Factors&#8221; in this prospectus. In addition, any compensation
disclosure contained in this prospectus regarding our officers and directors is likely to increase in the near term following completion
of the offering, and therefore all such disclosures made within this prospectus reflect historical facts and will not reflect forward
looking or anticipated compensation going forward. See the section entitled &#8220;Executive Compensation&#8221; below for a more detailed
discussion.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this
prospectus, except as required by U.S. federal securities laws.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
by Georgetown University Medical School faculty members, we are a discovery and development stage pharmaceutical company leveraging our
proprietary technology to develop novel therapies that are designed to cure cancer. Originally formed as Shuttle Pharmaceuticals, LLC
in 2012, our goal is to extend the benefits of cancer treatments by leveraging insights into cancer therapy with surgery, radiation therapy,
chemotherapy and immunotherapy. While there are several therapies being developed with the goal of curing cancer, one of the most effective
and proven approaches to this is radiation therapy (RT). We are developing a pipeline of products designed to address the limitations
of this current standard of cancer therapies. We believe that our product candidates will enable us to deliver cancer treatments that
are safer, more reliable and at a greater scale than that of the current standard of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
to date have focused on continuing our research and development efforts to advance Ropidoxuridine clinical testing and improved drug
formulation, to advance HDAC6 inhibitor (SP-2-225) preclinical development, and complete SBIR contract work on predictive biomarkers
of radiation response, as well as prostate cell lines for health disparities research. We have received SBIR contract funding from the
NIH for the aforementioned projects. The clinical development of Ropidoxuridine has shown drug bioavailability and a maximum tolerated
dose has been established for use in Phase II clinical trials. The radiation biomarker project and the health disparities project have
been completed. Changes in operational, administrative, legal and professional expenses related to our operations are set forth in more
detail in the discussion below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three months ended September 30, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September
    30,</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; padding-bottom: 1.5pt">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development, net of contract expense reimbursements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">669,038</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">186,958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">482,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">258</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">81,864</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,422</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75,442</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1175</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">70,566</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48,736</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,830</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">821,468</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">242,116</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">579,352</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">239</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense - related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,725</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,178</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(604,716</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(113</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(604,603</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">112,797</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(26,685</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">139,482</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on settlement of accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">328,687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">328,687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Forgiveness of PPP note payable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">62,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(62,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other Income (expense)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(176,957</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,155</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(202,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">998,425</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">216,961</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">781,464</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">360</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development &#8211; Net of contract expense reimbursements. </i>Research and development &#8211; net of contract expense reimbursements
(&#8220;R&amp;D&#8221;) was $669,039 for the three months ended September 30, 2022, as compared to $186,958 for three months ended September
30, 2021. For the three months ended September 30, 2022, the Company received $0 in reimbursements and incurred $669,038 in R&amp;D expenses.
For the three months ended September 30, 2021, reimbursement from the NIH totaled $211,455 and total expenses related to R&amp;D was
$398,413. Quarterly expenses increased by $579.352, or 239%, in the third quarter of 2022 primarily due to the first milestone payment
for TCG GreenChem of $450,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
related expenses were $220,801 in the three months ended September 30, 2021 as compared to $202,041 in the three months ended September
30, 2022. Compensation related expenses decreased from 55% of total R&amp;D in the three months ended September 30, 2021 to 30% for the
three months ended September 30, 2022. Subcontract work made up 39% of total R&amp;D expense in the three months ended September 30,
2021 and 67% of total R&amp;D expenses during the three months ended September 30, 2022. All other R&amp;D expenses were inconsequential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a breakdown of the actual costs and reimbursements received by the company for the three months ended September 30, 2022 and 2021,
and a breakdown of how such cost and reimbursements were distributed across research projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2022, total research and development costs were $669,038 for which all costs were funded by the
Shuttle. For the three months ended September 30, 2021, total R &amp; D costs were $398,413 for which 53% of the costs were allocated
to the NIH funded project (Topic 345) and Shuttle funded the remaining costs of $186,958, or 47% of the total costs. For the three months
ended September 30, 2021, total R&amp;D costs were $398,413 for which $211, 455 was reimbursed by NIH and the remaining costs were funded
by the Shuttle for a net R&amp;D loss of $186,958. Company funded R&amp;D activities increased in 2021 and decreased in 2022 due to NIH
no cost extensions required to complete contracted work and file the final reports before receiving payment from the NIH. In 2022, R&amp;D
activities increased with the new program with TCG GreenChem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Research and Development Projects</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R&amp;D,
    Net of Contract Expense Reimbursements </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
    Months</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Month Periods ending September 30, 2021 and 2022 (Q3)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Research &amp; Development</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 345</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shuttle Funded</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue and Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">NIH Reimbursement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(211,455</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(211,455</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,541</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Supplies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,007</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, Lab</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,742</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Expense total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">211,455</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">186,958</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">669,038</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">398,413</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">669,038</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">R&amp;D, Net of Contracts</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(186,958</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(669,038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(186,958</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(669,038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">53</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">47</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">100.0</td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Project
    352 reimbursements were not received in 2021 and research costs were Company funded through an NIH extension without cost Project
    345 reimbursement for the period of performance ending March 15, 2022, which reimbursement was received in April 2022</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the CEO and CMO are actively involved in the research and development activities, but neither receives a salary from the Company.
As such, research and development expenses are lower than might be incurred in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of costs to the NIH research project for the three months ended September 30, 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NIH
Cost Allocation for the 3-month Period Ending September 30, 2021</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
    </b>- $220,801, making up 55% of total R &amp; D, with 47% of all research costs allocated to Shuttle.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subcontracts
    - </b>$153,544, making up 39% of total R&amp;D, with 100% of costs allocated to Topic 345.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplies
    and Other Lab expenses - </b>$24,054, making up 6% of total R&amp;D expenses, with all costs allocated to Topic 345.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses. </i>General and Administrative expenses in the three months ended September 30, 2022 increased by $75,442,
from $6,422 in 2021 to $81,864 in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. During the three months ended September 30, 2022, legal and professional expenses increased by $21,830
or 45%. This increase in legal and professional fees was primarily due to increases in our expenses related to obtaining pre-IPO financing
and other expenses related to preparation for the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
(Income) Expense</i>. Other expense was $176,957 for the three months ended September 30, 2022, which consisted of $604,716 in interest
expense on convertible loans, $13,725 in interest expense on related party loans, a gain on change in warrant liability of $112,797,
and a gain on settlement of accounts payable of $328,687. Other income was $25,155 for the three months ended September 30, 2021, which
consisted of $113 in interest expense, $10,547 in interest expense on related party loans and a loss on change in warrant liability of
$26,685.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the nine months ended September 30, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Nine Months Ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; padding-bottom: 1.5pt">Revenue</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development, net of contract expense reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,048,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">579,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">505,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">326</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,813,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">754,453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,059,037</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">140</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,641</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,467</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(920,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(463</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(920,197</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,747</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,507</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other Income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(464,049</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(525,416</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(856</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,277,539</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">693,086</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,584,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">229</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development-Net of contract expense reimbursements. </i>Research and development-net of contract expense reimbursements (&#8220;R&amp;D&#8221;)
was $1,048,821 for the nine months ended September 30, 2022, as compared to $579,684 for nine months ended September 30, 2021. For nine
months ended September 30, 2022, the Company received $211,455 in reimbursement from the NIH contracts and incurred $1,260,276 in R&amp;D
expenses. For the nine months ended September 30, 2021, reimbursement from NIH totaled $422,910 and total expenses related to R&amp;D
were $1,002,594. The increase of $469,137, or 81%, is primarily related to the Company increasing R&amp;D spending as a result of funding
from the public offering and the NIH contracts ending. The no cost extension from the NIH ended on March 15, 2022, and the final report
to the NIH was filed and accepted, resulting in a payment of $211,455 during the nine months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expense reimbursements were $422,910 and $211,455 during the nine months ended September 30, 2021 and September 30, 2022, respectively.
NIH requires that milestones included in the fixed price contract be met, therefore, compensation related expenses continued in 2022
under the no cost extension from the NIH. Compensation related expenses were $667,281 in the nine months ended September 30, 2021 as
compared to $727,421 in the nine months ended September 30, 2022. Compensation related expenses increased from 74% of total R&amp;D in
the nine months ended September 30, 2021 as compared to 90.1% in the nine months ended September 30, 2022. Subcontract work made up 26%,
compensation made up 67%, and supplies and other expenses 8% of total R&amp;D expense in the nine months ended September 30, 2021. Subcontract
work made up 36%, compensation made up 58%, and supplies and other expenses 6% of total R&amp;D expense during the nine months ended
September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a breakdown of the actual costs and reimbursements received by the Company for the nine months ended September 30, 2022 and 2021,
and a breakdown of how such cost and reimbursements were distributed across research projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, total research and development costs were $1,260,276 for which $211,455 was paid by reimbursements
received from the NIH, leaving a net of $1,048,821. For the nine months ended September 30, 2021, total R&amp;D costs were $1,002,594
for which $422,910 was paid by reimbursements received from the NIH, leaving a net of $579,684. The Company funded R&amp;D activities
decreased in the nine months ended September 30, 2021 and increased during the nine months ended September 30, 2022 primarily due to
the funding provided by the public offering. A summary of the breakdown of costs is listed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Research and Development Projects</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R
    &amp; D, Net of Contract Expense Reimbursements </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
    Months</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
Month Periods ending September 30, 2021 and 2022 (Q3)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research &amp;
    Development</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 345</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shuttle Funded</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue and Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">NIH Reimbursement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(422,910</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(211,455</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(422,910</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(211,455</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,567</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">579,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">667,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,421</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Supplies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,206</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, Lab</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Expense total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">422,910</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">579,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,260,276</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,002,594</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,260,276</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">R&amp;D, Net of Contracts</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">211,455</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(579,684</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,260,276</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(579,684</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,048,821</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Project
    352 reimbursements were not received in 2021 and research costs were Company funded through an NIH extension without cost Project
    345 reimbursement for the period of performance ending March 15, 2022, which reimbursement was received in April 2022</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the CEO and CMO are actively involved in the research and development activities, but neither received a salary from the Company
prior to the completion of our initial public offering in September 2022. As such, research and development expenses for the nine months
ended September 30, 2022 are lower than might be incurred in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of costs to the NIH research project for the nine months ended September 30, 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NIH
Cost Allocation for the nine-month Period Ending September 30, 2021</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
    </b>- $667,281, making up 67% of total R&amp;D expenses, with $579,684 allocated to the Company. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subcontracts
    </b>- $256,400, making up 26% of total R&amp;D expenses. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
    costs </b>&#8211; $78,913, making up 8% of total R&amp;D costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses. </i>General and Administrative expenses increased by $84,828, from $19,883 in the nine months ended September
30, 2021 to $104,711 in the nine months ended September 30, 2022. The increase was primarily related to increases in insurance costs,
SEC and Nasdaq filing fees, processing fees and other expenses related to preparing for and closing on our IPO, which closed in September
2022. Website expenses during the nine months ended September 30, 2022 increased by $1,447 in order to maintain and update the Company&#8217;s
profile for the Company&#8217;s IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. Legal and professional expenses increased by $505,072, or 326%, primarily due to increases in fees related
to obtaining pre-IPO financing and expenses incurred related to preparing for the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
(Income) Expense</i>. Other expense was $464,049 for the nine months ended September 30, 2022, which consisted of $920,660 in interest
expense on convertible loans, $39,108 in interest expense on related party loans, a gain on change in warrant liability of $94,025, a
$328,687 gain on settlement of accounts payable, and a $73,007 gain on the forgiveness of the Company&#8217;s Paycheck Protection Program
loan. Other income was $61,367 for the nine months ended September 30, 2021, which consisted of $463 in interest expense, $31,641 in
interest expense on related party loans and a gain on change in warrant liability of $30,971, and a $63,054 gain on the forgiveness of
the Company&#8217;s Paycheck Protection Program loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years ended December 31, 2021 (Restated) and 2020</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations for the years ended December 31, 2021 (Restated) and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Years Ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Research and development, net of contract expense reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,021,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">161,772</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">860,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">532</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">684,684</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261,823</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">422,861</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,742,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,233,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">242</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest expense - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,771</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,176</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,841</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,859</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">579,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(256,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Gain on disposal of loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(296,210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">887,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">299</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,152,134</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(805,732</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(346,402</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development-Net of contract expense reimbursements. </i>Research and development-net of contract expense reimbursements was $1,021,808
for the year ended December 31, 2021, as compared to $161,772 for the year ended December 31, 2020. For the year ended December 31, 2021,
the Company received $505,377 in reimbursement from NIH contracts and incurred $1,527,185 in research and development expenses. For the
year ended December 31, 2020, reimbursement from the NIH totaled $1,258,141 and total expenses related to research and development was
$1,419,913. The increase of $860,036 or 532% is primarily related to the Company receiving $752,764 less in contract reimbursements in
2021 as compared to 2020. The lower contract reimbursements are due to the completion of Topic 345-Predictive-Biomakers and Phase 1 of
Topic 352-Prostate Health Disparity contracts in 2020. In 2021, the Company received $82,467 for Topic 352 Prostate Health Disparity
Phase 2 and $422,910 Topic 345-Predictive-Biomakers and Phase 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research and development expenses with the largest variances included compensation of $885,349, subcontractor expenses of $539,043, and
lab supply costs of $30,181 for the year end December 31, 2021, as compared to compensation of $888,001, subcontractor expenses of $403,409,
and lab supply costs of $57,355 for the year end December 31, 2020. Subcontractor expenses increased by $135,634, or 33.62%, between
2020 and 2021. These expenses increased as more subcontractor services were needed due to the Phase 2 NIH contracts and pending additional
financing. All other research and development expense variances between 2020 and 2021 are immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a breakdown of the actual costs and reimbursements received by the company for the years ended December 31, 2021 and 2020, and a breakdown
of how such cost and reimbursements were distributed across research projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Research and Development Projects</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development, Net of Contract Expense Reimbursements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Periods
ending December 31, 2020 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Research &amp; Development Revenue</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 345</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 352*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shuttle Funded</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">and Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">NIH Reimbursement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">845,820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">422,910</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">412,321</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">82,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1,258,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">505,377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">888,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">885,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">539,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">539,043</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Supplies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,181</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, Lab</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,969</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,179</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Expense total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">481,485</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">840,261</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">404,840</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">533,588</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">686,923</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,419,913</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,527,185</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Research and Development, Net of Contracts</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">364,336</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(417,351</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,481</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">82,467</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(533,588</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(686,923</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(161,772</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,021,808</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note:
The Project 352 final reimbursement was received in 2021 and research costs were company funded through an NIH extension without cost</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our CEO and CMO are actively involved in the research and development activities, but neither receives a salary from the Company.
As such, research and development expenses are lower than might be incurred in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses.</i> General and Administrative expenses decreased by $49,427, from $85,927 for the year ended December 31,
2020, to $36,500 for the year ended December 31, 2021. There were two changes that account for the decrease in expenses: (1) directors
and officers insurance decreased by $34,322 from $45,629 in 2020 to $11,308 in 2021; and (2) a decrease in travel and conference expenses
by $16,686 from $16,887 in 2020 to $202 in 2021. The decrease in costs for insurance was due to a negotiated reduction in premiums for
2021 and the reduction in the number of members serving on our board of directors from seven directors in 2020 to five directors in 2021.
Travel and conference fees decreased from 2020 to 2021 due to a shift to virtual investment conferences related to the ongoing Covid-19
pandemic and a change in company strategy from contacting investors through conferences in 2020 to contacting investors through introductions
made through an agreement with Boustead Securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. The 162% increase in legal and professional fees was primarily due to a non-cash payment of $420,000 for
business consulting services resulting from the transfer of 210,000 shares (105,000 shares on a post-split basis) of common stock from
a major shareholder, who is also the wife our Chairman and CEO, to a business consultant, and increases in accounting and consulting
fees of $684,684 for the year ended December 31, 2021 as compared to $261,823 for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (Expense).</i> Other income was $590,858 for the year ended December 31, 2021, which consisted of $3,841 for interest expense
on convertible loans, $46,947 interest expense on a loan-related party, gain on change in warrant liability of $579,146 and $62,500 gain
on the forgiveness of the PPP loan. Other expense was $296,210 for the year ended December 31, 2020, which consisted of $2,859 for interest
expense on convertible loans, $36,771 interest expense on a loan-related party and loss on change in warrant liability of $256,580.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
capital needs to date have been met by contributions from existing shareholders, as well as through private offerings of our securities,
SBIR contracts and other grants, and our public offering. In the nine months ended September 30, 2022, we raised a total of $10,696,228
through the sale of convertible notes, shares of common stock and warrants. In the year ended December 31, 2021, we raised a total of
$525,715 through the sale of convertible notes, warrants, and common shares. In addition, since inception, we have received a total of
$5,531,722 in SBIR contracts and other grants received primarily through the National Institutes of Health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we will continue to expend substantial resources for the foreseeable future on the completion of clinical development and
regulatory preparedness of our product candidates, preparations for a commercial launch of our product candidates, if approved, and development
of any other current or future product candidates we may choose to develop. These expenditures will include costs associated with research
and development, conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not able to enter
into planned collaborations, manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other
unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate
the actual amounts necessary to complete the development and commercialization of our current product candidates, if approved, or future
product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that additional financing will be available to us when needed, on favorable terms or otherwise. Moreover, any such
additional financing may dilute the interests of existing shareholders. The absence of additional financing, when needed, could cause
us to delay implementation of our business plan in whole or in part, curtail our business activities and seriously harm us and our prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,289,486</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">509,615</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,779,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,723</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">970,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,217,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,246,861</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Working capital (deficiency)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,319,016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,707,716</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,026,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(587</td><td style="padding-bottom: 2.5pt; text-align: left">%)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, total current assets were $9,289,486. Total current liabilities as of September 30, 2022, were $970,470, resulting
in working capital of $8,319,016. As of December 31, 2021, total current assets were $509,615. Total current liabilities as of December
31, 2021, were $2,217,331, resulting in a working capital deficit of $1,707,716 for the year ended December 31, 2021. The current assets
primarily resulted from $10,045,513 and $650,715 for a total of $10,696,228 cash received from the issuance of common stock and notes
payable, respectively, with a $50,000 note repaid to a related party during the period ended September 30, 2022 for net cash provided
by financing activities for the period of $10,646,228. The decrease in current liabilities is due to the repayment of notes payable,
forgiveness of the PPP loan, payment of dividends payable and payments on trades payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Nine Months Ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,030,587</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(165,185</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,865,402</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,129</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,646,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">193,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,453,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,416</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash on hand</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,120,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">144,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,975,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,191</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated positive cash flows from operating activities. For the nine months ended September 30, 2022, net cash flows used in
operating activities was $2,030,587, consisting of a net loss of $2,258,635, reduced by depreciation expense of $4,484, gain on change
in warranty liability of $94,025, amortization of right of use assets of $45,012, amortization of debt discount of $885,505, stock-based
compensation of $356,733, gain on forgiveness of the PPP loan of $73,007, gain on settlement of accounts payable of $328,687 and a net
change in working capital of $605,796. For the nine months ended September 30, 2021, net cash flows used in operating activities was
$193,007, consisting of a net loss of $693,086, adjusted for depreciation expense of $4,050, change in warranty liability of $30,971,
amortization of right of use assets of $45,408, stock-based compensation of $367,551, gain on forgiveness of the PPP of loan of $62,500,
and a net change in working capital of $209,363.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022 and 2021, we had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, we received $10,045,513 from the issuance of common shares and $650,715 from the issuance of
convertible notes. For the nine months ended September 30, 2021, we received $73,007 from the Paycheck Protection Program and $120,000
from the issuance of notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting
periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting
policies are described in more detail in the notes to our financial statements included elsewhere in this registration statement, we
believe that the following accounting policies are critical to understanding our historical and future performance, as these policies
relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most critical accounting policies and estimates relate to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development Expenses</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Lease Accounting</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Financial Instruments</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    Taxes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development expenses are offset by contract receivable payments from an NIH SBIR contract that supports this scientific research.
This is stated in the financials as research and development-net of contract expense reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Lease Right-of-use Assets and Operating Lease Liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease
term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair
value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based
derivative financial instruments, we use a Binomial Simulation model to value the derivative instruments at inception and on subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. As of June 30, 2022, our only derivative financial instrument was an embedded warrant feature associated with
warrants issuable to our Series A convertible preferred stockholders upon completion of our initial public offering or public listing
due to certain provisions that allow for a change in the warrant value based on fluctuations of our fair value of common stock at the
date of issuance of the warrant based on certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S1_007"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy
(RT) is one of the most effective modalities for treating cancers. We are developing a pipeline of products designed to address limitations
of the current cancer therapies as well as to extend to the new applications of radiation therapy. We believe that our product candidates
will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of
care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates include Ropidoxuridine, Extended Bio-availability Ropidoxuridine (IPdR/TPI), and a platform of HDAC inhibitors (SP-1-161,
SP-2-225 and SP-1-303). We have advanced Ropidoxuridine through a Phase I clinical trial using non-dilutive NIH SBIR contracts and are
currently preparing a Phase II study that we intend to commence in 2022. We also plan to submit investigational new drug applications
(INDs) for the extended Bio-availability Ropidoxuridine with the goals of initiating Phase I clinical trials in 2023, leveraging the
outcomes of the Phase I clinical study results of Ropidoxuridine. We have applied for and received FDA approval of Orphan designation
for Ropidoxuridine and RT for treating brain cancer (glioblastoma). In addition, we plan to continue to develop our pre-clinical products
SP-1-161, SP-2-225 and SP-1-303 with the goal of submitting INDs in 2023 and 2024. We believe our management team&#8217;s expertise in
radiation therapy, combined modality cancer treatment and immuno-oncology will help drive the development and, if approved, the commercialization
of these potentially curative therapies for patients with aggressive cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncology has gone through transformative technological innovation over the last several years to better define tumors, allow improved
shaping of radiation delivery and support dose escalation with shorter courses of treatment. Furthermore, achieving higher dose distributions
within tumor volumes has reached a practical plateau, since cancers are frequently integrated with or surrounded by more sensitive normal
tissues and further dose increases risk of tissue necrosis. To increase cancer cures at maximally tolerated radiation doses, pharmacological
and biological modifications of cells are needed to sensitize cancers, protect normal tissues, and stimulate the immune system to react
against antigens produced by irradiated, damaged cancer cells. Drugs that show sensitizing properties, or the ability to make cancer
cells more sensitive to radiation, offer a solution to this problem. Currently, such drugs are used off-label, and many have inherent
toxicities since they were designed for direct cancer treatments and not for sensitization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our products with the goal of addressing the unmet need in cancer treatment for a commercially marketable radiation response
modifier solution that leads to greater sensitivity of cancer cells to ionizing radiation therapy. The goal of our products is to increase
the therapeutic index for patients receiving radiation and to decrease radiation-related toxicities in patients with solid tumors. Our
products operate across three areas related to the treatment of cancer with RT:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitization
    of growing cancer cells, rendering them more susceptible to the effects of radiation therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the immune system to kill any remaining cells after RT.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology allows for the creation of an inventory of products for radiation sensitizing, immune modulation, and protection
of healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing a pipeline of small molecule radiation sensitizers and immune response regulating drugs. Our most advanced product
candidate is Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties in preclinical
studies. In addition to our clinical study-ready candidate, we have a pipeline of complimentary product candidates that we are developing
to address a host of solid tumor cancer indications. Our pipeline is represented in the diagram below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_007.jpg" alt="" style="height: 204pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timeline
for clinical phase (Ropidoxuridine) and pre-clinical phase (HDAC inhibitors) pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidates include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    (IPdR)</span></b> is our lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and
    sarcomas. Phase I clinical trial results supported by Shuttle Pharma and the NCI (CTEP) were reported at the 30th EORTC-NCI-AACR
    Symposium in November 2018 and in a full report in the medical journal, Clinical Cancer Research, in July 2019, by our SBIR subcontractor.
    Eighteen patients completed dose escalations to 1,800 mg/day for 30 days, establishing the maximum tolerated dose (MTD) of 1,200
    mg/day in combination with RT. Four partial responses, nine stable disease and one progressive disease in target lesions were reported.
    Four patients did not have measurable disease and, as a result, were not evaluable. These Phase I trial results demonstrate oral
    bioavailability and an MTD of 1,200 mg per day for 28 days for use in combination with radiation for Phase II clinical trials in
    brain tumors and Phase II clinical trials in sarcomas and/or unresectable pancreatic cancers. These disease sites are eligible for
    orphan disease designations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    and Tipracil (IPdR/TPI)</span></b> is a new combination formulation demonstrating extended bioavailability after oral administration
    in an animal model system. The IPdR/TPI formulation will be developed for use as a radiation sensitizer of stage II and stage III
    rectal cancers with an endpoint of pathologic complete response rate (pCR) of greater than 40% as the therapeutic target. The pCR
    is recognized as a surrogate of survival in patients with solid tumors. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-161
    </span></b>is Shuttle Pharma&#8217;s pre-clinical candidate lead HDAC inhibitor product. This pan HDAC inhibitor initiates the mutated
    in ataxia-telangiectasia (ATM) response pathway. Using rational drug design, we discovered HDAC inhibitors and ATM activators capable
    of radiation sensitizing cancer cells and protecting normal cells. These candidate drugs may serve as direct chemotherapeutic agents
    or as radiation sensitizers for treating cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225
    </span></b>is Shuttle Pharma&#8217;s pre-clinical class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6. SP-2-225
    has effects on the regulation of the immune system. The interactions of RT with the immune response to cancers are of great current
    interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. With the introduction of check-point
    inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response following RT is of significant
    clinical and commercial interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
    </span></b>is Shuttle Pharma&#8217;s pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases
    HDAC1 and HDAC3 and is a member of the class I HDAC family. SP-1-303 data show direct cellular toxicity in ER positive breast cancer
    cells. Furthermore, SP-1-303 increases PD-L1 expression.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Approach</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have established a leadership position in radiation sensitizer discovery and development. Over approximately six years
of research, we have identified two clinical phase product candidates and discovered new pre-clinical molecules using our proprietary
platform technologies to increase the therapeutic index for patients receiving radiation for treatment of solid tumors. Our development
strategy has four key pillars: (1) to improve the efficacy of RT by demonstrating improved disease-free survival rates in patients who
undergo radiation therapy, (2) reduce the amount of radiation needed for a favorable tumor response, thereby limiting the potential for
radiation related toxicities to healthy cells, (3) decrease the extent of surgery needed to remove cancers and improve quality of life,
and (4) leverage our next generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T
therapies and other personalized medicines targeting cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
propose to perform Phase I and Phase II clinical trials to advance our clinical product candidates. In addition, candidate HDAC inhibitor
molecules will be tested, and IND-enabling studies will be performed to prepare for Phase I clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have been awarded three SBIR contracts from the NIH to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    IPdR as a radiation sensitizer for the treatment of gastro-intestinal cancers, in combination with radiation therapy. This funding
    provided partial support for the Phase I clinical trial of Ropidoxuridine and RT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell cultures from African-American men, with donor matched normal prostate cells, with the goal of establishing
    50 pairs for accelerating research to reduce prostate cancer health disparities in African-American men. This project was funded
    under &#8220;Moonshot&#8221; designation and Shuttle Pharma is eligible to submit an application for additional SBIR (Phase IIb)
    funding to establish the infrastructure required to expand and distribute cells for research purposes. Cells from African-American
    patients are distributed to investigators who are conducting health disparities research.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    predictive biomarkers for determining outcomes for prostate cancer patients following treatment with SBRT. This SBIR-funded project
    was completed on March 15, 2022 and Shuttle Pharma is eligible to apply for additional funding through the SBIR (Phase IIb) mechanism
    to de-risk clinical validation to develop the predictive biomarkers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
three SBIR funded projects have been completed. The Company is eligible to apply for SBIR Phase IIb funding to &#8220;bridge&#8221; the
funding gap should Shuttle Pharma elect to advance the &#8220;Moon shot&#8221; health disparities or the predictive biomarker project.
The NIH SBIR program is designed to encourage small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;)
that has the potential for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key
elements of our strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. </b>To date, there is one drug (Cetuximab, a monoclonal
    antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining
    FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expand
    our leadership position within radiation sensitizers</b>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</b>. We have built our current product
    pipeline through in-house development, partnerships with leading academic institutions and through successful in-licensing deals.
    We will continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other
    biotechnology companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability
    of clinical success, including programs beyond our target franchise areas and current technology footprint.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invest
    in our HDAC platform technology and maximize its utility across cancer therapies</b>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization and normal tissue radiation protection. In addition, based on the data we have obtained
    thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform technology, as well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enter
    into collaborations to realize the full potential of our platform</b>. The breadth of our HDAC technology platform enables other
    therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our
    platform to maximize applications for cancer treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Radiation
Therapy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant
sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination
treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external
beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic
agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater
effectiveness, increased quality and better tolerability for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
&#8220;chemo-radiation&#8221; treatments are established in cancers of the head and neck, esophagus, lung, stomach, breast, brain, pancreas,
rectum and uterine cervix. The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the
tumor, as compared to surrounding normal tissues. It would have predictable pharmacokinetics for timing with radiation therapy and could
be administered with every radiation treatment approach. The ideal radiation sensitizer would have minimal toxicity or manageable enhancement
of radiation toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the introduction
of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns. New agents have
been introduced, including bevacizumab (Avastin&#174;, Roche), panitumumab (Vectibix&#174;, Amgen), temozolomide (Temodar&#174;, Merck)
and cetuximab (Erbitux&#174;, Eli Lilly/Imclone), with potential as radiation sensitizing agents (though all but cetuximab are used off
label); and all are recommended by the NCCN&#174; (National Comprehensive Cancer Network) in clinical practice guidelines for use in combination
with established therapies such as FOLFOX (leucovorin, 5-FU, oxaliplatin), CapeOX (capecitabine, oxaliplatin) and FOLFIRI (leucovorin,
5-FU, irinotecan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growth in the number of patients with cancers is being driven by an aging population and improved diagnostic tools. According to the
National Cancer Institute (NCI), more than half (~50 - 60%) of all cancer patients undergo some type of radiotherapy during the course
of their treatment. Confirming the patient estimate from the NCI, the American Society for Therapeutic Radiology and Oncology
(ASTRO) factsheet states approximately 67% of approximately 1.25 million cancer patients are treated with radiation therapy
annually, either one or more times during the course of treatment. In addition, in a study published by the Journal of Clinical
Oncology in 2016, it is estimated that the number of cancer patients needing radiation therapy will increase by 22% in the next 10
years. (<i>See &#8220;The Future of Radiation Oncology in the United States From 2010 to 2020: Will Supply Keep Pace With
Demand?&#8221; Benjamin D. Smith, Bruce G. Haffty, Lynn D. Wilson, Grace L. Smith, Akshar N. Patel, and Thomas A. Buchholz Journal
of Clinical Oncology 2010 28:35, 5160-5165).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Society of Clinical Oncology (ASCO) estimates more than 80% of cancers in the U.S. occur in people in the age group of 50 and
above with over 60% of cancers occurring in those 65 and over. (<i>See</i>, 2018 Clinical Cancer Advances Report, American College of
Clinical Oncology, 2018). For example, according to the American Cancer Society (ACS), more than 90% of colorectal cancer patients are
individuals aged 50 years and older, with approximately 40% of all cases occur in patients aged 75 years and over. The Colon Cancer Alliance
estimates that 90% of new cases and 95% of deaths from colorectal cancers occur in people aged 50 or older. Also, the U.S. Census estimates
that the age group of 65-84 will grow by 23% within the next five years, indicating a likely increase in the overall number of cancer
patients in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the number and rate of cancers occurring in the United States in 2018:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
New Cancer Cases in the US</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Male</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Female</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%">Prostate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">174,650</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%">Breast</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">268,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">38</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lung &amp; bronchus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Lung &amp; bronchus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Colon &amp; rectum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Colon &amp; rectum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Urinary bladder</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Uterine corpus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Melanoma of the skin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Melanoma of the skin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kidney &amp; renal pelvis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Thyroid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-Hodgkin lymphoma</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Non-Hodgkin lymphoma</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Oral cavity &amp; pharynx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Kidney &amp; renal pelvis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Leukemia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Pancreas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Pancreas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Leukemia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All sites</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">677,720</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">All sites</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">701,860</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018
Clinical Cancer Advances Report, American College of Clinical Oncology, 2018</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colon
Cancer Alliance. Colorectal Cancer Survival Rates from Facts and Figures, 2017. Chicago, IL; 2017</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. 2019 estimated incidence, deaths and five-year survival rate of cancer patients responsive to radiation therapy is significant (ACS
Facts &amp; Figures, 2019). The top cancers responsive to radiation are shown, based on the number of newly diagnosed patients. The incidence
rates for some cancers are increasing by approximately 1-2% per year in the U.S. The number of newly diagnosed patients is significant
and growing due to the aging of the population and improved diagnostic techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the listed cancers illustrate the opportunity presented for radiation sensitizers. Of note is the low five-year survival of pancreas,
brain, lung and esophagus cancers&#8212;all are candidates for Shuttle&#8217;s pipeline of radiation sensitizing compounds. Cancers with
low survival rates are of interest since they show a high unmet need for new therapeutics and an opportunity for Shuttle to gain significant
uptake of their pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that are challenges and may restrict growth in the radiation sensitizer market include the safety and tolerability of many of the newer
agents with radiation sensitizing properties; a regulatory environment that engenders greater levels of scrutiny of clinical practice
issues; the high cost of newer agents; and the changing (and more restrictive) reimbursement environment in radiation oncology through
CMS (Center for Medicare and Medicaid Services) and private payors. These factors may negatively impact the potential for growth in the
US market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the drugs used &#8220;off-label&#8221; as radiation sensitizers currently require close scrutiny of their potential for side effects
that can affect the safety and tolerability of their use with patients. All of the current agents carry significant potential for side
effects that can affect patients&#8217; therapies and quality of life. Radiation sensitizing agents can cause both acute and chronic
side effects in patients. Side effects can vary from person to person depending on age, sex, type of cancer, dose given per day, total
dose given, and the patient&#8217;s general medical condition. Some common side effects of currently used radiation sensitizers include
leukopenia, skin damage, hair loss, fatigue, bladder problems, nausea, fibrosis, memory loss, infertility, and enhanced risk of developing
a second cancer, which may arise as a result of the patient&#8217;s weakened immune system due to cytotoxic drugs used in treatment or
when newer biologic agents cause the over-production of specific cytokines or proteins, which can lead to developing secondary cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past five years, the FDA has taken an increasingly conservative approach to the approval of new agents for oncology treatment. There
is greater scrutiny of results from clinical trials regarding progression free survival, overall survival, and safety and tolerability
of new agents. Restrictions such as black box warnings and REMS (Risk Evaluation and Migration Strategies) are being applied to more
new products over the past five years compared to the previous five years. These restrictions require physicians to be more careful in
evaluating the use of newer agents and newer diagnostic tools to select the most appropriate patients for newer approved agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the new agents are molecularly targeted therapies that are biologic in their development and manufacturing. The cost of the newer
agents can be significant. For example, the cost for Avastin for one treatment course as a radiation sensitizer is estimated at $9,000-12,000
according to one Key Opinion Leader in the U.S. (Carl Schmidt, Consultant, Shuttle Pharmaceuticals Holdings, Inc., Business Plan 2018).
Recently, a CAR-T gene therapy from Novartis was launched with a yearly cost of $475,000. Further, as many private payors scrutinize
the cost and appropriate use of newer drugs, they require physicians to provide justification for use of newer agents through prior authorization
requests, use of step therapy and to follow guidelines that delay treatment, increase administrative costs and limit the therapeutic
choices for physicians and hospitals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
payors for radiation oncology therapies such as CMS have instituted reimbursement reductions that potentially affect the overall cost
of therapy and can limit the acceptance of newer agents. With CMS announced reductions in reimbursement for radiation oncology, there
is increased pressure to find a more potent radiation sensitizer agent with reduced side effects, and greater cost-effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escalating
healthcare spending is adding pressure on government and commercial payors to contain drug costs. While the oncology space is arguably
not as tightly managed by payors as other therapeutic areas, utilization management of costly cancer therapeutics has become an increasing
priority for US payors, especially with the advent of biologics. Payors (and market access agencies in the EU) will most often restrict
high-cost drugs, drugs with limited or no survival benefits, and drugs deemed to be at high risk for widespread off-label use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
efforts at cost containment by insurers (which often require patients to first be prescribed lower cost drugs in order to determine effectiveness
prior to allowing for reimbursements for more expensive (or less cost effective) drugs), payors are also looking toward implementing
clinical pathways as a way to maintain or improve health outcomes while lowering costs. Clinical pathways are designed to address the
limitations of prior authorization and of reduced fee schedules, offering more durable cost containment to payors. These pathways may
lead to cost savings by encouraging the use of generics, streamlining treatment choices, and reducing side effects while maintaining
outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Engineered
Radiation Sensitizers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for radiation sensitizers in selected cancer types is defined by the need to improve local-regional tumor control. Treatment regimens
have been developed to address patient needs for tumor control and quality of life. Since the initial applications of Ropidoxuridine
and selective HDAC inhibitors are as adjuncts to the standard of care for the treatment of radiation responsive cancers, the unmet needs
of the market lie in the potential for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in efficacy of radiation treatments as determined by overall survival, progression free survival and response rates in comparison
    to currently used &#8220;off-label&#8221; sensitizer drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in radiation
    doses needed to affect a positive clinical response for the patient.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in the surgical
    extent that is needed to remove residual cancer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement in quality
    of life outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
sources have estimated that more than 800,000 patients in the US are treated with radiation therapy for their cancers. According to the
American Cancer Society about 50% are treated for curative purposes and the balance for palliative care. The market opportunity for radiation
sensitizers lies with the 400,000 patients treated for curative purposes. The number of patients being treated with RT is expected to
grow by more than 22% over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug therapy (off
label at this time) of $12,000 per patient&#8212;the market size would be in excess of $4.0 billion. This would represent about 4% of
the annual cost of cancer care in the US.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past two decades, developments in the field of oncology have resulted in an increase in the number of clinical trials of marketed
products that exhibit radiation sensitizing properties. The following are a few examples of recently approved products that exhibit radiation
sensitizing properties: topotecan (Hycamtin&#174;) was approved for ovarian and small-cell lung cancer and also in cervical cancer when
used in combination with cisplatin. Irinotecan (Camptosar&#174;) is used for metastatic colorectal carcinoma, trastuzumab (Hercepetin&#174;)
for breast cancer, and gefitinib (Iressa&#174;) for locally advanced non-small-cell lung cancer. However, the claims on radiation sensitization
are anecdotal in the scientific literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, clinical trials are in progress to develop novel molecules (such as poly (ADP-ribose) polymerase (PARP), histone deacetylase
(HDAC) inhibitors (such Zolinza&#174; (vorinostat) and heat-shock protein 90 (hsp90) inhibitors with potential to increase the therapeutic
use of compounds with radiation sensitizing properties for other cancers. Several drugs with radiation sensitizing properties are currently
in Phase III clinical trials, such as nimorazole (for head and neck cancer), motexafin gadolinium (for brain metastases), and cisplatin
(for cervical cancer); though none are likely to apply for a radiosensitizing claim with the FDA since the radiosensitizing element in
their clinical trials are not primary endpoints. While additional drugs with radiation sensitizing properties are expected to be launched
in the future, thereby driving the radiation sensitizers market further, to date, there is no indication that any drug in development
is expected to be approved specifically as a radiation sensitizer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive environment for &#8220;off-label&#8221; radiation sensitizers for solid tumor cancers is anticipated to become predominantly
generic. Avastin, Erbitux, Camptosar and Xeloda have or will lose patent protection in the next three years. Newer products under investigation
or approved, such as Vectibix&#174; (panitumumab) from Amgen will be promoted as having radiation sensitizing properties, along with indications
for treatment for specific cancers. The high cost of these new therapies coupled with limited efficacy compared to current standard of
care will be constrained by both public and private payors. Other new agents are in development but will face similar challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that new products launching into the cancer market with anecdotal claims for use as radiation sensitizers with improved effectiveness,
quality and tolerability will initially be limited in their growth until they have been added to established clinical pathways and guidelines.
If their effectiveness, quality and tolerability are demonstrated clinically, as determined by the FDA, it is anticipated the National
Comprehensive Cancer Network (NCCN), the leading authority in oncology drug evaluation for treatment guidelines, would issue a recommendation
and addition to standard of care within approximately six to twelve months after launch. An NCCN recommendation would positively impact
the growth potential for a new product entering the market. Also, payors, both public and private, would add the new product to their
approved drug lists and provide reimbursement giving providers incentive to use the product as neoadjuvant and adjuvant therapy to standard
of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with many cancer therapies, side effects can often have a distinct impact on quality of life and influence the potential for market growth.
Patients increasingly have a stronger voice in the decision-making process for the appropriate therapies and costs to treat their cancers.
As payors are increasingly placing more of the financial burden of the cost of therapy directly on patients, patients are voicing their
opinions to their physicians and payors which have a direct effect on which products are selected. Many of the current therapies have
significant side effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
insurers are expected to have more restrictive formularies and medical benefits in which patients will be expected to carry more of the
burden of the cost of drugs. Also, it is anticipated that increased application of third party developed treatment guidelines, such as
those from the NCCN (National Comprehensive Cancer Network), are expected to be used by private payors to limit the access to products
for specific conditions through prior authorizations and implementation of step therapy or increased out of pocket cost approaches. As
many of the current drugs used as radiation sensitizers are expensive and not approved for use as radiation sensitizers (thus, such treatment
is &#8220;off label&#8221;), and as many of the products in clinical trials are expected to be at the current or higher price levels,
new products that may be specifically approved for an indication as the only approved product as a radiation sensitizer will have increased
consideration for reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
is increasingly moving many patients to private insurance through Medicare Advantage and ACOs. Medicare Advantage plans are capitation
HMO and PPO plans offered through private insurers to Medicare patients. ACOs are being developed to increase quality of care for their
patients. Most of the new ACOs are initially positioned for Medicare patients with over 400 approved by CMS. Several studies from the
Center for Health Strategies, 2017, Journal of American Medical Association, 2018 and the Brookings Institute, 2015 estimated that almost
1000 ACOs for Medicare and non-Medicare patient populations would be approved by CMS or developed by a variety of healthcare entities
to begin operating under the ACA in 2017. We expect the growth in ACOs to continue, regardless of any changes that may be made to the
ACA going forward. In early 2017, Health Affairs, a magazine tracking ACOs, estimated that over 22 million patients are enrolled in Medicare
and private ACOs. To address the quality of care measures designated by CMS and to gain additional incentives, use of clinical pathways
or treatment guidelines is anticipated to be increasingly instituted to manage patient care. The impact on the uptake of new products
in this environment can be profound if the new product is first in class and is included in national guidelines from organizations such
as the NCCN and/or approval by the regional CMS contracting groups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ROPIDOXURIDINE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
halogenated thymidine (TdR) analogs, bromodeoxyuridine (BUdR) and iododeoxyuridine (IUdR), are a class of pyrimidine analogs that have
been recognized as potent radiosensitizing agents since the early 1960s. (<i>See</i> Kinsella TJ. An Approach to the Radiosensitization
of Human Tumors. <i>Cancer J Sci Am.</i> Jul-Aug 1996:2(4); 184-193). Their cellular uptake and metabolism are dependent on the TdR salvage
pathway where they are initially phosphorylated to the monophosphate derivative by the rate-limiting enzyme, thymidine kinase (TK). (<i>See
</i>Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. <i>J Clin Oncol, </i>Sep 10 2007; 25(26):4043-4050). After sequential phosphorylation
to triphosphates, they are then used in DNA replication, in competition with deoxythymidine triphosphate (dTTP), by DNA polymerase. DNA
incorporation is a prerequisite for radiosensitization of human tumors by the halogenated TdR analogs, and the extent of radiosensitization
correlates directly with the percentage TdR replacement in DNA. (<i>See </i>Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.
The Dependence of Halogenated Pyrimidine Incorporation and Radiosensitization on the Duration of Drug Exposure. <i>International Journal
of radiation oncology, biology, physics.</i> Jun 1990; 18(6);1393-1398). The molecular mechanisms of radiosensitization are most likely
the result of increased susceptibility of TdR analog-substituted DNA to the generation of highly reactive uracil free radicals by ionizing
radiation (IR), which may also damage unsubstituted complementary-strand DNA. Repair of IR damage may also be reduced by pre-IR exposure
to these analogs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rationale for using Ropidoxuridine as a radiation sensitizer is based on prior clinical studies with the active metabolite IUdR; identified
in NIH laboratories as a potent radiation sensitizer. Ropidoxuridine is an orally available prodrug of IUdR. In the body, Ropidoxuridine
is metabolized in the liver into IUdR. IUdR is incorporated into the DNA of actively growing cells and when cells are exposed to ionizing
radiation, DNA strand breaks are generated, resulting in more cell death and radiation sensitization. (<i>See</i> Gurkan E, Schupp JE,
Aziz MA, Kinsella TJ, Loparo KA. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA
incorporation. Cancer Res. Nov 15 2007; 67(22):10993-11000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of the clinical efficacy data were obtained from NIH supported studies performed with IUdR, the active metabolite of Ropidoxuridine.
However, IUdR requires constant infusion over six weeks of therapy which creates a significant compliance issue for patients. Ropidoxuridine
can be given as a capsule for oral administration, resulting in greater ease of medication delivery and potentially improved compliance
and fewer complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last 20 years, there has been renewed interest in these halogenated TdR analogs as experimental radiation sensitizers in selected
cancer patient groups. These analogs are rapidly metabolized in both rodents and humans, principally with cleavage of deoxyribose and
subsequent dehalogenation by hepatic and extrahepatic metabolism, when given as a bolus infusion with a plasma half-life of &lt;5 min.
Consequently, prolonged continuous or repeated intermittent drug infusions over several weeks before and during irradiation are necessary,
based on in vivo human tumor kinetics, to maximize the proportion of tumor cells that incorporate these analogs into DNA during the S
phase of the cell cycle. (<i>See</i> Fowler JF, Kinsella TJ. The Limiting Radiosensitization of Tumors by S-phase Sensitizers. <i>Br
J Cancer</i>. 1996;74 (Suppl)(27):294-296). Phase I and Phase II trials using prolonged continuous or repeated intermittent intravenous
infusions of BUdR or IUdR before and during radiation therapy (RT) have focused principally on patients with high-grade brain tumors.
These clinically radiation resistant tumors can have a rapid proliferation rate (potential tumor doubling times of 5&#8211;15 days) and
are surrounded by non-proliferating normal brain tissues that show little to no DNA incorporation of the TdR analogs. As such, high-grade
brain tumors are ideal targets for this approach to radiation sensitization. In Phase I/Phase II clinical trials, prolonged survival
outcomes were observed compared to RT alone in patients with anaplastic astrocytomas and in patients with glioblastoma multiforme IUdR
continuous IV infusion (1000 mg/m<sup>2</sup>/ day/ 14 days), Total 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994;
30(3):583-90.) A therapeutic gain in clinical radiation sensitization using these halogenated TdR analogs was proposed for other types
of clinically poorly radiation responsive (radiation resistant) cancers, including locally advanced cervical cancer, head and neck cancers,
unresectable hepatic metastases from colorectal cancers, and locally advanced sarcomas, based on the results of other Phase I/Phase II
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target
Indication: Glioblastoma, Sarcomas and Rectal Cancers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the Phase I clinical trial of Ropidoxuridine and RT in advanced GI cancers, we proposed to perform Phase II efficacy clinical
trials in brain tumors (glioblastoma), soft tissue sarcomas, and rectal cancers. Glioblastoma multiforme is a deadly malignancy of the
brain with no known cure. Radiation therapy provides delay of disease progression and is standard of care following surgical resection
or biopsy. Radiation therapy is combined with Temodar, a drug that has shown activity (~ four months survival benefit) in treating brain
tumors. Preliminary data using radiation therapy in combination with IUdR resulted in a delay of disease progression of up to six months.
We propose to test IPdR in combination with radiation therapy in the Phase II clinical trial. Similarly, delay in disease progression
has been observed following treatment of sarcomas by the combination of IUdR and RT. Based on the Phase I data of our clinical trial
we know that therapeutic levels of IUdR are reached by administering the orally available prodrug, IPdR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I results of the clinical trial supported by an SBIR contract to Shuttle Pharma and a sub-contract to the Brown University Oncology
Group (BrUOG) at the LifeSpan/Rhode Island Hospital were reported by the subcontractor at the 30th EORTC-NCI-AACR Symposium in November
2018 and in the medical journal, Clinical Cancer Research, in 2019. Eighteen patients completed dose escalation to 1800 mg/day for 30
days, establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Therapeutic blood levels of IUdR were achieved.
Four patients were scored as partial responses, nine patients had stable disease and one patient progressed in the target lesions. These
data support advancing IPdR and RT to clinical trials for the FDA to determine efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key to driving the Ropidoxuridine product forward, the new formulation of IPdR/TPI, is the development of a clinical plan with aggressive
timelines and support within the radiation oncology community to participate in clinical trials with the appropriate patients to ensure
a comprehensive NDA dossier for each product. Initially, the plan is focused on the Phase I and Phase II clinical trials. Upon completion
of these studies, we will determine whether to extend the Phase II study to a randomized Phase II, or to perform a randomized Phase III
clinical trial. Such determination will be based, in part, on results of the initial clinical trials and the end of a Phase II meeting
with the FDA. Shuttle Pharmaceuticals requested and received FDA orphan drug status for Ropidoxuridine as a clinical radiation sensitizer
for treatment of glioblastoma and pre-operative treatment of soft tissue sarcomas. As a result, the application for &#8220;orphan&#8221;
designation for Ropidoxuridine with RT for glioblastoma has been approved. The application for sarcomas, however, was not approved and
will require addressing certain FDA comments and resubmission. The IPdR/TPI formulation clinical plan will focus on resectable stage
II and III rectal cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical plan for Ropidoxuridine development includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP manufacture and formulation
    of 25 kg of Ropidoxuridine for use in clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of pre-clinical
    Ropidoxuridine and Temodar drug-drug interaction safety study.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission of an IND for
    a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negotiations for CRO contracts
    to perform the Phase II clinical trial.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of the Phase
    II clinical trial in glioblastomas to determine appropriate dosing, quality, effectiveness and tolerability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the data obtained from the NIH/NCI SBIR funded Phase I clinical trial supports efforts to raise additional capital to enable
performing the Phase II clinical trials of Ropidoxuridine. We aim to conduct and complete the Phase II clinical trial so that we may
present data to the FDA for its determination of efficacy. We believe this will support our efforts to raise the additional required
capital to fund Phase III clinical trials and seek FDA approval of an NDA with &#8220;orphan&#8221; designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical plan for the IPdR/TPI formulation will focus on resectable Stage II and Stage III rectal cancer patients. Nonetheless, we cannot
guarantee the successful completion of any of these trials. Our inability to meet any of the aforementioned milestones in the Phase II
or Phase III clinical trials will cause us to be unable to proceed with our present efforts and will likely cause us to be unable to
raise additional funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
HDAC Small Molecule Delivery Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the founding of Shuttle Pharma, our discovery research and development efforts have been focused on our small molecule technology delivery
platform which uses HDAC inhibitors, designed to target cancer cells, while protecting healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HDACs
are a class of enzymes that regulate gene expression through chemical modification of histones and non-histone proteins. Increased HDAC
activity leads to a more condensed chromatin (which is a protein complex consisting of DNA and other proteins), decreased gene expression
and loss of key gene products, including tumor suppressor gene function. Inhibition of HDAC activity leads to a more open chromatin and
increased expression of the key gene products. This chromatin modification underlies the epigenetic cellular regulatory system and is
an area of intense investigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts to date have focused on the discovery of novel, dual functional molecules for potential use in cancer
treatment as radiation sensitizers of cancers, protectors of normal tissues, and activators of the immune responses to antigens expressed
by irradiated cancer cells. To date, we have produced three candidate molecules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161, a candidate lead
    of compounds demonstrating activation of the &#8220;ATM&#8221; gene product (mutated in Ataxia-Telangiectasia). Ataxia-Telangiectasia
    is a human genetic disease characterized by neurological, immunological and radiobiological clinical features.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225, a candidate lead
    of compounds demonstrating Class II (HDAC6) selective inhibition. HDAC6 is a molecule integral to the presentation of antigens by
    macrophages to T-lymphocytes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303 is a candidate
    Class I HDAC inhibitor with preferential efficacy against ER positive cancers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-161
</span>- A Dual Functional Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
is an HDAC inhibitor of the hydroxamate chemical class of compounds and an ATM activator of the indole chemical class. HDACs modify histones
and non-histone proteins, which are key components of the chromatin structure, gene expression regulation, and cell growth. HDAC inhibitors
inhibit cell proliferation, angiogenesis and immunity. Eighteen human HDACs have been identified, subdivided into four classes based
on sequence and functional homology. In cancer cells, HDAC activity silences tumor suppressor genes important for cell growth regulation
and to chromosomal instability. Abnormal HDAC activity is also associated with tumor cell growth, invasion, metastasis and resistance
to therapy. Therefore, inhibitors of HDACs have emerged as anti-cancer agents for cancer therapy. Vorinostat and romidepsin have been
approved by the FDA for treatment of patients with relapsed or refractory T-cell lymphomas. In addition, panobinostat received FDA approval
for treatment of recurrent multiple myeloma in combination with bortezomib and dexamethasone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 inhibited the activity of pan-HDACs and activated the ATM gene product. ATM is a critical protein for the
activation of the cell stress response for cellular recovery from radiation exposure in normal cells, but not in cancer cells. ATM activates
the P53 protein, referred to as the &#8220;guardian of the genome,&#8221; and serves as a tumor suppressor critical for normal cell function
and activation of programmed cell death in cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 protected normal breast epithelial cells (184A1) following exposure to ionizing radiation while increasing
sensitivity of breast cancer cells (MCF7). SP-1-161 provides this dual function in a single molecule and this molecule is differentiated
from other HDAC inhibitors by treatment of cancers while protecting normal cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
is a selective HDAC inhibitor that affects histone deacetylase (HDAC6) and is a member of the class IIb HDAC family. Class II HDACs play
important roles in cancer motility, invasion, neurological diseases, and immune checkpoint. HDAC6 inhibition has been most extensively
studied for its role in the treatment of hematological cancers. HDAC6 is unique among HDAC enzymes in having two active catalytic domains
and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates including &#945;-tubulin
and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging
class of pharmaceuticals due to the involvement of HDAC6 in pathways related to neurodegenerative diseases, cancer and immunology. Specifically,
its potential to affect regulation of the immune system and enhance the immune response in cancer is of great interest. With the introduction
of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response to this therapy is
of significant clinical and commercial interest. (<i>See</i> Grindrod S, Brown M, Jung M. &#8220;Development of dual Function Small Molecules
as Therapeutic Agents for Cancer Research,&#8221; Poster presentation #A178, American Association of Cancer Research Oct 2017).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
inhibition of HCAC6 reduces dose limiting side effects associated with non-selective HDAC inhibitors. Selective HDAC6 inhibitors may
be combined with other cytotoxic agents. Shuttle&#8217;s discovery of selective HDAC inhibitors has yielded several HDAC6 selective candidate
molecules including SP-2-225. HDAC6 inhibitors are under investigation for roles in the treatment of diseases such as multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
</span>- Target Indication: Breast Cancer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Histone
deacetylase inhibitors sensitize cancers to the effects of radiation, protecte normal tissues from radiation injury and activate the
immune system. SP-1-303 is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER positive
breast cancer cells. Furthermore, SP-1-303 increases the PD-L1 expression level in a time-dependent manner, support combination of SP-1-303
with an immune checkpoint blocker to enhance the therapeutic benefits. We are currently conducting preclinical efficacy studies of these
molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HDAC inhibitor platform of candidate molecules will require pre-clinical evaluation, completion of IND-enabling studies and the lead
drug candidates will be tested in Phase I clinical trials for pharmacokinetics and MTD determination. We have three lead candidates for
potential development for the treatment of solid tumors, including breast cancer, lung cancer and multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of Phase I and Phase II clinical trials will determine further drug development and Shuttle will seek to establish collaborative
partnerships with other pharmaceutical companies to complete pre-clinical and clinical development, drug manufacturing and marketing
of our product candidates. In the event we are unsuccessful in completing our clinical trials at any stage, or in the event we obtain
negative results, we will likely be unable to raise additional funding related to our HDAC studies or will have to change direction of
our research efforts regarding the HDAC inhibitor platform of candidate molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Manufacturing Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no manufacturing facilities that are company owned or operated. We have performed laboratory scale synthesis and testing in our
research laboratories in Gaithersburg, Maryland. GMP synthesis of API, drug formulation and human dosage preparation will be performed
under contracts with third-party manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed important strategic agreements with academic institutions for access to resources such as intellectual property, core
facilities and contracting relationships. In addition, we have established an agreement with Propagenix for intellectual property in-licensing.
Our current and ongoing relationships include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgetown University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor for the
    SBIR supported African-American prostate cancer patient health disparities project (completed). The conditional reprogramming of
    cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix
    holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for
    cells derived from African-American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.
    based on our sub-licensing agreement with Propagenix.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor for the
    SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs to Georgetown
    University and Shuttle Pharma holds an exclusive option to license the intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor of the SBIR supported Phase I clinical
    trial of IPdR and RT (completed).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">University of Virginia</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research collaboration to develop heavy oxygen molecules
    for proton radiation sensitizer applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Washington University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material transfer agreement
    for testing HDAC inhibitor effects in immune model systems</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The material transfer agreement
    that protects our HDAC inhibitor intellectual property is with George Washington University, transferring drugs for research purposes
    and sharing authorship on publications. There is no transfer of funds related to such activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagenix, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License agreement for &#8220;conditional
    re-programmed cell&#8221; (CRC) technology. The cells established by Shuttle Pharma scientists at Georgetown University belong to
    us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid to Propagenix. No other future milestone
    or royalty payments owed related to the Propagenix agreement. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition
&#8220;Off-Label&#8221; Use</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_003.jpg" alt="" style="height: 215.25pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
with radiation sensitizing properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are advancing a clinical stage product candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue
when used in conjunction with RT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ropidoxuridine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine,
an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead &#8220;clinical phase&#8221;
product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the
effects of RT. We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University
at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In
connection with the trial, NCI has approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode
Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical
trials of brain tumors, sarcomas and other tumors through contracted research organizations (or CROs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provide data from reported clinical trials of Iododeoxyuridine and RT therapy in brain cancers (glioblastoma multiforme)
and high-grade sarcomas. Our primary strategy for Ropidoxuridine and RT therapy is to provide oral drug delivery to effect radiation
sensitization of cancers and validate effectiveness in glioblastoma and sarcoma, potential &#8220;Orphan&#8221; indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brain
Cancer Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade primary brain tumors (RTOG*, NCI** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_004.jpg" alt="" style="height: 139.5pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR continuous IV infusion
    (1000 mg/m2/ day/ 14 days), Total of 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994; 30(3):583-90)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR continuous IV infusion
    (2000 mg/m2/ 4 day infusion/ 6 week treatment), Total of 21 patients (R. Urtasun, et al. Int J Radiat Oncol Biol Phys. 1996;36(5):1163-7.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sarcoma
Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade sarcomas (University of Michigan*** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_005.jpg" alt="" style="height: 139.5pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16 patients were treated
    with continuous infusion (1000-1600 mg/m2/day) plus RT (J.M. Robertson, et al. Int J Radiat Oncol Biol Phys. 1995; 31(1):87-92).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our primary product candidate, we are developing and planning to develop other cancer radiation sensitizers and radiation
protectors, which target protecting normal tissue during the administration of RT, and other products utilizing our HDAC small molecule
technology platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SBIR
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
SBIR Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Small Business Innovation Research program, as developed by Congress under the Small Business Innovation Development Act of 1982, is
designed to encourage domestic small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;) that
has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological
potential and provides the incentive to profit from its commercialization. Some of the SBIR&#8217;s program goals include stimulating
technological innovation, meeting Federal research and development needs and encouraging participation in innovation and entrepreneurship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SBIR program is a three-phase program. Phase 1 is to establish the technical merit and commercial potential of the proposed R/R&amp;D
efforts. Phase 2 is to continue the R/R&amp;D efforts initiated in Phase 1 and funding is based on the results achieved in Phase 1. Phase
3 allows for the small business to pursue commercialization objectives resulting from the Phase 1 and 2 R/R&amp;D activities. In addition,
companies that have successfully completed Phases I and II are also eligible to apply for Phase IIb funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the SBIR contract to fund our Phase I clinical study on Ropidoxuridine in combination with RT for treatment of advanced gastrointestinal
cancers, we have also received awards of SBIR contracts from the NIH to address prostate cancer health disparities and prostate cancer
radiation biomarker development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, all SBIR contracts received by the Company have been completed. The Company submitted a final report
for SBIR contract # 75N81018C00031 on March 28, 2022. The following summary of terms for the three Phase II SBIR contracts is provided
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Summary
of SBIR Contracts</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR contract #261201400013C:
    Phase I ($191,971) and Phase II ($1,428,117) for Clinical Development of IPdR for Radiosensitization, dates September 19, 2014 through
    August 3, 2017, Subcontract to Brown University/LifeSpan Rhode Island Hospital. No related intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR contracts # HHSN261201600038C;
    Phase I ($224,687) and #261201800016C: Cell-Based Models for Prostate Cancer Health Disparity Research - Moonshot Project (Phase
    II), award amount $1,484,350, dates September 19, 2016 through September 16, 2021, Subcontract to Georgetown University, Intellectual
    property consists of cell cultures and is property of Shuttle Pharmaceuticals, Inc. via licensing agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR contracts #HHSN261201600027C
    ($299,502) and #75N81018C00031: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effects, award amount
    $1,903,015, dates September 16, 2019 through March 15, 2022. Subcontract to Georgetown University, Intellectual property is owned
    by subcontractor Georgetown University with option to license to Shuttle Pharmaceuticals, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Studies to Address Health Disparities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
cancer health disparities studies have shown that African-American men are at higher risk for developing prostate cancer, as well as
at higher risk of cancer specific death rates as compared to Caucasian American men. The causes of disparities have been attributed to
socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population based, in part,
due to the lack of relevant in vitro and in vivo models to support biological studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma has been awarded Phase I and II SBIR contracts entitled &#8220;Cell-based models for prostate cancer health disparity research&#8221;
to develop African-American prostate cancer cell lines with donor matched normal prostate epithelial cell lines from African American
men.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercialization of the prostate cells will require additional support through the SBIR funding mechanism. Companies that have completed
Phase I and II SBIR awards are eligible to apply for Phase IIb SBIR funding. These awards are intended to de-risk a project by providing
up to $4 million of matching funding for product development to commercialization. We intend to apply for such government funding to
advance laboratory facilities and to expand the availability of the cell cultures. We are not raising capital through this offering for
the health disparities project. Should we not be successful for SBIR IIb funding, we will pause and may have to terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Biomarker Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
treated for prostate cancer may experience treatment related late effects that adversely affect quality of life and may prove life-threatening.
Shuttle has been awarded a Phase I SBIR contract entitled &#8220;Predictive biomarkers for prostate cancer patient sensitivity for radiation
late effects&#8221; to determine the technical and commercial feasibility of a biomarker panel predictive of radiation mediated late
effects in patients treated for prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
collaboration with Georgetown University, patients treated with SBRT for prostate cancers will be analyzed for urinary and rectal symptoms
and their blood will be analyzed by mass spectroscopy for predictive biomarkers. The discovery and validation of metabolite panels to
serve as a predictive biomarker of patient outcomes following radiation therapy will support future development and commercialization
of a diagnostic product through a Phase 2 SBIR effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development to commercialization of the metabolite predictive biomarker panel will require additional support through the SBIR funding
mechanism. We will be eligible to apply for Phase IIb SBIR funding the next round of solicitation. A Phase IIb will help de-risk the
project by providing up to $4 million of matching funds for performing the clinical validation trial for product development to commercialization.
We intend to apply for such government funding to advance this project. We do not intend to use the funds raised through this offering
for the health disparities project. Should we not be successful for SBIR IIb funding, we will terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to enter into collaborative arrangements to further develop our drug candidates in the future, at present we have not entered
into any collaborative arrangements with third parties to develop our drug candidates as we are still completing clinical trials and,
as a result, there can be no assurance that we will be able to do so on commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
invest significant amounts in research and development. Our research and development expenses before contract reimbursements were $591,237
and $604,181 for the six months ended June 30, 2022 and 2021 respectively. After reimbursements for contracts of $211,455 for the six
months ended June 30, 2022 and 2021, net research and development expenses were $379,783 and $392,726, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking multifaceted protection for our intellectual property that includes licenses, confidentiality and non-disclosure agreements,
copyrights, patents, trademarks and common law rights, such as trade secrets. We enter into confidentiality and proprietary rights agreements
with our employees, consultants, collaborators, subcontractors and other third parties and generally control access to our documentation
and proprietary information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have filed four patent applications with the USPTO with respect to various aspects of our HDAC small
molecule delivery platform and Ropidoxuridine, our lead product candidate. The following is the status of the patent applications Shuttle
has filed to date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Shuttle Pharma&#8217;s Intellectual Property Portfolio</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USPTO
    number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    Filed</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    Granted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anticipated
    Expiration Date**</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Application No.: 16/475,999</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and compositions
    for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/3/2019</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Application No.: 17/484,876</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual function molecules
    for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/24/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Application No.: 17/315,567</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective histone deacetylase
    inhibitors for the treatment of human disease</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/10/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Application No.:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/959,570</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective histone deacetylase
    inhibitors for the treatment of human disease</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Patent No.: 9,809,539</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual function molecules
    for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/7/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Patent No.: 11,034,667</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective histone deacetylase
    inhibitors for the treatment of human disease</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/3/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2021 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/9/2038</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Patent No.: 10,730,834 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective histone deacetylase
    inhibitors for the treatment of human disease</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4 /2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Patent No.: 10,745,352 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective histone deacetylase
    inhibitors for the treatment of human disease</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2020 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2020 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
Lewis &amp; Bockius LLP prepared patent applications related to Ropidoxuridine (IpdR) and HDAC inhibitors, and, in the fourth quarter
of 2018, found no freedom to operate (FTO) issue for Ropidoxuridine used as radiosensitizer and used with tipiracil, and HDAC inhibitors
SP-1-161 and SP-2-225.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage
with a focus on jurisdictions that represent significant global pharmaceutical markets. Generally, patents have a term of twenty years
from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed
and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened.
We are obtaining worldwide patent protection for at least novel molecules, composition of matter, pharmaceutical formulations, methods
of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our
research and development efforts. We continuously assess whether it is strategically more favorable to maintain confidentiality for the
&#8220;know-how&#8221; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we
strategically tailor our claims in accordance with the existing patent landscape around a particular technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should
the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued
patents can be subject to oppositions, interferences and other third-party challenges that can result in the revocation of the patent
limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant. Competitors
may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial delays
and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short
period of time following commercialization. We cannot predict with any certainty if any third-party U.S. or foreign patent rights or
other proprietary rights will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if any, of these
rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against any such claims,
substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief,
which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad, and could result
in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more
licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we deem it necessary
to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material adverse effect
on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully
protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary
information or otherwise gain access to our trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who
receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships.
These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s
relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances.
The agreements provide that all inventions conceived by an employee will be the property of our company. There can be no assurance, however,
that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use
or disclosure of such information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from
infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other
territories worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Supply</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any
of our product candidates. We currently use a number of our suppliers for the raw materials and formulation to meet the preclinical and
any clinical requirements of our product candidates. We do not have a long-term agreement with any of these parties and we believe alternative
sources of supply exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into collaborations for the manufacture of our product candidates, with our collaborators assuming responsibility for
such manufacturing. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements,
which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Any
collaborator or third-party contract manufacturer we use would need to be compliant with cGMP. cGMP is a regulatory standard for the
production of pharmaceuticals that will be used in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors
have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that
enter the market. We believe that a significant number of products are currently under development, and may become commercially available
in the future, for the treatment of conditions for which we may try to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we are able to obtain approval for any product candidate, we will face competition based on many different factors,
including the quality and effectiveness of our products, the ease with which our products can be administered and the extent to which
patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability
and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could
present superior treatment alternatives, including by being more effective, safer, and less expensive or marketed and sold more effectively
than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover
the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could
negatively impact our level of expertise and our ability to execute our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following figure provides summary information about cytotoxic drugs that may be used with radiation therapy for their sensitizing properties
that currently comprise the competition for Shuttle&#8217;s agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_006.jpg" alt="" style="height: 305.25pt; width: 6in" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fluorouracil
</span>(5-FU) is an anti-metabolite used to treat cancer, by injection, for colon cancer, esophageal cancer, stomach cancer, pancreatic
cancer, breast cancer, and cervical cancer. Fluorouracil was patented in 1956 and is an effective and safe drug with radiation sensitizing
properties. Capecitabine, an orally available formulation of 5-FU and was patented in 1992. It is used for the treatment of gastric,
esophageal and other cancers for sensitization to radiation therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cetuximab
</span>is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal, lung cancer and head and
neck cancers. This monoclonal antibody is administered by intravenous infusion and improves the 5-year survival of patients when used
in combination with radiation therapy, compared with radiotherapy alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Platinum
</span>based compounds (cis-platin, carbo-platin and oxaloplatin) also exhibit radiation sensitizing properties. Platinum and radiation
are used together for the treatment of locally advanced cervical cancer and for head and neck cancers. Cisplatin is believed to augment
the effects of radiation by inhibiting the repair of radiation-induced sub-lethal damage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Bevacizumab
</span>works as an anti-angiogenic agent. It was approved for medical use in the United States in 2004. The addition of bevacizumab to standard
treatment can prolong the lives of breast and lung cancer patients by several months and may be used with radiation therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Irinotecan
</span>is given by injection and is used to treat colon cancer and small cell lung cancer and can be combined with radiation therapy. For
colon cancer it is used either alone or with fluorouracil.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research,
development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import
of products such as those we are developing. Our product candidates must be approved by the FDA through the NDA process before they may
be legally marketed in the U.S. and will be subject to similar requirements in other countries prior to marketing in those countries.
The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
government regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NDA
approval processes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and implementing regulations.
Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval,
may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions
could include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of an approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical hold;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial suspension of production or distribution;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions, fines, disgorgement, or civil or criminal
    penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of nonclinical
    laboratory tests, animal studies and formulation studies conducted according to GLPs or other applicable regulations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    an IND, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate
    and well-controlled human clinical trials according to GCPs to produce data that the FDA may review to determine safety and efficacy
    of the product candidate for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    an NDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion
    of an FDA inspection of the manufacturing facility or facilities at which the product candidate is produced to assess compliance
    with cGMPs to assure that the facilities, methods and controls are adequate to preserve the product candidate&#8217;s identity, strength,
    quality and purity; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval
    of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include
laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results
of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical
testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also
include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring quality
and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes
effective thirty (30) days after receipt by the FDA, unless the FDA, within the thirty (30) day time period, places the IND on clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical
hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be
conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria
and the quality and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress
reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must timely report to FDA serious
and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed
in the protocol or investigation brochure or any findings from other studies or animal or in vitro testing that suggest a significant
risk in humans exposed to the drug. An institutional review board (IRB) at each institution participating in the clinical trial must
review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding
the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the
study until completed and otherwise comply with IRB regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase I</b>&#8212;The
    product candidate is initially introduced into healthy human subjects and tested for quality, dosage tolerance, absorption, metabolism,
    distribution and elimination. In the case of some product candidates for severe or life-threatening diseases, such as cancer, especially
    when the product candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is
    often conducted in patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase II</b>&#8212;Clinical
    trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily
    evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase III</b>&#8212;Clinical
    trials are undertaken to further evaluate dosage and produce data that the FDA may determine to establish clinical efficacy and safety
    in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall
    risk-benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are inherently uncertain and Phase I, Phase II and Phase III testing may not achieve desired results or otherwise be
completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research
subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product
candidate has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new product candidate, sponsors are given opportunities to meet with the FDA at certain points. These points may
be prior to the submission of an IND, at the end of Phase II and before an NDA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide
advice on the next phase of development. Sponsors typically use the meeting at the end of Phase II to discuss their Phase II clinical
results and present their plans for the pivotal Phase III clinical trial that they believe will support the approval of the new drug.
If a Phase II clinical trial is the subject of discussion at the end of Phase II meeting with the FDA, a sponsor may be able to request
a Special Protocol Assessment (&#8220;SPA&#8221;), the purpose of which is to reach agreement with the FDA on the Phase III clinical
trial protocol design and analysis that will form the primary basis of an efficacy claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to published guidance on the SPA process, a sponsor which meets the prerequisites may make a specific request for a SPA and provide information
regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within forty-five (45) days
of the request to assess whether the proposed trial is adequate, which evaluation may result in discussions and a request for additional
information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins.
If a written agreement is reached, it will be documented and made part of the record. The agreement will be binding on the FDA and may
not be changed by the sponsor or the FDA after the trial begins except with the written agreement of the sponsor and the FDA or if the
FDA determines that a substantial scientific issue essential to determining the safety or efficacy of the product candidate was identified
after the testing began.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, sponsors usually complete additional animal safety studies and also develop additional information about the chemistry
and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product candidate. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
not undergo unacceptable deterioration over its proposed shelf-life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may be obtained
under specified circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review
before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA
must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it
for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug representing
a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA may refuse to approve
an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data are
submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to determine,
among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The
FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured and tested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expedited
review and approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify
the process for reviewing product candidates, or provide for the approval of a product candidate on the basis of a surrogate endpoint.
Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product candidate no longer
meets the conditions for qualification or that the time period for FDA review or approval will be shortened. Generally, product candidates
that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet
medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate
the development and expedite the review of product candidates to treat serious or life-threatening diseases or conditions and fill unmet
medical needs. Priority review is designed to give product candidates that offer major advances in treatment or provide a treatment where
no adequate therapy exists an initial review within six months as compared to a standard review time of ten (10) months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings
with a sponsor of a Fast Track designated product candidate and expedite review of the application for a product candidate designated
for priority review. Accelerated approval, which is described in Subpart H of 21 CFR Part 314, provides for an earlier approval for a
new product candidate that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need
based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement
representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving
accelerated approval perform post-marketing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;), the U.S. Congress encouraged the FDA to utilize innovative
and flexible approaches to the assessment of product candidates under accelerated approval. The law required the FDA to issue related
draft guidance within a year after the law&#8217;s enactment and also promulgate confirming regulatory changes. In June 2013, the FDA
published a draft Guidance for Industry titled &#8220;Expedited Programs for Serious Conditions&#8212;Drugs and Biologics,&#8221; which
provides guidance on FDA programs that are intended to facilitate and expedite development and review of new product candidates as well
as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and
review programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new
program for Breakthrough Therapy designation. The FDA defines a Breakthrough Therapy as a drug that is intended, alone or in combination
with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. A drug designated as a Breakthrough Therapy is eligible for accelerated
approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development
and review of an application for approval of a Breakthrough Therapy. Even if a product qualifies for one or more of these programs, the
FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review
or approval will not be shortened. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment
to an IND. FDA has already granted this designation to approximately thirty (30) new product candidates and has begun approving Breakthrough
Therapy designated drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
term restoration and marketing exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-
Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product
development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond
a total of fourteen (14) years from the product candidate&#8217;s approval date. The patent term restoration period is generally one
half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of
an NDA and the approval of that application. Only one patent applicable to an approved product candidate is eligible for the extension
and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and
approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term
for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected
length of clinical trials and other factors involved in the submission of the relevant NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity.
A product candidate is a new chemical entity if the FDA has not previously approved any other new product candidate containing the same
active moiety, which is the molecule or ion responsible for the action of the product candidate substance. During the exclusivity period,
the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company
for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required
for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement.
The FDCA also provides three years of marketing exclusivity for an NDA, 505(b) (2) NDA, or supplement to an approved NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential
to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year
exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs
for product candidates containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate quality and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
drug designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to product candidates intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S.
and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a product candidate for
this type of disease or condition will be recovered from sales in the U.S. for that product candidate. Orphan drug designation must be
requested before submitting an NDA. After the FDA grants orphan drug designation, the FDA publicly discloses the identity of the therapeutic
agent and its potential orphan use. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory
review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such
designation, the product candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications
to market the same product candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity,
however, could also block the approval of one of our product candidates for seven years if a competitor obtains approval of the same
product candidate as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product
candidate for the same indication or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pediatric
exclusivity and pediatric use</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;), certain product candidates may obtain an additional six months of exclusivity
if the sponsor submits information requested in writing by the FDA (a &#8220;Written Request&#8221;) relating to the use of the active
moiety of the product candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved indications
or where it determines that information relating to the use of a product candidate in a pediatric population, or part of the pediatric
population, may not produce health benefits in that population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric studies for most product candidates
and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under
PREA, original NDAs, biologics license application and supplements thereto must contain a pediatric assessment unless the sponsor has
received a deferral or waiver. The required assessment must assess the quality and effectiveness of the product candidate for the claimed
indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which
the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the product candidate or biologic is ready for
approval for use in adults before pediatric studies are complete, or that additional quality or effectiveness data needs to be collected
before the pediatric studies begin. After April 2013, the FDA must send a noncompliance letter to any sponsor that fails to: submit the
required assessment, keep a deferral current, or submit a request for approval of a pediatric formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-approval
requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems
occur after the product candidate reaches the market. Later discovery of previously unknown problems with a product candidate may result
in restrictions on the product candidate or even complete withdrawal of the product candidate from the market. After approval, some types
of changes to the approved product candidate, such as adding new indications, manufacturing changes and additional labeling claims, are
subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect
of approved product candidates that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product
candidate based on the results of these post-marketing programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidates manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">record-keeping requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting of adverse experiences with the product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing the FDA with updated data for the FDA&#8217;s
    continuing safety and efficacy determination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug sampling and distribution requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">notifying the FDA and gaining its approval of specified
    manufacturing or labeling changes; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with FDA promotion and advertising requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
manufacturers and other entities involved in the manufacture and distribution of approved product candidates are required to register
their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some
state agencies for compliance with cGMP and other laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
outside of the U.S.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial
sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the
comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval
of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or
areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary
greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized
procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat
AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines which are highly innovative, provides for the
grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for
mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit
an application to the remaining member states. Within 90 days of receiving the applications and assessments report, each member state
must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed points are
eventually referred to the European Commission, whose decision is binding on all member states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
in the U.S., we may apply for designation of a product candidate as an orphan drug for the treatment of a specific indication in the
European Union before the application for marketing authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits,
including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer,
more effective or otherwise clinically superior to the orphan-designated product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as
government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging
the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal
and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party
payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approved
as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;) imposed new requirements for the distribution
and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans
offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription
drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage
is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan
can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription
drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the
drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and
therapeutics committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which
we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely
be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries,
private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment
that results from the MMA may result in a similar reduction in payments from non-governmental payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different
treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency
for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related
expenditures will be made to the U.S. Congress. Although the results of the comparative effectiveness studies are not intended to mandate
coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product,
if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness
research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates. If third-party
payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products as a
benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively
referred to as the &#8220;ACA,&#8221; enacted in March 2010, had a significant impact on the health care industry by expanding coverage
for the uninsured. With regard to pharmaceutical products, among other things, ACA is expanded and increased industry rebates for drugs
covered under Medicaid programs and made changes to the coverage requirements under the Medicare Part D program. The administration and
Congress which will take office in January 2017, has pledged to repeal and replace the ACA, largely because of significantly increasing
health insurance premiums and decreasing participation by members of the insurance companies. We cannot predict the impact of any repeal,
replacement or modifications which may be enacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed.
The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its
member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and
to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the
European Union do not follow price structures of the U.S. and generally tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third-party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including
U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others.
Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred,
and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject
to significant penalties for failure to comply with these laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current focus is on the development of our existing portfolio, the completion of clinical trials and, if and where appropriate, the registration
of our product candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization
approval for any of our product candidates, we intend to market the product either directly or through collaborations, strategic alliances
and distribution agreements with third parties. The ultimate implementation of our strategy for realizing the financial value of our
product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability
to negotiate acceptable commercial terms with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have five employees, including our three executive officers, one engaged in research and development
and one in administration. We consider our relationship with our employees to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Rockville, Maryland, where we lease shared access to office space and reception services. Our research
and development activities are performed in approximately 1,727 square feet of laboratory and office space located in Gaithersburg, Maryland.
All of such space is leased from a non-affiliated third party, pursuant to leases expiring in 2023, which provide for an aggregate monthly
rental of $5,757.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists
as we grow. When our lease expires, we may exercise our renewal options or look for additional or alternate space for our operations.
We believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no legal proceedings pending or threatened against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gv_001"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers and their respective ages and titles are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s) and Office(s) Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Vander Hoek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, VP for Operations and Regulatory</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Dritschilo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mira Jung, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer for Biology </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin Rich, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Clinical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Schafer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Richards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Brown, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris Senanayake, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">Bette Jacobs, Ph.D.</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">71</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Independent
                                            Director</p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a description of the background and business experience of our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anatoly
Dritschilo, M.D.</b> is a co-founder of the Company and has served as Chairman of the Board and Chief Executive Officer since the Company&#8217;s
formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health
care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2018; Chief
of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2016; Medical Director of Georgetown University Hospital
from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served
on the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Health
Research Institute. His experience with Pharma includes Board of Directors membership of NeoPharm, Inc, and he was a founding director
of Oncomed (Neopharm). His 200+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy
of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, his medical
degree from the College of Medicine of New Jersey and residency training from the Harvard, Joint Center for Radiation Therapy. His qualifications
support his service as our Chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
P. Vander Hoek</b> serves as the Company&#8217;s Chief Financial Officer, a position he was appointed to in August 2019, and Vice President,
Operations and Regulatory, a position he has held since 2019. From November 2019 until April 2021, Mr. Vander Hoek served as Director,
Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (&#8220;LCCC&#8221;), where he directed a new five-year
$221.9 million institutional commitment for cancer center research under a new NCI-approved cancer consortium arrangement and recruited
scientists to fulfill strategic objectives with senior leaders to improve cancer research and treatment. From 2007 until November 2019,
Mr. Vander Hoek served as Associate Director, Administration, at Georgetown&#8217;s LCCC, where he was responsible for direct administrative
operations for more than 400 faculty and staff in the department of oncology, radiation medicine, pathology and biostatistics, bioinformatics
and biomathematics, including managing $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center
(&#8220;JTCC&#8221;), and Georgetown University. and implementing an enterprise-wide clinical trial management system for Georgetown
University and Medstar Health. From 2004 until 2007, Mr. Vander Hoek served as Chief Financial Officer at Georgetown&#8217;s LCCC. During
his time at Georgetown, Mr. Vander Hoek negotiated a series of 12 research integration agreements between LCCC and the JTCC that resulted
in the approval of an NCI recognized Consortium in 2019. From 2001 until 2004, Mr. Vander Hoek served as Vice-Chair, Planning and Administration,
at MedStar Georgetown University Hospital, where he was responsible for managing administrative and financial operations for some 440
staff, physicians, residents and fellows in the departments of Medicine and Neurology. From 1996 until 2001, Mr. Vander Hoek served as
Senior Associate Administrator, Finance and Information Systems, for the Department of Medicine, Georgetown University Medical Center,
where he designed and managed the faculty compensation system, while managing the finances and information systems for the department.
His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America
from 1990 to 1993 and Regional Controller for Laboratory Corporation of America (LabCorp) from 1993 to 1996. His responsibilities at
both companies included extensive financial management related to mergers, acquisitions, and start-up operations. Mr. Vander Hoek holds
a Master&#8217;s in Health Services Administration from The George Washington University and a Bachelor of Arts in Biology and Psychology
from Hope College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter
Dritschilo </b>has served as our President and Chief Operating Officer since Shuttle was formed in December 2012. He also served as our
Chief Financial Officer from December 2012 until August 2019. Mr. Dritschilo has over 20 years of business management experience in medical
services and cancer treatment. He has held administrative positions with Medstar-Rad America from 2001 to 2005, Georgetown University
2005 to 2006, Prince William Hospital and the Fauquier Hospital Cancer Center 2006 to 2011 and Inova Health System&#8217;s Schar Cancer
Institute from 2011 to 2018. In 2014, Mr. Dritschilo filed for Chapter 7 bankruptcy protection due to the failure of a personal business
venture. Mr. Dritschilo graduated from Georgetown University and received his MBA from the George Washington University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mira
Jung, Ph.D.</b>, a co-founder of our company, presently serves as our Chief Scientific Officer for Biology and was a member of our board
of directors from our formation in December 2012 until 2019. Since 2005, Dr. Jung has served as Professor of Radiation Medicine and Microbiology
at Georgetown University Medical School, with over 20 years of experience in molecular radiation biology research. She is an expert in
mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung&#8217;s research
has been funded by NIH and the DOD leading to 100 publications and six issued patents, including the first reports of HDAC inhibitor
drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree
and a PhD in Microbiology and Molecular Virology from the University of Kansas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tyvin
A. Rich, M.D.</b> serves as our company&#8217;s Chief Medical Officer and is responsible for the clinical development of novel radiation
sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton
Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010,
Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center. And prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department
of Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials
that advanced the use of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional
5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and
book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and
completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General, Harvard
Medical School.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joshua
Schafer </b>was appointed to be a member of our company&#8217;s board of directors in 2019. Since 2015, he has served as Senior Vice
President and Head of Corporate Strategy and Business Development for Mallinckrodt Pharmaceuticals Incorporated. From 2009 until 2015,
he served as Vice President and Oncology Therapeutic Area Head at Astellas Pharmaceuticals Incorporated, where he was responsible for
building the company&#8217;s global oncology franchise. From 2000 until 2009, Mr. Schafer served in positions of increasing seniority
at Takeda Pharmaceuticals North America, including Manager and Senior Manager, New Product and New Business Development; Senior Product
Manager, Gastrointestinal Marketing; and Director, Oncology and Renal Marketing and Commercial Development. He began working in the healthcare
and pharmaceutical industry in 1998, and has served in various positions including management consulting at Accenture (formerly Anderson
Consulting), G.D. Searle &amp; Co. (later acquired by Pfizer) and Cognia Corporation. He received his Bachelor of Arts in Biology and
German at the University of Notre Dame, his MS in Biotechnology from Northwestern University and his MBA from Northwestern University.
We believe Mr. Schafer&#8217;s extensive experience in pharmaceutical strategy, marketing and business development will assist our board&#8217;s
oversight role as we build and develop our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steven
Richards </b>was appointed to be a member of our company&#8217;s board of directors in 2019. He is CEO and Founder of Endurance Media,
a media finance company based in Santa Monica, California, that launched in 2014 with a strategic alliance with eOne Entertainment and
a mandate to produce and finance commercially driven feature films. From 2006 to 2014, Mr. Richards served as Co-President and Chief
Operating Officer of Silver Pictures where he oversaw all business activities and managed a team of more than 20 people responsible for
film development, production and financial information. From 2000 to 2006, he served as Chief Financial Officer at Silver Pictures and
from 1995 to 2000 as Vice President, Finance, at Silver Pictures. Mr. Richards holds an MBA in Finance from UCLA, a BBA in accounting
from Temple University, and holds his CPA license. We believe his experience as a chief financial officer and in accounting will assist
in providing our board guidance and oversight as we grow our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milton
Brown, M.D., Ph.D.</b> is a co-founder of our company, previously served as our Chief Scientific Officer for Chemistry, and has served
a member of our board of directors since we were formed in December 2012. Since August 2022, Dr. Brown has also served as Vice Dean of
Research at Eastern Virginia Medical School. Dr. Brown was a founder in 2004 of Rivanna Pharmaceuticals, a Virginia-based biopharmaceutical
company engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurological diseases and
cancer. Since 2012, Dr. Brown has served as Director of the Drug Discovery Center at Georgetown University Medical School and since 2010,
he has been the principal investigator of the NIH/NCI funded Chemical Diversity Center. He brings to Shuttle 15 years of experience in
drug discovery with over 80 publications and eight issued patents, including discovery of novel HDAC inhibitors and has two drugs currently
in clinical trials. He has served on government committees including the NIH Experimental Therapeutics Study Section, the NIH Drug Discovery
and Molecular Pharmacology Study Section and was a scientific counselor to the U.S. Secretary of Health. Dr. Brown holds a Ph.D. in synthetic
chemistry from University of Alabama, and an MD from the University of Virginia. His extensive experience and expertise in drug discovery
makes him uniquely qualified to direct the company&#8217;s drug discovery program and serve as our director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chris
Senanayake, Ph.D. </b>was appointed to be a member of the Company&#8217;s board of directors in 2021. He is CEO and Founder of TCG GreenChem,
Inc., a US subsidiary of TCG Lifesciences Pvt. Ltd., a leading global Contract Research and Manufacturing Services (CRAMS) company in
the area of drug discovery, development and commercialization. Dr. Senanayake has more than 30 years of pharmaceutical industry experience,
making him an invaluable asset to Shuttle Pharma&#8217;s mission as the Company advances its pharmaceutical candidates in clinical trials.
He is the Founder and Chief Executive Officer (CEO) of TCG GreenChem Inc. and Chief Scientific Officer of TCG Lifesciences, Pvt. Ltd.
He has held positions of Senior Scientist at Dow Chemical, and Research Fellow at Merck &amp; Co, Inc. Director and Executive Director
of Process Research at Sepracor, Inc. (1996 to 2002), Director of Chemical Development and Vice President of Chemical Development for
Boehringer Ingelheim Pharmaceuticals, Inc. In 2018, he was appointed as the CEO of Asta GreenChem, Inc in Richmond VA and Astatech (Chengdu)
Biopharmaceuticals Corp. in China. He has a record of leading and delivering on high complexity APIs for manufacturing. Dr. Senanayake
participated in development activities of many drugs, including multi-billion-dollar blockbuster drugs, such as Crixivan, Lunesta, Jardiance,
Formotorol, Desvenlafaxine and other drug candidates. He is co-author of 425 scientific publications and is co-inventor of more than
150 patents. We believe he will provide value to us by introducing potential joint venture partners, as well as enhancing our oversight
through his in-depth understanding of and experience in the pharmaceuticals industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Bette Jacobs, Ph.D.</b>&#160;was appointed
to be a member of the Company&#8217;s board of directors in October 2022. Dr. Jacobs is an experienced researcher, administrator and
businesswoman currently serving as a professor in the department of health systems administration at Georgetown University and as a distinguished
scholar at the O&#8217;Neill Institute for National and Global Health Law. Dr. Jacobs holds her Ph.D. from the University of Texas and
is noted for her groundbreaking transdisciplinary and cross-sector work in systems design. As a voting member of the Cherokee Nation,
she has lifetime involvement in equity programs and has testified before Congress. In addition to serving on several start-up boards,
Dr. Jacobs founded the National Coalition of Ethnic Minority Nurse Associations funded by the NIH National Institute of General Medical
Sciences. Prior to her current role at Georgetown, she served as dean at the Georgetown School of Nursing and Health Studies, vice president
for Honda of America Manufacturing, associate director of applied research at UAB Civitan International Research Center, and acting dean
of graduate studies and research at California State University. She has been a fellow and visiting professor at the University of Oxford
and an academic guest scholar and lecturer at several acclaimed universities worldwide. Her wealth of experience in research, administration
and serving on boards coupled with her unique background and perspectives makes her ideally suited to serving as a member of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theodore
L. Phillips, M.D.</b> has served as the Chair of our Scientific Advisory Committee since 2018. He held the position of Chief Medical
Officer and Clinical Director at Shuttle Pharmaceuticals from 2014 until 2018. Dr. Phillips&#8217; distinguished career has included
positions of Chair of the Department of Radiation Oncology (from1978 to 1998) and Associate Director (from 1996 to 1999) of the UCSF
Cancer Center at the University of California at San Francisco. He is highly experienced in radiation oncology clinical trials of hypoxic
radiation sensitizers. Dr. Phillips served as the principal investigator of the SBIR contract for the Phase I clinical trial of Ropidoxuridine.
He previously served as Associate Director of the Northern California Oncology Group from 1983-1990, president of the American Society
of Therapeutic Radiation Oncologists from 1984 to 1985, and is an elected member of the Institute of Medicine of the National Academy
of Science. Dr. Phillips holds a BS degree from Dickinson College in Carlisle, Pennsylvania and a MD from the University of Pennsylvania.
He provides advice to the leadership team to help design and implement clinical trials of radiation therapy and radiation response modifying
drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ralph
R. Weichselbaum, M.D. </b>has served as Scientific Advisor to Shuttle Pharmaceuticals for translational research for the discovery and
development of radiation response modifiers since 2013. Dr. Weichselbaum is the Daniel K. Ludwig Professor and Chairman of the Department
of Radiation and Cellular Oncology, the University of Chicago, a position he has held since 1985. He is also an elected member of the
Institute of Medicine, National Academy of Sciences. He has devoted his career to translational research in cancer with combined radiotherapy
and chemotherapy. Dr. Weichselbaum and his colleagues conceived &#8220;genetic radiotherapy&#8221; and developed viral constructs for
use in clinical tumor radiation sensitization. These were commercialized as TNFerade (GenVec, Inc.) and tested in a Phase I clinical
trial in prostate cancer and a Phase III clinical trial for pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
Martin Brown, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals for translational research for the development
of hypoxic radiation sensitizers since 2017. Dr. Brown received his Ph.D.in Cancer Biology from Oxford University in 1968 and was Director
of the Division of Radiation and Cancer Biology at Stanford University from 1984 to 2004. He is an expert in the radiation biology of
hypoxia in cancers and has more than 300 peer-reviewed published articles. He has received awards in recognition of his work, including
the Gold Medal, American Society for Therapeutic Radiology and Oncology (1999, the Failla Memorial Award, Radiation Research Society
(2000), the Weiss Medal, Association for Radiation Research (2001) and the Henry S. Kaplan Distinguished Scientist Award, International
Association for Radiation Research (2007). He developed etanidazole, a hypoxic radiation sensitizer, and tirapazamine, a hypoxic cytotoxic
drug, from bench to clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alejandro
Villagra, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics
and immunology since 2017. Dr. Villagra received his Ph.D. in Molecular Biology from the University of Concepcion, in Chile in 2004 and
completed post-graduate training at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in Molecular Immunology
in 2009, in the Laboratory of Eduardo Sotomayor, MD. He joined the faculty of the Moffitt Cancer Center and Research Institute, as a
research scientist from 2009 through 2015 and advanced to Assistant Professor of Oncologic Sciences. He became an Assistant Professor
in the Department of Biochemistry and Molecular Medicine at the George Washington University (GWU) School of Medicine and Health Sciences
in 2015, as a member of the GWU Cancer Center. His research is focused on molecular and cellular roles of histone deacetylases (HDACs)
in tumor immunology and as adjuvants for immunotherapy of cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joseph
Armstrong, III, Ph.D.</b> joined as a Scientific Advisor to Shuttle Pharmaceuticals in 2021, He received his Ph.D. from the University
of Colorado in 1988, completed his post-doctoral work at the University of Virginia at Charlottesville and holds the position of Chief
Operating Officer at and Global Head of Business Development TCG GreenChem, Inc. He provides industry experience in chemistry, drug development
and process research, having previously held positions at Merck &amp; Co. Inc. in Rahway, N.J and in the U.K. for two pharmaceutical
companies in the areas of Pharmaceutical Research and Development. His primary areas of focus have been in the design and implementation
of efficient synthesis of drug candidates amenable to large scale production. Dr. Armstrong led the development team that designed, developed
and implemented the manufacturing process for the new treatment for Type II diabetes, Januvia TM. His team was awarded the Solvias Prize
in 2004 (Basel, Switzerland), the IChemE Aztra-Zeneca Award for Green Chemistry and Engineering in 2005 (London, England), Dr. Armstrong
has more than 40 publications and holds 10 patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Anatoly Dritschilo and Peter Dritschilo are father and son. There are no other family relationships among our directors and executive
officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is responsible for overseeing the Company&#8217;s business consistent with its fiduciary duty to the stockholders.
This significant responsibility requires highly skilled individuals with various qualities, attributes and professional experience. There
are general requirements for service on the board that are applicable to directors and there are other skills and experience that should
be represented on the board as a whole but not necessarily by each director. Our Corporate Governance and Nominating Committee, detailed
below, considers the qualifications of director candidates individually and in the broader context of the board&#8217;s overall composition
and the Company&#8217;s current and future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors were initially appointed for staggered two and three-year terms as initial appointments. The Chairman of the Board is also
the CEO and was appointed for an initial three-year term. Following this offering, we intend that all of our directors will be elected
to one-year terms to hold office until the next annual meeting of our stockholders and until a successor is appointed and qualified,
or until their removal, resignation, or death. Executive officers serve at the pleasure of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to qualify to list our shares of common stock for trading on Nasdaq, our board of directors must consist of a majority of &#8220;independent&#8221;
directors, as defined under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. At present, four of the six directors
serving on our board of directors qualify as &#8220;independent.&#8221; Our independent directors consist of Messrs. Adkins, Richards
and Schafer and Dr. Senanayake.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established three committees consisting of an audit committee, a compensation committee, and a nominating and
corporate governance committee. The members of each committee qualify as &#8220;independent&#8221; as defined under Nasdaq listing standards
and Rule 10A-3(b)(1). Moreover, at least one member of the audit committee qualifies as an &#8220;audit committee financial expert&#8221;
as the term is defined under Nasdaq listing standards and applicable rules and regulations of the SEC, based on their respective business
professional experience in the financial and accounting fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee, which consists of Steve Richards, MBA, CPA (Chair), Bette Jacobs and Chris Senanayake, assists our board
of directors in its oversight of the Company&#8217;s accounting and financial reporting processes and the audits of the Company&#8217;s
financial statements, including (a) the quality and integrity of the Company&#8217;s financial statements (b) the Company&#8217;s compliance
with legal and regulatory requirements, (c) the independent auditors&#8217; qualifications and independence and (d) the performance of
the Company&#8217;s internal audit functions and independent auditors, as well as other matters which may come before it as directed
by the board of directors. Further, the audit committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be responsible for the
    appointment, compensation, retention, termination and oversight of the work of any independent auditor engaged for the purpose of
    preparing or issuing an audit report or performing other audit, review or attest services for the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss the annual audited
    financial statements and the quarterly unaudited financial statements with management and the independent auditor prior to their
    filing with the SEC in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review with the Company&#8217;s
    management on a periodic basis (i) issues regarding accounting principles and financial statement presentations, including any significant
    changes in our company&#8217;s selection or application of accounting principles; and (ii) the effect of any regulatory and accounting
    initiatives, as well as off-balance sheet structures, on the financial statements of the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor the Company&#8217;s
    policies for compliance with federal, state, local and foreign laws and regulations and the Company&#8217;s policies on corporate
    conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain open, continuing
    and direct communication between the board of directors, the audit committee and our independent auditors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor our compliance
    with legal and regulatory requirements and will have the authority to initiate any special investigations of conflicts of interest,
    and compliance with federal, state and local laws and regulations, including the Foreign Corrupt Practices Act, as may be warranted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee, which consists of Steve Richards (Chair) and Joshua Schafer, aids our board of directors in meeting its responsibilities
relating to the compensation of the Company&#8217;s executive officers and to administer all incentive compensation plans and equity-based
plans of the Company, including the plans under which Company securities may be acquired by directors, executive officers, employees
and consultants. Further, the compensation committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review periodically our
    Company&#8217;s philosophy regarding executive compensation to (i) ensure the attraction and retention of corporate officers; (ii)
    ensure the motivation of corporate officers to achieve the Company&#8217;s business objectives; and (iii) align the interests of
    key management with the long-term interests of the Company&#8217;s shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review and approve corporate
    goals and objectives relating to chief executive officer compensation and other executive officers of Shuttle;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make recommendations to
    the board of directors regarding compensation for non-employee directors, and review periodically non- employee director compensation
    in relation to other comparable companies and in light of such factors as the compensation committee may deem appropriate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review periodically reports
    from management regarding funding the Company&#8217;s pension, retirement, long-term disability and other management welfare and
    benefit plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee, which consists of Joshua Schafer (Chair), Steve Richards and Bette Jacobs,
recommends to the board of directors individuals qualified to serve as directors and on committees of the board of directors to advise
the board of directors with respect to the board of directors composition, procedures and committees to develop and recommend to the
board of directors a set of corporate governance principles applicable to the Company, and to oversee the evaluation of the board of
directors and Shuttle&#8217;s management. In addition, the nominating and corporate governance committee will consider diversity of background
including diversity of race, ethnicity, international background, gender and age when evaluating candidates for board membership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the nominating and corporate governance committee, to the extent it deems necessary or appropriate, among its several other responsibilities
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend to the board
    of directors and for approval by a majority of independent directors for election by shareholders or appointment by the board of
    directors as the case may be, pursuant to our bylaws and consistent with the board of director&#8217;s evidence for selecting new
    directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review the suitability
    for continued service as a director of each member of the board of directors when his or her term expires or when he or she has a
    significant change in status;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review annually the composition
    of the board of directors and to review periodically the size of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make recommendations on
    the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make recommendations regarding
    the chairmanship and composition of standing committees and monitor their functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review annually committee
    assignments and chairmanships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend the establishment
    of special committees as may be necessary or desirable from time to time; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and periodically
    review corporate governance procedures and consider any other corporate governance issue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge,
to any shareholder requesting a copy in writing from our Secretary at our executive offices in Rockville, Maryland. A copy of our code
of ethics is available on our website at www.shuttlepharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the board of directors have periodic meetings with management and the Company&#8217;s independent auditors to perform risk oversight
with respect to the Company&#8217;s internal control processes. The Company believes that the board&#8217;s role in risk oversight does
not materially affect the leadership structure of the Company. The Company believes that its founders, leadership team and members of
the board of directors exemplify diversity and inclusivity with respect to race, sex and ethnic origin. The board of directors presently
has two diverse directors and is in the process of reviewing and vetting a female candidate to serve as a director. As such, the Company
anticipates being in full compliance with Nasdaq&#8217;s newly adopted diversity requirements by the end of its first year of listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gv_002"></span>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and
certain of our other executive officers for 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Name
and principal position</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Salary ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bonus<br /> ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Stock Awards ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Option Awards ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Non-Equity Incentive Plan Compensation ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Nonqualified Deferred Compensation Earnings<br /> ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">All Other Compensation ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total<br /> ($)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Anatoly Dritschilo M.D., CEO</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">18,829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">18,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Michael Vander Hoek, CFO, VP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Dritschilo, President and COO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,534</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,970</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our executive officers has entered into an employment agreement with us. The employees each will receive compensation on an annual
basis in cash, payable in monthly installments commencing at the completion of this offering, as well as restricted stock units subject
to achieving certain key performance indicators. Certain of our executive officers are entitled to various target bonuses, upon achievement
of certain milestones. The terms of the employment agreements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Anatoly Dritschilo, MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2019, we entered into an employment agreement with our Chief Executive Officer and Chairman of the Board, Anatoly Dritschilo,
M.D. Under Dr. Dritschilo&#8217;s employment agreement, Dr. Dritschilo will receive base compensation of $274,000 per year. Dr. Dritschilo
also received an initial restricted stock unit grant of 45,495 restricted stock units (&#8220;RSUs&#8221;) (22,747 on a post-reverse
split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal one-third
installments on each one year anniversary of the agreement. Under his employment agreement, if Dr. Dritschilo terminates his employment
for &#8220;Good Reason,&#8221; as defined in the agreement, Dr. Dritschilo will be entitled to his then applicable base salary for period
of 12 months, subject to his continued compliance with certain requirements of his employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Vander Hoek</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2019, we entered into an amended employment agreement with our Chief Financial Officer and Vice President for Operations
and Regulatory, Michael Vander Hoek. Under Mr. Vander Hoek&#8217;s employment agreement, he will receive base compensation of $227,000
and is entitled to a target bonus of $72,000 upon achievement of certain milestones. Mr. Vander Hoek also received an initial restricted
stock unit grant of 6,096 RSUs (on a post-reverse split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs
vest over three years in substantially equal installments on each one year anniversary of the agreement. Under Mr. Vander Hoek&#8217;s
employment agreement, if he terminates his employment for &#8220;Good Reason,&#8221; as defined in the agreement, he will be entitled
to his then applicable base salary for period of 12 months, subject to his continued compliance with certain requirements of his employment
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Peter Dritschilo</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2019, we entered into an employment agreement with our President and Chief Operating Officer, Peter Dritschilo. Under Mr. Dritschilo&#8217;s
employment agreement, Mr. Dritschilo will receive base compensation of $236,000 and is entitled to a target bonus of $72,000 upon achievement
of certain milestones. Mr. Dritschilo also received an initial restricted stock unit grant of 20,760 RSUs (10,380 on a post-reverse split
basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments
on each one year anniversary of the agreement. Under Mr. Dritschilo&#8217;s employment agreement, if Mr. Dritschilo terminates his employment
for &#8220;Good Reason,&#8221; as defined in the agreement, he will be entitled to his then applicable base salary for period of 12 months,
subject to his continued compliance with certain requirements of his employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Tyvin Rich, MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2019, we entered into an employment agreement with our Chief Clinical Officer, Tyvin Rich, M.D. Under Dr. Rich&#8217;s employment
agreement, Dr. Rich receives base compensation of $218,000 per year and is entitled to a target bonus of $43,000 upon achievement of
certain milestones. Dr. Rich also received an initial restricted stock unit grant of 3,843 RSUs (on a post-reverse split basis) issuable
under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one
year anniversary of the agreement. Under Dr. Rich&#8217;s employment agreement, if Dr. Rich terminates his employment for &#8220;Good
Reason,&#8221; as defined in the agreement, he is entitled to his then applicable base salary for period of 12 months, subject to his
continued compliance with certain provisions of his employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Mira Jung, Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2019, we entered into an employment agreement with our Chief Scientific Officer for Biology, Mira Jung, Ph.D. Under Dr. Jung&#8217;s
employment agreement, Dr. Jung receives base compensation of $46,800 and is entitled to a target bonus of $14,200 upon achievement of
certain milestones. Dr. Jung also received an initial restricted stock unit grant of 892 RSUs (on a post-reverse split basis) issuable
under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one
year anniversary of the agreement. Under Dr. Jung&#8217;s employment agreement, if Dr. Jung terminates her employment for &#8220;Good
Reason,&#8221; as defined in the agreement, Dr. Jung is then entitled to her then applicable base salary for period of 12 months, subject
to her continued compliance with certain requirements of her employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a post-reverse split basis, a total of 384,167 RSUs have been granted to our executive officers under our 2018 Equity Incentive Plan
(the &#8220;Plan&#8221;), of which 357,390 have vested to date yet remain unissued. After completion of this public offering, it is our
intent to file a registration statement on Form S-8 to register the shares granted under our 2018 Equity Incentive Plan, at which time
we will issue all such vested shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018
Equity Incentive Stock Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee
or, alternatively, if there is no compensation committee, the Company&#8217;s board of directors. We have reserved 3,000,000 shares of
our common stock for issuance under the 2018 Equity Incentive Plan (the &#8220;Plan&#8221;), of which 384,167 shares have been granted
under the Plan as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of our non-employee directors, pursuant to
the terms of director agreements (the &#8220;Director Agreements&#8221;), between each of the directors and the Company, receives
compensation on an annual basis consisting of $25,000 in cash, payable in quarterly installments commencing 90 days after completion
of our initial public offering, and received $100,000 in restricted stock units (&#8220;RSUs&#8221;) upon their respective dates of
election. The RSUs vest over a two-year period in one third increments, with one-third vesting immediately upon signing and one-third
vesting on each of the first and second anniversary of election. In addition, non-employee directors will also be reimbursed for out-of-pocket
costs incurred in connection with attending meetings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gv_003"></span>PRINCIPAL
STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this prospectus, the beneficial ownership of our common stock by each director and executive
officer, by each person known by us to beneficially own 5% or more of our common stock and by directors and executive officers as a group.
Unless otherwise stated, the address of the persons set forth in the table is c/o Shuttle Pharmaceuticals Holdings, Inc., One Research
Court, Suite 450, Rockville, Maryland 20850.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Unless
otherwise indicated, the stockholders listed in the table below have sole voting and investment power with respect to the shares indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share ownership figures include shares of our commons stock issuable upon securities convertible or exchangeable into shares of our common
stock, whether or not convertible or exchangeable within 60 days of the effective date of this registration statement. Such shares are
deemed outstanding and beneficially owned by such person only for purposes of computing his or her percentage ownership, but not for
purposes of computing the percentage ownership for any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 23, 2023, there were issued and outstanding 13,630,129 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Names and addresses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> shares of<br /> common
    stock<br /> beneficially<br /> owned (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of<br /> shares of<br /> common stock<br /> beneficially<br /> owned before<br /> offering (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> shares of<br /> common
    stock<br /> beneficially owned<br /> after the offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of<br /> shares of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock
                                            beneficially<br /> owned after<br /> offering (%) (1)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo, M.D.<sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,309,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">31.6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,309,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">17.6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Brown, M.D., Ph.D.<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,072,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,072,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mira Jung, Ph.D.</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,071,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,071,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Vander Hoek</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Dritschilo</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin A. Rich, M.D. </span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Richards</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Schafer</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris Senanayake</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette Jacobs<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All directors and officers as a group (ten persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,466,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,466,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other 5% beneficial owners:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir F. Heshmatpour<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,569,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,569,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes the holder owns
    less than one percent of the outstanding common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#177;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The persons named above
    have full voting and investment power with respect to the shares indicated. Under the rules of the SEC, a person (or group of persons)
    is deemed to be a &#8220;<b>beneficial owner</b>&#8221; of a security if he or she, directly or indirectly, has or shares the power
    to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition of such security. Accordingly,
    more than one person may be deemed to be a beneficial owner of the same security.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Assumes all 10,762,684 shares registered in this resale
    registration statement are actually issued, thus causing there to be a total of 24,392,813 shares outstanding following such issuance.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 1,085,191 shares of common stock held of record by Dr. Anatoly Dritschilo and (ii) 3,204,407 shares of common stock and
warrants to purchase 20,000 shares of commons stock, each held of record by Joy Dritschilo, his spouse. Dr. Dritschilo disclaims beneficial
ownership over all securities held by Mrs. Dritschilo.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dr. Jacobs holds 7,496 shares of common stock and
    23,725 restricted stock units which remain subject to vesting conditions.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 1,119,581
    shares of our common stock held of record by AFH Holding &amp; Advisory, LLC, of which Mr. Heshmatpour is the sole member and over
    which he has sole voting and investment control; (ii) 300,000 shares of our common stock held of record by KIG LLC of which Mr. Heshmatpour&#8217;s
    spouse, Kathy Heshmatpour, exercises sole voting and investment control; and (iii) 150,000 shares held by Angelina Heshmatpour, the
    minor daughter of Mr. Heshmatpour.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gv_004"></span>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we were a party
or will be a party, in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amounts involved exceed
    or will exceed $120,000; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any of our directors, executive
    officers or holders of more than 5% of our capital stock, or any member of the immediate family of any of the foregoing had, or will
    have, a direct or indirect material interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2018, Shuttle entered into a loan from Joy Dritschilo, the wife of our Chief Executive Officer, Anatoly Dritschilo, in the
amount of $300,000 (the &#8220;January 2018 Loan&#8221;). The January 2018 Loan bears an interest rate of 7.5% per annum. The loan plus
accrued interest was payable in full on January 25, 2019. On January 25, 2019, the Company amended the terms to extend the maturity date
from January 25, 2019 to October 25, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2018, Shuttle entered into a loan from Mrs. Dritschilo in the amount of $50,000 (the &#8220;April 2018 Loan&#8221;). The April
2018 Loan bears an interest rate of 7.5% per annum. The loan plus accrued interest were payable in full on September 4, 2018. On October
31, 2018, the Company amended the terms to extend the maturity date of the April 2018 Loan from September 4, 2018 to April 4, 2019. On
April 4, 2019, the Company amended the terms to extend the maturity date from April 4, 2019 to October 25, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2018, our predecessor in interest, Shuttle Pharma Acquisition Corp. Inc. (&#8220;Acquisition Corp.&#8221;), issued 3,600,000
shares to its founders, AFH Holding &amp; Advisory, LLC and its affiliates (together, &#8220;AFH&#8221;). Such shares were issued at
par value. AFH has also served as an advisor and consultant to the Company, and its owner, Amir Heshmatpour, has also served as a board
member to our Company, a position he relinquished in advance of our commencement of the IPO process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2018, the Company entered into a loan with our Chief Executive Officer in the amount of $25,000 (the &#8220;May 2018 Loan&#8221;).
The May 2018 Loan bears interest at the rate of 7.5% per annum. The loan plus accrued interest were payable in full on July 15, 2018.
On October 31, 2018, the Company amended the terms to extend the maturity date from July 15, 2018 to November 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2018, the Company entered into a loan with our Chief Executive Officer in the amount of $25,000. The loan bears an interest
rate of 7.5% per annum. The loan plus accrued interest were payable in full on August 15, 2018. On December 6, 2018, the Company amended
the terms to extend the maturity date from August 15, 2018 to February 15, 2019. On February 19, 2019, the Company paid off this note
in full. The interest expense incurred on this loan was $1,223 for the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the Company entered into a loan from Mrs. Dritschilo in the amount of $70,000. The loan bears an interest rate of 7.5%
per annum. The loans plus accrued interest are payable in full on June 23, 2020. This loan has since been satisfied in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fall of 2018 through to June 2019, we paid a total of $500,000 in cash to pay for a deposit on Acquisition Corp. in order to facilitate
the process of taking the Company public.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company issued 639,161 RSUs to our then consultant, AFH, to satisfy certain compensation owed to the consultant in
relation to certain advisory services provided during 2018 and 2019. Such shares were issued pursuant to the Company&#8217;s 2018 Equity
Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2019, the Company entered into a loan with our Chief Executive Officer in the amount of $70,000. The loan bears interest at
the rate of 7.5% per annum. The loan plus accrued interest is due and payable in full on August 24, 2020. This loan has since been satisfied
in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company entered into a loan with our Chief Executive Officer in the amount of $100,000 (the &#8220;September
2019 Loan&#8221;). The September 2019 Loan bear interest at the rate of 7.5% per annum and the loan plus accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the January 2018 Loan and the April 2018 Loan into a single loan between Mrs. Dritschilo and
the Company (the &#8220;2018 Consolidated Loan&#8221;) such that, with accrued interest, the 2018 Consolidated Loan had a principal balance
of $424,005.65, bears interest at a rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2018 Consolidated Loan
was extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022. On July 29,
2022, the Company and Mrs. Dritschilo entered into an amendment to the 2018 Consolidated Loan, pursuant to which repayment was extended
through June 30, 2023. </span>On January 15, 2023<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
following closing on the Convertible Note and Warrant offering to Ayrton Capital, the 2018 Consolidated Loan was paid off in full.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the May 2018 Loan and the September 2019 Loan with our Chief Executive Officer (the &#8220;2019
Consolidated Loan&#8221;), such that, with accrued interest, the 2019 Consolidated Loan had a principal balance of $138,448.20, bears
interest at the rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2019 Consolidated Loan was extended until June
30, 2022, pursuant to an amendment to the 2019 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and
our Chief Executive Officer entered into an amendment to the 2019 Consolidated Loan, pursuant to which repayment was extended through
June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan agreement with Mrs. Dritschilo in the amount of $120,000 (principal), bearing interest
at the rate of 7.5% per annum, with a single balloon payment due at maturity on June 21, 2022 (the &#8220;June 2021 Loan Agreement&#8221;).
On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the June 2021 Loan Agreement, pursuant to which repayment
was extended through June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2021, Mrs. Dritschilo, who is one of our major shareholders, transferred 210,000 shares (105,000 shares post-split) of
common stock of the Company in a private transaction to Steven Bayern, who had also been engaged by the Company to perform certain consulting
services for the Company. Such shares, which represent approximately three percent of her total share ownership, were sold at par value
pursuant to an exemption from registration under Section 4(a)(7) of the Securities Act. As a result of the transfer, the Company recognized
$420,000 in non-cash stock compensation in legal and professional fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with our private placement of $125,000 of units consisting of 10% notes and warrants to purchase common
stock, which were sold to three accredited investors in total, Mrs. Dritschilo purchased a $50,000 note and received warrants to purchase
20,000 shares of common stock at $2.50 per share. The notes and warrants were sold pursuant to an exemption from registration pursuant
to Rule 506(b) of Regulation D of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval and Ratification of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_001"></span>DESCRIPTION
OF CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 20,000,000 shares of preferred
stock, par value $0.00001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had 13,575,990 shares of common stock issued and outstanding. Each holder of common stock is entitled
to one vote for each share owned on all matters voted upon by shareholders, and a majority vote is required for all actions to be taken
by shareholders. In the event we liquidate, dissolve or wind-up our operations, the holders of the common stock are entitled to share
equally and ratably in our assets, if any, remaining after the payment of all our debts and liabilities and the liquidation preference
of any shares of preferred stock that may then be outstanding. The common stock has no preemptive rights, no cumulative voting rights,
and no redemption, sinking fund, or conversion provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive dividends, if and when declared by the board of directors, out of funds legally available for
such purpose, subject to the dividend and liquidation rights of any preferred stock that may then be outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority, without further action by the shareholders, to issue shares of preferred stock in one or more series
and to fix the rights, preferences and the number of shares constituting any series or the designation of such series. While our Certificate
of Incorporation and Bylaws, each as amended to date, do not contain any provisions that may delay, defer or prevent a change in control,
the issuance of preferred stock may have the effect of delaying or preventing a change in control or make removal of our management more
difficult. At present, our board of directors has authorized the issuance of up to 10,000 shares of Series A preferred stock, of which
1,212.5 shares are issued and outstanding as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has designated and authorized the issuance of up to 10,000 shares of Series A Convertible Preferred Stock, par value
$0.00001 per share (the &#8220;Series A Convertible Preferred Stock&#8221;), of which there are presently 1,212.5 shares outstanding.
A total of $1,212,500 was raised during 2018 and 2019 from the sale of our Series A Convertible Preferred Stock. The Series A Convertible
Preferred Stock has a stated value of $1,000 per share, is entitled to receive a dividend at the rate of 8.5% per annum, which dividend
is cumulative and will be payable at our option in shares of common stock or cash upon the date of conversion or redemption, as so determined
by the Company. The Series A Convertible Preferred Stock will be automatically convertible upon the earlier of (a) the closing of the
sale of shares of common stock to the public at an offering price of at least $5.00 per share in a firm commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act, resulting in gross proceeds to us (before underwriter&#8217;s
discounts, commissions and expenses) of an amount of at least $10 million (a &#8220;Qualified IPO&#8221;), or (b) listing of the common
stock on the NYSE or Nasdaq (a &#8220;Qualified Listing&#8221;). All shares of Series A Convertible Preferred Stock will be convertible
at either (i) 90% of the gross public offering price per share of the Qualified IPO (before deducting underwriter&#8217;s discounts,
commissions and expenses) or (ii) in the case of (b) above, $5.00 per share. Following consummation of our IPO, the Series A Convertible
Preferred Stock was converted into a total of 336,810 shares of common stock, plus an additional 100,517 shares of common stock paid
to the Series A Convertible Shareholders as dividends payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with our sale of Series A Convertible Preferred Stock, our board of directors authorized the issuance of warrants to purchase
up to approximately 336,810 shares of common stock (the &#8220;Series A Warrants&#8221;), to the holders of Series A Preferred
Stock. The Series A Warrants were issued following consummation of our IPO, are exercisable for a period of three years following
issuance, and have an exercise price of $4.00 per share,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
and Warrants</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, we completed a private placement offering (the &#8220;2022 Note and Warrant Offering&#8221;) pursuant to which we
sold to three accredited investors (the &#8220;Note and Warrant holders&#8221;) an aggregate of $125,000 of our 10% promissory
notes, which are due upon completion of this Offering, and warrants to purchase 50,000 shares of common stock, at an exercise price
of $2.50 per share. Such issuance was completed pursuant to an exemption from registration under Rule 506(b) of Regulation D of the
Securities Act. Boustead Securities, LLC acted as placement agent in the Note and Warrant offering but deferred its cash compensation
in relation to such offering. At the time of the IPO, 30,000 of the warrants sold in 2022 Note and Warrant Offering were registered for resale
pursuant to a separate resale prospectus and were subsequently exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6%
Convertible Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, we completed private placement offerings pursuant to which we sold to several accredited
investors an aggregate of $365,000 and $225,000, respectively, of our 6% convertible notes due three years from the date of issuance
(the &#8220;Convertible Notes&#8221;), pursuant to an exemption from registration under Rule 506(b) of Regulation D of the Securities
Act. Boustead Securities, LLC acted as placement agent in the Convertible Note and Warrant offering and received commissions and non-accountable
reimbursements of 10% of the gross proceeds received and warrants to purchase 10% of the common stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completion of this Offering, the Convertible
Notes will automatically convert into units, comparable to those issued in this Offering, at a conversion price equal to 50%
of the per share price in our initial public offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Convertible Note offering, each purchaser of Convertible Notes entered into an investor rights and lock-up agreement
(the &#8220;Investor Rights and Lock-up Agreement&#8221;) pursuant to which the Company has agreed, upon conversion of the Convertible
Notes, to register the shares of common stock underlying the Convertible Notes and the Convertible Note holders have each agreed not
to sell their shares of common stock for a period of 180 days following completion of this offering. The Convertible Notes were registered in the resale offering prospectus accompanying our IPO prospectus and converted
into shares of common stock upon completion of the IPO.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to a registration rights agreement with the holders of Series A Convertible Preferred Stock pursuant to which
we are obligated to register the shares of common stock underlying the Series A Convertible Preferred Stock and Warrants. The registration
of these shares of common stock would enable the holders to sell their shares without restriction under the Securities Act when the registration
statement is declared effective. We will pay for the registration expenses, other than underwriting discounts and commissions, of any
shares subject to registration rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, in an underwritten offering, the managing
underwriter, if any, has the right, subject to specific conditions, to limit the number of shares such holders may include. As a result
of the underwriter objecting to the registration of the common stock underlying the Series A Convertible Preferred shares in this
offering, we may be required to file a resale registration statement registering the shares, with an obligation of having such registration
statement declared effective within 180 days of the initial filing of such resale registration statement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions
more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal
of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter
transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that
might result in a premium over the market price for our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the
benefits of increased protection of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delaware
Anti-Takeover Statute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Delaware corporations are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
    the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
    persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
    determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
    of the stockholders, and not by written consent, by the affirmative vote of at least 66<sup>2</sup>/<sub>3</sub>% of the outstanding
    voting stock that is not owned by the interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    corporation does not have a class of voting stock that is: (i) listed on a national securities exchange; or (ii) held of record by
    more than 2,000 stockholders, unless any of the foregoing results from action taken, directly or indirectly, by an interested stockholder
    or from a transaction in which a person becomes an interested stockholder</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines business combination to include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge, or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
    of the corporation beneficially owned by the interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or
    through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
or any entity or person affiliated with or controlling or controlled by such entity or person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are currently not subject to the restrictions contained in Section 203, we will become subject to these restrictions if our common
stock is listed on a national securities exchange or we have more than 2,000 stockholders of record of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are traded on The Nasdaq Capital Market under the symbol &#8220;SHPH.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer agent and registrar of our common stock
is VStock Transfer, LLC, of Woodmere, New York. Our transfer agent&#8217;s telephone number is (212) 828-8436.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_002"></span>SHARES
ELIGIBLE FOR FUTURE SALE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock, and we cannot assure you that a liquid trading market for our
common stock will develop or be sustained after this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
90 days after the date of this prospectus, subject to lock-up agreements of 365 days for directors, officer and affiliates and 180 days
for holders of 1% or more of our comment stock (excluding the non-affiliate stockholders whose shares are being registered in the resale
offering), the 9,312,991 shares of our common stock outstanding as of the date of this prospectus will be eligible for sale in the public
market from time to time thereafter pursuant to Rule 144 under the Securities Act, and in some cases, subject to the volume and other
restrictions of Rule 144. In addition, we have 1,212.5 share of Series A convertible preferred common stock, which shares will be convertible
into approximately 336,805 shares of common stock upon the earlier of completion of the offering or the Company&#8217;s listing
on a national securities exchange, as well as warrants to purchase up to 336,805 shares of common stock, which will be issuable
upon closing of this offering. We also have 3,000,000 shares of common stock reserved for issuance under our 2018 Equity Incentive Plan,
of which 384,167 shares have been granted to date. The sale of a significant number of shares of our common stock in the public market
or the perception that such sales may occur could significantly reduce the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
144</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 under the Securities Act, beginning 90 days after the effective date of the registration statement of
which this prospectus is a part, a person (or persons whose shares are aggregated) who is not deemed to have been an affiliate of ours
at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule
144 for at least six  months (including any period of consecutive ownership of preceding non-affiliated holders) would be entitled
to sell those shares, subject only to the availability of current public information about us. A non-affiliated person who has beneficially
owned restricted securities within the meaning of Rule 144 for at least one year would be entitled to sell those shares without regard
to the provisions of Rule 144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person (or persons whose shares are aggregated) who is deemed to be an affiliate of ours and who has beneficially owned restricted securities
within the meaning of Rule 144 for at least six  months would be entitled to sell within any three-month period a number of shares
that does not exceed the greater of one percent of the then outstanding shares of our common stock or the average weekly trading volume
of our common stock reported through Nasdaq or such other market on which our shares of common stock are listed for trading during the
four calendar weeks preceding such sale. Such sales are also subject to certain manner of sale provisions, notice requirements and the
availability of current public information about us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018
Equity Incentive Plan Form S-8 Registration Statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock that we
may issue upon exercise of awards which may be granted under our 2018 Equity Incentive Plan. Such registration statement is expected
to be filed and become effective as soon as practicable after the effectiveness of this registration statement. Accordingly, shares registered
under such registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume
and manner of sale limitations, if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_004"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock being offered hereby has been passed upon by Michelman &amp; Robinson, LLP, California and New York. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_005"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Shuttle Pharmaceuticals Holdings, Inc. appearing in this prospectus and related registration statement
for the years ended December 31, 2021 and 2020 have been audited by BF Borgers CPA PC, an independent registered
public accounting firm, as set forth in their report thereon and are included in reliance upon such report given on the authority of
BF Borgers CPA PC as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_006"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed a registration statement on Form S-1 under the Securities Act with the SEC with respect to the shares of our common stock
offered through this prospectus. This prospectus is filed as a part of that registration statement, but does not contain all of the information
contained in the registration statement and exhibits. Statements made in the registration statement are summaries of the material terms
of the referenced contracts, agreements or documents of the company. We refer you to our registration statement and each exhibit attached
to it for a more detailed description of matters involving the company. You may inspect the registration statement, exhibits and schedules
filed with the SEC at the SEC&#8217;s principal office in Washington, D.C. Copies of all or any part of the registration statement may
be obtained from the Public Reference Section of the SEC, 100 F Street, N.E. Washington, D.C. 20549. Please Call the Commission at 1-800-SEC-0330
for further information on the operation of the public reference rooms. The SEC also maintains a web site at http://www.sec.gov that
contains reports, proxy Statements and information regarding registrants that files electronically with the SEC. Our registration statement
and the referenced exhibits can also be found on this site.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_007"></span>DISCLOSURE
OF SEC POSITION ON INDEMNIFICATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR SECURITIES ACT LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions in our Certificate
of Incorporation, as amended, we will indemnify an officer, director, or former officer or director, to the full extent permitted
by law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_008"></span>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 0.6in; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#fina_001">Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 (unaudited)</a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2 </span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fina_002">Consolidated Statements of Operations for the
    three and nine months ended September 30, 2022 and 2021 (unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3 </span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fina_003">Condensed consolidated Statements of Changes in Stockholders&#8217; Deficit for the three and nine months ended September 30, 2022 and 2021 (unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fina_005">Condensed Consolidated Statements of Cash Flows
    for the three and nine months ended September 30, 2022 and 2021 (unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#fina_006">Notes to Consolidated Financial Statements (unaudited)</a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vba_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: 5081)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-17   </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vba_002">Consolidated
    Balance Sheets as of December 31 2021, and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vba_003">Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vba_004">Consolidated
    Statements of Changes in Stockholders&#8217; Deficit for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vba_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ed_001">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 103; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fina_001"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_zjxYtc8r991d" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20220930" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20211231" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Cash_i02I_maACz5I0_zgpzfLLlmwX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,120,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz5I0_ztPOtudDjzE8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_maACz5I0_zwYBEwQlIFLc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accounts receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0039">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommodityContractAssetCurrent_i02I_maACz5I0_zQsesQyYhI2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contracts receivable</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_mtACz5I0_maAzm1t_z96YLN4RQ01e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,289,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzm1t_z0hNezGfHY27" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssets_i01I_maAzm1t_zI103XW1SPc1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzm1t_zpiqM0nUpVx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,970</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_mtAzm1t_z3rHWNhnufY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,382,016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_i02I_maLCzU5X_zZ0lW09f6b38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maLCzU5X_zW0iarH6jbqa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueToOtherRelatedPartiesClassifiedCurrent_i02I_maLCzU5X_z4fCQoMhOikh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesClassifiedCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesClassifiedCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,947</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DividendsPayableCurrent_i02I_maLCzU5X_zP1MOUIfVEY6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividends Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_i02I_maLCzU5X_z1WnpLmmb0Qa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NotesPayableToBankCurrent_i02I_maLCzU5X_zc9jd7pg7o2a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,021</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNotesPayableCurrent_i02I_maLCzU5X_zdz7zd04A0Ze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Paycheck Protection Program note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLCzU5X_znbIPAx5Jhs7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0086">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzU5X_z4cz13aemtbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,934</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzU5X_maLz9Jx_zIC6AyiFXyV6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">970,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,217,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLz9Jx_z85bR7hRFQPb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,671</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_i01TI_mtLz9Jx_maLASEzl8z_zG6u18wVi9u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,279,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zMCZ059umyge" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Series A convertible preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdwxEL3BZoya" title="Preferred stock, par value (in dollars per share)"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmr4rVfEHlAd" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z9au83J3TJfl" title="Preferred stock, liquidationPreference per share"><span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfVLiG5g9KXl" title="Preferred stock, liquidationPreference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share liquidation value or aggregate of $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zsDCxZ2FsCB3" title="Preferred stock, liquidationPreference"><span id="xdx_908_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ziJp516eFKF6" title="Preferred stock, liquidationPreference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,212,500</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zN1hU1vHnFG2" title="Preferred stock, shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zorOgdyVqG42" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVUWVmrB6Ieh" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares outstanding at September 30, 2022 and <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zgyq4cvx3458" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></span> shares outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i01I_maSEz7eV_zfc4mJTz1787" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockValue_i01I_maSEz7eV_ziDDTUl3Ezlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220930_pdd" title="Common stock, par value (in dollars per share)"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220930_pdd" title="Common Stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common Stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220930_pdd" title="Common Stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220930_pdd" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,586,393</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common Stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maSEz7eV_zXTB6ztVOckf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,548,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CommonStockToBeIssued_i01I_maSEz7eV_zykh9iZBCz92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:CommonStockToBeIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEz7eV_z5iHoGsFReY6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,143,980</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_i01TI_mtSEz7eV_maLASEzl8z_zfoTWCRb6Y21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,404,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzl8z_z9FTTyTxkj31" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,382,016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fina_002"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_zw04s9gdWcG4" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20220701__20220930_z8WMqWUfPOr8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49A_20210701__20210930_zIBVUq9Sg6i8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20220101__20220930_z8J1tj7rRFrj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_497_20210101__20210930_z3XGoub8hbmb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
    Months Ended</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
    30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
    30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_maOILzuGz_zYGaSmw161Pi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0164">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0165">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0166">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0167">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzIyY_zlFUB6tgxbK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development, net of contract expense reimbursements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,038</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,048,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,684</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzIyY_ztxaztsOAYka" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,864</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,422</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,711</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,883</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LegalFees_i01_maOEzIyY_zVqezK0krINl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    and professional</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,566</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,736</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">659,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,886</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_mtOEzIyY_msOILzuGz_zZhwWhmdMoU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">821,468</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,116</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,813,490</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,453</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtOILzuGz_maILFCOzies_zNAlLM2GKvOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">821,468</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242,116</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,813,490</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">754,453</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z4zN3DyfJKy7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseCustomerDeposits_msNIEzEIZ_z0pe1mmkEjsa" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on write off of deposit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseRelatedParty_i01N_di_msNIEzEIZ_zyE9SW94Nfq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense - related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,725</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,547</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,641</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpenseDebt_i01N_di_msNIEzEIZ_zAWXu5Loq8Td" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,716</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">920,660</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzEIZ_zlWDzIVMcto" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,685</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,971</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--GainLossRelatedToLitigationSettlement_i01_maNIEzEIZ_z6f4smeeQZ9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on settlement of accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzEIZ_zJIkauc8az9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on forgiveness of Paycheck Protection Program note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzEIZ_maILFCOzies_zrqSjK1mH4Vj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,155</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">464,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,367</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_maNILzQrA_mtILFCOzies_z8gg5jPvwCRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
    before income taxes</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">998,425</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216,961</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,277,539</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">693,086</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_msNILzQrA_zcr3nO1691m1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
    for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0246">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_maNILATzfbT_mtNILzQrA_zviMHTSMCcKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    loss</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">998,425</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216,961</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,277,539</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">693,086</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILATzfbT_zPUts4XptqV3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    on Series A Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,473</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,304</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzfbT_zB3URCvk51ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    loss attributable to common stockholders</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,017,898</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242,729</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,348,548</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">770,390</ix:nonFraction></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_ztzxrbfuC2Ag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common shares outstanding - basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,164,979</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,723,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,298,332</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zpovwOfOiH61" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_i_pdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per shares - basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.07</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fina_003"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Nine Months Ended September 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zfhi70b4j4Ui" summary="xdx: Statement - Condensed Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zTx1kk0HJEp5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z0A4ZzTYQf64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zqCfXgf9BJo1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_zf9TpFIoAbAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zPMI9TW7tYAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_zZCYyA82vOE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Common Stock to be</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Stockholders&#8217; <br />
Equity</td><td style="font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20220331_eus-gaap--StockholdersEquity_iS_z4SQVawjKDIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKCDO7UHhm9d" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJzPwh6JY2Fl" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zY8nJiZ6wZn3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrants issued for financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zgnoOwKAfbY7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzLnLTSoCFf1" title="Common stock issued for conversion of accrued interest, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ziclsygnIafe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqtfj61z66sf" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DividendsPreferredStock_iN_di_zHWkZj2naRib" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zH4yWkuconUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">681,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">681,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zpoinvOhXGT3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance - March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSrmUi4x3Q13" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDmTiuDzmIQ" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,318,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,653,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,503,039</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,849,563</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_z1TPfOqLIL6c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmr8CgD1tSy8" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DividendsPreferredStock_iN_di_z4GZ0v7lTqKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zE5HAaijvlL2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">597,275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">597,275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zP1QUeNIMINj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - June 30,2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSCE9ObkZHRe" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3cF3LGzt773" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,323,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,819,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,126,082</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,306,073</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z2wvXpzZ64Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6v9h06kSbp6" title="Common stock issued for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,031,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,031,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zthkx0X07PIi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrants exercised for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlFicEoW5ms8" title="Warrants exercised for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,084</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zR5BSuscVWG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrants issued for financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zXhoxsEdAyfk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGa5KjmJypGg" title="Common stock issued for conversion of convertible debt, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zWgoJpfYFXyg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of accrued interest convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXKPF7fKhxoc" title="Common stock issued for conversion of accrued interest convertible debt, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_z6TRdsOhLal5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHqmkF50rsJj" title="Common stock issued for exercise of warrants with settlement of notes payable, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,467</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zLMD0A9Vbetf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zexpTeiVbPjf" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DividendsPreferredStock_iN_di_zTXYsmx0r8yc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,473</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,473</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_z2asap1AYehi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQkF3SGsBE93" title="Common shares issued for dividends on and conversion of Series A preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9pfPjMhPHC" title="Common shares issued for dividends on and conversion of Series A preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zKGE8NQ8Pwbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">998,425</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">998,425</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20220701__20220930_eus-gaap--StockholdersEquity_iE_z8iLX08BHdPh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - September 30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4EnyJCLTBYf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKDEtKGxlbV2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,586,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,548,719</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,143,980</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,404,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fina_004"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Changes in Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Nine Months Ended September 30, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_znRmSzJZcPJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_za4W5hRa7Y9f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzFo1U5cVsLl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_zVv1Jbhbi4z8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z2E2GfHvJVyj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B0_zG3n1L58KUk1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Preferred Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Common Stock to be</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_434_c20210101__20210331_eus-gaap--StockholdersEquity_iS_z2Ap3gGnFyZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 28%; font-weight: bold">Balance - December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzPqkLV93SX3" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZGBPlPXYFI7" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,833,507</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,540,236</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,690,296</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zkmkf0OAmGZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DividendsPreferredStock_iN_di_zY7lT4HX9Bmf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zXAX9AislMFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zCVsoCWwG44d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold">Balance - March 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJDBH74YqeN8" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFgoGP2E4p4i" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,956,024</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,695,328</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,722,871</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zAEIbwsTiPdk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE0qZAwbYmN8" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPreferredStock_iN_di_z3tohhk5KwW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zjOVPeoPxB4j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">346,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">346,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zn31sjABt41a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold">Balance - June 30,2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZCcveYOeKP5" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsk7AE3b9Fff" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,299,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,078,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,067,897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,972,923</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_431_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zRzvWYxm3bza" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zig25lojBf02" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQspABYvrBB4" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,299,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,078,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,067,897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,972,923</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zJqYgWV4Xcuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYsx7Vy9QOvf" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DividendsPreferredStock_iN_di_zIBzYsK78A76" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zL3DdUWoi2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20210701__20210930_eus-gaap--StockholdersEquity_iE_z4utN8cglXW6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 2.5pt">Balance - September 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR8i13qSV9w1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn6LUFh0rZi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,308,646</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,201,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,310,626</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,093,135</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20210701__20210930_eus-gaap--StockholdersEquity_iE_zIZIYJTrhndd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpnjQ4B4bhF3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYFuYKEpwK" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,308,646</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,201,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,310,626</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,093,135</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fina_005"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zXpagPW7zfhh" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20220930_zI6qY1nvmXWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20210930_zoAUMDVZKAXb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z6YNY8cguGb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_maNCPBUzxJJ_zUvi96ohDquc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,277,539</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">693,086</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zBZZisrs4bBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Depreciation_i02_pp0p0_maNCPBUzxJJ_zgpxEqsXi273" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzxJJ_zIzM7nEkL4Nf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">94,025</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">30,971</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzxJJ_zp5ET45RCoWb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,408</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzxJJ_z6R5FPDFxtq3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossRelatedToLitigationSettlement_i02N_di_msNCPBUzxJJ_zEiD6m7ql9Za" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzxJJ_zOpbaE9ntKGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on forgiveness of Paycheck Protection Program note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DebtSecuritiesGainLoss_i02N_di_msNCPBUzxJJ_znb86vnofWFe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on interest relief on conversion of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzxJJ_z1eAcqwu1yI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,733</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_msNCPBUzxJJ_zrSCaR9uIIdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contracts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,954</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">211,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzxJJ_z1kPMAEc9X46" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,276</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i02_maNCPBUzxJJ_z3zoG0Mi3jwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">392,473</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maNCPBUzxJJ_zuK4eavjBFyi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_maNCPBUzxJJ_zHBYxI2mXGDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzxJJ_zwdoEK6Xcxd4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzxJJ_maCCERCzcX2_zBrHQDye773l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Cash used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,030,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">165,185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzlsX_zerK9sUPRZe1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzlsX_maCCERCzcX2_zZIi7agiWIke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Cash used in Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzHBB_zfmFQf1MPw51" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from issuance of common shares and exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,045,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msNCPBUzHBB_zeZkfgct2Io3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Repayment of note payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzHBB_zDpx70EdkIbi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from notes payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromOtherShortTermDebt_i01_maNCPBUzHBB_zPHNh4FghG9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUzHBB_zBNJlI4EfhH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Proceeds from notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzHBB_maCCERCzcX2_ze3nWjoj74ib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Cash provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,646,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzcX2_zhsqSpixuMRe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,615,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cash, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">504,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,120,390</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,975</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zQyWX8aL00We" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zZcYXqlyY6pi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zrklgUrNyc38" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Supplemental non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssued1_i01_zc482qxoXood" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Shares issued for conversion of accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommonStockIssuedForConversionOfConvertibleDebt_i01_zACHVStPIxYf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for conversion of convertible debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfConvertibleDebt" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zA8JiIn0RAVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CommonStockIssuedForDividendPayable_i01_zPgscln7g4a6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for dividend payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForDividendPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,067</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fina_006"></span><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Unaudited Condensed Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Nine Months Ended September 30, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUWPhsGrtOBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span>Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82F_zvrcvWircP1h" style="display: none">Organization
and Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkO5fO6ylmb" title="Number of convertible shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000,000</ix:nonFraction></span> shares of common
stock in exchange for <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxJA6Qa3Ja8i" title="Sale of stock membership percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, the Company has been working on developing products through NIH grants,
including a product to predict late effects of radiation with metabolite biomarkers and develop prostate cancer cell lines in health
disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zSGzuPRKQiHh" title="Reverse stock split"><ix:nonNumeric contextRef="From2022-03-282022-04-02" name="us-gaap:StockholdersEquityReverseStockSplit">2-for-1 reverse stock split</ix:nonNumeric></span> of our issued and outstanding shares of common stock (the &#8220;Reverse Stock
Split&#8221;). All references to shares of our common stock in this report refers to the number of shares of common stock after giving
effect to the Reverse Stock Split (unless otherwise indicated).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zh8HybQdj397" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_823_zZWvXrhpJe05">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhSeyCkF9SFi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z0W8FiA8tXZh">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX3kHkk5xqEg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zkpAz40vtY5g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zPEiyQuA66c7">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFFpvu1BVnNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zPpD978nUCdj">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zrejJygRHQC4" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_EquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span>
    years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zrSjsjleiadg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqDNlRLgmH2b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoyPOKzGk12h">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zAX85jorC2o8" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,502</ix:nonFraction></span> Phase I award includes funded research from September 19, 2016 through September 18, 2017
and was advanced to Phase II of the awards with funding of $<span id="xdx_90B_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zrl1OPzzKA4k" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,903,095</ix:nonFraction></span> with a fixed price contract period of September 17, 2018 through
September 16, 2020 and subsequent no cost extensions through September 15, 2021 and then March 15, 2022 (Reference 75N91019C00031). The
Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zLUMgHUOD9v2" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span> for a total of $<span id="xdx_902_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zHVzt4MlVLvc" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">845,820</ix:nonFraction></span> in 2020; and 2 quarterly payments related to Topic 345 for a
total of $<span id="xdx_901_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_z5byWYRT12H5" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,910</ix:nonFraction></span> in 2021. On April 6, 2022, the Company submitted the final invoice for &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects,&#8221; for $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220425__20220426__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zdHXKcE9yNBg" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-04-252022-04-26_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span>, following the completion of the Final Quarterly Progress
Report to NIH covering the performance period of September 16, 2019-March 15, 2022. The invoice was paid in full on April 27, 2022. In
Phase II of the SBIR effort, the Company completed an analytical validation of the metabolic test kit, extended the option to license
the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221; test and developed
plans for a multi-institutional clinical trial to be implemented in the Phase III effort. This contract included a subcontract to Georgetown
University (&#8220;Georgetown&#8221;) for use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended
to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZDynIs5qjMc" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,248</ix:nonFraction></span> subcontract of its Phase II contract #HHSN75N91019C00031. The
Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zD1dF4GG7wYc" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,248</ix:nonFraction></span>. Georgetown invoiced the
Company for a total of $<span id="xdx_90E_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zk3255qtn7m3" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">791,017</ix:nonFraction></span> as of September 30, 2022, leaving a balance of $<span id="xdx_907_ecustom--AccruedInvestmentIncomeReceivableOutstanding_iI_c20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zbLnUtrmaXe5" title="Research and development invoice receivable, outstanding"><ix:nonFraction name="SHPH:AccruedInvestmentIncomeReceivableOutstanding" contextRef="AsOf2022-09-30_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231</ix:nonFraction></span>. Depending on the resources it uses, Georgetown
may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable amount, the
Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $<span id="xdx_902_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220401__20220430_zE9fjBl3FtLl" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-04-012022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">791,017</ix:nonFraction></span> were made to Georgetown, including
an additional invoice for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220701__20220930_zPTpk6s8LFmj" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,643</ix:nonFraction></span> which was received but not paid until the second quarter of 2022. All invoices have now been paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_90A_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zanyYyghAh34" title="Proceeds from contract awards for research and development"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-09-172020-09-16_custom_PhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,484,350</ix:nonFraction></span> to fund research
from September 17, 2018 through September 16, 2020 and was extended without cost through November 16, 2021 due to delays caused by the
impact of COVID-19. For the entire contract period, the Company invoiced and received a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211116__20211116__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVAJShB1sPPd" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2021-11-162021-11-16_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,411,883</ix:nonFraction></span>. The final draft report was
filed with the NIH along with the final invoice for $<span id="xdx_90B_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211202__20211203__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfrcR6AlrTFj" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2021-12-022021-12-03_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, which payment was made on December 3, 2021, and no additional payments are
expected. The Phase II contract also includes a subcontract to Georgetown University for $<span id="xdx_906_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zeOLO5T65Yv7" title="Business development new establishment"><ix:nonFraction name="us-gaap:BusinessDevelopment" contextRef="From2021-01-012021-12-31_custom_PhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">742,002</ix:nonFraction></span> to establish prostate cancer cell lines
from African American patients undergoing prostate surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z2CdTdQbva21" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">742,002</ix:nonFraction></span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zMG2pQQCfA07" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-09-30_custom_SubcontractPhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,866</ix:nonFraction></span> as of September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the quarter ended September 30, 2022, the Company recorded a
net deficit of $<span id="xdx_90C_ecustom--ResearchAndDevelopmentDeficitNet_c20220101__20220930_zoT3CbZyLPwk" title="Net deficit on research and development"><ix:nonFraction name="SHPH:ResearchAndDevelopmentDeficitNet" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,868</ix:nonFraction></span> with the Company funding the NIH no-cost extension along with other R&amp;D activities. The NIH made the final
payment of $<span id="xdx_90F_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zor9EaiE5Fu5" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-09-30_custom_PhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span> in April 2022 for Topic 345.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September of 2022, TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;) was contracted for process research, development and cGMP compliant
manufacture of IPdR. The total project cost is $<span id="xdx_90C_eus-gaap--CapitalizedContractCostNet_iI_c20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_z0ryukO7eiIc" title="Project cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2022-09-30_custom_TCGGreenChemIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span> based on four milestone payments, the first payment of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zYKX6wr2MDMh" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-09-30_custom_TCGGreenChemIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span> was paid during
the quarter ended September 30, 2022, pursuant to which TCG GreenChem commenced work on the project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue or other income. Due to the terms of the contracts we have entered into, the Company concluded that the
reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zPlBfuV8LKl9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_za7MJc2KLRf">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of September 30, 2022, the Company had no derivative instruments. As of December 31, 2021
the Company&#8217;s only derivative financial instrument was an embedded warrant feature associated with its Series A Convertible Preferred
Stock due to certain provisions that allow for a change in the warrant value based on fluctuations of the Company&#8217;s fair value
of common stock at the date of issuance of the warrant based on certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVgFsM34CXt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zOeVLCJpuOoc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GTWgulRiA7" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.22</ix:nonFraction> </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FYyHnhqDba" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span> in 2021, $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLPlikArwB8" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> through March 31, 2022 and $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUXJKtHAQEP7" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction> </span>through June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2022, the Company identified <span id="xdx_904_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_do_c20220930_zygmAQg0VFEb" title="Financial liabilities fair value"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> liabilities required to be presented on the balance sheet at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock"><p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGngUoQuWHod" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Warrant Liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zsd9NRdAjIL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSMPJgjkKtRe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zGDBm12N3Bgh">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed
    contracts with the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of performance obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of the transaction price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation
    the transaction price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
    of revenue only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from NIH contracts is received in accordance with Federal grants and contracts policies. Research and development expenses
are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zcExFdFHdFK3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z6PnT83yyhM">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
shares of common stock outstanding during the period using the treasury stock method and as if converted method. Dilutive potential shares
of common stock include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu2C2gyHdXxj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti dilutive securities excluded from
    computation of earnings per share</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,594</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zXv2XedQLmv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9PcSCc4vTKf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z0Lznkh5Cw24">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

</ix:nonNumeric><p id="xdx_855_zOFftms3vb0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxAmmBNyUPr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_820_zzo393qkBFad">Property and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHw4g6hhBnUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zgIcSqP1GQel" style="display: none">Schedule
of Property and Equipment Net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20220930_zIuASPNq3qll" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zr4QYBfzAWEd" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zU5MxQUAw8E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-09-30_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zwWSOCdm4pAl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-09-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzwPA_zbpLEntztHr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,466</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzwPA_zk6WVvG8Nbf5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,386</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzwPA_zAsg6aOTm5zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,080</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zPydfRBEeKO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the nine months ended September 30, 2022 and 2021, were $<span id="xdx_908_eus-gaap--Depreciation_c20220101__20220930_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,484</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20210101__20210930_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,050</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zuv0V6rq4jj3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zMjBSD57lQej">Operating Lease Right-of-use Asset and Operating Lease Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20220101__20220930_zIbc0fPlyQ28" title="Interest rate used to lease, description"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</ix:nonNumeric></span> Operating lease expense is recognized on a straight-line basis over the lease
term. During the nine months ended September 30 2022, and 2021, the Company recorded $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20220101__20220930_zPsAhOsQYJ41" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,631</ix:nonFraction> </span>and $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20210101__20210930_zEQJOlnYwN2" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,445</ix:nonFraction></span>, respectively, as operating
lease expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $<span id="xdx_90F_ecustom--OperatingLeasePayment_c20180929__20181001_zHIwK06J5LAa" title="Lease payment"><ix:nonFraction name="SHPH:OperatingLeasePayment" contextRef="From2018-09-292018-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,291</ix:nonFraction></span>, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on <span id="xdx_906_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zGzBQnCk7Hd9" title="Operating lease expiration date"><ix:nonNumeric contextRef="From2018-09-292018-10-01" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">October 31, 2023</ix:nonNumeric></span>. A security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zSUIHXH46n4h" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2018-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span> is being held for the duration of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#8216;package of practical expedients,&#8217; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of <span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20220930_zyxAeXkmYHJl" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-09-30" format="ixt-sec:durmonth" name="us-gaap:LessorOperatingLeaseTermOfContract">12</ix:nonNumeric></span>
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zWm8Fs7Ed7R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zAImY9PDHMUg" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20220930_z1midZtHPzW3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zAPSmuBNbsTj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zj9387NWMqbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="SHPH:OfficeLease" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,207</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="SHPH:OfficeLease" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,207</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_ztbnQ85VGf8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:AccumulatedAmortizationOnRightOfUseAssets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:AccumulatedAmortizationOnRightOfUseAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zYVRdiQfZ24a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,970</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zyzsMs5EExFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of-use asset is included in rent expense on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zxqoKB1Dwu8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zH01tCtnTGW9" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20220930_zOkTDA3D9pE3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zf8g6zEjZ5V8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zPgpaBsyNEYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,376</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zuhPVK1tOQza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,934</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF267iEwqDW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zgOSKTLN20g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI3LHmxEst4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zeTus9Yk7gqg" style="display: none">Schedule Of Operating Lease Maturity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220930_zdlre74HLWW3" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz4Xq_zApK0lBgQLz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 75%; text-align: left">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,440</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz4Xq_ztBHxWzLa5Da" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz4Xq_zmHWBOXUo113" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Total future minimum lease payments</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNs3XD3FUEd1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zCqRaCFYxwo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">PV of Payments</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z8DNgHe4XlDi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaMZoFHT4i5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zfGWuPdewMyh">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_90C_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZOFY1AwSQg1" title="Notes payable related party debt principal balance"><ix:nonFraction name="SHPH:RelatedPartyTransactionAmountsOfTransactions" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,243</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCy9ehTHkvwa" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity date of <span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zRLDPj45LaN3" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>; and (ii) a single loan
owed to an officer of the company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zzor0xXKoNrk" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,229</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z486baGpwzp3" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity
date of <span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zYNOE6FGcfVe" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>. <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211230_z0tSNlGSIn2d" title="Debt maturity, description"><ix:nonNumeric contextRef="From2021-12-012021-12-30" name="us-gaap:DebtInstrumentMaturityDateDescription">In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the
notes were extended to June 30, 2023</ix:nonNumeric></span> (Note 8). As of September 30, 2022, the accrued interest was $<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zmlntEGsiPUd"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-09-30_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,592</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zlw8S2lqMxM9"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-09-30_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,150</ix:nonFraction></span>, respectively,
and the total balances with accrued interest of $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwYaXOagoI5" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">481,835</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zsYOz269cZih" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2022-01-012022-09-30_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,379</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zN6ODjJNjKrh" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (principal) with
an interest rate of <span id="xdx_903_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWb90yOLkMD7" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum due <span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZ5YMQoAWv1e" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">June 21, 2022</ix:nonNumeric></span>, due at maturity. <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20210621__20210621_ziq4T2WoR643" title="Debt maturity, description"><ix:nonNumeric contextRef="From2021-06-212021-06-21" name="us-gaap:DebtInstrumentMaturityDateDescription">In July of 2022 the notes were extended to June 30, 2023</ix:nonNumeric></span> (Note
8). As of September 30, 2022, the accrued interest was $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ze5eZcGl12lb" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,491</ix:nonFraction></span> and the total balance with accrued interest was $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zc88cZ7OnoLl" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,491</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with a private placement of 10% notes and warrants (as detailed in Note 6 below), in exchange for a $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zBRBBQsMjfI5" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
payment upon subscription, the Company issued a note to the spouse of an officer of the Company in the amount of $<span id="xdx_90B_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zEG3d94KjpQc" title="Notes issued"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> (principal)
with an interest rate of <span id="xdx_90E_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zQQSHlaQcnn4" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum due <span id="xdx_90F_eus-gaap--RelatedPartyTransactionDate_dd_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zag9YEyK59ji" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">August 31, 2022</ix:nonNumeric></span>, with interest due at maturity, and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zzynqJftCic3" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-08-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares of
common stock, at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_ziRlJzGF9Ht7" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span> per share. The value of the warrants was determined using a computed volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zuCupUQpvt75" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span>%,
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zsOSczY4n4h9" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% dividend rate, and a risk free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zdp2m5tb6USa" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>%, and was applied as a discount on the notes payable. The loan was fully repaid
including $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zLnGUxarbx43" title="Repayments of accrued interest"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822</ix:nonFraction></span> of accrued interest in September of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_ztol0MmZp7kf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - <span id="xdx_826_zd1TOgmUHXV6">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_908_eus-gaap--MediumTermNotes_iI_c20210309_zNsNktLppFdg" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2021-03-09" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zlZhTSb6ols2" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-03-09" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. <span id="xdx_901_eus-gaap--ShortTermDebtDescription_c20210309__20210309_z3rNThwCFcHg" title="Term note description"><ix:nonNumeric contextRef="From2021-03-092021-03-09" name="us-gaap:ShortTermDebtDescription">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</ix:nonNumeric></span> As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the
requested documentation and during the quarter ended March 31, 2022 the note liability was reduced in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $<span id="xdx_90C_eus-gaap--MediumTermNotes_iI_c20200515_zI4nrf1tdYpk" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2020-05-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_z3dN2O76sNLk" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-05-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. <span id="xdx_903_eus-gaap--ShortTermDebtDescription_c20200515__20200515_zF98mIUB8pni" title="Term note description"><ix:nonNumeric contextRef="From2020-05-152020-05-15" name="us-gaap:ShortTermDebtDescription">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</ix:nonNumeric></span> A &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zBuehpHgeOmh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8B7_zh3WL2OqTeea" style="display: none">Schedule
of Notes Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220930_zCOLUnMIYUub" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zhTWY6hOtPcj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PPP Note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zV3AXygSN6yh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">PPP Note <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zLqQeYshslhh" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">May 15, 2020</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zgEHevVdpow9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PPP Note <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zyRSdphG0GA7" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 9, 2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zyqQSYNNAWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:LoanForgiveness" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:LoanForgiveness" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_zSmWxVZcgvbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zv7ZlW0MOIk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20211228_znE5S8lRaJTi" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> note units, consisting of two $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zbghPOeTdQW7" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> notes, for a total of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zmc9hJwVpeKb" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_z1pVK4Psebo9" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% unsecured promissory
notes with a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_zCZuBWQ4Wiuh" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-12-282021-12-28" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 28, 2022</ix:nonNumeric></span>, and warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zlUonDf1vJfd" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of common stock exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zaxpfbxbx4D8" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share
with an expiry date of December 28, 2026, and fees of $<span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zi4Ukw48HLJ2" title="Debt fee amount"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,075</ix:nonFraction></span>. The value of the warrants was determined using a computed volatility of
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxiYBqqVCKba" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.5</ix:nonFraction></span>%, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IYQPeqxcAa" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% dividend rate, and a risk free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqPoFqdf29rk" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.27</ix:nonFraction></span>% and was applied as a discount on the notes payable. In September 2022,
the warrants were exercised fully reducing the principal and the Company paid $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20211228__20211228_zP4GuXcpTjIj" title="Warrants exercised to payment of debt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-12-282021-12-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,667</ix:nonFraction></span> of interest in cash. As of September 30, 2022,
$<span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--NoteTwoMember_zhv9jfCzr4ue" title="Accrued interest payable"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2022-01-012022-09-30_custom_NoteTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,904</ix:nonFraction></span> of accrued interest is payable on the second note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, the Company sold $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220208_zaZ8Z5J146o" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-02-08" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220311_z1bi1WgRaY9k" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-03-11" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,985</ix:nonFraction></span>, respectively, in <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208_zOOSldRDENG8" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-02-08" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% convertible notes (the &#8220;Notes&#8221;),
which notes bore <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311_zlGt98vomy9c" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-03-11" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% interest, were repayable three years from the date of issuance, and, upon completion of the Company&#8217;s initial
public offering, converted automatically into units, with each unit consisting of one share of common stock and a warrant to purchase
one share of commons stock (the &#8220;Conversion Units&#8221;) at a conversion price equal to <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208_zEMYxukktWoh" title="Debt instrument conversion rate"><span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311_z0awGhG58UX8" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-02-082022-02-08" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-03-112022-03-11" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></ix:nonFraction></span></span>% of the per unit offering price upon
closing of our initial public offering. Boustead Securities LLC acted as placement agent for the convertible note offering and received
compensation of $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20220208__20220208_zoUoxSp0kmO6" title="Proceeds from convertible notes payable"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-02-082022-02-08" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,500</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220311__20220311_zliJ0BM2kW3f" title="Proceeds from convertible notes payable"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-03-112022-03-11" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,250</ix:nonFraction></span>, respectively, and warrants to purchase shares of common stock equal to 10% of the Conversion Units,
exercisable at the conversion price of the Convertible Notes. The value of the warrants was determined using computed volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0ifbTPrWJ64" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.4</ix:nonFraction></span>%,
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY9QrLuU5egl" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% dividend rate, and a risk free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdYbIRrp4jI9" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.27</ix:nonFraction></span>%, and computed volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze5AjFzg6tU4" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.5</ix:nonFraction></span>% %, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGEOPUhsgM2f" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% dividend rate, and a risk free interest
rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEW2I5goaJ04" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.96</ix:nonFraction></span>%, and was applied as a discount on the notes payable. In September 2022, the notes were fully converted,  relieving the
Company of $<span id="xdx_906_eus-gaap--DebtSecuritiesGainLoss_iN_di_c20220101__20220930_zftj2yXZnIh6" title="Gain on interest relief on conversion of notes payable"><ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,625</ix:nonFraction></span> of accrued interest recorded as a gain on settlement of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, the Company issued $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20220801_zB7CTt40IFq1" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span>
in <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801_zzvCTmDcnWj3" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-08-01" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
convertible notes payable and warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zNOFTL3lMIHi" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-08-01_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
shares of common stock to three accredited investors (which amount includes the $<span id="xdx_90A_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zCc08vTUCt65" title="Notes issued"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2022-08-012022-08-01_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
note and warrant purchased by a related party as detailed in Note 5 above). The warrants issued in this transaction were exercisable
at price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zEWdjNy4L0df" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span> per share. The value of the warrants was
determined using a computed volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbl3f0ru4UCh" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span>%, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zZzDMYWjaf9i" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%
dividend rate, and a risk free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbdAG69gbbfd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>%
and was applied as a discount on the notes payable. In September 2022, <span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220901__20220930_zakHV9tn7kV2" title="Warrants exercised to payment of debt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-09-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span>
warrants were exercised in exchange for cancellation of $<span id="xdx_906_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7HMePc1r7oh" title="Debt forgiveness"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span> in notes, thus reducing $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_znfSheCRRF33" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>
of the principal. The remaining $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zv2sMilMt14a" title="Debt remaining amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-09-30_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
note owed to the related party was then paid off in full.</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYzIEK2eVmQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zwWGyadF88hh" style="display: none">Schedule
of Promissory Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z8sz6rbUuhP7" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zGN2XUdpFHY8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z8rCGaaJjyP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Promissory note issued on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zw3T5TSJyY52" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PromissoryNoteOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 28, 2021</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zVhNOEpSV6nf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promissory note issued on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zrdUXY9T00Y3" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PromissoryNoteTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">February 8, 2022</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zw5zFEWoegz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note issued on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zvymj71KTPZa" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PromissoryNoteThreeMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 11, 2022</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zcRQi5sCgQ57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Promissory note issued on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zXkxFE5K93x1" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_PromissoryNoteFourMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 1, 2022</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzxfV_zaBoiXSvwhI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zxwXaJH3mH72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zHKNNzyBPYGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,021</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zkicrC7Cmmv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ending September 30, 2022, the Company fully amortized the debt discount and included $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220930_z0kIM3m07Bf" title="Amortized debt discount"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,979</ix:nonFraction></span> in interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxRJE3vYPZJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_821_zhYyZ2od3pAb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s amended and restated articles of incorporation, the Company is authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zD7b65CwANT9" title="Common Stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of common
stock, with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zwHgHRxOgj99" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_zpdqMosGBgg9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of preferred stock, with a par value of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zjBTp9hZfGX3" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#8217;s common stock on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2022, the Company converted <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zysPduE62CKh" title="Converted shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Preferred Stock into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGqislf6LlI7" title="Converted shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,810</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase
<span id="xdx_905_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMvG6hvR7ng" title="Purchase up warrants shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,810</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, which conversion shares
and warrants were calculated using a conversion price of <span id="xdx_909_ecustom--DebtInstrumentConvertibleConversionPricePercentage_iI_pid_dp_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFqdTaco7AF8" title="Conversion price percentage"><ix:nonFraction name="SHPH:DebtInstrumentConvertibleConversionPricePercentage" contextRef="AsOf2022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90</ix:nonFraction></span>% of the IPO price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYZ0SOMJSdT5" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in a discounted conversion
price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930_z8Z9SpoKwDYb" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The warrants issued to the Series A Preferred Stockholders are exercisable at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930_zpUsyRLcr86l" title="Exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dt_c20220101__20220930_zcseRHSywJsi" title="Remaining contractual term"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">three years</ix:nonNumeric></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, the Company accrued $<span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztK97ATl9iCl" title="Dividends on preferred stock"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></span> for the <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoOPrvkdYbN1" title="Preferred stock dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>% cumulative dividends on the Series A Preferred stock
and $<span id="xdx_900_eus-gaap--DividendsPreferredStockCash_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWqcisRwodE6" title="Dividends on preferred stock"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></span> for the year ended December 31, 2021, for a total of $<span id="xdx_90F_eus-gaap--DividendsShareBasedCompensation_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1YIxjGJzwg" title="Dividends total"><ix:nonFraction name="us-gaap:DividendsShareBasedCompensation" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DividendsShareBasedCompensation_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHpH2VNhCRA9" title="Dividends total"><ix:nonFraction name="us-gaap:DividendsShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,059</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2022, the Company paid the dividend payable balance of $<span id="xdx_90F_eus-gaap--DividendsCommonStock_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLxXy8ZdoY7j" title="Commons stock dividend"><ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></span>
to the Series A Stockholders through the issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlRcBiJtDOLg" title="Common stock issued for cash, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,517</ix:nonFraction></span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znMFb6GdN5q" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares of Series A Preferred Stock outstanding, and <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRzGJoa4QEp2" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></span> shares as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022 and December 31, 2021, the Company had <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20220930_zyK4ucXu9E02" title="Common Stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20220930_zAVlHx39w4v8" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,586,393</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20211231_zWDNxwbzx2Vd" title="Common Stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zSlmTeZoglFe" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></ix:nonFraction></span></span> shares of common stock issued and outstanding,
respectively. The balance includes <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOoy8zoPAyhd" title="Common stock issued for restricted stock units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,626</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5jxBFcjiqj" title="Common stock issued for restricted stock units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,530</ix:nonFraction></span> shares of restricted stock issued in 2021 and 2020 respectively and <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNPfk1gGbaD2" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839</ix:nonFraction></span> shares of
common stock issued to settle shares of common stock owed to Shuttle&#8217;s original membership holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_zoIvY7momya6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B2_zlcBSojejxUa" style="display: none">Schedule of
Sale of Equity or Issued</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issuance</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value $</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><span id="xdx_F4C_zVQnroxtrN48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zGz90CtsNEja" title="Stock issued during period, shares" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_IPOMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zVMczMb85TE9" title="Stock issued during period, Value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_IPOMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,031,415</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zI1ZZDkuYRll" title="Stock issued during period, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zfUkLCAktb1c" title="Stock issued during period, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F49_z4m8t1dYYtpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant exercises<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_zOLfHvinhUdc" title="Stock issued during period, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_NoteWarrantMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,267,551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_ziQh59zpa9Pc" title="Stock issued during period, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_NoteWarrantMember" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_zh3yWT2pEEAl" title="Stock issued during period, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_custom_CommonStockPayableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_z0haD5Kr4GCl" title="Stock issued during period, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_custom_CommonStockPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F42_z27rO27rUT38" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Share and Dividends Payable<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_z5rP5B6sdQr1" title="Stock issued during period, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember" id="Fact001182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_zudb7kxpNvP4" title="Stock issued during period, Value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember" id="Fact001184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_zpaba9E4mGZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zVTbfqbW6iba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001185" xml:lang="en-US">Value
                                            is net of $<span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,407,262</ix:nonFraction></span> of fees associated with the issuances.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zlejtRyQe31c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zoZjkIOtyHI6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001188" xml:lang="en-US">Includes
                                            <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,273</ix:nonFraction></span> broker warrants exercised on a cashless basis for <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,280</ix:nonFraction> </span>shares of common stock
                                            and warrants to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction> </span>shares of common stock exercised as part of the Company&#8217;s
                                            initial public offering.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_z24ejyBVEFq1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zkLhD1kqAUba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001195" xml:lang="en-US">Includes
                                            <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,810</ix:nonFraction></span> shares of common stock issued upon conversion of <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></span> Preferred Shares and <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,517</ix:nonFraction></span>
                                            common shares to settle dividends payable balance.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A1_zjCfC19j6Sl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock to be Issued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $<span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zwHhIwAEzAuf" title="Convertible notes"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2018-06-04" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,250</ix:nonFraction></span> outstanding convertible notes were converted to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_ztKaKDNIn7Y8" title="Debt converted into common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,182</ix:nonFraction></span> shares of common stock of the Company at a price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z6asrYHk8upb" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.44</ix:nonFraction></span>
per share. The Company recorded $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zdsTjGnoIQKj" title="Debt converted into common stock, value"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></span> of common stock to be issued for the accrued interest. As of September 30, 2022, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_z2ZquAj5Eolg" title="Stock issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839</ix:nonFraction></span> shares of
common stock were issued to settle the $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_zSRH7R6eSTxd" title="Stock issued during period, Value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,340</ix:nonFraction></span> of common stock to be issued to Shuttle&#8217;s original membership interest holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the Company&#8217;s 2018 and 2019 private placement offerings included warrants to be issued upon the
earlier of a closing of the sale of shares of common stock to the public at a prices per share of at least $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20220930_z1tTtPcgJDxd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> or in a firm commitment
underwritten public offering pursuant to an effective registration statement resulting in gross proceeds of at least $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB2KU2vdlv3" title="Proceeds from initial public offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>. The
warrants shall be exercisable for a period of three years after the date of issuance. The warrant exercise price is contingent on the
terms of the public offering. If an initial public offering occurs at a price at or above $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRR6lqHIg3yl" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-09-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> per share, then the exercise price shall
be set to the issuance price of the common stock with the number of warrants determined based on a 10% discount to the per share common
stock issuance price. In the scenario where the common stock is listed with the common stock issuance price below $<span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_c20220101__20220930_z5P9n8rrD4Kl" title="Warrant exercise low price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, the exercise
price will be set to $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930_zzdRjpgjWnri" title="Warrant exercise price increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.82</ix:nonFraction></span> with the number of warrants based on a fixed conversion price of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20220930_zqFHOFxm4Owd" title="Common stock, Conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.49</ix:nonFraction></span>, which represents a 10.0% discount
to the $<span id="xdx_90D_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930_zhRwRdpzY0Ve" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> threshold. The warrants also have contingent call features based on the terms of the public offering. If an initial public
offering occurs at a price at or above $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjKtYc3NwVd7" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2022-01-012022-09-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, then the warrants are callable if the 20-day VWAP of the common stock in at or above 150%
of the variable exercise price. In the scenario where the common stock is listed with a common stock issuance price below $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbtx0LXUF6T" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2022-01-012022-09-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, then
the warrants are callable if the 20-day VWAP of the common stock is at or above the $<span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztYOrsqyePJ4" title="Warrant exercise price increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.82</ix:nonFraction></span> exercise price. The detachable warrants contained
terms and features that gave rise to derivative liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 6, 2022, the Company amended its certificate of designation for the Series A Preferred Stock (the &#8220;Amended Series A
Preferred Certificate of Designation&#8221;) in order to modify the conditions pursuant to which the Series A Preferred Stock would
automatically convert. Under the Amended Series A Certificate of Designation, the automatic conversion feature was amended so as to
allow for conversion upon completion of a $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrVPdWFRuO2j" title="Proceeds from initial public offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span>
public offering or the listing of the Company&#8217;s common stock on a qualified exchange, in which case the Series A Preferred
Stock would convert at either 90% of the per share IPO price or $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziRG45hYCN92" title="Common stock, conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span>
per share. As a result, upon completion of our initial public offering, the Series A Preferred Stock was converted and warrants were
issued in relation to the conversion, with each warrant then exercisable at the equivalent of the per share initial public offering
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative warrant liability linked to the Series A Preferred Stock as of September 30, 2022 and December 31, 2021 was $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_dxL_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgFf9ljfN3j8" title="Derivative warrant liabilities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1239">0</span></span> and $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkf9RBW6mOGd" title="Derivative warrant liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></span>,
respectively. For the period ended September 30, 2022 and 2021, the change in fair value of warrant liability was a gain of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTxTNHtR5OCk" title="Fair value of warrants liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></span> and
a gain of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1DELF0Ddi9l" title="Fair value of warrants liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,971</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjFxAl0mLK3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zBaWiW2hUbo9" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zhMcG7Vze4z1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_z7TmHT9meRab" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zj4OzbZ2MUfg" title="Expected life"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.33</ix:nonNumeric></span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zJiIunAv2NNg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.73</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zDgPwOwoBaI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zykKzq1xTiEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zAI1VcyQekT9" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlqKbqQNTHXh" title="Number of Warrants Outstanding, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHSY18pcFCve" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc0uoL4xYoje" title="Weighted Average Remaining Life in Years Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear" name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">3.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEgcPNiFzEod" title="Number of Warrants, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWGdzP4hgfd5" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDJ8BkLCpngh" title="Number of Warrants, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcMdvhnPUqSl" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Z2V48oZPpc" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXVFuH1uPzt8" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z21PCphyMc5g" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze8hCGHfFJ8a" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5ZW4uR86yU8" title="Weighted Average Remaining Life in Years Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear" name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">2.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAd8zJkaU7dg" title="Number of Warrants, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcgLjEuctt5e" title="Weighted Average Exercise Price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCfXWpepbsC" title="Number of Warrants, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zREYA2RzJlWi" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrJXH3EJHUl4" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxVBHHEKMvKe" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0MKUidIv8Zf" title="Number of Warrants Outstanding, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7GPzqiGfWx6" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the common stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfwUq0E6s3c" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCQq5BYydFa" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0KcnPEUWxa" title="Number of Warrants, granted" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,304,544</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOnBZehpQzm2" title="Weighted Average Exercise Price, granted" style="width: 12%; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxqi6r40Aq1" title="Number of Warrants, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOOZUfB75Rua" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup id="xdx_F45_zMhcIcLQEOg3">(1)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zPAiB1fqCrda" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,284,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z3Jr1f2NZ178" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAPnlh9J9We" title="Number of Warrants Outstanding, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DbtcWe9i2d" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zPB1oqRtX8Ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zZ50IP42y1W5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001318" xml:lang="en-US">Includes
                                            <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,273</ix:nonFraction></span> warrants exercised on a cashless basis for <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-09-30_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,280</ix:nonFraction></span> common stock.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A9_z4f0j9hJ2Zs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxdfGHb6KhW1" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of September 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzL6U5wIodUi" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,167</ix:nonFraction></span> shares have been granted under the
2018 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement outlining the terms of their service as a director and pursuant to which they would each receive a grant of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCPIhiIAP2p" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> worth
of Restricted Stock Units (&#8220;RSUs&#8221;) issuable under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;).
The RSUs vested annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z5ooPFBxfCBf" title="Restricted stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2019-08-162019-08-16_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022 and 2021, pursuant to the agreements with directors and officers, compensation expense for the
RSUs of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVM5fAAQtaok" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,733</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHaDH6jUr0h" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,551</ix:nonFraction></span> was included in compensation, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, there was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VSL6Fw3YDf" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,334</ix:nonFraction></span> of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the current year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zQUTKItLSwyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSUs) is set forth as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zEPSKpTDUEX2" style="display: none">Schedule
of Restricted Stock Units (RSUs) </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br />
RSU</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise <br />
Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zucGsO7jApGk" title="Number of Stock Option Outstanding, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,884</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh2nhdHl9H4d" title="Weighted Average Exercise Price, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxjCwRdW8aBh" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVwpB3WDjyb" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaC85nk4TjE9" title="Number of Stock Option Outstanding, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,702</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8IQpkJhHpBk" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAkqKJsJkf35" title="Number of Stock Option Outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNTQQ0pKQNEe" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoTwwRxCwFd3" title="Number of Stock Option Outstanding, Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqJQarbmomS" title="Weighted Average Exercise Price, Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRzMbmLfLjD" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0yYtPiigZh7" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwpyGG1LxO97" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLRpATl7oARd" title="Number of Stock Option Outstanding, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMSs7ioeWlI4" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKNoINGNfkac" title="Number of Stock Option Outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZdWes1Tiv1k" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjVqgVvh1vkl" title="Number of Stock Option Outstanding, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm4QxHnPnqtb" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk6uMcKKK4p7" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.58</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFSAFrLb73b" title="Number of Stock Option, exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1SVsH5cj8Ok" title="Weighted Average Exercise Price, exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs5wrkCUxacl" title="Exercisable Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.58</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zYGyYMXhjXe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zUvfGAU5tdAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_821_z3MypG20efs4">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through November 14, 2022, the date the financial statements were
available to be issued, and determined that no items were required to be disclosed.</span></p>

</ix:nonNumeric><p id="xdx_81F_z4qPK3aXKS24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vba_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the shareholders and the board of directors
of Shuttle Pharmaceuticals Holdings, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Shuttle Pharmaceuticals Holdings, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related statements
of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred
to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended,
in conformity with accounting principles generally accepted in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restatement of December 31, 2021 Financial
Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 9 to the financial statements,
the financial statements have been restated to correct certain misstatements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&#8217;s
significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ BF Borgers CPA PC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BF Borgers CPA PC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Served as Auditor since 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lakewood, CO</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 3, 2022, except for the effects of the
restatement disclosed in Note 9, as to which the date is June 23, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vba_002"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zXDqLraqyGmk" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zyRJM4n9pJs7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20201231_z1HCgDPv6Zu6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">(As Restated)</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zIo0RRmWuVd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zbesb149xNn6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_i02I_zKQ4ET2OWT8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_z3trUTEkJhme" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,579</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommodityContractAssetCurrent_i02I_zdylARgyf136" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contracts receivable</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommodityContractAssetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_z9FMIXPguORl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zx8DPRbTu6Bc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssets_i01I_zYgdQUlZzBA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zEiOSgymjeea" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_zrX6NFjcBUh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zD7Vcji6sbrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zSDOwKwG2h94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_i02I_zAsoq0UtK597" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,966</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_z0I20qt647X6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesClassifiedCurrent_i02I_znS0Zlv6Asqf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesClassifiedCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DividendsPayableCurrent_i02I_zY1A4snS54Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividends Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,059</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_i02I_zuFqq7MmEPpi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NotesPayableToBankCurrent_i02I_z7KuVsiPTA84" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNotesPayableCurrent_i02I_zMCWO68JJDgg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paycheck Protection Program note payable, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_i02I_zDY2zYSh7ODl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">673,171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_z8IeKErSSzUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liability current portion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_z6AZhMe0fqo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,217,331</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,104,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_znfbWXeklrR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability non-current</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_z4DKgc2BTlS9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,279,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,343</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_iB_zFw6GvUsrHA4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Deficit:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zH1SXZmqD4S6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zyAwhWGs3SZ4" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zPcHx2jpWHe3" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znFcSmaJImme" title="Preferred stock, liquidationPreference per share"><span id="xdx_908_eus-gaap--PreferredStockLiquidationPreference_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3bD39C56Mcf" title="Preferred stock, liquidationPreference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share liquidation value or aggregate
    of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znOA1aheN2jj" title="Preferred stock, liquidationPreference"><span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zTl7mf28Q9R2" title="Preferred stock, liquidationPreference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,212,500</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8FTrDhHYPO7" title="Preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zByvQKQuRy0g" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdsUkvLGTtE2" title="Preferred Stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNLO7qBeasw4" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockValue_i01I_zR7l63I5CaR6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1487">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CommonStockValue_i01I_zid920wr3Wud" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zUeAbljnnIq3" title="Common stock, par value (in dollars per share)"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zlVtWw53VSzf" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zHZrGrRT6Vj4" title="Common Stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zG9RVRPQ6Bog" title="Common Stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20211231_z5ILZxLhoT2" title="Common Stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zcvvQ1APh807" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20201231_zov4o7qvSPtd" title="Common Stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zoU0VD8a2Ur7" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></ix:nonFraction> </span></span>shares issued
    and outstanding at December 31, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_zCkrBGIpoRP1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_z4HlOEL6A3tc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,833,507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommonStockToBeIssued_i01I_zWVN1wmYVzUa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:CommonStockToBeIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:CommonStockToBeIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zDruxVxnykGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,540,236</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i01TI_zo0r02ZuTx4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,690,296</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_zSK22Eh8USr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total liabilities and stockholders&#8217;
    deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vba_003"></span><br />
Shuttle Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zEwN2UhlFAzb" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231_zqTRgMO4Dgak" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20201231_zEsbFko62a5i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(As Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_zVStEhIC0vy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_z9UrQ9oYV6q3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zaSBHsyO68fk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,808</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,772</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_z5TLR1y26fc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LegalFees_i01_zAEVVHykaH3g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_zZdr43o7Xom4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,742,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_zxi6nRfSR5Ti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,742,992</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">509,522</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z2C9LX3kEYd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseCustomerDeposits_zigUUeJtGAFc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on write off of deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1551">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpenseRelatedParty_i01N_di_zkJAvmXe4xae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,947</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,771</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpenseDebt_i01N_di_z06kG3YovcEf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,841</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,859</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfKjCexlPUMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">579,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,580</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zV6xRvM7YcP3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note
    payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1563">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01T_zO5gjsLQiWke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">296,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zZFqo7MbBSKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">805,732</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zvhBhJEclqql" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1571">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_zy6FSAnsjzO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">805,732</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zOBxH6jIrd4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividend on Series A preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_zJ6qhAXiGbCj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,255,196</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">908,794</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zmMvxSVhjvAh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,301,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_zuswsQxzzF1g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per shares - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vba_004"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Changes in Stockholders&#8217; Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_zJ57Jc01HIn5" summary="xdx: Statement - Condensed Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zvpY8sp7eVql" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zWlnYJxy2bZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zSZr0FZKLLq4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_zi8pRuxkzZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">be&#160;Issued</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zJEf2zPcfaAg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_zMVqWqfBdom2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series A Convertible</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Common</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock to</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">be&#160;Issued</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_439_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zyKG1vLSw15c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">Balance, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znBdRDfznyj5" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1589">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGNl4zAiHgxk" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,269,996</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,373,918</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,631,442</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,241,091</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zHmIFuQRmUvf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1600">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn3Myt9XXiO4" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1601">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1603">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1604">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DividendsPreferredStock_iN_di_zKy5xwRbKrci" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1610">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zE0Vhq41QPQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1617">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1618">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">805,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">805,732</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43E_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zEUc32qss3Ee" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zT01qHiXC4Gd" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJCi6cI7mtE3" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,833,507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,540,236</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,690,296</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z78rKC2h3sy6" style="vertical-align: bottom; background-color: White">
    <td>Stock based compensation (As Restated)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1635">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1637">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1638">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z0vZrTK7Qd41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued for financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1642">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1644">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zFRSXdl5S5jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8Wwf2gTJAw3" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1649">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,067</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DividendsPreferredStock_iN_di_zyk7NvmB0N6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1659">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,062</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zizSkOzfSTm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1664">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1665">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1667">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zkgP0Z0eiEW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, December 31, 2021 (As Restated)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7A5hhzxzBq8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4xBVRe0sLP7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43D_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zA9FHkQ7qZxc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Ending Balance, value</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zl3ukBt5ZIi7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1682">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkMMm7wFC6fj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vba_005"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_112_zwWZNLOAEuye" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_z8pOWezG76il" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20201231_zhrHFf8ut31l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(As Restated)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNzDICDIMiqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_zCqUI8Rwklg" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">805,732</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zQPi30Ww7nAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Depreciation_i02_pp0p0_zUaj4PA56SUd" style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,218</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_zkoDHDp2wBxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">579,146</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_zAc66RfXZjPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zXr2O91FoAK9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1712">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zyts8PLruNLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on forgiveness of Paycheck Protection Program note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1715">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_zexcW5SK5Mxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zmpMKXYmHH6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_z4hutVbIoqd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contracts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">211,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">164,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_zEHdVUO6bOsf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">586</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i02_zzLUHENhCvt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,127</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zYGXRIyoz1Mh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_z4QWps4pWfsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,959</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_z77b67jcK4We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,866</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_zkM06Aoe0yQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">300,336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,831</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zAF5vhGuQLS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_zHanPdeh0kC9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_zRuNx5gb6fb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1750">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zviaUDHhnAzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromRelatedPartyDebt_i01_zRytHd1Aboo3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from notes payable-related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,573</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromOtherShortTermDebt_i01_zpXCyI6XNJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_zG0pGLi1h01j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zXWKYYF2GoU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,073</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_zwJTh6nmKj05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">387,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zyENqJEOM8Jc" style="vertical-align: bottom; background-color: White">
    <td>Cash, beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,729</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zVvtOTMsxe35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cash, end of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">504,749</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zXPacwHYTpJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_ziU4yY5tNT95" style="vertical-align: bottom; background-color: White">
    <td>Interest</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,886</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zNxPQ8eS89u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1783">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_041_c20210101__20211231_zaR4aMoPJ9vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ed_001"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2020 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zfW6OIA38t38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zA3NBGJxSpV9">Organization and Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a corporation and the Company changed its name to Shuttle
Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z980VB5bNKS6" title="Number of convertible shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000,000</ix:nonFraction></span> shares of common stock
in exchange for <span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQh8FlUdslqc" title="Sale of stock membership percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the outstanding membership interests prior to conversion. On June 4, 2018, Shuttle completed a reverse merger
with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp.), a Delaware corporation (the &#8220;Company&#8221;),
pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies which has produced a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (SBIR) contract provided by the
National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH). Ropidoxuridine has been further developed though
the Company&#8217;s collaborations with the University of Virginia for use in combination with proton therapy to improve patient survival.
The Company is working on developing products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zt1vsqnk4tA5" title="Reverse stock split"><ix:nonNumeric contextRef="From2022-03-282022-04-02" name="us-gaap:StockholdersEquityReverseStockSplit">2-for-1 reverse stock split</ix:nonNumeric></span> of our issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;).
All references to shares of our common stock in this registration statement on Form S-1 refers to the number of shares of common stock
after giving effect to the Reverse Stock Split (unless otherwise indicated).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&#8217;s only revenue source since inception has been government awarded contracts totaling
$<span id="xdx_900_eus-gaap--GovernmentContractReceivable_iI_c20211231_zQhXS9JD3uvf" title="Awarded contracts"><ix:nonFraction name="us-gaap:GovernmentContractReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,531,722</ix:nonFraction></span>, and the Company has incurred losses since inception, having accumulated a deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_zRDBDopnla4g" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></span> as of December 31, 2021.
The Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient
to cover operating costs over an extended period. These factors, among others, raise substantial doubt about the Company&#8217;s ability
to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing
through debt or equity financings with an aim to continue progress toward commercial viability of its products. The Company continues
to submit Federal grant and contract applications which have historically been the primary source of revenue. The financial statements
do not include any adjustments that might result from the outcome of the uncertainty of raising additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zaCWCeJJoHH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_829_zDwoeqdcnG92">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzSeCibrySFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zHFk2Mm9gwU8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_848_eus-gaap--ConsolidationPolicyTextBlock_zpCW6ei1Xrg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z9MlYvZzbJ37">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zeUqtynLxD3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zHxcJoKlrWk3">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy"><p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_z1VY8Pmu6GNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUGWDSisXQa6">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounts receivable consists of amounts due from the National Institutes of Health (&#8220;NIH&#8221;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on research
and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and payments
from the contracts are generally collected within 30 days of the Company&#8217;s submission for reimbursement. The Company currently
does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection
information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance of the invoice and typically
would be considered past due when the term expires. The Company&#8217;s allowance for doubtful accounts was $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zkVwpc8cgnp9" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zBypMpqdf6y2" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> at December 31, 2020 and
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeRTsuUFY894" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zy1ME33lauv2">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvG7r2Lue0g" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</span></td>
    </tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zoq40ARkvugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGp2dE9hhrRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zgQsodqcjYxk">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zaeusPjbqBc2" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,502</ix:nonFraction></span> Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZxtPV2c0e48" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,903,095</ix:nonFraction></span> with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zUPYw14OkS5l" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span>
for a total of $<span id="xdx_90D_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zRHHZEcba5ki" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">845,820</ix:nonFraction></span> in 2020; and 2 quarterly payments related to Topic 345 for a total of $<span id="xdx_909_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_zP3SGc96Lxwi" title="Proceeds from contract awards for research and development"><ix:nonFraction name="SHPH:ProceedsFromContractAwardsForResearchAndDevelopment" contextRef="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,910</ix:nonFraction></span> in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown University to perform the $<span id="xdx_903_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zM0qWX69QD7a" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,248</ix:nonFraction></span> subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z3cnkMBBBhNf" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,248</ix:nonFraction></span>. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211201__20211231_zDFLz35b8ZD" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2021-12-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,829</ix:nonFraction></span> were made to Georgetown,
and additional invoices for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231_zdbj5Zip7kb" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,188</ix:nonFraction></span> were received but not yet paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_z3qXOJD0BmS" title="Proceeds from contract awards for research and development"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-09-172020-09-16_custom_PhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,484,350</ix:nonFraction></span> to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zajbxohgsNr4" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,321</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0Q4mmcdceZb" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,467</ix:nonFraction></span> in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $<span id="xdx_90C_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zjZOQRhRSoT5" title="Business development new establishment"><ix:nonFraction name="us-gaap:BusinessDevelopment" contextRef="From2021-01-012021-12-31_custom_PhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">742,002</ix:nonFraction></span> to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z9lcD8RCIC0j" title="Proceeds for research and development from collaborators"><ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">742,002</ix:nonFraction></span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_903_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zG9gSpfZ7Rp8" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2021-01-012021-12-31_custom_SubcontractPhaseIIMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,252</ix:nonFraction></span> as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $<span id="xdx_908_ecustom--ResearchAndDevelopmentDeficitNet_c20210101__20211231_z4cRZ85dT5Ai" title="Net deficit on research and development"><ix:nonFraction name="SHPH:ResearchAndDevelopmentDeficitNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,808</ix:nonFraction></span> from these two SBIR contracts which is the result of recording $<span id="xdx_909_eus-gaap--CapitalizedContractCostNet_iI_c20211231__dei--LegalEntityAxis__custom--SBIRMember_zgGdHtrh81Xk" title="Project cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2021-12-31_custom_SBIRMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,527,185</ix:nonFraction></span> in SBIR contract related expenses
on revenues of $<span id="xdx_908_eus-gaap--CapitalizedContractCostNet_iI_c20201231__dei--LegalEntityAxis__custom--SBIRMember_zoZGhm200M6h" title="Project cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2020-12-31_custom_SBIRMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,377</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_841_eus-gaap--DerivativesPolicyTextBlock_zDJe5Tlsf9bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zCUUvceE5Y19">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&#8217;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&#8217;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKwi81zQZRlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zKgD4N7HXxc5">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation
    methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets
    in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially
    the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation
    methodology us one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8I5At1BUld" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.22</ix:nonFraction> </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY7PlvqW9iE8" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span> in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock"><p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z5wlC8g4VNF4" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">673,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zMFIwN4l8G2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zF0u8ua9DnYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z4tzmmsrb0zi">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed contracts with
    the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification of performance
    obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of the transaction
    price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation the transaction
    price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition of revenue
    only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net
of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zPau7tRPvDne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z6G31CPqBJC7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9PNW0W5dLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zjn1rBexH1P3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMMOgYBJyl01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zbbuukvDA6n5">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zLrPHxK3r8ik" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zmayAC6bl05j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3igIdv3U6A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z20jsWIwjfHk">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

</ix:nonNumeric><p id="xdx_85E_z3agHB8KBysk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z7xeq4BqZwSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_828_zPZ4ViShhbq5">Property and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z293shVBnX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following as of December 31, 2021, and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zUr4lrOJYvF3" style="display: none">Schedule
of Property and Equipment Net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zSEQkOppiO5i" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zkJJtHp8oFWl" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOKWx4HrW392" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zLyb9JAYDobb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_zMWGxtXnHRM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,466</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zwkuXQRcad9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zc6buQvCEHzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,782</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zoUlaKjS5kU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the twelve months ended December 31, 2021, and 2020 were $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zru2PqkqicX1" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,218</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zXK7hqXRAlZj" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,782</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zyBTUAHGSRD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_829_zco7edg7vAk7">Operating Lease Right-of-use Asset and Operating Lease Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. <span id="xdx_907_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20210101__20211231_zP1K07qIF6Q8" title="Interest rate used to lease, description"><ix:nonNumeric contextRef="From2021-01-012021-12-31" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</ix:nonNumeric></span> Operating lease expense is recognized on a straight-line basis over the lease
term. During the twelve months ended December 31, 2021, and the year ended December 31, 2020, the Company recorded $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zyxBDvt1RKC" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,028</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20200101__20201231_zTvLFQFhMsn" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,872</ix:nonFraction></span>,
respectively, as operating lease expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $<span id="xdx_902_eus-gaap--OperatingLeasePayments_c20180929__20181001_zBlZi2wzv0B8" title="Lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2018-09-292018-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,107</ix:nonFraction></span>, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on <span id="xdx_90F_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zsuGo17UZjf" title="Operating lease expiration date"><ix:nonNumeric contextRef="From2018-09-292018-10-01" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">October 31, 2023</ix:nonNumeric></span>. A security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zwDFKEoT6KKi" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2018-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span> is being held for the duration of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#8216;package of practical expedients,&#8217; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of <span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20211231_z8MnUaYYMk5c" title="Lease term"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:durmonth" name="us-gaap:LessorOperatingLeaseTermOfContract">12</ix:nonNumeric></span>
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zGNZoOUwWE2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1CVxMNAGGw7" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zIPeQCOX6197" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zGRdq5m7ruo" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zByLv4uguS7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="SHPH:OfficeLease" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,207</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="SHPH:OfficeLease" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,207</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_za6ldmTid0xk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:AccumulatedAmortizationOnRightOfUseAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:AccumulatedAmortizationOnRightOfUseAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,609</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zQxRuTcj6KK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,598</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z42s2REETpNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of -use asset is included in rent expense on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRhltcKRLqyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zZms85qMdgaf" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zdZcv5DI5bpg" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zSX1D7qU6WY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,376</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zeMS8XHFzwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,934</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_znebceF7M491" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zZTR5TCyHSN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z98Fy6YXydx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zMMRA9wuYNOj" style="display: none">Schedule Of Operating Lease Maturity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20211231_ztevs8lGFSs" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zHj2r2sgCHW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,248</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zMl8VEXKF1s5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zzzVCxMlgfGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,048</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQoP45FoKrEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zuRGKEbQQBi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">PV of Payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,376</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z7JAV7O5pPTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgV7cbTOJVHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82B_zue1ELM5AIeb">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_ziaj3PvHRAmb" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>. The loan bears
interest at the rate of <span id="xdx_90F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zxv3KbgJXN33" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum. The loan plus accrued interest was payable in full on January 25, 2019. On January 25, 2019,
the Company amended the loan for purposes of extending the maturity date from <span id="xdx_905_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zc013yLOUBOe" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">January 25, 2019</ix:nonNumeric></span>, to <span id="xdx_906_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_z9D8xe0Q60Rh" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">October 25, 2020</ix:nonNumeric></span>. On <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20180124__20180125_zkIxMRnmJS55" title="Debt maturity, description"><ix:nonNumeric contextRef="From2018-01-242018-01-25" name="us-gaap:DebtInstrumentMaturityDateDescription">December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021</ix:nonNumeric></span>, bringing the total amount owed under the loan,
together with accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zD63Fsdxwbsi" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,084</ix:nonFraction></span>, to a total of $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zcNp4SbZ0cH2" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,084</ix:nonFraction></span>. This note was rolled into the note referenced below with a principal
amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zH39XI1L8eIl" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,056</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zTiCpL3U3hlb" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>. The loan bears
an interest rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z69480AXTxgf" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum. The loan plus accrued interest was payable in full on September 4, 2018. On October 31, 2018, the
Company amended the terms to extend the maturity date from <span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z6RsAiK6BqMh" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">September 4, 2018</ix:nonNumeric></span>, to <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zqvxRWSCRsff" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">April 4, 2019</ix:nonNumeric></span>. On April 4, 2019, the Company amended
the terms to extend the maturity date from April 4, 2019, to October 25, 2020. On <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20180403__20180404_zZXawIIW4KW4" title="Debt maturity, description"><ix:nonNumeric contextRef="From2018-04-032018-04-04" name="us-gaap:DebtInstrumentMaturityDateDescription">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</ix:nonNumeric></span>, bringing the total amount owed under the loan, together with accrued interest of
$<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zf0XvZ6quGL5" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,972</ix:nonFraction></span>, to a total of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zpArJH6UU8fi" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,972</ix:nonFraction></span>. This note was rolled into the note referenced below with a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z3dN2qTgVwl9" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,056</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2018, the Company entered into a loan with an officer of the Company in the amount of $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zCAgiurrO8rc" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>. The loan bears an interest rate
of <span id="xdx_908_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zHMFD4PKABwd" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum. The loan plus accrued interest was payable in full on July 15, 2018. On October 31, 2018, the Company amended the
terms to extend the maturity date from <span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zllr31sa1F9" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">July 15, 2018</ix:nonNumeric></span>, to <span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zzX8SlZEoREc" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">November 30, 2020</ix:nonNumeric></span>. On <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20180529__20180530_z5uXZGEZvGFc" title="Debt maturity, description"><ix:nonNumeric contextRef="From2018-05-292018-05-30" name="us-gaap:DebtInstrumentMaturityDateDescription">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</ix:nonNumeric></span>, bringing the total amount owed under the loan, together with accrued interest of
$<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zuJ3zeqqiY8g" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,698</ix:nonFraction></span>, to a total of $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_z4R4JbzIWDz" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,698</ix:nonFraction></span>. This note was rolled into the note reference below with a principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zXw7NUwGwtDf" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,448</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zAtaw5etE5sd" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>. The loan bore interest
rate of <span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zdzVaV8LZCL1" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum and required monthly payments of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zuYg1aef7bH4" title="Monthly payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,073</ix:nonFraction></span>. The loan plus accrued interest was paid in full on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_z5PhWEq2L4rl" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 30, 2020</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zhB7TV86pA67" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>. The loan bore
an interest rate of <span id="xdx_909_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zGlhPkLe7MD2" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum and required monthly payments of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_z1jrzoeS9Yh5" title="Monthly payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,073</ix:nonFraction></span>. The loan plus accrued interest was paid in full on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zrYsvyir1byk" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August
23, 2020</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zde2Jp2Lp7e9" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. The loan
bore an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_z5zZGaYsHaw1" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum and became payable in full on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zQF7WgHVecC" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">September 22, 2020</ix:nonNumeric></span>. This note was rolled into the note reference
below with a principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zi6mQafHA2Jj" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,448</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zvSTsmjveRp2" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,056</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_902_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z1qcw8IFirVd" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity date of <span id="xdx_901_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCKaR0uOZh5b" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>; and (ii) a single loan
owed to an officer of the company in the principal amount of $<span id="xdx_908_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zLUZIfTwEEck" title="Notes payable related party debt principal balance"><ix:nonFraction name="SHPH:RelatedPartyTransactionAmountsOfTransactions" contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,449</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zvBk6xrXF8gc" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity
date of <span id="xdx_90D_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zviIvjcujOa1" title="Notes payable related party maturity date"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:datemonthdayyearen" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>. In December of 2021 the maturity dates of these loans were extended to June 30, 2022. As of December 31, 2021,
the accrued interest was $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zjRZs7A3t3j" title="Interest payable current"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,804</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zbWGQaY9snX6" title="Interest payable current"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,384</ix:nonFraction></span>, and the total balances with accrued interest of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zIP9oj6WWQvj" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,047</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z5po8X8hcDjj" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,613</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zDHoYtcfSsrb" title="Notes payable related party debt principal balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (principal) with
an interest rate of <span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zOUt5WlmIToe" title="Notes payable related party transaction rate"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum due June 21, 2022, due at maturity. As of December 31, 2021, the accrued interest was $<span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zZTGcwZ2cfg" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,759</ix:nonFraction></span> and the
total balances with accrued interest of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zoPLNMS0oK63" title="Notes payable related party debt plus accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,759</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zeswcbZw9T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - <span id="xdx_828_zF9fjtDCFVra">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_90D_eus-gaap--MediumTermNotes_iI_c20210309_z1t8aWehYrWh" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2021-03-09" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zBkMzrjwAEE1" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-03-09" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the
requested documentation and subsequent to the close of the December 31, 2021, reporting period the note liability was reduced in its
entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $<span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20200515_zWqO2LbvoP6a" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2020-05-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_zQqWltLwz2Ic" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-05-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. A &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zEJQH7FsQBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z7x0Bf5QV6J7" style="display: none">Schedule
of Notes Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zs8ZjEzR5as6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20201231_z5ddmsxg9gG3" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zlKWCVwANhc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">PPP Note <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zAwg53kad8Uj" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">May 15, 2020</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zKIGQqEGOeIc" style="vertical-align: bottom; background-color: White">
    <td>PPP Note <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_ztFm5G3svYx7" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 9, 2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zed16WxGRXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:LoanForgiveness" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayable_iI_zCp6BUuAMjk8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z3EMa0tpeiZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20211228_zcmhoubBafya" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> note units, consisting of two $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zUFrLFDAvifi" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> notes, for a total of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zZlcggDXmFga" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zrCIkl2P8ikd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% unsecured promissory
notes with a maturity date of <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z4Dxj02eBRtc" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-12-282021-12-28" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 28, 2022</ix:nonNumeric></span>, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zXo1AtI4bHj4" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> warrants exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zXs4eR6Ol0ta" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share with an expiry date of December
28, 2026, and fees of $<span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zcE58aOZgKAf" title="Debt fee amount"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2021-12-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,075</ix:nonFraction></span>. The value of the warrants was determined using a computed volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSx2U7ZLDDt5" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.5</ix:nonFraction></span>%, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF8MylifPkUj" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% dividend rate, and a
risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMlII9Z5iwQg" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.27</ix:nonFraction></span>% and was applied as a discount on the notes payable as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4nwu7JkSlxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zF9q91NBsww7" style="display: none">Schedule
of Promissory Notes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zScL1QxrrD58" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z7eF9AhBvJH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Promissory notes issued on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zEYM2T1Dfl7c" title="Debt maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_PromissoryNoteOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 28, 2021</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zwVIHIq0ckw6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized discount on notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zRjlbHqT2Zb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,021</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zAIXs23KZWDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJOFMLgMcr2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82F_zYWN4IZTowha">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s amended and restated articles of incorporation, the Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zqmLmrckmf51" title="Common Stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of common
stock, with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zmu3E0EDFesh" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z2Y5sNmXI658" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of preferred stock, with a par value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zdNWjXHIUN8l" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#8217;s common stock on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOTJy3GY9uFa" title="Preferred Stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsjVxLIUMvzd" title="Preferred Stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJgeknCVqbCf" title="Preferred Stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zE0wdkBs3Ue7" title="Preferred Stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series A Preferred Stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had accrued the <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zj8eEaa8Nol4" title="Preferred stock dividend rate"><span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHD9RT1BBwDe" title="Preferred stock dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></ix:nonFraction></span></span>% cumulative dividends on the Series A Preferred stock of $<span id="xdx_90D_eus-gaap--PreferredStockValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUPcQNVJm4M3" title="Preferred stock value"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,059</ix:nonFraction></span> and
$<span id="xdx_90F_eus-gaap--PreferredStockValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFisKpopTzcl" title="Preferred stock value"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,997</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20211231_zDdr296UZk3b" title="Common Stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_ztynPIhxgAsf" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20201231_z6RWhStahwGh" title="Common Stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zEAN0207Spo2" title="Common Stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,291,526</ix:nonFraction></ix:nonFraction></span></span> shares of common stock issued and outstanding, respectively.
The balance includes <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofyvVudYVxc" title="Common stock issued for restricted stock units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,626</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoj8d0RhakV5" title="Common stock issued for restricted stock units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,530</ix:nonFraction></span> shares of restricted stock issued in 2021 and 2020 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock to be Issued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zU2hW2gE3742" title="Convertible notes"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2018-06-04" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,250</ix:nonFraction></span> outstanding convertible notes were converted to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z3u4hGHNlJD4" title="Debt converted into common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,182</ix:nonFraction></span> shares of common stock of the Company at a price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zJ12HcFHlna4" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.44</ix:nonFraction></span>
per share. The Company has recorded $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z5OcV4XFuU01" title="Debt converted into common stock, value"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></span> of common stock to be issued for the accrued interest. As of December 31, 2020 and 2021,
the common stock has not been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the private placement offerings, included warrants to be issued upon the earlier of a closing of the
sale of shares of common stock to the public at a prices per share of at least $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20211231_z8xagu8x2f2a" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> or in a firm commitment underwritten public offering
pursuant to an effective registration statement resulting in gross proceeds of at least $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zycRFeTR9Urg" title="Proceeds from initial public offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>. The warrants shall be exercisable
for a period of three years after the date of issuance. The warrant exercise price is contingent on the terms of the public offering.
If an initial public offering occurs at a price at or above $<span id="xdx_908_eus-gaap--SharePrice_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z62X2QT8yqFe" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> per share, then the exercise price shall be set to the issuance price
of the common stock with the number of warrants determined based on a 10% discount to the per share common stock issuance price. In the
scenario where the common stock is listed with the common stock issuance price below $<span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20210101__20211231_zaNFx9nt96Lb" title="Warrant exercise low price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, the exercise price will be set to $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231_zIDoOwqh0cn6" title="Warrant exercise price increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.82</ix:nonFraction></span>
with the number of warrants based on a fixed conversion price of $<span id="xdx_90C_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20210101__20211231_zZYrxwzjqw86" title="Common stock, Conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.49</ix:nonFraction></span>, which represents a 10.0% discount to the $<span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231_zPoS7a33NwV" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span> threshold. The
warrants also have contingent call features based on the terms of the public offering. If an initial public offering occurs at a price
at or above $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVTqfcwTRkZk" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2021-01-012021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, then the warrants are callable if the 20-day VWAP of the common stock in at or above <span id="xdx_90F_ecustom--PercentageOfVariableExercisePrice_pid_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs0BeknGg207" title="Percentage of variable exercise price"><ix:nonFraction name="SHPH:PercentageOfVariableExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">150</ix:nonFraction>%</span> of the variable exercise
price. In the scenario where the common stock is listed with a common stock issuance price below $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zhTBmM4kryXf" title="Increase in common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2021-01-012021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.88</ix:nonFraction></span>, then the warrants are callable
if the 20-day VWAP of the common stock is at or above the $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za22Npow9PX7" title="Warrant exercise price increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.82</ix:nonFraction></span> exercise price. The detachable warrants contained terms and features
that gave rise to derivative liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability linked to the Series A Preferred Stock as of December 31, 2021 and 2020 was $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwaJvWUkYSz7"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZ7vcqJAGOWd"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">673,171</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The change in fair value of warrant liability was a gain of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBi59iJAXl"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,146</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2021 and a loss of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znbzoMXbSu3h"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,580</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zqrSyCvFjEMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zS9WSxHJNIXh" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zzZd2zSHWZb5" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zxheEKRT7OYf" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">69.8</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zpgZ1YZFEyve" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zv1bW8CFMpw9" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zlNTKtD2QOnj" title="Expected life"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.33</ix:nonNumeric></span> Years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z59ra0LR6fpd" title="Expected life"><ix:nonNumeric contextRef="From2020-01-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.33</ix:nonNumeric></span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zlxJazmtaUHj" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.73</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zZ9jfDpLPPI5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.17</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zeDQOtB9mNm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zTzjVKqsXQ0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zoAtzKTNqnb4" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br />
Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br />
Average <br />
Exercise <br />
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br />
Average Life <br />
(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br />
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGJXH4vqT4g3" title="Number of Warrants Outstanding, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxacmSgngLd1" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUF19Q2fWyOb" title="Weighted Average Remaining Life in Years Outstanding"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear" name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">4.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwXUtfIylJwe" title="Intrinsic Value, Outstanding Beginning Balance" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCpyCdI6bKig" title="Number of Warrants, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziER2wFJ8At9" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCI3PYy22nyk" title="Number of Warrants, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3FRt72pUq7k" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhjBy06R5li3" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2239">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zggVAJWPLXyd" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZXwl3qiVQUh" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1UF2OS1H3h7" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyYeEN31fxOc" title="Weighted Average Remaining Life in Years Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear" name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">3.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCv4qGki3iv4" title="Intrinsic Value, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyUcgegtfU0d" title="Number of Warrants, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2251">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoTiqWpp5v77" title="Weighted Average Exercise Price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2253">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjyGRJa1HEhf" title="Number of Warrants, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8gAZuUdIi3f" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg3J5QbCGnU6" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2259">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTvaRVkvP63a" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding and Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zciR8WEnUiXh" title="Number of Warrants Outstanding, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cSpiTgKCcd" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.98</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5EEhfd6Lr21" title="Weighted Average Remaining Life in Years Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear" name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">2.33</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4uV5MkPbHi" title="Intrinsic Value, Outstanding Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zNG4gJ7WsYa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee or,
alternatively, if there is no compensation committee, the Company&#8217;s board of directors. We have reserved <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zC4rmGYlSjsc" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of December 31, 2021, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zGVxAssdvL8l" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,167</ix:nonFraction></span> shares have been granted under the 2018
Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement pursuant to which they will serve as a director and pursuant to which they would each receive a grant of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFeLlgpGRcM5" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> worth
of Restricted Stock Units (&#8220;RSUs&#8221;) issuable under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;).
The RSUs vest annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RZrX46Zjme" title="Restricted stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2019-08-162019-08-16_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, pursuant to the agreements with directors and officers <span id="xdx_901_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zhzvnX1ARNmj" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,626</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zRYz075b8zUk" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,530</ix:nonFraction></span> RSUs were issued
with a value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8ylF59eZsg6" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,067</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQdA6Nr8en2c" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,589</ix:nonFraction></span> included in wages, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuaVhtPSHXPg" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,067</ix:nonFraction></span> of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the next two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z7J26BhMgTZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSU) follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zD2cjcYwwuee" style="display: none">Schedule
of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br />
Average <br />
Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br />
Average Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGy8hGU7H6Xk" title="Number of Stock Option Outstanding, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfV9RQHPHnO" title="Weighted Average Exercise Price, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.02</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28RkmioCX4d" title="Weighted Average Life (Years)"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN4n3nTXpXob" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8Xq9TXq6oca" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOH1D3MKKA46" title="Number of Stock Option Outstanding, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,702</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zebTa7ZZJWMg" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjwYmKlTdna" title="Number of Stock Option Outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlNxm3U5p3jj" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhYdez79ua7j" title="Number of Stock Option Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,884</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EEh9u8Rny9" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcTHzBsvqd9" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvGxO5u1nf9" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQZHtFixO4o1" title="Number of Stock Option Outstanding, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,702</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfMc4kDyj2b2" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztWDydoEqsd9" title="Number of Stock Option Outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJkxxHKumOpe" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmHKnly3tlMb" title="Number of Stock Option Outstanding, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJO11isFw8pk" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc9pi5v9Xl3g" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.33</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZO4vwClYXi3" title="Number of Stock Option, exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTf5l0KEVdf1" title="Weighted Average Exercise Price, exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.93</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoj6q8oIA391" title="Exercisable Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.33</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zKgTM9QEZJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82C_zRXUrVVPJdTl">Income Taxes (Restated)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not made provision for income taxes for the years ended December 31, 2021, since the Company has the benefit of net operating
losses in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zfpTJrpMXd9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcC0lCcc0xA5"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z0l80A5F9c28" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zjx3wEimIymc" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20201231_zmrMSFl6fEi8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zMQzg6FtDgxl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">241,948</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,111</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zEsuz5Cwkrxl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,051</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,293</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_zgPBp4WFMv3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,381</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zMNAxT1v2cy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,023</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zEOpZnHn4vZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense (benefit)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2354">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2355">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zxVODHcZRn3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVqWKqV9sse3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3jVIxUWCK47" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zm8TRJoHJWl6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20201231_z62SpSjAcV7k" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred income tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzOFC_zzmIcFjC0vv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operation loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">890,970</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,699</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzOFC_zg6BYHQ13JA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzOFC_z6hOw8owWjlf" style="vertical-align: bottom; background-color: White">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,788</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetInterestCarryforward_iI_maDTAGzOFC_zFYATNHgeXYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzOFC_z4t5PiJIEgv1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzOFC_maDTANzoN8_zQdjZxKskwAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,039,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoN8_zzcDn27G6w6a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,039,612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoN8_zb7Vji106gv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred income tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2380">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z0qYBc8kUl23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zQSm8R518ktg" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> of net operating losses (&#8220;NOL&#8221;) carried forward to offset taxable income, if any, in
future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on
the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs for every
period because it is more likely than not that all of the deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ErrorCorrectionTextBlock"><p id="xdx_805_eus-gaap--ErrorCorrectionTextBlock_ziNNLYktv2F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_z3AQT96MY1i6">Restatement of Financial Statements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements as of and for the year ended December 31, 2021, contained an understatement of legal and professional
expenses of $<span id="xdx_90D_eus-gaap--LegalFees_c20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zwd2SFrgbQHj" title="Legal and professional"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></span> for the valuation of a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231_zPA07Qu17mz2" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></span> shares (<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20210101__20211231_zXbkI9X12ch4" title="Post split"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,000</ix:nonFraction></span> shares on a post-split basis) of incentive stock transferred
from a significant shareholder of the Company , who is also the wife of our Chairman and CEO, to a consultant for the Company in a private
transaction.</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zrQCbsF8GlR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zHqsuMlFkPke" style="display: none">Schedule
of Error Corrections and Prior Period Adjustments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7rhXTFinxua" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Originally</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reported<br /> ($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zA3FNhfJBlJa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br />
Adjustment<br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zcqwd6LQgrzd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zDBaXJwDx9Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_zln5uBsBYHn5" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Additional paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,730,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zMPE94sVvJVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,375,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPifdA6smGZ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br />
Reported <br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zws6ZyNjQgkd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br />
Adjustment<br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_zTZDMpCuETek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As <br />
Restated <br />
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zPrs4NLrg89i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LegalFees_i01_z0Hbf5NRlM45" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Legal and professional</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,684</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,684</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01_zAJ0lsN7xFVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,322,992</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,742,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zMIZK59m6f5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,322,992</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,742,992</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zSedjX2VsXOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Loss before Income Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">732,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zlloZelMBcB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">732,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJhHtr5hWeEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">835,196</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,255,196</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zKPH6nydBU59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss per shares - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.04</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeVIxtMrSjn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br />
Reported <br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyfQ25RK6Ach" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br />
Adjustment<br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zfIlx8K5HED8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As<br />
 Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zs4cRQ0OtDG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zIkx9Tj0O3gk" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">732,134</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">420,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,152,134</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zdOSwsZHODke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,067</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zV1WtBGFe06a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-012021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z343XKlw7CQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82B_zWuhxLDwk3wj">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through June 3, 2022, the date the financial statements were available
to be issued, and determined the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2022, the Company received notice of forgiveness for the PPP loan entered into on March 9, 2021 for $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220121__20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzkm1op1Eps9" title="Debt instrument decrease forgiveness"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2022-01-212022-01-22_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--InterestReceivable_iI_c20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpcJCURlSL3a" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2022-01-22_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">641</ix:nonFraction></span> in interest
that reduced the note liability in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022, and March 11, 2022, the Company sold $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGm5pZdmdnG1" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-02-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkYdx1sLJb0i" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-03-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,985</ix:nonFraction></span>, respectively, in <span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwn4ary0nN99" title="Conversion ratio"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% convertible notes (the &#8220;Notes&#8221;),
which bear <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztLohKgLkqY4" title="Conversion ratio"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% interest, are repayable three years from the date of issuance, and will convert automatically into shares of common stock
(the &#8220;Conversion Shares&#8221;) at a conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9ZVzY2PLokh" title="Conversion price"><span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zea8xCWlhm7e" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-02-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-03-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></ix:nonFraction></span></span> per share upon closing of this offering. Boustead Securities LLC
acted as placement agent for this offering and received compensation of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9q7eG1gwJUl" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,500</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXkEALhBootf" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,250</ix:nonFraction></span>, respectively, and warrants to purchase shares
of common stock equal to <span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxh0jNKYsmT2" title="Conversion shares"><span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWXIjTdDQ05f" title="Conversion shares"><ix:nonFraction name="SHPH:DebtInstrumentConvertibleConversionSharesPercentage" contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="SHPH:DebtInstrumentConvertibleConversionSharesPercentage" contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% of the Conversion Shares, exercisable at the conversion price of the Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 30, 2022, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwZ9OkBXUNz8" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,678</ix:nonFraction></span> shares (<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQeN58VOlfrf" title="Post reverse split"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839</ix:nonFraction></span> shares post-reverse split) of common stock to correct an issuance error on completion
of the 2018 share exchange which is valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO0sgTPNFE9l" title="Value  issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></span> common stock to be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, pursuant to the consent of the Company&#8217;s board of directors and a majority of its common stockholders, the Company
effectuated a two-for-one reverse split, pursuant to which each stockholder received one share of common stock for every two shares held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company submitted the final invoice for &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity
for Radiation Late Effects,&#8221; for $<span id="xdx_904_ecustom--PaymentOfInvoice_c20220405__20220406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQ4Xvb2fA5" title="Value  issued"><ix:nonFraction name="SHPH:PaymentOfInvoice" contextRef="From2022-04-052022-04-06_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span>, following the completion of the Final Quarterly Progress Report to NIH covering the
performance period of 9/16/2019-3/15/2022. The invoice was paid in full on April 27, 2022.</span></p>

</ix:nonNumeric><p id="xdx_811_zCDQm8TLfEEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><img src="forms-1_008.jpg" alt="" style="height: 326px; width: 470px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">PROSPECTUS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
__,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 138 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ed_002"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN THE PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ed_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Financial Printing Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SEC Filing Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,757</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">FINRA Expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer Agent Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,397</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting Fees and Expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal Fees and Expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">131,623</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous Fees and Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">186,577</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amounts are estimates other than the SEC and FINRA filing fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ed_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEMNIFICATION OF DIRECTORS AND OFFICERS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the Delaware General Corporation Law, as amended, authorizes us to indemnify any director or officer under certain prescribed
circumstances and subject to certain limitations against certain costs and expenses, including attorney&#8217;s fees actually and reasonably
incurred in connection with any action, suit or proceeding, whether civil, criminal, administrative or investigative, to which a person
is party by reason of being one of our directors or officers if it is determined that such person acted in accordance with the applicable
standard of conduct set forth in such statutory provisions. Our certificate of incorporation contains provisions relating to the indemnification
of directors and officers and our by-laws extend such indemnities to the full extent permitted by Delaware law. We currently maintain
insurance for the benefit of any director or officer which cover claims for which we could not indemnify such persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ed_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECENT SALES OF UNREGISTERED SECURITIES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past three years, we effected the following transactions in reliance upon exemptions from registration under the Securities Act,
as amended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the period commencing
October 29, 2018 through February 11, 2019, we issued 1,215.5 units (the &#8220;Units&#8221;), at a purchase price of $1,000 per Unit,
which Units consisted of a total of (i) 1,215.5 shares of Series A convertible preferred stock, par value $0.001 per share, which
shares automatically converted into 2336,810 shares of common stock upon completion of our initial public offering (&#8220;IPO&#8221;),
and (ii) warrants to purchase up to 336,810 shares of common stock, which warrants were issued upon completion of our
IPO. The Units were sold to a total of 21 accredited investors pursuant to an exemption from registration under Rule 506(b) of the
Securities Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company issued to AFH Holding &amp; Advisory, LLC, as consultant (&#8220;AFH&#8221;), 639,161 restricted stock units
(319,580 shares post-reverse split) under the Company&#8217;s 2018 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, in conjunction with entering into two loan agreements for a total of $500,000, which were repayable at the
time of our IPO, we issued warrants to purchase a total of 500,000 shares of our common stock, exercisable at $1.00 per share. Such warrants
were sold to two accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities Act. Boustead Securities
LLC acted as placement agent, but waived its cash compensation related to such offering and, to date, has received no warrant compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 8, 2022 and March
11, 2022, the Company sold to certain accredited investors $365,000 and $224,985, respectively, in 6% convertible notes (the &#8220;Notes&#8221;),
which bore 6% interest, were repayable three years from the date of issuance, and converted automatically into shares
of common stock or, in the event that units are sold in the offering, units, at a conversion price of $4.00 per unit upon closing
of our IPO. Such notes were sold to accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities
Act. Boustead Securities LLC acted as placement agent and received compensation of (i) $36,500 in cash and warrants to purchase 10% of
the total number of shares issuable upon conversion of the Convertible Notes, exercisable at the conversion price of the Convertible
Notes for the February offering and (ii) $22,750 in cash and warrants to purchase 10% of the total number of shares issuable upon conversion
of the Convertible Notes, exercisable at the conversion price of the Convertible Notes for the March offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 30, 2022, the Company issued a total of 1,678 shares (839 shares on a post-reverse split basis) of common stock (the &#8220;Issuance&#8221;)
to some 23 existing shareholders in satisfaction of certain interest that had accrued as the result of an inaccurate conversion of convertible
notes in our 2018 share exchange. The Issuance satisfied in full all interest owed or otherwise accruing as the result of the inaccurate
conversion. Such issuance was made in accordance with Rule 506(b) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August, 1 2022, in conjunction
with entering into three loan agreements for a total of $125,000, which were repayable following consummation of our IPO,
we issued warrants to purchase a total of 50,000 shares of our common stock, exercisable at $2.50 per share. Such warrants were sold
to three accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities Act. Boustead Securities
LLC acted as placement agent, and received warrants to purchase 5,000 shares of common stock exercisable at $2.50 per share, equal to
10% of the value of the note offering, and $12,500 in cash compensation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above disclosures do not include 768,334 shares (384,167 shares on a post-reverse split basis) granted pursuant to the Shuttle Pharmaceuticals
Holdings, Inc. 2018 Equity Incentive Plan, which were issued to certain employees, directors and consultants, and vest on a periodic
basis in accordance with the grant agreements between such individuals and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 139; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ed_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective March 30, 2022 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-3.htm" style="-sec-extract: exhibit">Amended and Restated By-Laws (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-4.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Designation for Series A Convertible Preferred Stock, effective April 6, 2022 (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective June 22, 2022 (incorporated by reference to Exhibit 3.5 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on June 23, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex4-1.htm" style="-sec-extract: exhibit">Form of Convertible Note, dated February 2022 (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-2.htm" style="-sec-extract: exhibit">Form of 10% Promissory Note, dated August 2022 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-3.htm" style="-sec-extract: exhibit">Form of Warrant, dated August 2022 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-4.htm" style="-sec-extract: exhibit">Form of Public Offering Warrant (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex4-2.htm" style="-sec-extract: exhibit">Form of Underwriting Warrant issuable to Boustead Securities LLC (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Michelman &amp; Robinson, LLP*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex5-2.htm" style="-sec-extract: exhibit">Intellectual Property Opinion (Morgan Lewis) (incorporated by reference to Exhibit 5.2 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-1.htm" style="-sec-extract: exhibit">Form of Subscription Agreement for Series A Convertible Preferred Stock (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-2.htm" style="-sec-extract: exhibit">2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-3.htm" style="-sec-extract: exhibit">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-4.htm" style="-sec-extract: exhibit">Employment Agreement, dated July 30, 2014, between Shuttle Pharmaceuticals Holdings, Inc. and Tyvin Rich (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-5.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C, dated September 19, 2014, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-6.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C Amendment of Solicitation/Modification of Contract, dated August 3, 2015, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Radiosensitizer Option Phase II) (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-7.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201600027C, dated September 19, 2016, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-8.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261600038C dated September 19, 2016 between Shuttle Pharmaceuticals, LLC. and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-9.htm" style="-sec-extract: exhibit">Material Transfer Agreement, dated April 25, 2017, between Shuttle Pharmaceuticals, Inc. and George Washington University (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-10.htm" style="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Peter Dritschilo (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-11.htm" style="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Mira Jung (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-12.htm" style="-sec-extract: exhibit">Employment Agreement, dated June 28, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-13.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated September 1, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Michael Vander Hoek (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-14.htm" style="-sec-extract: exhibit">Form of Letter Agreement with Director (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-15.htm" style="-sec-extract: exhibit">Subaward Agreement dated October 28, 2014 between Shuttle Pharmaceuticals, LLC and LifeSpan/Rhode Island Hospital (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-16.htm" style="-sec-extract: exhibit">Sublicense Agreement, dated February 15, 2019, between Shuttle Pharmaceuticals Inc. and Propagenix, Inc. (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-17.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201800016C/75N91018C00016 Agreement between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-18.htm" style="-sec-extract: exhibit">Promissory Note, dated as of August 24, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-19.htm" style="-sec-extract: exhibit">SBIR Phase II Contract #75N9101C00031, dated September 6, 2019, between Shuttle Pharmaceuticals, Inc. and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-20.htm" style="-sec-extract: exhibit">Director Offer Letter, dated December 2, 2020, between Chris Senanayake and Shuttle Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-21.htm" style="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-22.htm" style="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-23.htm" style="-sec-extract: exhibit">Non-Disclosure, Evaluation and Option Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals, Inc. and University of Virginia Licensing &amp; Ventures Group (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-24.htm" style="-sec-extract: exhibit">First Amendment to Non-Disclosure, Evaluation and Option Agreement, dated November 30, 2019, between Shuttle Pharmaceutical, Inc. and University of Virginia Licensing &amp; Ventures Group (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-25.htm" style="-sec-extract: exhibit">Form of Note and Warrant Subscription Agreement, dated December 28, 2021 (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-26.htm" style="-sec-extract: exhibit">Form of Note, dated December 28, 2021 (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-27.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, dated December 28, 2021 (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-28.htm" style="-sec-extract: exhibit">Consulting Agreement, dated January 1, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Steven Bayern (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-29.htm" style="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-30.htm" style="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-31.htm" style="-sec-extract: exhibit">Form of Convertible Note Subscription Agreement and Investor Rights Agreement (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-32.htm" style="-sec-extract: exhibit">Amendment No. 1 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.32 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-33.htm" style="-sec-extract: exhibit">Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.33 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-34.htm" style="-sec-extract: exhibit">Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.35</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.36</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-2.htm" style="-sec-extract: exhibit">Form of Note, dated January 11, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.37</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-3.htm" style="-sec-extract: exhibit">Form of Warrant, dated January 11, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.38</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-4.htm" style="-sec-extract: exhibit">Form of Security Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC &#8211; Segregated Portfolio B (incorporated by reference to Exhibit 10.4 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.39</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-5.htm" style="-sec-extract: exhibit">Form of Intellectual Property Security Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.5 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.40</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-6.htm" style="-sec-extract: exhibit">Form of Subsidiary Guaranty (incorporated by reference to Exhibit 10.6 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.41</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-7.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.7 to the Current Report on form 8-K filed January 12, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex15-1.htm" style="-sec-extract: exhibit">List of Subsidiaries (incorporated by reference to Exhibit 15.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of BF Borgers CPA PC.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Michelman &amp; Robinson, LLP (included in Exhibit 5.1).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex5-2.htm" style="-sec-extract: exhibit">Consent of Morgan Lewis (included in Exhibit 5.2).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#POA_005">Power of Attorney (included in the signature page to this registration statement).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex107.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table*</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated,
    all exhibits previously filed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span id="ed_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
  17.</b></span></td>
  <td style="text-align: justify"><b>UNDERTAKINGS</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high and of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in this registration statement
or any material change to such information in this registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time to be
deemed the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. <i>Provided, however,</i> that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ed_008"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing this registration statement on Form S-1 to be signed on its behalf by the undersigned, in
Rockville, Maryland, on January 25, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin: 0"><i>/s/ Anatoly Dritschilo,
                                            M.D.</i></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo, M.D.,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Executive Officer)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><p style="margin: 0"><i>/s/ Michael Vander
                                            Hoek</i></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="POA_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signatures</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Anatoly Dritschilo</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Vander Hoek</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Vander Hoek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Chris Senanayake</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris Senanayake, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/
                                            Steven Richards</i></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Richards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/
                                            Josh Schafer</i></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Schafer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/
                                            Milton Brown</i></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Brown, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bette Jacobs</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    25, 2023</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette
    Jacobs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 144; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 100px; width: 670px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
                                            York Office</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">800
    Third Avenue, 24<SUP>th</SUP> Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10022</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.75pt 0 0.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>P
    </B>212.730.7700 <B>F </B>212.730.7725 www.mrllp.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 25, 2023</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Research Court, Suite 450</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
MD 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle Pharmaceuticals
    Holdings, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration Statement
    on Form S-1</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection
with the Registration Statement on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;), filed with the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;), for purposes of registering for resale under the Securities Act of 1933, as amended
(the &ldquo;<U>Act</U>&rdquo;), of: (i) up to 9,744,605 shares (the &ldquo;<U>Conversion Shares</U>&rdquo;) of common stock, par value
$0.00001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company, issuable from time to time upon conversion of a senior secured
convertible note (the &ldquo;<U>Senior Secured Convertible Note</U>&rdquo;) and (ii) up to 1,018,079 shares (the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock issuable upon exercise of a warrant (the &ldquo;Warrant&rdquo;) to purchase Common Stock, each held
by Alto Opportunity Master Fund, SPC &ndash; Segregated Master Portfolio B (the &ldquo;<U>Selling Stockholder</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act and cannot be relied
on for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion letter, we have examined the Registration Statement, the Senior Secured Convertible Note and Warrant, and
originals, or copies certified or otherwise identified to our satisfaction, of (i) the Certificate of Incorporation of the Company, as
amended to date (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;), (ii) the By-Laws of the Company, as amended to date (the &ldquo;<U>Bylaws</U>&rdquo;),
(iii) certain resolutions of the Company&rsquo;s board of directors (the &ldquo;<U>Board of Directors</U>&rdquo;) relating to the Registration
Statement, and (iv) such other documents, records and other instruments as we have deemed appropriate for purposes of the opinions set
forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted
to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies,
the authenticity of the originals of all documents submitted to us as copies and the persons identified as officers are actually serving
as such and that any certificates representing the securities will be properly executed by one or more such persons. With respect to
matters of fact relevant to our opinions as set forth below, we have relied upon certificates of officers of the Company, representations
made by the Company in documents examined by us, and representations of officers of the Company. We have also obtained and relied upon
such certificates and assurances from public officials as we have deemed necessary for the purposes of our opinions set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles&nbsp;&nbsp;&nbsp; |&nbsp;&nbsp;&nbsp; Orange County&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp; San
Francisco &nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp; Dallas &nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp; Houston
&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp; Chicago&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp; New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">Shuttle Pharmaceuticals Holdings, Inc.</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>January
                                            25, 2023</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>Page 2</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that the Conversion Shares and Warrant, when issued to the Selling Stockholder upon conversion
or exercise in accordance with the terms of the Senior Secured Convertible Note or Warrant, will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not express any opinion herein concerning any law other than the General Corporation Law of the State of Delaware. We hereby consent
to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus and to the references to us in the Registration Statement. In giving such consents, we do not hereby admit that we
are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michelman &amp; Robinson,
    LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICHELMAN &amp; ROBINSON,
    LLP </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc. Limited&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in the Form S-1 Registration Statement of Shuttle Pharmaceuticals Holdings, Inc. of our report dated June 3,
2022 (except for the effects on the financial statements of the restatement described in Note 9, as to which the date is June 23, 2022),
relating to our audit of the balance sheets as of December 31, 2021 and 2020, and statements of operations, stockholders&rsquo; equity
and cash flows for the years ended December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
BF Borgers CPA PC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
Colorado</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
25, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ex107.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>S-1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shuttle
Pharmaceuticals Holdings, Inc. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Type</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Calculation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>or Carry</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rule</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registered</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price Per</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Share</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price </B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rate</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registration</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="26" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Newly Registered Securities</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Convertible Note</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">-
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0; font: 11pt Calibri, Helvetica, Sans-Serif">-</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Shares of common stock, par value $0.00001, issuable upon conversion of Convertible note</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,744,605</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,545,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">$110.20 per $1,000,000</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,493.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant to purchase common stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock, par value $0.00001 per share, underlying Warrant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1,018,079</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">2.35</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">2,392,486</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$110.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    per $1,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">264.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Offering Amounts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">15,937,486</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fees Previously Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fee Offset</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Fee Due</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1,757.00</P></TD><TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    additional registration fee is payable pursuant to Rule 457(i) under the Securities Act.</FONT></TD></TR>

  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z S,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BO4_P#A0GB?_H(:5_WW)_\ $T?\
M*$\3_P#00TK_ +[D_P#B:P^LTOYD5RL\LHKU/_A0GB?_ *"&E?\ ?<G_ ,31
M_P *$\3_ /00TK_ON3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A
M/$__ $$-*_[[D_\ B:/K-+^9!RL\LHKU/_A0GB?_ *"&E?\ ?<G_ ,31_P *
M$\3_ /00TK_ON3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A/$__
M $$-*_[[D_\ B:/K-+^9!RL\LHKU/_A0GB?_ *"&E?\ ?<G_ ,31_P *$\3_
M /00TK_ON3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A/$__ $$-
M*_[[D_\ B:/K-+^9!RL\LHKU/_A0GB?_ *"&E?\ ?<G_ ,31_P *$\3_ /00
MTK_ON3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A/$__ $$-*_[[
MD_\ B:/K-+^9!RL\LHKU/_A0GB?_ *"&E?\ ?<G_ ,31_P *$\3_ /00TK_O
MN3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A/$__ $$-*_[[D_\
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M7_?<G_Q-'_"A/$__ $$-*_[[D_\ B:/K-+^9!RL\LHKU/_A0GB?_ *"&E?\
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MN3_XFCZS2_F0<K/+**]3_P"%">)_^@AI7_?<G_Q-'_"A/$__ $$-*_[[D_\
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MGB?_ *"&E?\ ?<G_ ,311]9I?S(.5GT51117SYN%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<\  5:\5:O?^%M&T%Y]54EM1A@O;N2-4#QG.XD=%Z#I1[-WY;ZA<[2BN%O\
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M+_\ /-V].@_(^M>Q@Y&156_TRQU6 0:A9P740;<$FC#@'UP:L(BQQJB*%10
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M%DTFTMM2%K&EQ+'&N\OM&[YAUYS72T45,I.3NQA1114@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y+KKIXE6(2-]B$@M7'
ME$KYA&=V_&.#A,9ZFNCJ,P0F,QF)-A.XKM&"<YSCUSS5)I;@9-@ES)J>JPR7
M]PZ1,J1@[?DW(&STZY/&:JPW=Y;^'&NFOG>62X\KSI0I$2^:4W8  X'//>NB
M6-%9F5%#/RQ Y/;FD\F+R6A\I/*;(*;1@YZ\>]/F$<]=WMW8VNM0Q7C7#6UJ
M)HI6"[HV(;Y3@8/W01D=_I4)U#5#HLOE7!CO%U!+=!.JLR#<HVOMX.<GD=F'
M>NAM[*UAM6@BMH4B?.Z-8P%/U%2F"$LS&)"68,25')'0_48%/F78+'-2:W<W
M>F:A/;NZ.EU#"J#:'C)*!TR>,Y+#)J_J%U?:=IEO>Q!I3'A)8)67+[B%!W#C
M(8CIVS[5IR65J\4R/;0LDQW2*8P0YXY/J>!^5+';P+;+ L,8A'2,*-H[]*7,
MNP&1J,E]I]M:33W4CV\*DW;PA5<GCYL$<J.<@<].M;,TT=O!)/*P6.-2[,>P
M R:CN+2VN)(FGMXI61LH70,5^F>G2IG1)$*2*K(>"K#(-)M,9SFCZG<ZDEY;
M7,\T4S(+F(^5Y;(C?P#<.=I&">>HK4T%II-%M)I[B2>66-9&=\=2!TP!Q5\Q
MH7#E%+@%0Q'(!ZC]!0B+&BHBA548"J, "AR3V$4;"[>6XU)9I%VP7.Q,X&U?
M+1OYDUD:9K-UJ-S>0"9T-S$TUD7A*B, [<9(^;^!N_WC6\;*T^U//]EA\YUP
M\GEC<PQC!/?@5-Y4>8SY:9C^X=H^7C''I3NNP'(KXBO9AYR2JL=S&+6W7:/E
MNAC=S]688_Z9FNP P ,Y]ZB%I;!546\0".9%&P<.<Y8>_)Y]S4U*33V0!111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G 8P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^E>RV\RW%NDJ]&&:^+I0EAZD\+/>.WH]O\ (]*HU-*JNOYDM%%%=!D%%%%
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M3K3_ (\X?]P?RI+PA;.8G^X?Y4D$B16UNCL%9E  /<XKPSI,CP__ ,?NI?\
M7:J_C'3+BZT6[^R]9(R'4?3@U8\/D"^U)3][S<XK?(!&#R*=[.X'P[<0R6]Q
M)#*I5T8JP/K4=>V_&KP#%:)_PDNFQ[4+;;J,#@$]&KQ*OJ:%:-:"G$XI1<79
MA70>#/$+>&_$EO>$DP,?+G7U0]:Y^BM)P4XN,MF)-IW1]B:#>HK^0'#0RJ)(
M6SP0>:Z*O!OA5XH;4=,_L>>3_3+(;[<D\M'W'X5[?I]XM[:+(/O=&'H:^+5*
M6%JRPTNFJ]/^ >E*2J151?/U+5%%%;&84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RVMWZW$
MYC\P);P@M(Y/ QU-:NLZA]E@\J,_O7&!["O$?BEXK^P6?]@6<G^DSC==N#]U
M>R_CWKE=.6-KK"4]MY/R[?,W@U1A[66_0X7Q[XI;Q-K[O$2+&W_=VZ>P[_4U
MRM%'7I7VU*G&E!0@M$>7*3D[L*FMK6:[F$4$9=SV%:FF>'KB\Q)-F*'WZFNM
ML[&"QBV01A?4]S5N_0Y*N*A#1:LTOAYJ,G@B2:9K=)Y9P%<9Z#VKVGP_XK.O
M6K3QZ?,JJVTD$'FO#*]F^&UN8/# 8LI,DA? /0=LUY>94::A[2WO:!@<14J5
M>5O0VKK4[:YFCL5<K.\@!C88.!R:J^()6BN+8J<%&4K^)Q7+>-)[K1];34K.
M5/-0[@#SUX/%%SXOM-3M([CS#YMO&K3 I@9SV]:\Q8>3@IQU1Z+Q$54<):'1
M&XCT_P 6L9&"1SH,^Y-:E]KEO8Q&22.8J.X3BO/]*U:Z\5^,(&+(EO"0YXP>
M.U=WXG@,^ARJ& *_-SWJ:M%TFE+<=*JJJ;CL>=>,/'<7B#0KW2(;(HLZE#([
M9Q[XKP2_TRYT^0K*F5[..AKTBYB:&YDC;J&-5I88YXS'*@93U!%?1T*-.E']
MWLSQ?KM13]_4\SHKI-4\,LFZ6RRR]3&>H^E<XRLC%6!##J#6YW4ZL:BO%E[1
M=6N-#U>VU&U8B6%PWU'<5]0^%]?MKVVMM1M7S:7B@D?W&[@_0U\GUZ)\+O%8
MTS43HU[)BRO&^1B>(Y.Q^AKQ\XP3KTE5I_'#5>?=';AJJC+EELSZB!R,BBLC
M1KXR1FVE/[V/CZBM>O#I555@IHWG!PE9A1116A(4444 %%%% !1110 4444
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MX?8^=I]Z+FPT2TN(X+BY,<LO"(S\M]*/K&;7M>/W#^J9?O9_><G_ &0/^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1_002.jpg
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 'Y!2<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1=)Y[?\ !//1K7<3M@F^+EDSJ/\ :*1%<_0T[_A?W_!27_HP+0?_  [%I_\
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M\D']N8?_ )]5?_!53_Y$^EJ*^:?^%_?\%)?^C M!_P##L6G_ ,9H_P"%_?\
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MG_QFC^R:_P#S\I_^#(?_ "0?VYA_^?57_P %5/\ Y$^EJ*^:?^%_?\%)?^C
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M>^\?_ E=?B=&&S3+\9/DI5$Y?R[2_P# 79_@=E10&!Z&BN,] **** "BBB@
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M<+_T%4_NJ?\ RL/[2QG_ $!U?OI?_+3ZCW+ZT;E]:^7/^&8_^"DG_23BW_\
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MRY_PS'_P4D_Z2<6__AG-+_\ BZ/^&8_^"DG_ $DXM_\ PSFE_P#Q='U'"_\
M053^ZI_\K#^TL9_T!U?OI?\ RT^H]R^M&Y?6OES_ (9C_P""DG_23BW_ /#.
M:7_\71_PS'_P4D_Z2<6__AG-+_\ BZ/J.%_Z"J?W5/\ Y6']I8S_ * ZOWTO
M_EI]1[E]:-R^M?+G_#,?_!23_I)Q;_\ AG-+_P#BZ/\ AF/_ (*2?]).+?\
M\,YI?_Q='U'"_P#053^ZI_\ *P_M+&?] =7[Z7_RT^H]R^M&Y?6OES_AF/\
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MQG_0'5^^E_\ +3ZCW+ZT;E]:^7/^&8_^"DG_ $DXM_\ PSFE_P#Q='_#,?\
MP4D_Z2<6_P#X9S2__BZ/J.%_Z"J?W5/_ )6']I8S_H#J_?2_^6GU'N7UHW+Z
MU\N?\,Q_\%)/^DG%O_X9S2__ (NC_AF/_@I)_P!).+?_ ,,YI?\ \71]1PO_
M $%4_NJ?_*P_M+&?] =7[Z7_ ,M/J/<OK1N7UKY<_P"&8_\ @I)_TDXM_P#P
MSFE__%T?\,Q_\%)/^DG%O_X9S2__ (NCZCA?^@JG]U3_ .5A_:6,_P"@.K]]
M+_Y:?46]<XS2[QG KY93X"?\%1/#4K:IHO[>/A?Q3)&N8])\3?#2WL;65QR
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M&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%%
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MTOQAXZT_3+BY@+L@DCCN9D9U+HZ@J""RL.H. 9Z=FBOE[_@L/^V1\2?V'O\
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MAU+4HQOR\%L[B69?W<G**1\C?W3C'^&O[6_[+/QE\>ZO\*OA%^TEX!\5>*-
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M$6-74L 4E85]*^&=!T?PMH-GX<\/:7!8V&GVD=M8V=K"(XX(8U"I&BCA550
M . !7S7XTA;XD?\ !6OP7X>U"X+6?PY^$FH>(-/6, A+Z^N_L$BN>V8 "![5
M]1#C@5ZF-_=8/#T5V<WZR?\ \C&/WGBY<O;8_%8A_P RIK_#!7?_ )/*7X!1
M117EGM!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKK.M>,O%%J^G::UW'>V$@@06\4\T=O';V05-WFLTSRR?NUE\N/V#PA_P2_\
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M7^*-1\1Z5K6F375SHEY=RWVK2Q6TDCV\<ZQ-#J0#2B$M'(F5211AO*/VP?\
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M./3?C)X,G.E2>,+/1;/;<7$>KVD8N?LK1-;AGMKE4=?+V[PS*JY4+@?M _\
M!=/]JO\ 9B_X-W_@M^U4_BO3?$7QP^,TMWHUOXDUC3[6-;$+-?\ G:H+..%;
M>9X8X8(DB*K'YD\;R+*J/#++CRJ5^CBOON*/OV:\_P -_N/VLW+_ 'J,U^-\
M?[$G_!RI^PKX@\&_M*?"/]N&\_:>U3Q%KEK+\7O@QKEY::?I]E'Y1DF33;K4
M[CRH8 YDB#VJ6CAC WV>2/>D?O?_  61\)_\%1_BA\2O"?A+X ?MH^%_V;_V
M=YO#\\7Q3^+5Y?V4&J:??2"?8 UQ+"\4:^5;11R6MQ#)YEY(69EC4J?\,-:_
M=<_1-V/&UJ^:_P!BK_@J3\ OV[?V@OCA^S=\(_"7C#3M<^ 7BO\ X1_QC=>)
M-/M(;2\NOM5]:[[-H;F5Y(]]A,<RI$VUD^7)8+^9O_!%[_@H=^TU\-_^"P>M
M?\$K/'?_  4/A_:D^&LGA6XG\(?$M9H+QWODLX=0:07HFN)9D56NK=HGN9@K
MHA4IAE/>_P#!N'G_ (>L?\%*0?\ HN0_]/GB6B,>::5]XM_<TO\ ,7==FE]^
MI^K?[07QG\-?LY? GQG^T%XTL+^ZT?P-X5U'Q!JUKI<2/=36ME:R7,J0K(Z(
MTA2)@H9U4L1EE&2/+_\ @FQ_P4:^"?\ P5%_9P_X:>^ GACQ5H^@_P!OW6D?
M9/&%C;6]YYT"QL[;+:XG38?,7!WYX.0.\W_!5'_E&+^T9_V0KQ=_Z9KNOQE_
MX)T?M,_&_P#8[_X-(/BM^T7^SCXX;PWXS\/?%%?['UI=/M[HV_VC6-%M9OW5
MS')$^Z&:1/F0XW9&" 01UY[]$FO5R2_4J2^"W5V_"Y_0IN'K1FOY]_C1XZ_X
M+V>//^"2>A_\%J?%/_!3:X\(2>%](TO5-#^$WA/PG!:0:A8F6UTXZE?3HPCN
MIKDEKYK6:&:!?/Q&(05@C^AOVJ_^"\?[1OP?_P"#=OX4_M[^%])TU?BY\6'A
M\*V^L36L;6^FZBHOTN=7%OM$;MC3I7CA8&))9X]ZRQHT<CDG&Z>Z=K>HH^]:
MW6[^[<_1S]O;]M_X5?\ !.O]E7Q/^U_\;-"\0:KX9\)O8KJ-CX5M()KZ3[5>
MP6<?EI/-#&<27",VZ1<*&(R0%/C_ .UK_P %M/V6?V./V"OAA_P43^)?@'X@
M7W@GXKMHX\/:7H.E6,NJ6_\ :6FS:C!]ICEO(X4VPP.K[)GPY4#<,L/RD_X*
MK_L7_P#!9;]E7_@CGXT^)'[4G_!0>;XN>'/B%=:+<_%CX=^)-'\QO!MU-J5C
M<13:;J#7#L4CNX8+4V\216P2ZD9(<A73W'_@HG^W)^U1^P#_ ,&W/['OQC_9
M$^*TG@_Q)J>C^!M%OM2CTFSO?-L9/"MW,\.R[AEC ,EO"VX*&&S (!(*Z/\
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MBW]G73;>W_X5QJ^D^+[:TU/Q)>KA)'GE^UV,X.79I%-PL2*UHB13.99EX_\
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M)MI;5KX:KI(>Y@@N!-&5ELM00,KIA96E" !4:E*\;WW6Z]= 7O25NNB/V2W
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M )&V%_[B?^DGT[1117F'L!1110 4444 %%%% !1110 4444 %?E/_P 'BO\
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M\[R-_P WE;]N[G&>:EQ37+]FR7W7_P V.^MWO>_]?@?SW_\ !)/X+^//C_\
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M +.6\4_^VU?34GW#7S+_ ,$S^GQ^_P"SEO%/_MM7IX7_ )%N(_[<_,\?&?\
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M.>.0W5M,9MAC>:&##;?F#8%3*5KV[7*C'F:7R/U^HK\N_P#@V$_:G\?>//\
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M+Q-KUU<:+';6*:2+FWMH(X/)"Q)M\V,>6B+_ !,<L23]V_M\?M\? G_@F_\
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M_P"(EG\0M4\733:9X$NO!5]'K%W&=4TMP\5DT0GD79'(V50C:C'H#2?M+?\
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M2O*_VW_^3//BM_V3G6O_ $AFKJP/^_4O\4?_ $I'#FG_ "+:_P#@E^3/"_\
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MQI\([?P?9_$J-H94U74XI]/L[V2.[N2=T:^;:7ENZR AI-493RQ5_K#X!?\
M!IY_P2^^"/Q6T'XH>)O$'Q2^)</AEEDT?PI\2/$]G=Z/%(LBR(S6]M96YE56
M4?N7=H7!(DC<'%?:O[='[%'PE_X*#?LI^*/V/_C;J>N6/AGQ9':+J%YX<NH8
M;Z$VUW#=Q-$\T4L:GS($SNC8%=PQSFIC+V>JU?,I+RM_GJ&CLGM9I_/_ "/Y
MM=.\3ZV?C%#_ ,'+<_BKQ1'X?E_;I;29M)DM6:Y7PHT?VHLK<@J+/=I^T-MR
M!&.F*_2;_@UC\'7W[1?C']I[_@K7XVTQH]2^,OQ9NK'PW;ZE:F2ZTW3H97O9
M(XKE\EH&:]MH-B84'2U'.U0OUXG_  0^_9%'_!+(?\$C'\5>.&^'*S^>NOMJ
M%A_;PE_M?^U/,\_['Y&_S?W6?(_U/R=?FKVS]AC]C'X3_P#!/S]EKPG^R+\$
M;_6KOPSX/AN4TVZ\0W44][,;B[FNY7E>*.)"QEGD/RHH ( '%.+48V731>C4
M;_\ I/XA)REJ^KU^3;7Y_@?.O_!R=/X]@_X(F_'5OAN^IKJ+:/IBW!TG?YOV
M ZQ8B^W;.?)^R>?YO\/E>9N^7-?-?[-OA[]CZ/\ X-&-631X-!;PW<? '7[K
M79-3A0"3Q4L=QO9C.!NNDU5(UMR<MOCMQ%P(Z_6;QKX+\)_$;PCJG@'Q[X;L
M=9T/6M/FL-8T?4[5)[:^M9D,<L$L;@K)&Z,RLK AE8@@@U^:_A+_ (-*?^"5
M/A#XBZEXQBO/BAJ&AWMY=75G\/=4\7P3:%I\T@80R1Q?91-,;?(\L7,TP;8!
M,)@6#0_AE'O;7TO_ %ZE1?O1?9_Y?Y?<?F%\+I_B;#_P9T>/AX!C@.F/\>H5
M\9M)C>NF&ZT[88_]LWOV$''\!?MFOTNGT3]DF7_@TQ6$67@[_A%?^&4Q=KC[
M-]D/BK^RMV\G[GV_^W..OF?;/E_UG%?5/[%G_!([]E+]B3]B_7/V"?"I\0>-
M/A[XDOKZXUJS^(%U:WDMTMW'''+"QM[>!-F(UQA P.3NSC'RF?\ @T&_X)6-
MXY77V\7_ !D;PRNN?VBOPW;QU!_8@&?^/?\ X]/MGE[?DW_:?.V_\M<\UI4?
M/S)=>77TBE^ER:?N*+[.7XNY^3O[1.I?']_^#47X"VWC6RAB\*']I+4U\-S0
MS$R2Z<(=7:/S /\ I^.J#YL'$<1QC::^O/\ @JI^Q7_P4A_;"_8X^%_@3]K7
M]HS_ ()O_"GX:Z)?6=W\+_%6@^*]<T2)[?[ Z0V-E<WL,L+6LEN4D\F$#>+:
M%@=L8K]E?C1^PA^RK\?_ -E"3]B/XE?"'3YOAG_9%MIMGX:L<VL=A!;;?LPM
MVB*M"T11"C*01MP<@D'XD^ O_!II_P $O_@E\5_#OQ/U_P 3?%3XB6_A6Z^U
M:/X1^(GBBRN]&28.)%9[>WL8&D0.H8PLYBDQME2125(Y*51OS3^Y)??I?U8H
M^[%>2?XN_P#P#P?_ (*8_LA?''XA?\%2/AK\?_V ?^"CWPD\*_M@:;\-8-+U
M_P"&^LZ@D\UQ-'IMQ+/<V:S6US&/.M9GVP7%O"OEJ)PP+<'_  2Q_;G_ &E_
M!?\ P6@7]E+_ (*F?\$]OASX0_: ^)W@TRV?Q2\&6=K_ &O>0V^G-,1J,L%Y
M<PR0S6^E*!]F:,1RVR@PD2EHONS_ (*5?\$-OV(/^"I'B?0?B/\ ':'Q7X=\
M9>'84M]/\;> =8BL=2-HCO(MM(9H9HGC61V=28_,1B=KJ&8',_X)R?\ ! O]
MA+_@F?\ %K4OC]\*9O&GC+QYJ%I):0^,/B3KD-_>6%O($$L=N(+>")"X0 RF
M-I=I=!($=T8C+77S_&^W;<)1]VR[+\+;]S[6E_U'X5_/5_P0#S_Q#C_MT #_
M )@?C+_U$5K^A:6,21F,]#Z5\F_L"_\ !&?]DO\ X)Z?LQ>/OV1?AOJWB[Q9
MX-^)5W=2^*K7QWJ5K<2SQW%FEG-;JUI;6X6)H5P1@MEFPW3"3]RHOYE9>MTQ
M_:B^SO\ @SYU_P"#1DJG_!'/P^&."WCK7=OO^_6OKK_@JM^R<?VXO^">7Q:_
M9?M;%;C4?$W@VY_X1^&2X,*MJ]L5N]/W. 2$%Y! 6X.5!&#G%>0_\$S_ /@@
M?^R3_P $J?C;K7QN_9R^*WQ3U*XUOP]<Z/-H/C#Q#8W.FV\,US;7#211064+
MB4&TB0.SM\FX$$X(^X'7<,4JEJD?5?\  %2O3E?S;_&__ /Y3_A#K'Q&_P""
M[7AK]F;_ ()Z:3HUSKM]\!/V<_'DNK7T;?9'MM2$=S;:) S,0LD$9M/#,99?
MO&ZE5\;68>J?\$R/BSXD_P""N_[<?[ _P!U9Y+G0OV5?AC/K/B[[' 8FL+O3
M-0>.SW,XQ-'(ECX95MF<&XE&00V/V<_87_X(A_L8?\$]OVJ?B1^U_P# 6;Q4
MWB?XE"\BO+'5]0M6T_1;2YO1>2V=A#;VT)BA,B0 "5I65+>,!A\Y>7_@GS_P
M10_8S_X)J?';XC?M!_L\1^)IM:^(TC+<6_B"_M9K;0[5KF2Y:SL%AMXFC@9V
MC!$K2MBVA^;(8M49QYDVO/\ [>U_S_ <OA:7HO\ #I?YZ'YX_L/)9:U_P>$?
MM"O^U!!H/_"2VO@V[/PW6\\O>K+#HXLFM W/VDZ,9V?9\VQKDGC>1!^WC!#H
MW_!X/^SS+^RQI_A^3Q1=^$]//Q&CLVA#G='JZZ@]UC_EY&A^6R[_ )R@M\<%
M*_0O_@I#_P $+_V$O^"G_B;2OB5\;](\2>&_'&CK'%9^//A_JT6GZH;="2L$
MC2PS0RJ&.59XS(G1'4$@R_\ !-G_ ((>?L/?\$N/$.M_$'X#V/B;Q!XS\0QR
M0:GXZ\>:M%?:HUJ[*[6R-%##%'&9$#L5C$CL!O=PJ!9I^[R7^ROO]?7J%3WN
M:WVOPV_+H?EU_P $M/V=/@M^T-_P=%?M=6?QP^%6@>+M/\/?\)5J&EV/B+2X
M;R""];7;&!9Q%*K*7$4TZ E3@2'OBL#_ (.%OA%\?;__ (+T_L\_ 3_@GS]E
M\(>-+KX#:;X?\"MHTD6FPZ);O?:_:NT+*N+1(;,R[6B7?$J P@.J5^O'[+O_
M  1__9J_9)_;P^)__!0KX;^,_'%YXT^+,=\GB33-;U.SDTNV%U>PWDAMHXK6
M.5,20*%WRR84L#DX(O\ QI_X)0_L]?'?_@HQ\//^"F_C#QEXTM_'GPT\/)H^
M@Z/INH6:://"K7[!YXGM7F:3.H3<I,@^6/C@[B-OW=_L[_C_ )E.5Y5'WV_
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MQJ7*A06(49P ,] .E;%5*7-(B-U%7WZ^H4445)04444 %%%% 'QM_P %L?\
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M "0/X<_]EGTG_P!)+ZO9?V2O^1%M?^N*_P#H$5>-?\%L?^2!_#G_ ++/I/\
MZ27U>R_LE?\ (BVO_7%?_0(J]3$_\BK#_P"*I_[8>+@_^1YB_P##2_\ ;SV2
MBBBO+/:"BBB@#Y;_ &7_ /E)A^T]_P!>_@W_ --35]25\M_LO_\ *3#]I[_K
MW\&_^FIJ^I*];./]ZA_U[I?^FH'BY#_N<_\ K[6_]/3"BBBO)/:"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^!OVP?^4K7A__ +)%:?\
MIYDK[YKX&_;!_P"4K7A__LD5I_Z>9*]3+?AK_P#7M_\ I43Q\V_B87_K['\I
M'V[\/O\ D6+7_KC_ %-;E8?P^_Y%BU_ZX_U-;E>6>P%%%% !1110 4444 %%
M%% !1110 C-M&:8;B,=_UI[_ '>:_E/\2_M[_MDZ3K<^G6O[3/CQHX]N#)XR
MOR3E0?\ GM[U[649-+-N=J?+RVZ7O>_IV//QV8+ \MXWYK];;6_S/ZK?M*>O
MZT?:4]?UK^43_AX1^VC_ -'+^.O_  L+_P#^/4?\/"/VT?\ HY?QU_X6%_\
M_'J]C_4^7_/_ /\ )7_F>?\ V]'_ )]_^3+_ "/ZN_M,?K^M'VE/7]:_E$_X
M>$?MH_\ 1R_CK_PL+_\ ^/4?\/"/VT?^CE_'7_A87_\ \>H_U/E_S_\ _)7_
M )A_;T?^??XK_(_J[^TIZ_K1]IC]?UK^43_AX1^VC_T<OXZ_\+"__P#CU'_#
MPC]M'_HY?QU_X6%__P#'J/\ 4^7_ #__ /)7_F']O1_Y]_\ DR_R/ZNS=1J,
MD_K7S'_P31E5'^/N?^CE/%/_ +:U_/!_P\(_;1_Z.7\=?^%A?_\ QZJ&A?MO
M_M5^%_MG_",_'3Q5IW]H7TE[J'V'Q)>0_:;F3&^>39*-\C;5RYRQP,DX%=5'
MA=T\+4I>V^/EUY7I9W[G'7S/VV,HUU#X.;2ZUYE;\#^LK[3'Z_K1]I3U_6OY
M1/\ AX1^VC_T<OXZ_P#"PO\ _P"/4?\ #PC]M'_HY?QU_P"%A?\ _P >KE_U
M/E_S_P#_ "5_YG9_;T?^??XK_(_J[^TIZ_K1]IC]?UK^43_AX1^VC_T<OXZ_
M\+"__P#CU'_#PC]M'_HY?QU_X6%__P#'J/\ 4^7_ #__ /)7_F']O1_Y]_\
MDR_R/ZN_M*>OZT?:4]?UK^43_AX1^VC_ -'+^.O_  L+_P#^/4?\/"/VT?\
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M?\__ /R5_P"8?V]'_GW^*_R/ZN_M*>OZT?:4]?UK^43_ (>$?MH_]'+^.O\
MPL+_ /\ CU'_  \(_;1_Z.7\=?\ A87_ /\ 'J/]3Y?\_P#_ ,E?^8?V]'_G
MW_Y,O\C^KO[3'Z_K1]I3U_6OY1/^'A'[:/\ T<OXZ_\ "PO_ /X]1_P\(_;1
M_P"CE_'7_A87_P#\>H_U/E_S_P#_ "5_YA_;T?\ GW_Y,O\ (_J[^T)ZT?:4
M]?UK^43_ (>$?MH_]'+^.O\ PL+_ /\ CU'_  \(_;1_Z.7\=?\ A87_ /\
M'J/]3Y?\_P#_ ,E?^8?V]'_GW_Y,O\C^KO[2GK^M'VA/6OY1/^'A'[:/_1R_
MCK_PL+__ ./4?\/"/VT?^CE_'7_A87__ ,>H_P!3Y?\ /_\ \E?^8?V]'_GW
M_P"3+_(_J[^TIZ_K1]I3U_6OY1/^'A'[:/\ T<OXZ_\ "PO_ /X]1_P\(_;1
M_P"CE_'7_A87_P#\>H_U/E_S_P#_ "5_YA_;T?\ GW_Y,O\ (_J[^TIZ_K1]
MH3UK^43_ (>$?MH_]'+^.O\ PL+_ /\ CU'_  \(_;1_Z.7\=?\ A87_ /\
M'J/]3Y?\_P#_ ,E?^8?V]'_GW_Y,O\C^KO[2GK^M'VE/7]:_E$_X>$?MH_\
M1R_CK_PL+_\ ^/4?\/"/VT?^CE_'7_A87_\ \>H_U/E_S_\ _)7_ )A_;T?^
M??\ Y,O\C^KO[0GK1]I3U_6OY1/^'A'[:/\ T<OXZ_\ "PO_ /X]1_P\(_;1
M_P"CE_'7_A87_P#\>H_U/E_S_P#_ "5_YA_;T?\ GW_Y,O\ (_J[^TIZ_K1]
MH3UK^43_ (>$?MH_]'+^.O\ PL+_ /\ CU'_  \(_;1_Z.7\=?\ A87_ /\
M'J/]3Y?\_P#_ ,E?^8?V]'_GW_Y,O\C^KO[2GK^M'VE/7]:_E$_X>$?MH_\
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M^QP\*;IWLDMUT5NQ_5W]H3UH^TIZ_K7\HG_#PC]M'_HY?QU_X6%__P#'J/\
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M1_J?+_G_ /\ DK_S#^WH_P#/O_R9?Y']7?VF/U_6C[2GK^M?RB?\/"/VT?\
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M:/M*>OZU_*)_P\(_;1_Z.7\=?^%A?_\ QZC_ (>$?MH_]'+^.O\ PL+_ /\
MCU'^I\O^?_\ Y*_\P_MZ/_/O_P F7^1_5W]H3UH^TIZ_K7\HG_#PC]M'_HY?
MQU_X6%__ /'J/^'A'[:/_1R_CK_PL+__ ./4?ZGR_P"?_P#Y*_\ ,/[>C_S[
M_P#)E_D?U=_:4]?UH^T)ZU_*)_P\(_;1_P"CE_'7_A87_P#\>H_X>$?MH_\
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MK_S#^WH_\^__ "9?Y']7?VF/U_6C[2GK^M?RB?\ #PC]M'_HY?QU_P"%A?\
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M (6%_P#_ !ZC_AX1^VC_ -'+^.O_  L+_P#^/4?ZGR_Y_P#_ )*_\P_MZ/\
MS[_%?Y']7?VA/6C[2GK^M?RB?\/"/VT?^CE_'7_A87__ ,>H_P"'A'[:/_1R
M_CK_ ,+"_P#_ (]1_J?+_G__ .2O_,/[>C_S[_\ )E_D?U=_:4]?UH^TIZ_K
M7\HG_#PC]M'_ *.7\=?^%A?_ /QZC_AX1^VC_P!'+^.O_"PO_P#X]1_J?+_G
M_P#^2O\ S#^WH_\ /O\ \F7^1_5W]H3UH^TIZ_K7\HG_  \(_;1_Z.7\=?\
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M0 449HH **** "BBC- !1110 4444 %%%% !111G/2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#W;_@F/\ \I!O@Q_V5#P__P"G*WK^JX=*_E1_X)C_
M /*0;X,?]E0\/_\ IRMZ_JN'2OAN+OXM#TE^:/H<BVJ?+\@HHHKY ]\****
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M:^3?8G$X&-"DY<VJM?;JKZ:WT\TO(^:****]H\\**** "BBB@ HHHH ****
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M]A\,[O4M/B@UBZLVMKU;ZQA2<&WD3>RI-)A7W)ELE3@5UUG\0_\ @D;^T_\
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M^">G26'A4^ [G4=)TN:[DN&L5FT]2\/F2LSNHD$A4L20K*"6(S61^P)^Q/\
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M0U]^UG9V]Y72OY_AU(^IUN63T]V]U?73<^&Q\.OB-_PKY?BTWP]UQ?"C:O\
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MHXVG%V84444 %%%% !1110 4444 %%%% !1110![M_P3'_Y2#?!C_LJ'A_\
M].5O7]5PZ5_*C_P3'_Y2#?!C_LJ'A_\ ].5O7]5PZ5\-Q=_%H>DOS1]#D6U3
MY?D%%%%?('OA1110 U^E?QY^./\ D:KS_>3_ - 6O[#'Z5_'GXX_Y&J\_P!Y
M/_0%K[C@_P#AXC_MS_VX^=S[XJ7_ &]_[:9-%%%?8'@A1110 4444 %%%% !
M1110 4444 %%%% !1110 5[Y^QG_ ,%%?C7^P[X!^)GPY^%'A;POJ%C\5-'A
MTWQ#-X@L[F66WABBNXP;<PSQ!7(O),EPXRJ\<$'P.BLZU&EB*;IU%=/=?._Z
M%4YRIS4XNS6QZW^Q'^VI\:?V!?C?#\>?@>^FRZDNFW&GWFF:U#++8ZA:R@9B
MG2*2)W4.L<BX=</&AY *GTKX3?\ !7;]I[X'?M5^.?VJ?A=X8\&:3)\2IFG\
M<>!H]+N9- U.5D8,[0/<&97,LDMQN68$22R ?NI&CKY:HK*I@\+6FY3@FVK/
MS5[V^\TC7K0BHQDUK?Y]SZA_:A_X*O\ QT_:2^ T/[+^@?"CX;_"WP#)?B^U
MCPS\*_#3:7;ZK.KQR(9U,L@*J\:OM39N8 OO*IM^W?C'_P % M+_ &:O^"-?
M[.NA^#-"^&'Q#&JZ?;Z=XQ^'_CS3X=7M'A6)YD:>T$BNKQRQJRDD*&P2"=N/
MR!I&&>:Y*N4X6I3A3BK1C+F:WOHUJ[WZ[WNK&U/'5HRE*3NVK>FJ9],?M _\
M%6?VG?VD?VEOAQ^TEXZLO#=J_P *=3L;WP/X-TG3YH=%TZ2VG@FP(3,9")7M
MXO,_>ABJ*JLH5-JI_P %8_VK]/\ V]]3_P""BGAB70-&\;:Y;V]MK6DZ;93C
M2+ZTBM+>V^RRPR3M(\3K:PNP\T,)%#HT95=OF/QF_8^_:2^ 'C_PS\)_BE\*
M]0L?%GC#1K'4_#_A>W9+G4+B&\E>*WC-O"S2).TD;)]G8"96P&0$C/U5I?\
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M_&CXY:[X*\1:Y\#_ (VZ%9Z/XDT5[2&.]40:;!;I<M#O/F!6%U"8Q*F8[MI
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MW:KJOY'8!I-HSFC^PZ/UB-7G>CB]E>\4EOO;RV#^T)^S<.5:IK=]?+8_>?\
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M>?CC_D:KS_>3_P! 6ON.#_X>(_[<_P#;CYW/OBI?]O?^VF31117V!X(4444
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M  U^)OA?7'T/-YJ_CK2;O[3IMOI(2&3[9\A+%RMQ#%Y(SB>3RV=55Y5_4/\
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M1@UJU>^_W?H<M\//^"+'[,VL^)/A_P#!WXE_\%5O!>C?$SXA:;'<Z7X1\/\
MA%M<M0[%L0#48;U(&<E2J[MGF.&6,28!;B_V5_\ @C!\1_VAOVO_ (M?L8^*
M_BY:>%_$GPLTV>X-U!HK7UOJSK-&D03=- 8HY5E217()"L,IG(K]8M#^&6N_
MLR?M ?#!/V(OAY^SU\/_ -G76]%TJ/6OBB(X#KNMS/<QB+38;II@;Q[U#:I'
M*PE9B97,ID\I#YM^RC9:EHG_  7F_:X>[B:%W^'EG<0MZI);Z<Z,#_NE?H<@
MX(KGAFV-E&K)3TY')74=&I)6LEIH]FV]F5+ T(\B<5\44]]4T[ZMZZ];+YGP
M%JW_  1G^%WBG]EOXD?'W]F+_@H;X1^)VM?"/36N_'GAG2?#<UM;VPBA:><P
M7CSL;F+RHIS#,L(CN#"P5E(8+S_[/O\ P29\$^*OV-;/]N;]K[]LK2?@UX)U
MS5/L/A7S_"4^L7>IMYLL1;R8IHI%RT4A5461C'&\I"H Q];_ ."'K/\ \._?
MV\%WY_XL[&0NX<?\2OQ!^7:N_N_@OXG_ ."N'_!&;X._#;]D+6]&OOB!\%]4
MBL/%G@BZUA+6=(2DMLL^9=J[GC$<ZLS!&3[0JNTL9C/94QF,HU)TIU=%."<[
M+12C=]+;Z7>W4QIT</4A"HH[QE[MWJXM6^=F]/N(?^"[/P\M?A-_P32_9/\
MAK8>-M+\36VAZ<UI9^(M$DWV>J0I86XCNH6R<QR)M=2"00PP2.:X;_@UI&?^
M"@?B_C_FCVH?^G32JZ?_ (+9:%I'@_\ X)>?LG^ ]$^(6D^*X_#=K<:+=>(-
M!OFNK"[N[.TBMKDVTS*ID@$\4BQM@;D52!BN7_X-:&'_  \#\7C/_-'=0_\
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M,5B:,HN7,O<DD[;\Z5M$K>:UMW.R&&HT:T6E9W:ZVMRO75N_KIZ'YT_M9_\
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MY\'0_#^W2\OKR1-)T^\U9KR]8P)';0R237!A2(DB,@(J[F'R@_!_[<?_  6
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M&-7A8/:HNX%@R_57P9\<>)+[_@ZEUPS:@R_;-4U73+KRV*B6U@\-OY4;8/S
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MMX&DM[@;U2*2, (#B9OF'(;]1OBO\?O^"=/PT_X)D?#K_@HU_P .@/A;>?\
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M /*0;X,?]E0\/_\ IRMZ_JN'2OAN+OXM#TE^:/H<BVJ?+\@HHHKY ]\****
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MK7U?F/FDTD^@44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *,#KBBB@   & *, =!1118!-J_P!T?E2X
M&<XHHHL%PQCG%%%% !@>E%%%&VP!@>E&!Z444 & #D"C SG%%%  %4# 6@
M;0.*** #'M1@9SBBB@ *@G)6@*%.0M%% !@9SBC ]*** NP"@# 6C ZXHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110![M_P3'_Y2#?!C_LJ'A_\ ].5O7]5PZ5_*C_P3'_Y2#?!C_LJ'A_\
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MUK]S/^(5[X(?]'-ZM_X2L/\ \?H_XA7O@A_T<WJW_A*P_P#Q^C_6#)?^?O\
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M "?BC\,]P]:-P]:_<S_B%>^"'_1S>K?^$K#_ /'Z/^(5[X(?]'-ZM_X2L/\
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M ,GXH_#/(]:-P]:_<S_B%>^"'_1S>K?^$K#_ /'Z/^(5[X(?]'-ZM_X2L/\
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MXA7O@A_T<WJW_A*P_P#Q^C_B%>^"'_1S>K?^$K#_ /'Z/]8,E_Y^_P#DLO\
M(/[+Q_\ )^*/PSW#UHW#UK]S/^(5[X(?]'-ZM_X2L/\ \?H_XA7O@A_T<WJW
M_A*P_P#Q^C_6#)?^?O\ Y++_ "#^R\?_ "?BC\,]P]:-P]:_<S_B%>^"'_1S
M>K?^$K#_ /'Z/^(5[X(?]'-ZM_X2L/\ \?H_U@R7_G[_ .2R_P @_LO'_P G
MXH_#/</6C</6OW,_XA7O@A_T<WJW_A*P_P#Q^C_B%>^"'_1S>K?^$K#_ /'Z
M/]8,E_Y^_P#DLO\ (/[+Q_\ )^*/PSW#UHW#UK]S/^(5[X(?]'-ZM_X2L/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M - BKU,3_P BK#_XJG_MAXN#_P"1YB_\-+_V\]DHHHKRSV@HHHH ^6_V7_\
ME)A^T]_U[^#?_34U?4E?+?[+_P#RDP_:>_Z]_!O_ *:FKZDKULX_WJ'_ %[I
M?^FH'BY#_N<_^OM;_P!/3"BBBO)/:"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^!OVP?^4K7A_P#[)%:?^GF2OOFO@;]L'_E*UX?_ .R1
M6G_IYDKU,M^&O_U[?_I43Q\V_B87_K['\I'V[\/O^18M?^N/]36Y6'\/O^18
MM?\ KC_4UN5Y9[ 4444 %%%% !1110 4444 %%%% !12/]VOY _%?BS7M/\
M$%Q96=Z$CCVA5\E#C* ]2/4U[N2Y+'-E4<JG)R6^SS7O?S5MCS<PS!X'EM'F
MYK];;6\GW/Z_:*_CQ_X3GQ1_T$A_X#Q__$T?\)SXH_Z"0_\  >/_ .)KV_\
M4^C_ -!#_P# /_MSS_[>G_SZ_P#)O_M3^PZBOX\?^$X\4?\ 02'_ (#Q_P#Q
M-'_"<^*/^@D/_ >/_P")H_U/H_\ 00__  #_ .W#^WI_\^O_ ";_ .U/[#J*
M_CQ_X3GQ1_T$A_X#Q_\ Q-'_  G'BC_H)#_P'C_^)H_U/H_]!#_\ _\ MP_M
MZ?\ SZ_\F_\ M3^PZOF+_@F?]_X^_P#9R?BG_P!M:_F._P"$Y\4?]!(?^ \?
M_P 31_PG/BC_ *"0_P# >/\ ^)KJI<+T:>&J4O;OW^77DVL[_P _4XZV:3K8
MNE7Y+<G-I??F5M^72WS/[#J*_CQ_X3CQ1_T$A_X#Q_\ Q-'_  G/BC_H)#_P
M'C_^)KE_U/H_]!#_ / /_MSL_MZ?_/K_ ,F_^U/[#J*_CQ_X3GQ1_P!!(?\
M@/'_ /$T?\)QXH_Z"0_\!X__ (FC_4^C_P!!#_\  /\ [</[>G_SZ_\ )O\
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M?V'45_'C_P )QXH_Z"0_\!X__B:/^$Y\4?\ 02'_ (#Q_P#Q-'^I]'_H(?\
MX!_]N']O3_Y]?^3?_:G]AU%?QX_\)SXH_P"@BO\ X#Q__$T?\)SXH_Z"0_\
M >/_ .)H_P!3Z/\ T$/_ , _^W#^WI_\^O\ R;_[4_L.HK^/'_A.?%'_ $$A
M_P" \?\ \31_PG/BC_H(K_X#Q_\ Q-'^I]'_ *"'_P" ?_;A_;T_^?7_ )-_
M]J?V'45_'C_PG/BC_H)#_P !X_\ XFC_ (3GQ1_T$A_X#Q__ !-'^I]'_H(?
M_@'_ -N']O3_ .?7_DW_ -J?V'45_'C_ ,)SXH_Z"0_\!X__ (FC_A.?%'_0
M17_P'C_^)H_U/H_]!#_\ _\ MP_MZ?\ SZ_\F_\ M3^PZBOX\?\ A.?%'_02
M'_@/'_\ $T?\)SXH_P"@D/\ P'C_ /B:/]3Z/_00_P#P#_[</[>G_P ^O_)O
M_M3^PZBOX\?^$Y\4?]!%?_ >/_XFC_A.?%'_ $$A_P" \?\ \31_J?1_Z"'_
M . ?_;A_;T_^?7_DW_VI_8=17\>/_"<^*/\ H)#_ ,!X_P#XFC_A.?%'_017
M_P !X_\ XFC_ %/H_P#00_\ P#_[</[>G_SZ_P#)O_M3^PZBOX\?^$Y\4?\
M02'_ (#Q_P#Q-'_"<^*/^@D/_ >/_P")H_U/H_\ 00__  #_ .W#^WI_\^O_
M ";_ .U/[#J*_CQ_X3GQ1_T$5_\  >/_ .)H_P"$Y\4?]!(?^ \?_P 31_J?
M1_Z"'_X!_P#;A_;T_P#GU_Y-_P#:G]AU%?QX_P#"<^*/^@D/_ >/_P")H_X3
MGQ1_T$A_X#Q__$T?ZGT?^@A_^ ?_ &X?V]/_ )]?^3?_ &I_8=17\>/_  G/
MBC_H(K_X#Q__ !-'_"<^*/\ H)#_ ,!X_P#XFC_4^C_T$/\ \ _^W#^WI_\
M/K_R;_[4_L.KRO\ ;?\ ^3//BM_V3G6O_2&:OY1?^$Y\4?\ 02'_ (#Q_P#Q
M-'_"<>)_^@BO_@/'_P#$UMA^$Z-&O&I]8;Y6G\'9I_SG/BLXGB<+.C[.W,FK
M\VUU;^4_I&_X);_\D7\,_P#8OV7_ *26]?9%?QX_\)SXH_Z"0_\  >/_ .)H
M_P"$Y\4?]!(?^ \?_P 34UN$Z-:M*I]8:NV_@[_]OE4,ZG1HPI^SORI+XNR_
MPG]AU%?QX_\ "<^*/^@BO_@/'_\ $T?\)SXH_P"@D/\ P'C_ /B:S_U/H_\
M00__  #_ .W-O[>G_P ^O_)O_M3^PZBOX\?^$Y\4?]!(?^ \?_Q-'_"<^*/^
M@BO_ (#Q_P#Q-'^I]'_H(?\ X!_]N']O3_Y]?^3?_:G]ADGW#7S+_P $S^GQ
M^_[.6\4_^VU?S&_\)SXH_P"@D/\ P'C_ /B:/^$X\4?]!(?^ \?_ ,3752X7
MHT\-4I>W?OVUY-K._P#.<=;,YU<92K\EN3FTOOS)+?ETM8_L.HK^/'_A.?%'
M_02'_@/'_P#$T?\ "<^*/^@D/_ >/_XFN7_4^C_T$/\ \ _^W.S^WI_\^O\
MR;_[4_L.HK^/'_A./%'_ $$A_P" \?\ \31_PG/BC_H)#_P'C_\ B:/]3Z/_
M $$/_P  _P#MP_MZ?_/K_P F_P#M3^PZBOX\?^$Y\4?]!(?^ \?_ ,31_P )
MSXH_Z"0_\!X__B:/]3Z/_00__ /_ +</[>G_ ,^O_)O_ +4_L.HK^/'_ (3C
MQ1_T$A_X#Q__ !-'_"<^*/\ H)#_ ,!X_P#XFC_4^C_T$/\ \ _^W#^WI_\
M/K_R;_[4_L.HK^/'_A.?%'_02'_@/'_\31_PG'BC_H)#_P !X_\ XFC_ %/H
M_P#00_\ P#_[</[>G_SZ_P#)O_M3^PZBOX\?^$Y\4?\ 02'_ (#Q_P#Q-'_"
M<^*/^@BO_@/'_P#$T?ZGT?\ H(?_ (!_]N']O3_Y]?\ DW_VI_8=17\>/_"<
M>*/^@D/_  'C_P#B:/\ A.?%'_02'_@/'_\ $T?ZGT?^@A_^ ?\ VX?V]/\
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M_P!J?TU?LO\ _*3#]I[_ *]_!O\ Z:FKZDK^/'_A.?%'_02'_@/'_P#$T?\
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MW_VI_8=17\>/_"<^*/\ H)#_ ,!X_P#XFC_A.?%'_02'_@/'_P#$T?ZGT?\
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M.?%'_02'_@/'_P#$T?\ "<^*/^@BO_@/'_\ $T?ZGT?^@A_^ ?\ VX?V]/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY_O)_P"@+7]AC]*_CS\<?\C5>?[R?^@+7W'!_P##Q'_;G_MQ\[GWQ4O^WO\
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M45J_AB[K[G_D6L97C*]^KEMU:M^3/JOX/_\ !07P7\-O^"47Q/\ ^">5_P"
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MV)CCL1&3DK:VZ+1K9KLP9Y)':25RS,<LS=2?6BBBO32MHCCWU84444 %%%%
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M[5Y<<CR^FH<L;<NEU:\DU9J6FMT]=M3MEF&*ES<SO?IT6MU;TZ'Z>_%#4O\
M@WT^(_[3GC#]MGXC_M!^*_$UCXFLYM8NO@C9^#]7LYY=:G7?.3J">7&2TC,_
MEB9(Q*2?.,>$/*?L+?M??L&^)/\ @GU\=_V$_P!I'XF77P;L_B#XY_MWPS=:
M?H6HZU!90N;5X[9/+22600-81J3*ZM(DBX<MN(_.W%''2G_8]/V#I.I)K2VJ
M]U1=U;2W;5J_Y LPE&LJBBD[W?FWN?>'Q<_:V_98G_X(A>'?V(/!7Q?_ +6\
M<:!\5+J_.F_V#?0^=IWVV_:.Y\V2!8OGCFA?9OWC?@J"& ]Q_P""<O\ P6C^
M ?[._P#P32O? 7Q<UZW/Q@^&MEK6G_".WN/#MW>2W<%TB36X:YV-%$@N',3I
MYD8$%K& "0 ?R>QWQ115R?"UJ,J4V[2ESMZ7OHGTV:T]&R*>,JTJD9QM[JLO
M2]_S/O3_ ((D_MT_LW?LKZK\9?#/[37Q$U;P9=_$KPM%9Z'\3M+TJ6^O-&N%
M^U"1D\J*:42.UQ%,K;"F^T4O_#7JWQT_;G_8G?\ X)7?&#]BG0/V^?'GQ8\>
M:YJVG:K9^,/B%H.JXUZ:.ZTZ=X+,RI-);0I'9[ ERZ_OFD8.48$?EK1@=<45
MLGP];%>V;:^%V5K7CMTNEY)I%4\=6ITN2R>^NO7?K^)^CW[97[8G[&/[0?[
MG[/&M_#C]IZ^T7XQ?L^^"]-M-*\"W'@R];[=J2MI$,KF[,9M42);"2=?F?S
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M.WMTU[Q-]EN89A]MO0LC@[(=@#2SDO(\DDDI*A-2U_X+1^-?"?\ P5*\2_\
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M_P (?KWA:;Q"MQ-=VS75Q<F:&X^SH(W$DD1"E"&$3*6 DRJI9?B\/:5.#O\
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M#]5L(KG2KN\%L\(@D\UY9%1X"KS/)Y;Q,4VI*\;?I=J7P<UOPU^TY#^PX?\
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M\M-^?FS7,?\ !!WXS^ OAC_P4ITGXG?'3XIZ1X?TY]!U?[=X@\5ZY#:0M-+
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M*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'T?_P3P_X)O^.OV_M;\4:I!\3_  [X$\#^ K&*^\=>-_$MPHAT
MNWD$C*5C+)O;9!/(2[QQ*L+%I%)0-V?[;W_!):?]EGX5Z?\ M(?![]J3PE\7
MOA;<ZW'I&I>,?"L.3I5TX/\ KXH);B,)D!=RS,VYU4JI9=WJ'_! #6/VO]#U
MSXM7_P"Q]X_^'UYJT/AVUN]0^%?C6-_/\4>1]H:%[1EDB\IT9F@,AE$2&\0S
M*1Y9'MO_  5A_9B_9[C_ .";^J?M$_&C]@CPC^S7\8-+\46VG^"_#/A/Q%I\
MZZ[%)-;?:&<:=&D$P,)N9 &0RQFT!#A79'^<Q.88FCFRI<ZY+Q5E9O7>Z=G\
MXMI=4]CU</A:53!N7+[UI.[O;3;5:?)[GPM^UO\ \$M_C]^R3^T=X!_9IUG6
M]#\2ZI\2H+%O">K^'Y)CI]U-=7AM8X!-+&F7#^6S8! 6>,Y^:O3M#_X(6?&R
M^_:L\9?LW:W\?_ .GZ7\,_#-GKOQ,\>2W-PNG>'X+E7ECA?S8XRTYMT:X^8I
M$(U8M*I !^^/^"7E_P#!W]MS]B[X"_M5?''6[>WUK]DG5M8T[5+O5+=?LS6$
M.EGRGVAR/W4']E7'VAEWB6PE &6+U\N_\$J?VD/VV/VCOVXOCY^T%^S9\4_
M]KXC\66]QK5Q\+?'TL\P\20AYVM+6W9'CVFU7R[<3-(HB2=25=-P&3S#,N6K
M#F2E23YFUHVY>[\N6[VM=J^A<<-A?<DTVIM65]59>]^.G_!/&OVJO^".1^#?
MPCM?VD_V=_VR_A[\7?ADOB2RT+7O%V@SK$NA75Q*D?F70BEN(4@1I8 [>=O!
MGC/E[26'M/\ P5M_X)G?LZ_LW?\ !/\ ^"WQ!^#GQ#^%NFZKI/AW[7XBFM=>
M,FH?$:[O!I$3WFF.Y9[RVB=Y+C:I$4,-QN15#$'UC_@J#^S9\'->_P"":7BG
M]I']I;]@'P?^SG\6M%\16]EX/L?#?B73[AM?>:6U>61O[/$<5R75KO$<JR31
M+;R2A@I;.#_P4G^'OCN\_8"_8?\ VP-#^'L/B;P'\'/ >BWWC]O[2M5CB2:/
MP_%#;M')('E\V2)X2(TDV'[X4<UA1QV(Q%2@YU;)5&F_=L_=NE>+Y7U5U:U^
MZ1M]5HT_:<L+WA=;][;/5=]W]QXWX._X-Y_'%WX4T7PQ\6OVT_AEX'^,/BK2
MX]0\*?"+6;K==W43INVRR"02HZE)E;R;>X0-"V';!(\?_91_X(X_M0_M4^+/
MBQ\/+?5O#_@OQ%\';J&V\5:3XRN9(29I?M6P1RPI)&8_]%<^;N\LHZ.K,IS7
MZJ?M0?LW?$;]J3]NKX8_M=_LY_LH?#+XC>&YM+TG5= ^-FM?$'5(8]$:VE>X
MA'V&VU&-;A0X6152!E=I=LF '(\<^ 'QGUGXXP_\%-?B?K6O^$]0U!_AI:VD
M^J>!I)VTJZ:ST'6K,26[3_.ZD6XRW*,V3&SQE7:*><9A+#SGS*ZBFU9>Z^=1
MM9.]K.UI6?5!+ X55(JVE]]?>7+?TW[:?,^:-=_X-^_$&H_#30?C/\&/V]/@
M_P"+/!IEDA\?^,CK<=MI'AB2.$R2/]J625;J)6 BW?NI-\L),:H9)(_(_P#@
MI!_P2K\0?L%>$O!_QB\&_'31/BA\.?'"[-#\8Z'9_9U,WE"559!+-&4D3>T;
MQS/N$4FX)\N[W;]FHK%_P;&?M!)&WRK\8K+Y<\ ?:O#9_*C]KF5YO^#:K]FN
M=GWM_P +3NPK'G@2^(0 /88 Q["NZGBL?'%*,ZG,E4Y/A2NG'FOZKR^=S#ZO
MAJE/2-FX.6[T:=OQ/SW^$UU\/;'XK>&+_P"+VDW5_P"$;?Q#9S>*K&P<K//I
MJS(US'&0RD.T0< [EP3U%?T4?M/6OA'X/Z3XU\/?M;^%?@_H_P"QS;?#>W@\
M-Z"NBFTU5M8?)%K;0@A1*J1RO'Y*QR*S6WE#?',Z_D'_ ,$$+C]G:V_X*5^#
MI/VADM/^/:X'@>34FC%I'X@^3[(TOF';NV^=Y/5OM)M]GS[2/U,^!_PC_;9O
MM=^/7@+_ (+ 1^!=?_9_US4)=4L=<\0>)H8;6S1)D,0M4W%K2T1(XF F>%XI
M8@Z%V>20\G$53FQ$(-V45??5W=O<6W,K7O?J:95&T)22O=V]+*^O]U[,_GDB
M9&+!)"VUB/F(R/KCO7U'_P $_?\ @E+\?/\ @HYX7\4^)/@GXL\-6'_"*ZEI
M]I>6VO7$T32?:B_[Q2D;C9&L;,W\1 PJL< ]I_P7J_9^LO@'^WG=P^%/!O@'
MPWX2U_P_8WW@O0O 5O9VL4%@$\II)K>WBB*R27$<\GF,KA@P597$9">T?\$:
M+B2U_P""5'[;<T+A7_X0&95)[9TC4@?T->MB<PJ5,G^M4-&^6W6UY)-/O:[N
M<E'"Q_M#V-35:^71OY(\M@_X(@Z[XU_:NUKX&_!/]KCP/XG\"^$_!^G^)?&7
MQ:D7[/IVC6=TCR(DBI+*C2F&-YTQ-Y30@.TL?(7A_P!O3_@E1XF_9%^&6F_M
M'?!OX\^&?C-\*=2U+^S6\<>#64BPO<?ZNYBCEF2-68,BR+*Z[U"/Y;/&K_2W
M_! ;Q;X1^(?[+?[1_P"Q[IWAC0]:\=>*O#XOM#\-ZUJ<UFOB>W-K-#)9&>"2
M*5$5BH8K(I479;@!S5[]M3PM\=OV*?\ @D=K?P+\?_L__"/X.:1\3O&T+R?#
MFP\5:MK.N7%Q#-92M=P3275Y!C;8PEU,JQ(FT[O.E6-N">.Q]#,%AY3O9P5F
MHKF4MWWTV7+HK:F\,/AZF%=51M=2ZMVMMY:[Z_(\E\&?\$%O&EU\"O#/C;XT
M_M@?#GX9_$#X@1PR?#SX9^-+P6D^L"3RML+3/(KI<?O4!AB@G*M)&C%78JOM
M'_!9[]BI_P!J?_@L!\*_V4_@/:^&?"MYXL^$"3P7,EK]GLE>WGUFY9G%O&26
M:.#:"%)^[G@<=9_P5M_8=^.7_!5KXA?"']M;]C+4=$UKX<ZO\/;6RU#6[[Q)
M:V</AI8KR>>2ZNA-(&"HMRRR+$LDL;6<J,@8*K>H?M<^*/#OA7_@Y8_9NUGQ
M-KMII]K-\*Y+2.XNYQ&C3W*>(K>",$\;I)I(XU7JS.H&20*XY8[$5*T*KG>:
M55\J7P-1T3ZO;KZ['3'#T8T9Q4?=?)[U][M7_/H?E[^S)_P2R^,/[4G[9_Q"
M_8C\'?$'PUI_B#X='5AJ6K:DUP+.Z_L_48K&3RMD32?,\H9<H/E!S@X!7]@W
M_@EY\1_VTK+Q)\2?$GQ2\-_#?X9^"KQ;;Q9\1/$\V+6VD(SY<*LT:R. R%A)
M)$JB1,MEU5OU,_X)X?L%_M&_LV_\%COCE^TK\9M TK2/"?Q F\2)X'N_[>MI
M)M9-[K,&HKY5NCF1!'!"WF>8J;6*@;@<U\P?\$_/!UU^V1_P1J_:"_8.^!NH
M:5-\5&^(<?B"T\-76HK;2ZG9+<Z5(KAY=J<FSEA!+!$=81(R"16KIEG&(GS.
MG-<O+3N[)\KDTI/Y=GHC".!I1^-->]))=THW2^;ZGS/^V_\ \$E_B/\ LJ^'
M/"'Q9^#_ ,7/#OQF^'GC[7/[%\)^*_ H,SW6H<A;8P1-*IDD>.=(Q#+-EK:1
M6V-M5O9HO^#=_P :C0K?X>:E^VU\+[/XZ76E_P!I0?!>>^7[4;?:7(\\2F0R
M!%?.VV:+*'$I0>97.W/_  3JU/\ X)9^(/V=/VJ_VQ/C5:Z'K]Q\9-)OM<^%
MJ6\=U<:3I]EJ/G37XFMKF5;A%BBA8B.,D-=JN25-?HE\3?V:OCAKG_!3T_MI
M? G]DWX4W6AWNCP:KHW[06L?$;4Y$1!HJVQ$MC;ZBL3*RJ8@\=NT1AD25F9M
M]+%9IB*5.*IUDU[_ +]DKM6M'71[ZN.KZ!1PM*<I.5.S]WW;M[[O2[]$]MWH
M?E)^QE_P2>^)/[2X\:>,?C/\6O#?P;\#?#C75T7QMXL\;OL^PZB7\MK18W:-
M/.25HHW666+#31@%F;;4?[?7_!+/Q+^QG\-_#_[17PZ^/WA'XL_"?Q5JCZ;H
MOCOPG=)M^UJ'_=2QI)*@W-#<(&BFE :W=7\MBBM]D?\ !,OXL_MK?$CXF?M,
M?$O]E3Q=\'O'2ZMXVN=2U[X+7EY>+;^('EN"LVHZ;+=&);6*=&D59)F</M59
MHDS$XH?\%J/V9OV:_"7["GA']H+QM^Q[X5_9[^,^J^*/[/M/A[X4U6RNHKRQ
MC,_F[Q8"*V<!/)G-PL19&>&%F^=<:1S3&?VC"%22LW%<JM=7CU3M+=_$KJVZ
M%]4H/#2E%;<VKOT?E=;='OT9\U_\&_WAOPYXM_X*A^"="\5^'['4[&32=8:2
MSU"U2:)R-.G()1P0<$9''!KW+XT_\$)-1^/GQ8^,WB+X)_M@?"W4/B+;>,M<
MUG3_ (,:)?1/<6NGO?.Z0W$HE4V<X\U8_+:#R4=D5IE5MP\:_P"#=T_\;6/
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M+-,3_:BIJ?N\SBU9?RWNOM;]79/:Q7U&G'"R;CJDW?7H[>FW3?K<^*/VH?\
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M][:CN]C3L_&WC73O"EYX$T[QEJUOH>H3)-J&C0:E*EI=2(P9'DB#;'92 0S
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M91_R+X?/\V%%%%>&>D-?I7\>?CC_ )&J\_WD_P#0%K^PQ^E?QY^./^1JO/\
M>3_T!:^XX/\ X>(_[<_]N/G<^^*E_P!O?^VF31117V!X(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?M3_P:C?\ (L?&
M3_=\.?\ H>KU^O=?D)_P:C?\BQ\9/]WPY_Z'J]?KW7YGQ+_R.JOI'_TB)]=E
M'_(OA\_S84445X9Z0U\XK^//QQG_ (2J[X_B3_T!:_L.(R,5^==Q_P &R7[
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M_H,_XAB?^"??_10/BA_X--(_^5M'_$,3_P $^O\ HH'Q/_\ !II'_P K:/\
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M0_\ !II'_P K:/\ 63)_YW_X"_\ ,/[)Q_\ *OO1_/GGVHS[5_09_P 0Q/\
MP3[_ .B@?%#_ ,&FD?\ RMH_XABO^"??_10?BA_X--)_^5M'^LF3_P [_P#
M6']DX_\ E7WH_GSS[49]J_H,_P"(8G_@GW_T4#XH?^#32/\ Y6T?\0Q/_!/O
M_HH'Q0_\&FD?_*VC_63)_P"=_P#@+_S#^R<?_*OO1_/GGVHS[5_09_Q#%?\
M!/O_ **#\4/_  ::3_\ *VC_ (AB?^"??_10/BA_X--(_P#E;1_K)D_\[_\
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MYW_X"_\ ,/[)Q_\ *OO1_/GGVHS[5_09_P 0Q/\ P3[_ .B@?%#_ ,&FD?\
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MX--(_P#E;6/^LF3_ ,[_ / 7_F=']DX_^5?>C^?//M1GVK^@S_B&*_X)]_\
M10?BA_X--)_^5M'_ !#$_P#!/O\ Z*!\4/\ P::1_P#*VC_63)_YW_X"_P#,
M/[)Q_P#*OO1_/GGVHS[5^U%G_P $$OV+E_;SN/V5M0\6>/#H<GPO7Q1I]_'?
M::MT)QJ'V1X78V!1EQ\P"H".Y->R?\0Q/_!/O_HH'Q0_\&FD?_*VMJV>970Y
M>:;]Y)KW7LSGP^!Q6(YN2/PR<7KU6_\ FO(_GSS[49]J_H,_XABO^"??_10?
MBA_X--)_^5M'_$,3_P $^_\ HH'Q0_\ !II'_P K:Q_UDR?^=_\ @+.C^R<?
M_*OO1_/GGVHS[5_09_Q#$_\ !/O_ **!\4/_  ::1_\ *VC_ (ABO^"??_10
M?BA_X--)_P#E;1_K)D_\[_\  7_F']DX_P#E7WH_GSS[49]J_H,_XAB?^"??
M_10/BA_X--(_^5M'_$,3_P $^O\ HH'Q/_\ !II'_P K:/\ 63)_YW_X"_\
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M#/\ B&)_X)]_]% ^*'_@TTC_ .5M'_$,3_P3[_Z*!\4/_!II'_RMH_UDR?\
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MO1_/GGVHS[5_09_Q#%?\$^_^B@?$_P#\&FD?_*VC_B&)_P""??\ T4#XH?\
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M+N>+AW]5SBM1>U5*I'U24)KY)0=O-GK]%%%>6>T%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !11020,B@"MJUY;Z?837MW,D<,,3/+)(VU44#))/
M8 5^:G[ $=Q\;/BIXK_:!DL957QMXXOM7M4N)/,FAMFNU$4+G/\ RS"E0!D
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MDS#;$N\!;>$;3Y<2+&JA1U"+V50/T,^'W@JQ\(:#!IMM#M\N%%Z^BX]!6?\
M##X6:3X"TB*TM(<,HY/S<\D]S[UV &.@KS\3B:V+K.K4>K^226B26R26B78]
M7!X2C@<.J-):+YMMZMM]6W=MO=L****YSI"BBB@ HHHH *" >"*** /E']MC
MX-?$'X5_$_2?V]?V9/##ZAXN\-6[6OC+PS;SM'_PE.AXS)"0H.Z>/:K(0I8[
M5XE,449]W_9\_: ^&O[2_P +M-^+?PLUP7FF:C'\T;8$UI,,;[>902%E0G!
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M_P /F?@W_P!&P?'#_P (NW_^2Z]H_P"&3? W_0+@_P# >'_XBC_ADWP-_P!
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MBF_^(H^I9?\ ]!4?_ 9_Y!]?S3_H#E_X'#_Y(_1/<OK1N7UK\[/^&5_VV_\
MH]'XK_\ A13?_$4?\,K_ +;?_1Z/Q7_\**;_ .(H^I9?_P!!4?\ P&?^0?7\
MT_Z Y?\ @</_ )(_1/<OK1N7UK\[/^&5_P!MO_H]'XK_ /A13?\ Q%'_  RO
M^VW_ -'H_%?_ ,**;_XBCZEE_P#T%1_\!G_D'U_-/^@.7_@</_DC]$]R^M&Y
M?6OSL_X97_;;_P"CT?BO_P"%%-_\11_PRO\ MM_]'H_%?_PHIO\ XBCZEE__
M $%1_P# 9_Y!]?S3_H#E_P"!P_\ DC]$]R^M&Y?6OSL_X97_ &V_^CT?BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?V-D_P#T#T__  "/^1\._P##IWX._P#1/M+_ / /_P"PH_X=._!W_HGVE_\
M@'_]A7W%Y4?]P4>5'_<%']J9E_S_ )_^!2_S#^QLG_Z!Z?\ X!'_ "/AW_AT
M[\'?^B?:7_X!_P#V%'_#IWX._P#1/M+_ / /_P"PK[B\J/\ N"CRH_[@H_M3
M,O\ G_/_ ,"E_F']C9/_ - ]/_P"/^1\._\ #IWX._\ 1/M+_P# /_["C_AT
M[\'?^B?:7_X!_P#V%?<7E1_W!1Y4?]P4?VIF7_/^?_@4O\P_L;)_^@>G_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1_007.jpg
<TEXT>
begin 644 forms-1_007.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" )N!28# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHR* 0>E !1110 4444 %%%% !1110 4444 %%%% !10#GI10 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOVSOVD-0\63_ !.O'TFS\?+X4^R+>W@\^3?-;QX\A0D17A3D@8'->O?LN?\
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MV]^+/Q2^,W_!.H^-/B]\1]>\4ZPWQ"UR$ZIXBU::]N/*2<!(_,F9FV*. N<
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MYXP%^; SUJ:?[SFMT5_E=+]5IU'/]W%-]7;[_P#AC] E)(YHH'3-% !1110
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MF]?65T_6*]=K;,QI^ZZ;>T5'3T5FO23WMW\CX*_X(M_'KXG?\%B?B1X[\?\
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=^#7C'XWZ?\ LU>#?"K^*[-+CXY6<=]KG@W>E]I,;Q,OVF.54<0.N<K(5(!
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M!TQ30F.M9TOW<F^Z:\K.VZZM6T+J?O(J/FG]W;M?J.' HHHH&%%%% !1110
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MYAE!4E4/RG'!Y%?9#>+]/\*?\'"FD^/=8A6*TTW]DM;^ZCMXPJI''ND8*O0
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M1110 4444 %%%% !1110 4444 %%%% !12;E]:4,#T- !1110 4444 %%%%
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M%V_#3_H8&_\  .;_ .(KP:BC^QL/_,_P_P @_M*MV1[S_P +M^&G_0P-_P"
M<W_Q%'_"[?AI_P!# W_@'-_\17@U%']C8?\ F?X?Y!_:5;LCWG_A=OPT_P"A
M@;_P#F_^(H_X7;\-/^A@;_P#F_\ B*\&HH_L;#_S/\/\@_M*MV1[S_PNWX:?
M]# W_@'-_P#$4?\ "[?AI_T,#?\ @'-_\17@U%']C8?^9_A_D']I5NR/>?\
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M/V3/AG_X0>G_ /QFJLO[%_['8Z?LG_#7_P (73__ (S6BR6?\XOK\5T/G/\
MXC5?^"6O_1!/C_\ ^$KH?_RXH_XC5?\ @EK_ -$$^/\ _P"$KH?_ ,N*^@Y/
MV,?V/01C]E'X:_\ A"Z?_P#&:K2_L:?L@#_FU3X;?^$+I_\ \9JXY'-_;_ G
M^TH_RG@O_$:K_P $M?\ H@GQ_P#_  E=#_\ EQ1_Q&J_\$M?^B"?'_\ \)70
M_P#Y<5[LW[&O[(/_ $:I\-O_  A=/_\ C-1O^QO^R$!Q^RK\-_\ PAM/_P#C
M-7_8-3^=?<3_ &E#^4\-_P"(U7_@EK_T03X__P#A*Z'_ /+BC_B-5_X):_\
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M]H#_ ,)70_\ Y<5]@3?L/?L6#I^R%\+^O_0@:=_\9JO)^Q!^Q=SC]D3X8?\
MA Z=_P#&:YUE\G]HU^M1['R/_P 1JW_!++_H@?[0'_A*Z'_\N*/^(U;_ ()9
M?]$#_: _\)70_P#Y<5]92?L1_L8#I^R-\,?_  @=._\ C-5Y?V)?V,NW[)'P
MQZ_]"%IW_P 9K3^RY?S"^MQ['RK_ ,1JW_!++_H@?[0'_A*Z'_\ +BC_ (C5
MO^"67_1 _P!H#_PE=#_^7%?4<G[$_P"QJ.G[)7PSZ_\ 0AZ=_P#&:@D_8J_8
MV'3]DKX9]?\ H0]._P#C-5'*9O[1/UV/8^8S_P 'JW_!++M\ _V@/_"5T/\
M^7%-_P"(U7_@EK_T03X__P#A*Z'_ /+BOI>3]BS]C@'(_9,^&?7_ *$/3_\
MXS4$O[%W['7_ $:=\-.O_0B:?_\ &:T633_G%]>CV/F__B-5_P""6O\ T03X
M_P#_ (2NA_\ RXH_XC5?^"6O_1!/C_\ ^$KH?_RXKZ(D_8O_ &//^C4/AKU_
MZ$73_P#XS4$G[&7['PZ?LH_#7K_T(NG_ /QFJ625']LEYC%?9/G[_B-5_P""
M6O\ T03X_P#_ (2NA_\ RXH_XC5?^"6O_1!/C_\ ^$KH?_RXKWF3]C3]D '_
M )-3^&W_ (0NG_\ QFF_\,:_L@?]&I_#;_PA=/\ _C-5_8-3^=?<3_:4?Y3P
MC_B-5_X):_\ 1!/C_P#^$KH?_P N*/\ B-5_X):_]$$^/_\ X2NA_P#RXKW0
M_L;?LA9_Y-4^&_\ X0VG_P#QFF-^QO\ LA[O^35?AO\ ^$-I_P#\9JO[!J?S
MK[@_M*'\IX=_Q&J_\$M?^B"?'_\ \)70_P#Y<4?\1JO_  2U_P"B"?'_ /\
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MV4?AK_X0NG__ !FM%DE3^<G^T(_RGSZ?^#U;_@EGCCX!_M ?^$KH?_RXI/\
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M_DU;X;_^$/8?_&:5?V-OV0L_\FK?#?\ \(>P_P#C-']@U/YU]P?VI#^4\/\
M^(U/_@EI_P!$#^/W_A*Z'_\ +BC_ (C5/^"6G_1 _C]_X2NA_P#RXKW/_AC7
M]D+_ *-6^&__ (0]A_\ &:>/V-?V02/^35/AO_X0VG__ !FE_8-3^?\  ?\
M:</Y3PG_ (C5O^"6O_1 _C]_X2NB?_+BE'_!ZK_P2S'7X"?M ?\ A*Z'_P#+
MBO>%_8U_9 V?\FI_#;_PA=/_ /C-7?@;^Q?^Q[J'BWQE!?\ [*/PUF2"^LQ"
MLW@73V$8-JI(7,/&3SQWK.IDDZ=)SYUH..90E-1Y=SY[_P"(U;_@EE_T0/\
M: _\)70__EQ1_P 1JW_!++_H@?[0'_A*Z'_\N*^PY/V'OV+ <?\ #(/PO_\
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MBB@"0=:E3[U1#K4J?>J&!C?%#_DE?BS_ +%/5/\ TCEKW"'_ (]8_P#KFO\
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M_5>_4>@^@(SGI6V(PU;"UN2HK,RPV(I8FGSTW=$B=*P?B7_R+4/_ &'-+_\
M2^"MY.E8/Q+_ .1:A_[#FE_^E\%<\?B-9_ SW:?[]5IONU9G^_5:;[M?-Q/8
M*\O]*K3=:LR_TJM/SQ6\3/[)7FZ57E[U8FZ57E[UM$S*TO\ 6JTO6K,O]:K2
M]:WB9E>2JTO]*LR56E_I71$S*TW2HSTJ2;I49Z5M$S(SUIK^M./6FN>U6@&G
MK2+W^M*>M(O?ZTS,4=*5>M(.E*O6@!]2#I4=2#I4OJ4.7[AJ]\ O^1R\;?\
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M0S6O_ Z&C_A_E\-?^B&:U_X'14?ZF<3?] [^]?YA_K/D?_/Y?B?H)17Y]_\
M#_/X:#_FANM?^!\5(/\ @OG\,^@^!NM?^!T5'^IG$W_0._O7^8?ZT9%_S^7X
MGZ"T5^??_#_+X:_]$,UK_P #H:/^'^7PT/!^!FM?^!T-'^IG$W_0._O7^8?Z
MSY'_ ,_E^)^@E%?GW_P_S^&?3_A1VM?^!T-'_#_'X:?]$,UK_P #XJ/]3>)O
M^@=_>O\ ,/\ 6C(O^?R_$_02@]*_/L_\%\?AF>3\#-:_\#XJ/^'^'PSS_P D
M-UK_ ,#H:/\ 4WB;_H'?WK_,/]:,B_Y_+\3ZDNS^\;_>-49NAKXTG_X+._#Z
M1F?_ (5#JW))_P"/R.H'_P""R7@%QC_A4NJ_^!D=>S'A7/O^?#_ \_\ UBR;
M_G\OQ/LB;I5:;[U?'4G_  6*\!OT^$^J_P#@7'4,G_!8#P*YS_PJC5/_  ,C
MK>/#&>?\^7^!F^(,GV]LOQ/L&;[M5INM?(<G_!7GP,XP/A7JG_@5'43_ /!7
M'P,W_-+=4_\  J.MH<,YXO\ ER_P,Y9_E'_/U?B?6\W4U5FZU\FR?\%:/!#G
M(^%^I_\ @5'4+_\ !5_P3)S_ ,*RU/\ \"HZVCP[G2_Y<O\  S>?93_S]7XG
MU=)U6JLW6OE5_P#@JMX*8Y'PSU+_ ,"HZB?_ (*G>#&//PUU#_P)2M8\.YQ_
MSZ?X$//,J_Y^H^J6ZU&_2OE<_P#!4KP8>?\ A6^H?^!"4T_\%1O!IZ_#G4/_
M  (2M5D.;K_ETQ?VYE7_ #]7XGU0>M(GW:^5C_P5$\&'_FF^H_\ @0E _P""
MHG@P#'_"M]0_\"$JO[!S?_GTR?[;RO\ Y^K\3ZJHKY5_X>B^#,?\DWU+_P "
M$H'_  5%\&=OAOJ/_@2E']@9O_SZ?X$_VYE?_/U'U<.M2K]ZOE ?\%1_!@Y_
MX5QJ'_@2E.'_  5+\&#G_A6^H?\ @0E1_8&;_P#/I_@5_;>5_P#/U'TI\4#_
M ,6K\6?]BGJG_I'+7N$/_'K'_P!<U_E7YV^*O^"F_@_Q%X2UCPU%\/-0C;4]
M'N[)9&N$PC30/&&/L"V:[Y/^"S'@!85B/PCU;Y5 _P"/R.N+&<-YW4BE&B_P
M-L/GV4QFVZJV\^Y]GS_UJ"3H:^,W_P""R?@%_P#FDNK?^!<?^-1M_P %C/ 3
M _\ %I]6_P# R.N./"^??\^7^!U/B')O^?R_$^QY?ZU7E_K7QX__  6$\"-_
MS2G5?_ N.HF_X*_>!6_YI5JG_@7'6RX9SS_GR_P(EQ!D_P#S]7XGV!*?YU7E
M_K7R$W_!7CP.W_-*]3_\"HZC?_@KCX&;I\+=3_\  J.M(\-9W_SY?X$?V_E#
M_P"7J_$^N9?ZU7E_K7R4_P#P5I\#MT^%VI]?^?J.HW_X*Q>"&_YICJ7_ (%1
MULN',Z_Y\O\  EY]E/\ S]7XGUC+_6J\O]:^46_X*M^"C_S3/4O_  *CJ)O^
M"JG@MO\ FF>I?^!*5I'AW./^?+_ S>>Y3_S]7XGU5+UIM?*;?\%3?!CG/_"M
MM1_\"$I/^'I?@WM\-]0_\"$K3_5_-_\ GTR?[<RK_GZOQ/JD]:8_WJ^5_P#A
MZ1X-)S_PKC4/_ A*:W_!43P8W/\ PKC4/_ A*M9#FW_/IB>>97_S]7XGU0W;
MZTM?*I_X*B>#C_S3?4/_  )2C_AZ+X._Z)MJ'_@4E/\ L'-O^?3_  %_;65_
M\_5^)]55P_QKGEM_"EQ+$Y4K&QX_W&KPX_\ !47P;C_DF^H?^!*5SWC[_@HC
MX4\8Z++I4'@.^A:16&YKA#C*D?UH_L'-O^?3_ 7]M97;^*CYCLM5U+0]7CU;
M2+R2WN;>8/#-$Q5D8<@@U]V?L>?MA:;\7;&+P)XYN8[;Q'!'B*1FVK?J!U7_
M &_5>_4=P/@6:Y5Y693QNR*FTO7+_1-1AU?2KR2WN;>020S1,59&!R"#VK]$
MS/)Z.98.,9:325G\MF?!9;FU;+<4Y1U@WJOU/UXC.5XK!^)?_(M0_P#8<TO_
M -+X*\;_ &-_VQM-^,5A%X&\;7<=OXC@CQ&[,%6]4#[P_P!OU'XBO9/B40?#
M46#_ ,QS2_\ TOMZ_*<1A:^"Q#I559H_2J.*HXS#>TINZ:/=I_OU6F^[5F?[
M]5IONU\G$^@*\O\ 2JTQJS+_ $JM-6\>AG]DKS=*KR]ZL3=*KR]ZVB9E:7^M
M5I>M69?ZU6EZUO$S*\E5I?Z59DJM+_2NB)F5INE1GI4DW2HSTK:)F1GK37IQ
MZTUSSBK0#3UI%[_6E/6D7O\ 6F9BCI2KUI!TI5ZT /J0=*CJ0=*E]2AR_<-7
MO@%_R.7C;_L(6/\ Z2+5%?N&KWP"_P"1R\;?]A"Q_P#21:Y\1_NL_E^:*I_Q
MH^OZ'HTO6JLW7\*M2]:JS=?PKQ(GIRV*\O>JLGWOQJU+WJK)][\:Z5L9RV*T
MO]*K3=*LR_TJM-TK:!E(K2_UJM-5F7^M5IJZ(F<BK-TJO-UJQ-TJO-UK>)G(
MCJ.I*CK6)(Q_O4U>_P!:<_WJ:O?ZU1$MP_C_  I1UI/X_P *4=:!#DZ5(G2H
MTZ5(G2E("6+^M=5^RY_R<+JA_P"I-C_]*S7*Q?UKJ?V7#_QD+J@_ZDV/_P!*
MS7!F7^X5/3]4=&'_ -XAZGTI1117PY](%!( R:*9<?ZEOI4SERQ;!&5X(^(G
MP_\ B9I4NO?#CQSH_B"Q@O9K.:\T34HKJ*.XA<QRPL\3,!(CJRLI.58$$ C%
M;!( R37Y/_"W]KCXO_L4?\$H_$WQK^!WAS3=6\0']IK5=*@TW5HRT5Q'>>*Y
M+:1,AEVL5D.&)(4X)!QBOH#X'?M:_P#!0/X=?MS^'OV6OVYM$^&\VF_$SPSJ
M&L^";KP&MTLFDR6AB\RQN3.2+AMLF?-4(#MZ57>W]/E4K?<R9246T^E_N4G&
M_P"!]C>#OB/\//B)%?W'P_\ '>CZY'I>J3:;JDFCZG%=+9WL)VS6TIC8^7,A
MX:-L,IZ@4OB7XB?#_P %ZKH^A>,?'.CZ3?>(;XV6@6>I:E%!+J=R$:0P6Z.P
M::38K-L0%MJDXP":_&[]NKXL_M/_ !Y_X)Y_'*X^$.F?"GP?I/A7]J75-$U^
MVM?",D$FJPPZC:BWN28) KW;3,K33."9 .@/-?6GQ'^*_P"U+\#X?V1_!_[4
M6G?"CQGXT\7?&!M*U37M+\(2>1IUJVGW<D,VG?:9&DM;H1*L;R@G(+@##4XQ
MYDO6*_\  DG^H5I>QE)/HI/_ ,!O_D?>V<]*-PSC-?E;_P %0?\ @L3^T?\
ML._%GQ%-IG[2?[.&EV'AE9+BP^%6M/J-YXD\1PH 0@FM_P!S8S2 X5) >WK6
M/^WKXB_;T^.?_!0+]E7XM_LM_$SX8Z/IOB[PQ=:GX!A\6>'[VY>REFT]9KDW
M9AE7S$:-U"!-I4@DYI4[U(QDMF[7[:7'4:I73W2OZZI?J?K51FOS!_X*,_\
M!:;Q;^SG^TK-^Q[X)_:7^"?PS\1>%?#&G:EXN\4?%73]2NK;4+NY4N+.RMK,
M;EQ& [22,-HE08/./JW_ ():?MUP?\%"OV3-/^/)MM-6\CU2\TK4YM%DD>QN
M;BVE,;3VS2 ,8GQN7< 0#@\BB/[RFYQU2_*]K_>.7N249=?\K_D=WXI_;O\
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M'.>*=^V!^R+\0?V@_P!H/X#_ !:\):_H]II_PL\=3:WKEOJ,TJS7,#V4L 2
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M_M'>-_'MEJ&O>%,_\(OIPTU8M,TQ< %([=&'!P,Y8G@#. !7CW^E_P#/-O\
MODT?Z7_SS;_ODUXO]AY-[:5;V2YI7;]7O]]STO[3S'V*I>T?*DE\EJEZ'I7A
M?]J_X^^%?V@;_P#:FTCQ99V?C;4M5N+^ZN[.Q"VSM-G?'Y+$_NR#@KG/H0<&
MNS\:?\%,OVP/'7P[\6_"J\;X?:7H?C2QFM=<LO#_ ()2S$OFY\V<%),^<P/+
MMN^E>!?Z7_SS;_ODT?Z7_P \V_[Y-%;(\FQ"@JE)/D22\DME\AT\US.E*4HU
M'>3N_-]SU^^_;9_:#OM(^&?A674M$_LKX3W N?"L*Z6?-\X*0#,^_P#>#!Z
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M'FVUGPW_ ,)1\1-*73==F;16^S"W$,4(\N/S<JVR)>=QYR<=JYG]G/\ :?\
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M[/?[+GP_^-/PYL=3N/\ A!?&&I?$A?#]YH>FRRETMK^VDMY3=&(NRAX2"R(
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MKT1F$\<]S@[8(Q;R,7"EB ,#)JS^P)^W%^WM\>/VK/B!^S3^UU^S+X \#2>
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M\ 6FDZQXUU!;[Q1?6\DA;4+A5VB1PS$ X_N@"N9T#]A#]D?PM\4O%WQJ\-_
M_2;'Q3X[LYK3Q9K%J\R2:C#-CS58!]J[L DH%)/.<DFIHX:KA_9\K7NPL_\
M%RM)K[]3:IB*=;G4D]9:>ETVOPT/R_\ V<_'W[8W[37Q+_:5_:3^&G_!.Z^^
M,WA7XPW=SX2L=;D^*&DZ''9:7:B2#[.D-YEY.6#;AA24&.037TI_P;N_''Q7
MKG[*VM_LG_%/39M/\7_!OQ)/HFHZ;=7"R20PEV9%+*2K;6W+N4E3U'%?;7P1
M^ _PC_9P^'-G\)/@CX'M/#OAW3VD:STNS9RD;.Q=SEV9B2Q))))R:R_AS^RI
M^S]\(_BMXH^-_P ./AI9Z3XI\:.C^*-6M9I=VH,OW2Z%R@(]545KA<.\-45G
M>/)ROU6J?WN7WF>(Q$<1!W5GS<RM]SO_ -NI>6A\0?\ !2O2K'7O^"R/[*&A
MZK;+-:WFGZW!<1,N0\;^4K*?J#7R'HT_Q)D^)5Y_P;X_V/J*6EU\?O[5DUGY
M?*C\)K_Q,&B'S;MQ=1)C;MV\9R<5^TGC?]FKX&_$CXK^&?CCXX^'=GJ/BSP:
MLR^&=:FDD$E@)<;]@5@ISM'W@>E5HOV5/V>8?VAG_:OB^%6FK\1)-)_LQ_%0
MW_:#:X \O&[9T &[;NQQG'%9T\+*-2+;TYI.2[KF4HKY-*_DV5+%+E=EKRQ4
M?*23BW]S?S/SC_9ZL_%OA'_@H;^W5I_P5LO*US3/AQ#'X6M[?"E+F.RF%NJ\
M<$,%Q[XKYT_9+_9E_:O_ &J/^"65OX8\#77[*ND^'[V^NKS4/'7C#7M4MO%F
MG7J7CNTUU,L#QQ2@@8.2-A4GDU^U_@G]FGX&_#GXL^)OCIX*^'5EI_BSQBD2
M^)M:A>0R7XCSL#!F*C&?X0/>O-O$'_!*;_@G5XI^*3?&?7OV1/!]QXB:X\^2
M\-BRQR29)+M K"%F))))0DGK41P=3W.9WM%)Z]5)RNOO\C:6-A)RY5;6Z_\
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MZ7_@3_S-OJ."_P"?4?N1\%_\.POA_P#]$[L/_ (__%4'_@F#\/S_ ,T\L/\
MP#/_ ,57WI]EM_\ GDO_ 'R*/LMO_P \E_[Y%']I9C_S^E_X$_\ ,/J."_Y]
M1^Y'P7_P[!^'_P#T3RP_\ C_ /%4?\.POA__ -$[L/\ P"/_ ,57WI]EM_\
MGDO_ 'R*/LMO_P \E_[Y%']I9C_S^E_X$_\ ,/J."_Y]1^Y?Y'P7_P .POA_
M_P!$[L/_  "/_P 51_P["^'_ /T3NP_\ C_\57WI]EM_^>2_]\BC[+;_ //)
M?^^11_:68_\ /Z7_ ($_\P^HX+_GU'[D?!?_  ["^'__ $3NP_\  (__ !5'
M_#L+X?\ _1.]/_\  (__ !5?>GV6W_YY+_WR*/LMO_SR7_OD4?VEF/\ S^E_
MX$_\P^HX+_GU'[D?!?\ P["^'_\ T3NP_P# (_\ Q5'_  ["^'__ $3NP_\
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MP^HX+_GU'[D?!?\ P["^'_\ T3O3_P#P"/\ \51_P["^'_\ T3NP_P# (_\
MQ5?>GV6W_P">2_\ ?(H^RV__ #R7_OD4?VEF/_/Z7_@3_P P^HX+_GU'[D?!
M?_#L+X?_ /1/+#_P"/\ \51_P["^'_\ T3RP_P# (_\ Q5?>GV6W_P">2_\
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M !5?>GV6W_YY+_WR*/LMO_SR7_OD4?VEF/\ S^E_X$_\P^HX+_GU'[D?!?\
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M)+:'_GFO7^Z*K2VL'_/)>O\ =%:QQ6,_Y^R^]_YD/"X5?\NX_<CXP?\ 8+T
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M;B5O5B!D_B:](HH7NWMU!Z[A1110 4444 %%%% !7C'[1/\ R.UK_P!@N/\
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ME^=X>GD^S[?^/CS<7:^;O_@V^7Y?\7FTZ:P^)[7;-!XJT-83K$<D:-H$S,+
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MJ5\CF7^^S^7Y(^@P/^ZQ"BBBN$[ HHHH **** "BBB@ HHHH **** "BBB@
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M/_'K'_US7^5>'_%#_DE?BS_L4]4_](Y:]PA_X]8_^N:_RKSLP^&/]=#JPO\
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MBC/:@ HHSCK10 444 @]* "BBB@ HHHSGI0 4444 %%%&1ZT %%%% !1110
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MU]RC_P -P_M;_P#1QOC#_P *"?\ ^+I?^&X?VM_^CC?&'_@_G_\ BZ]+O_\
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M G:,Y. 3CH#TK:IEF34X.<Z,$DKM\JV7R,8X_,I22566OF_\SOO^&X?VM_\
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M_7\R_P"?LO\ P)_YGJ__  W#^UI_T<7XP_\ !_/_ /%4?\-P_M:?]'%^,/\
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M_:T_:0/7XW^)O_!S-_\ %4G_  UE^T=U/QM\2_\ @XF_^*KS'S_]L?G1Y_\
MMC\ZK^S\O_Y]1_\  4+ZYCO^?DOO9Z:?VK_VBVZ_&KQ)_P"#B7_XJFG]JO\
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MC4A;297V&$>R;=N>^,]Z^T_^"9WPU_9PL_"/Q*O]!_:SAU+4-2^%DJ^)-/\
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MZ24_>O>?-ZO[/7Y'FYYF. QV'J0I;\Z<=+>[RZ_^3#/M*T?:5K/\]2<YI?M
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M)!UJ5/O5$.M2I]ZH8&-\4/\ DE?BS_L4]4_](Y:]PA_X]8_^N:_RKP_XH?\
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MWQ)@?\N\7_H,M?BC^U7\-OB!J7[0_BZ^L/"6H202:[<F.06KX8>8W(XK]O\
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MI_A1_P ,2>'O0?\ CG^%'_$2L1_T#K[V'^HU'_G\_N1^%H^$_P 2N_@[4/\
MP%;_  I?^%4?$G_H3M0_\!6_PK]T?^&)/#W7:OY)_A1_PQ)X=_N+_P!\I_A1
M_P 1*Q'_ $#K[V'^HU'_ )_/[D?A=_PJCXD_]"=J'_@*W^%'_"I_B3_T)VH?
M^ K?X5^Z/_#$GAW^XO\ WRG^%'_#$GAW^XO_ 'RG^%'_ !$K$?\ 0.OO8?ZC
M4?\ G\_N1^%P^%'Q*Z?\(=J'_@,W^%'_  JCXE'_ )D[4/\ P%;_  K]T?\
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MT?\ G\_N1^%H^%/Q)[>#M0_\!F_PI?\ A5'Q*[^#M0_\!F_PK]T?^&)/#O\
M<7_OE/\ "C_AB7P]_=7_ +Y3_"E_Q$G$?] Z^]A_J-1_Y_/[D?A=_P *I^)0
MZ>#M0_\  5O\*7_A5/Q+/7P=J'_@*W^%?NA_PQ)X>]!_XY_A1_PQ)X=_N+_W
MRG^%'_$2<1_SX7WL/]1Z/_/Y_<C\+C\*/B4?^9.U#_P%;_"@_"GXE_\ 0G:A
M_P" K?X5^Z)_8D\.G^%?R3_"C_AB3P[_ '5_)/\ "G_Q$K$?] Z^]A_J/1_Y
M_/[D?A4/AG\00/\ D6+S_OR:/^%:^/\ '_(LWG_?DU^P-W^QUH/FMA /F/\
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M_P >L?\ US7^5>'_ !0_Y)7XL_[%/5/_ $CEKW"'_CUC_P"N:_RKSLP^&/\
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MZ%11[279?<@]BN[^]GGO_",_M3?]%B\!_P#AN;W_ .6]'_",_M2_]%B\!_\
MAN;W_P"6]>A44>TEV7W(/8KN_O9Y[_PC/[4O_18O ?\ X;F]_P#EO1_PC/[4
MO_18O ?_ (;F]_\ EO7H5%'M)=E]R#V*[O[V>>_\(S^U+_T6+P'_ .&YO?\
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M_:!%K'GXG^#L>6N/^*%N_3_L)UP?Q0_Y)7XL_P"Q3U3_ -(Y:]PA_P"/6/\
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MI/QL'7X@^%__  C[G_Y85V<E5I?Z5O&M*^R^Y$>Q7=_>SCI-)^-'4_$#PO\
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MLON0>Q7=_>SSW_A&?VI?^BQ> _\ PW-[_P#+>C_A&?VI?^BQ> __  W-[_\
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M?R."HHHKZH\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLA1=A *X'RD C&*QI^[&S]/ES*5WYZ6_$T^TFO)_='ET\NIF_ GX,_";X*^
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MKL=<\9Q?3C*4Y27*FW>VB5K_ )['OO\ P_?_ &L?^A!^'_\ X*;W_P"3:/\
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M:527+)V3[L^S?^'[W[6/_0@_#_\ \%-[_P#)E'_#][]K'_H0?A__ ."F]_\
MDRO*-7_X)J_%GP[J,?@[Q+\<_A'IOC*2Q^U+\/[[Q]%'K13!.!!LP3@$\.1Q
MUKC?@G^QO\6_C5X:UGQ__;/AGPGX4\/RM#JWC#QMKB:?ID$H."GG$-DYXR 5
M&>37)'+/#^I1E5C&'+'=W=M=%ZWZ6O<Z)8SBZ%2,'*=Y;+\?E\SZ(_X?O?M9
M?]"!\/\ _P %-[_\F4O_  _>_:Q_Z$'X?_\ @IO?_DRODCXS?"V;X->*8?#3
M?$CPCXKAN;&.[M=:\$Z\NH6,T;$@;95 YRI!! KJOV??V/\ XK?M#^%M:^(N
MCZUX;\->$O#S;=8\8>,]:6PTVVDP&\LR$,=V""?EP,C)&1GIEP_P33P?UN5*
M*I_S-NVNB^_MN8+-N*'BOJZJ2<^RW/HW_A^]^UC_ -"#\/\ _P %-[_\F4G_
M  _?_:P_Z$'X?_\ @IO?_DROE3X\? [Q%\ ?$%CHNM>,O"_B"WU33Q>Z9K'A
M'7$O[.ZA+%=RR* >JGJ!7#?:O>NC#\*\(XJBJM&A%Q>SU_S,J^><18:HZ=2K
M)-=#[D_X?O?M8_\ 0@?#_P#\%-[_ /)E+_P_>_:Q_P"A!^'_ /X*;W_Y,KP#
MQ[^R1>^!OV./!_[7<OC^.XA\7:M+8QZ"NFE6MMCSIO,WF$-GR,XV#[W7CGQ@
MW?;-1A>&>#\8INC0B^63B]])1T:+K9UQ)AU!U*K7,E)>:>S/N;_A^_\ M8#_
M )D'X?\ _@IO?_DRC_A^]^UC_P!"#\/_ /P4WO\ \F5\-?:O>NQ^"WP*^+O[
M1'B.Y\)_!SPBVLZA9V+WES;B^@@V0K]Y]TTB*<9Z D^U;5N$N$\/3=2I0C&*
MU;;:27WF-/B#B"K-0A6DV]$EU/K/_A^]^UC_ -"!\/\ _P %-[_\F4#_ (+O
M_M8'_F0?A_\ ^"F]_P#DROF/X%?![X:_$NX\36_Q:_:2\+_#7_A']/::U;Q-
M/&HU*<,P-O%NE3+_ "_P[F.1A37FR7B2*'CDW*>5;U'K6-+AG@^M6E1A03E%
M)O?9ZK79_(UGG7$=.BJDJSLVUTW6^FZ/N;_A^]^UC_T(/P__ /!3>_\ R91_
MP_>_:Q_Z$'X?_P#@IO?_ ),KX:^U>]'VKWKJ_P!3>%_^@>/X_P"9A_K)GO\
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M^8YI?_I?!6D4XSL8SE>FVNQ[O.,G-5)CQ@5:G;'2O+?AA^UW^SO\;/C%XW^
M'PQ^(B:IXN^',T,7C/2%TVZA.G/-N\L>9+$L<N=C?ZIG QSCBOFHZRY5OO\
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M\(=)FU'4O#_A_6#JN@0ZJ+!FM]1TR7Y2F48DJR(ZD_,#UIU/=Y[/9)_)VO\
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MQK#6S:8OE2Q^8L8B?SO];G!9/N]>>&_LQ?MH>)/V5_"GC[PIH'PUL_$"^/\
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M^T[^UG\3OVNOB)'X^^(FEZ9H]KI]A'I_AWPUHN?LNE6:#B-20"['NV #@
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MXH\6?L._\%#/%WPA\,^.->DUCQ5X+C\%Z7KD#W<K9F>SEO4+69;+= Y!.>0
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M,R<A/N[!UZTJ-"HI85N-N1237;1JZ]6[_,JM4C+ZPD[\UK?>G;Y6L>Z^*_\
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M\+?'3]JKX*?M4>-/&?[8GQ0TN/X7^,/$5QX/L=!\436ZPSP+/,GFR F22(;
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M:)U;.^_/?D^ZZ6NQ.'J454IMO6U-;;<K7-^'WGP/^R9HO[3'[1'_  1M\?\
M[97C/]NOXN6_B7X9ZOJC^#[?3?%LL<*/;LDI-T3E[P,92H61BJJH %>F?MB?
M\%.?CWKO[,_['7@67Q#XVT\_&[PZ-4^)&L?#/27N=?NK>WCMQ)!8I&-PDD:5
MF)3Y@ ,8K["_9S_X(^:#^SM_P3H\=?\ !/BT^.UYJUKXVNM2FD\4R>'UADLS
M=+&,"W$S!]OEC^,;L]JB\9_\$=_ GBG]E7X-_ RQ^.>OZ#XU^!5K#_P@/Q0T
M*PACNK:X5%5W>VD+H\3[4+1%N=B_-USY<J<K.,?A_=.W>R:GOYVOKK8[G.$I
M.3WO4L^R;7+^MNUSPC_@E#\8/CA8_MS>)?@AX-T3]H:]^"%YX).I:7J7Q^\.
MWT5[INK1S1*\*75TN9%D61B%+9^3@  U]"?\%:?V ?&'[>_P3T/1OA5\0H/#
M?C+P5XF@U_PK?7L9>V:ZB.0DBCMD#!P<$=#7??LM?LQ_M,?!_P 0W?B_]I7]
MO3Q3\7]0FL39VEK=>%=-T/3;5"X;S!:V* /-\H7S'<D D #)K2_:R_9_^,'Q
MRT+3#\#OVL?$_P )?$&DW#RVNKZ'IMKJ%M<[E"E+JSNE,=PH R 2""<YKKJ4
M^;#0@[MKJM[WNG\CGIRY<1*2:5_N>EG]Y\4_ #]N7]L?XH_$[Q1_P2A_;Z^&
M\?@WXI:M\/[J[\)^-O!>J/'#J48A<+<(T;!HFW1N0RD$&-@0.*^;-4_X*%_M
M"7__  2BL_V-[7X@Z]%\=IOC%;_"^;5/[6E&JG_2!+]J$V[S=S1*D9DW9!DZ
MU^BO[,7_  35F^$G[0]S^V)^TI^TCKWQD^+,VA_V-9^*=7T2TTJUTVQ#.?*M
MK*T'EQ$AR&;)R2Q !8U\;_"+]A'PU\5O^#B?QQ^T-H'@O5K3PA\/[==7NKJ^
MTUHK2^\0RPB$"%F4!PK,\NX9PT0]:(TZM2M2IS?QKWWY1ES)^MM'W;!RITZ4
MYP^Q9Q]6N5KTOJO0S_VYY_C7^SS^T]HUC^U]\1OCU:_ O0O!&FVGAOQM\+-8
MG5;75(D5)[K5&BRT@+ ,?-RIYZ\BN7_X*<_!/X;_ !P_;"_8W\9>'OV@?&^N
MZ;\1(X;-?$FG^)I;9I+>*&W"7UJ$ %I<2[RTCH 2V,@8Q7W9^U__ ,$__P!H
M7]IS7M>T?PW_ ,%"?%O@_P"'_BZS^R>*O ,?A'3=0CGA*[)$M;J=?.LPZY!V
M;ADD^HK$_:,_X)+> ?B7\(_A'\//@=\7]8^&VL?!"6%OA_XHM]/AU22W"1A"
M)HIR%FW8#') W=B.*UA1J2M*<;\M2,K:7:N^;RZZ;-B52G!V4MX.-^B=E;SW
M6NZ/E/\ ;]_:'\2^!?VV/!O_  3MNO&OQR_X5CX7^'*:EKDGPKCN=1\5:Y<$
M[8C-<Q?OA$OREI%/+<'.[ P/"'[07[5.G?L(?M4>';N\^,6F^%O"NBI<?"SQ
M7\2=*O-+UZ.WD*AXS/(%=W0Y^<,6P>M?9'QU_P""8_BKXI^,/!/[0_@S]K[Q
M-X/^-W@WPY_8TGQ.T_P]8S1ZS;LV9!=Z:RBW<$LY50552W(;:N-#Q!^P/\6/
MB3^RM\0/V?/C[^VIXF\=:Q\0-+^Q7/BC4O#ME:V^F@8P;:PM1'&@X&X;R6/\
M0I2PV*=*JKMR:DO)W:MUOHN]K"C6P_-3[)Q]5;?RUZZNY\"_&5?VGOA3^Q'^
MSW^WKX<_;2^(DWC[QC=:#8ZA;WFKF32%M;R-4"?8ON.Z @F1]SNP))YKVC4;
M#XR_L3_\%6/@7X#T3]ICQUXOT/XSZ'J0\9Z5XPUDW=O]JMT#+/;1X"6PW2#"
MQ@ !<'.>/>/BM_P2YTKXG_L9?"K]D!_C-<6<7PONM%GAUY=#61M1.GA>##YP
M$7F;>SMMS_%76?'#]A*S^-7[7/P=_:MF^)DVG3?".WOXH=#721*NI_:41<F7
MS5,6W9V5\Y[5Z,:$H8KGAM[1-:_8<=?O9RRJ*5#E>_(U_P!O7]W[D>^'K2+W
M^M.;[U-7O]:[CC#^/\*4=:3^/\*4=: ')TJ1.E1ITJ1.E*6P$L7]:ZK]ES_D
MX75/^Q-C_P#2LURL7]:ZG]ES_DX75#_U)L?_ *5FN#,O]PJ>GZHZ,/\ [Q#U
M/I2BBBOASZ0*.O!%%!) X% 'SC\??^"1/_!-?]J+XJ1?&WX]?L?>$?$7BJ.1
M9&UB>WDADN&&,-,(71;@_*!^\#<#'3BO4-%_9<^ 'AKQSH_Q'\-_"[3-/UCP
M_P"%V\.:+<V*M$MGI;.'-JD2D1A-RJ?NYXZUQ/Q3_P""C'[+'P:_:V\+_L2^
M/_&5Y9^//&&GPWFBVO\ 9,S6ICEEEAB$EP!Y<3/)"Z*K$$M@#J*]!_: ^/GP
MR_9D^$.L_'#XOZVUAX?T*W$M[-# TTC%F")''&H+22.[*BHH)9F '6I]V-._
MV=?3L_\ (=G*IR_:T]==5]YROAW]A#]DKPI\//!WPF\/_!BPMO#_ ,/]<;6?
M!^F+=7!33+XR22&="9"S'?+(<,6'S=.E=/JW[.?P7UWXS1_M"ZMX$MYO&4/A
M>;PY%KK32B1=+EE$LEMM#;-K2 -G;NXX.*A_9G_:/^%7[6WP/\/_ +1/P2UN
M;4/"_BBS-SI-W<6CP2.@=D(:-P&1@RL"",@BNPUS58M T2\URX1GCM+9YI%3
M[Q55+$#WXJJG[N_-I:]_NL_PT8HOFUCU_P _\SRW6OV"_P!C_P 3?LXR?LC>
M(_@+H>H?#E]__%*WT;S0(S.SEU9V,B/N9B'5@RD\$5S_ (&_X)9?\$]OAM\
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M%_W['_Q-'_$2I?\ 0/\ ^3?\ /\ 45?\_OP/PK_X1+Q?_P!"W>?^ [?X4?\
M")>,#_S+=Y_WX;_"OW4_X8<\/?\ 0/B_[]C_ .)H_P"&'/#W_0/B_P"_8_\
MB:/^(E2_Z!__ ";_ ( ?ZBK_ )_?@?A7_P (EXP_Z%N\_P"_#?X4?\(EXO\
M^A;O/_ =O\*_=3_AASP]_P! ^+_OV/\ XFC_ (8<\/?] ^+_ +]C_P")H_XB
M5+_H'_\ )O\ @!_J*O\ G]^!^%?_  B7B_\ Z%N\_P# =O\ "C_A$?%_3_A&
M[S_P';_"OW4_X8<\/?\ 0/B_[]C_ .)H_P"&'/#W_0/B_P"_8_\ B:/^(E2_
MZ!__ ";_ ( ?ZB_]/OP/PK_X1'Q>.GAN\_\  =O\*/\ A$O&'_0MWG_?AO\
M"OW4_P"&'/#W_0/B_P"_8_\ B:/^&'/#W_0/B_[]C_XFC_B)4O\ H'_\F_X
M?ZBK_G]^!^%?_")>,/\ H6[S_OPW^%'_  B7C#_H6[S_ +\-_A7[J?\ ##GA
M[_H'Q?\ ?L?_ !-'_##GA[_H'Q?]^Q_\31_Q$J7_ $#_ /DW_ #_ %%7_/[\
M#\*_^$2\8?\ 0MWG_?AO\*/^$2\7_P#0MWG_ (#M_A7[J?\ ##GA[_H'Q?\
M?L?_ !-'_##GA[_H'Q?]^Q_\31_Q$J7_ $#_ /DW_ #_ %%7_/[\#\*_^$2\
M8'_F6[S_ +\-_A1_PB7B_P#Z%N\_\!V_PK]U/^&'/#W_ $#XO^_8_P#B:/\
MAASP]_T#XO\ OV/_ (FC_B)4O^@?_P F_P" '^HO_3[\#\*_^$2\7_\ 0MWG
M_@.W^%'_  B7B_\ Z%N\_P# =O\ "OW4_P"&'/#W_0/B_P"_8_\ B:/^&'/#
MW_0/B_[]C_XFC_B)4O\ H'_\F_X ?ZBK_G]^!^%?_")>,/\ H6[S_OPW^%'_
M  B?B_/_ "+MY_WY;_"OW4_X8<\/?] ^+_OV/_B:/^&'/#V,_8(O^_0_^)H_
MXB5+_H'_ /)O^ '^HJ_Y_?@?A2/"_BKOH%U_WY-'_",>*C_S +K_ +\FOV$N
M?V,]#\QA]CC^\?\ EF/7Z55D_8WT)>?L<?\ W['^%=\>/)R_Y<?C_P  YY<&
MQC_R^_ _(7_A&?%/_0!NO^_1H_X1GQ3_ - *Z_[]-7ZY2_L=:&.EG'_W['^%
M5I?V/-$#<VL?_?L?X5HN.:G_ #X_'_@$_P"I\?\ G[^!^2W_  C/BG_H!77_
M 'Z:C_A&/%7_ $ KK_OV:_6"7]C_ $8#_CU3_O@?X57E_9!T;O:I_P!^Q_A5
M+C:H_P#EQ^/_  "7PC%?\O?P/RG_ .$9\4_] *Z_[]-_A1_PC/BG_H!W/_?L
MU^J$W[(6CY.+9?\ OV/\*KR?LCZ0.#;K_P!^Q_A6BXSJ/_ES^(O]4X_\_?P/
MRW_X1KQ/WT2Z_P"_1I/^$:\4?] .Y_[]&OU!D_9(T?J+=/\ OV/\*JR?LEZ4
M#_J$_P"^!_A5KC"I_P ^?Q(_U5A_S]_ _,C_ (1KQ1_T [G_ +]FC_A&O%'_
M $ [G_OT:_3-_P!DW2QTA7_OC_ZU1G]DW2NI@7_O@?X52XNJ_P#/G\1?ZJQ_
MY^_@?F@?#?B?'&B77_?HT?\ ".>)O^@)<_\ ?LU^E_\ PR=I7_/!/^_8_P *
MP?'?[-NF:%HDUZL"92,G[GL?:J7%E7_GS^)/^J]/_G[^!^<%QY]I,UO<HT<B
M\,K=13/M/^U^M7/B,PB\;:E%G[MTP_6NP_9^^ /B+XOZ]&XM)%L5;,DGEG#5
M]3/&4Z.']K4=E:Y\W3PM2M6]E35W>Q9^ GP+\1?%[7HA';2+9*P\R3:3D5^C
M?[/_ .S_ *+X T6VAAL%C\L="ISWY/%-^ 7P T+X?Z);P1Z:B;%XW(,D[FY.
M1Z8KV"VA6#;&B8 ]!7YYFF:5LRJWV@ME^K\S[O+,LIY?3[R>[_1&/\2($@^$
M_BN) /E\)ZGT_P"O.6O<H?\ CTC_ .N:_P J\0^)W_)+/%G_ &*>J?\ I'+7
MM\/_ !ZQ_P#7-?Y5\QCO@7K^A[>%_B/T_4BG_K4$G0U//_6H).AKBB=DBM+_
M %JO+_6K$O\ 6J\O]:W1G(K2@?K4$O/7UJQ+_6J\O]:VB9R*\O\ 6J\O]:L2
M_P!:KR_UK:)$MBO*,_\ ?55Y?ZU8E_K5>7^M;1,I%:7K3:=+UIM;$D9 W9Q3
M'^]3SUIC_>JT3(:W;CO2X[TC=OK2TR0(SP:***3V <G(J1!@5&G2I$Z4=2HD
MB=*P?B7_ ,BU#_V'-+_]+X*WDZ5@_$O_ )%J'_L.:7_Z7P4H_$3/^&SW:?AJ
MJS#C-6I_OU6F^[7S<3V"O+_2JLW3%6I?Z56FZUO'H9_9*\HP,"J\H[U8FZ57
ME[UM$S*TO]:K2]:LR_UJM+UK>)F5Y*K2_P!*LR56E_I71$S*TH '%1GI4DW2
MHSTK:)F1G[U-D S3CUIK^M6@&GK2+W^M*>M(O?ZTS,4=*5>M(.E*O6@!]2#I
M4=2#I4OJ4.7[AJ]\ ?\ D<O&W_80L?\ TD6J*_<-7O@%_P CEXV_["%C_P"D
MBUSXC_=9_+\T53_CQ]?T/1I>M59ASGVJU+UJK-U_"O$B>F]BO+WJK)P<>]6I
M>]59/O?C72C.6Q6E_I5:8 CI5F7^E5INE;0,I%:7^M5IJLR_UJM-71$SD59N
ME5YJL3=*KS=:WB9R(\ ]JCJ2HZUB2,?[U-7O]:<_WJ:O?ZU1$MP_C_"E'6D_
MC_"E'6@0Y.E2)TJ-.E2)TI2 EB_K75?LN'_C(75!_P!2;'_Z5FN5B_K75?LN
M?\G"ZH?^I-C_ /2LUP9E_N%3T_5'1A_]XAZGTG1117PY](%!.!FBD8$\9H _
M*+_@H?\  /4_VB/^"M?Q$\&>%]\?B33/V0;'7?!]U&VU[?5K#Q.UU:NI[?O(
M@I]0Q'>O5-9_:$TK_@I5X@^!'PZT55DT6T\+M\2?B78QN)$M[NT4P66GS#'!
M%_YLN#@YLQQ7U%'^QCX5B_;OO/V[SXNU!M7O/A?'X)DT$PI]E%LM^UYY^[[W
MF%FVX^[CWKF/V/O^"9WP5_8P\2_%'Q5\-]8U.YN/BAKTVHW8U!@PTR-P3]DM
M_P"["'>1P/5S4*_U=4WT3:_Q7E;Y---_X2G+_:/:+O%?]N\L4_N:=O4^"OV*
M_B]\3OA9_P $I/V&;7X=>.=2T6/Q#\4(]-UQ-/N3&+ZS>[OBT$F/O(2!D>U?
M6'Q?^,WQ2M?^"O\ :? 2W\>:@O@V]_9=UG6+KPW]H/V5]035(XDN2G3S!&Q7
M=UP<5H+_ ,$=/A-'_P $_P#P3^PA:_&#Q19_\*[OEU#P?X_T\Q0:I87R7$DZ
M7"@ QD@RE2I&&'!JU\!/^"3^C_![]H6']J3QO^U'X^^(7C:3X<WOA'6-8\72
MPN;V&XFBE$JI&JI!L,6!'&H4^8Q.36LFJE23EM>;]>:#2^Y_YF=./LX_)+TM
M.]_N/S7^+7[.&O\ Q;_8:_8AUS2_VD_B%X034/CQI?AZ.P\*ZM#!!:2SWVH,
M-4B#Q.5O8L;8Y"2H!.4-??UWK_Q?^!7_  4L_9[_ &5(?V@/&7B3PZWPEU^3
M7)O$FJ":?7+JW> 17=WL5$DF 8_,%'7@5T_C?_@D+\-?&7[%/@W]D&T^,_BC
M1[KX>^)H/$7@OQ[I:PIJ.F:I#-++#<JA!C;:96&U@01UKL_#G[ EKI7QU^%_
M[17C#XY>)/$_B;X:^";_ ,/M?:O#!OULW;(TEU.450LF4X5 % ..U$JD>67:
M\GZWA9?<RG[TKOLU_P"3W_%'PG\(M$_;\_:5_8F\=_MA_P##S#X@>&=4^&WC
M7QA_PAOAW28;?^S[J'3M5N]L6JF5'FOE(3RU4/$D<2HH4D%F]:^$WQPUWXX?
M\%"/V:?V@?%&C_9=2\0_LF^(-6O[-4(VRO>:6[@#L"<X'O7G'["W_!(WXB_'
M+]GOQ%9?$W]H3XR?#'1/$7Q6\6/XU^&D(^RVGB*R;6;DP/LN8_-MDEAV_/"5
M652&YSD_>MK^PW\-](_:1\"_M">'M7NK%? 'PWO?!ND^'(84^RM97$UM)O9C
M\VY?LRJ ."&.::?+'Y*WE>#3U\VU]UR9>]*7767_ *4K+Y),_(9O^"CG_!0O
MXX1W_P"UE\&O _[=>I^+%UV[;PCX5\&_!^QN?AI<6D-VT:6DQ$AN;@-&A62X
MP'5RV$^45^UOC'P-'^T)^S[?> /'UC=:4OB_PN]IJMNIVS6?VB JZ^SH6(^H
MKYC'_!'2\\+^.M0;X*_MY?%WP'\.M8U:XU'5/A=X;OK9;$S3R&280SO&9[9&
M=BVV-@ 2<8KZN^)GPSMOB9\+M4^&$OB?5])CU/3FM/[6TB],-Y;Y'$D<HY5Q
MC.:RDHRPO);Y==M=?-E:_6.9:+_@JWW(^&_@;\6_VE_^"8'C#X5_L7?MK^ O
M#?B[X:Z]X@@\(_"7XT^#X1#-97S0M]CLM6T^09AED5)$6YMV9"5^8+N)'S+_
M ,%#KGXP_M)_L%_MOIXS_:2\=6=C\,_B;*NCZ5INKJMM<V(M[7&GS*Z-FVW.
M7V*5.X YK[>^$7_!)+4]#^+WAOXH_M._MP?$[XU6_@?6%U;P+X;\:-:1V.D7
MRQR1QW++;Q*;F1%D.QI"=K?,.:ZJZ_X)9_!K7OAE\>OA)XR\6:OJ6C_'W6YM
M2\01_)$^GO)#'&%@91_"8U<%N<CTHG[T4WJ[?^W1:^=D]10]VI'ET2DF_2TK
MV\M5H?*O[8?Q,^.W_!-+]BGX4_ /X<?&W]H#XFZU\4_%B6MSXKTG2[7Q%XPL
M;)K+SI+;38F6"'<!'MC+9,>YF^8C%2?\$NOCY^W]J_Q&^)'P2M_AO^U)=^#U
M^&\FK>"?%W[6O@FWTS4[;Q&LQC^Q+<VQ,=S;R))'(H;#1F%QC:<GZ.?_ ()6
M6_B?]E32?V>/C'^UE\0O%_B+PSKBZMX2^*%Y);V^L:)<QH$@\CR4$85$&W:P
M.\%MV<UTG[.G[ OC_P"$6@>)K;XO_MS?%/XH:QXDT232EUKQ%?6]J=-@8D[K
M>&UC2-)@<?O<%OE^M:2E>=5O7FO;T:5OFF)1M3IQ6EK7];W;]&NA\[_\$E/B
M!\4O^%V7?@?]J7]LGXQR?%ZZT&:Z\:?!3XMZ/;PVD,XD13>Z'+%"J262G*CR
M9)5(D7=M(Y_1H=*^4_V7/^"8]]\#/CU'^T;\:?VN_B!\8O$VEZ3<:5X3N/&J
MVJ+H=C.R-)%&+>-/,9MB R/EL#WKZLQ@8%$FG&/IK^/Z"BK2EZA1114EA111
M0 4444 %>,?M$_\ ([6O_8+C_P#1DE>SUXQ^T3_R.UK_ -@N/_T9)7I95_OB
M]&<68?[L_D<%1117U1X 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4?A110!ZA^S6!YFL\?PV_P#[4KU3 ]*\K_9K_P!9K/\ NV__ +4K
MU2OD<R_WV?R_)'T&!_W6(8'I1@>E%%<)V!@>E&!Z444 &!Z48'I110 8'I1@
M>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8
M'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z4A QT
MI:#TH \>N@/,;C^(U2F5<'Y:O77^L;_>-49NAKZ&)Y95F QTJK,!NZ5:FZ56
MF^]73'X3*6Q4F V]*K3 9Z5:F^[5:;K6U,RD5)@,GBJLP&>E6YNIJK-UKIB9
MR*D@&5XJK,!GI5N3JM59NM;1,I;D+ 9Z5&X&.E2-UJ-^E;Q$-(&>E<;\8QCP
MG<8'_+(_R-=D>M8?C+01K^DO8Y^^N*HS/RV\#_L]>(OC#\7-0E:U9=/COV+O
MM.&P>E?H3\!?@!H'P^T.WMXM+C7RUQ\T:DGDC)..M:7PM^ _AKP)'ML].1?F
M+?=4DD]23CDUZ1%&L2;%7%=V.S&MCFD](JUE^K.' Y?2P=Y;R>[_ ,B2")80
ML:+@+Z5.GWJB'6I4^]7G,[S&^*'_ "2OQ9_V*>J?^D<M>X0_\>L?_7-?Y5X?
M\4/^25^+/^Q3U3_TCEKW"'_CUC_ZYK_*O.S#X8_UT.G"_P 1^GZD4_\ 6H).
MAJ>?^M02=#7!$[)%:7^M5Y?ZU8E_K5>7^M;HSD5Y?ZU7E_K5B7^M5Y?ZUM$S
MD5Y?ZU7E_K5B7^M5Y?ZUM$B6Q7E_K5>7^M6)?ZU7E_K6T3*16EZTVG2]:;6Q
M)&>M,?[U//6F/]ZK1,AK=OK2TC=OK2TR0HHHI2V <G2I$Z5&G2I$Z4?:*B2)
MTK!^)?\ R+4/_8<TO_TO@K>3I6#\2_\ D6H?^PYI?_I?!2C\1,_@9[M/]^JT
MWW:LS_?JM-]VOFXGL%>7^E5IQG@U9E_I5::MX]#/[)7FZ57E[U8FZ57E[UM$
MS*TO]:K2]:LR_P!:K2]:WB9E>2JTO]*LR56E_I71$S*TW2HSTJ2;I49Z5M$S
M(SUIKGM3CUIKU: :>M(O?ZTIZTB]_K3,Q1TI5ZT@Z4J]: 'U(.E1U(.E2^I0
MY?N&KWP"_P"1R\;?]A"Q_P#21:HK]PU>^ 7_ ".7C;_L(6/_ *2+7/B/]UG\
MOS15/^-'U_0]&EZU5FZ_A5J7K56;K^%>)$].6Q7E[U5D^]^-6I>]59/O?C72
MC.6Q6E_I5:;I5F7^E5INE;0,I%:7^M5IJLR_UJM-71$SD59NE5YNM6)NE5YN
MM;Q,Y$=1U)4=:Q)&/]ZFKW^M.?[U-7O]:HB6X?Q_A2CK2?Q_A2CK0(<G2I$Z
M5&G2I$Z4I#)8OZUU7[+A_P",A=4'_4FQ_P#I6:Y6+^M=3^RXP_X:&U0$_P#,
MFQ_^E9K@S+_<*GI^J-\/_O$/4^E**3<OK1N7UKX<^DNA:*3<OK1N7UH"Z%HI
M-R^M&Y?6@+H7'M1@'J*3<OK1N7UH"Z%HZ]12;E]:-R^M 70N,=!12;E]:-R^
MM 70M%)N7UHW+ZT!="T4FY?6C<OK0%T+12;E]:-R^M 70M%)N7UHW+ZT!="T
M4FY?6C<OK0%T+12;E]:-R^M 70M%%% !7C'[1/\ R.UK_P!@N/\ ]&25[/7C
M'[1/_([6O_8+C_\ 1DE>EE7^^+T9Q9A_NS^1P5%%%?5'@!17DOAK]M;X&>+/
MVN_$'[$.C:CJ3>//#'A^+6=6MWT]EMDM9!$5VS9PS8FC^7'?VJ1?VR_@BW[7
M#_L2KJ.H?\)U'X7;7VM_L#?9OL895SYV<;\N/EQTJ(U*<E%I_%>WG:][>EF7
M*G4BVFMK7\K['JU%?&\__!<O]B[_ (3'7_!VD^&OBAJO_"+ZW-I6O:IHOPXO
M;NQLYXI"DF^:(,JJ"I.3C@9KZ1_9_P#VCO@G^U+\.;?XK_ 3XA6'B30KF1HU
MO+&3/ER+]Z-U.&1QD95@#R#T(-*G5IUHW@[A4IU*3M-6.WHKYS\/_P#!4_\
M8^\3?MFS?L':5XRU!O'T-Q/;^6VF,+*2XAA\Z2!;C.TR*@/R^HQ7K'Q[_:'^
M#/[,/PYN_BQ\=?']CX=T&S(62^OI,;G/W411R[GLH!-'M:?LO:7]WOT&Z515
M/9M:]CM**^<_@!_P5$_9I_:*\?VOPW\*Z-X\T;4-28C1YO%G@6]TVWU+ )S!
M+*FQP5&1R,@BO3OVG?VE/A?^R+\$-;_:#^,EY>0>'/#\<3:A+86AGE'F2I$N
MU!RWS.M$JE.-/VC>G<(TZDJGLTM>QWU%87PR^(GAKXM_#W1?B=X.FFDTKQ!I
MD-_I[W$7EN894#IN7L<'I6S<3BWMWN&&0BEN/85I4_=WYM+&<?>:2ZDE%>$_
ML"?MW>!_^"@'PR\0_$WP+X+U30[;P]XPO/#UQ;:M)&SRS6Z1.95\LD;2)1C/
M/!K6_:G_ &L)_P!F76O >CV_P.\7>,O^$X\50Z*TWA73_.32 [*/M5R?X(AN
MR3QT//%2Y12BW]JUOGM]]RN27/*/6-[_ "W/8**\*\ _MW>"?B!^W#XR_8:L
M/!6J0:UX,\/VVJWFM2RQFUN$FQA$4'>&&><C%>B_'WXM-\"_@WXA^+J>"-8\
M2'0--DO/[#T&W,UY>[1_JXD'WF/85/M:?L?:W]WOZ?\ #%>SG[3V=M=-/6UO
MS.PHKQG3/VY?@GI/P?\ A_\ %CXWWMQ\.6^(]S;V6@:#XLMWBO#?3?<M&55.
MV3ZX'TKV8$'I6G?RT,PHHS1D>M !1110!ZA^S7_K-9_W;?\ ]J5ZI7E?[-?^
MLUG_ ';?_P!J5ZI7R.9?[[/Y?DCZ# _[K$****X3L"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/2B@]* /
M'[K_ %C?[QJC-T-7KK_6-_O&J,W0U]#$\LJS=*K3?>JS-TJM-]ZNF/PF4MBK
M-]VJTW6K,WW:K3=:VIF4BK-U-59NM6IOO&JLW6NF)G(JR=5JK-UJU)U6JLW6
MMHF4MR%NM1OTJ1NM1OTK>(AIZTU0"N"*<3DYI$^[5&8H4#H**** )!UJ5/O5
M$.M2I]ZH8&-\4/\ DE?BS_L4]4_](Y:]PA_X]8_^N:_RKP_XH?\ )*_%G_8I
MZI_Z1RU[A#_QZQ_]<U_E7G9A\,?ZZ'5A?XC]/U(I_P"M02=#4\_]:@DZ&N")
MV2*TO]:KR_UJQ+_6J\O]:W1G(KR_UJO+_6K$O]:KR_UK:)G(KR_UJO+_ %JQ
M+_6J\O\ 6MHD2V*\O]:KR_UJQ+_6J\O]:VB92*TO6FTZ7K3:V)(SUIC_ 'J>
M>M,?[U6B9#6[?6EI&[?6EIDA1112EL Y.E2)TJ-.E2)TH^T5$D3I6#\2_P#D
M6H?^PYI?_I?!6\G2L'XE_P#(M0_]AS2__2^"E'XB9_ SW:?[]5IONU9G^_5:
M;[M?-Q/8*\O]*K359E_I5:<XYK>/0S^R5YNE5Y>]6)NE5Y>];1,RM+_6JTO6
MK,O]:K2]:WB9E>2JTO\ 2K,E5I?Z5T1,RM-TJ,]*DFZ5&>E;1,R,]::YYQ3C
MUIKU: :>M(O?ZTIZTB]_K3,Q1TI5ZT@Z4J]: 'U(.E1U(.E2^I0Y?N&KWP"_
MY'+QM_V$+'_TD6J*_<-7O@%_R.7C;_L(6/\ Z2+7/B/]UG\OS15/^-'U_0]&
MEZU5FZ_A5J7K56;K^%>)$].6Q7E[U5D^]^-6I>]59/O?C72C.6Q6E_I5:;I5
MF7^E5INE;0,I%:7^M5IJLR_UJM-71$SD59NE5YNM6)NE5YNM;Q,Y$=1U)4=:
MQ)&/]ZFKW^M.?[U-7O\ 6J(EN'\?X4HZTG\?X4HZT"')TJ1.E1ITJ1.E*6PR
M2+@<#O5[X*_#CPA\1OCY?6GB_3IKB.W\(H\*Q7TT&&-T0>8G4G\<U1CKJOV6
MQ_QD-JA_ZDV/_P!*S7!F$I1P%1KM^J-:$8RKP3[GJ/\ PRY\%?\ H6;S_P '
MU]_\>H_X9<^"O_0LWG_@^OO_ (]7H=%?%^VK?S/[_P#@GT/L*/\ *CSS_AEW
MX*_]"S>?^#Z^_P#CU'_#+GP5_P"A9O/_  ?7W_QZO0\C&<T4>VK?S/[_ /@A
M["C_ "H\\_X9<^"O_0LWG_@^OO\ X]1_PRY\%?\ H6;S_P 'U]_\>KT/-&:7
MMJW\S^__ ((>PH_RH\\_X9<^"O\ T+-Y_P"#Z^_^/4?\,N?!7_H6;S_P?7W_
M ,>KT//.,4$XI^VK?S/[_P#@A["C_*CSS_AEWX*_]"S>?^#Z^_\ CU'_  RY
M\%O^A9O/_!]??_'J]#) &:0,"<"CVU;^9_?_ ,$/84?Y4>>_\,N?!7_H6;S_
M ,'U]_\ 'J/^&7/@K_T+-Y_X/K[_ ./5Z'F@G'6E[:M_,_O_ ."'L*/\J///
M^&7/@K_T+-Y_X/K[_P"/4?\ #+OP5_Z%F\_\'U]_\>KT,'/2@D#K1[:M_,_O
M_P""'L*/\J///^&7/@K_ -"S>?\ @^OO_CU'_#+GP6_Z%F\_\'U]_P#'J]#H
M!SVI^VK?S/[_ /@A["C_ "H\\_X9=^"O_0LWG_@^OO\ X]1_PRY\%?\ H6;S
M_P 'U]_\>KT.C-+VU;^9_?\ \$/84?Y4>>?\,N?!7_H6;S_P?7W_ ,>H_P"&
M7/@K_P!"S>?^#Z^_^/5Z'FBCVU;^9_?_ ,$/84?Y4>>?\,N?!7_H6;S_ ,'U
M]_\ 'J/^&7/@M_T+-Y_X/K[_ ./5Z'13]M6_F?W_ /!#V%'^5'GG_#+OP5_Z
M%F\_\'U]_P#'J!^R[\%?^A9O/_!]??\ QZO0Z#R,4O;5OYG]_P#P0]A1_E1'
M9VD%A:16-LI6.&-4C4L3A0,#D\G\:*DHJ#4*\8_:)_Y':U_[!<?_ *,DKV>O
M&/VB?^1VM?\ L%Q_^C)*]+*O]\7HSBS#_=G\C@J#THH/(Q7U1X!^2/B/XD_M
M'_#'_@XC^,6N?LR_LT6_Q2UN;X7Z9#=Z%=>-[?05@MS;Z>3/Y\\4BN0P5=@&
M3OSGBM;]F/X@_'_XD_\ !P9=>(?VD/V>+?X9^(/^%&W$8\.6WC&#7%\D2P;9
M?M$$<:_-_=VY'K7V!X _X)]ZAX(_X*=^./\ @H:WQ0AN+;QCX+MM"'A7^R2K
MVK1+;+YWVCS"&!%O]W8,;NO%6(_V"+]/^"FLO_!0C_A9D7V>3X>MX:_X1;^R
MSO#%XV\_S_,QC"8V;,\]:\W#8>M2CA^9WY5.Z?2ZE:WK=?>>EB,11J5*O+U4
M;/O:U_NL?/'_  0'AAFE_:6BFB5U;XZZJ&5ER"//FX->>_L=?%OPK^QU^WK^
MW9=>$/)M?ASX1A@U]K&W<):V^IF!7DC11D*6E>93C^[@C@8]6^#O_!*+]NO]
MFSQCX_N/V=O^"ANA^'/#OQ"\:7>O:GI\GPNCNKR#SY6<I'<27/RNJN0&VXSS
MM[5L^+/^")OA>']C/Q/^RY\+?C;?V.M?$/Q+!J_Q*^(&OV/VV_\ $!$OF31L
M%>,('RP&"0NXG!)-3[/$2HTW&/*XT^3S;:2^Y:LERHJM/FE=2J<WHD[_ 'O8
M_,[7_C5^SWX._8_^%'[;/AG]H3P?=?'G0?CC-XW\2>&[?7$.I36=_.%EMWC!
MW$I'';!ACA!)QUK[:_X*<^.?#O[1W[<?[%_AW4+^.\^&OBS6EUU8I&#6U[<;
M5DA5UZ-T08/]XBOL3XF?\$X_V8OB#^S+JW[.-O\ "7PMIZZEX3DT6'7+?PW;
M"ZMV,'EK<!P@;>#AL[@<CK7C0_X(QZ5XS_8<\ _LL_&'XZWUYXL^&-]]K\$_
M$KP]I_V.[TYUDWQA4=Y,@< @MS@8P16OL:E.7+:\8SA-);-)<K2^24M>MQ>V
MIU+2O:4HSB[[J^J>G9MK0^VQI]CB+%G#^X&(?W8_=\=O3\*^._\ @OYS_P $
MF_BH#_SQTW_TXVU=O^SQ^S3^W[X/\;:;K'[2?[?EOXTT32<>3HNA?#^WTDWF
M%V_Z3-YDC2#H>-N3UKJO^"A'[)5U^W%^R+XM_9@LO&\?AV7Q-%;K'K,MB;E;
M<Q7$<V3$'3=GR\?>'6KQU.IB,%.,5J^GS7R(P,Z>'QL)2>B:U/@SX\?%S]I3
MPEI_["/PD_9\^/>K>!1XZT2/3-6N+)?.A9)+.&/S9+=CY<[QAV:,2 JKA20<
M$'T7]G[QU\>/V7/^"N&M?L)^)OVH/'7Q,\&^)OAJWB6SE^(FH0WE[87NZ3>L
M<L44:K%^[.(U544-@#C->M>.?^"7.I>,?%G[,OB5/C)!;K^SYY7VF$Z*6_MO
M9%&GRGS1Y&3'GD/P<>]=-KW_  3[OM:_X*76/_!0,?$^*.WL_A^_AL^%_P"R
MR79B9#Y_G^9@#]Y]W9VZU52G4E6E+O*I?_"X^[^(H5*:IV?2,+?XE+7\#\S_
M /@G=\$?CQXK_P""=GQX^-WPY_;/\??#V/P/\1M>U+0-!\$RP6D-UJ$-K!(\
ME_*8VEN867RT$"M&J[&8[BW'L7QR_;Q_:6\?_LB?L2_&;3OBMK.@ZSX]^*&E
M6?C.30;Y[1=6C\^..2.98RH>-QG<A&T[CQ7U-^R9_P $M-0_9F_8R^*G[)US
M\98=8D^)&O:QJ$>N)HIA6P%[;Q0A#%YK>9L\O).Y=V>@KC]2_P"",FL:A^S7
M^SK\ C\?;59?@5XTM==N-4_X1UBNL+%,LAA6/S_W!.W 8L^,]#6<:56$H17P
MKV/7K'X_PW_ UJ5J-2<Y/=NI;3HT^7\3PVX^"'Q+^/W_  7K^-'@7P1^T3XF
M^&]C)\/]-;7M6\&&"/59X=B;(H+B6.06_P V"7"[L# (ZU5^#/[9'[5_A_\
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MK=OK2TC=OK2TR0HHHI2V <G2I$Z5&G2I$Z4?:*B2)TK!^)?_ "+4/_8<TO\
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MLN?\G"ZI_P!B;'_Z5FN6B_K75?LN?\G"ZI_V)L?_ *5FN#,O]PJ>GZHZ,/\
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M<2<22E95'I_=_P" ?='_  _J^,G_ $1OP_\ ^!DO^%'_  _J^,G_ $1OP_\
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M/</X_P *4=:3^/\ "E'6@0Y.E2)TJ-.E2)TI2 EB_K74_LN?\G#:I_V)L?\
MZ5FN6B_K75?LN?\ )PNJ?]B;'_Z5FN#,O]PJ>GZHZ,/_ +Q#U/I.@Y["BBOA
MSZ0;LSUK@;W]EKX"ZCXE\<>,+WX>V\FI?$C2(=+\;77VJ;.J6<4<D4<3#?A
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M?@C^WO\ $'P7KFJ?"_P_X<OM&\3:QH^CRWP\/32X*7,L<*M($.<;@I^[@<D
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M?\(3HX;K_9=OG/\ US6M6@#' HKLE+FDWW..,>6*CV"BBBI*"LOQ7_R!Y_\
MKF?Y5J5E^*_^0//_ -<S_*@#\E/VG9DC^/'B92?^8M-_Z&:^HOVT[:Y\4?\
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M>_8!\4:IHOPG^(EOK:>)(_%&F+#KD,9B<K%&\RO$<J5^<=17UCXA_9D^"O\
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MF@ZGJ<,S0Q++)LCMHGBAEW3C]Y)L)R.<*<>1V/[,W_!2KQ9^PQI'_!)?Q/\
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MD#RY#[ 5".JH QYX%?6/Q&_8U_:5U[]I']BGQQIGPPN)-+^&'A.*T\=77VR
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MI2 EB_K74_LN?\G"ZI_V)L?_ *5FN6B_K75?LN?\G"ZI_P!B;'_Z5FN#,O\
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M?M$_\CM:_P#8+C_]&25Z65?[XO1G%F'^[/Y'!4445]4> %!S110!\J?MN_\
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M?\$]?%?B7]K'_@IY\?/VJ[?Q?<W7@OPH;?P9X2AM[QVLYVC&Z:55SL8[MPW
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M%][#_4?#?\_7]R/PL_X4;\6NW@G4/_ =O\*#\$/BVO\ S).H?^ [?X5^Z?\
MPQEX=_YY+_W[7_XJC_AC+P[_ ,\E_P"_:_\ Q5'_ !$C%?\ /A?>P_U'P_\
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M&,O#O_/)?^_:_P#Q5+_B)&+_ .?"^]A_J/AO^?K^Y'X6?\*.^+8Z>"-0_P#
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M_P"*JM-^R5H&?]6O_? _^*K5<;XS_GROO9'^J.'_ .?K^Y'Y*?\ "IOB*O\
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M#BD3[M49BT444 2#K4J?>J(=:E3[U0P,;XH?\DK\6?\ 8IZI_P"D<M>X0_\
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M:C?I4C=:C?I6T1#3UI$^[2GK2)]VJ,Q:*** )!UJ5/O5$.M2I]ZH8&-\4/\
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MYE8;BAP.@KZ1TG_@G7I?@K]I3X)_%KX>^+(;'PU\'?AY?^%K709K5GFNTG$
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M8OZUU/[+G_)PNJ?]B;'_ .E9K@S+_<*GI^J.C#_[Q#U/I2BBBOASZ0*,T44
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MM?\ L%Q_^C)*]+*O]\7HSBS#_=G\C@J***^J/ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H[FX2VB,LA^45)69XJ9AH\Y!_@/\ *@#\
M[O!GQCT[]D#_ (++?%C]OR'1Y-;N/$O@G_A"V\.M<"%(5BDTW_21+M8DG^SA
M\N/^6O7CGZD_X?\ K?\ 1NR_^% ?_C-?!?[2MPQ^.OB<MSG6)S_X^:X8W1'!
MK]&PO!7#N*PT*U2E>4DF_>>[1\-B.*L\H8B5.%31-I:+8_2W_A_Z3_S;NO\
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M^G_X$P_UNS[_ )^+[D?I9_P_]/\ T;LO_A0'_P",T?\ #_UO^C=E_P#"@/\
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MGW:Q-!:*** )!UJ5/O5$.M2I]ZH8&-\4/^25^+/^Q3U3_P!(Y:]PA_X]8_\
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M+C_]&25Z65?[XO1G%F'^[/Y'!4445]4> %%%% !1110 4444 %%%% !1110
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MXHU W-[=8EO/GD? !8^P Z"OT_ZG(-?E#_P3;^*_QH^%_P#P48^-/Q5\>_\
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M+\8? (Z%I_C*72Y5T^6ZE6SC\N.? 1I%VN=H.1M-=,95HSERZZU4O^W;N/\
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M'WGH?[+'Q?\ V@?BOX>OI/VBOV<?^%=ZQ9R1^5;VOB:'5[.]B<,0\-S$JAL
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M;G:,X'J?C/\ 8@MO%W[<MK^VJWQ(DMY;7X1WW@;_ (1S^R@RLMS>)<_:_/\
M-&"NW;Y>SG.=PZ5[E;ZC87<LMK;7T4DD#8FCCD!:,GD CJ./6B+4;&YDFCM[
MV&1H&VS*D@/EG&<-Z''/-/\ X/XKE?X:!]IOO_G?\]3XQOO^"-VBG]D'P#\
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M_/[\/^"?A5_P@GCCK_PC=U_W[H_X07QL.OAJZ_[]U^ZO_#$VD_\ /+_QY_\
M&C_AB;2/^>7_ (\_^-'_ !$JI_T#K_P+_@!_J-3_ .?WX?\ !/PH/@OQD/\
MF 7 _P" T?\ "&>,?^@%<?\ ?-?L)=_L=Z6)6PG\1_B;U^M4Y?V/=*P?E_\
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M:]6@&FD7O]:4]:1>_P!:9F*.E*O6D'2E7K0 ^I!TS4=2#I4]RAR_<J]\ O\
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MIK^U]X>\2?LR_&_QX^L>.M"GCNOA3\,;G7H+8+HT VSO"0(G.<A3U )KK_\
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ME1ITJ1.E*0R6+^M=5^RX?^,A=4'_ %)L?_I6:Y6+^M=5^RY_R<+JG_8FQ_\
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M-JD'2O1_^&6O'?\ T&M)_P"_TO\ \;IP_9=\= 8_MG2?^_TG_P ;I?VE@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_003.jpg
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M EP# 2(  A$! Q$!_\0
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M_P"Q\1[+7_H>G].__#TO]D'_ *&KQ?\ ^$#XD_\ D2C_ (>E_L@_]#5XO_\
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MC'#NM2]K*"J0D_Z)/^'I?[(/_0U>+_\ P@?$G_R)1_P]+_9!_P"AJ\7_ /A
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M^&/_ !,LH_\ F,_!2FNN]'0':65E#8SM)! ;!X.#S@\'&#7[V_\ #K7]FO\
MZ*;\8?S\.?\ S/4?\.M?V:_^BF_&'\_#G_S/4?\ $U/@PM?[>S33_JG\?_\
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M5*?/&53$?@I17[U_\.M?V:_^BF_&'\_#G_S/4?\ #K7]FO\ Z*;\8?S\.?\
MS/5ZW_$U/@Q_T/LT_P#$?Q__ ,T'A_\ $HOC9_T*^&/_ !,LH_\ F,_&K4_^
M2$^#/^RO>/O_ %#O!5>4U_0G<_\ !-3]GF?P3H_A1_B+\6%TO3/%>N>(K>Z4
M^'_MLFH:OI.CZ;=6\Q.@F+[+%;Z9;20!8UD$LDV^1EV*O+_\.M?V:_\ HIOQ
MA_/PY_\ ,]7%@/I0^#F'ABHU<]S-.MF>98NG;(,>[T,7B*56C)VQ"LY0A)N.
M\6K-NYZ69_1-\9\34P4J.6<--4<GRC!U.;B_*H6KX3"5Z5=)/"/F@ISBHS7N
MS5VDDFC\%**_>O\ X=:_LU_]%-^,/Y^'/_F>H_X=:_LU_P#13?C#^?AS_P"9
MZNW_ (FI\&/^A]FG_B/X_P#^:#S?^)1?&S_H5\,?^)EE'_S&?C)\$/$.C^$O
MC1\)O%7B*]73M \-?$7PCKNMZ@T4TZV.E:9K-K=WUVT%M'+<3""WB>0QP122
MOMVHC,0*]6^%GCSP1;ZQ^TQX3\1^(X_".D?'7POXF\-^'_B%+IFJ:C8Z!<_\
M+!@\9:8-;M-*CEUF/PWXGM+)=,U62RL[FYM?M%O)/:R0I/%7ZB_\.M?V:_\
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M(^+)-/U?X=>-O$%]=_&?XS^(=7\+:I#>:%>6VBPZ1'\/?#[>'/%-T-43X/\
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MW=I;0?2M<DH\LI1;3<6TVG=-K>SLKKSL<[7*VKIV=KK5?+^N@4444A!1110
M4444 %:)_P"00G_83?\ ])%K.K1/_((3_L)O_P"DBU=/_EY_UZJ?^XRH?;_P
M2_\ ;3XL\+_L;^'/"W[</Q0_;G@^+?Q>U/Q1\4OA#X?^#]]\%]3URUE^"7AK
M3_#Z>'8XO%?AGP^L(O+7Q9?#PW U]>2W#PL^HZH\4:-=.3Z3^U!\)_$?QS^
M7Q"^%/A34=,TC7/%+^!IK74];-\NCV<?ACXD^#O&%ZU^^G6]U=H+C3_#]W9V
MC1V[J;^XM4E,<+22)YWX9UO]MN7]MOXG:!XL\&?"*U_8!M/A)X>O/A-X[TR_
MC?XUZG\:9%T+_A)-(\2Z<->GEB\*1/+XD6RE;PY8HB6>F.FHW)N75?/_ -NG
MPE\<O&'B']CB#]GSQ=XB\%^/_#OQ^\:>-K/4;&35%\!ZY=>$?@-\1M7T/P#\
M;(;%)+*X^$_Q&UB*#P/KAU8*NFWNNZ?KFBR1^(=*TQAI'G=6ES5(74*;C*ZE
M&$8PE*$9J*C9Q2Y91=Y)R7-*1I%2=2G>4;\L+25I**47RII<NJV:;OKJV>2_
MM*?L$?$7XL>*_CSXI\-S?"MY_C3\<)O'ETWB"2[T/Q;_ ,(%_P ,O:=\%O#.
ME2^-)_ WC9](G\+>/(M0\9'2=)T6>2_T*_D?PSXH\(>*I&U,^3Z+_P $POB%
M:^ ]-TSQ1JGPR\5^-+W5O&;?$C7=/\6^-O!_B+Q]X3UG]FKX.?"?0?##?$^V
M\*ZQXGM(]-^)/PM_X3A(-8TG7O#L<8TJYU/0M<FNM:TZ;PCX=?M??MGZ9I'P
MI@\.> ?BIX)G\7?%[6M8\0?"SXO_  TUW7/%,VC_ !<_:N^,OAGQ)H46J2^%
M?$^K:E;?![0+7P^L>L0>+/AEX+\&:##X>UDR^-M \5Z9:67I]_\ MI_M8ZKX
M9L/$>FZWJVDZ;X3\!?LX7?C_ $NU^ ^JZ+XZ\8_%/7?A)XZUKXT_#WX77?BS
MX8>)/!-]XRTKXE:)HFEW?@/7HO#EC?S3'PAX5^(/AG59#-<=?+BE:*J4;7=G
M>-]++5IRT?*N5)M-K1]5T6K])TM6W?1=>NKT;5DDWT\BYKG_  32_:0U^;2M
M;UGXA?"741I>DZ7HC?#72H=&\*>%M6TJ"W_:"TO3$UV>#X+ZQ\/Y?$/@&Q^+
MNA:A:>(=!^#V@Q>*]:M_%FIZ3I?@'5I=%U%='Q/_ ,$K_'NI^!=;T*'Q-\)_
M$7BW6O%7Q4U7Q!XK\6Q>(+_5/B#X;U[P+\ M'^'OAOQIKFIZ'K6K:A!IWBSX
M-76J:FNI_P!KVVD+J&GZWIL-_K+7Z54?]L3]MP7'Q*GU_P *:OX,M_\ A)[C
M0=8T6?X?6]SJ/[.EK=_'/2O!_@;5-3U!?ASJNDZ1H?B'X4W-UX@\5>)?%>H_
M')K&^DA\6>&O#L^AVMUI4/Z0_L5?$KXG_%[]F#X7?$#XT6)T_P"*&K)XRT[Q
M9&?#&K>#&O)O"_C_ ,4^%](UIO#&MZ1X?U+2CK_A_1])UO9+H.B0W?V_^T+3
M2--M;N&R@FK4Q5**E*=%QYK6@HMWDE/5*SLK*^N^EVFFIG4KTU=RIV;M:*3:
MO:7RV7IW/E+]N3]F3XR_$#Q_>?&_X*30Z3\4[[P?\"_A)\)FT&RU+4KCP'J=
MQXY^*FC?&[5_%M[!#IVF:/\ "]O@A\7?$MK!KCW4,L7B30M$?^RUN%TRWE\^
MU+_@E<D!\9V_A"/X.:=+>6?[66F> O$.J:?JTVNZ(?BU?? A?@/K&IZL=%GO
M5U3X8:;\*-:DN+ZWDGN/#.HZQ!=>#V,M]JTP_9*BN>.)JQC&,>5*.E[:R5[I
M-WV6NG7F;>KUQ5>:2245;=VU:O>SUM9;:(_"[X#?\$\?B7XFTWX$>(OBQ\._
MA%\.M&^'_P 3[7Q!\0?AE?Q:GKFJ_'+2M"_:#^*GQ'7QS\7M%O-!.BS>.(-*
MU[28O!NEZE?>*;>>T\1>(+J]\0:=IDFF:'!=L/\ @F'\=U^'@^'5S\2?ACIN
MNSKI&JQ?'W2[WQA-\4?"^D^'O@IXA^$%K^SAH-M)HMK.WP/UF;4+#7+^ZA\2
MZ?#:Z7>:_IX\$WVNKI>MI^XE%4\97;;O%=ER)I;;7;?17O>_5-))4\35?\J7
M;EVT2ZN^R/R1\??L>^,_'7Q8^!'AJR^&OP_^$'PV\0>!_'4'[5/@WX5V&H:I
M\$-0\/\ P^UG4/&W[..BV.LWF@^#;+5?&3_&#Q#J.M>*/#UMX6@M[WPI<ZV\
MT2VT$$][\X_$?_@G#\?=#_9H\8>$=&\/_"'Q/XKT?X<:7>Z;?^"+OQ%<?$?Q
M.WA3]EFR_9Y'[*V@VP\.>&;8?!3QAXCLF^)%S<IKFFPP#5M2LI?!5QXIC7Q5
M+^_E%)8NK'EMR6C9V:;NTV[MN7->SY=W[JBM;*R6(FK64;:75MVKZWO=.SMI
MV6Y^+'B+_@F]\9O$_CD^/+3Q%\-/AMH7B?5=2F_X49\/]?O-/^'G[/[7FM?"
M+4AXU^$^KW/PLN=2N_%NM1_#2]U3Q1%X/L/@_JQ\1:Q:+IOC%+(:])J3)?\
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MP73-8U#X>ZSX1B\+? NY^#WC^6'7=,\&^*]!TSQ9XG;5]=GFEU/P=XRT;7]
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M.!8OJ%S!XFN%\1VKPK!XSTO3M$T#7Y)-.T3219?PE_V3I?\ T#K'_P !8/\
MXBC^R=+_ .@=8_\ @+!_\154_H2\%TIN<.+<^4W*4Y/ZNY<TIVYW-2S:2GSN
M,7-34HSE"$IPG.$9)Q\&LFB^:.9XU.[;?+)W<K<S=\4^;FLG).ZDXQ;3<4U_
M<L__  31\;Z[JG@F;Q[_ ,%5OV>_%.A>"OB'X5^)5GHVG^'/!'A2[_MWP=K&
MJ:WH,6FZWIOCNXGT:QT^ZUB_M+"R@M+BQL=*D@TV"T\BRL_(\2^('_!$_1_B
M9XF\5>+O%/\ P4K_ &8[G6_&7BOQ7XQUV^A\->'X+V]U3QAJDNJZE%<7J?%8
M3W-C:RRM#I5K*?+TZW+QVRQK(RU_&M_9.E_] ZQ_\!8/_B*/[)TO_H'6/_@+
M!_\ $5G5^@_P-7CR5^*<[K1<E-JKAI5&Y*G[*+;GG#;Y:;<(ZKEC*26DFB9^
M"^25%:>8XR:;3?/&<KM1Y%>^+>T;I=DVENT?VPW_ /P2:\1:G-XYO;S_ (*C
M?LLR:Q\1;)=+\4>)8_AWX!MO%<FDGPMI_@F\T?1_$MO\1HM6T#2=9\)Z79:%
MKNG:9<0VVJ6:W'G(LU]?2W&+KG_!'S5/$=W\4+[6?^"IO[-]U=?&:'PW;?$>
M5/"GA.V_MZS\(ZAIFJ>';"!;?XG1IHNGZ9>:-I31V&CBTM98=/M;6:)[:)8J
M_BX_LG2_^@=8_P#@+!_\11_9.E_] ZQ_\!8/_B*4OH/<#25I<4YY)7DVGAYV
M;FJBFW_PL*[FJM53;O*2J34I-2LD_!?)'H\QQC6KUC/>7-S/_>UK+GFF]VI2
M3;3L?U]?\.&?!O\ TDL_9Q_\$^B?_/5H_P"'#/@W_I)9^SC_ ."?1/\ YZM?
MR"_V3I?_ $#K'_P%@_\ B*/[)TO_ *!UC_X"P?\ Q%8?\2*^'O\ T4.;?^$?
M_P"&"/\ B"7#_P#T&XG_ ,%R_P#FH_LC\+?\&\+^.+B[M/!7[?GP:\875A"E
MQ?6WA;P/%X@N+."1_+CGNX=)^)5W);PR2?NTDF5$=_E5BW%?J?\ L(?\$SO$
MO_!.W1O'-EKWQ<T;XKR?&'XJ?".ZLGTKPE=>$5T(>"]"\?V\\=Q]MU[6A?'4
M/[<1XF1K46_V9E83&5=O^>=\,/B+\0?@EXOTWX@?!KQQXK^%/CG1Y4FTWQ9\
M/];O?"^MVS(P81O=:9+"+RU<C$UC?QW5C<*2D]M(A*U_=;_P1\_;Q_:'_;L_
M93U_6OVD-:\/^*_%WPB_:6\(_#S2O%^DZ!;>'=5\2:)-\/5UZ.\\4V>G.FC7
M&MQ7-_-#)?Z78:9%=PK')<6ANO-FE^$XT^BAD_AS0I<39-F$<=@:5?#Y?7JX
MB>+PV98.IF\IY<JE/"3Q&+P&,I2]I*.E:E5HW4ITYJTEXV;>%V"X>C#,<'65
M:C&<*$ISE6IXBE+%\V'YHTI5*M"K%\S7Q1E'1N+W7[C_ -GW?_/-/^_]O_\
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M 4 8 %*L.J((PDLB"'=Y06]C41;\A_+ G 3<"0VW&[)SG->2S>)O#5OXKL_
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M[_V__P =H_L^[_YYI_W_ +?_ ..UQ.!Z#\A1@>@_(4?\0\P7_0SQG_A/A?\
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M_A/A?_DP_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
MCM<3@>@_(48'H/R%'_$/,%_T,\9_X3X7_P"2#_5^A_T$5O\ P"F=M_9]W_SS
M3_O_ &__ ,=H_L^[_P">:?\ ?^W_ /CM<3@>@_(48'H/R%'_ !#S!?\ 0SQG
M_A/A?_D@_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
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MC ]!^0H_XAY@O^AGC/\ PGPO_P D'^K]#_H(K?\ @%,[;^S[O_GFG_?^W_\
MCM']GW?_ #S3_O\ V_\ \=KB<#T'Y"C ]!^0H_XAY@O^AGC/_"?"_P#R0?ZO
MT/\ H(K?^ 4SMO[/N_\ GFG_ '_M_P#X[1_9]W_SS3_O_;__ !VN)P/0?D*,
M#T'Y"C_B'F"_Z&>,_P#"?"__ "0?ZOT/^@BM_P" 4SMO[/N_^>:?]_[?_P".
MURGCNQND\$>+F9$"KX?U$DB: G BR>!(2?H 2>PJI@>@_(5S?C(#_A$O$O _
MY M]V'_/(TGX?X.DG5698N3I)U5%T,,E)TDZJBVI72DZ:3:U2;:U2#^P:,/?
M6(JMPO-)PIV;@G))^O+;YGW(O0?0?RI:1>@^@_E2UQB"FO\ <;_=;^1IU-?[
MC?[K?R- '^/MXV_Y'KQ__P!E!\>_^ICK=<U72^-O^1Z\?_\ 90?'O_J8ZW7-
M5_K+2_A4?^O-#_TQ0/Z>I_PZ?_7NG_Z;IA4<LJ0Q232'$<4;RN<9PD:EV.!R
M<*"<=ZDIKHLB-&ZAD=61U(R&5@592.X()!'H:M6NK[75[;VOK;SM>Q1]V?%3
M]COP%\%O!=O8?$;]IWPSX?\ VG;[X/\ PQ^-6E_LZS?#GQ1<:3K>C_%Y-,U3
MP5\/-&^,-I?7&BW'Q<NO!^M:7XNO=!NO#]EX8LK*>>RE\6"YLKATZJ^_X)3?
MMMZ5J<.GZQX'^&FBV4GPRUSXP3>+]9^._P *-,^'>F^ /#'B?1/!OB;5=7^(
M%UXDC\+:==^'O$GB/1M/U739]1\^+[:D]NUS"KN.*G_;^^,=_P"!M(\+:UX"
M_9[\3^--$\%?#[X96GQ\\6_!_2O%'QTF^&7PL\0:;X@\"^!;WQ-K=_>>'+C3
M]$;1]+T(:Z/"4?C&[\+6-OH%UXCDLTKZ_E_X+1_%'QOI7Q@MOCU\"O@5\28?
M&7P7^(?PS\%>%;;PEJ]I\-K#4OBA\3O 7Q)\877Q(\/ZOXUU#5O$GA&>\\%.
M^CZ%X9UGP_>>&M2OX#H%SI^E:?9V-K^?8FIXBX6G2^J8?*\?-UJ_UV>)Q&7S
MG:=?#4L/+*,/1I9;&EA(4JM6O[#-L3BL535"I'$XF:Y(UO J2X@I1C[*GAJ\
MN>I[9U*E"3LYPC3>&IPCA^2E&,I3<,14J5(J$O:5)))3^6]5_P""7?[>&B>$
M_BQXUU+X!:M#HOP7U?Q#HWC.*'7_  Y>:UJ$GA*RT;4_$VJ^ -%L]1GO?B'X
M;T72_$.BZI>>(/"ZWNG-8:A'<6LESY5PD.E;_P#!,_\ :)TK4O&FB?$0>"_!
MFM^$OA;XM^(=QIVD_$7X7^-9/#NK>#=8\$:/K?@KXQ+I7CJWN/@UJ6CMX]T.
MZ\1/XCM;J_TBWD=H](OQ!>&U]5^(O_!1C_@H;XB\#_$CP-\0_",5K9^/QXZ^
M+6E>(+OX4^+/#FM?"+PAJ#^%?#?C2]^%9M=5L/#>B?#_ $(^%?#GAU;SQ5H?
MBH>#KP26MEJ>G:IJUQ]H\G\:?\%#/CYXWM_BGX^E^$GP!\,ZE\;?"'C'X-_&
M[XL^"_@M-H7B/XI^(/B'%X5\0^(=:\:^,?[9NVN?B/<V_@JPUW3=&LWT_P ,
MZ;#=:[K%CX.C_M&:Y2L/7\0Z\&JZX2@IU8PC6RW%>W4%*.6N+<L37J*?.X9R
MH0I0>(J5:4*/(L%R8RF4ZN?5%:?]F).:2GAZO/RIK#M7=2<KWMB[**YY2BH6
M5+EJKL_B_P#\$E?VJ?AMX[_:0\+^$!\/OC!X:_9?FE;X@>,?"GQ \&V-_=Z9
MI?@_1?&GBK5-&\ WFOS^*I1X2TK6/,UO3YH([^U6!%>,7DS6</5_$?\ X)"?
M';X;_&+Q5X$F\1Z+XT^&/AZP^([P_%_X?W'@_P 2W=OKWP[^!=Q\>I/#'C[X
M<0^.X-;^%NK:]X5L[VXTBR\7:C;:G?Z+9SZYI6FZF_E:9)-J?_!8#]L'Q+X5
M^-5_#\-?@-;Z'\6+WQ1I_P 5/&7ASX4>*K.-O$GQF^'UE\._%,]]K%GXU?1_
M^$G\=Z!X6M+_ $^/7;?4I-/U;2+NY\(6FDVDFH6<V'XO_P""LO[6NM2W'B5O
M 7P+\"Q_%%/'^M>,-5\)_"75?#UO\;]7\3?"#5OV:KSQEXKU"[\37G_"1:QX
M#\!:AK'A[PU/HEQIVG:-X@FN=0UK3]3U%W5^&B_%5^QA7?#*<*$<+5E#$895
M*N(^J9?.OB:D:<)>SQ,<13Q]3#4<-25-4,536+PJH1AB*>,7Q,^2,GEVD/9S
M:J4^:4_8T'.HU%/EJ*I&M*G"$5%0J156GR)3CYM-_P $KOVZ(X_!0M/A/X<\
M0ZCXZUWX<^'+#0?!_P 5OAWXK\1>'M1^+/@N\^(GP_N?'VA:3KTNJ> M#\1>
M"M.U/Q%;:WXHM=.LDT[3+^:8H(!O^8/C_P#L\?&#]E[XCW7PG^.'A0>$?&MO
MHFA^)K>WMM4T_7M&UKPSXEM#>Z%XB\.^(-)FN-,UK1M2A658;RTE/EW-O<VE
MQ'#<V\L:_77AG_@JQ^UCX-\:Z]\0/"\WPTT;Q+XF\0?L\Z_K5S;^#;I[>\'[
M-/PGU3X)>"=#-O+KS[-"\1?#S6M4TSQW L@OM5N[HZAHVH>'YXH=GR-^T!\>
M?&G[2/Q)N_B=XZL/#6C:G+HNB>'-.\/^#K35[+PQH.A^'[3[+86&EQ>(-<\2
M:Y,TCO/?:A?ZOKNIZCJ.H75Q=75T[N OT642XU>8*.>4^'UE?U2M*53+W76-
M>-E.A*C35.56I25"E&6(I2J+F=>-.%>HJ%:4:+]'"/./K"6-C@5AO93;E0YU
M5]LW!PC9SE'DBG.+>O.DIRY)-1?BM%%%?5GJ!7]BO_!MY_R:1\=_^ST?!7_J
MH;"OXZJ_L5_X-O/^32/CO_V>CX*_]5#85^1^.'_)O,;_ -COAC_U<H^6XR_Y
M$57_ +#<N_\ 4L_9GXU_LK>)_B[^TY^RG^T1I/[2'Q9^&&@?LTWOBN[\1? O
MP?<7$?PW^/Z>)8XTMK?XFP1:]IT$R>'S&3IIN='UU0DDJI';NPD7TW]I3X5Z
M[\9_@WXB\!^%KO2[7Q,VN> /&/A^#7C./#FN:Q\-?'_AKXAV'A3Q.]M;WEQ!
MX<\63^&4\/:O>0V5\^GV^H'4!8W@M6MI?-_C1\1?VP/#/[3/[*W@?X*_ 3PA
M\0_V8_'MYXKC_:K^,FM>(HM-\3?!*ST^.)O"D_A;1'\3:5)KCZVYE%UY6@>)
M/),:(T5H'\T9W_!0?7_$OAC]DKXA:QX2\0WWA75XO%?P5L9?$%CKWB+PJ-.T
M'5_C;\/M)\5-JGB;PBR>)_#_ (<N/#5[JMKXHUC0WCU'3_#LVIW,$D9C+K_'
M$O91CC)1A4NE)U;\\5-JDG^[E-RC;E25X*R>Z:T/R=V2F[/O+=7]U;-Z?#97
MBDKIW3DI7\8_:#^"'[3_ .T'K0\9>)?A%\(=/TN.U^(V@Z5\%I_BQ<P^((/$
MGB[X::?X9\"_M ?$/XHZ)I%MH'B[Q1\(/%<6K-X!\,:3IXU;PKX0U1]5T'6I
M/&#16-CX+X<_8(_:>T#5=?;5?$?A'QCK_B#QEI.N^#/C-+\0-8T?7O@9J>E?
M&J[^(7Q%^(^C>%$T_/B7Q#^T/X2GBT7Q+86MS'>VE]"NA>+;G4/"S2$\QH7[
M3/[4?PRLOB]IGPSDTCXI^$O >F?M6?%GP:-';QQ\=?"?C_2_ LG[/VG>"?!7
MPL^*_CJ^L/&MSX$\(ZA\1O'^K^,FU:?7]:O=>\*:UX?\(ZO;>&K+;:4O&O\
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M'@;QEH.;_P 0?M"_">[^*&JZ58?M&:\/V@/BWXVT'0_$WB+4;*[L'BT7X?\
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M8MIVKWG@VV\<?M/:C\8?B)K@\>Z1?>)O"OB+6?!5Q^S=X1?1==T:U\!Q^'/
MUM+KNE?#K7? OB+7$UOP]INHZM)9>'WFUBUN.:.-DW33P\_?M?EYFTOWEVDX
M*]G!;M73;6EKI2NXVB_>:7I=R7;5+EU>FCNM-_TS )( &22  .I).  .Y)X
M[FIFMYT4LT$RJ!DLT;A0,$Y)*@ 85CUZ GL:_#/2_B__ ,%!8/"4'B[7?$7Q
M#\275UX,^$7B/4?A_=_L_P#A33M,NM4^)WQU^-'PN\=^$I#IGA"#Q)#I7@KX
M7>'/ GB^"SCU!==T[4[X>)M=U2X\/Z]!I*> >!=>_;4\->,=.\<>'/AO\2/$
M7C'4]0LKFU\*>*?!GBO_ (0>;6-1F^%>K1:?9Z-?^1HW@^T.L6%UIUE?V+V
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M:(2.(G(+QAV$;D="R [6([$@XIE% $K33,XD:65G5=JNTC%PH!4*&)R%P2,
MXP2,8--,CLB1L[M&F=D98E$W?>V*3M7/? &>],HH D\Z;.?-DSECGS&SEE"L
M<YSEE 5CU*@ \ 4IFF((,LI# A@9&((.<@@G!!R<@]<GU-144 2M<3NVYII6
M;Y/F:1RW[LDQ\EB?W9)*?W"25P3474DGDDDD]R3R2?<GDT44 %%%% !1110
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M[_T!XK_P]\1?_1"'_$:?%/\ Z+7./_ L+_\ ,I^\3?\ !;GP:RE6_P""5?[
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M:KVEUJUH^FNUKRL=GKDX+'9BY)V<5C*K=U%S=K56G:*NVFTMFTW8^_?[1?\
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M?'2?_!9:_P#Q-']HO_SXZ3_X++7_ .)K/HH]A2_D7WS_ /E@?VQFW_0SQ_\
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M ,36?11["E_(OOG_ /+ _MC-O^AGC_\ PKK_ /R9H?VB_P#SXZ3_ ."RU_\
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MMM1N=.BMKB]N-3TQ5U3Q#9P*G-^"/V'_ /@G1XTA^*FOWWB3P3H6@^(_@O\
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M ?#WB77[Z?\ M?5[:6\E%C':V=@DUQ+,7"1/^BW_  XC_P""F/\ T2/X;_\
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M)(;O5O$MC'#<>%=2U?Q99_$#39)Y'\,ZWXFGAU.SL]5\2VGVS]#-,_X)G?\
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MC\Q0%UW7WK_,6BDR/4?F*,CU'YB@+KNOO7^8M%)D>H_,49'J/S% 77=?>O\
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M:YU#5/\ D=O&8XU34  !XIU<  "Y      KG_/N_^@AJG_@UU'_Y*K;\6_\
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M#5/_  :ZC_\ )51T5SW?=_\ @4O_ )(U^2^Z/_R)ZU\'/CU\:OV?/&-IX_\
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M7O[2OO\ GO\ ^0;?_P",T?VE??\ /?\ \@V__P 9JC11]=QO_0;C/_"O%?\
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MI-)0]QJ/*FTW&[?O-+\><*MJR]JGSW]E[O+[/W;:R3;EKK>RMZGPWXZ_:/\
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MO4C-?948J*6N^U]M$FV^^HVBBBL#H"BBB@ J^?\ D%+_ -A.3_TCCJA5\_\
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MBFWHDVWHF?Y??B[4=/'C'QJ#?V8(\;^-,@W4 (_XJG5^Q>N?_M+3O^?^R_\
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M.P%+_:6G?\_]E_X%0?\ QROTW_XB(?$__2-;]@G_ ,)74/\ Y3T?\1$/B?\
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MV\UXT4DGBGQAJ412.U@A9OM#_A*;#_H"W'_@U_\ N.C_ (2FP_Z MQ_X-?\
M[CK26&S*2Y77HV7)9*HDE[-IPM:AIRN,7OK;6^J>:RF:U6"G=N3NZM%N\[\V
MKK^;MV;NM=5^</P7_P""9'A'X->-/#7CJU^,?B_Q7K7AWXA?!SXEM)KGAS2$
M;4/$OP\\!>,O#WQ'OVFAOGDMK_X\_$'QK?\ Q>\:WZB6;2_$5K::5IRW-BBW
M$?GT'_!(WPC#X-3P8WQT\436;:<=.N[QO!UK:7$R6GA3X)Z3H<D/]E^)["2W
M^P^)_@/X0\1:A&+ECJ.CZCKOAJUETN>2PUZS_5__ (2FP_Z MQ_X-?\ [CH_
MX2FP_P"@+<?^#7_[CI_5\RYG+V]&[LF_:+IM_P P]M/3MV5C^R)VM]2GO?\
MC4K_ '_6+]7IMJ^Y\<VO[&MYHWP>\*?#_P +?%*S\.^-O#'[3NF?M8'QR?A]
M)K_A[4_B'8>);KQ#<:+=^#O$'C6_U^Y\.:FD\6F7FJZK\0M5\<.L)U5_$LFJ
M.DT/B>@?\$P['P1J>L^)_ 7QYU?1O&/B?PMXJ\$^)-7USX::!XBTF\\.?%'P
MK>:'\8)-.\.#7=,M=)UWQ+KETGBOP;>0W,VE^"VMD\-ZAH_BO1)[F.3],O\
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M_P"R\3_-0_\ !K_^4FGU3%_] T__  9A_P#Y<;E%8?\ PE-A_P! 6X_\&O\
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M%3^'4_Z]U/\ TW,Z,)_O6%_["L-_ZDX<_P ?NQ_X\[7_ *]X?_1:U:JK8_\
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MA/Q!9Q:->26&OVVH:>(KS3((;NTGE\1T?_@IW^SQX@MM2GT/PS\7];G\-?\
M">77CNTT/P]X0UV/X?Z!\-=.^'6M>+_%'B'6])\<W?AN_P!&T_1?BGX3U*&/
MPGK'B/5KPG6M-@TYM6T:YLC[U8_LS?LY^&?"^L^ &TJVA\._%7X->$/V:;W1
MM<\<WCS^,?AAX%TKQ3;^&?"FB2W>IPWVH:S::9XQ\07$VKZ(\VN7Z75O>7$C
MK:6[CR[3_P!CW]C[1;;XFZK>Z_>ZQ)X[T3QA\-/B=XI\7?'F;5+N>V\6^%_
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MN:1R^O\ [=FC^'-<^'#:Q\$?B_H/@7Q[\)/BM\7)?$GB2R\):7K-CHG@*_\
MA39^%9K+1$\7W-E>:-\08_BIIEQ!KUWK%C9^%_(=/%?]B)9:W-IECX/_ +>7
MPP^,NI?$_7=#ADTCX1?"OX'R_%OQ+XPU<B37=+U#PY\0OBGX%^(GAZ\TW1I]
M7T34=/\ #2?#*;5-(USPUK&KVGB6/4HWTV>>V>V=^KU_]AWX#^*?#?A7POXD
MD^*VN67@FTU33?"M_JOQ;\5W^NZ+H]_>^!M3L-!M-4NI)B- \*:K\,_ 6J^#
M](:W-GHNI>&K:[FCU%[W51?])\._V0?@-\,8OB/#H'AS7M7'Q>\/>)/"WQ,?
MQOXQU_QG+XQT7QCXF\6^,/%5MJDFK7+%9->\1>.?%5_?36OV<JFK-96:VEE:
M65O;C='ET4N:]EO:U]7J][:+I=;:W'&.8^TCSRHJG9N2]V_-RZ1]V/-RJ7Q6
M=VG=2323\]^(7[>WPB^$GA/P)XP^*O@SXO?#O3O'\ZR6%EXI\.>&+/5=-T"?
M5_#6CZ=XJN+:#QE=1Z]IVKR>+-)O['1_!DWB7Q=%I4.M7VI>'M/30M06.MIG
M_!0#X0:S-9Z?IG@7XU7?B+Q-J4FE_"SPK_PB7AZ#7OC1-:^.O&OPZU2?X>13
M^,([%+31_$GP\\5M?3>,K[PF7T:RM-9LDNK74K/?M>*?V#?V?_&VCZ5HOBZ;
MXO\ B&#2_"]_X$DO]2^,_C2;7-;\ 7NN>'O$EOX"U_61<+>7OA#1-:\*>'[S
M0=(LSIJV/]GM!<37T%_J<=[N77[%'[/L\/A<V>B^,-"U;P+IMWIO@;Q7X=\?
M^(]'\7^#3??$+Q!\4+O5?#NOPSR3V&O3>+?%?B5GU4Q32MH>LWGA\QG3C&D;
M_P!GM_R\OKMMOIOKMH^OS)MFEY-/#*/*N5-)R<O9VEK%**_>:J^FG\C9Y]XT
M_P""C/[.?@+6_'^@:\/'CZA\.+?7;?6[73=%\/WNKW7C/PMX>\/^*/%/PSL/
M"J^*E\76_C+0-*\26$=U<ZWH>D>#;S6+76="TGQ7?ZII4]N?N'2[NZO],TZ_
MO='U+P]>7ME;W5UH&LMI[ZOHL\T8>33-4;2;[4]*-_9L3#=?V=J5_9^:K""[
MG3#GY6UO]AW]G/Q%?^+;W5_#OBVZA\<PW4GB;1Q\0?%,6B:CX@U+2_#VB:WX
MZDLUNS/)X_\ $>D^%M&L]?\ %%Y>WDVH/%>:C]EAU?4K_4)_KJ21I7>1R"[L
M78@8!9CDG X&22<#@=JSG[/3DYO/F]%HOG=_<=&'6+O-XETK7:IJDM&N9N[;
MU2Y;))Z[N6MAE%%%0=(4444 %;#?\B['_P!AZ3_TV)6/6PW_ "+L?_8>D_\
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M?&X?$;P'K>L:7INEW'AGQ?I_BV.QEU"PT"\O?!6H^#-1\2ZM=W.O^,-(NHM
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MO5_$6B>*=;%YX.OEFN[G5]=U*ZU?3[#^SM#NA.(;32M/B#*_SAND_P">T_\
MW_F_^.4;I/\ GM/_ -_YO_CE='^JF6VC%U\S:BHJ*^ORM%0245'_ &?3E225
MGLDG?KYR\8^*5.=19=PFIU95)U)+AVDG4E6E*=64_P#A2M-SG.<Y<R:YI.24
M7JO:+/\ X(K_ /!6RU\=^-_B%-\1OV'M2U?XF>#/"'@3XAZ5J'C+Q2OACQCH
M_@*+PXGA.]U?2=-\(Z;/'K^DS^$]!OEU;2]1T\W-W:W"W5O-9:CJ%E<^J>%/
M^"3G_!573/#FK>$O&UQ_P3T^(GA:S^%GBOX<?##PGK&LWUIX3^',WC/Q/X-\
M6>(K]-)LOA[%-KNB>(?$/A%/%WB;P]=WT?\ ;'CR[7Q0+^U,4]A=_(>Z3_GM
M/_W_ )O_ (Y1ND_Y[3_]_P";_P".4H<*99!WC5S!:R;3QCDFYMRES1EAY*2E
M)\[4DX\]I\O,N8=7QDXKKQ4:F"X8:BJ,8..0QIS@J$8PH^SG2S2G.FZ=*"HQ
ME"49^P<J'M/8R=-?77AW_@E/_P %@T^(OP@^(/Q!^*_[(GC:X^"_C'6/B'X;
M6V^(5WHNKZSXNU'PQK_AU/\ A*M5?X6W]MK'AZ^77IHO$>CS:9Y.HZ09K&U6
MUD,$L/S)X"_X-^_^"EGP[^(GA3XIZ7XD_81USQEX2U*_UV"?QGXM\1>*M&US
MQ+J-UJ-\WB;Q1H>I>"C9ZSKEA>:DUWH]V1:IIEW8Z5>0P->:?'.V!ND_Y[3_
M /?^;_XY1ND_Y[3_ /?^;_XY2EPEE<W%SJ9A-PG[2,I8V4I*:4$I<TJ$G=*G
M!*][)6UNS2EXU<7T(U84,+PS1A7H/"U:=+(:=*G/#RG7J2I.%/,::4)SQ->4
MU%QYG4;7):-O6M?_ ."(/_!5#7_ 7B[X<MXH_8'TG0O&EMXOTO5-3T?Q7XN7
MQC9^'/B%XFT'QIX]\):/XPU?PSK.M6GAKQEXO\.:=XD\06EW/J%]=ZG+JABU
M*"VU:_MIN<\9_P#!"#_@JMX^TSQ[H_B3XH_L;2Z?\3-?^%WB;QC%8>.]<TY]
M1U7X->#KWP+X ,$L'P_WV=GIF@:A=&\L8B8-2U0Q:K< 7,28XC=)_P ]I_\
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M@!P%;*@< 5[5Y\__ #WG_P"_TO\ \71Y\_\ SWG_ ._TO_Q=']DQ_P"?\O\
MP7'_ .3#_7.K_P!"^E_X4U?_ )2>(MINJL=S:=J+$XR6L[HDX&!R8L\  #T
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M?_DP_P!<JO\ T+Z7_A35_P#E)XA_9>I_] W4/_ *Y_\ C5']EZG_ - W4/\
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M3YJDZG^\U=.=IV_@]+6OU/$/[+U/_H&ZA_X!7/\ \:H_LO4_^@;J'_@%<_\
MQJO;_/G_ .>\_P#W^E_^+H\^?_GO/_W^E_\ BZ7]DQ_Y_P O_!<?_DR_]<JO
M_0OI?^%-7_Y2>(?V7J?_ $#=0_\  *Y_^-4?V7J?_0-U#_P"N?\ XU7M_GS_
M //>?_O]+_\ %T>?/_SWG_[_ $O_ ,71_9,?^?\ +_P7'_Y,/]<JO_0OI?\
MA35_^4GB']EZG_T#=0_\ KG_ .-4?V7J?_0-U#_P"N?_ (U7M_GS_P#/>?\
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M"N?_ (U1_9>I_P#0-U#_ , KG_XU7M_GS_\ />?_ +_2_P#Q='GS_P#/>?\
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M%/PMI%Y-+9^#?&VNJVEP '#>)?V$_P!KCQ!?>$O&/A+PGJ/P_P!1\):)XO\
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MEM%C96-@$5$06%E:V(5(L>5&HM(80(XMJ^6@&V/ V 5-10!GC1]$6.UA70=
M$-C-<W%A"-#TD0V%Q>;_ +;<6$(L_+L;B]\R3[;/:K#+>;W^TO+O;,TMAIUQ
M!+:7&F:7<VDT)MY[.YTRPN+.:V,JSFVFM)K=[>6V-PJW)MY(VA-RJW)3SP)*
MM44 5S96!GDNVT[36NY[6*PGNVTZR:[N+""7SH-/N+IH#//I]O-^^@L9I'M(
M9@)8H4D 86*** "BBB@ HHHH *M'_CP7_K^;_P!)DJK5H_\ '@O_ %_-_P"D
MR4 ?-NB?M8_L\^)/VG?&_P"QEHGQ(LK_ /::^''P^TGXJ^-?A8NC>(XK[0_
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MOQ*U/QMJ?C[Q'%XSO-&N[6>3Q2?B-XRT^^LKC0I-/M]+U=;;3K:RDT[39[0
M\I^*?_!1KX'>!KKQQX9\+G4O&'Q \&^(-/\ "L.AZC;MX:\/^(O$UIXQ^'OA
MKXB^%M*UUWOM67Q-\,M-^(5IK/B&PO\ PW864UUIFI:/IVI7UUIVJFQ]"\%?
MMA^%->^$/[//Q&U[P;XR'BS]HVVUVX\(?"SX;:+>?$CQ0L/A6]O8_%FJ+%"-
M'DG\.^%-+@LM6U[4VC2ZC74K6RTW3=4OI8K>3'U7_@GS^S7K/B/QGXEN]+\:
MQS>.]>E\7:YI=GXKCM--'C6_U[PCXE\0>,8;J+2!XDO-;\4ZUX)T>_UR+7O$
M&M:)'=7?B&\T+1]%OO$&H73][_PR3\*K3P9\%O!?AS5?B5X(7]GX>(+?X7>+
MO!GC9])\>Z/I/B\31^,= O/$EQIFH#4-(\56\L=MJRO817\*V>GW.D7^F:A9
M0W@ .<A_;F_9^F\2Z/X9.H>.(&\6>/XOAI\//$5QX$U2+PA\4/$T7Q4TCX)Z
M\_P\U_SV37=$\&_$W7=+\.>+M7N;;2X]/CN1K6G0ZOHD<E^OFFO?\%,/V==/
MT[QC=:!I?Q9\4W/A'2=6=Y+;X>7FF>&KKQ?%I_Q3N?"G@&X\4ZC?Q6NGZ_X[
MU#X/>--*T"0VEU8036^G3:Q<Z='K.E"\[C4/V!_@#J%XUZ+CXGZ=)I/B2[\8
M?#*#3?'LL5E\"O$VJ_%71?C;KVK_  :LKG2KNW\/S>(OB?X>TKQ'K%OXB3Q9
M9O!!+H%C;V/A^XETULK0_P#@G3^S)H7A2^\&)I_Q#U?1=5\2>$?%FKOX@^(6
MI:IJ>KZYX*?XD2:3=:AJ+6L,LRW<OQ8\:2ZS"JQK?O=Z>%-NFFP*0#ZL^%OC
M?_A9OPP^&WQ*_L+4O"X^(G@#P=X['AK6?(.K: OB[P]I^O+H^H-;2SV[W6GK
M?BV>6&5DF"+, GF;%[JN4\!^#]-^'G@?P;\/]&O=8U+1O OA;0?!^C7_ (AO
M(-1UZYT?PWIMMH^DMK&H6UGI\%]?QZ=:6T$]W'8VOV@Q"5XA(SLW5T 6G_X\
MK?\ Z^KC_P!$PU5JT_\ QY6__7U<?^B8:JT %%%% !1110 53ETW3)]0L-7N
M-+TNXUC2H+ZUTK6+C3;&?6-*M=35%U.UTO598'U#3K74ECC74+>RN((;U407
M22A0!<HH K3V5A=1&"[T_3KRW-S#>M;WFGV=W;M?6[B2WU!H+B"6)M0MY%62
MWOF0W<,BJ\4R,JD/6VM$NKF_CL[*+4+U(8[[4HK.VBU*^CMLBVCOM0CB6]O8
M[8,?LT=U/*D&?W2I4U% $/V6TQM^PV&W"KM^PVFS;&S21KM\G;LBD=Y8EQMB
MFDDEC"R2.S"6UI&Z21V5A%)&RO')%8VD4D3H04DBDCA5XY(V561T971D1E(*
M*1-10!5AL-.MH1;VVEZ5:VX>ZD%M:Z786UL)+YS)J$@MX+>.'S-1D)?47V;K
M]OFO#.>:M       8   4 = JC 50. H      &*** "BBB@ HHHH *Y#X@_
M\B'XR_[%S4__ $0:Z^N&^)M]8Z;\.O&MYJ5]9:=9Q^'K])+O4+NWL;5'EC\N
M*-KBZDBA$DLA"1(7WR.0J*S'% 'U O0?0?RI:@M;FVO+:WN[.X@N[2YABGMK
MJVECGM[B"5 \4T$\3/%-#*C*\<D;,CH0RL00:GH *.M%% 'YQW7_  2B_8EO
M;N\O;CX;Z\]Q?7EW?W+CXB>.4#W-]<RW=PX1=="H'GFD8(H"H"%4!0 (/^'3
M/[$'_1-=?_\ #C>._P#Y?5^D=% 'YN?\.F?V(/\ HFNO_P#AQO'?_P OJ/\
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M?^_'@K_YCZ]5HH \J_X5C=?]%#\:_P#?CP5_\Q]'_"L;K_HH?C7_ +\>"O\
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M8^O5:* /*O\ A6-U_P!%#\:_]^/!7_S'T?\ "L;K_HH?C7_OQX*_^8^O5:*
M/*O^%8W7_10_&O\ WX\%?_,?7D_Q*^#?B635O ?BK3(!\9+/P=JFLW.H?#7Q
MW=^&-)TW5&UG2O[-M-=TZ[A\-0:6VN>')0TME#KMO<6CVE]J#6DUEJ"VTS?5
MM% 'CGP+\$:UX!\"MI&NVVF:3=:AXE\4>)+;PMH=S)>Z'X*T[Q%K-SJECX/T
?>[>&U6>RT2&X$)DMK.SL3<O<BPM8;(0+7L=%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_004.jpg
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) F\# 2(  A$! Q$!_\0
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M_05U3_P97O\ \?JC11RQ_EC_ . P_P#D YI?S2_\"G_\F7O[4U7_ *"NJ?\
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M"NJ?^#*]_P#C]4:*.6/\L?\ P&'_ ,@'-+^:7_@4_P#Y,O?VIJO_ $%=4_\
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MX%/_ .3+W]J:K_T%=4_\&5[_ /'Z/[4U7_H*ZI_X,KW_ ./U1HHY8_RQ_P#
M8?\ R <TOYI?^!3_ /DR]_:FJ_\ 05U3_P &5[_\?H_M35?^@KJG_@RO?_C]
M4:*.6/\ +'_P&'_R <TOYI?^!3_^3+W]J:K_ -!75/\ P97O_P ?H_M35?\
MH*ZI_P"#*]_^/U1HHY8_RQ_\!A_\@'-+^:7_ (%/_P"3+W]J:K_T%=4_\&5[
M_P#'Z/[4U7_H*ZI_X,KW_P"/U1HHY8_RQ_\  8?_ " <TOYI?^!3_P#DR]_:
MFJ_]!75/_!E>_P#Q^C^U-5_Z"NJ?^#*]_P#C]4:*.6/\L?\ P&'_ ,@'-+^:
M7_@4_P#Y,O?VIJO_ $%=4_\ !E>__'ZWO#NIZFU[<!M3U)A]@E.&U"\89%U9
M<X,Q&>O/N:Y.M_PY_P ?UQ_UX2_^E=E7#F<8_P!FX_W8_P"YXC[,?^?;_NG?
ME<I/,L!>4G_M=#>4G_R\71R:_ P****[SSPHHHH **** "BBB@ HHHH ****
M ..^(GC$?#SP!XV\?'PMXR\<CP5X6UOQ2?!7PZT/_A)OB!XM&B6$U^?#G@CP
MY]ILO[>\5:OY/V/0](^V6OV^_EAM_M$6_>/R:\"_\%K?A'\0/BMK/P7TG]B_
M_@HYIOC[P?>^$X/B7IGB']FO1]*7X0Z;XUN$AT#Q1\5RWQ+EN/ _A2YA,VHG
M6]6MH[<Z=9WEU")A;LE?LN W)4'Y06)&?E ZL2.@'<]!ZU_,5\:OA#\5?B!^
MT1_P<=>'?"/P^\8:UJWQ,_8P^!WA[X?P1:!JD,'C;7+;P3XBNI=)\,W]U;06
M&MW\<2$"VL+F>0S 6ZCSR(Z\K-*^+P_U:>&J64ZE6%2E]7IUG-4\+BL4G&<I
M<T)2>'C1249+]YS*]10B_3RVEA*_UB&)A=PA2G3J/$3HJ'M,5AL,^:$5RSC!
M8B59WDG^[Y7:#E)?TSRZIH\-Q:VS:WH9FU%)YM*C&L:=OUFVME#SWFC1M<K+
MJMG#$R3RW5@D\,4$B32ND;JQIVWB3PQ>R+%9>*O"E[*]C<ZFD-EXGT&[EDTN
MS:=+W5$BMM0ED?3+)[6Z2\U%5-G:-:W2W$\;6TXC_E/^&_QRTS]IG]JG_@C+
M:_#GX4_'JQTS]G/]E/\ :7^&?Q-\1>._@GX^\$>'='^)5Y\"?"]E?>#--U77
M=%MK/5KS14T:WDO-1T^6329U\1:/:V-W<7<T\$7QO^S9^P5\/KWX"_\ !%7Q
M5K7P$\<V?C;XX_M8_M'>#?VH=46Q^)GAW7M>^"L'C_QUIMCX"\>QV<VGR^'/
MA7JVGVT4&H:-+;Z-H^O6.MZ[]N>Z@UJ^DDY'G=2;_P!GPL*T+I.;K581:?\
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MF?\ J/:O7-5A0WQ'_856_P#2<,;5MJ'_ &#4O_2L0%36T0GN((6)43311%@
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MZ&WXIW/BN3P1#X8_L%O#@\1$/XGB?3?[8&EG1%5?MC:@+$BX/E'Q"_X*X_\
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M9XJU7PUK^J^!_&'Q/\)>&+VX.BMIK3:QH7B)=.\2VD<5]J*Z8^BPQW[? ?\
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MD=Q8[ CV44D@D3Y,_:@_8._:G\!?"7_@G;\$/V1_!Q^)7P3_ &>_ GB7X?\
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M#>H>*/'^O0V^K:WXENM"9-7M]!\+^&X=2U2ZDL'68WQTR.3%K)<LGQ?\,/\
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M*[LM6:/]D?"7_HFMM_X,KK_X]1_9'PE_Z)K;?^#*Z_\ CU9U%7RU/^@O'_\
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M1_LCX2_]$UMO_!E=?_'J;-8_#*RL[ZZL/A[!:SQ6\>94U"X9C&]]9QM'\TK
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M-^'=;^"GBWXYZ1#>VVD2^ ;_ ,):1X$\3>)=4O\ 0O#NIW5UH]MJ _?OXJ_
M;_@D)\-OCW^SO^S!X\_9-_9SD^-/[3%WXM/PJ\':9\&O#NJ2S:5X)T:XUGQ%
MK?C*:(1#0/!EQ%;OI<,NHQ7=GX@U<#3EL;E+:YFM>;U3X&?\$;_#G@?XS^/_
M !7^QI\#O#.E_L\^/-9^'?Q=T37/V=K>^\4^&-<L[&/Q!I%SJWAO1+'7Y)?
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MGAKX[>*/B#J6NCXHZ/XZBTJUF\%Z-X?BM;C2-7U."'3K74;[5)[N.3ZY\8_
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M2CS\-<\X.=.5W/V/)[94Z<*49RA*E>,9SIRI<\'_ #__ ++'[*'[0>N^*_\
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ME@E420RQ.I*O%+$RR1.I*NC*RDJ0:*Z#$**** "BBB@ HHHH **** "BBB@
MJ"^_Y!>J?]>T'_IRL*GJ"^_Y!>J?]>T'_IRL*PQ7^[8C_KQ5_P#2&;8?_>*'
M_7ZG_P"E(GHJ]_9FI?\ /A>?^ TW_P 11_9FI?\ /A>?^ TW_P 16O/#^>'_
M (''_P"2,N67\D__  "?_P @4:*O?V9J7_/A>?\ @--_\11_9FI?\^%Y_P"
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MMRU?8Z*E6<XRA[.HE*2DVU4>TISM_#2Y8\W+37V(JWI_,?XW^&7[8W@;]O\
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MGH[-7L3[:IJO9U+6@E95%RJ$:2LKTVK-TN9JS5Y:IM7/P7_8?\=?#.X\,_\
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M_P !IO\ XBKYX?SP_P# X_\ R1'++^2?_@$__D"C15[^S-2_Y\+S_P !IO\
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MBKW]F:E_SX7G_@--_P#$4?V9J7_/A>?^ TW_ ,11SP_GA_X''_Y(.67\D_\
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M%H_RQ_\  8__ "(7?=_>_P#,L?:[O_G[NO\ P)F_^+H^UW?_ #]W7_@3-_\
M%U7HHM'^6/\ X#'_ .1"[[O[W_F6/M=W_P _=U_X$S?_ !='VN[_ .?NZ_\
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M?_D0;=MW][_^2/CGQ1_P48_8S\%>(_&/A3Q3^T=H^D:S\//$.H>%/'Q;PO\
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MS?\ Q='VN[_Y^[K_ ,"9O_BZKT46C_+'_P !C_\ (A=]W][_ ,SP[XH_M7?
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MW][_ ,RQ]KN_^?NZ_P# F;_XNC[7=_\ /W=?^!,W_P 75>BBT?Y8_P#@,?\
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MN_\ P"I_\K,N679?^!T__EAD45K_ -F6W_09T[\KS_Y%H_LRV_Z#.G?E>?\
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M4NVVVVWJVVWJS(HK7_LRV_Z#.G?E>?\ R+1_9EM_T&=._*\_^1:/:0[O_P
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M;?\ 09T[\KS_ .1:/[,MO^@SIWY7G_R+1[2'=_\ @%3_ .5ARR[+_P #I_\
MRPR**U_[,MO^@SIWY7G_ ,BT?V9;?]!G3ORO/_D6CVD.[_\  *G_ ,K#EEV7
M_@=/_P"6&116O_9EM_T&=._*\_\ D6C^S+;_ *#.G?E>?_(M'M(=W_X!4_\
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M<RI!;6EE9PO<W=W<SR,L<-O;6\4D\\TC*D44;NQ"J37\V?[$WQF_:4U#7/\
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MXPU'4)M;^)_B/5-$UV]TV>3Q=<ZA:Q6D6FP6MM;PZ791PS>,OV(?V=?'-O\
M$I-7\.^+=.U+XK?'SP)^U!XD\3^%?B)XN\+^+]*^._PTM]!M/!7Q \#>)-)U
M&'4/ ]]H]IX;TNU-EX?>VTV\M_M\5W:RKJ-UO^R/[1MO^@-IG_?6I?\ RPH_
MM&V_Z VF?]]:E_\ +"G[.#7+]65G>ZO1ZKE?7JM&W>_6X<SO?V[OWM5OOS=O
MYM5T3V70^(F_8+_9XN?&.F>*]7/QC\0Z7I'Q+M/C)8?"OQ/\=OB?XE^!MO\
M%6QN?[1M/B /A!K/B"Z\(S>(K/7"WBFSDFMFLK3Q4QUVULX+P(R=)\!_@+KG
M@/XG_M&?'OXD:KHVM_%S]HCQAH(O?^$=FU"[\/>"_A'\,-.O/#OPC^'NB7NK
M6&F:C=R6UE?ZYXQ\77<MA;0W/C3Q=K,-D)],T_3KB3ZY_M&V_P"@-IG_ 'UJ
M7_RPH_M&V_Z VF?]]:E_\L*%!1=XT&GS.>DZ2O)IIR>NK2;2OM=V6H-MIIUD
MTU;6-1Z74K+31.23=M7RJ[=C*HK5_M&V_P"@-IG_ 'UJ7_RPH_M&V_Z VF?]
M]:E_\L*TYI?\^I?^!TO\R.6/_/R/_@%3_(RJ*U?[1MO^@-IG_?6I?_+"C^T;
M;_H#:9_WUJ7_ ,L*.:7_ #ZE_P"!TO\ ,.6/_/R/_@%3_(RJ*U?[1MO^@-IG
M_?6I?_+"C^T;;_H#:9_WUJ7_ ,L*.:7_ #ZE_P"!TO\ ,.6/_/R/_@%3_(RJ
MU;C_ ) VF?\ 7[JO_HO3*/[1MO\ H#:9_P!]:E_\L*TI[^W&DZ<W]D:<0UYJ
M8"$ZAM0A-.)9?]/W;GW -EBOR+M53N+1.4KT_P!W+^(OMTOY*OF7&,;3_>1_
MAO[%3^:GY?U<YBBM7^T;;_H#:9_WUJ7_ ,L*/[1MO^@-IG_?6I?_ "PJ^:7_
M #ZE_P"!TO\ ,CEC_P _(_\ @%3_ ",JBM7^T;;_ * VF?\ ?6I?_+"C^T;;
M_H#:9_WUJ7_RPHYI?\^I?^!TO\PY8_\ /R/_ (!4_P C*HK;%R&4.OAZR9",
MA@FJE2/4,+_!'OG%"W(=0Z>'[)U.<,J:JRG!P<$7Y!P00<'J,4<TO^?4O_ Z
M7^8<L?\ GY'_ , J?Y&)16LU_ C%6T33593@JQU,,#Z$'4 0?8TG]HVW_0&T
MS_OK4O\ Y84<TO\ GU+_ ,#I?YARQ_Y^1_\  *G^1E45L"]B(!&A:>05+@@:
MF044X9@?[0Y53P6Z \$TW[?!M+?V)INT$ MG4MH)Y )_M#&2 2!UXHYI?\^I
M?^!TO\PY8_\ /R/_ (#4_P C)HK86]B?&S0]/;<VU=HU-MS8SM&-0.6QS@<X
MYQ3GNDB :30+&-2< NNJ("<$X!:_ )P"<=< T<TO^?4O_ Z7^8<L?^?D?_ *
MG^1BT5J_VC;?] ;3/^^M2_\ EA1_:-M_T!M,_P"^M2_^6%'-+_GU+_P.E_F'
M+'_GY'_P"I_D95%:O]HVW_0&TS_OK4O_ )84?VC;?] ;3/\ OK4O_EA1S2_Y
M]2_\#I?YARQ_Y^1_\ J?Y O_ " IO^PS;_\ I!=5E5TZW]O_ &-*_P#9&FX&
MK0*8\ZAM)-C<D2$_;]^]0"HPVW:S94MAAF_VC;?] ;3/^^M2_P#EA40E*]3]
MW+^)+[=+^6GYERC'W/WD?X<?L5.]3R,JBM7^T;;_ * VF?\ ?6I?_+"C^T;;
M_H#:9_WUJ7_RPJ^:7_/J7_@=+_,CEC_S\C_X!4_R,JBM7^T;;_H#:9_WUJ7_
M ,L*/[1MO^@-IG_?6I?_ "PHYI?\^I?^!TO\PY8_\_(_^ 5/\C*HK5_M&V_Z
M VF?]]:E_P#+"C^T;;_H#:9_WUJ7_P L*.:7_/J7_@=+_,.6/_/R/_@%3_(R
MJ*U?[1MO^@-IG_?6I?\ RPH_M&V_Z VF?]]:E_\ +"CFE_SZE_X'2_S#EC_S
M\C_X!4_R,JBM7^T;;_H#:9_WUJ7_ ,L*/[1MO^@-IG_?6I?_ "PHYI?\^I?^
M!TO\PY8_\_(_^ 5/\C*HK5_M&V_Z VF?]]:E_P#+"C^T;;_H#:9_WUJ7_P L
M*.:7_/J7_@=+_,.6/_/R/_@%3_(RJ*UAJ%NV<:+IIP"3@ZD< #))QJ'  Y)Z
M <FI$NT=2Z:!8N@SET75&48&3EA?D# Y// HYI?\^I?^!TO\PY8_\_(_^ 5/
M\C%HK5_M&V_Z VF?]]:E_P#+"C^T;;_H#:9_WUJ7_P L*.:7_/J7_@=+_,.6
M/_/R/_@%3_(RJ*U?[1MO^@-IG_?6I?\ RPH_M&V_Z VF?]]:E_\ +"CFE_SZ
ME_X'2_S#EC_S\C_X!4_R,JBM7^T;;_H#:9_WUJ7_ ,L*/[1MO^@-IG_?6I?_
M "PHYI?\^I?^!TO\PY8_\_(_^ 5/\C*HK5_M&V_Z VF?]]:E_P#+"C^T;;_H
M#:9_WUJ7_P L*.:7_/J7_@=+_,.6/_/R/_@%3_(RJ*U?[1MO^@-IG_?6I?\
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M6>&:.-DB:..:*1)$1HHV16"M&A!0%*S%B6.,GT554>@55"JJ@<*JJJJ %4
M"DKK6R]# **** "BBB@ HHHH **** "BBB@ J"^_Y!>J?]>T'_IRL*GJ"^_Y
M!>J?]>T'_IRL*PQ7^[8C_KQ5_P#2&;8?_>*'_7ZG_P"E(T/L5Y_SZ7/_ 'XE
M_P#B*/L5Y_SZ7/\ WXE_^(KQ:BO*_ME_] R_\&O_ .5GI?V2O^@A_P#@I?\
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M^_$O_P 11]BO/^?2Y_[\2_\ Q%>+44?VR_\ H&7_ (-?_P K#^R5_P!!#_\
M!2_^3/:?L5Y_SZ7/_?B7_P"(H^Q7G_/I<_\ ?B7_ .(KQ:BC^V7_ - R_P#!
MK_\ E8?V2O\ H(?_ (*7_P F>T_8KS_GTN?^_$O_ ,11]BO/^?2Y_P"_$O\
M\17BU%']LO\ Z!E_X-?_ ,K#^R5_T$/_ ,%+_P"3/:?L5Y_SZ7/_ 'XE_P#B
M*/L5Y_SZ7/\ WXE_^(KQ:BC^V7_T#+_P:_\ Y6']DK_H(?\ X*7_ ,F>T_8K
MS_GTN?\ OQ+_ /$4?8KS_GTN?^_$O_Q%>+44?VR_^@9?^#7_ /*P_LE?]!#_
M /!2_P#DSVG[%>?\^ES_ -^)?_B*/L5Y_P ^ES_WXE_^(KQ:BC^V7_T#+_P:
M_P#Y6']DK_H(?_@I?_)GM/V*\_Y]+G_OQ+_\11]BO/\ GTN?^_$O_P 17BU%
M']LO_H&7_@U__*P_LE?]!#_\%+_Y,]I^Q7G_ #Z7/_?B7_XBC[%>?\^ES_WX
ME_\ B*\6HH_ME_\ 0,O_  :__E8?V2O^@A_^"E_\F>T_8KS_ )]+G_OQ+_\
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MLE?]!#_\%+_Y,]I^Q7G_ #Z7/_?B7_XBC[%>?\^ES_WXE_\ B*\6HH_ME_\
M0,O_  :__E8?V2O^@A_^"E_\F>^K:77]B2K]EN-W]L6YV^1+G'V"ZYQLZ9X)
MZ D#J:R_L5Y_SZ7/_?B7_P"(KRU?^1=G_P"QAL__ $TW]9%3'.&N;_9U[TW+
M^*]+J"M\']W?S*EE2?+^_>D5'^&M;.6OQ_WMO(]I^Q7G_/I<_P#?B7_XBC[%
M>?\ /I<_]^)?_B*\6HJO[9?_ $#+_P &O_Y63_9*_P"@A_\ @I?_ "9[3]BO
M/^?2Y_[\2_\ Q%'V*\_Y]+G_ +\2_P#Q%>+44?VR_P#H&7_@U_\ RL/[)7_0
M0_\ P4O_ ),]I^Q7G_/I<_\ ?B7_ .(H^Q7G_/I<_P#?B7_XBO%J*/[9?_0,
MO_!K_P#E8?V2O^@A_P#@I?\ R9[3]BO/^?2Y_P"_$O\ \11]BO/^?2Y_[\2_
M_$5XM11_;+_Z!E_X-?\ \K#^R5_T$/\ \%+_ .3/:?L5Y_SZ7/\ WXE_^(H^
MQ7G_ #Z7/_?B7_XBO%J*/[9?_0,O_!K_ /E8?V2O^@A_^"E_\F>T_8KS_GTN
M?^_$O_Q%'V*\_P"?2Y_[\2__ !%>+44?VR_^@9?^#7_\K#^R5_T$/_P4O_DS
MVG[%>?\ /I<_]^)?_B*/L5Y_SZ7/_?B7_P"(KQ:BC^V7_P! R_\ !K_^5A_9
M*_Z"'_X*7_R9[3]BO/\ GTN?^_$O_P 11]BO/^?2Y_[\2_\ Q%>+44?VR_\
MH&7_ (-?_P K#^R5_P!!#_\ !2_^3/:?L5Y_SZ7/_?B7_P"(H^Q7G_/I<_\
M?B7_ .(KQ:BC^V7_ - R_P#!K_\ E8?V2O\ H(?_ (*7_P F>T_8KS_GTN?^
M_$O_ ,11]BO/^?2Y_P"_$O\ \17BU%']LO\ Z!E_X-?_ ,K#^R5_T$/_ ,%+
M_P"3/:?L5Y_SZ7/_ 'XE_P#B*/L5Y_SZ7/\ WXE_^(KQ:BC^V7_T#+_P:_\
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$_0__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1_005.jpg
<TEXT>
begin 644 forms-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #( FT# 2(  A$! Q$!_\0
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MM']8BKK31VTNK.VE[-I_1\)M_P!N875ZTL5?5Z_[.WKKKKKK?77?4Y?XH_\
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M7QJTNRO9]3BL&U*YT*VMM.\4PVQU)1%-I\=TEI)/!\M>$OC1^W!>_"?]E?\
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M%-?\)7"ZY:>*/#NB07^HQ>$+".)99/$4UC9ZGJ]SIEH-.THQS7DI;V3]H?\
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MFS\730Z_X7U7Q,F@P7WA2U#>)X7U&/Y=_;1_X**?MZ^/OV%?VC-+M?#WPC^
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MWJX7,:=5UE[?EJ.G5J8%Q<(P?NU9TVG=GR7X,_X*V?M2CX7?ML?M8?$[X#?
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M'MHV&IP6,>N#^TZQ],_X(Z_LXZ?X;\9^&;OXI_M*>)X_B#^TE\(_VL?%VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYDCAF>/,^,_[=O[%7[.>N1^&?CW^U7\#/A#XAG\&:3\1K31O'/CO3=)OM0\
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M@J_\*X^#WKXV_P# ZU_^1J/^%<?![U\;?^!UK_\ (U6J*/;8S_H99E_X5_\
MWN'L,'_T+LO_ /"7_P"^"K_PKCX/>OC;_P #K7_Y&H_X5Q\'O7QM_P"!UK_\
MC5:HH]MC/^AEF7_A7_\ >X>PP?\ T+LO_P#"7_[X*O\ PKCX/>OC;_P.M?\
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M]3^1+_@H#\;?A7\!OVF?^"ZOP;\7?#OX#_M"^+_VH_V>_ /B+P_\4?%GQ/\
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M6? WA/XZ>&/@I_P0B^(G[*]K\6;O5/ _BCP;+^U5J?B'Q%<:!X"\*#Q-J_\
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MPI_X*(?%'XS>#_@'JW@O]DRSA\;_ +5-EX[\7_ 3P!XC_:*T;1_[0^%'PO\
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MG[A_V9J/_/C=?]^)/_B:^5OVA?V%_@)^U3K?@GQ#\=/!/C_Q7J/PWU32M?\
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M&Z_[\2?_ !-'/#^>'_@<?_D@Y9?R3_\  )__ "!1HJ]_9FH_\^-U_P!^)/\
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MW=<DDO>?,U_#ORWV7-97=K7/SW_X)M_LF3_L??LX2>"-;TA- \;?$'XE^/\
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M&BKW]F:C_P ^-U_WXD_^)H_LS4?^?&Z_[\2?_$U7/#^>'_@<?_DB.67\D_\
MP"?_ ,@4:*O?V9J/_/C=?]^)/_B:/[,U'_GQNO\ OQ)_\31SP_GA_P"!Q_\
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MKO[SN^I9^VWG_/W<_P#?^7_XNC[;>?\ /W<_]_Y?_BZK45W6C_+'_P !C_\
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MJ*+1_EC_ . Q_P#D0N^[^]_YEG[;>?\ /W<_]_Y?_BZ/MMY_S]W/_?\ E_\
MBZK446C_ "Q_\!C_ /(A=]W][_S+/VV\_P"?NY_[_P O_P 71]MO/^?NY_[_
M ,O_ ,75:BBT?Y8_^ Q_^1"[[O[W_F6?MMY_S]W/_?\ E_\ BZ/MMY_S]W/_
M '_E_P#BZK446C_+'_P&/_R(7?=_>_\ ,L_;;S_G[N?^_P#+_P#%T?;;S_G[
MN?\ O_+_ /%U6HHM'^6/_@,?_D0N^[^]_P"99^VWG_/W<_\ ?^7_ .+H^VWG
M_/W<_P#?^7_XNJU%%H_RQ_\  8__ "(7?=_>_P#,L_;;S_G[N?\ O_+_ /%T
M?;;S_G[N?^_\O_Q=5J*+1_EC_P" Q_\ D0N^[^]_YFC9W=VUY9 W5R0;RT!!
MGEP0;B/(/S]#W'>G7UW=K?WZK=7(47UZ !/+@ 74H  W\ #@#L.*JV7_ !^V
M/_7[9_\ I3%3M0_Y"&H?]?\ >_\ I5+4\L?:?#'^'_+'_GXO[I=W[/=_Q.[_
M .?;\QOVV\_Y^[G_ +_R_P#Q='VV\_Y^[G_O_+_\75:BJM'^6/\ X#'_ .1(
MN^[^]_YGR+XT_;M^&'@WXA_$[X86_@K]J;XC>)O@R="3XGW7P;_9R^*7Q2\,
M>$)_$GAB#QEI%I?^)O#-A/IDUY/X:N8M4DM;)[F6",M%(HG4QUS?CK_@H_\
M 3P'X=^&_C:33/VC_'/P[^+Z_#N'X9_$SX4?L^_$[XD?#SQCK/Q6O(],\"^$
MM+\4>'K":T'C/5M8ECT.X\,7*0:EI6ML=+U*.VND=%^*?'W[.O[7GC3XR?\
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MU6.32M#N;JZN]1TN[T2T636?)L9=K]I6Y^+W[57Q/^+/QJ_8QT'XP1-\,_\
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M^SS?_#[X._MQ?MM0>!?$VB?M'_L\_P#!0KXY?M1>$?%.MMXJL=<\8_ #X/\
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MVV\_Y^[G_O\ R_\ Q='VV\_Y^[G_ +_R_P#Q=5J*+1_EC_X#'_Y$+ON_O?\
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M?_+#+HK4^R:9_P!!N/\ \%NH_P#QNC[)IG_0;C_\%NH__&Z/:1[5/_!57_Y
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MNC[)IG_0;C_\%NH__&Z/:1[5/_!57_Y .27]W_P92_\ EA4LO^/VQ_Z_;/\
M]*8J=J'_ "$-0_Z_[W_TJEK1M+331>69768V87=J57^SM07<PN(R%W&/ W'
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MXRA+B[-'"<90E#GR51<91E%QY5P_%*/+)Q44HJ,5",%!4Z2I9?'8     9P
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M,,4:K'%#%&JQQ11JL<<:JB*JJ -7[)IG_0;C_P#!;J/_ ,;H^R:9_P!!N/\
M\%NH_P#QNGSPNWRSN[)OV52[2O97Y.EW;U#DE:UXV5[+VE.ROOI[3K97]#+H
MK4^R:9_T&X__  6ZC_\ &Z/LFF?]!N/_ ,%NH_\ QNG[2/:I_P""JO\ \@+D
ME_=_\&4O_E@L'_(&U#_K]T[_ -%WM95=-#:Z<-)OE&L1E#>6!:3^SK_Y2$O
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M:3[[)(ZE\Y)WD$%N23SGJ:C#, 0"0&QN ) ;!R,CH<'D9Z&M/[)IG_0;C_\
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M#_PEXVN[/PSKEQJK:E?P:GIMIJ-FWYN_&3]LZ7XG_P#!/?\ X)6^"?'GC/\
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M'_(0U#_K_O?_ $JEJ?\ EY_W#_\ <B*_Y=_]Q/\ W&RI1115$A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &K!_P @;4/^OW3O_1=[656K
M!_R!M0_Z_=._]%WM953'>?\ U\?_ *13*EM#_KVO_2Z@44451(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5-I_\
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M]VVR>OQ+1OI:SM?=-:'Q'9?MY_&3PW\1/^"B2_&GX&:1\,?A[^Q]^SIX0_:
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M[1?^ =E_\CUI>?\ +#_P-_\ RLBT/YI_^ +_ .6&516K_;6I?\]HO_ .R_\
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M &UJ7_/:+_P#LO\ Y'H_MK4CTEB)]!9V9/Y"WHO/^6'_ (&__E86A_-/_P
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M>$E1-"LYEB++YBKN&5S2OR_N^:U[>T=[=[<@[0WO.W?V:M_Z6)16K_;6I?\
M/:+_ , [+_Y'H_MK4O\ GM%_X!V7_P CU5Y_RP_\#?\ \K%:'\T__ %_\L,J
MBM7^VM2_Y[1?^ =E_P#(]']M:E_SVB_\ [+_ .1Z+S_EA_X&_P#Y6%H?S3_\
M 7_RPRJ*U?[:U+_GM%_X!V7_ ,CT?VUJ7_/:+_P#LO\ Y'HO/^6'_@;_ /E8
M6A_-/_P!?_+ @_Y VH?]?NG?^B[VLJNGAU>_.DWTAEBW+>6"J?LEG@!DO">/
ML^"3M')!(Q\I&3G-_MK4O^>T7_@'9?\ R/40=2\_=A_$?VW_ "4_^G9<E"T/
M>G_#7V%_-4_OF516K_;6I?\ /:+_ , [+_Y'H_MK4O\ GM%_X!V7_P CU=Y_
MRP_\#?\ \K(M#^:?_@"_^6&516K_ &UJ7_/:+_P#LO\ Y'H_MK4O^>T7_@'9
M?_(]%Y_RP_\  W_\K"T/YI_^ +_Y895%:O\ ;6I?\]HO_ .R_P#D>C^VM2_Y
M[1?^ =E_\CT7G_+#_P #?_RL+0_FG_X O_EAE45J_P!M:E_SVB_\ [+_ .1Z
M/[:U+_GM%_X!V7_R/1>?\L/_  -__*PM#^:?_@"_^6&516K_ &UJ7_/:+_P#
MLO\ Y'H_MK4O^>T7_@'9?_(]%Y_RP_\  W_\K"T/YI_^ +_Y895%:O\ ;6I?
M\]HO_ .R_P#D>LW6/&EKX=TZ;6/$?B+P]X;T>WDABN-8\1WN@:!I$$MRXBMH
M9]4U=K.PBFN)2([>*2X62>3Y(E=N*3<TFVH)+5MS:27_ (+':'\T_P#P!?\
MRP913=5\>:;H-O87>O\ BOPKH%GJUS!9:3>:[JOAG1;/5[VYC6:VL])NM3FM
M;?5+NYA9)K>VL)+B:>)TEB1XW5C:F\7);ZI;:%<ZYHEMKU[:W-_8Z!<7&AP:
M]?6%F[1WE_8Z++LU2\L+.1'CN[VVM);6VDCD2>5&C<*<TMK4[Z*WM'N]E\'6
MSMW"T/YI_P#@"Z;_ &^G7MUL5Z*O0>)9[OS_ +)J.GWGV6ZN+&Z^R+I=T+6_
MM'\N[L+HV\<GV:^M)<Q7=E/Y=S:R@QSQ1N"M3_VUJ7_/:+_P#LO_ )'HO/\
MEA_X&_\ Y6%H?S3_ / %_P#+#*HK5_MK4O\ GM%_X!V7_P CT?VUJ7_/:+_P
M#LO_ )'IWG_+#_P-_P#RL5H?S3_\ 7_RPRJ*U?[:U+_GM%_X!V7_ ,CT?VUJ
M7_/:+_P#LO\ Y'HO/^6'_@;_ /E86A_-/_P!?_+#*HK5_MK4O^>T7_@'9?\
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MF5TY?_N6%_Z]+_TJH<V._P!\Q/\ U]?_ *33"BBBNPY0HHHH **** "BBB@
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M 7B#Q-+I5OJOB;31X%\/:EXG\?65MJUQHK61_6RO./BC\'?A+\;_  Y'X/\
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MH **** "BBB@ J;3_P#C_O/^O'3O_2G5JAJ;3_\ C_O/^O'3O_2G5J\S./\
MD7UO\5'_ -.H]'*O]_H_X:O_ *:9NZ]X4\1:3J$/_$KN=5MKK2]'B%QHL%S?
MFWN='T72M)N(;J+R(C$D\L$DUG*&;S8482)%(H0Y']EZY_T+7B;_ ,$EU117
MBT,UQ-"E"C&-&48*T7.$G*UVTFXSBG:[L[7[MGK5LLP]:K.K*56,IOFDHRBH
MWLDVE*$FKV5U>W9(/[+US_H6O$W_ ()+JC^R]<_Z%KQ-_P""2ZHHK7^V\7_S
M[P__ (!/_P"6F?\ 8^&_GK_^!P_^5A_9>N?]"UXF_P#!)=4?V7KG_0M>)O\
MP275%%']MXO_ )]X?_P"?_RT/['PW\]?_P #A_\ *P_LO7/^A:\3?^"2ZH_L
MO7/^A:\3?^"2ZHHH_MO%_P#/O#_^ 3_^6A_8^&_GK_\ @</_ )6']EZY_P!"
MUXF_\$EU1_9>N?\ 0M>)O_!)=444?VWB_P#GWA__  "?_P M#^Q\-_/7_P#
MX?\ RL/[+US_ *%KQ-_X)+JC^R]<_P"A:\3?^"2ZHHH_MO%_\^\/_P" 3_\
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M^]K?B5_[+US_ *%KQ-_X)+JC^R]<_P"A:\3?^"2ZHHI_VWB_^?>'_P# )_\
MRT7]CX;^>O\ ^!P_^5A_9>N?]"UXF_\ !)=4?V7KG_0M>)O_  275%%']MXO
M_GWA_P#P"?\ \M#^Q\-_/7_\#A_\K#^R]<_Z%KQ-_P""2ZH_LO7/^A:\3?\
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M_GK_ /@</_E8?V7KG_0M>)O_  275']EZY_T+7B;_P $EU111_;>+_Y]X?\
M\ G_ /+0_L?#?SU__ X?_*P_LO7/^A:\3?\ @DNJ/[+US_H6O$W_ ()+JBBC
M^V\7_P ^\/\ ^ 3_ /EH?V/AOYZ__@</_E8?V7KG_0M>)O\ P275']EZY_T+
M7B;_ ,$EU111_;>+_P"?>'_\ G_\M#^Q\-_/7_\  X?_ "L/[+US_H6O$W_@
MDNJ/[+US_H6O$W_@DNJ**/[;Q?\ S[P__@$__EH?V/AOYZ__ ('#_P"5A_9>
MN?\ 0M>)O_!)=4?V7KG_ $+7B;_P275%%']MXO\ Y]X?_P  G_\ +0_L?#?S
MU_\ P.'_ ,K#^R]<_P"A:\3?^"2ZH_LO7/\ H6O$W_@DNJ**/[;Q?_/O#_\
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MM#^Q\-_/7_\  X?_ "L/[+US_H6O$W_@DNJ/[+US_H6O$W_@DNJ**/[;Q?\
MS[P__@$__EH?V/AOYZ__ ('#_P"5A_9>N?\ 0M>)O_!)=5TGAKP5X@U)KZ_F
MM?[(A/V:RMX-52YM[Z;[*UU-+<M;>01%;N;Q8X&,KO(8I69(U";RBN?$YEB,
M52=&I&E&$G%RY(R3?*[I7E.5E?71)Z6O:Z-\/E]##556A*I*<5)1YY1:7,K-
,V4(W=KK6ZUVOJ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1_006.jpg
<TEXT>
begin 644 forms-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &= D@# 2(  A$! Q$!_\0
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M.QSA8VZ*Y(1F(0$L0#YJE6=E%WNO=2O=JR>B2_E:?HT]FB"_]NO_ /G^N_\
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M#X^C2DI.-:2NU*DFYT)Q]^E5LX*2G-'3A<75PE12@_<=E./J]W;73H^GX/\
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M_A7'Q#_\(7Q7_,Z1CZ'I[U_,?]F9E_T+\=_X28G_ .4G@J$WM&7W/_(X^@G
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M 4444 %%%(3@$]^/Y_\ UZ3VMW:MZ[_H! Z!N_#;B1C[VTGKDD8P<?=#+U#
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M0Z/IFMZQX7\,:Y<2ZE.U_9VD2ZIK%C8Z2]Q"C/'+]NA5'8=<XQ@'#!N0.OS
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M[4HOS>_X#3:_Y@J<O-M)_P!+^F>-^ /VN_CAXM^*5C\-I_@S;ZCJ$'PDT?\
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M.OPOT?X7Z9:VBZMXC^)6N:U<:XOB;Q[XU^-1M]$\(_#"3QF+'0;C4=/\*?\
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M8K:VB2"%#+(\TK+'&%7?++(\LCD%GD=G8EB35B@QV;<8QBG_ "MW>O7I;<3
M!<C@R9\PC +AL%@Y !;<RAFSU89/4Y6BB@5DKM7UWO\ \.PH/W7_ -T_S%%!
M^Z_^Z?YBCJO\-7_TF(/;YK\T?6_P0_Y$E/\ L*ZG_P"C(J]AKQ[X(?\ (DI_
MV%=3_P#1D5>PU^Y9%_R)\N_[!:?Y,]6E_#A_A04445ZQH%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^Y9%_R)\N_[!:?Y,]6E_#A_A04445ZQH%%%% !1110 4444 %%%% !1110
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MXI_MB^!?#WPIT+0O"_Q1U*:_\?\ BWQ!XOO_ !=\-'OX?$7A;Q'^T%=:;/\
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MQ#W.O^@C+/\ PIJ__,P?V1BOYZ/WR/[T,CU'YBC(]1^8K^"__A^A_P %(_\
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M0 6.%)8X7#<Y#8.&Q@8^8C(S^^OA/_@G=^S!XSU/0?CHUGXH\!_"#6/V)O\
MAK&X_9^\??$>_P!(U+1_$B>*K?PBFAZ[\5H]"OO%NG_#&0SC6/\ A)$\.W6N
M^0KP@)'(1%R&K?L-?LD:?XH^)GQ:T"?QA\1OA5\,?V.K+]I;6?V?/!GC/6+S
M5[_QM?\ B67PS)X2T/XKW_A?3_$GB'X56T5L=8;Q98>'VU,6]U':3'=%&&(\
M4X&3=.,<;*<(0YY<E-14YM)0O]8Y5-MI>T;>&?2=U9RL=1YE%0<Y-72Y%&RL
MGNO5?E=GX>)#<2^:8+:ZG$"LTYAMII?LZI]YKGRT?[,@/R^;<>5#O*Q^9O8+
M42,LFXHP958HSK\P5P<;3MSR,@.!EHRRK(%9L5^SGPI^&'PSN?#'[:?C/X;_
M  W_ &C/V>_ .H?\$Z=>^*]CX!^(&OPSQ^+)8?$-K:ZM9^%_%L]@^K^+?A/J
M+;TT[4=2L](UZ.]:[!V>7&!](_M!?L[_  !^*OQ[_9X\+^&OV8]8TCP)X#_8
M%\)_'#XAWNF_%ZU^&7@"U\'/X>L+[2)?&WBN;PT\VG6/AO59[Z[\:>,/#D&L
M>,O%4MY;G^RXIK8K(3XFH0Q+I2HXJ-.,>?F;I72A@Z>(E3F_;\LISE-1A*E*
M5/WE&[ERQ*>,@FDZ&[L]/)-)]K[:7L?SK1Q33[_(@N+@QJ9)/LUO/<^7$O+S
MN(8W9;:)/GEN646\0!6216&*5()YG$5O!<74[*S+;VEO/=3N%4.WEPVT4LDA
M6,F1]JD(JDL0!FOZ<_@S^RW\"/@C^U:[?##1M>\0_#3X^?\ !+3XX?%75O!V
M@:]JOC6X2XN[G2]*N],^%WBCQ=X?T[Q%>V^L6R,_A2_U_P /Q7\%Y<I/%:-'
M<('\0_9/_9E^"7B#QU^PS^T%\'=#^+W[.^G?'K0_VH_"&O\ PUU+QQ/XE\1Z
M=J/PJ\#7-S:^*_"7B[7M&M=4NM \3KOM=9MK[2A;)=K);V+6J+Y3X+BW#S<G
M&ABHQE0HU:";@^>K5IXJ7L)OVUX6>%F^?5NRORW5Y^O4^9I47;2VFNJD^E_Y
M6?S[@$DX!(!(+#E01@$$^H)"D#)#?+U!I0"3C_=P1R#D[6/7("-\IR 6/W P
M()_<SX#_ +('[&FN:9_P3=\-_$CX>?%/Q5XY_;OT7XH:=KWBW1?BM+X<T/X?
MZIX0\1^(K/2O%.C>'X]&O6U?491IUK:3Z3<W=MH45H)+M8+BX;R&Z'X+_P#!
M/3]E&Q^%?P6UCXV>(I=?UK]HCXF?&WP3;>(X/B?KG@W6_AKHWPO\6Z[X/TL>
M O /AWP?XFM/B3XVD?1TU_Q+HOB34-+@AM;E%L8TAB!;;_6O+]8R6,A-NIR)
MTT^?V;Q$)VDJKA'V=3#UE[\DZBI15--U+IO'8>UG%PE??DYE:[76VTHR6Y^"
M1&/T(/.&5@"K*>X89ST92"K &DKI/&FAV7A;QIXQ\+Z;K$?B#3?#?BSQ)H.G
MZ_#:R6D6NV.D:O<V5IK(MY8XY;634(8UN)K658S%(Y6.-8Q7-U]'"K[2$*D7
M)*=.G/>2^*G"5[2:E'F4E+EDE*/-9K1'6G%I./+)-+5Q2UZJW2VP44457-+^
M9_>_\QZ?RQ_\!04-AU*. 5P5'4-M[?,I7:RDL<A3\P20;94#T44M==79[Q^R
M[[W6SO=W)2LFM6F[V>JU[7V6NQ_6E_P0E_X*&_&#XP:]??L>?&":X\=0>"?
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M (;TOQKH.H:W\2]'>6_A35? ]A;7,L^NV$<VE:I;WDD2LUI<V%S;S;)H)8U
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M1[ZPN_$-A?Z+;-;HS2:C97\)1S93(@!Y[_PQ_P#$7_H:?AI_X4\__P JZ/\
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M^7/3^ZQ'XU]5?"G_ )$ZVZ?\?VH]  /^/I^P  _ "@#TBBBB@ HHHH ****
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MET[)[KSOZ6MT/I7]F[Q+/;ZSJWA2:0FUO[1]5LHL?)#=6Y$=RL9S\BR0E7=
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MY99X3<6T$=[J\DEU"/+9[NW@36Y/-M29$BDNH)&MP7C(E,L\>*M__P $X_\
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M#7Q+K/BCQ'XA=Y=:UJ_O\MO,,DQ%I&,_=BM8F6V"@G(PKL <%^,#"P,'@88
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MFOCC52<7+[5KIQM>]MK:)76I\XCXERDA1H\&T_*%%X5R&P-N0N0#@#(S@*H
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M7ZGN=Q)]2PPY)[[EX8GJ.#Q2DMG))R0>23D@@*?P*@ ^H '05G]8G_+#[O\
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M"SBN[OSG0'YHNO\ @H'_ ,$Q- \(>"?%K^//AC9>$]>?QCXZ\*O8_!3Q!/\
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M-*$4E&$&FK='IU>[3UOOJ?-MRDW*3O*3;D[MW;U>K;ZA1115""BBB@ HHHH
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M.1N_)KXT?'/Q5\8M:E-Q<7&E^$K6>1-!\+V\TB0PVRN/(OM2\E@E]K$JY!#
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M6UJ63Q'XC^&%U9_##7/ \$$>H:7_ &+]E>[ETG7M3:@#]TOAS^R'\*/AM?>
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M>'/#^G_ [1KZ>>ZM-2^*>O6;6>RV<3VGA'3[CRWEA#C.;R7'F2LIC:YD2-U
MAB8NR?XH:S#8MI?AG2M"\$Z;(ICEA\/6<-O<R(?^GLAY$<#CS8RK$9QMS@>=
M.TDLC2S2232.Q=Y)6,DDCL<L\LK9>5FZMYC,"P#  U]G@\EK2]C]:4*5&F_@
MA-5'4>C:GRI)134=%?FV<K73^7Q>:4[U'A;SG/:4XN'*G=75VW=JZN]N@W+D
MEGD>1V)+O(=S.6;+,QXR[<$MU+[F/WL!:**^H222BDE&"48VZI=7Y_UL>%=R
M]Z7Q2UEUU]0HHHI@%%%%'S2\V[(/DWZ*X4444:Z>[+5VV_%^79@%%%%$?>NT
MG9;W5OZ[^@!1111^/FM5]X?AY/1_<%%%% !1111MK:[6J3V?D_ZW!J^YU7@[
MQ';Z#>WUKJ]DFK>&M?L;C2?%&CNBR17VF7,3Q2.8)#L9X@^ !DE#(N?G!7X*
M_: _9+\1_#R2X\:?#6WN?'GPDU$SW=C?Z0DFH:QX565_,.EZ_8Q;[HVML,I!
MJ,$;@'$=XD);:?LK P ><'/S<G!SE<]=I/)!STX(K?T'Q1KWA>>2YT+4I[$R
MX-Q!D36ES@@_Z3:R*\,Q(&PL4+^62F2#7-#Z[@\3]=P-2$:D[+$86I=4:\8:
M0O)?!.,6U&:3TM&<91MR^O@,VEA;4ZM)U:6EGS*\+;VB]T^JOTNGL?EOX#UH
M:AILMA+/NN]*<P?>V2/;R$E?,0Y<2(4*,CA63:>!C%=NTJJ57<A+$!1N.XD\
M!0J[RQ). NW))X&2!7Z;Z7-\,?&GBC3D\:_"+P!=7^LSPZ9<^(+#2TL+O$[%
M4>Z$*1&?=.4#$D'YR<\<_5GA[X,?"KPO,EUH7@#POIUS$S-%<1:7;R3*3T99
M;A965NASU5AD<@$<&9\22P=9/$9>J=>LN=*-6%2G)MM<W/&UO>7PR@G;5[GW
M&#SJAB:#=%2_=^[)2BTT[7^T]5YKJ?F+\"_V8O%/Q+U*QUGQ587_ (;\!12+
M/<2WL4EEJ_B"*-U(M-*M)0+B&TN>4FU&:-$$'F)$C2.IK]$_&W@O5KFXTFR\
M-Z;$-$TC2H;&RM8);>WMK$P2/$+>"W+*P2.WCA0$K]T8#,!Q[GY:D#J,CGIS
M['CG X&>@X&*<$7TR?4\GV&>O'..>]?%XS.,3CL3&M.,80I\RA2BVX0VNUKJ
MY;N6CMI:Q-2O.K)2?PJSBO/KI\D?*Q^'GC%O^80"O(V_;(-N&!5LA9!D[&8+
MG(!P0,C!7_A7OC,-N72%#9;.ZYMI%.[:"/+=FC/RY&"A4EBSJV,5]58 Z#%%
M8_VEB/Y8_>#K3\OQ_P CY8'P_P#&@!7^ROE;R\J;JS?B(8CQYN_:8@%$&!F+
M!(RVUD#\/O&3"3.BP$RAT<&2P*F*1D=X"&!+6TKH&EMF8V[$!DCC<N[?4]%#
MS'$]&EZ-H/;3\OO?^1\L-\/_ !HV=VDJQ;<&9KFT8NK8)4DG(&1P$*!5 5 H
MW[Q?A_XT5BXTE [!M["XLT$C.FUY)DC*I/(YY=[A92PRI^4C'U/01FC^T,3_
M #+\?\Q^VF?+2> O&T;%H])BC)6)/DFLU7RH% @A\OF/9$P,B+LVI)L,81%V
MGE/!OP(E^'>@Q>%? O@;1_"OAN'5-;UF/1-'%C;Z?_:GB/5[S7M=OFA8OYL^
MJZSJ.HZG=-.9 ;R_NYHUC>7C[.VC_(7_ .)I0 /_ -0'\@*/[1Q3^U_7WA[>
MIUE==CXB\7?LZVOC[4?!6K^-?A_I7B;4?AQXBB\7>!I]4N(YH_#GBBW@-M:Z
M]:6@G6SFU2RA(^PW5Y!</9RJD\&R5$9>V/P^\9EF8Z0C9;=B2YM)EW;@X<I.
MTJ%PZJ^\KO,@#L2P4K]444+,,1W7XH7MI^7]?(^63X \:EMQTA"=H0-]HLO,
M1!)YNQ)/OB/S-SB)F:,.\D@42D. > /&HY72(U8-(RLD]FC1-*I\QH"I!A:5
M\&=HR'N$W1S,X=F/U-13_M'$=U][?YA[>?6WX_Y'RJ/AWXP7@:+%MVNFQI[)
MX]DC NIC;='AE!4C;MSA]NY0:4_#SQB56(Z- 856-5A9]/:)!%)YT0BA96@A
M6*4EX_*B1@X5]V]%8?5-%+^T,1_,OQ#VTO(^61X \:[FD_LI?->,Q/*+FS$I
MC!9HX_.),S0K))+(T$DDD3,VY51MS,T?#WQBHC5-$@2.(8BC26P2.%#EC%#$
MH\J. .S.D*IY2EL["_SU]444?VAB/YE^(_;3\CY77X>^,UV_\2>,[&61"9[)
MC'(HPLL)8DPRIUBD0[XB25/3!_PK[QGEF.D1[V50T@N+0.^Q'C02MN)F6-)'
M6)9O,,0=S$R.Q>OJBBC^T,1_,OQ#VT_(^3;;X8>);$W36?ARSMC?7<]_?>2]
MDJWNH7+1M<7]X@.RZO9O+427,ZR2.4C).4&;"?#SQC&-L>BV\2^8LP2$Z=&B
MW"JZ)<HB($2X19,+,JAMH"-NC&P?55%/^TL1VB_.[U%[:?E_7R/E;_A7WC/
M4:3M&QD8BYM"71T5&1@^Z,(44J8T1$?<1*LBA5I?^%?>,R5+:0F%41@+<VR*
M(PRGRU57 CC&U D482(+'&&1PF3]444?VEB/Y8_>'MI^7X_Y'B'P\\):_HNN
MS7NIV(M[9[&:!7^T0R$R/(A *QLV,[/7OVHKVT(!C!( [ X'7/( _P YHKDJ
MU95INI-)2=KV\C-R<G=[BX'3Z=SVZ=Z,#W_,_P"-+168A,#W_,_XT8'O^9_Q
MI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/\ C1@>_P"9_P :6B@!,#W_ #/^-&![
M_F?\:6B@!,#W_,_XT8'O^9_QI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/\ C1@>
M_P"9_P :6B@!,#W_ #/^-&![_F?\:6B@!,#W_,_XT8'O^9_QI:* $P/?\S_C
M1@>_YG_&EHH 3 ]_S/\ C0!CUZ <G/2EHH *^7/VC=3POAW0U9E61KO5KD*Q
M4,(U6SMP<<@_/-MY R2>U?4=?$GQYNS/X]:W+EEL]*T^/:2"$WF>Y91Z;O,1
MC[@>F*]C(J2J9E1<E>--2J-6O>W+%?C*_P CR\XJ^SP-1=:C4%Y-W=WY::GC
M?(R,@'H2H Z>G' ]!T%)2#.!GK@9^M+7Z4TDDEM=OT6B5_N/BH[)O>UG\KA1
M114C"BBB@ KQ_P",OQ^^#/[/.AZ1XF^-OQ&\._#3P_K^L_\ ".Z'JOB1KT6^
MJZ]]DFU%M*M5L+6[G:Y^P6TLZ*(F+X< $H!7L%?E#_P5+T#Q9XEU/]@32? ^
MJQ^'/%%W^VGX5@TGQ7<^%8?&FE^%;J7PIKB0Z[K7AJZ*6.JZ=8R?-=6U_)'9
MS1,('D#R!#K0ITZTW"I)0CW>B]?D9U9RA%.GK+M^GY'W5\&_VFOV??VAY-;M
MO@?\7_!GQ(O?#45M-XATO0;Z;^V]%M[UI!97E[H]_:V5^EC<.A@%\UO';M*$
M1<.WS=)X/^-7PD^(/Q ^(?PG\$?$3PQXH^)?PFFLH/B3X-T>^^TZSX,DU$ V
M::U 8U2(3,5C+P27 AD<1RA7&*_%+X>_$7Q%^RG^TW^V?\7?VT-0N_$_[4/P
MS_9X5?@OJO@#X?Z5X.^#_P :?@=9ZE%=:*W@_0?#&GM+=?$=_&$^EZ3XET[7
M)[V]TB&9YK#RK=9R/ _V?O"?[2/[&7Q*_93_ &M?BS^S_K'@O3?B#XGUWP=^
MUQ\5[?QYI/C2]^)=M^TMXEC\5^$_$VN>!M%A.L^$X_AUK$^FQ1-J$]R^E:3'
M<V5RL4Q5#W?487K-596G3C&DE*+4)*.KN^5N+Z65];-)WMR?6:O6&O4_;0?\
M%!_V(V\53>")/VF_AC:^*+?Q#/X3N--OM1O=+BMO$UI?2:5/HMUJNH:='I=K
M>?VE&]IB>Y5#<1F-&&]:^@E^+'PU/Q%UKX2GQQH(^)'ASP19_$O7O",EVL=_
MI/@#4+BXMK'Q?>W,B)IL7A^YFM9T6]-Z2D<,UPX$6PU_.U\+_C9^SQX>_8E_
M;;_9M\?:+=^,?C?\0OCM^UM8_#_X4:=\*?$_B;Q9XDU;QKXGEM/AW?Z#JUOX
M5FM+6!M90:E97_\ ;<,=DMJ]S#(D8S)+XT^!_P"T/JOB3X^_!G3;/7K[X\_\
M.7_@3X(NQ:27)N-9\5Z+XE$OB/P9::\B/;7&OSZ/9W>B[8KDR7USNC<*UPS.
M?V?2YDE4J*-U>\XNZTNVDWU;NM=+?)/%SL^6W-;3W9;].G<_;;P+^W/^Q[\3
M/'UO\+_ 7[17PW\3>.]0O+G3='T.SU.YMH_$&J61D^V:?X9UC4+.VT;Q%>0F
M.15M-'OKZ:95^0[T<-]6G(9E( *DC;A@Q&Y@KL&^YN55/EGYT);<3D*G\\G[
M0'QK_9X_:0_8X^!7[*_[+?@C5)OVF(?$WP#L/A]\+]*^%7B#POXO_9W\1^!=
M7T2?QIXF\6:S+H&G6O@RR\.0:?JCZEK!U>7^W8Y2?],:X9A_0Q&LJQ6ZW$ZW
M-S':6L-W<)@I<7D-M#%>7"X^4+/<)),BJ2JB4G)<O7)6ITX1YJ>B4W#E;][1
MOWK+3E?S?7J;T*M2HDZF[[+R\TGH/HHHKG.D**** "BBB@ 5WA=9XLK+"ZSQ
MD$@B2%A*A'/564$>XK])?#^IIJ^C:3J:$E+_ $^UNATQNFA5V!(_VF(QV*_@
M/S989&.HR,_3(S7WC\'+O[9\//#I+%FMHKFU)//_ ![7<\0 R. JA5 [!1WS
M7R?%5&+HX:OUC4=-[;-<RU[<RV/>R&HU7K4M>5TN:WG>VWH>GYYQ[9_7%+2'
M'7..V>/RY_I4;,XST/XXQGT[_G_^OXI6;:6^N^G:^I]4ODE;JTEMM=DM%0J7
MQR&')'(R>._;CT^GUR_+>_\ WS_]?_.?I@;LVM-/[R%=+1Z/JM_QBFG\F/HI
MF6_VO^^?_KT9;W_[Y_\ K_A_]?FES>G_ ($@NN_X/_(?13,M_M?]\^WU_'Z^
MW%&6]_\ OG_Z_P"'_P!?FCF]/_ D%UW_  ?^0^BF9;_:_P"^?_KT9;W_ .^?
M_K_YQ]<G-Z?^!(+KO^#_ ,A]%,RW^U_WS_\ 7_SD^V#+?[7_ 'S]??\ SCZY
M.;T_\"077?\ !_Y#Z*9EO?\ [Y_^O_G/TP9;_:_[Y_\ KT<WI_X$@NN_X/\
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M_-2_\#?_ ,B'S7WK_(GHJ'_@(_\ 'O\ &D_X"/\ Q[_'W'YT7?\ -2_\#?\
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MH[)EV+?+CYCNY)Y4\APT<3K* )%E59%D )(#(RE6498A6& >@&2:_$?]JO\
M;K_:!^%G[1OQ)^&#?%3X/_LI>&?"GA3P?K'P0U+XZ?!KQAXQ\#_M,:IX@T*V
MU+6TU'XMZ3/'H?PYTF#5Y!H:1):W%WIC[[V\<QH57Z'U?]HW]HOQ9^TO\#OV
M??!6O?"3P1<_&+]BCQ-\;)]?AL/^%K>$M"^*^F^(=#TRWU#0->L+VP;Q7\/C
M:WEZ]O;PBVEU#=#<B[B\N:)Y>#J633J:I/XY)7LGIIJEW7:V^A2Q&';:M>U]
M;)7:=KVM\]_T9^F4:I$5EBCBBE'RB2.VBCE (*D"5$#@;3M.&'''2@!0YD
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MQWPQ=E0H65XQ=E>3=E?JV?QROI8\065^%,H?IC,6NKMHHV6EMM#^O;_AI?\
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M\.^__3_[?S].?Y"A%'G:(T)QG&T$X)P#C&<$G _*D,<9_@4XXZ#C';CTI?\
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MA0?Z@_I8<0)M?ZJY,[.UXX[&27G=\N][G]>W_#2_[//_ $6KX8_^%OX=]_\
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M_7;./Y<)_P""'_\ )C_XEL\._P"?/_\ PZ+_ .9#^X+_ (B(/V ?^?;X\?\
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M6^X_N"_XB(/V O\ GU^/'_AL)/3_ +#/K^G/M1_Q$0?L _\ /M\>/_#82?\
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M))V6D[+77H[;VL?DV94Y5L#B(\J=H<R2DF[I]-&KVN?$J]!WX'\J6F[ER1D
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M714_6:SWG?U7:]GONKNWJ_DEAJ2:?+MMM_D/D=I)))&ZR.S\DD_,20"69F)
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MM>K!TU**5-R<>6I'?GC+F347HK2@GUV9*6!!QSP>Q]*^"O\ @I=_R:)\0?\
ML)^#O_4FL*^\5 ^;&>%/4D_H0./?I^E?!W_!2[_DT3X@_P#83\'?^I-85Q<+
M-/B7(;.]LWP*>EM5B(W6O8\GQ&?_ !K_ (Q;27_&-9QHI<ZM]2E9W26_:WWG
M\QYZ+]/ZFDI3T7Z?U-)7]FSW7^"G_P"FX'^3RV04445 PH_3W[ #DD^@ ZT4
M#J.<#/)P#QWX/!!Z$>A--;JR4O[LGRQEY-]$]F^B8T^5J3=K-.^FEG>_O7CI
M_>T[Z7/2_A5\)_%/QA\3R^&/"[:99O8:1J'B/7=>UZZ6P\/^&/#FDKOU+7=:
MOGC?R;.U7(1(Q]HN92([?YCFNL^(OP-A\%^#[;XA>%/BK\._BUX-FUE?#>HZ
MAX/NM1L]4T?7)$+K:WN@:ZD&KS6]PHQ;:G:V\EM(S*K;02R[G[-/Q(\&^"=7
M^)'A?X@W=]HOA'XP?#;5?AUJ/BC3;6;4;KPK=W,OVO3M9GTZ%TEO--6[5$NX
M;=UDBB;<0R;P>JT'3/V;O@CK'PP\32_$9/CCXPT;XF^'M<UBW\&Z;>V'@:Q^
M'FE/_IB:E;:U:1W6J>))'5+J&UM3Y<4R(DOF)O8_)8O,LSP^:8J,8YC[.@L)
M+!9;A<KJ8C#9E*KAL54Q5/$X[FY<+*E7AAX4TI>ZIJ4U6=51I_I&4Y%P]C.&
M\$ZKP$LPJUL93SG-<5GD\'7R2O/%Y=3RZOA<HA+V6847A<3BZ]:BX595X4:C
MHSP\J/[SY^A^%OQ(FUGPMX<F\">+M/U?QK>6VG^$K75_#VJ:6-8GO'6)#9R7
M]E''.B1.9[DH'DMK,/=>7L"N;7Q!^%'C[X9>(?%?ASQ7X=U2VG\%ZA#IFOZK
M#IVHMX?MYKC"6=Q#J\UK#:G3M1?<FEW3M'%>LC1VYED4K7Z(?%?]I?X>I)I<
M_AWQ]X:\20ZK^T#X6^*$/_"+S_$S5O$WA?PUI^J6]Q?ZG>:EXMU"2R\)ZK+8
M23:5JWACPM;?V;=60FC@B1%45E_$GXC?"7X@+^U[X&N/V@?#GV7XT>+/ 7CW
MP'XPU:U\57_A[2M%\.ZO)=W'@9U^R2WUKJVEVT<<]KI]G FF2R7JK#M,5P!Y
M5'B;/IU*56MDW+1G1<IT:='&NHI?7L-AYU$U2E*,:=&M4FJ4J3E-TW-3=--1
M^@Q7 /!T,-F-# \64,7C,/5I1P^)E7P-'#RG6RG'8W"X6<)SC*4L9BL+2I0Q
M5.JJ-&GB:5.<75NY?G!=^#?&&GPZC<WWA/Q+9VVD6UG>ZO<W6A:K!!I5EJ,8
METV]U.:6T2.PM-2C._3KJ[:&WOA_QZ23'BNFLOA=X@E\/^.=;UDW7A>[\%Z/
MHNN+H&N^&_$D>J^(K/6;QK6R6P==.:UL84D4W45QJ\EK;WB/&E@99"2OZ-I^
MT9\%=!_:'\2?&)?B(OBSX=Z7\"? /@-?AU9Z//)<?&+6[#118'1[C2M7M#8V
M=MX>N8'U)[F^,<T%XYMX7>WDOUD\N\9?%[X<7 _;+O(_BXGCM_C9I7PTU7X?
MW5W97<>IF'2_%(U.]\%W=F;5(-.N_"5@?L:PP"*TEME$MN6G$N;?$F>U:M.E
M_8F(P_/ALOK*?L\3_'Q%>C3Q6'E[6C&*6&IN=2J]^22Y&I4ZCBGP'PAA'5JU
M.*,)B)87'YAA)TZV(P#A3P]#+:F(PN:-T<2FJ.,Q<:F!I4G>:J4)5)7I5J4I
M?$DOPR^)44*W,GP[\>);R:A!I4<TGA'Q"!)J=UM^S:>K-8$R7UQO3R[=2\TA
M8;0V<U2@\">.;CQ#)X1A\%^+)_%D"M)<^&(?#NKR:_;PHJL\\VDQVHOHH%5T
M)F>-(LL@$N6%?I%\1_VJO#VHZU^U[)X8^+.K'3O&'PD^'.@?!Z.TO-9AMG\2
MZ=NM]>3P["ZK'H]^$>5+B\2.TN)"Q8W)=%D5&^-'P:\3?$&]\1WWQ4.G:Q-^
MS-\-?"-MJ.J:YXV\->$/$'CK1EE'BC3/'VM^$8XO%MW-;!EE@2SF@34)W=7N
MI@[!:_UFX@HP=:KD,I0^KRJ0E1ABY3C4G1H5Z<:JY;VC[65*HH+F]I3DU;EG
M%1'@+@RK/#8?"<81@ZF)A2Q#K5< J=2C6Q&-H8BIA)4YRDERX6E7P_M7).C7
MC%WE*,CX8\#? CQYX[C^*2VFGW6CZY\)O"T'B?6O#.KZ'JZ^)=3^V:A%IUKI
M>F:5%9_:TO)KJ2-H%N8G\^$GRM^0U>7:SH.N^&M0DTGQ'H>L>'M6@CBEGTK7
M-.O-+U""*Y036\KVE[#!.L,J^8L,A3RW*.%8LI _636OVB_@UJGQ+^-&NZ3\
M8K+PA#\0OV6_ GPWT'QGI^E^(V:Q\?Z9J]\-10V[I)KEM]E@G@DN+AYY;^/2
MYC.9Y;RV4/\ &_[3GQ"\+>*]%^!/@W1_&J?%+Q)\+_ &H^'/&GQ2@CU VGB>
M^OM734;#2[2^U:"'5=6M?#]JHMH;Z^57((" NTI.^49[G.,S+#T,3E=6EA<9
M2H5G*=*M"="4LNE7KJ$Y1]E.DL7".'49M5HSKP332;.+B?@_A+*\AJ8G*\_H
M5\?@/K.'ITJ%;"5J>:3AGU+"T+T8UEBZ56KE->ICE7A">%<<+-)J4E$^3Z**
M*^UZ1=FKQ3L]];_EMZQEY'Y0]]8N#ZPD[R@_Y9-))R2LWRZ+F2WC(****!!_
MG_/%'K_G_#^G]:**=WT=O)#O+W?>?+%WY-.5OSTO]S-;P]J%_I'B+0-6TF]N
M],U73=8TV\TW4["YGM;^RO([F'9<6ES;O');R!1L<!F0XP0RDT53L/\ D(Z9
M_P!A*P_]*HJ*X<90P]6=-SPN$FU2BN:KA,-7GNV[U*]&I-W;O;FMY'T&58K%
M4*%2&'Q>,PU/VK?L\+C<7A:=^5*[IX?$482E;1S<>>7VFS\"]4_Y"VI_]?EY
M_P"E;U1J]JG_ "%M3_Z_+S_TK>J-?Y.'_7=2_@1^7Y(****!A7TO^QI\%?#G
M[1W[5/P-^!7B^_UG2O#'Q/\ &L'AK6M4\/36UMK=C9365Y=--IL][;W=FMSO
MM45//M+A0I<E.1GYHKZ)_9'^-^F?LU_M-?!?X]:SH.H^*-+^%?C"'Q->^'=)
MFL[;4M5A%E>6)@L[B^VV\4@>Y21F=P"J!3@-N&V&=%8B@Z]O9*M1Y[IM<OMJ
M7.FEK9T_:7MJMUJD>3GRS!Y)F\<I51YI++<?'+O93I4ZBQSP>)^IRA4K)TH2
MCB?824JB<;I*6DF?I;^T1_P3E^"W@+X!?M*?%C0O W[:/[/>J_L]WEA'HFK?
MM/Z9\/[CP'\<I[[Q1+X=MM'^'D_@ZUL=86^U&2WCU32+R>/R&^VZ=#-#MEF"
M?"WB7]@/]I3PAX"O_B#KVC>!(#H/A#PY\0_&_P /H/B'X>O?BU\._AWXNFA3
M0?B#X\^'UM/)KF@^%[J.YBOKV^GB:72K%A=:E!;)Q7U5KW_!0;X#^%O"G[2L
M'P;^'7[36N^-OVD_"OBCPKJ:?M'_ !JTKQ[\,? 2>*=>EUNZU[P]X*M8)%;7
M=#EE,'AEC+')I<"PQQ77E(Z2=-\<_P#@JKI'Q?\ A9X^@M_#WQI\,_%WXI?"
M#1/A#XHT:S\7>"+#X(Z;:6NF0Z)K_BBP_LSP_'\1]?C\5:=%(+CP;XBU5]"L
M+B<26[8B!F^FQ,<BK.I5E4BG"C&,51O22G[:O=RY8-2_=^Q2C:*M=MN4M/R'
M*L9XMX.%##SR_$8O#U<UPT<5C<T=/$5L-1JX++X5:-*G6Q,L31I0Q%3,<0Z]
M6I6A*=*C"C"GAFX/X:U[]AK]H[PQXM^-_@[7/#?AZQO?V>OAOX?^+/Q'UE_%
M.F?\(K'X&\7K"?!^J>'/$6X:?XCE\4R3I;:+::>[375TLD PT9J_\0OV#OV@
M_AK\+M<^+NIQ?#/Q5X6\(ZQX2\/^/-/^&/Q/\+_$+Q1\/=<\=)&WA/2?%FB^
M&KJ[-M?:P\T$$<%G<7C0W$R03;)-P7VGXB?\%$[CX@?LA?!W]G*^^&]O<>-?
M#&I_#71OC=\2KZ^B$?QJ^$OP6U2YOOAA\,]0>VE?5K>RM+6\>SUIIT,0M+&W
MG@D:4[A]"?&W_@J;\*O&OP?^,?PR^%OPF^)O@Q/B+KOP<\;> M%UF\^&5I\+
M?@YXD^$FO:)K=IX5\,>%_!FC:1?:GX4U:?2)+R_UW6-0U'Q-=W$RP2P64*?-
MS0P^1.592KU%:%.5-.<D^:7,VOA]ZUE%Z[ZJ]W;UZF;>*D*V77R'#.G_ &M/
M"8WECAHTZN PDHX>6-G4J8B-3"T\R7M,PPZIIRPU./U:HW42IU/B'Q]_P3__
M &B?A/X;?Q;X]T_X>)%X=U3P);?$GP'X<^*GA#5?BM\-;7Q]?:=!H7_":>#8
M;UM0T6?4(=0MU8F.Z&ER7,,NH1K"'KVOQ%_P3$^+WC+]H/XE?!SX&6W@W1+O
MP;XDT'PSIGPY^,GQQ^'-I\6;^_OO ^A>+;I[.RTEX+/Q3IWDZNUU;ZCH5FUM
M9V[&SO;C[;:W$:X?[0W[4W[(OQE\1?$+XX:;^SI\5;+]I?XO^)/ GB'Q-J/B
M/XEZ:_PL^&^L>%[S0I?$NJ_#O2M BL-;\3WOBFTT80Q6/C_[1I&A-=O+:(BQ
MC'TW8_\ !2[]E>[^*?[5'QLU?X!?&_0_BS^TA_8OAC2?BGX"\7> ;+X@?#/X
M::9X(\,^%=1\,>"]5UVTU"W\-ZUXFN=)U:^UC7M(A-]-I=Y806U[;&,E[IX?
M)755-XAJBZM&]YR4W3;K*M::A>+E%4=+-0;;O:Z.;%9EXGK!_6,-E.+EFBPN
M(4*=3 8&E3AB?KF7.+IX.GG-6GCLNPU"IF</K7M*6.KPP]":H\U>,E^<OC+]
MC3X[>!-&MO$6MZ9X/GT6]_:(O_V5[+4=$\9Z1K5G=?&33A ;G2K>XLY'BET-
M3<QQIXB1C8-('4,!S7JND?\ !-#]J;5=6^(VE7%K\*?#</PJ^+T/P)\<Z[XO
M^*WACPUX?TCXE7VG:=J6EZ+!JFI311ZFNK#5=.T_3YK%9OM&IW:6JH"LC)Z7
MX%_;%_96\-_!RT^ VM_!GX\ZOX ^%O[4\7[4'P).G_$?PC!XIO\ 4/[,TNRN
M_"?Q?U6\TNYBN(&N;&[U)]5\/6<EW>_:(X=T4J/+-:^-O_!0OP7\7=(^,VF6
MGPR\4:<_Q2_;N\"?MB64MWJNC7":3X?\':7X?L[GP7<)"S&?6[^;19;BTU")
M)-/A%['%*RS0N*SAALCA"<IUYS:4VH*I.[<4WK+D3MS."2TO%WLM;;SSKQ-Q
M%98;!Y3AJ5-JNHYC4P6']ZF\3@GA\5+"O,FJ4_J7UZ=7#2D^2LZ<)2DXQY_!
M?BW_ ,$]OVG_ ()>"O&7CGQ]X<\$Q6GPW\6^'_!?Q&\.^'/B)X;\3>-? 6J^
M+;M=/\'77BSP[I5U+<:3I/BRXEMVT:_N)%66VNH+N=88&9DB\;?L&_'?X:^!
MA\3_ !'-\,=?\$:%XU\"^"?B3_PK+XI>%_'NO?#'5?'E_8VFD:?XTTW0;B\A
MT^\NEU".%9([F\M['4)K>"ZP6)'OWQ%_X*%> O'>H_M^W;?"/7+JS_;-^+GP
M)^(NDZ/K&KZ4+31-#^$GB&SUK5O#GC.YLG>:\MO$]C:2:?&=):46D=P4FC4>
M8I]:_: _X*>?!SXI?!7XQ_![P+\*?BOX8T7XI>*?@YXU\-:#JFH?##3? 'PD
ME^&'B?0M:N_ 7@KPWX+T32KB;PMJ5IH\G_%0:O=:EXBN=0OHS=K:6UJA%?5\
M@4L14AC*D7"%)482<Y<M18BK&K*5X)24Z,:;Y96Y'+3JXXPS7Q753+L/B<FI
M1CB,1"GFN(P\,#1]G@*^7Y?5JT86QE6I0JX/$XC,%[>+G*JL"HRM*2C4\L_;
M-_X)>_$CX!?$'X_'X07>A^/?A/\ !'3M"\3:AI5U\1O"NL_'#2?A_JFGV+2^
M//%/@'2%MM4MO#(U22[Q>I802)9P&YDMEB_>R?E0"" 5.5(!4^H/(/XCFOV6
M^,7_  4C^ GB?QU^UQ\>?A1\"_BCX7_:"_:O^%,_P,UNZ\8^-O#&K_#;PWX&
MU33]-TS6?%%EI6EV2Z[)XNU73["*WATN6YOM$TV2*"]M+F+?<VS_ (T(@C54
M&0$54&>#A0 ,\GGCGD\]SUKSLWCEL,1*6 K7I2E-I)RFDG)\MN:*:335HJ]D
MDKMWM]9P'7XJJ98J'%U%T<72CE='#5)4J-'&5ZD<M4<RAB:="IC*4J<<QC"-
M/'<M&=>G.O55&$80'4445YA]R%%%%)[?=^:$[6;>R3::=FI+6+3[QDHR7IL]
M@'51\OWU*EL-M?G!6,C+/C<%.0$/S'D+C^Y?_@A1XAT+P?\ \$R?"OB#Q!J%
MKI&C:?\ $7XPWM[>W4JPPJO_  F=Z\CD.2[SRD_+$IEGN) 0AD=N/X9B<8.2
M".A '!Z9R1QCH,$=:_ID_P""='C;6-1_8<^&W@/>;7P_X>\>_%#4!:PR.J:C
MJ.I>)KJZ6\OH\[)'LDD$=H&#&*0/.C(TA4?3<,8V&!S#$56M94:BC&.B<G&-
MFULEI>^[VTO=?CGC=PX^)>&<MR]UHX>G#/\ #5L95:NU0A3J5JO)&S7MJLJB
M7.[7N^:\8*#_ ')^(7[=&J37,]E\,O#MI;6:ET37O$:32W%RF,)<VNE0RQ"%
M'P&B%W.9"A!D@0Y4>&-^UM\>WE:0^+[*.-CDVZ>'M','S*0XVRVTCE0<%49W
MR,AF.:^;XP"$15)=V&%&2SF3<JQQ@GF1Y%_U8VJ 21R"#\Q>(_VV?V-_!WB;
M4?!7BS]J?X$>&O&&D:M)H.J^&-<^(&EZ;KFGZVDPMCI=UIUP5GBO4N2L4T+
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MB!)HWCD:_C@,+(Z3!)0$8?B5Q)4:?U#*VTK)JCBW=.]VVL5._-S)R>S]W71
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M>).W]N4':Z4ED.7J5NW.K3MV7-9+166C_F2_XAY?C9_T=5^S_P#^"OQEZ?\
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MBBBH6FVE][:?D:7?=A1113N^[^]DM)ZNS\V%%%%+K?KWZ_>/3R"BBB@!\?\
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M +>>DT445ZI\,%%%% !1110 4UE# @@,"""I *D'J"#P1CL?4TZBEHFY=?\
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MW?\ %_(\>$(4URPBHKLDE^@4444RPHHHH 3 ]!^5+110 8'I7&^//^1<NO\
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MAPNJOK7AWQ'KGBW6=$^'UE-X^\202>*=0OM=OOB7<> HH8Y6?4?"UCXC6_\
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M]Z')*UWN[)+5M^25V[=;*RZM!W\E=WT26VK=DO+77H2UQOCS_D7+K_KM;_\
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M*(_]9'_OK_Z$**PG"3:LK[]5W]3M@U9^?D^WH>KM\(O#K$M]JU49QQYT'O\
M],.O.,^O/2D_X5!X;!R+K50?7SX/?U@/J?S]:]6Q_M-^GICT_P GGK1C_:/Z
M?7T_STZ5\9[&E_S[C]Q^L_VGF/\ T&5?_ O^ >5?\*B\._\ /WJV<'GS[<'U
MQQ;X[X]/TI/^%0>'""#=ZISD$^=;C()Y&!!QD?S]:]6Q_M-^G^%&/]H_I_A[
M_P"<"CV%+^2*]$/^T\Q_Z#*O_@7_  #RK_A4/AW(8WFJ%@0=QE@)X&.OV?T
M'MC/4TG_  J'PZ"I^UZJ67<0QFM]Q)]3Y SCIV_G7JV/]IOT_P /;^?J:,?[
M3?I[^WO_ )P*7L*7\B?JD']IYC_T%U?O_P" >4?\*@\.?\_6J9( )$UOR0^\
M$_N.<$]^P/J*&^$?AS/_ !^ZJ"-Y!\Z$E3(,-_RPQ@Y/RC"@$C%>KX_VC^G^
M'M_G)H QW)SZ\T_84O\ GW'[A?VGF6ZQE5-:_%_P#R@_"+PV2"+C4V'0#SH
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M+:>(QVNED_9T59MM:^Z_D?N_@5*,<9Q"I22:PV 7K^^KRNOE)&?12;_]I/\
MO@_3^[WZ_ACJ<TF_U:/\%/\ \0?Q^HZ5_.+C*,7*46HJUW\5K[:1NW\D?T>I
M*348>])[*Z6V]W*T5\V.HI-_^U'[_*3].B=^AXX_0&\>J?D?_C=').R:BVI*
M\7HKKO9M-?-(?,KM/1Q=I+L^UUH_5:"TUL8R<<9(R,[2HW*VW#!OG"J $9OF
MR .<KO']Y/3HW?\ [9TA=>Y7U!53D=N"$!'7L>>O852C+W;P?N\[6JM><5%<
MROLFM?+[AMT^5IRLYN%^]H2<O=\VG;U/Y//VIOB_\5O@-\6?^"[/Q+^!OCW6
M/A;\3[/XR_\ !./P_H_C;P_# VJ:59^+?$4?AW5TCCN8+JWN8[O3K^ZM[JWE
MC99H&DA<+YH%?5_Q5U3XT?LS_MB:%\,$_:(^)WQ@OM(_X)4_M8_&W_A9GQ,L
M_"%U\0S\1+7Q!J&LZ'=VNNZ3X=L)='T7PE=1_9O#&AV4B:9:VJPI=PW=SF2O
MWOO?!_@C4FU9M1\&>#M1;Q!<6%UXA-_X1\/WW_"17>DN'TF[\0?:M,F&N7>D
MR(LNE7.J_:Y]-E59;&2"15<7+O0?#6H7W]J:AX=\/ZAJ@TJYT(:G?^']*O=2
M&@WK%KW01J%S8RW:Z%>L2UYHHF&EW;$M<6DAYK]!GQI1E3HT_P"Q:$IT\+6H
M5<1+ZNZM9O 9?@\/%R=+G]C1GA<14Y/:V:Q-O9MPN_@7PAB>:K*.;580E7I5
M:5&,ZRI4[8G&XFM4M>WM9/$45'W+_NFW45S^:[]G;]H#]L/P=XP_X)/_ !#U
MS]IKXO\ [0M_^W3^S)\?_%GQ-^#WQ!&@_P#"O[CQE\./A=KOBSX?0>"=/T?1
M-,NM U:]U?3=,TS5M3N+JXNM8<W4TNUKYDKB_@!^V/\ 'K7I_P!@/XA^%?VX
M/B)\<_VI?VJ/V@KKX9_M:?L1WL?AM?#WP6^'][J>N67BK4]!^'$&A0:_\&;O
MX'Z=:V>L:5XHUR]9-=G(,K7<0DMS_4!#X9\)VSZ!+:^%_#-K+X3AFM_"<MKX
M;T>VE\*6]S$8+BW\+R06$;^&X+B#]S/#HIL8YHOW<BNAP:FG>"? 6C^)=4\:
M:+X&\$:-XSUV'R-;\8Z1X.\.:7XLUJ'=N:+5O$MCI5OK6I1NXW2I>WTPE(!D
M#G)K6?&.626(OPWAE.I&O",H+!I5J4_[1C0PV)2PL52H48XVA/FP?LL1*K@*
M#=:46^7&'!^9PA1OQ%7:A*E*49RQ+]E4@\)SUZ$G6;J5:D:%>GRU[Q4<34>K
M;O\ QD?";XZ?%S]F7]FWXI^#?A+^T[\1U\0>//\ @JQ\6?A5^TA=:Q\1O!WA
M7Q+\%/A8-?=-$^*-QXOUWPOJ5G\(/%'[0FK6=QHVO_%CQ+876@[_  _Y6E6E
MF%GS]@:9^V9^UC#\ / .@^,OVJ)O#_P)\7_\%"(O@+XL_;5\)^.O#7Q5^(OP
ME^ 3^%;G7'\,^+OC1I7@S1O 5QKL?C&*U\/V_P 6[+1Y=.ETR],370>%'K^F
MQOAU\,I/^$JW_#?X>2_\)WY8\=";P'X4F7QOY/\ JO\ A,UDT5E\4F$_-"=>
M%^8'S)%LD)<W8_!'@.'PHO@&'P1X'B\ ?9/L!\!Q^$/#J>"GL=XE-F_A%=*'
MA^2V,P$QBDTYU,V)B#(H<=F*X[RRO4C5GPY1G5>*5>I.HL)*2@\+'#\U*;I3
M?MJ5OW//%T73C"-6E)\U^7"\%9G0A.E3XAKQIQPRITXQE72E..)>(7M8J<7[
M*:M&IR253WIN$H^ZU_/7\8?VN]$\#_L^^&OAW\,O^"AOQ^_:#MO%W[9>K_!O
MP]\?-(U#X<_!V]ATG2O#XURY^%WCC]KKQSX9G\"GPCIF;>\/QB\*:'JM_J=P
MRZ#';^6P9/F?X1?MJ?MD?%#]FK]D;P_'^U3X[T+QAXN_X*W>-/V2O%'Q9T"_
MT/QCXPUKX)6_@5M;TK3M7\1WGARPTSQQ/;/?O>:-XMG\.V*7Y33=5%I&D,<(
M_J=G^&WPPN_"EKX!N_AK\.;GP!8R1S67@2Y\ >%)_!-E- _FPSVGA.716T"V
MGCE_>K/!IT<XEQ)OW_-5R+P3X#MWB>W\"^![8P:NOB&W^S>"_#=L+7Q$ENMF
MGB"T6#2(UM->2S5;1-:MQ%JB6JK;+="$!*XX<8932P\XQX>C7Q+QU?%QK8I8
M%KWZ.-ITI.-'"4(1G"6)I3E%0<+T7*-I2N=M3A/-JU:+EGM2CAU@Z&&E3PSQ
M,9)PK8.I4DI5:U5M3C0K1C)S4DJL4[I-O\U?^":_C[XN7?Q*_P""AW[/_P 3
MOC'X]^.>B_LM?M3CX=?"[QU\5;G3M4^(DG@W5/#::L=-\0:YIFGZ7!K*VMW&
MTMI.+--GGS",B%T1?U6Q@#GD@$Y[$@9']:R[+2=%TVYU.]TO1]%TN]UJ\74-
M;O=/T>QT^]UO4$C\E+_6;RSM(;G5[Y(AY2W>HRW-PL0$:R! %K3WCU3MV/;@
M?\L_2OB<WQBS/'U,93P=/"*I1PL72I>SC%5:6'A2Q$DH1IP4:]:,L0^6$7[2
M;NM6W]=E&"J9;@HX2KBJF*DJV)G[6JY2DZ=2LYT8WDY2O"FU"5W962BVD+12
M;QZI^1_^-T;QZI^1_P#C=>;R3_E?WQ_S/3O'^9?B+12;QZI^1_\ C=&\>J?D
M?_C=')/^5_?'_,+Q_F7XBT9Q@CL5_F*3?[IQST/T_N#/6C>#@%D.?16[8QC"
MY_ITSQD$]G-J6EK>S?37]XI:6?:#W[HERIIPYIJ+M4Z2=M*=KV3W>Q^AO[,(
M'_"M%/\ U']8_61?\!7T97SG^R^0?AFHY!&NZJ<,"#S)'S@\X)SS[XKZ,K^X
M^!FGPAP[9I_\)>'O;H_WK:?FKV?H?Q#QM_R5_$=MO[7Q=M&M.:&MGKKOJ%%%
M%?5GRX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %(>A^AI:*3T3>]M;?-":NFMKIZ]M-R%N0>O(7)]BN#S[Y_&OG.?2=)-Q<
MEM)TQF-U<EF:PM2S,9W+,Q,1+,QY8DDDDDDDG/T@W0CZ?J?_ *U?/]P,75UW
MS=7!QG./WS@C/U!_.OD^**-*I3PKJTZ=1P>(E'GI0JZS4)1@HRA4=VU:\5=)
M7>A]5PK4J0JXM4YU(\\</&7).I!VIN<92E*G*"TO=*;LV[+74R/[&TCY<Z1I
MP+G" 6-D3G_:419 ."1D8Q7EWQ)^*GP3^#8T1OBAXH\%^"O^$EEO8/#R:[!;
MPS:U+ID*7&HQ6-M#:S3W,EC Z3W3QKL2.920 !7,^ OV<M"^'OQX^,7Q_LO'
MWQ(UO6_C/8:)I^J>"O$?B&6_^'OA1=%\F.&7P;X?+&'2;BZ\B/[9+$ \[3%C
MSD5Y-^UO^SY\3OC+XS^!GB_X:MITC_# _$>+7=/G^(GB3X7:M>V_C;1=/TRS
METGQ7X7T_4]2MTMI;'S;ZT>V"W$+QQDY0U^<XR6)H8&6(P^54'C%B8TH4*>&
MH8M^PG7]E&OR0PT%-R@Z=2=-N+HJ34I/E;?Z#0]A5QD*%;-*]/"2PLZU2O5K
MXC!J.(AA_:/#\]3$3:2K_P"S1JJ+C6;4XQ@I12^LO"VI>!O'/A_2_%W@^Y\+
M>*/#&N6@N]'U_0AI.HZ5J=OO9#<6<]JK0R!94>&=8W8V\D4BW CD#@;_ /8V
MC,IQIFD\@;7^Q6!C?><)Y;A=KEB"HVLV6&!SP/R7\*_\$_\ XP>%/"FJ03>*
M_!.J>,-%_9_/PU^%EO)XB\>6?A#PIXTUCXB^)O$WB6\U6RT74]%_MR6Z\#ZZ
MOAB?QK?P2:WK&JI-KMQ;VXF>-\;3/^"?/QTNO!=UX8\5^/-&N%T_PG^T9;>!
M+*T^('C<6WA?Q9\3[SPAJ'PNO!<6,^F&:V\ :AH^JE&V20:=+=QRZ7:HMQ.I
M\VGCLU_=1K\*Q=6<W3JM1PZ<*JQ'L+2@L+*%.,J<:N(7+4G!4U37.YSG&GZ,
M\'EJC5G2XK;ITY4U3@_K#E4A.A.K.5*<L5%U51J>RP\W.-&<ZLJKIP<*<'5_
M6#6-3\"^'M2\+Z-K<_AK2=6\::G-HOA#3KVWLH+SQ#JMMIUUJMSIVG6S1F2Z
MNH].LKN^:(!2+6WED4D(U= NC:62,:3IC%ANQ]@L7;;N*D*@0,8T88!*E@3E
ML J:_-;PO^QW\8]/_:0^''Q:\4ZYX-\5V7@WXKZG\0]1\>W?BWQA=^-M2\-:
MK\)QX#M/AY8^%+QG\,65AX2U]KR_T_5(1%/J-E<F9T2[EOFN>E\:_LD?%76?
MC7XI^-'ACQEH^FZ[?_&W3O&GAR>^\3^,_LFG_"^#X)-X#U3P3=Z%9:A;:6T.
MH^,UM];U#3[.WMS=6L O5NTU.*,UT4,5CITYXA\,W;Q,:7U14L+[>&&CAJM:
MIB7_ +.HN4:L%24(RE"7/&2J;HYJE+!*<*2XC=GAG5^M2>)C1EBY8R&'AA8W
MK^TC!T9^WE4J056/+*+H:P/T%&C:.W(TO1_EW*7-G8A<J2'W, %5E;(=3@IC
MD "E.CZ1\Q_LG2U"DAMUC8A5Q@MYDFW9%MR/OE<@CG!&?Q]^'_[ 'Q]M;1=*
M^(?C'PQ<^&;OQE:>,M6\):'X]\=3:0UU'\$O%W@/5HK4BZM[S[-<_$'5-!\6
M"SEO+B&XMX/M&J/=ZE;!WMM^P)^T!9> ;GPSH7Q,LYOMVE?L\WWBSPY=^./&
ML]C\1_%7PZT+Q+HWQ,&N:UJ-Q>76G6WBR^U30-5LKN"(1ZA-X:M8]7M&@6,'
MEAF.93@I/A!TFH*7L:BPL:UW2JU.6,?JCA)1G"E3D_:)J5>-D[6?75P. C4Y
M*?%L*R<K>VIQQ;P\8^TI0;G/ZTJBDX3J58Q5)J4:,_>BFK?KJVCZ4#@Z1I8S
MDJOV&Q#LBD R+&8][H,\NH([D]ZP_$E_X(\'Z)J/B3Q1)X>T#0-*C\_4M8U:
M'3[2PM(O-B@Q//)&N&>::*&*.-6>22XC2,,X45^:_A/]BG]H7PE\8_@WXWM_
MB@EU9^#/#_A#1?&6K^(O&7BCQC<BQT+1-=T_4].\/Z#J4%BUOJL<NH6<.F:K
M)=S:-JT6GQS^(]+NKR*&5?L'QI\(/'VM_#+PWH5Q\14^(WQ \"_$/PQ\3-*U
M_P =:)IWA[1_%>H>%]6DO;3POXBTWPTCVEKIUQ:7%Q;V%_:0R/9:M;Z?JMU%
M<&T5*[L/7Q->EB)5^'/[.E0E"/)6C@*DY\V'I5KNG"BYIIU'!J*:O%OFU1P8
MNE2PM6@J&?QS.%6,I3EA)X^,:3C6J4K.=6HJ>L84ZFKYN6JO=]UGJ7@GQ3\-
M?B+I<VN>";_PSXCTNVU"72;VYLK>VC?3]2CCCD.F:C9WEO:W6G7R1RPRO9WU
MM%<K%/!*H=9T-=D=&T@\_P!DZ3&_0A[&Q4JI)4,5=5V@L"JD@!FRH);@?!?Q
MS^!G[1?QOT&X2>V^$7@^^UC5_$MU)I&@ZMJZZCH:W7A6'0O#'B/6?%\$%C%X
MNU_3-4\^[N9#I4-[I=@NG6WARYBEBFF.4_[%_BS6;>2\\5Z[8:UXFO[7XDPZ
MUJ;^+O&9&IG6OA-X8\'^ !(L6H6T'D>%OB)HVH^+/)6U$=O<7":K:^=J#S-4
M1KUU4JT5D'M*5&-*<<54P^'I>T<I)5%&DJ-25Z46Y6YFY<MK)M"5.E["GB)9
MXX5ZLJT)8*A6Q%:=+DA*5-RJRKT*<E5E%05E&*<XM.24FOOW4(/#6DV%[JFI
MPZ#INF:9:RWVH7]_!IME;6EE;@M-=W,\X"6L$&-TDTB[!@C!8@59ATK1)HXY
M$T_2I4DB25#%:V3QM$X!CN WE;1#/'MEBG#".17=D(11C\NG_95^+GQ#D^+V
MEZ_8Z-8?VEJ?C?1#XQ\1>+/%MW?_ !#T74OA1X6\-Z?X6D\.&XDTNR^'EUXS
MMKC6UUJ!3=BXM+F\M[.'4WFF?L9OV3?BWJ1U6""Y\->'I+W2_$B2^)M(^)'C
M6WU_6]#U?PE8Z1X?^#=TD$3V>D>%_!>I1&:Q\2VD$T]U::9ITR627>H:NUSC
M''8R5-5/]696<:DN7ZM337(Y<L;RPJC>:2Z\MVW%RARR>TL/AXRM_K#57[V%
M-R<I^S49<O-4;CC92Y8N4G91=1+E4XPJ<\8_HL='T4A"-,TCRY#M1OLFGL)6
M(W(D#!<3,0"0L1=F SCBE_LC1N,:3I18@%E^PV99">@=0A*G ! 8*2,$ @YK
M\NM;_9"_:0U;P7X%\,P^)_ >FS^$YM:N-)U"VUO7;35_!]W-XWTCQ'IOFW%I
M(=/U34)-'LKO3[G4?#VG:0T5Q<#8EMI$MS:'[O\ @9\,KGX7^$-2TW59+6]\
M3Z_XM\5>*/$&LV]]J.H-J<FM:W=7FGM+/J<TSJ]II3V=@+>T$&GP+;A+.WBA
M 4]> Q%;%UW2Q'#ZP5.-&E5=:K1PSA>K3<G#3#_%&HO9W^U\6EK&>,HTL-1A
M4H<0+'SG6K4O84:F*C.,:<K1JR<L0O=G3]^RO)75E*#YSU;^R-'_ .@1I?\
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M_87%I?:S;P'[=6#J?[47[;=KINI>(+?PMX5EL(/"WCKQS:^&D^#WC"35Y8_
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MI'#*EB\+4GF']DT?8<T)2H.,9T*:PN+I-QG^^YHINE+#U7.?.YSF]4N0^/\
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M114R^%^G^0#7^Z?P_F*^?[C_ (^;G_KXG'_D5Z^@&S@^F!^>>?Z5\_W)S<W1
M];FX_P#1SC^E?,<2V]GA%?5RGRK^:2IMQC?I=I*_2Y]+PP[5,4TKRY8J,7IS
M7JI2N^EE[WG:W4R(-8T>ZOKO2[75]*NM4L%1]0TNWU*RGU+3TE.(6OM/BF>\
MLQ,=WD_:8(A(%)1F!&?!OC1\6_@_\)/&?POUCXAV7BF]\=:A;>/[+X<1^#/"
M7B;QCKPT^.PTVY\>O%I?AR*=TL8]-BTM[ZYN8)56,1O;2&1S6CX)_9L^$_P]
M^-/Q4_:"\+:/J5E\4?C1::/IWQ U6XU[6+W3]7M= 6--*AL]&N;F31]*GA2,
M'S-/AMGE02>8Q(.>=^.'[,WA[X]?$#X->*O&6LZ@GAGX5Q?$&.]\,Z5J^N^&
MM2\22^.M'LM+M$3Q%X>U?2-2L+/2C:2S75B//M-52Y6">...)0?SO$SS5X*7
M^RX>AC7BJ?LZ%:<:F$]A3JN4*U2M)-JI9*<*<83NVU9V/O:$< \4E5Q.(EA5
MAJBK2HTN7$QJU:%G0I0;Y:D)3O2<YRBITUSM4[V5%+3]E3XT>&K#Q3;:]X4U
M'3OB%,?C5IFM6OC"Y\*>*KR:WT%=!O\ QGHZ0:MI_BK1%L_#>DMI&MK8+;PV
M\%C>VE^@DCN V9X;^''['?Q-M_!'C+P\_@7QCI/C'PE-:^ H7\77%]I'B+PW
M'I'_  C]QJ.B>%;W73#>ZC;:1$NG:AK46FR:S9M&YO)X;L&1?&O%?_!/RWUC
MXV> O'?AWQ?X7\)_#'X=7'@V+PS\,[#P5*D^DZ#X?\(^)_"6J^$8];M=4@AU
M?2/$"^)+K6I+K7+'4[Y+V$V?F-;SRD<%X#_X)I7WA#Q1\)-8O_B=X>O+/X<:
M+\/]%O+#3?#'B30)H3\+;_Q#=^'-4\)II?BJSM-)U/Q-%KD3>.X]4@U&TOM7
MM9;VUMGANIK5?G*LL\K5VY<+Y?5<)J,<1[:FH8MTJ<94ZE)73ITI2J8N@U*/
M,IN$I*,>='O4Z63QP\?9\49A0E*FY2P\</7E]552<HU*%;V?NU:_+2P=252G
M)4U:<(\W[MGU-J.B_LB?#'PGJ.MZ]XI\&VGAW3_M'@_6==U?XC7/B>[@/Q5@
MT_PD_A_4M3FUW4]25_$EI!IVC::EY*?LEK;Q2:9)!#%)(G0^)/@!^S3]JT*R
M\4:1X9TJYU*ZO8M'L+CQO>>'CXKN-2U/2]9N-)73AKEFGC'3WUK1]#U2WL)H
M]2A@U"TAN[2..1BTGQW/_P $R;3_ (0JP\+Z/XX\)VNJV'PS^'OA:ZNKKP$;
MK2_$/B[P!\9I?B]9^,O$FG1:K#+J-OJ5K)-X7;#F_MK.:]F6[-N5M![1^U7^
MQYXC_:5\3> =7A^)>B>"M$\(Z/HUK=Z2/"%S>W5MK6E^-= \7'6O#VJV6KZ;
M>6UO=QZ,-#GT?4#>:;';&&]CAGO86!ZK9C##XFLN&<!4JT%0CAL*JT$ZJFZ2
MKN4[MP=*G4E*-TN>5)Q5XS1SQ6 EB:%.7$F-ITZWMWB\8Z%1JDZ,:GU2,:2D
MISC6G34)2U]G&JI64H-'M&@?#3X!^'O$WB+Q#X6US1M(\5_;M)U7Q7?6'Q%2
M]U/3M,TKQ'-JQT>]M[W6KP^&?"5]X@DNH]5TJ.WT[2+BZGEM[B-'"HFMXP\*
M?L[?$/2?&%SXQF^'?B;0_BSHFG?#WQ3-J'BK2)M+\6Z5X8U*X;3?#<5U#K*6
MS7^A7VIW+0KIDD>IV=_/'D)=K P_+_6OV /C/KOPO^->HW<?A'3_ !SK2_M0
MZ?X%\#Z+96ECKWBU/C7\0=/U*QG^(OC\ZV=*UWPYI^C:7#J^@:/<6>GSV-]<
M>1?S"X@83?27A+_@GUIR^-?#OCOX@Z_X.UHZ;XW\9>.]2\#^&? RZ!X,TC5O
M$?PJT3X9:+=>$='NM5U--&UW0GT>#Q;J>KE;G^T?%,R7-K#;QQHS9X>OFM2'
MU>/#&&AA:EJKIU,2O9N<J]3#RJ3I;WC2DZLHI<TXM1@O9QDR\1ALKC+ZS/B3
M$5,53<J:=/#2=3EI4Z6+IPIUG..DZZC2A-RY*4XKGE[3DY?IW1/A5^SG;>*;
MS7M$B\)76M17%WX2NK"'QJ=7TW3M<U?1(M!U6RB\)/KEYI&E>,];\/6*Z=J<
M]OIEKXBU*R@F6Y>X3[2PY.Z_9X_9(G@\">%YM%\%VT6A^'QX/\$^&K3Q[/:-
M?:)X<U^?Q&-)BTR+7XY_%K>'?$_G:D7NX]3N[#5?.669;E6C'S+I'_!.75M/
M\+ZKIH^+6D:-XKT3P!X<\%_"7QKX+\#R:'J.F^*/ _CB?QQX6^,/Q'CFUN]C
M\=?%&VU&[FTR]NK:6Q@U'2KO6(6$JZI+!#H^)?\ @GC=WWBGX(7?ASXI:;I?
MA7X,Z;\)VM-,O/"=Q)XAU#Q+X"\777B_Q;K8\16&L64DX^)VKZGJM_J,>I6^
MI_V->W,JV"+;W%Q555CW1<I<*X"2<\(N2=2E*+A6FX5ZLKV3E2G&\8[37)).
M\G:::P+KIT^)L93G"&*M.-"M%^TH4V\-27+4<N6M&2@YZ2I2E5B^904I_2OA
MSPM^S'\3OAYX+^*&E6VF#X>Z?9>*+;P[K^M:MJ?A?2(],N_'[ZKXBMM9&I:K
M86DEDWQ#T235+:WUPS)!?VT<E@8H9PIROA1IG[+M_);^//A5XDLM&NO%GC?4
M=(M[ZY\:7UGJ_BW4?AOXAUS2+[P9I-KXFUB6\U'P;I_B%]2DBT;0HWT:[)M[
MV%##]F<<U>?L?WUQ^S1\-/@+;>.-)N]6^%GQ%TKXCV6K:]X4N-3\%^*;S2/&
M?B'Q9'X>\:^#XM1@GO\ PY-%XA-C?0MJ(<7UAINH ,R&)/G.?_@FKXLN+3X;
MZ4OQF\,0:9X!\23>,!8V'PYN=*6'59_CE)\9'A\-/::^+BPT>YAF/A"33-4E
MU6QL+>"*^TZV$[SAG6EFM"K@W0R'!3K?5<'*I4H5:49K'1P]JZA:HW&.$G"I
M1II*7/"6FD1T:>55X8U5<_QE&#Q6+C2IUJ%:=.6#EB)NC.HN6"G/&PG2KU'+
MD]E/G;C*4K1_0+2/'/P'^)]SX0^(&C^-O GB.[\,>+/&/A/P-KL7B33X)$\8
M1K/X4\8Z!H\%S>VYU356BAN=-GLUM[V22)8KFR5X)X9Y,Z+]FGX&VVC^-?#I
M\$V8\,^/]"OO#GBG0=0UG69O#Z^';J[EU/4-(TFTNM0:R\*Z-/=DZA=1^'XM
M)2.XB-PK1/;H8_A+5?\ @F->:CJ&FF/XB^&;;1-/\3?$>8Z);>%/$.F0_P#"
M,?$#XJV?Q7%["/#WBO1S'X_T>^MQX83678:3>:%;Z<_V6![26WE^[?$'P6U*
M_P#A[\4_ ^A_$[QZMS\4YI;>[UOQEKMYXLD\(:%J7EV?B/2/!$6+5]$MKG0&
MN["PBAGF73[B\2_<RO#M/3@ZF98Q5)9GD.'P]:ES5**E6A5^M3]@Y.G.^M-5
M*G[B]](RY]M^?'4LNPDH+*\[K8FE5;A6:P]:@L+#V\.2I:,E[94X)XJ,%%25
M2+A3CSNYP?@GX>?LJ_%MO#?QE\&:39ZAY&L6&F^'=575O$.@+#KWPOLY_"FE
M7MIX>GU&QC77O#^E:<]I8ZF+-[RXT6WBOUEN;?R[H?1UMXB\':8^E^'8O%7A
MU+H:5;SZ?I]WXJTNXU>ZTR)&C744BN=0EU/4+3=!*)-4Q<12>6\K7,AWL/D^
M7]DK5O"6IV^H?"?XB3Z99:9XE\-^+]%\/_$H:YX[M;+7M-\#ZW\,M;EDU$ZS
M87SZ5>^";[1ET^SCF$%EK?AR*]D^TP7UPJ_/\7[(7Q-L?&G@_P !6^E:/JW@
M32K[0]:U_P",6IZ+HR:WY>E?"K5O ^H6/ABZ/B6?Q!I.G"ZOENX/!EWHLJ@M
M=SMK3V=XTD.:Q&8Y?3<J604/K%1S==8:2DG*$E&G9TW?EQ23JSJ;4E2C=V=F
M*A@L94DIYY5AAJ*A['ZU!NHJ+A.=12C5ERJKAF_90I0DWB)UI.BGRSD?IU?>
M*_"VE11SZKXF\.:7!+-96Z3ZEKNEV,#3ZC$)]/@6:YNHHVGOX")]/A#&2^MW
MBGM5EBD5JK>'/&OA+Q?)XB@\+^(=*UV?PCXDO/"'B>'3;N&Z?1/$VGQV\M[H
M]^(G;R+NVCN87=7PK*^8V<*Q'P7XC_8C\<^+M'WZY\2_!C>+;=? UCI.KZ=X
M5\26%KH.E>"OAY:?#VWO;.*'Q/-)<ZQ>V=FFJZG9ZS#>:'=&1["YLH[817J?
M3GPF^%OB?X5:UXL@@OO"VM>&?&_C/6?'6M:Q;Z*= \3+J-UX>\/6%NEW%:2O
MI=^;G4--U347>VBABM;&>&"&#Y4=NZACLTJ8SEJY;2P^'E*+BYXE2K3IRHP;
ME.CSPG24*[E!2;?,FM.JY*E#+EA%4HX^=?%J+56BJ#A1ISC7G'W*[BXU^>@H
M348Q@XRYD]K/I?$'QU^%/A;7?&7AG7/%]C::Y\/_  9;>/O&%A%!>7;:)X;O
M=0;2[&:>:"W:&;4;^_"VMAHUJ\VJ7,LD*K:@SQ;N2U#]JCX,:1IVFZCJVL^(
M--^W7FLV=YI=YX1UV#7_  P/#L>G3Z_?>,-%>V%[X<TS1K?5],NKZ_O4,"VU
M[!/ 9T+%9_B?\"T\?ZWXMUD:CHVGIXH^#=U\+_L6HZ*-0M8=2N/%'_"0V>OW
MWD7UC+=^1(+>(1"ZMM2@>%+RPU*WN8X3'\T:G^PQK&JZ8DVH^//#NL>)M9U+
MQ9J?B:_\4:5XI\4Z?HVJ>*+3P_I]CXK\"WNL>*Y_$2>-O"^F>&K)--U'Q1JF
MJ6=]<2^==6L4,*0S1B\1GU.O..&PE"K3A4JR25DY4%4DH6?M9MM0<$VK7=Y.
MVQIA*655:4)8G%5Z$I4Z::BHS_>N*YV_W48QBY*32]Z2]VFDW)S7V'X7^-/P
M]\9^,=5\#^'-3U&_UC2EU$F\_L/58?#FIR:)<I9:];Z+XCDMQI>I76AWLB6>
MI01S(T=P)8[<W+03B+U0]/Q7^8KY%^$/[+LWPH^(R>++/Q'I$FAZ9'X^^S0:
M=H]_8>,_%4_Q&UQ_$5TOQ-UF75;C2-=C\,WT]Y)X?.EZ99RE[E)KAU:*5+CZ
MZ/3\5_F*]++IX^IA54S*A&AB5*;4(;*G4LHMJ^_)9-];<R2O9<F-6"CB>7 5
MJE?#J*2J5$HR=11:J:)*RYDI*.KAS>S<YN//+UCP4/\ B5'VNKC/Y@5V-<?X
M+_Y!3?\ 7U<?^A+785^KY:K8'#16T:48KT2T/RS,?]^Q7_7Z?YA1117<<044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%3
M+X7Z?Y -?[I_#^8KY_NO^/FZ/ /VJYQVY\^3'Y\'CUKZ /\ %_NC_P!FKP:Y
MAW75TP8KFYG., ]9&.,GTR:^8XE2Y,)=M*\[N-K^]3<5OYOH?2\-7;QME%M1
M@U&6SM5O:ZVV/F?X?^&/VC--^/'Q@\2_$'XF>$O$7P#UZPT-?@Y\/-+T!;#Q
M3X(OX!&FN7'B/6OL4*ZM;WDJR&VC.H7+1++M\I1D5X+^V5\#_'_QO^*/[-NG
M>&-%T#4_"6CP_&6;QM=>.+#Q1K'P_P!$?4/#FEV?AR;7],\'^)?"^IW.I7-\
M+EO#).II;VMS'-(\)(4K^AGV<\GS6!( )  /RG(YZG!P>2>@]!1Y!8#]X1SO
M!"C*L00'7^ZR[GP1TWL0 2:_/*N44L7@)9=4KUU3J8B6*E><I?!/VBIWDY-Q
ME=KE;<8QT25E;[REF=;"XNEF%*E156GA_JL(J$8J//2=!U4HV7M8*TU4OSSJ
M+GF_>DG^0ZZ1^V=\+?B-\(O@7X&U/XN>*?A7X-T'PEX!\5?$J_T'0=2TKQ5H
MNL>"O&#Z[X[MM8GTG4-3T?5O#7B]_#NDV$6L>*+^_P!(BL[-UTV^L[BYO)N0
M^"FH_P#!0+PY<_L\>#+^W^)B>%=+\*^ -,\3W/CKP99ZK<ZKK4>H^(XOC#9_
M$/68-*6;3YM)AM]#?P%K,VNZ7'J%C)#J40\03W5RL?[3&U']X8YXV \$!2O)
M(VE0%8?Q #/(S2^0V6(F<;E"G  X!)P #C!R>W=N<' \N7"%2JXXBGF^:454
MG6A&%&O%0HTJL,/3C3IJHY.*IRPJG%16CG)7M*2EZT.*X4XRH5,GR>O*$*?-
M5KX23J5ZM)XF<JM7V?*ISJ+&2C*5X?"K:QA*'XG^,]-_X*">)/A4+3Q%J_QG
MN]1U/P1\(?B)K4'A?PEX1T7Q5X8\8Z)\>HK+QGX'\-)I&FQ2:C&?A=#!K]]H
ME\EY+J LVE,Y@N9;:3ZD_:F\2_MAZ;\2_A19? 2TU?\ X0#4/#=I<W^KVGA*
MT\1R7WCX^+](MI]*^(=F--NKCP]X5;P3-J%\T]K=^&H(M4-X1JBW%G:6<OZ%
MFV/'[P\$$#& "&#=B,YPH.3RJA3E1BC[,<D^:V20S$@$L1C!?)(;@!>F H
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MT8#^E=;7Z5EU_J6'OH_9Q_(_-LP_W[%?]?I_F%%%%=QQA1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1_008.jpg
<TEXT>
begin 644 forms-1_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,?Q#<^58B$'YI3@_0=:YN74HO#^@:IKTV-MI"1&#
MW<]!^>*MZU<_:=2?!RL?R+_6O-OC9K/V'1]+\,Q/B23_ $JZ /\ WR#^.?RK
MS<%2^O9E_=C_ %_F=E5^QPUNLCQ>XN);NYEN9F+2RN7<GN2<FFQQO-*D4:EI
M'8*JCJ2>@IM>D?!;PTNN>-!>SINMM-7SB".#(>%']?PK[VK45*FY/H>+%<SL
M>W_#KP?%X/\ "\-LR@WLX$MT^.K$?=^@Z5YK\8?".3)?VT?[R >8,#[T1ZC\
M#7O-<YXPLEN-,6<KGRCAAZJ>#7S<,1.-7VO4['!./*?'E=C\,=972/&MLDS[
M;6^!M)L]/F^Z?P;%8?B32O[&\07=D ?+5MT?NAY%9:.T;JZ$JZD,I'8BOHYQ
MC7HM=)(Y$W"5^Q]::3,UGJJJ_&28W_S]:[&O--(U0:YH.FZPAYNH 9,=I5X8
M?F,_C7H5A<"ZLHIAU*\_7O7P>!3H5*F%E]EZ>A[&(]^,:JZEFBBBO2.0****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JM?W(M+&6;NJ\?7M5FN>\27/,5JI_
MVV_I7-BZWL:,I_U<UHPYYJ)E:=$LUZ'F($40,LK'H .:^;?&>OOXF\7:CJC$
MF.24K$#VC7A?TKVWQ_K7_"._#NZ:-]MWJC?9HL=0G\1_+-?.E>EPS@_98?VL
MMY&>85>>IRK9!7TO\"](%AX%-ZRXDOIVDSC^$<#^M?-!Z5]A> +9;3P#HD*C
M&+5#^)Y_K7J9I-JFH]V<M%:W.DJMJ$ NM/N(2/OH15FBO".D^6?BG:!+ZPN\
M89XVC;_@)X_F:\_KUKXO0A+.' P4O&4?3!KR6OI,!*]!')57O'L'P<UC[1IN
MI:!(WSPG[9;#VZ.!^AKV7PU<\2VS'_;7^M?*W@_7&\.>+-/U,']W%*%E']Z-
MN&'Y&OI:"0:?JJ2(VZ+(*D?Q(W0_D:^8SVC]6QD,4MI:,]'!R]I1E2>ZU1VE
M% ((!'(-%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S!5))P ,FN)N)
M'U'4F*_>E?:OL.@KH]=NOL^GE%.'E^4?3O7)7.IQ>']"U+79L8LX2(@?XI#P
MHKR<8GB,13PL?5_U_6YV4/W=*55^B/'_ (RZ\NI>+UTNW?-II48@4#H7_B/]
M/PKS^VMY;NZBMX5W2RN$4>I-)<3RW5S+<S,6EE<N['N2<FNX^$&CC5_B%:;T
MW16J-.V>V.!^IK[Q)87#Z?91X_QS-KQU\*[3PQX1M;ZUEG>]2(/<[CE7/&<#
MMC->\^%%V>$='7&,6<7_ *"*S?&]ND^FPB2,/&6*."."".E;FCJ%T:R4# $*
M@ ?2O!JXB=6"C/6S.F,4GH7:***YRSY_^,$#W!2&(9>34=BCW((%5_'OPIL]
M"\-6=WI@E^V1P;KE6;<)" -Q'H?\*]$GTNVU7QG$ER@<07IG0'^\N<5T/C*!
M9=*C9AD+)@CV(Q793Q4J<81CT=V9N%VSX\ZBOH;P%K']O^ [*5VW7.GG['/Z
ME1RA_+C\*\$U2V6SU>\MD^[%.Z#Z FN[^#FM"S\42Z/,^+?5(O*&>@E'*G^E
M=V<858O!R2WM=$X6K[*JF?1^BW7VG3DW'+Q_(W]*T:Y70+@V^H-;OP)/EQZ,
M*ZJOFL#6]K03>ZT?R.RO#DJ-+8****ZS$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
MK7]T+2REF/4#"_7M4RDHIR>R&DV[(YG7+K[3J#*IRD7R#W/>O+?C5K7V2QTW
MPQ$_SX^UW8'J?N@UZ59"/SWNKI@+>V0SS,>F!S7S/XHUR7Q)XEO]6E)_TB4E
M ?X4'"C\JCAS#NO7GBYKT_K^MC;'S4(QHKH9%>R_L]0 ZYK,Y RMNB ^F6S_
M $KQJO;/V>!_I^N'_IG'_,U]3C_]WE_74\VE\2/6?&'_ "!T_P"NH_K6KI7_
M "";3_KDO\JRO&'_ "!T_P"NH_K6MIG&DVN?^>*_RKYLZQM]J45B54QR2N06
M*QC)"CJQ]JM0S1SPI+$P9'&5([BLW2U^UO=7\@R)V*1_]<QP/S.35;PY*8FO
M--?K;2G9_NDT 96GJ#XWFSVDD/Z5L>*Q_P 2-O\ KHO\ZR-+Y\:W!_VI*V/%
M7_(#?_?7^=,#Y&\1C'B;4Q_T\O\ SJE:74MC>P7<#%98)%D0CL0<UH>*!CQ3
MJ8_Z>&K)KZNGK35^WZ'"_B/JB'48]3LM/URU(V7D2S#'9Q]X?G7<VTZW-M',
MO1U!KPCX/:U]O\/W^@2MF6S;[5;@GDH>' _G7K_ANZW0R6Q/*'<OT/\ ]>OA
MYTG@\?.B]I:H];F]K04^JT-VBBBNPYPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO$=
MWOF2U4\)\S?7M70S2K!"\KG"H"37&P(^I:D-Y_UC%G/H.]>9F51\BHPWF[?(
MZL+%<SJ2V1QWQ2UO^P? BZ?&VV\UAL-CJL(Z_G_6O *[#XF^)!XE\:W<T+9L
M[7_1K<#IM7J1]3FN/K[3+,*L-AHTT>97J.I4<F%>W?L\#_2M</\ L1?S->(U
M[A^SN/WNNGVB'_H55F'^[R^1-+XCU7QA_P @=?\ KJ/ZU:DF-OX6#J<-]G55
M^I  _G57QA_R"$'_ $U']:??,?["T^('!E>%/Y'^E?.G6/?6+'1H(K)BTDD2
M ,D2YQQWK*T_4X;CQ=Y\ 98KA-A##!SC_$5T>GZ;%81. ?,ED8M)(PY8FN6U
MF.+3O$]O+"H0$K(0.F<X- $NB_-XONC[R?SK6\5_\@-O^NB_SK)T$@^*KL^N
M\_K6KXL_Y ;?]=%_G0!\E^*/^1IU/_KX:LFM;Q/_ ,C1J?\ U\-_.LFOJZ7\
M./HCAENSH/!.OMX:\76&I9/DK)LF'K&W#5]*P2#3=81T;,)(((Z,C=#7R5UK
MZ(\!ZS_PD/@*TE=MUUIQ^R3^I7^ _EQ7SO$F&?LXXJ&\'^!WX":YG3EM(]>!
MR,T5GZ+=?:M.3)R\?R-^%:%<5.:J04X[,<HN+:844459(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%(S!5+,< #)- &'XCN]D*6JGF3YF^@KB?&.N_P#"+> [V^1MM[??Z+:^HS]Y
MA]!FMZ>1]4U0E<YD;:OL*\2^,/B--7\5C3+5\V6EKY*8/!?^(_TKBRFC]>Q[
MK/X8['5B9>PH*GU>YYW1117WIXP5[G^SN/\ D/'WA_\ 9J\,KW3]G?[FO?6'
M_P!FKBS#_=Y?(TI?$>G^,3_Q*XAZRC^55]0G^?0+<>J.?T%3>,C_ ,2Z ?\
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M47ZH[6BFHZR(KJ<JPR#3J9D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M*JYPY)_%'1G?7@HRO'9ZH6BBBNPP"BBB@ HHHH **** "BBB@ HHHH ****
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MYRIREA:OQ1V\T>I7BI)58[/\RW1117H',%%%% !1110 4444 %%%% !1110
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M92T] >3XQOF:U(/^$SUC^]!_W[_^O1_PF>L?WH/^_?\ ]>I38Z/_ ,^ER/\
MMO\ _6I/[/T?O;W0_P"VP_PK/^ULL[_@:?V=F/?\3*OM6N-0OXKR98_-C '
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MWU+#M3>K.OHHHKVCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:??.H/W@$&?UJZ>0TZBO"#:]299E*#M*2-G_ (1_4/[L?_?='_"/W^/NQ_\
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MG&!@>G]:]-\7Q20?#.ZAE_UD=HBM]1@&NBM-*T^P)-G86UN3U,42K_(5C?$
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MG["EKT?YBI)>TF<;\4 !X&G Z"6/^=2?#'_D1;/_ 'G_ /0C3/BD?^*'N/\
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MW->K=S22[_/5=OSCL?J*]']W53P\9*UO=]5_F<GOP:JM/S^9[=?_ /(.NO\
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M=C7D5HJ-223OKN=]-W@G:P4445D6%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>shph-20220930.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOK6bP9z5Z8+ekhvWB7bbk6vy0godveUyXjGyb2kaoF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SHPH="http://shuttlepharma.com/20220930" elementFormDefault="qualified" targetNamespace="http://shuttlepharma.com/20220930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://shuttlepharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcern" id="OrganizationAndGoingConcern">
	  <link:definition>00000007 - Disclosure - Organization and Going Concern</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000009 - Disclosure - Property and Equipment, Net</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" id="OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability">
	  <link:definition>00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" id="NotesPayable-relatedParty">
	  <link:definition>00000011 - Disclosure - Notes Payable-Related Party</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000012 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000013 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000014 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesRestated" id="IncomeTaxesRestated">
	  <link:definition>00000015 - Disclosure - Income Taxes (Restated)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatements" id="RestatementOfFinancialStatements">
	  <link:definition>00000016 - Disclosure - Restatement of Financial Statements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000019 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" id="OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables">
	  <link:definition>00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/NotesPayableTables" id="NotesPayableTables">
	  <link:definition>00000021 - Disclosure - Notes Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" id="IncomeTaxesRestatedTables">
	  <link:definition>00000023 - Disclosure - Income Taxes (Restated) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" id="RestatementOfFinancialStatementsTables">
	  <link:definition>00000024 - Disclosure - Restatement of Financial Statements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" id="OrganizationAndGoingConcernDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Organization and Going Concern (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" id="ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" id="ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" id="ScheduleOfPropertyAndEquipmentNetDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Property and Equipment Net (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Property and Equipment, Net (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" id="ScheduleOfOperatingLeaseRightOfUseAssetsDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" id="ScheduleOfOperatingLeaseMaturityDetails">
	  <link:definition>00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" id="OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" id="NotesPayable-relatedPartyDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" id="ScheduleOfNotesPayableDetails">
	  <link:definition>00000037 - Disclosure - Schedule of Notes Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" id="ScheduleOfNotesPayableDetailsParenthetical">
	  <link:definition>00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" id="ScheduleOfPromissoryNotesDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Promissory Notes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" id="ScheduleOfPromissoryNotesDetailsParenthetical">
	  <link:definition>00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000041 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" id="ScheduleOfSaleOfEquityOrIssuedDetails">
	  <link:definition>00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" id="ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical">
	  <link:definition>00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" id="ScheduleOfStockOptionsValuationAssumptionsDetails">
	  <link:definition>00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000045 - Disclosure - Schedule of Warrants Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" id="ScheduleOfWarrantsActivityDetailsParenthetical">
	  <link:definition>00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" id="ScheduleOfRestrictedStockUnitsRsusDetails">
	  <link:definition>00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitDetails">
	  <link:definition>00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
	  <link:definition>00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" id="IncomeTaxesRestatedDetailsNarrative">
	  <link:definition>00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" id="ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails">
	  <link:definition>00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" id="RestatementOfFinancialStatementsDetailsNarrative">
	  <link:definition>00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="shph-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="shph-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="shph-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="shph-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="SHPH_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockToBeIssuedMember" name="CommonStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OneQuarterlyPaymentsMember" name="OneQuarterlyPaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoQuarterlyPaymentsMember" name="TwoQuarterlyPaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PhaseIIMember" name="PhaseIIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SubcontractPhaseIIMember" name="SubcontractPhaseIIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TCGGreenChemIncMember" name="TCGGreenChemIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SBIRMember" name="SBIRMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OfficersSpouseMember" name="OfficersSpouseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RelatedPartyOfficerMember" name="RelatedPartyOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesOneMember" name="NotesPayableOtherPayablesOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesTwoMember" name="NotesPayableOtherPayablesTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesThreeMember" name="NotesPayableOtherPayablesThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesFourMember" name="NotesPayableOtherPayablesFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesFiveMember" name="NotesPayableOtherPayablesFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableOtherPayablesSixMember" name="NotesPayableOtherPayablesSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_UnsecuredPromissoryNotesMember" name="UnsecuredPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NoteTwoMember" name="NoteTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccreditedInvestorMember" name="AccreditedInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaycheckProtectionProgramNotePayableOneMember" name="PaycheckProtectionProgramNotePayableOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaycheckProtectionProgramNotePayableTwoMember" name="PaycheckProtectionProgramNotePayableTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PromissoryNoteOneMember" name="PromissoryNoteOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PromissoryNoteTwoMember" name="PromissoryNoteTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PromissoryNoteThreeMember" name="PromissoryNoteThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PromissoryNoteFourMember" name="PromissoryNoteFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MembershipInterestHoldersMember" name="MembershipInterestHoldersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DirectorsAndOfficerMember" name="DirectorsAndOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableMember" name="NotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockPayableMember" name="CommonStockPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PreferredStockDividendPayableMember" name="PreferredStockDividendPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockToBeIssued" name="CommonStockToBeIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForConversionOfConvertibleDebt" name="CommonStockIssuedForConversionOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" name="CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForDividendPayable" name="CommonStockIssuedForDividendPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" name="DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" name="ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" name="ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" name="ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" name="ProceedsFromContractAwardsForResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentsToInvoicesInResearchAndDevelopment" name="PaymentsToInvoicesInResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccruedInvestmentIncomeReceivableOutstanding" name="AccruedInvestmentIncomeReceivableOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ResearchAndDevelopmentDeficitNet" name="ResearchAndDevelopmentDeficitNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OfficeLease" name="OfficeLease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccumulatedAmortizationOnRightOfUseAssets" name="AccumulatedAmortizationOnRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OperatingLeasePayment" name="OperatingLeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RelatedPartyTransactionAmountsOfTransactions" name="RelatedPartyTransactionAmountsOfTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LoanForgiveness" name="LoanForgiveness" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DebtInstrumentConvertibleConversionPricePercentage" name="DebtInstrumentConvertibleConversionPricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PercentageOfVariableExercisePrice" name="PercentageOfVariableExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DebtInstrumentConvertibleConversionSharesPercentage" name="DebtInstrumentConvertibleConversionSharesPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentOfInvoice" name="PaymentOfInvoice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NoteOneMember" name="NoteOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NetDeferredTaxExpenseAfterValuationAllowance" name="NetDeferredTaxExpenseAfterValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>shph-20220930_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="shph-20220930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20220930.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable" xlink:href="shph-20220930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20220930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:href="shph-20220930.xsd#IncomeTaxesRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableTables" xlink:href="shph-20220930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20220930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20220930.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:href="shph-20220930.xsd#ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20220930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="shph-20220930.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseMaturityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="shph-20220930.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20220930.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20220930.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20220930.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityContractAssetCurrent" xlink:label="loc_us-gaapCommodityContractAssetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCommodityContractAssetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="loc_us-gaapNotesPayableToBankCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableToBankCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssued" xlink:label="loc_SHPHCommonStockToBeIssued" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_SHPHCommonStockToBeIssued" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCustomerDeposits" xlink:label="loc_us-gaapInterestExpenseCustomerDeposits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseCustomerDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:title="00000007 - Disclosure - Organization and Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - Property and Equipment, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:title="00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000011 - Disclosure - Notes Payable-Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable" xlink:title="00000012 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:title="00000015 - Disclosure - Income Taxes (Restated)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:title="00000016 - Disclosure - Restatement of Financial Statements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - Property and Equipment, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:title="00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableTables" xlink:title="00000021 - Disclosure - Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:title="00000023 - Disclosure - Income Taxes (Restated) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:title="00000024 - Disclosure - Restatement of Financial Statements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - Schedule of Property and Equipment Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000031 - Disclosure - Property and Equipment, Net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:title="00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:title="00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:title="00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:title="00000037 - Disclosure - Schedule of Notes Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:title="00000039 - Disclosure - Schedule of Promissory Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:title="00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:title="00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:title="00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Warrants Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaapDeferredTaxAssetInterestCarryforward" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetInterestCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:title="00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>shph-20220930_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="shph-20220930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20220930.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable" xlink:href="shph-20220930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20220930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:href="shph-20220930.xsd#IncomeTaxesRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableTables" xlink:href="shph-20220930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20220930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20220930.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:href="shph-20220930.xsd#ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20220930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="shph-20220930.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseMaturityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="shph-20220930.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20220930.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20220930.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20220930.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SeriesAConvertiblePreferredStockMember" xlink:label="loc_SHPHSeriesAConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SHPHSeriesAConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityContractAssetCurrent" xlink:label="loc_us-gaapCommodityContractAssetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCommodityContractAssetCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssets_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableOtherCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDividendsPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="loc_us-gaapNotesPayableToBankCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableToBankCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherNotesPayableCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssued" xlink:label="loc_SHPHCommonStockToBeIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_SHPHCommonStockToBeIssued_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SeriesAConvertiblePreferredStockMember" xlink:label="loc_SHPHSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SHPHSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:title="00000007 - Disclosure - Organization and Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - Property and Equipment, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:title="00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000011 - Disclosure - Notes Payable-Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable" xlink:title="00000012 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:title="00000015 - Disclosure - Income Taxes (Restated)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:title="00000016 - Disclosure - Restatement of Financial Statements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - Property and Equipment, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:title="00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableTables" xlink:title="00000021 - Disclosure - Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:title="00000023 - Disclosure - Income Taxes (Restated) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:title="00000024 - Disclosure - Restatement of Financial Statements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaapGovernmentContractReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGovernmentContractReceivable_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_80" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="loc_us-gaapAdditionalFundingAgreementTermsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapAdditionalFundingAgreementTermsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OneQuarterlyPaymentsMember" xlink:label="loc_SHPHOneQuarterlyPaymentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHOneQuarterlyPaymentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoQuarterlyPaymentsMember" xlink:label="loc_SHPHTwoQuarterlyPaymentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHTwoQuarterlyPaymentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PhaseIIMember" xlink:label="loc_SHPHPhaseIIMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_SHPHPhaseIIMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SubcontractPhaseIIMember" xlink:label="loc_SHPHSubcontractPhaseIIMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_SHPHSubcontractPhaseIIMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SBIRMember" xlink:label="loc_SHPHSBIRMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHSBIRMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaapProceedsFromCollaborators_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromCollaborators_360" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" xlink:label="loc_SHPHProceedsFromContractAwardsForResearchAndDevelopment_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromContractAwardsForResearchAndDevelopment_360" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_360" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccruedInvestmentIncomeReceivableOutstanding" xlink:label="loc_SHPHAccruedInvestmentIncomeReceivableOutstanding_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHAccruedInvestmentIncomeReceivableOutstanding_360" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaapBusinessDevelopment_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessDevelopment_360" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ResearchAndDevelopmentDeficitNet" xlink:label="loc_SHPHResearchAndDevelopmentDeficitNet_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHResearchAndDevelopmentDeficitNet_360" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet_360" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_360" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_360" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_360" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - Schedule of Property and Equipment Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LaboratoryEquipmentMember" xlink:label="loc_SHPHLaboratoryEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SHPHLaboratoryEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000031 - Disclosure - Property and Equipment, Net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:title="00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:title="00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:title="00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesOneMember" xlink:label="loc_SHPHNotesPayableOtherPayablesOneMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesOneMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesTwoMember" xlink:label="loc_SHPHNotesPayableOtherPayablesTwoMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesTwoMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesThreeMember" xlink:label="loc_SHPHNotesPayableOtherPayablesThreeMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesThreeMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFourMember" xlink:label="loc_SHPHNotesPayableOtherPayablesFourMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesFourMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFiveMember" xlink:label="loc_SHPHNotesPayableOtherPayablesFiveMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesFiveMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesSixMember" xlink:label="loc_SHPHNotesPayableOtherPayablesSixMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesSixMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyTransactionAmountsOfTransactions" xlink:label="loc_SHPHRelatedPartyTransactionAmountsOfTransactions_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SHPHRelatedPartyTransactionAmountsOfTransactions_420" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate_420" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate_420" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_420" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_420" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_420" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_420" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesIssued1_420" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_420" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_420" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_420" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_420" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_420" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_420" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_420" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_420" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_420" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:title="00000037 - Disclosure - Schedule of Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LoanForgiveness" xlink:label="loc_SHPHLoanForgiveness_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_SHPHLoanForgiveness_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:title="00000039 - Disclosure - Schedule of Promissory Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteOneMember" xlink:label="loc_SHPHPromissoryNoteOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteTwoMember" xlink:label="loc_SHPHPromissoryNoteTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteThreeMember" xlink:label="loc_SHPHPromissoryNoteThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteFourMember" xlink:label="loc_SHPHPromissoryNoteFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:title="00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteOneMember" xlink:label="loc_SHPHPromissoryNoteOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteTwoMember" xlink:label="loc_SHPHPromissoryNoteTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteThreeMember" xlink:label="loc_SHPHPromissoryNoteThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteFourMember" xlink:label="loc_SHPHPromissoryNoteFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_UnsecuredPromissoryNotesMember" xlink:label="loc_SHPHUnsecuredPromissoryNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHUnsecuredPromissoryNotesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NoteTwoMember" xlink:label="loc_SHPHNoteTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNoteTwoMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccreditedInvestorMember" xlink:label="loc_SHPHAccreditedInvestorMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHAccreditedInvestorMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotes" xlink:label="loc_us-gaapMediumTermNotes_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMediumTermNotes_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShortTermDebtDescription_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtSecuritiesGainLoss_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesIssued1_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_250" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_250" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:title="00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableMember" xlink:label="loc_SHPHNotesPayableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHNotesPayableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaapNoteWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapNoteWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockPayableMember" xlink:label="loc_SHPHCommonStockPayableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHCommonStockPayableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PreferredStockDividendPayableMember" xlink:label="loc_SHPHPreferredStockDividendPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHPreferredStockDividendPayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:title="00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PreferredStockDividendPayableMember" xlink:label="loc_SHPHPreferredStockDividendPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHPreferredStockDividendPayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_110" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_MembershipInterestHoldersMember" xlink:label="loc_SHPHMembershipInterestHoldersMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHMembershipInterestHoldersMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DirectorsAndOfficerMember" xlink:label="loc_SHPHDirectorsAndOfficerMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficerMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionPricePercentage" xlink:label="loc_SHPHDebtInstrumentConvertibleConversionPricePercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SHPHDebtInstrumentConvertibleConversionPricePercentage_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaapDividendsPreferredStockCash_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockCash_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaapDividendsShareBasedCompensation_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsShareBasedCompensation_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaapDividendsCommonStock_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsCommonStock_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_390" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_390" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_390" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_390" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_390" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_390" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_390" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_390" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_390" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockValue_390" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PercentageOfVariableExercisePrice" xlink:label="loc_SHPHPercentageOfVariableExercisePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SHPHPercentageOfVariableExercisePrice_390" xlink:type="arc" order="38" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapLegalFees_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:title="00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLegalFees_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapInterestReceivable_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensation_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionSharesPercentage" xlink:label="loc_SHPHDebtInstrumentConvertibleConversionSharesPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_SHPHDebtInstrumentConvertibleConversionSharesPercentage_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentOfInvoice" xlink:label="loc_SHPHPaymentOfInvoice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_SHPHPaymentOfInvoice_110" xlink:type="arc" order="11" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>shph-20220930_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SeriesAConvertiblePreferredStockMember" xlink:label="SHPH_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SeriesAConvertiblePreferredStockMember" xlink:to="SHPH_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="SHPH_CommonStockToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockToBeIssuedMember_lbl" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFundingAgreementTermsMember" xlink:to="us-gaap_AdditionalFundingAgreementTermsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember_lbl" xml:lang="en-US">Additional Funding Agreement Terms [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OneQuarterlyPaymentsMember" xlink:label="SHPH_OneQuarterlyPaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OneQuarterlyPaymentsMember" xlink:to="SHPH_OneQuarterlyPaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OneQuarterlyPaymentsMember_lbl" xml:lang="en-US">1 Quarterly Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoQuarterlyPaymentsMember" xlink:label="SHPH_TwoQuarterlyPaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoQuarterlyPaymentsMember" xlink:to="SHPH_TwoQuarterlyPaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoQuarterlyPaymentsMember_lbl" xml:lang="en-US">2 Quarterly Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US">Project [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PhaseIIMember" xlink:label="SHPH_PhaseIIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PhaseIIMember" xlink:to="SHPH_PhaseIIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PhaseIIMember_lbl" xml:lang="en-US">Phase II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SubcontractPhaseIIMember" xlink:label="SHPH_SubcontractPhaseIIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SubcontractPhaseIIMember" xlink:to="SHPH_SubcontractPhaseIIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SubcontractPhaseIIMember_lbl" xml:lang="en-US">Subcontract Phase II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TCGGreenChemIncMember" xlink:label="SHPH_TCGGreenChemIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TCGGreenChemIncMember_lbl" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SBIRMember" xlink:label="SHPH_SBIRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SBIRMember" xlink:to="SHPH_SBIRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SBIRMember_lbl" xml:lang="en-US">SBIR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LaboratoryEquipmentMember" xlink:label="SHPH_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LaboratoryEquipmentMember" xlink:to="SHPH_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OfficersSpouseMember" xlink:label="SHPH_OfficersSpouseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OfficersSpouseMember_lbl" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="SHPH_RelatedPartyOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RelatedPartyOfficerMember_lbl" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesOneMember" xlink:label="SHPH_NotesPayableOtherPayablesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesOneMember" xlink:to="SHPH_NotesPayableOtherPayablesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesOneMember_lbl" xml:lang="en-US">Notes Payable Other Payables One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesTwoMember" xlink:label="SHPH_NotesPayableOtherPayablesTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesTwoMember" xlink:to="SHPH_NotesPayableOtherPayablesTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesTwoMember_lbl" xml:lang="en-US">Notes Payable Other Payables Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesThreeMember" xlink:label="SHPH_NotesPayableOtherPayablesThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesThreeMember" xlink:to="SHPH_NotesPayableOtherPayablesThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesThreeMember_lbl" xml:lang="en-US">Notes Payable Other Payables Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFourMember" xlink:label="SHPH_NotesPayableOtherPayablesFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesFourMember" xlink:to="SHPH_NotesPayableOtherPayablesFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesFourMember_lbl" xml:lang="en-US">Notes Payable Other Payables Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFiveMember" xlink:label="SHPH_NotesPayableOtherPayablesFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesFiveMember" xlink:to="SHPH_NotesPayableOtherPayablesFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesFiveMember_lbl" xml:lang="en-US">Notes Payable Other Payables Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesSixMember" xlink:label="SHPH_NotesPayableOtherPayablesSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesSixMember" xlink:to="SHPH_NotesPayableOtherPayablesSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableOtherPayablesSixMember_lbl" xml:lang="en-US">Notes Payable Other Payables Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_UnsecuredPromissoryNotesMember" xlink:label="SHPH_UnsecuredPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_UnsecuredPromissoryNotesMember" xlink:to="SHPH_UnsecuredPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NoteTwoMember" xlink:label="SHPH_NoteTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NoteTwoMember" xlink:to="SHPH_NoteTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NoteTwoMember_lbl" xml:lang="en-US">Note Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccreditedInvestorMember" xlink:label="SHPH_AccreditedInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccreditedInvestorMember" xlink:to="SHPH_AccreditedInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccreditedInvestorMember_lbl" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:label="SHPH_PaycheckProtectionProgramNotePayableOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:to="SHPH_PaycheckProtectionProgramNotePayableOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaycheckProtectionProgramNotePayableOneMember_lbl" xml:lang="en-US">PPP Note Payable One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:label="SHPH_PaycheckProtectionProgramNotePayableTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:to="SHPH_PaycheckProtectionProgramNotePayableTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaycheckProtectionProgramNotePayableTwoMember_lbl" xml:lang="en-US">PPP Note Payable Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteOneMember" xlink:label="SHPH_PromissoryNoteOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteOneMember" xlink:to="SHPH_PromissoryNoteOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PromissoryNoteOneMember_lbl" xml:lang="en-US">Promissory Note One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteTwoMember" xlink:label="SHPH_PromissoryNoteTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteTwoMember" xlink:to="SHPH_PromissoryNoteTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PromissoryNoteTwoMember_lbl" xml:lang="en-US">Promissory Note Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteThreeMember" xlink:label="SHPH_PromissoryNoteThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteThreeMember" xlink:to="SHPH_PromissoryNoteThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PromissoryNoteThreeMember_lbl" xml:lang="en-US">Promissory Note Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteFourMember" xlink:label="SHPH_PromissoryNoteFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteFourMember" xlink:to="SHPH_PromissoryNoteFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PromissoryNoteFourMember_lbl" xml:lang="en-US">Promissory Note Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_MembershipInterestHoldersMember" xlink:label="SHPH_MembershipInterestHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MembershipInterestHoldersMember" xlink:to="SHPH_MembershipInterestHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MembershipInterestHoldersMember_lbl" xml:lang="en-US">Membership Interest Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DirectorsAndOfficerMember" xlink:label="SHPH_DirectorsAndOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsAndOfficerMember" xlink:to="SHPH_DirectorsAndOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DirectorsAndOfficerMember_lbl" xml:lang="en-US">Directors And Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableMember" xlink:label="SHPH_NotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableMember" xlink:to="SHPH_NotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableMember_lbl" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoteWarrantMember" xlink:to="us-gaap_NoteWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoteWarrantMember_lbl" xml:lang="en-US">Note Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockPayableMember" xlink:label="SHPH_CommonStockPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockPayableMember" xlink:to="SHPH_CommonStockPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockPayableMember_lbl" xml:lang="en-US">Common Stock Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PreferredStockDividendPayableMember" xlink:label="SHPH_PreferredStockDividendPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PreferredStockDividendPayableMember" xlink:to="SHPH_PreferredStockDividendPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PreferredStockDividendPayableMember_lbl" xml:lang="en-US">Preferred Stock Dividend Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityContractAssetCurrent" xlink:label="us-gaap_CommodityContractAssetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommodityContractAssetCurrent" xlink:to="us-gaap_CommodityContractAssetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommodityContractAssetCurrent_lbl" xml:lang="en-US">Contracts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Dividends Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Notes payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Paycheck Protection Program note payable, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssued" xlink:label="SHPH_CommonStockToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssued" xlink:to="SHPH_CommonStockToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockToBeIssued_lbl" xml:lang="en-US">Common stock to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidationPreference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidationPreference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of contract expense reimbursements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCustomerDeposits" xlink:label="us-gaap_InterestExpenseCustomerDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseCustomerDeposits" xlink:to="us-gaap_InterestExpenseCustomerDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseCustomerDeposits_lbl" xml:lang="en-US">Loss on write off of deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividend on Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per shares - basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Warrants issued for financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest convertible debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Common stock issued for restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Common stock issued for restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends on Series A preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Warrants exercised for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation (As Restated)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending Balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_2_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="us-gaap_DebtSecuritiesGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesGainLoss_lbl" xml:lang="en-US">Gain on interest relief on conversion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Contracts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common shares and exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of note payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from notes payable-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Proceeds from PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares issued for conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForConversionOfConvertibleDebt" xlink:label="SHPH_CommonStockIssuedForConversionOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfConvertibleDebt" xlink:to="SHPH_CommonStockIssuedForConversionOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForConversionOfConvertibleDebt_lbl" xml:lang="en-US">Common stock issued for conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForDividendPayable" xlink:label="SHPH_CommonStockIssuedForDividendPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForDividendPayable" xlink:to="SHPH_CommonStockIssuedForDividendPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForDividendPayable_lbl" xml:lang="en-US">Common stock issued for dividend payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease Right-of-use Asset And Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Lease Right-of-use Asset and Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable-Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes (Restated)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionTextBlock" xlink:to="us-gaap_ErrorCorrectionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionTextBlock_lbl" xml:lang="en-US">Restatement of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Lives for Property Plant Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value by Liabilities on Balance Sheet</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment Net</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" xlink:label="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" xlink:to="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Right of Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Operating Lease Maturity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Promissory Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" xlink:label="us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" xlink:to="us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Sale of Equity or Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Stock Options, Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (RSUs)</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of convertible shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Sale of stock membership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractReceivable_lbl" xml:lang="en-US">Awarded contracts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US">Proceeds for research and development from collaborators</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" xlink:label="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" xlink:to="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment_lbl" xml:lang="en-US">Proceeds from contract awards for research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xml:lang="en-US">Payments to invoices in research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccruedInvestmentIncomeReceivableOutstanding" xlink:label="SHPH_AccruedInvestmentIncomeReceivableOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInvestmentIncomeReceivableOutstanding" xlink:to="SHPH_AccruedInvestmentIncomeReceivableOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccruedInvestmentIncomeReceivableOutstanding_lbl" xml:lang="en-US">Research and development invoice receivable, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDevelopment" xlink:to="us-gaap_BusinessDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDevelopment_lbl" xml:lang="en-US">Business development new establishment</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ResearchAndDevelopmentDeficitNet" xlink:label="SHPH_ResearchAndDevelopmentDeficitNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ResearchAndDevelopmentDeficitNet" xlink:to="SHPH_ResearchAndDevelopmentDeficitNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ResearchAndDevelopmentDeficitNet_lbl" xml:lang="en-US">Net deficit on research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Project cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial liabilities fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Right Of Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OfficeLease" xlink:label="SHPH_OfficeLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficeLease" xlink:to="SHPH_OfficeLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OfficeLease_lbl" xml:lang="en-US">Office Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccumulatedAmortizationOnRightOfUseAssets" xlink:label="SHPH_AccumulatedAmortizationOnRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccumulatedAmortizationOnRightOfUseAssets" xlink:to="SHPH_AccumulatedAmortizationOnRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_AccumulatedAmortizationOnRightOfUseAssets_lbl" xml:lang="en-US">Less accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract_3_lbl" xml:lang="en-US">Schedule Of Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Office Lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">PV of Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_lbl" xml:lang="en-US">Interest rate used to lease, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OperatingLeasePayment" xlink:label="SHPH_OperatingLeasePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OperatingLeasePayment" xlink:to="SHPH_OperatingLeasePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OperatingLeasePayment_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Operating lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyTransactionAmountsOfTransactions" xlink:label="SHPH_RelatedPartyTransactionAmountsOfTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyTransactionAmountsOfTransactions" xlink:to="SHPH_RelatedPartyTransactionAmountsOfTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RelatedPartyTransactionAmountsOfTransactions_lbl" xml:lang="en-US">Notes payable related party debt principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Notes payable related party transaction rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="us-gaap_RelatedPartyTransactionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Notes payable related party maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Notes payable related party debt principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt maturity, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Notes payable related party debt plus accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Monthly payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument, maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LoanForgiveness" xlink:label="SHPH_LoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LoanForgiveness" xlink:to="SHPH_LoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_LoanForgiveness_lbl" xml:lang="en-US">Loan Forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Promissory notes issued on December 28, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less unamortized discount on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotes" xlink:label="us-gaap_MediumTermNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MediumTermNotes" xlink:to="us-gaap_MediumTermNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MediumTermNotes_lbl" xml:lang="en-US">Term notes issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtDescription" xlink:label="us-gaap_ShortTermDebtDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtDescription" xlink:to="us-gaap_ShortTermDebtDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtDescription_lbl" xml:lang="en-US">Term note description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt fee amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Warrants exercised to payment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Accrued interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Debt instrument conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Debt forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt remaining amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants, share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants issued for common stock, share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xml:lang="en-US">Conversion of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Warrants, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Stock Option, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable Weighted Average Life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt converted into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Purchase up warrants shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionPricePercentage" xlink:label="SHPH_DebtInstrumentConvertibleConversionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DebtInstrumentConvertibleConversionPricePercentage" xlink:to="SHPH_DebtInstrumentConvertibleConversionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DebtInstrumentConvertibleConversionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="us-gaap_DividendsPreferredStockCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US">Dividends on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="us-gaap_DividendsShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensation" xlink:to="us-gaap_DividendsShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsShareBasedCompensation_lbl" xml:lang="en-US">Dividends total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US">Commons stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt converted into common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from initial public offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant exercise low price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price increase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Common stock, Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Increase in common stock conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair value of warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share granted under equity incentive plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2_lbl" xml:lang="en-US">Restricted stock value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PercentageOfVariableExercisePrice" xlink:label="SHPH_PercentageOfVariableExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PercentageOfVariableExercisePrice" xlink:to="SHPH_PercentageOfVariableExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PercentageOfVariableExercisePrice_lbl" xml:lang="en-US">Percentage of variable exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax expense (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operation loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_2_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_2_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Post reverse split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xml:lang="en-US">Debt instrument decrease forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_3_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Conversion ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionSharesPercentage" xlink:label="SHPH_DebtInstrumentConvertibleConversionSharesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DebtInstrumentConvertibleConversionSharesPercentage" xlink:to="SHPH_DebtInstrumentConvertibleConversionSharesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DebtInstrumentConvertibleConversionSharesPercentage_lbl" xml:lang="en-US">Conversion shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Value issued</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentOfInvoice" xlink:label="SHPH_PaymentOfInvoice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentOfInvoice" xlink:to="SHPH_PaymentOfInvoice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentOfInvoice_lbl" xml:lang="en-US">Value issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssued" xlink:to="SHPH_CommonStockToBeIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockToBeIssued_doc" xml:lang="en-US">Common stock to be issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SeriesAConvertiblePreferredStockMember" xlink:to="SHPH_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfConvertibleDebt" xlink:to="SHPH_CommonStockIssuedForConversionOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForConversionOfConvertibleDebt_doc" xml:lang="en-US">Common stock issued for conversion of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForDividendPayable" xlink:to="SHPH_CommonStockIssuedForDividendPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForDividendPayable_doc" xml:lang="en-US">Common stock issued for dividend payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockToBeIssuedMember_doc" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PhaseIIMember" xlink:to="SHPH_PhaseIIMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PhaseIIMember_doc" xml:lang="en-US">Phase II [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LaboratoryEquipmentMember" xlink:to="SHPH_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccumulatedAmortizationOnRightOfUseAssets" xlink:to="SHPH_AccumulatedAmortizationOnRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccumulatedAmortizationOnRightOfUseAssets_doc" xml:lang="en-US">Accumulated amortization on right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficeLease" xlink:to="SHPH_OfficeLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OfficeLease_doc" xml:lang="en-US">Office Lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" xlink:to="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Operating Lease Right Of Use Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OfficersSpouseMember_doc" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_UnsecuredPromissoryNotesMember" xlink:to="SHPH_UnsecuredPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_UnsecuredPromissoryNotesMember_doc" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NoteTwoMember" xlink:to="SHPH_NoteTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NoteTwoMember_doc" xml:lang="en-US">Note Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LoanForgiveness" xlink:to="SHPH_LoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LoanForgiveness_doc" xml:lang="en-US">Loan Forgiveness.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NoteOneMember" xlink:label="SHPH_NoteOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NoteOneMember" xlink:to="SHPH_NoteOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NoteOneMember_doc" xml:lang="en-US">Note One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteOneMember" xlink:to="SHPH_PromissoryNoteOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PromissoryNoteOneMember_doc" xml:lang="en-US">Promissory Note One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteTwoMember" xlink:to="SHPH_PromissoryNoteTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PromissoryNoteTwoMember_doc" xml:lang="en-US">Promissory Note Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteThreeMember" xlink:to="SHPH_PromissoryNoteThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PromissoryNoteThreeMember_doc" xml:lang="en-US">Promissory Note Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PromissoryNoteFourMember" xlink:to="SHPH_PromissoryNoteFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PromissoryNoteFourMember_doc" xml:lang="en-US">Promissory Note Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableMember" xlink:to="SHPH_NotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableMember_doc" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockPayableMember" xlink:to="SHPH_CommonStockPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockPayableMember_doc" xml:lang="en-US">Common Stock Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PreferredStockDividendPayableMember" xlink:to="SHPH_PreferredStockDividendPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PreferredStockDividendPayableMember_doc" xml:lang="en-US">Preferred Stock Dividend Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_WarrantsMember" xlink:label="SHPH_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsMember" xlink:to="SHPH_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments cancelled in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exexcises in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xml:lang="en-US">&#160;Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" xlink:to="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ProceedsFromContractAwardsForResearchAndDevelopment_doc" xml:lang="en-US">Proceeds from contract awards for research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoQuarterlyPaymentsMember" xlink:to="SHPH_TwoQuarterlyPaymentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoQuarterlyPaymentsMember_doc" xml:lang="en-US">2 Quarterly Payments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OneQuarterlyPaymentsMember" xlink:to="SHPH_OneQuarterlyPaymentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OneQuarterlyPaymentsMember_doc" xml:lang="en-US">1 Quarterly Payments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInvestmentIncomeReceivableOutstanding" xlink:to="SHPH_AccruedInvestmentIncomeReceivableOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccruedInvestmentIncomeReceivableOutstanding_doc" xml:lang="en-US">Research and development invoice receivable, outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xml:lang="en-US">Payments to invoices in research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SubcontractPhaseIIMember" xlink:to="SHPH_SubcontractPhaseIIMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SubcontractPhaseIIMember_doc" xml:lang="en-US">Subcontract Phase II [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ResearchAndDevelopmentDeficitNet" xlink:to="SHPH_ResearchAndDevelopmentDeficitNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ResearchAndDevelopmentDeficitNet_doc" xml:lang="en-US">Net deficit on research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TCGGreenChemIncMember_doc" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RelatedPartyOfficerMember_doc" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:to="SHPH_PaycheckProtectionProgramNotePayableOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaycheckProtectionProgramNotePayableOneMember_doc" xml:lang="en-US">PPP Note Payable One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:to="SHPH_PaycheckProtectionProgramNotePayableTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaycheckProtectionProgramNotePayableTwoMember_doc" xml:lang="en-US">PPP Note Payable Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MembershipInterestHoldersMember" xlink:to="SHPH_MembershipInterestHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MembershipInterestHoldersMember_doc" xml:lang="en-US">Membership Interest Holders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccreditedInvestorMember" xlink:to="SHPH_AccreditedInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccreditedInvestorMember_doc" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DebtInstrumentConvertibleConversionPricePercentage" xlink:to="SHPH_DebtInstrumentConvertibleConversionPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DebtInstrumentConvertibleConversionPricePercentage_doc" xml:lang="en-US">Conversion price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SBIRMember" xlink:to="SHPH_SBIRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SBIRMember_doc" xml:lang="en-US">SBIR [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesOneMember" xlink:to="SHPH_NotesPayableOtherPayablesOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesOneMember_doc" xml:lang="en-US">Notes Payable Other Payables One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesThreeMember" xlink:to="SHPH_NotesPayableOtherPayablesThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesThreeMember_doc" xml:lang="en-US">Notes Payable Other Payables Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesTwoMember" xlink:to="SHPH_NotesPayableOtherPayablesTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesTwoMember_doc" xml:lang="en-US">Notes Payable Other Payables Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesFourMember" xlink:to="SHPH_NotesPayableOtherPayablesFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesFourMember_doc" xml:lang="en-US">Notes Payable Other Payables Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesFiveMember" xlink:to="SHPH_NotesPayableOtherPayablesFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesFiveMember_doc" xml:lang="en-US">Notes Payable Other Payables Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableOtherPayablesSixMember" xlink:to="SHPH_NotesPayableOtherPayablesSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableOtherPayablesSixMember_doc" xml:lang="en-US">Notes Payable Other Payables Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsAndOfficerMember" xlink:to="SHPH_DirectorsAndOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DirectorsAndOfficerMember_doc" xml:lang="en-US">Directors And Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xml:lang="en-US">Schedule Of Pretax Income From Continuing Operations [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NetDeferredTaxExpenseAfterValuationAllowance" xlink:label="SHPH_NetDeferredTaxExpenseAfterValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NetDeferredTaxExpenseAfterValuationAllowance" xlink:to="SHPH_NetDeferredTaxExpenseAfterValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NetDeferredTaxExpenseAfterValuationAllowance_doc" xml:lang="en-US">Net deferred tax expense after valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DebtInstrumentConvertibleConversionSharesPercentage" xlink:to="SHPH_DebtInstrumentConvertibleConversionSharesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DebtInstrumentConvertibleConversionSharesPercentage_doc" xml:lang="en-US">Debt instrument convertible conversion shares percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentOfInvoice" xlink:to="SHPH_PaymentOfInvoice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentOfInvoice_doc" xml:lang="en-US">Payment of invoice.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PercentageOfVariableExercisePrice" xlink:to="SHPH_PercentageOfVariableExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PercentageOfVariableExercisePrice_doc" xml:lang="en-US">Percentage of variable exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OperatingLeasePayment" xlink:to="SHPH_OperatingLeasePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OperatingLeasePayment_doc" xml:lang="en-US">Operating lease payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyTransactionAmountsOfTransactions" xlink:to="SHPH_RelatedPartyTransactionAmountsOfTransactions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RelatedPartyTransactionAmountsOfTransactions_doc" xml:lang="en-US">Related party transaction amounts of transactions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_2_lbl" xml:lang="en-US">Interest Expense, Related Party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_2_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_3_lbl" xml:lang="en-US">CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccumulatedAmortizationOnRightOfUseAssets" xlink:to="SHPH_AccumulatedAmortizationOnRightOfUseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccumulatedAmortizationOnRightOfUseAssets_3_lbl" xml:lang="en-US">AccumulatedAmortizationOnRightOfUseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_2_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_3_lbl" xml:lang="en-US">Notes Payable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_2_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_2_lbl" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>shph-20220930_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="shph-20220930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20220930.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable" xlink:href="shph-20220930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20220930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:href="shph-20220930.xsd#IncomeTaxesRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableTables" xlink:href="shph-20220930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20220930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:href="shph-20220930.xsd#OrganizationAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20220930.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:href="shph-20220930.xsd#ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20220930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="shph-20220930.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="shph-20220930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:href="shph-20220930.xsd#ScheduleOfOperatingLeaseMaturityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:href="shph-20220930.xsd#OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfNotesPayableDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfPromissoryNotesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:href="shph-20220930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="shph-20220930.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20220930.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20220930.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20220930.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20220930.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:href="shph-20220930.xsd#IncomeTaxesRestatedDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20220930.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:href="shph-20220930.xsd#RestatementOfFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SeriesAConvertiblePreferredStockMember" xlink:label="loc_SHPHSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SHPHSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityContractAssetCurrent" xlink:label="loc_us-gaapCommodityContractAssetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCommodityContractAssetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="loc_us-gaapNotesPayableToBankCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableToBankCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssued" xlink:label="loc_SHPHCommonStockToBeIssued" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_SHPHCommonStockToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SeriesAConvertiblePreferredStockMember" xlink:label="loc_SHPHSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SHPHSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCustomerDeposits" xlink:label="loc_us-gaapInterestExpenseCustomerDeposits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseCustomerDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_SHPHCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForConversionOfConvertibleDebt" xlink:label="loc_SHPHCommonStockIssuedForConversionOfConvertibleDebt" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForConversionOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockIssuedForDividendPayable" xlink:label="loc_SHPHCommonStockIssuedForDividendPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForDividendPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcern" xlink:title="00000007 - Disclosure - Organization and Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - Property and Equipment, Net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability" xlink:title="00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000011 - Disclosure - Notes Payable-Related Party">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable" xlink:title="00000012 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestated" xlink:title="00000015 - Disclosure - Income Taxes (Restated)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatements" xlink:title="00000016 - Disclosure - Restatement of Financial Statements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="loc_us-gaapErrorCorrectionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapErrorCorrectionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaapFairValueByBalanceSheetGroupingTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - Property and Equipment, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables" xlink:title="00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" xlink:label="loc_SHPHScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_SHPHScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableTables" xlink:title="00000021 - Disclosure - Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" xlink:label="loc_us-gaapScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedTables" xlink:title="00000023 - Disclosure - Income Taxes (Restated) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables" xlink:title="00000024 - Disclosure - Restatement of Financial Statements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaapGovernmentContractReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGovernmentContractReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="loc_us-gaapAdditionalFundingAgreementTermsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapAdditionalFundingAgreementTermsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OneQuarterlyPaymentsMember" xlink:label="loc_SHPHOneQuarterlyPaymentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHOneQuarterlyPaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoQuarterlyPaymentsMember" xlink:label="loc_SHPHTwoQuarterlyPaymentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHTwoQuarterlyPaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PhaseIIMember" xlink:label="loc_SHPHPhaseIIMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_SHPHPhaseIIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SubcontractPhaseIIMember" xlink:label="loc_SHPHSubcontractPhaseIIMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_SHPHSubcontractPhaseIIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_SBIRMember" xlink:label="loc_SHPHSBIRMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHSBIRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaapProceedsFromCollaborators" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromCollaborators" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ProceedsFromContractAwardsForResearchAndDevelopment" xlink:label="loc_SHPHProceedsFromContractAwardsForResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromContractAwardsForResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccruedInvestmentIncomeReceivableOutstanding" xlink:label="loc_SHPHAccruedInvestmentIncomeReceivableOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHAccruedInvestmentIncomeReceivableOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaapBusinessDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ResearchAndDevelopmentDeficitNet" xlink:label="loc_SHPHResearchAndDevelopmentDeficitNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHResearchAndDevelopmentDeficitNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - Schedule of Property and Equipment Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LaboratoryEquipmentMember" xlink:label="loc_SHPHLaboratoryEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SHPHLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000031 - Disclosure - Property and Equipment, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails" xlink:title="00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OfficeLease" xlink:label="loc_SHPHOfficeLease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_SHPHOfficeLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccumulatedAmortizationOnRightOfUseAssets" xlink:label="loc_SHPHAccumulatedAmortizationOnRightOfUseAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_SHPHAccumulatedAmortizationOnRightOfUseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails" xlink:title="00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative" xlink:title="00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:label="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OperatingLeasePayment" xlink:label="loc_SHPHOperatingLeasePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_SHPHOperatingLeasePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLessorOperatingLeaseTermOfContract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapLessorOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesOneMember" xlink:label="loc_SHPHNotesPayableOtherPayablesOneMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesTwoMember" xlink:label="loc_SHPHNotesPayableOtherPayablesTwoMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesThreeMember" xlink:label="loc_SHPHNotesPayableOtherPayablesThreeMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFourMember" xlink:label="loc_SHPHNotesPayableOtherPayablesFourMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesFiveMember" xlink:label="loc_SHPHNotesPayableOtherPayablesFiveMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableOtherPayablesSixMember" xlink:label="loc_SHPHNotesPayableOtherPayablesSixMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNotesPayableOtherPayablesSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_RelatedPartyTransactionAmountsOfTransactions" xlink:label="loc_SHPHRelatedPartyTransactionAmountsOfTransactions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SHPHRelatedPartyTransactionAmountsOfTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails" xlink:title="00000037 - Disclosure - Schedule of Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_LoanForgiveness" xlink:label="loc_SHPHLoanForgiveness" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_SHPHLoanForgiveness" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableOneMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaycheckProtectionProgramNotePayableTwoMember" xlink:label="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPaycheckProtectionProgramNotePayableTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails" xlink:title="00000039 - Disclosure - Schedule of Promissory Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteOneMember" xlink:label="loc_SHPHPromissoryNoteOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteTwoMember" xlink:label="loc_SHPHPromissoryNoteTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteThreeMember" xlink:label="loc_SHPHPromissoryNoteThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteFourMember" xlink:label="loc_SHPHPromissoryNoteFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical" xlink:title="00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteOneMember" xlink:label="loc_SHPHPromissoryNoteOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteTwoMember" xlink:label="loc_SHPHPromissoryNoteTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteThreeMember" xlink:label="loc_SHPHPromissoryNoteThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PromissoryNoteFourMember" xlink:label="loc_SHPHPromissoryNoteFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHPromissoryNoteFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_UnsecuredPromissoryNotesMember" xlink:label="loc_SHPHUnsecuredPromissoryNotesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHUnsecuredPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NoteTwoMember" xlink:label="loc_SHPHNoteTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SHPHNoteTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_AccreditedInvestorMember" xlink:label="loc_SHPHAccreditedInvestorMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHAccreditedInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotes" xlink:label="loc_us-gaapMediumTermNotes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMediumTermNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShortTermDebtDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails" xlink:title="00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_NotesPayableMember" xlink:label="loc_SHPHNotesPayableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaapNoteWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapNoteWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockPayableMember" xlink:label="loc_SHPHCommonStockPayableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHCommonStockPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PreferredStockDividendPayableMember" xlink:label="loc_SHPHPreferredStockDividendPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHPreferredStockDividendPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical" xlink:title="00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PreferredStockDividendPayableMember" xlink:label="loc_SHPHPreferredStockDividendPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHPreferredStockDividendPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_MembershipInterestHoldersMember" xlink:label="loc_SHPHMembershipInterestHoldersMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHMembershipInterestHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DirectorsAndOfficerMember" xlink:label="loc_SHPHDirectorsAndOfficerMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionPricePercentage" xlink:label="loc_SHPHDebtInstrumentConvertibleConversionPricePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SHPHDebtInstrumentConvertibleConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaapDividendsPreferredStockCash" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaapDividendsShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaapDividendsCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PercentageOfVariableExercisePrice" xlink:label="loc_SHPHPercentageOfVariableExercisePrice" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SHPHPercentageOfVariableExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaapDeferredTaxAssetInterestCarryforward" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetInterestCarryforward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative" xlink:title="00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_DebtInstrumentConvertibleConversionSharesPercentage" xlink:label="loc_SHPHDebtInstrumentConvertibleConversionSharesPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_SHPHDebtInstrumentConvertibleConversionSharesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20220930.xsd#SHPH_PaymentOfInvoice" xlink:label="loc_SHPHPaymentOfInvoice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_SHPHPaymentOfInvoice" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904717536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001757499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5089826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One
Research Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">403-4212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733905710800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 9,120,390<span></span>
</td>
<td class="nump">$ 504,749<span></span>
</td>
<td class="nump">$ 117,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">163,142<span></span>
</td>
<td class="nump">4,866<span></span>
</td>
<td class="nump">12,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,954<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommodityContractAssetCurrent', window );">Contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">211,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,289,486<span></span>
</td>
<td class="nump">509,615<span></span>
</td>
<td class="nump">341,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,080<span></span>
</td>
<td class="nump">18,564<span></span>
</td>
<td class="nump">24,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">6,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">71,970<span></span>
</td>
<td class="nump">116,982<span></span>
</td>
<td class="nump">171,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,382,016<span></span>
</td>
<td class="nump">651,641<span></span>
</td>
<td class="nump">544,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">107,153<span></span>
</td>
<td class="nump">828,313<span></span>
</td>
<td class="nump">516,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued interest payable</a></td>
<td class="nump">18,904<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="nump">85,233<span></span>
</td>
<td class="nump">46,947<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends Payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">331,059<span></span>
</td>
<td class="nump">227,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes payable - related parties</a></td>
<td class="nump">685,473<span></span>
</td>
<td class="nump">685,473<span></span>
</td>
<td class="nump">565,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,021<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Paycheck Protection Program note payable, current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,007<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">94,025<span></span>
</td>
<td class="nump">673,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability current portion</a></td>
<td class="nump">73,707<span></span>
</td>
<td class="nump">66,934<span></span>
</td>
<td class="nump">58,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">970,470<span></span>
</td>
<td class="nump">2,217,331<span></span>
</td>
<td class="nump">2,104,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability non-current</a></td>
<td class="nump">6,671<span></span>
</td>
<td class="nump">62,442<span></span>
</td>
<td class="nump">129,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">977,141<span></span>
</td>
<td class="nump">2,279,773<span></span>
</td>
<td class="nump">2,234,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">16,548,719<span></span>
</td>
<td class="nump">4,150,867<span></span>
</td>
<td class="nump">2,833,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockToBeIssued', window );">Common stock to be issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,143,980)<span></span>
</td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="num">(4,540,236)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="nump">8,404,875<span></span>
</td>
<td class="num">(1,628,132)<span></span>
</td>
<td class="num">(1,690,296)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">9,382,016<span></span>
</td>
<td class="nump">651,641<span></span>
</td>
<td class="nump">544,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommodityContractAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the asset arising from commodity contracts such as futures contracts tied to the movement of a particular commodity, which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommodityContractAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733994632032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">13,586,393<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">13,586,393<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidationPreference per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidationPreference</a></td>
<td class="nump">$ 1,212,500<span></span>
</td>
<td class="nump">$ 1,212,500<span></span>
</td>
<td class="nump">$ 1,212,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SHPH_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906738080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="nump">669,038<span></span>
</td>
<td class="nump">186,958<span></span>
</td>
<td class="nump">1,048,821<span></span>
</td>
<td class="nump">579,684<span></span>
</td>
<td class="nump">1,021,808<span></span>
</td>
<td class="nump">161,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">81,864<span></span>
</td>
<td class="nump">6,422<span></span>
</td>
<td class="nump">104,711<span></span>
</td>
<td class="nump">19,883<span></span>
</td>
<td class="nump">36,500<span></span>
</td>
<td class="nump">85,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="nump">70,566<span></span>
</td>
<td class="nump">48,736<span></span>
</td>
<td class="nump">659,958<span></span>
</td>
<td class="nump">154,886<span></span>
</td>
<td class="nump">684,684<span></span>
</td>
<td class="nump">261,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">821,468<span></span>
</td>
<td class="nump">242,116<span></span>
</td>
<td class="nump">1,813,490<span></span>
</td>
<td class="nump">754,453<span></span>
</td>
<td class="nump">1,742,992<span></span>
</td>
<td class="nump">509,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(821,468)<span></span>
</td>
<td class="num">(242,116)<span></span>
</td>
<td class="num">(1,813,490)<span></span>
</td>
<td class="num">(754,453)<span></span>
</td>
<td class="num">(1,742,992)<span></span>
</td>
<td class="num">(509,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseCustomerDeposits', window );">Loss on write off of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense - related parties</a></td>
<td class="num">(13,725)<span></span>
</td>
<td class="num">(10,547)<span></span>
</td>
<td class="num">(39,108)<span></span>
</td>
<td class="num">(31,641)<span></span>
</td>
<td class="num">(46,947)<span></span>
</td>
<td class="num">(36,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(604,716)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(920,660)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(3,841)<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">112,797<span></span>
</td>
<td class="num">(26,685)<span></span>
</td>
<td class="nump">94,025<span></span>
</td>
<td class="nump">30,971<span></span>
</td>
<td class="nump">579,146<span></span>
</td>
<td class="num">(256,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on settlement of accounts payable</a></td>
<td class="nump">328,687<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">328,687<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">73,007<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(176,957)<span></span>
</td>
<td class="nump">25,155<span></span>
</td>
<td class="num">(464,049)<span></span>
</td>
<td class="nump">61,367<span></span>
</td>
<td class="nump">590,858<span></span>
</td>
<td class="num">(296,210)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(998,425)<span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
<td class="num">(2,277,539)<span></span>
</td>
<td class="num">(693,086)<span></span>
</td>
<td class="num">(1,152,134)<span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(998,425)<span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
<td class="num">(2,277,539)<span></span>
</td>
<td class="num">(693,086)<span></span>
</td>
<td class="num">(1,152,134)<span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A preferred stock</a></td>
<td class="num">(19,473)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
<td class="num">(77,304)<span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,017,898)<span></span>
</td>
<td class="num">$ (242,729)<span></span>
</td>
<td class="num">$ (2,348,548)<span></span>
</td>
<td class="num">$ (770,390)<span></span>
</td>
<td class="num">$ (1,255,196)<span></span>
</td>
<td class="num">$ (908,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">10,164,979<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="nump">9,723,510<span></span>
</td>
<td class="nump">9,298,332<span></span>
</td>
<td class="nump">9,301,750<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - basic and diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseCustomerDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest expense recognized during the period on customer deposits or security deposits held in interest bearing accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseCustomerDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733899758944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock To Be Issued [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 2,373,918<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="num">$ (3,631,442)<span></span>
</td>
<td class="num">$ (1,241,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,269,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">459,589<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">459,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,833,507<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(4,540,236)<span></span>
</td>
<td class="num">(1,690,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">122,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(129,324)<span></span>
</td>
<td class="num">(129,324)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,956,024<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(4,695,328)<span></span>
</td>
<td class="num">(1,722,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,833,507<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(4,540,236)<span></span>
</td>
<td class="num">(1,690,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(693,086)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Sep. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">3,201,058<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,310,626)<span></span>
</td>
<td class="num">(2,093,135)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,308,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,833,507<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(4,540,236)<span></span>
</td>
<td class="num">(1,690,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">407,293<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">407,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">490,067<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">490,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
<td class="num">(103,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,152,134)<span></span>
</td>
<td class="num">$ (1,152,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation (As Restated)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,150,867<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="num">(1,628,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">2,956,024<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(4,695,328)<span></span>
</td>
<td class="num">(1,722,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">122,517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">122,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(346,801)<span></span>
</td>
<td class="num">(346,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">3,078,541<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,067,897)<span></span>
</td>
<td class="num">(1,972,923)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,299,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">122,517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">122,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Sep. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">3,201,058<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,310,626)<span></span>
</td>
<td class="num">(2,093,135)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,308,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,150,867<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="num">(1,628,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for conversion of accrued interest convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(16,340)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of accrued interest convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(681,839)<span></span>
</td>
<td class="num">(681,839)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,653,383<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,503,039)<span></span>
</td>
<td class="num">(1,849,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,318,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,150,867<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="num">(1,628,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,277,539)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">16,548,719<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,143,980)<span></span>
</td>
<td class="nump">8,404,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,653,383<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,503,039)<span></span>
</td>
<td class="num">(1,849,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,318,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
<td class="num">(25,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(597,275)<span></span>
</td>
<td class="num">(597,275)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">4,819,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,126,082)<span></span>
</td>
<td class="num">(2,306,073)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,323,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">92,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">92,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for conversion of accrued interest convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">588,523<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">588,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of accrued interest convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,473)<span></span>
</td>
<td class="num">(19,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(998,425)<span></span>
</td>
<td class="num">(998,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">10,031,401<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,031,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Warrants exercised for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">14,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">576,467<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">576,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for exercise of warrants with settlement of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock, shares</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="nump">437,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 16,548,719<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (8,143,980)<span></span>
</td>
<td class="nump">$ 8,404,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906635840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,277,539)<span></span>
</td>
<td class="num">$ (693,086)<span></span>
</td>
<td class="num">$ (1,152,134)<span></span>
</td>
<td class="num">$ (805,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">4,484<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">5,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(94,025)<span></span>
</td>
<td class="num">(30,971)<span></span>
</td>
<td class="num">(579,146)<span></span>
</td>
<td class="nump">256,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">45,012<span></span>
</td>
<td class="nump">40,408<span></span>
</td>
<td class="nump">54,616<span></span>
</td>
<td class="nump">49,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">885,505<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on settlement of accounts payable</a></td>
<td class="num">(328,687)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of Paycheck Protection Program note payable</a></td>
<td class="num">(73,007)<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesGainLoss', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="nump">12,625<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">356,733<span></span>
</td>
<td class="nump">367,551<span></span>
</td>
<td class="nump">910,067<span></span>
</td>
<td class="nump">459,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Contracts receivable</a></td>
<td class="num">(5,954)<span></span>
</td>
<td class="nump">211,455<span></span>
</td>
<td class="nump">211,455<span></span>
</td>
<td class="nump">164,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(158,276)<span></span>
</td>
<td class="nump">5,281<span></span>
</td>
<td class="nump">7,713<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(392,473)<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
<td class="nump">311,347<span></span>
</td>
<td class="num">(51,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="nump">5,727<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued interest payable - related parties</a></td>
<td class="nump">38,286<span></span>
</td>
<td class="nump">31,641<span></span>
</td>
<td class="nump">46,947<span></span>
</td>
<td class="num">(54,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(48,998)<span></span>
</td>
<td class="num">(42,930)<span></span>
</td>
<td class="num">(58,468)<span></span>
</td>
<td class="num">(50,866)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,030,587)<span></span>
</td>
<td class="num">(165,185)<span></span>
</td>
<td class="num">(300,336)<span></span>
</td>
<td class="num">(26,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,818)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares and exercise of warrants</a></td>
<td class="nump">10,045,513<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of note payable-related party</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from notes payable-related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">7,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,007<span></span>
</td>
<td class="nump">73,007<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">600,715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">494,925<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,646,228<span></span>
</td>
<td class="nump">193,007<span></span>
</td>
<td class="nump">687,932<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">8,615,641<span></span>
</td>
<td class="nump">27,822<span></span>
</td>
<td class="nump">387,596<span></span>
</td>
<td class="nump">32,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of period</a></td>
<td class="nump">504,749<span></span>
</td>
<td class="nump">117,153<span></span>
</td>
<td class="nump">117,153<span></span>
</td>
<td class="nump">84,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of period</a></td>
<td class="nump">9,120,390<span></span>
</td>
<td class="nump">144,975<span></span>
</td>
<td class="nump">504,749<span></span>
</td>
<td class="nump">117,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">17,489<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued for conversion of accrued interest</a></td>
<td class="nump">16,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForConversionOfConvertibleDebt', window );">Common stock issued for conversion of convertible debt</a></td>
<td class="nump">588,524<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="nump">576,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForDividendPayable', window );">Common stock issued for dividend payable</a></td>
<td class="nump">$ 402,067<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForDividendPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for dividend payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForDividendPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for exercise of warrants with settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733907538960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Going Concern</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUWPhsGrtOBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span>Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82F_zvrcvWircP1h" style="display: none">Organization
and Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkO5fO6ylmb" title="Number of convertible shares issued">45,000,000</span> shares of common
stock in exchange for <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxJA6Qa3Ja8i" title="Sale of stock membership percentage">100</span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, the Company has been working on developing products through NIH grants,
including a product to predict late effects of radiation with metabolite biomarkers and develop prostate cancer cell lines in health
disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zSGzuPRKQiHh" title="Reverse stock split">2-for-1 reverse stock split</span> of our issued and outstanding shares of common stock (the &#8220;Reverse Stock
Split&#8221;). All references to shares of our common stock in this report refers to the number of shares of common stock after giving
effect to the Reverse Stock Split (unless otherwise indicated).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zfW6OIA38t38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zA3NBGJxSpV9">Organization and Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a corporation and the Company changed its name to Shuttle
Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z980VB5bNKS6" title="Number of convertible shares issued">45,000,000</span> shares of common stock
in exchange for <span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQh8FlUdslqc" title="Sale of stock membership percentage">100</span>% of the outstanding membership interests prior to conversion. On June 4, 2018, Shuttle completed a reverse merger
with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp.), a Delaware corporation (the &#8220;Company&#8221;),
pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies which has produced a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (SBIR) contract provided by the
National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH). Ropidoxuridine has been further developed though
the Company&#8217;s collaborations with the University of Virginia for use in combination with proton therapy to improve patient survival.
The Company is working on developing products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zt1vsqnk4tA5" title="Reverse stock split">2-for-1 reverse stock split</span> of our issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;).
All references to shares of our common stock in this registration statement on Form S-1 refers to the number of shares of common stock
after giving effect to the Reverse Stock Split (unless otherwise indicated).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&#8217;s only revenue source since inception has been government awarded contracts totaling
$<span id="xdx_900_eus-gaap--GovernmentContractReceivable_iI_c20211231_zQhXS9JD3uvf" title="Awarded contracts">5,531,722</span>, and the Company has incurred losses since inception, having accumulated a deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_zRDBDopnla4g" title="Accumulated deficit">5,795,432</span> as of December 31, 2021.
The Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient
to cover operating costs over an extended period. These factors, among others, raise substantial doubt about the Company&#8217;s ability
to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing
through debt or equity financings with an aim to continue progress toward commercial viability of its products. The Company continues
to submit Federal grant and contract applications which have historically been the primary source of revenue. The financial statements
do not include any adjustments that might result from the outcome of the uncertainty of raising additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904528704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zh8HybQdj397" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_823_zZWvXrhpJe05">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhSeyCkF9SFi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z0W8FiA8tXZh">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX3kHkk5xqEg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zkpAz40vtY5g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"/>

<p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zPEiyQuA66c7">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFFpvu1BVnNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zPpD978nUCdj">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zrejJygRHQC4" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life">10</span>
    years</span></td></tr>
  </table>
<p id="xdx_8AD_zrSjsjleiadg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqDNlRLgmH2b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoyPOKzGk12h">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zAX85jorC2o8" title="Proceeds for research and development from collaborators">299,502</span> Phase I award includes funded research from September 19, 2016 through September 18, 2017
and was advanced to Phase II of the awards with funding of $<span id="xdx_90B_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zrl1OPzzKA4k" title="Proceeds for research and development from collaborators">1,903,095</span> with a fixed price contract period of September 17, 2018 through
September 16, 2020 and subsequent no cost extensions through September 15, 2021 and then March 15, 2022 (Reference 75N91019C00031). The
Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zLUMgHUOD9v2" title="Proceeds from contract awards for research and development">211,455</span> for a total of $<span id="xdx_902_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zHVzt4MlVLvc" title="Proceeds from contract awards for research and development">845,820</span> in 2020; and 2 quarterly payments related to Topic 345 for a
total of $<span id="xdx_901_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_z5byWYRT12H5" title="Proceeds from contract awards for research and development">422,910</span> in 2021. On April 6, 2022, the Company submitted the final invoice for &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects,&#8221; for $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220425__20220426__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zdHXKcE9yNBg" title="Payments to invoices in research and development">211,455</span>, following the completion of the Final Quarterly Progress
Report to NIH covering the performance period of September 16, 2019-March 15, 2022. The invoice was paid in full on April 27, 2022. In
Phase II of the SBIR effort, the Company completed an analytical validation of the metabolic test kit, extended the option to license
the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221; test and developed
plans for a multi-institutional clinical trial to be implemented in the Phase III effort. This contract included a subcontract to Georgetown
University (&#8220;Georgetown&#8221;) for use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended
to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZDynIs5qjMc" title="Proceeds for research and development from collaborators">795,248</span> subcontract of its Phase II contract #HHSN75N91019C00031. The
Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zD1dF4GG7wYc" title="Proceeds for research and development from collaborators">795,248</span>. Georgetown invoiced the
Company for a total of $<span id="xdx_90E_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zk3255qtn7m3" title="Payments to invoices in research and development">791,017</span> as of September 30, 2022, leaving a balance of $<span id="xdx_907_ecustom--AccruedInvestmentIncomeReceivableOutstanding_iI_c20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zbLnUtrmaXe5" title="Research and development invoice receivable, outstanding">4,231</span>. Depending on the resources it uses, Georgetown
may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable amount, the
Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $<span id="xdx_902_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220401__20220430_zE9fjBl3FtLl" title="Payments to invoices in research and development">791,017</span> were made to Georgetown, including
an additional invoice for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220701__20220930_zPTpk6s8LFmj" title="Payments to invoices in research and development">282,643</span> which was received but not paid until the second quarter of 2022. All invoices have now been paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_90A_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zanyYyghAh34" title="Proceeds from contract awards for research and development">1,484,350</span> to fund research
from September 17, 2018 through September 16, 2020 and was extended without cost through November 16, 2021 due to delays caused by the
impact of COVID-19. For the entire contract period, the Company invoiced and received a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211116__20211116__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVAJShB1sPPd" title="Payments to invoices in research and development">1,411,883</span>. The final draft report was
filed with the NIH along with the final invoice for $<span id="xdx_90B_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211202__20211203__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfrcR6AlrTFj" title="Payments to invoices in research and development">10,000</span>, which payment was made on December 3, 2021, and no additional payments are
expected. The Phase II contract also includes a subcontract to Georgetown University for $<span id="xdx_906_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zeOLO5T65Yv7" title="Business development new establishment">742,002</span> to establish prostate cancer cell lines
from African American patients undergoing prostate surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z2CdTdQbva21" title="Proceeds for research and development from collaborators">742,002</span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zMG2pQQCfA07" title="Payments to invoices in research and development">305,866</span> as of September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the quarter ended September 30, 2022, the Company recorded a
net deficit of $<span id="xdx_90C_ecustom--ResearchAndDevelopmentDeficitNet_c20220101__20220930_zoT3CbZyLPwk" title="Net deficit on research and development">83,868</span> with the Company funding the NIH no-cost extension along with other R&amp;D activities. The NIH made the final
payment of $<span id="xdx_90F_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zor9EaiE5Fu5" title="Payments to invoices in research and development">211,455</span> in April 2022 for Topic 345.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September of 2022, TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;) was contracted for process research, development and cGMP compliant
manufacture of IPdR. The total project cost is $<span id="xdx_90C_eus-gaap--CapitalizedContractCostNet_iI_c20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_z0ryukO7eiIc" title="Project cost">1,500,000</span> based on four milestone payments, the first payment of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zYKX6wr2MDMh" title="Payments to invoices in research and development">450,000</span> was paid during
the quarter ended September 30, 2022, pursuant to which TCG GreenChem commenced work on the project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue or other income. Due to the terms of the contracts we have entered into, the Company concluded that the
reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zPlBfuV8LKl9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_za7MJc2KLRf">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of September 30, 2022, the Company had no derivative instruments. As of December 31, 2021
the Company&#8217;s only derivative financial instrument was an embedded warrant feature associated with its Series A Convertible Preferred
Stock due to certain provisions that allow for a change in the warrant value based on fluctuations of the Company&#8217;s fair value
of common stock at the date of issuance of the warrant based on certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVgFsM34CXt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zOeVLCJpuOoc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GTWgulRiA7" title="Share price">25.22 </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FYyHnhqDba" title="Share price">5.00</span> in 2021, $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLPlikArwB8" title="Share price">4.00</span> through March 31, 2022 and $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUXJKtHAQEP7" title="Share price">6.00 </span>through June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2022, the Company identified <span id="xdx_904_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_do_c20220930_zygmAQg0VFEb" title="Financial liabilities fair value">no</span> liabilities required to be presented on the balance sheet at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGngUoQuWHod" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Warrant Liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zsd9NRdAjIL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSMPJgjkKtRe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zGDBm12N3Bgh">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed
    contracts with the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of performance obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of the transaction price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation
    the transaction price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
    of revenue only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from NIH contracts is received in accordance with Federal grants and contracts policies. Research and development expenses
are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zcExFdFHdFK3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z6PnT83yyhM">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
shares of common stock outstanding during the period using the treasury stock method and as if converted method. Dilutive potential shares
of common stock include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu2C2gyHdXxj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti dilutive securities excluded from
    computation of earnings per share</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zXv2XedQLmv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9PcSCc4vTKf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z0Lznkh5Cw24">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

<p id="xdx_855_zOFftms3vb0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zaCWCeJJoHH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_829_zDwoeqdcnG92">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzSeCibrySFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zHFk2Mm9gwU8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ConsolidationPolicyTextBlock_zpCW6ei1Xrg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z9MlYvZzbJ37">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zeUqtynLxD3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zHxcJoKlrWk3">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_z1VY8Pmu6GNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUGWDSisXQa6">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounts receivable consists of amounts due from the National Institutes of Health (&#8220;NIH&#8221;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on research
and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and payments
from the contracts are generally collected within 30 days of the Company&#8217;s submission for reimbursement. The Company currently
does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection
information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance of the invoice and typically
would be considered past due when the term expires. The Company&#8217;s allowance for doubtful accounts was $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zkVwpc8cgnp9" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zBypMpqdf6y2" title="Allowance for doubtful accounts">0</span></span> at December 31, 2020 and
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeRTsuUFY894" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zy1ME33lauv2">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvG7r2Lue0g" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life">10</span> years</span></td>
    </tr>
  </table>
<p id="xdx_8AF_zoq40ARkvugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGp2dE9hhrRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zgQsodqcjYxk">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zaeusPjbqBc2" title="Proceeds for research and development from collaborators">299,502</span> Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZxtPV2c0e48" title="Proceeds for research and development from collaborators">1,903,095</span> with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zUPYw14OkS5l" title="Proceeds from contract awards for research and development">211,455</span>
for a total of $<span id="xdx_90D_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zRHHZEcba5ki" title="Proceeds from contract awards for research and development">845,820</span> in 2020; and 2 quarterly payments related to Topic 345 for a total of $<span id="xdx_909_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_zP3SGc96Lxwi" title="Proceeds from contract awards for research and development">422,910</span> in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown University to perform the $<span id="xdx_903_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zM0qWX69QD7a" title="Proceeds for research and development from collaborators">795,248</span> subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z3cnkMBBBhNf" title="Proceeds for research and development from collaborators">795,248</span>. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211201__20211231_zDFLz35b8ZD" title="Payments to invoices in research and development">354,829</span> were made to Georgetown,
and additional invoices for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231_zdbj5Zip7kb" title="Payments to invoices in research and development">436,188</span> were received but not yet paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_z3qXOJD0BmS" title="Proceeds from contract awards for research and development">1,484,350</span> to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zajbxohgsNr4" title="Payments to invoices in research and development">412,321</span> and $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0Q4mmcdceZb" title="Payments to invoices in research and development">82,467</span> in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $<span id="xdx_90C_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zjZOQRhRSoT5" title="Business development new establishment">742,002</span> to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z9lcD8RCIC0j" title="Proceeds for research and development from collaborators">742,002</span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_903_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zG9gSpfZ7Rp8" title="Payments to invoices in research and development">292,252</span> as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $<span id="xdx_908_ecustom--ResearchAndDevelopmentDeficitNet_c20210101__20211231_z4cRZ85dT5Ai" title="Net deficit on research and development">1,021,808</span> from these two SBIR contracts which is the result of recording $<span id="xdx_909_eus-gaap--CapitalizedContractCostNet_iI_c20211231__dei--LegalEntityAxis__custom--SBIRMember_zgGdHtrh81Xk" title="Project cost">1,527,185</span> in SBIR contract related expenses
on revenues of $<span id="xdx_908_eus-gaap--CapitalizedContractCostNet_iI_c20201231__dei--LegalEntityAxis__custom--SBIRMember_zoZGhm200M6h" title="Project cost">505,377</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--DerivativesPolicyTextBlock_zDJe5Tlsf9bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zCUUvceE5Y19">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&#8217;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&#8217;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKwi81zQZRlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zKgD4N7HXxc5">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation
    methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets
    in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially
    the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation
    methodology us one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8I5At1BUld" title="Share price">25.22 </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY7PlvqW9iE8" title="Share price">5.00</span> in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z5wlC8g4VNF4" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">673,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zMFIwN4l8G2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zF0u8ua9DnYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z4tzmmsrb0zi">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed contracts with
    the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification of performance
    obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of the transaction
    price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation the transaction
    price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition of revenue
    only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net
of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zPau7tRPvDne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z6G31CPqBJC7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9PNW0W5dLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zjn1rBexH1P3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMMOgYBJyl01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zbbuukvDA6n5">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zLrPHxK3r8ik" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zmayAC6bl05j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3igIdv3U6A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z20jsWIwjfHk">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

<p id="xdx_85E_z3agHB8KBysk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904856288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxAmmBNyUPr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_820_zzo393qkBFad">Property and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHw4g6hhBnUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zgIcSqP1GQel" style="display: none">Schedule
of Property and Equipment Net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20220930_zIuASPNq3qll" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zr4QYBfzAWEd" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zU5MxQUAw8E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zwWSOCdm4pAl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzwPA_zbpLEntztHr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzwPA_zk6WVvG8Nbf5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzwPA_zAsg6aOTm5zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,080</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zPydfRBEeKO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the nine months ended September 30, 2022 and 2021, were $<span id="xdx_908_eus-gaap--Depreciation_c20220101__20220930_pp0p0" title="Depreciation expense">4,484</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20210101__20210930_pp0p0" title="Depreciation expense">4,050</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z7xeq4BqZwSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_828_zPZ4ViShhbq5">Property and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z293shVBnX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following as of December 31, 2021, and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zUr4lrOJYvF3" style="display: none">Schedule
of Property and Equipment Net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zSEQkOppiO5i" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zkJJtHp8oFWl" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOKWx4HrW392" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zLyb9JAYDobb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_zMWGxtXnHRM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zwkuXQRcad9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(102,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zc6buQvCEHzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zoUlaKjS5kU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the twelve months ended December 31, 2021, and 2020 were $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zru2PqkqicX1" title="Depreciation expense">6,218</span> and $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zXK7hqXRAlZj" title="Depreciation expense">5,782</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733909039168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Right-of-use Asset and Operating Lease Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Lease Right-of-use Asset and Operating Lease Liability</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zuv0V6rq4jj3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zMjBSD57lQej">Operating Lease Right-of-use Asset and Operating Lease Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20220101__20220930_zIbc0fPlyQ28" title="Interest rate used to lease, description">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</span> Operating lease expense is recognized on a straight-line basis over the lease
term. During the nine months ended September 30 2022, and 2021, the Company recorded $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20220101__20220930_zPsAhOsQYJ41" title="Operating lease expense">52,631 </span>and $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20210101__20210930_zEQJOlnYwN2" title="Operating lease expense">52,445</span>, respectively, as operating
lease expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $<span id="xdx_90F_ecustom--OperatingLeasePayment_c20180929__20181001_zHIwK06J5LAa" title="Lease payment">6,291</span>, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on <span id="xdx_906_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zGzBQnCk7Hd9" title="Operating lease expiration date">October 31, 2023</span>. A security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zSUIHXH46n4h" title="Security deposit">6,480</span> is being held for the duration of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#8216;package of practical expedients,&#8217; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of <span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20220930_zyxAeXkmYHJl" title="Lease term">12</span>
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zWm8Fs7Ed7R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zAImY9PDHMUg" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20220930_z1midZtHPzW3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zAPSmuBNbsTj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zj9387NWMqbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_ztbnQ85VGf8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(193,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zYVRdiQfZ24a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zyzsMs5EExFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of-use asset is included in rent expense on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zxqoKB1Dwu8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zH01tCtnTGW9" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20220930_zOkTDA3D9pE3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zf8g6zEjZ5V8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zPgpaBsyNEYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">80,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zuhPVK1tOQza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,707</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF267iEwqDW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zgOSKTLN20g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI3LHmxEst4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zeTus9Yk7gqg" style="display: none">Schedule Of Operating Lease Maturity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220930_zdlre74HLWW3" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz4Xq_zApK0lBgQLz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 75%; text-align: left">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">19,440</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz4Xq_ztBHxWzLa5Da" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz4Xq_zmHWBOXUo113" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Total future minimum lease payments</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNs3XD3FUEd1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zCqRaCFYxwo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">PV of Payments</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80,378</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z8DNgHe4XlDi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zyBTUAHGSRD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_829_zco7edg7vAk7">Operating Lease Right-of-use Asset and Operating Lease Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. <span id="xdx_907_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20210101__20211231_zP1K07qIF6Q8" title="Interest rate used to lease, description">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</span> Operating lease expense is recognized on a straight-line basis over the lease
term. During the twelve months ended December 31, 2021, and the year ended December 31, 2020, the Company recorded $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zyxBDvt1RKC" title="Operating lease expense">74,028</span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20200101__20201231_zTvLFQFhMsn" title="Operating lease expense">71,872</span>,
respectively, as operating lease expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $<span id="xdx_902_eus-gaap--OperatingLeasePayments_c20180929__20181001_zBlZi2wzv0B8" title="Lease payment">6,107</span>, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on <span id="xdx_90F_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zsuGo17UZjf" title="Operating lease expiration date">October 31, 2023</span>. A security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zwDFKEoT6KKi" title="Security deposit">6,480</span> is being held for the duration of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#8216;package of practical expedients,&#8217; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of <span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20211231_z8MnUaYYMk5c" title="Lease term">12</span>
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p id="xdx_890_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zGNZoOUwWE2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1CVxMNAGGw7" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zIPeQCOX6197" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zGRdq5m7ruo" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zByLv4uguS7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_za6ldmTid0xk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,609</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zQxRuTcj6KK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">171,598</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_z42s2REETpNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of -use asset is included in rent expense on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRhltcKRLqyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zZms85qMdgaf" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zdZcv5DI5bpg" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zSX1D7qU6WY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">129,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zeMS8XHFzwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_znebceF7M491" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zZTR5TCyHSN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z98Fy6YXydx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zMMRA9wuYNOj" style="display: none">Schedule Of Operating Lease Maturity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20211231_ztevs8lGFSs" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zHj2r2sgCHW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,248</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zMl8VEXKF1s5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zzzVCxMlgfGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,048</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQoP45FoKrEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zuRGKEbQQBi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">PV of Payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,376</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z7JAV7O5pPTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906774688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Notes Payable-Related Party</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaMZoFHT4i5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zfGWuPdewMyh">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_90C_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZOFY1AwSQg1" title="Notes payable related party debt principal balance">426,243</span>, bearing interest at the rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCy9ehTHkvwa" title="Notes payable related party transaction rate">7.5</span>% per annum, with a maturity date of <span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zRLDPj45LaN3" title="Notes payable related party maturity date">December 31, 2021</span>; and (ii) a single loan
owed to an officer of the company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zzor0xXKoNrk" title="Notes payable related party debt principal balance">139,229</span>, bearing interest at the rate of <span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z486baGpwzp3" title="Notes payable related party transaction rate">7.5</span>% per annum, with a maturity
date of <span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zYNOE6FGcfVe" title="Notes payable related party maturity date">December 31, 2021</span>. <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211230_z0tSNlGSIn2d" title="Debt maturity, description">In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the
notes were extended to June 30, 2023</span> (Note 8). As of September 30, 2022, the accrued interest was $<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zmlntEGsiPUd">55,592</span> and $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zlw8S2lqMxM9">18,150</span>, respectively,
and the total balances with accrued interest of $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwYaXOagoI5" title="Notes payable related party debt plus accrued interest">481,835</span> and $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zsYOz269cZih" title="Notes payable related party debt plus accrued interest">157,379</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zN6ODjJNjKrh" title="Notes payable related party debt principal balance">120,000</span> (principal) with
an interest rate of <span id="xdx_903_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWb90yOLkMD7" title="Notes payable related party transaction rate">7.5</span>% per annum due <span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZ5YMQoAWv1e" title="Notes payable related party maturity date">June 21, 2022</span>, due at maturity. <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20210621__20210621_ziq4T2WoR643" title="Debt maturity, description">In July of 2022 the notes were extended to June 30, 2023</span> (Note
8). As of September 30, 2022, the accrued interest was $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ze5eZcGl12lb" title="Accrued interest">11,491</span> and the total balance with accrued interest was $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zc88cZ7OnoLl" title="Notes payable related party debt plus accrued interest">131,491</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with a private placement of 10% notes and warrants (as detailed in Note 6 below), in exchange for a $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zBRBBQsMjfI5" title="Notes payable related party debt principal balance">50,000</span>
payment upon subscription, the Company issued a note to the spouse of an officer of the Company in the amount of $<span id="xdx_90B_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zEG3d94KjpQc" title="Notes issued">50,000</span> (principal)
with an interest rate of <span id="xdx_90E_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zQQSHlaQcnn4" title="Notes payable related party transaction rate">10</span>% per annum due <span id="xdx_90F_eus-gaap--RelatedPartyTransactionDate_dd_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zag9YEyK59ji" title="Notes payable related party maturity date">August 31, 2022</span>, with interest due at maturity, and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zzynqJftCic3" title="Warrants to purchase of common stock">20,000</span> shares of
common stock, at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_ziRlJzGF9Ht7" title="Exercise price of warrants">2.50</span> per share. The value of the warrants was determined using a computed volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zuCupUQpvt75" title="Volatility rate">101</span>%,
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zsOSczY4n4h9" title="Dividend rate">0</span>% dividend rate, and a risk free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zdp2m5tb6USa" title="Risk free interest rate">4.25</span>%, and was applied as a discount on the notes payable. The loan was fully repaid
including $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zLnGUxarbx43" title="Repayments of accrued interest">822</span> of accrued interest in September of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgV7cbTOJVHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82B_zue1ELM5AIeb">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_ziaj3PvHRAmb" title="Notes payable related party debt principal balance">300,000</span>. The loan bears
interest at the rate of <span id="xdx_90F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zxv3KbgJXN33" title="Notes payable related party transaction rate">7.5</span>% per annum. The loan plus accrued interest was payable in full on January 25, 2019. On January 25, 2019,
the Company amended the loan for purposes of extending the maturity date from <span id="xdx_905_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zc013yLOUBOe" title="Notes payable related party maturity date">January 25, 2019</span>, to <span id="xdx_906_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_z9D8xe0Q60Rh" title="Notes payable related party maturity date">October 25, 2020</span>. On <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20180124__20180125_zkIxMRnmJS55" title="Debt maturity, description">December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021</span>, bringing the total amount owed under the loan,
together with accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zD63Fsdxwbsi" title="Accrued interest">64,084</span>, to a total of $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zcNp4SbZ0cH2" title="Notes payable related party debt plus accrued interest">364,084</span>. This note was rolled into the note referenced below with a principal
amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zH39XI1L8eIl" title="Principal amount">424,056</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zTiCpL3U3hlb" title="Notes payable related party debt principal balance">50,000</span>. The loan bears
an interest rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z69480AXTxgf" title="Notes payable related party transaction rate">7.5</span>% per annum. The loan plus accrued interest was payable in full on September 4, 2018. On October 31, 2018, the
Company amended the terms to extend the maturity date from <span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z6RsAiK6BqMh" title="Notes payable related party maturity date">September 4, 2018</span>, to <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zqvxRWSCRsff" title="Notes payable related party maturity date">April 4, 2019</span>. On April 4, 2019, the Company amended
the terms to extend the maturity date from April 4, 2019, to October 25, 2020. On <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20180403__20180404_zZXawIIW4KW4" title="Debt maturity, description">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</span>, bringing the total amount owed under the loan, together with accrued interest of
$<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zf0XvZ6quGL5" title="Accrued interest">9,972</span>, to a total of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zpArJH6UU8fi" title="Notes payable related party debt plus accrued interest">59,972</span>. This note was rolled into the note referenced below with a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z3dN2qTgVwl9" title="Principal amount">424,056</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2018, the Company entered into a loan with an officer of the Company in the amount of $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zCAgiurrO8rc" title="Notes payable related party debt principal balance">25,000</span>. The loan bears an interest rate
of <span id="xdx_908_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zHMFD4PKABwd" title="Notes payable related party transaction rate">7.5</span>% per annum. The loan plus accrued interest was payable in full on July 15, 2018. On October 31, 2018, the Company amended the
terms to extend the maturity date from <span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zllr31sa1F9" title="Notes payable related party maturity date">July 15, 2018</span>, to <span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zzX8SlZEoREc" title="Notes payable related party maturity date">November 30, 2020</span>. On <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20180529__20180530_z5uXZGEZvGFc" title="Debt maturity, description">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</span>, bringing the total amount owed under the loan, together with accrued interest of
$<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zuJ3zeqqiY8g" title="Accrued interest">4,698</span>, to a total of $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_z4R4JbzIWDz" title="Notes payable related party debt plus accrued interest">29,698</span>. This note was rolled into the note reference below with a principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zXw7NUwGwtDf" title="Principal amount">138,448</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zAtaw5etE5sd" title="Notes payable related party debt principal balance">70,000</span>. The loan bore interest
rate of <span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zdzVaV8LZCL1" title="Notes payable related party transaction rate">7.5</span>% per annum and required monthly payments of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zuYg1aef7bH4" title="Monthly payment">6,073</span>. The loan plus accrued interest was paid in full on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_z5PhWEq2L4rl" title="Debt instrument, maturity date">June 30, 2020</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zhB7TV86pA67" title="Notes payable related party debt principal balance">70,000</span>. The loan bore
an interest rate of <span id="xdx_909_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zGlhPkLe7MD2" title="Notes payable related party transaction rate">7.5</span>% per annum and required monthly payments of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_z1jrzoeS9Yh5" title="Monthly payment">6,073</span>. The loan plus accrued interest was paid in full on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zrYsvyir1byk" title="Debt instrument, maturity date">August
23, 2020</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zde2Jp2Lp7e9" title="Notes payable related party debt principal balance">100,000</span>. The loan
bore an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_z5zZGaYsHaw1" title="Notes payable related party transaction rate">7.5</span>% per annum and became payable in full on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zQF7WgHVecC" title="Debt instrument, maturity date">September 22, 2020</span>. This note was rolled into the note reference
below with a principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zi6mQafHA2Jj" title="Principal amount">138,448</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zvSTsmjveRp2" title="Notes payable related party debt principal balance">424,056</span>, bearing interest at the rate of <span id="xdx_902_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z1qcw8IFirVd" title="Notes payable related party transaction rate">7.5</span>% per annum, with a maturity date of <span id="xdx_901_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCKaR0uOZh5b" title="Notes payable related party maturity date">December 31, 2021</span>; and (ii) a single loan
owed to an officer of the company in the principal amount of $<span id="xdx_908_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zLUZIfTwEEck" title="Notes payable related party debt principal balance">138,449</span>, bearing interest at the rate of <span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zvBk6xrXF8gc" title="Notes payable related party transaction rate">7.5</span>% per annum, with a maturity
date of <span id="xdx_90D_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zviIvjcujOa1" title="Notes payable related party maturity date">December 31, 2021</span>. In December of 2021 the maturity dates of these loans were extended to June 30, 2022. As of December 31, 2021,
the accrued interest was $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zjRZs7A3t3j" title="Interest payable current">31,804</span> and $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zbWGQaY9snX6" title="Interest payable current">10,384</span>, and the total balances with accrued interest of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zIP9oj6WWQvj" title="Notes payable related party debt plus accrued interest">458,047</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z5po8X8hcDjj" title="Notes payable related party debt plus accrued interest">149,613</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zDHoYtcfSsrb" title="Notes payable related party debt principal balance">120,000</span> (principal) with
an interest rate of <span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zOUt5WlmIToe" title="Notes payable related party transaction rate">7.5</span>% per annum due June 21, 2022, due at maturity. As of December 31, 2021, the accrued interest was $<span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zZTGcwZ2cfg" title="Accrued interest">4,759</span> and the
total balances with accrued interest of $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zoPLNMS0oK63" title="Notes payable related party debt plus accrued interest">124,759</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908112944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_ztol0MmZp7kf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - <span id="xdx_826_zd1TOgmUHXV6">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_908_eus-gaap--MediumTermNotes_iI_c20210309_zNsNktLppFdg" title="Term notes issued">73,007</span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zlZhTSb6ols2" title="Interest rate">1</span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. <span id="xdx_901_eus-gaap--ShortTermDebtDescription_c20210309__20210309_z3rNThwCFcHg" title="Term note description">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</span> As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the
requested documentation and during the quarter ended March 31, 2022 the note liability was reduced in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $<span id="xdx_90C_eus-gaap--MediumTermNotes_iI_c20200515_zI4nrf1tdYpk" title="Term notes issued">62,500</span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_z3dN2O76sNLk" title="Interest rate">1</span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. <span id="xdx_903_eus-gaap--ShortTermDebtDescription_c20200515__20200515_zF98mIUB8pni" title="Term note description">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</span> A &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zBuehpHgeOmh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8B7_zh3WL2OqTeea" style="display: none">Schedule
of Notes Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220930_zCOLUnMIYUub" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zhTWY6hOtPcj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PPP Note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zV3AXygSN6yh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zLqQeYshslhh" title="Debt maturity date">May 15, 2020</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zgEHevVdpow9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zyRSdphG0GA7" title="Debt maturity date">March 9, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zyqQSYNNAWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_zSmWxVZcgvbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zv7ZlW0MOIk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20211228_znE5S8lRaJTi" title="Notes payable">500,000</span> note units, consisting of two $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zbghPOeTdQW7" title="Notes payable">250,000</span> notes, for a total of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zmc9hJwVpeKb" title="Notes payable">500,000</span> <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_z1pVK4Psebo9" title="Interest rate">10</span>% unsecured promissory
notes with a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_zCZuBWQ4Wiuh" title="Debt maturity date">December 28, 2022</span>, and warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zlUonDf1vJfd" title="Warrants to purchase of common stock">500,000</span> shares of common stock exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zaxpfbxbx4D8" title="Exercise price of warrants">1.00</span> per share
with an expiry date of December 28, 2026, and fees of $<span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zi4Ukw48HLJ2" title="Debt fee amount">5,075</span>. The value of the warrants was determined using a computed volatility of
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxiYBqqVCKba" title="Volatility rate">85.5</span>%, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IYQPeqxcAa" title="Dividend rate">0</span>% dividend rate, and a risk free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqPoFqdf29rk" title="Risk free interest rate">1.27</span>% and was applied as a discount on the notes payable. In September 2022,
the warrants were exercised fully reducing the principal and the Company paid $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20211228__20211228_zP4GuXcpTjIj" title="Warrants exercised to payment of debt">16,667</span> of interest in cash. As of September 30, 2022,
$<span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--NoteTwoMember_zhv9jfCzr4ue" title="Accrued interest payable">18,904</span> of accrued interest is payable on the second note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, the Company sold $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220208_zaZ8Z5J146o" title="Convertible notes payable">365,000</span> and $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220311_z1bi1WgRaY9k" title="Convertible notes payable">224,985</span>, respectively, in <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208_zOOSldRDENG8" title="Interest rate">6</span>% convertible notes (the &#8220;Notes&#8221;),
which notes bore <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311_zlGt98vomy9c" title="Interest rate">6</span>% interest, were repayable three years from the date of issuance, and, upon completion of the Company&#8217;s initial
public offering, converted automatically into units, with each unit consisting of one share of common stock and a warrant to purchase
one share of commons stock (the &#8220;Conversion Units&#8221;) at a conversion price equal to <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208_zEMYxukktWoh" title="Debt instrument conversion rate"><span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311_z0awGhG58UX8" title="Debt instrument conversion rate">50</span></span>% of the per unit offering price upon
closing of our initial public offering. Boustead Securities LLC acted as placement agent for the convertible note offering and received
compensation of $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20220208__20220208_zoUoxSp0kmO6" title="Proceeds from convertible notes payable">36,500</span> and $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220311__20220311_zliJ0BM2kW3f" title="Proceeds from convertible notes payable">22,250</span>, respectively, and warrants to purchase shares of common stock equal to 10% of the Conversion Units,
exercisable at the conversion price of the Convertible Notes. The value of the warrants was determined using computed volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0ifbTPrWJ64" title="Volatility rate">83.4</span>%,
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY9QrLuU5egl" title="Dividend rate">0</span>% dividend rate, and a risk free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdYbIRrp4jI9" title="Risk free interest rate">1.27</span>%, and computed volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze5AjFzg6tU4" title="Volatility rate">85.5</span>% %, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGEOPUhsgM2f" title="Dividend rate">0</span>% dividend rate, and a risk free interest
rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEW2I5goaJ04" title="Risk free interest rate">1.96</span>%, and was applied as a discount on the notes payable. In September 2022, the notes were fully converted,  relieving the
Company of $<span id="xdx_906_eus-gaap--DebtSecuritiesGainLoss_iN_di_c20220101__20220930_zftj2yXZnIh6" title="Gain on interest relief on conversion of notes payable">12,625</span> of accrued interest recorded as a gain on settlement of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, the Company issued $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20220801_zB7CTt40IFq1" title="Convertible notes payable">125,000</span>
in <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801_zzvCTmDcnWj3" title="Interest rate">10</span>%
convertible notes payable and warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zNOFTL3lMIHi" title="Warrants to purchase of common stock">50,000</span>
shares of common stock to three accredited investors (which amount includes the $<span id="xdx_90A_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zCc08vTUCt65" title="Notes issued">50,000</span>
note and warrant purchased by a related party as detailed in Note 5 above). The warrants issued in this transaction were exercisable
at price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zEWdjNy4L0df" title="Exercise price">2.50</span> per share. The value of the warrants was
determined using a computed volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbl3f0ru4UCh" title="Volatility rate">101</span>%, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zZzDMYWjaf9i" title="Dividend rate">0</span>%
dividend rate, and a risk free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbdAG69gbbfd" title="Risk free interest rate">4.25</span>%
and was applied as a discount on the notes payable. In September 2022, <span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220901__20220930_zakHV9tn7kV2" title="Warrants exercised to payment of debt">30,000</span>
warrants were exercised in exchange for cancellation of $<span id="xdx_906_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7HMePc1r7oh" title="Debt forgiveness">75,000</span> in notes, thus reducing $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_znfSheCRRF33" title="Repayments of notes payable">75,000</span>
of the principal. The remaining $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zv2sMilMt14a" title="Debt remaining amount">50,000</span>
note owed to the related party was then paid off in full.</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYzIEK2eVmQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zwWGyadF88hh" style="display: none">Schedule
of Promissory Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z8sz6rbUuhP7" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zGN2XUdpFHY8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z8rCGaaJjyP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zw3T5TSJyY52" title="Debt maturity date">December 28, 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zVhNOEpSV6nf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zrdUXY9T00Y3" title="Debt maturity date">February 8, 2022</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zw5zFEWoegz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zvymj71KTPZa" title="Debt maturity date">March 11, 2022</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zcRQi5sCgQ57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zXkxFE5K93x1" title="Debt maturity date">August 1, 2022</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzxfV_zaBoiXSvwhI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zxwXaJH3mH72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(408,979</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zHKNNzyBPYGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,021</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zkicrC7Cmmv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ending September 30, 2022, the Company fully amortized the debt discount and included $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220930_z0kIM3m07Bf" title="Amortized debt discount">408,979</span> in interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zeswcbZw9T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - <span id="xdx_828_zF9fjtDCFVra">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_90D_eus-gaap--MediumTermNotes_iI_c20210309_z1t8aWehYrWh" title="Term notes issued">73,007</span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zBkMzrjwAEE1" title="Interest rate">1</span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the
requested documentation and subsequent to the close of the December 31, 2021, reporting period the note liability was reduced in its
entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $<span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20200515_zWqO2LbvoP6a" title="Term notes issued">62,500</span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bears an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_zQqWltLwz2Ic" title="Interest rate">1</span>% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#8217;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. A &#8220;Loan Forgiveness Application&#8221; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zEJQH7FsQBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z7x0Bf5QV6J7" style="display: none">Schedule
of Notes Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zs8ZjEzR5as6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20201231_z5ddmsxg9gG3" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zlKWCVwANhc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zAwg53kad8Uj" title="Debt maturity date">May 15, 2020</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zKIGQqEGOeIc" style="vertical-align: bottom; background-color: White">
    <td>PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_ztFm5G3svYx7" title="Debt maturity date">March 9, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zed16WxGRXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayable_iI_zCp6BUuAMjk8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z3EMa0tpeiZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20211228_zcmhoubBafya" title="Notes payable">500,000</span> note units, consisting of two $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zUFrLFDAvifi" title="Notes payable">250,000</span> notes, for a total of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zZlcggDXmFga" title="Notes payable">500,000</span> <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zrCIkl2P8ikd" title="Interest rate">10</span>% unsecured promissory
notes with a maturity date of <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z4Dxj02eBRtc" title="Debt maturity date">December 28, 2022</span>, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zXo1AtI4bHj4" title="Warrants to purchase of common stock">500,000</span> warrants exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zXs4eR6Ol0ta" title="Exercise price of warrants">1.00</span> per share with an expiry date of December
28, 2026, and fees of $<span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zcE58aOZgKAf" title="Debt fee amount">5,075</span>. The value of the warrants was determined using a computed volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSx2U7ZLDDt5" title="Volatility rate">85.5</span>%, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF8MylifPkUj" title="Dividend rate">0</span>% dividend rate, and a
risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMlII9Z5iwQg" title="Risk free interest rate">1.27</span>% and was applied as a discount on the notes payable as follows:</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4nwu7JkSlxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zF9q91NBsww7" style="display: none">Schedule
of Promissory Notes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zScL1QxrrD58" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z7eF9AhBvJH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Promissory notes issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zEYM2T1Dfl7c" title="Debt maturity date">December 28, 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zwVIHIq0ckw6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized discount on notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(408,979</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zRjlbHqT2Zb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,021</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zAIXs23KZWDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906985712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxRJE3vYPZJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_821_zhYyZ2od3pAb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s amended and restated articles of incorporation, the Company is authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zD7b65CwANT9" title="Common Stock, shares authorized">100,000,000</span> shares of common
stock, with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zwHgHRxOgj99" title="Common stock, par value (in dollars per share)">0.00001</span> per share, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_zpdqMosGBgg9" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, with a par value of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zjBTp9hZfGX3" title="Preferred stock par value">0.00001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#8217;s common stock on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2022, the Company converted <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zysPduE62CKh" title="Converted shares issued">1,213
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Preferred Stock into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGqislf6LlI7" title="Converted shares issued">336,810
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase
<span id="xdx_905_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMvG6hvR7ng" title="Purchase up warrants shares">336,810
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, which conversion shares
and warrants were calculated using a conversion price of <span id="xdx_909_ecustom--DebtInstrumentConvertibleConversionPricePercentage_iI_pid_dp_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFqdTaco7AF8" title="Conversion price percentage">90</span>% of the IPO price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYZ0SOMJSdT5" title="Conversion price">4.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in a discounted conversion
price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930_z8Z9SpoKwDYb" title="Conversion price">3.60</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The warrants issued to the Series A Preferred Stockholders are exercisable at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930_zpUsyRLcr86l" title="Exercisable">4.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dt_c20220101__20220930_zcseRHSywJsi" title="Remaining contractual term">three years</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, the Company accrued $<span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztK97ATl9iCl" title="Dividends on preferred stock">71,009</span> for the <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoOPrvkdYbN1" title="Preferred stock dividend rate">8.5</span>% cumulative dividends on the Series A Preferred stock
and $<span id="xdx_900_eus-gaap--DividendsPreferredStockCash_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWqcisRwodE6" title="Dividends on preferred stock">103,062</span> for the year ended December 31, 2021, for a total of $<span id="xdx_90F_eus-gaap--DividendsShareBasedCompensation_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1YIxjGJzwg" title="Dividends total">402,068</span> and $<span id="xdx_909_eus-gaap--DividendsShareBasedCompensation_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHpH2VNhCRA9" title="Dividends total">331,059</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2022, the Company paid the dividend payable balance of $<span id="xdx_90F_eus-gaap--DividendsCommonStock_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLxXy8ZdoY7j" title="Commons stock dividend">402,068</span>
to the Series A Stockholders through the issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlRcBiJtDOLg" title="Common stock issued for cash, shares">100,517</span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znMFb6GdN5q" title="Preferred Stock, shares outstanding">no</span> shares of Series A Preferred Stock outstanding, and <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRzGJoa4QEp2" title="Preferred Stock, shares outstanding">1,213</span> shares as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022 and December 31, 2021, the Company had <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20220930_zyK4ucXu9E02" title="Common Stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20220930_zAVlHx39w4v8" title="Common Stock, shares outstanding">13,586,393</span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20211231_zWDNxwbzx2Vd" title="Common Stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zSlmTeZoglFe" title="Common Stock, shares outstanding">9,312,152</span></span> shares of common stock issued and outstanding,
respectively. The balance includes <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOoy8zoPAyhd" title="Common stock issued for restricted stock units, shares">20,626</span> and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5jxBFcjiqj" title="Common stock issued for restricted stock units, shares">21,530</span> shares of restricted stock issued in 2021 and 2020 respectively and <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNPfk1gGbaD2" title="Sale of stock number of shares issued in transaction">839</span> shares of
common stock issued to settle shares of common stock owed to Shuttle&#8217;s original membership holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_zoIvY7momya6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B2_zlcBSojejxUa" style="display: none">Schedule of
Sale of Equity or Issued</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issuance</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value $</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><span id="xdx_F4C_zVQnroxtrN48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zGz90CtsNEja" style="width: 12%; text-align: right" title="Stock issued during period, shares">1,409,771</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zVMczMb85TE9" style="width: 12%; text-align: right" title="Stock issued during period, Value">10,031,415</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zI1ZZDkuYRll" style="text-align: right" title="Stock issued during period, shares">147,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zfUkLCAktb1c" style="text-align: right" title="Stock issued during period, shares">588,524</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F49_z4m8t1dYYtpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant exercises<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_zOLfHvinhUdc" style="text-align: right" title="Stock issued during period, shares">2,267,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_ziQh59zpa9Pc" style="text-align: right" title="Stock issued during period, shares">590,574</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_zh3yWT2pEEAl" style="text-align: right" title="Stock issued during period, shares">839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_z0haD5Kr4GCl" style="text-align: right" title="Stock issued during period, value">16,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F42_z27rO27rUT38" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Share and Dividends Payable<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_z5rP5B6sdQr1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, shares">437,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_zudb7kxpNvP4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, Value">402,068</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_zpaba9E4mGZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zVTbfqbW6iba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value
                                            is net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees">1,407,262</span> of fees associated with the issuances.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zlejtRyQe31c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zoZjkIOtyHI6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share">197,273</span> broker warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share">180,280 </span>shares of common stock
                                            and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise">1,409,771 </span>shares of common stock exercised as part of the Company&#8217;s
                                            initial public offering.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_z24ejyBVEFq1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zkLhD1kqAUba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock">336,810</span> shares of common stock issued upon conversion of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding">1,213</span> Preferred Shares and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock">100,517</span>
                                            common shares to settle dividends payable balance.</span></td></tr></table>

<p id="xdx_8A1_zjCfC19j6Sl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock to be Issued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $<span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zwHhIwAEzAuf" title="Convertible notes">120,250</span> outstanding convertible notes were converted to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_ztKaKDNIn7Y8" title="Debt converted into common stock">6,182</span> shares of common stock of the Company at a price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z6asrYHk8upb" title="Conversion price">19.44</span>
per share. The Company recorded $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zdsTjGnoIQKj" title="Debt converted into common stock, value">16,340</span> of common stock to be issued for the accrued interest. As of September 30, 2022, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_z2ZquAj5Eolg" title="Stock issued during period, shares">839</span> shares of
common stock were issued to settle the $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_zSRH7R6eSTxd" title="Stock issued during period, Value">16,340</span> of common stock to be issued to Shuttle&#8217;s original membership interest holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the Company&#8217;s 2018 and 2019 private placement offerings included warrants to be issued upon the
earlier of a closing of the sale of shares of common stock to the public at a prices per share of at least $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20220930_z1tTtPcgJDxd" title="Share price">13.88</span> or in a firm commitment
underwritten public offering pursuant to an effective registration statement resulting in gross proceeds of at least $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB2KU2vdlv3" title="Proceeds from initial public offerings">15,000,000</span>. The
warrants shall be exercisable for a period of three years after the date of issuance. The warrant exercise price is contingent on the
terms of the public offering. If an initial public offering occurs at a price at or above $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRR6lqHIg3yl" title="Share price">13.88</span> per share, then the exercise price shall
be set to the issuance price of the common stock with the number of warrants determined based on a 10% discount to the per share common
stock issuance price. In the scenario where the common stock is listed with the common stock issuance price below $<span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_c20220101__20220930_z5P9n8rrD4Kl" title="Warrant exercise low price">13.88</span>, the exercise
price will be set to $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930_zzdRjpgjWnri" title="Warrant exercise price increase">20.82</span> with the number of warrants based on a fixed conversion price of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20220930_zqFHOFxm4Owd" title="Common stock, Conversion price">12.49</span>, which represents a 10.0% discount
to the $<span id="xdx_90D_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930_zhRwRdpzY0Ve" title="Increase in common stock conversion price">13.88</span> threshold. The warrants also have contingent call features based on the terms of the public offering. If an initial public
offering occurs at a price at or above $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjKtYc3NwVd7" title="Increase in common stock conversion price">13.88</span>, then the warrants are callable if the 20-day VWAP of the common stock in at or above 150%
of the variable exercise price. In the scenario where the common stock is listed with a common stock issuance price below $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbtx0LXUF6T" title="Increase in common stock conversion price">13.88</span>, then
the warrants are callable if the 20-day VWAP of the common stock is at or above the $<span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztYOrsqyePJ4" title="Warrant exercise price increase">20.82</span> exercise price. The detachable warrants contained
terms and features that gave rise to derivative liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 6, 2022, the Company amended its certificate of designation for the Series A Preferred Stock (the &#8220;Amended Series A
Preferred Certificate of Designation&#8221;) in order to modify the conditions pursuant to which the Series A Preferred Stock would
automatically convert. Under the Amended Series A Certificate of Designation, the automatic conversion feature was amended so as to
allow for conversion upon completion of a $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrVPdWFRuO2j" title="Proceeds from initial public offerings">10,000,000</span>
public offering or the listing of the Company&#8217;s common stock on a qualified exchange, in which case the Series A Preferred
Stock would convert at either 90% of the per share IPO price or $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziRG45hYCN92" title="Common stock, conversion price">5.00</span>
per share. As a result, upon completion of our initial public offering, the Series A Preferred Stock was converted and warrants were
issued in relation to the conversion, with each warrant then exercisable at the equivalent of the per share initial public offering
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative warrant liability linked to the Series A Preferred Stock as of September 30, 2022 and December 31, 2021 was $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_dxL_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgFf9ljfN3j8" title="Derivative warrant liabilities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1239">0</span></span> and $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkf9RBW6mOGd" title="Derivative warrant liabilities">94,025</span>,
respectively. For the period ended September 30, 2022 and 2021, the change in fair value of warrant liability was a gain of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTxTNHtR5OCk" title="Fair value of warrants liability">94,025</span> and
a gain of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1DELF0Ddi9l" title="Fair value of warrants liability">30,971</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjFxAl0mLK3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zBaWiW2hUbo9" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zhMcG7Vze4z1" title="Expected volatility">85.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_z7TmHT9meRab" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zj4OzbZ2MUfg" title="Expected life">2.33</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zJiIunAv2NNg" title="Risk-free interest rate">0.73</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AE_zDgPwOwoBaI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zykKzq1xTiEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zAI1VcyQekT9" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlqKbqQNTHXh" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHSY18pcFCve" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc0uoL4xYoje" title="Weighted Average Remaining Life in Years Outstanding">3.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEgcPNiFzEod" style="text-align: right" title="Number of Warrants, Issued"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWGdzP4hgfd5" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDJ8BkLCpngh" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcMdvhnPUqSl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Z2V48oZPpc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXVFuH1uPzt8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z21PCphyMc5g" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze8hCGHfFJ8a" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5ZW4uR86yU8" title="Weighted Average Remaining Life in Years Outstanding">2.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAd8zJkaU7dg" style="text-align: right" title="Number of Warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcgLjEuctt5e" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCfXWpepbsC" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zREYA2RzJlWi" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrJXH3EJHUl4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(48,532</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxVBHHEKMvKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0MKUidIv8Zf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7GPzqiGfWx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the common stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfwUq0E6s3c" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCQq5BYydFa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0KcnPEUWxa" style="width: 12%; text-align: right" title="Number of Warrants, granted">2,304,544</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOnBZehpQzm2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, granted">2.89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxqi6r40Aq1" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOOZUfB75Rua" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup id="xdx_F45_zMhcIcLQEOg3">(1)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zPAiB1fqCrda" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(2,284,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z3Jr1f2NZ178" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">2.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAPnlh9J9We" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DbtcWe9i2d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">2.50</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zPB1oqRtX8Ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zZ50IP42y1W5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants">180,280</span> common stock.</span></td></tr></table>

<p id="xdx_8A9_z4f0j9hJ2Zs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxdfGHb6KhW1" title="Common stock reserved for future issuance">3,000,000</span> shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of September 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzL6U5wIodUi" title="Share granted under equity incentive plan">384,167</span> shares have been granted under the
2018 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement outlining the terms of their service as a director and pursuant to which they would each receive a grant of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCPIhiIAP2p" title="Share granted under equity incentive plan">75,000</span> worth
of Restricted Stock Units (&#8220;RSUs&#8221;) issuable under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;).
The RSUs vested annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z5ooPFBxfCBf" title="Restricted stock value">25,000</span> per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022 and 2021, pursuant to the agreements with directors and officers, compensation expense for the
RSUs of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVM5fAAQtaok" title="Share based compensation">356,733</span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHaDH6jUr0h" title="Share based compensation">367,551</span> was included in compensation, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, there was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VSL6Fw3YDf" title="Unrecognized compensation cost">8,334</span> of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the current year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zQUTKItLSwyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSUs) is set forth as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zEPSKpTDUEX2" style="display: none">Schedule
of Restricted Stock Units (RSUs) </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
RSU</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise <br/>
Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zucGsO7jApGk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">61,884</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh2nhdHl9H4d" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">23.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxjCwRdW8aBh" title="Weighted Average Life (Years)">4.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVwpB3WDjyb" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaC85nk4TjE9" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8IQpkJhHpBk" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAkqKJsJkf35" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNTQQ0pKQNEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoTwwRxCwFd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">59,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqJQarbmomS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">23.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRzMbmLfLjD" title="Weighted Average Life (Years)">3.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0yYtPiigZh7" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwpyGG1LxO97" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLRpATl7oARd" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMSs7ioeWlI4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKNoINGNfkac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZdWes1Tiv1k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjVqgVvh1vkl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance">59,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm4QxHnPnqtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance">23.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk6uMcKKK4p7" title="Weighted Average Life (Years)">2.58</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFSAFrLb73b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable">58,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1SVsH5cj8Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable">23.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs5wrkCUxacl" title="Exercisable Weighted Average Life (Years)">2.58</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zYGyYMXhjXe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJOFMLgMcr2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82F_zYWN4IZTowha">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s amended and restated articles of incorporation, the Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zqmLmrckmf51" title="Common Stock, shares authorized">100,000,000</span> shares of common
stock, with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zmu3E0EDFesh" title="Common stock, par value (in dollars per share)">0.00001</span> per share, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z2Y5sNmXI658" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, with a par value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zdNWjXHIUN8l" title="Preferred stock par value">0.00001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#8217;s common stock on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOTJy3GY9uFa" title="Preferred Stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsjVxLIUMvzd" title="Preferred Stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJgeknCVqbCf" title="Preferred Stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zE0wdkBs3Ue7" title="Preferred Stock, shares issued">1,213</span></span></span></span> shares of Series A Preferred Stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had accrued the <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zj8eEaa8Nol4" title="Preferred stock dividend rate"><span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHD9RT1BBwDe" title="Preferred stock dividend rate">8.5</span></span>% cumulative dividends on the Series A Preferred stock of $<span id="xdx_90D_eus-gaap--PreferredStockValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUPcQNVJm4M3" title="Preferred stock value">331,059</span> and
$<span id="xdx_90F_eus-gaap--PreferredStockValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFisKpopTzcl" title="Preferred stock value">227,997</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20211231_zDdr296UZk3b" title="Common Stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_ztynPIhxgAsf" title="Common Stock, shares outstanding">9,312,152</span></span> and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20201231_z6RWhStahwGh" title="Common Stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zEAN0207Spo2" title="Common Stock, shares outstanding">9,291,526</span></span> shares of common stock issued and outstanding, respectively.
The balance includes <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofyvVudYVxc" title="Common stock issued for restricted stock units, shares">20,626</span> and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoj8d0RhakV5" title="Common stock issued for restricted stock units, shares">21,530</span> shares of restricted stock issued in 2021 and 2020 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock to be Issued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zU2hW2gE3742" title="Convertible notes">120,250</span> outstanding convertible notes were converted to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z3u4hGHNlJD4" title="Debt converted into common stock">6,182</span> shares of common stock of the Company at a price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zJ12HcFHlna4" title="Conversion price">19.44</span>
per share. The Company has recorded $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z5OcV4XFuU01" title="Debt converted into common stock, value">16,340</span> of common stock to be issued for the accrued interest. As of December 31, 2020 and 2021,
the common stock has not been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the private placement offerings, included warrants to be issued upon the earlier of a closing of the
sale of shares of common stock to the public at a prices per share of at least $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20211231_z8xagu8x2f2a" title="Share price">13.88</span> or in a firm commitment underwritten public offering
pursuant to an effective registration statement resulting in gross proceeds of at least $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zycRFeTR9Urg" title="Proceeds from initial public offerings">15,000,000</span>. The warrants shall be exercisable
for a period of three years after the date of issuance. The warrant exercise price is contingent on the terms of the public offering.
If an initial public offering occurs at a price at or above $<span id="xdx_908_eus-gaap--SharePrice_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z62X2QT8yqFe" title="Share price">13.88</span> per share, then the exercise price shall be set to the issuance price
of the common stock with the number of warrants determined based on a 10% discount to the per share common stock issuance price. In the
scenario where the common stock is listed with the common stock issuance price below $<span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20210101__20211231_zaNFx9nt96Lb" title="Warrant exercise low price">13.88</span>, the exercise price will be set to $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231_zIDoOwqh0cn6" title="Warrant exercise price increase">20.82</span>
with the number of warrants based on a fixed conversion price of $<span id="xdx_90C_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20210101__20211231_zZYrxwzjqw86" title="Common stock, Conversion price">12.49</span>, which represents a 10.0% discount to the $<span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231_zPoS7a33NwV" title="Increase in common stock conversion price">13.88</span> threshold. The
warrants also have contingent call features based on the terms of the public offering. If an initial public offering occurs at a price
at or above $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVTqfcwTRkZk" title="Increase in common stock conversion price">13.88</span>, then the warrants are callable if the 20-day VWAP of the common stock in at or above <span id="xdx_90F_ecustom--PercentageOfVariableExercisePrice_pid_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs0BeknGg207" title="Percentage of variable exercise price">150%</span> of the variable exercise
price. In the scenario where the common stock is listed with a common stock issuance price below $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zhTBmM4kryXf" title="Increase in common stock conversion price">13.88</span>, then the warrants are callable
if the 20-day VWAP of the common stock is at or above the $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za22Npow9PX7" title="Warrant exercise price increase">20.82</span> exercise price. The detachable warrants contained terms and features
that gave rise to derivative liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability linked to the Series A Preferred Stock as of December 31, 2021 and 2020 was $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwaJvWUkYSz7">94,025
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZ7vcqJAGOWd">673,171</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The change in fair value of warrant liability was a gain of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBi59iJAXl">579,146
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2021 and a loss of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znbzoMXbSu3h">256,580
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zqrSyCvFjEMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zS9WSxHJNIXh" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zzZd2zSHWZb5" title="Expected volatility">85.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zxheEKRT7OYf" title="Expected volatility">69.8</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zpgZ1YZFEyve" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zv1bW8CFMpw9" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zlNTKtD2QOnj" title="Expected life">2.33</span> Years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z59ra0LR6fpd" title="Expected life">3.33</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zlxJazmtaUHj" title="Risk-free interest rate">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zZ9jfDpLPPI5" title="Risk-free interest rate">0.17</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_zeDQOtB9mNm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zTzjVKqsXQ0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zoAtzKTNqnb4" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average Life <br/>
(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br/>
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGJXH4vqT4g3" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxacmSgngLd1" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUF19Q2fWyOb" title="Weighted Average Remaining Life in Years Outstanding">4.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwXUtfIylJwe" style="width: 12%; text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCpyCdI6bKig" style="text-align: right" title="Number of Warrants, Issued"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziER2wFJ8At9" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCI3PYy22nyk" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3FRt72pUq7k" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhjBy06R5li3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2239">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zggVAJWPLXyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZXwl3qiVQUh" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1UF2OS1H3h7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyYeEN31fxOc" title="Weighted Average Remaining Life in Years Outstanding">3.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCv4qGki3iv4" style="text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyUcgegtfU0d" style="text-align: right" title="Number of Warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl2251">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoTiqWpp5v77" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2253">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjyGRJa1HEhf" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8gAZuUdIi3f" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg3J5QbCGnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2259">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTvaRVkvP63a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding and Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zciR8WEnUiXh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cSpiTgKCcd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">24.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5EEhfd6Lr21" title="Weighted Average Remaining Life in Years Outstanding">2.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4uV5MkPbHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zNG4gJ7WsYa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee or,
alternatively, if there is no compensation committee, the Company&#8217;s board of directors. We have reserved <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zC4rmGYlSjsc" title="Common stock reserved for future issuance">3,000,000</span> shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of December 31, 2021, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zGVxAssdvL8l" title="Share granted under equity incentive plan">384,167</span> shares have been granted under the 2018
Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement pursuant to which they will serve as a director and pursuant to which they would each receive a grant of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFeLlgpGRcM5" title="Share granted under equity incentive plan">75,000</span> worth
of Restricted Stock Units (&#8220;RSUs&#8221;) issuable under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;).
The RSUs vest annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RZrX46Zjme" title="Restricted stock value">25,000</span> per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, pursuant to the agreements with directors and officers <span id="xdx_901_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zhzvnX1ARNmj" title="Share based compensation">20,626</span> and <span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zRYz075b8zUk" title="Share based compensation">21,530</span> RSUs were issued
with a value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8ylF59eZsg6" title="Share based compensation">490,067</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQdA6Nr8en2c" title="Share based compensation">459,589</span> included in wages, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuaVhtPSHXPg" title="Unrecognized compensation cost">390,067</span> of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the next two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z7J26BhMgTZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSU) follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zD2cjcYwwuee" style="display: none">Schedule
of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGy8hGU7H6Xk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">60,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfV9RQHPHnO" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">24.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28RkmioCX4d" title="Weighted Average Life (Years)"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN4n3nTXpXob" style="text-align: right" title="Number of Stock Option Outstanding, Granted">4,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8Xq9TXq6oca" style="text-align: right" title="Weighted Average Exercise Price, Granted">22.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOH1D3MKKA46" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zebTa7ZZJWMg" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjwYmKlTdna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlNxm3U5p3jj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhYdez79ua7j" style="text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">61,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EEh9u8Rny9" style="text-align: right" title="Weighted Average Exercise Price, Granted">23.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcTHzBsvqd9" title="Weighted Average Life (Years)">4.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvGxO5u1nf9" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQZHtFixO4o1" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfMc4kDyj2b2" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztWDydoEqsd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJkxxHKumOpe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmHKnly3tlMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance">59,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJO11isFw8pk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance">23.57</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc9pi5v9Xl3g" title="Weighted Average Life (Years)">3.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZO4vwClYXi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable">43,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTf5l0KEVdf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable">23.93</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoj6q8oIA391" title="Exercisable Weighted Average Life (Years)">3.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908112816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zUvfGAU5tdAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_821_z3MypG20efs4">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through November 14, 2022, the date the financial statements were
available to be issued, and determined that no items were required to be disclosed.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z343XKlw7CQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82B_zWuhxLDwk3wj">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through June 3, 2022, the date the financial statements were available
to be issued, and determined the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2022, the Company received notice of forgiveness for the PPP loan entered into on March 9, 2021 for $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220121__20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzkm1op1Eps9" title="Debt instrument decrease forgiveness">73,007</span> and $<span id="xdx_90D_eus-gaap--InterestReceivable_iI_c20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpcJCURlSL3a" title="Interest receivable">641</span> in interest
that reduced the note liability in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022, and March 11, 2022, the Company sold $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGm5pZdmdnG1" title="Debt instrument face amount">365,000</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkYdx1sLJb0i" title="Debt instrument face amount">224,985</span>, respectively, in <span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwn4ary0nN99" title="Conversion ratio">6</span>% convertible notes (the &#8220;Notes&#8221;),
which bear <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztLohKgLkqY4" title="Conversion ratio">6</span>% interest, are repayable three years from the date of issuance, and will convert automatically into shares of common stock
(the &#8220;Conversion Shares&#8221;) at a conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9ZVzY2PLokh" title="Conversion price"><span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zea8xCWlhm7e" title="Conversion price">2.50</span></span> per share upon closing of this offering. Boustead Securities LLC
acted as placement agent for this offering and received compensation of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9q7eG1gwJUl" title="Share based compensation">36,500</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXkEALhBootf" title="Share based compensation">22,250</span>, respectively, and warrants to purchase shares
of common stock equal to <span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxh0jNKYsmT2" title="Conversion shares"><span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWXIjTdDQ05f" title="Conversion shares">10</span></span>% of the Conversion Shares, exercisable at the conversion price of the Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 30, 2022, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwZ9OkBXUNz8" title="Shares issued">1,678</span> shares (<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQeN58VOlfrf" title="Post reverse split">839</span> shares post-reverse split) of common stock to correct an issuance error on completion
of the 2018 share exchange which is valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO0sgTPNFE9l" title="Value  issued">16,340</span> common stock to be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, pursuant to the consent of the Company&#8217;s board of directors and a majority of its common stockholders, the Company
effectuated a two-for-one reverse split, pursuant to which each stockholder received one share of common stock for every two shares held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company submitted the final invoice for &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity
for Radiation Late Effects,&#8221; for $<span id="xdx_904_ecustom--PaymentOfInvoice_c20220405__20220406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQ4Xvb2fA5" title="Value  issued">211,455</span>, following the completion of the Final Quarterly Progress Report to NIH covering the
performance period of 9/16/2019-3/15/2022. The invoice was paid in full on April 27, 2022.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906526864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Restated)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes (Restated)</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zKgTM9QEZJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82C_zRXUrVVPJdTl">Income Taxes (Restated)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not made provision for income taxes for the years ended December 31, 2021, since the Company has the benefit of net operating
losses in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zfpTJrpMXd9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcC0lCcc0xA5">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z0l80A5F9c28" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zjx3wEimIymc" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20201231_zmrMSFl6fEi8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zMQzg6FtDgxl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(241,948</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(21,111</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zEsuz5Cwkrxl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(95,051</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,293</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_zgPBp4WFMv3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,381</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zMNAxT1v2cy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317,618</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zEOpZnHn4vZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense (benefit)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2354">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2355">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zxVODHcZRn3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVqWKqV9sse3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3jVIxUWCK47" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zm8TRJoHJWl6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20201231_z62SpSjAcV7k" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred income tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzOFC_zzmIcFjC0vv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operation loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">890,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">587,699</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzOFC_zg6BYHQ13JA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzOFC_z6hOw8owWjlf" style="vertical-align: bottom; background-color: White">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetInterestCarryforward_iI_maDTAGzOFC_zFYATNHgeXYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,574</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,596</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzOFC_z4t5PiJIEgv1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,801</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,801</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzOFC_maDTANzoN8_zQdjZxKskwAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,039,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,994</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoN8_zzcDn27G6w6a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,039,612</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(721,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoN8_zb7Vji106gv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred income tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2380">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z0qYBc8kUl23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zQSm8R518ktg" title="Operating loss carryforwards">3,000,000</span> of net operating losses (&#8220;NOL&#8221;) carried forward to offset taxable income, if any, in
future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on
the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs for every
period because it is more likely than not that all of the deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908154880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Restatement of Financial Statements</a></td>
<td class="text"><p id="xdx_805_eus-gaap--ErrorCorrectionTextBlock_ziNNLYktv2F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_z3AQT96MY1i6">Restatement of Financial Statements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements as of and for the year ended December 31, 2021, contained an understatement of legal and professional
expenses of $<span id="xdx_90D_eus-gaap--LegalFees_c20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zwd2SFrgbQHj" title="Legal and professional">420,000</span> for the valuation of a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231_zPA07Qu17mz2" title="Shares issued">210,000</span> shares (<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20210101__20211231_zXbkI9X12ch4" title="Post split">105,000</span> shares on a post-split basis) of incentive stock transferred
from a significant shareholder of the Company , who is also the wife of our Chairman and CEO, to a consultant for the Company in a private
transaction.</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zrQCbsF8GlR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zHqsuMlFkPke" style="display: none">Schedule
of Error Corrections and Prior Period Adjustments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7rhXTFinxua" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Originally</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reported<br/> ($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zA3FNhfJBlJa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zcqwd6LQgrzd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zDBaXJwDx9Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_zln5uBsBYHn5" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Additional paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">3,730,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">420,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,150,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zMPE94sVvJVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,375,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,795,432</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPifdA6smGZ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br/>
Reported <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zws6ZyNjQgkd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_zTZDMpCuETek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As <br/>
Restated <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zPrs4NLrg89i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LegalFees_i01_z0Hbf5NRlM45" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Legal and professional</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">264,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">420,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">684,684</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01_zAJ0lsN7xFVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,322,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,742,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zMIZK59m6f5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,322,992</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,742,992</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zSedjX2VsXOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Loss before Income Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(732,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,152,134</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zlloZelMBcB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(732,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,152,134</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJhHtr5hWeEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(835,196</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,255,196</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zKPH6nydBU59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss per shares - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.08</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeVIxtMrSjn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br/>
Reported <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyfQ25RK6Ach" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zfIlx8K5HED8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As<br/>
 Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zs4cRQ0OtDG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zIkx9Tj0O3gk" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(732,134</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(420,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(1,152,134</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zdOSwsZHODke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910,067</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zV1WtBGFe06a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733905671904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhSeyCkF9SFi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z0W8FiA8tXZh">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzSeCibrySFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zHFk2Mm9gwU8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX3kHkk5xqEg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zkpAz40vtY5g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"/>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--ConsolidationPolicyTextBlock_zpCW6ei1Xrg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z9MlYvZzbJ37">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zPEiyQuA66c7">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zeUqtynLxD3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zHxcJoKlrWk3">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFFpvu1BVnNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zPpD978nUCdj">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zrejJygRHQC4" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life">10</span>
    years</span></td></tr>
  </table>
<p id="xdx_8AD_zrSjsjleiadg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeRTsuUFY894" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zy1ME33lauv2">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvG7r2Lue0g" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life">10</span> years</span></td>
    </tr>
  </table>
<p id="xdx_8AF_zoq40ARkvugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqDNlRLgmH2b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoyPOKzGk12h">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zAX85jorC2o8" title="Proceeds for research and development from collaborators">299,502</span> Phase I award includes funded research from September 19, 2016 through September 18, 2017
and was advanced to Phase II of the awards with funding of $<span id="xdx_90B_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zrl1OPzzKA4k" title="Proceeds for research and development from collaborators">1,903,095</span> with a fixed price contract period of September 17, 2018 through
September 16, 2020 and subsequent no cost extensions through September 15, 2021 and then March 15, 2022 (Reference 75N91019C00031). The
Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zLUMgHUOD9v2" title="Proceeds from contract awards for research and development">211,455</span> for a total of $<span id="xdx_902_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zHVzt4MlVLvc" title="Proceeds from contract awards for research and development">845,820</span> in 2020; and 2 quarterly payments related to Topic 345 for a
total of $<span id="xdx_901_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_z5byWYRT12H5" title="Proceeds from contract awards for research and development">422,910</span> in 2021. On April 6, 2022, the Company submitted the final invoice for &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects,&#8221; for $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220425__20220426__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zdHXKcE9yNBg" title="Payments to invoices in research and development">211,455</span>, following the completion of the Final Quarterly Progress
Report to NIH covering the performance period of September 16, 2019-March 15, 2022. The invoice was paid in full on April 27, 2022. In
Phase II of the SBIR effort, the Company completed an analytical validation of the metabolic test kit, extended the option to license
the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221; test and developed
plans for a multi-institutional clinical trial to be implemented in the Phase III effort. This contract included a subcontract to Georgetown
University (&#8220;Georgetown&#8221;) for use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended
to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZDynIs5qjMc" title="Proceeds for research and development from collaborators">795,248</span> subcontract of its Phase II contract #HHSN75N91019C00031. The
Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zD1dF4GG7wYc" title="Proceeds for research and development from collaborators">795,248</span>. Georgetown invoiced the
Company for a total of $<span id="xdx_90E_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zk3255qtn7m3" title="Payments to invoices in research and development">791,017</span> as of September 30, 2022, leaving a balance of $<span id="xdx_907_ecustom--AccruedInvestmentIncomeReceivableOutstanding_iI_c20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zbLnUtrmaXe5" title="Research and development invoice receivable, outstanding">4,231</span>. Depending on the resources it uses, Georgetown
may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable amount, the
Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $<span id="xdx_902_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220401__20220430_zE9fjBl3FtLl" title="Payments to invoices in research and development">791,017</span> were made to Georgetown, including
an additional invoice for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220701__20220930_zPTpk6s8LFmj" title="Payments to invoices in research and development">282,643</span> which was received but not paid until the second quarter of 2022. All invoices have now been paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_90A_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zanyYyghAh34" title="Proceeds from contract awards for research and development">1,484,350</span> to fund research
from September 17, 2018 through September 16, 2020 and was extended without cost through November 16, 2021 due to delays caused by the
impact of COVID-19. For the entire contract period, the Company invoiced and received a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211116__20211116__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVAJShB1sPPd" title="Payments to invoices in research and development">1,411,883</span>. The final draft report was
filed with the NIH along with the final invoice for $<span id="xdx_90B_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211202__20211203__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfrcR6AlrTFj" title="Payments to invoices in research and development">10,000</span>, which payment was made on December 3, 2021, and no additional payments are
expected. The Phase II contract also includes a subcontract to Georgetown University for $<span id="xdx_906_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zeOLO5T65Yv7" title="Business development new establishment">742,002</span> to establish prostate cancer cell lines
from African American patients undergoing prostate surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z2CdTdQbva21" title="Proceeds for research and development from collaborators">742,002</span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zMG2pQQCfA07" title="Payments to invoices in research and development">305,866</span> as of September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the quarter ended September 30, 2022, the Company recorded a
net deficit of $<span id="xdx_90C_ecustom--ResearchAndDevelopmentDeficitNet_c20220101__20220930_zoT3CbZyLPwk" title="Net deficit on research and development">83,868</span> with the Company funding the NIH no-cost extension along with other R&amp;D activities. The NIH made the final
payment of $<span id="xdx_90F_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zor9EaiE5Fu5" title="Payments to invoices in research and development">211,455</span> in April 2022 for Topic 345.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September of 2022, TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;) was contracted for process research, development and cGMP compliant
manufacture of IPdR. The total project cost is $<span id="xdx_90C_eus-gaap--CapitalizedContractCostNet_iI_c20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_z0ryukO7eiIc" title="Project cost">1,500,000</span> based on four milestone payments, the first payment of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zYKX6wr2MDMh" title="Payments to invoices in research and development">450,000</span> was paid during
the quarter ended September 30, 2022, pursuant to which TCG GreenChem commenced work on the project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue or other income. Due to the terms of the contracts we have entered into, the Company concluded that the
reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGp2dE9hhrRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zgQsodqcjYxk">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#8220;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#8211; Moonshot Project&#8221; and (2) &#8220;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &#8220;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#8221; This $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zaeusPjbqBc2" title="Proceeds for research and development from collaborators">299,502</span> Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZxtPV2c0e48" title="Proceeds for research and development from collaborators">1,903,095</span> with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $<span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zUPYw14OkS5l" title="Proceeds from contract awards for research and development">211,455</span>
for a total of $<span id="xdx_90D_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zRHHZEcba5ki" title="Proceeds from contract awards for research and development">845,820</span> in 2020; and 2 quarterly payments related to Topic 345 for a total of $<span id="xdx_909_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_zP3SGc96Lxwi" title="Proceeds from contract awards for research and development">422,910</span> in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#8220;kits,&#8221;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown University to perform the $<span id="xdx_903_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zM0qWX69QD7a" title="Proceeds for research and development from collaborators">795,248</span> subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $<span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z3cnkMBBBhNf" title="Proceeds for research and development from collaborators">795,248</span>. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $<span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211201__20211231_zDFLz35b8ZD" title="Payments to invoices in research and development">354,829</span> were made to Georgetown,
and additional invoices for $<span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231_zdbj5Zip7kb" title="Payments to invoices in research and development">436,188</span> were received but not yet paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#8220;Topic 352 &#8211;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#8221; and was awarded to provide $<span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_z3qXOJD0BmS" title="Proceeds from contract awards for research and development">1,484,350</span> to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $<span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zajbxohgsNr4" title="Payments to invoices in research and development">412,321</span> and $<span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0Q4mmcdceZb" title="Payments to invoices in research and development">82,467</span> in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $<span id="xdx_90C_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zjZOQRhRSoT5" title="Business development new establishment">742,002</span> to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $<span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z9lcD8RCIC0j" title="Proceeds for research and development from collaborators">742,002</span> subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $<span id="xdx_903_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zG9gSpfZ7Rp8" title="Payments to invoices in research and development">292,252</span> as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $<span id="xdx_908_ecustom--ResearchAndDevelopmentDeficitNet_c20210101__20211231_z4cRZ85dT5Ai" title="Net deficit on research and development">1,021,808</span> from these two SBIR contracts which is the result of recording $<span id="xdx_909_eus-gaap--CapitalizedContractCostNet_iI_c20211231__dei--LegalEntityAxis__custom--SBIRMember_zgGdHtrh81Xk" title="Project cost">1,527,185</span> in SBIR contract related expenses
on revenues of $<span id="xdx_908_eus-gaap--CapitalizedContractCostNet_iI_c20201231__dei--LegalEntityAxis__custom--SBIRMember_zoZGhm200M6h" title="Project cost">505,377</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#8211; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zPlBfuV8LKl9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_za7MJc2KLRf">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of September 30, 2022, the Company had no derivative instruments. As of December 31, 2021
the Company&#8217;s only derivative financial instrument was an embedded warrant feature associated with its Series A Convertible Preferred
Stock due to certain provisions that allow for a change in the warrant value based on fluctuations of the Company&#8217;s fair value
of common stock at the date of issuance of the warrant based on certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--DerivativesPolicyTextBlock_zDJe5Tlsf9bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zCUUvceE5Y19">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&#8217;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&#8217;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVgFsM34CXt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zOeVLCJpuOoc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GTWgulRiA7" title="Share price">25.22 </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FYyHnhqDba" title="Share price">5.00</span> in 2021, $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLPlikArwB8" title="Share price">4.00</span> through March 31, 2022 and $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUXJKtHAQEP7" title="Share price">6.00 </span>through June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2022, the Company identified <span id="xdx_904_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_do_c20220930_zygmAQg0VFEb" title="Financial liabilities fair value">no</span> liabilities required to be presented on the balance sheet at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGngUoQuWHod" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Warrant Liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zsd9NRdAjIL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKwi81zQZRlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zKgD4N7HXxc5">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&#8217;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation
    methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets
    in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially
    the full term of the financial instrument.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation
    methodology us one or more unobservable inputs which are significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <i>Distinguishing Liabilities
from Equity</i>, and FASB ASC Topic 815, <i>Derivatives and Hedging</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&#8217;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8I5At1BUld" title="Share price">25.22 </span>(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY7PlvqW9iE8" title="Share price">5.00</span> in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z5wlC8g4VNF4" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">673,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zMFIwN4l8G2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSMPJgjkKtRe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zGDBm12N3Bgh">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed
    contracts with the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of performance obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of the transaction price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation
    the transaction price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
    of revenue only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from NIH contracts is received in accordance with Federal grants and contracts policies. Research and development expenses
are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zF0u8ua9DnYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z4tzmmsrb0zi">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed contracts with
    the Company&#8217;s customers that it believes are legally enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification of performance
    obligations in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of the transaction
    price for each performance obligation in the respective contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation the transaction
    price to each performance obligation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition of revenue
    only when the Company satisfies each performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &#8220;Research and development, net
of contract expense reimbursements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zcExFdFHdFK3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z6PnT83yyhM">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
shares of common stock outstanding during the period using the treasury stock method and as if converted method. Dilutive potential shares
of common stock include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu2C2gyHdXxj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti dilutive securities excluded from
    computation of earnings per share</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zXv2XedQLmv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMMOgYBJyl01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zbbuukvDA6n5">Basic
and Diluted Earnings Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&#8220;EPS&#8221;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zLrPHxK3r8ik" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zmayAC6bl05j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9PcSCc4vTKf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z0Lznkh5Cw24">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3igIdv3U6A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z20jsWIwjfHk">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#8220;Debt&#8212;Debt with &#8220;Conversion and Other Options&#8221;
and ASC subtopic 815-40 &#8220;Hedging&#8212;Contracts in Entity&#8217;s Own Equity.&#8221; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_z1VY8Pmu6GNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUGWDSisXQa6">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounts receivable consists of amounts due from the National Institutes of Health (&#8220;NIH&#8221;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on research
and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and payments
from the contracts are generally collected within 30 days of the Company&#8217;s submission for reimbursement. The Company currently
does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection
information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance of the invoice and typically
would be considered past due when the term expires. The Company&#8217;s allowance for doubtful accounts was $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zkVwpc8cgnp9" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zBypMpqdf6y2" title="Allowance for doubtful accounts">0</span></span> at December 31, 2020 and
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zPau7tRPvDne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z6G31CPqBJC7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9PNW0W5dLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zjn1rBexH1P3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI https://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904704192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock', window );">Schedule of Useful Lives for Property Plant Equipment</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zrejJygRHQC4" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life">10</span>
    years</span></td></tr>
  </table>
<span></span>
</td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvG7r2Lue0g" style="display: none">Schedule
of Useful Lives for Property Plant Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life">5</span> years</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life">10</span> years</span></td>
    </tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Fair Value by Liabilities on Balance Sheet</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zGngUoQuWHod" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Warrant Liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z5wlC8g4VNF4" style="display: none">Schedule
of Fair Value by Liabilities on Balance Sheet </span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">94,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Warrant Liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">673,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zu2C2gyHdXxj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti dilutive securities excluded from
    computation of earnings per share</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zLrPHxK3r8ik" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Series A preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">97,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>&#160;Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908171952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHw4g6hhBnUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zgIcSqP1GQel" style="display: none">Schedule
of Property and Equipment Net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20220930_zIuASPNq3qll" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zr4QYBfzAWEd" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zU5MxQUAw8E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zwWSOCdm4pAl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzwPA_zbpLEntztHr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzwPA_zk6WVvG8Nbf5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzwPA_zAsg6aOTm5zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,080</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z293shVBnX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following as of December 31, 2021, and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zUr4lrOJYvF3" style="display: none">Schedule
of Property and Equipment Net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zSEQkOppiO5i" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zkJJtHp8oFWl" style="white-space: nowrap; text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOKWx4HrW392" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zLyb9JAYDobb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Laboratory equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_zMWGxtXnHRM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,466</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zwkuXQRcad9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(102,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zc6buQvCEHzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733899655632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock', window );">Schedule of Operating Lease Right of Use Assets</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zWm8Fs7Ed7R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zAImY9PDHMUg" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20220930_z1midZtHPzW3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zAPSmuBNbsTj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zj9387NWMqbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_ztbnQ85VGf8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(193,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zYVRdiQfZ24a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zGNZoOUwWE2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1CVxMNAGGw7" style="display: none">Schedule of Operating Lease Right of Use Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zIPeQCOX6197" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zGRdq5m7ruo" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfficeLease_iI_zByLv4uguS7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">265,207</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_za6ldmTid0xk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,609</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zQxRuTcj6KK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">171,598</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zxqoKB1Dwu8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zH01tCtnTGW9" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20220930_zOkTDA3D9pE3" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zf8g6zEjZ5V8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zPgpaBsyNEYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">80,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zuhPVK1tOQza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,707</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF267iEwqDW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRhltcKRLqyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zZms85qMdgaf" style="display: none">Schedule
of Operating
Lease Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zdZcv5DI5bpg" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zSX1D7qU6WY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Office Lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">129,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zeMS8XHFzwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_znebceF7M491" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Operating Lease Maturity</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI3LHmxEst4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zeTus9Yk7gqg" style="display: none">Schedule Of Operating Lease Maturity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220930_zdlre74HLWW3" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz4Xq_zApK0lBgQLz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 75%; text-align: left">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">19,440</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz4Xq_ztBHxWzLa5Da" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz4Xq_zmHWBOXUo113" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Total future minimum lease payments</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNs3XD3FUEd1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zCqRaCFYxwo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">PV of Payments</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80,378</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z98Fy6YXydx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zMMRA9wuYNOj" style="display: none">Schedule Of Operating Lease Maturity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20211231_ztevs8lGFSs" style="text-align: center">As of</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zHj2r2sgCHW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,248</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zMl8VEXKF1s5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zzzVCxMlgfGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,048</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQoP45FoKrEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zuRGKEbQQBi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">PV of Payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,376</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Operating Lease Right Of Use Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904856416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Notes Payable</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zBuehpHgeOmh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8B7_zh3WL2OqTeea" style="display: none">Schedule
of Notes Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220930_zCOLUnMIYUub" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zhTWY6hOtPcj" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PPP Note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zV3AXygSN6yh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zLqQeYshslhh" title="Debt maturity date">May 15, 2020</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zgEHevVdpow9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zyRSdphG0GA7" title="Debt maturity date">March 9, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zyqQSYNNAWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_zSmWxVZcgvbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zEJQH7FsQBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z7x0Bf5QV6J7" style="display: none">Schedule
of Notes Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zs8ZjEzR5as6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20201231_z5ddmsxg9gG3" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zlKWCVwANhc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zAwg53kad8Uj" title="Debt maturity date">May 15, 2020</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zKIGQqEGOeIc" style="vertical-align: bottom; background-color: White">
    <td>PPP Note <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_ztFm5G3svYx7" title="Debt maturity date">March 9, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanForgiveness_iI_zed16WxGRXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayable_iI_zCp6BUuAMjk8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">62,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Promissory Notes</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYzIEK2eVmQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zwWGyadF88hh" style="display: none">Schedule
of Promissory Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z8sz6rbUuhP7" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zGN2XUdpFHY8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z8rCGaaJjyP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zw3T5TSJyY52" title="Debt maturity date">December 28, 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zVhNOEpSV6nf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zrdUXY9T00Y3" title="Debt maturity date">February 8, 2022</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zw5zFEWoegz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zvymj71KTPZa" title="Debt maturity date">March 11, 2022</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zcRQi5sCgQ57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Promissory note issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zXkxFE5K93x1" title="Debt maturity date">August 1, 2022</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzxfV_zaBoiXSvwhI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zxwXaJH3mH72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(408,979</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zHKNNzyBPYGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,021</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4nwu7JkSlxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zF9q91NBsww7" style="display: none">Schedule
of Promissory Notes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zScL1QxrrD58" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z7eF9AhBvJH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">Promissory notes issued on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zEYM2T1Dfl7c" title="Debt maturity date">December 28, 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zwVIHIq0ckw6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized discount on notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(408,979</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zRjlbHqT2Zb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,021</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904453984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock', window );">Schedule of Sale of Equity or Issued</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_zoIvY7momya6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B2_zlcBSojejxUa" style="display: none">Schedule of
Sale of Equity or Issued</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issuance</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value $</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><span id="xdx_F4C_zVQnroxtrN48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zGz90CtsNEja" style="width: 12%; text-align: right" title="Stock issued during period, shares">1,409,771</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zVMczMb85TE9" style="width: 12%; text-align: right" title="Stock issued during period, Value">10,031,415</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zI1ZZDkuYRll" style="text-align: right" title="Stock issued during period, shares">147,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zfUkLCAktb1c" style="text-align: right" title="Stock issued during period, shares">588,524</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F49_z4m8t1dYYtpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant exercises<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_zOLfHvinhUdc" style="text-align: right" title="Stock issued during period, shares">2,267,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_ziQh59zpa9Pc" style="text-align: right" title="Stock issued during period, shares">590,574</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_zh3yWT2pEEAl" style="text-align: right" title="Stock issued during period, shares">839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_z0haD5Kr4GCl" style="text-align: right" title="Stock issued during period, value">16,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_F42_z27rO27rUT38" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Share and Dividends Payable<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_z5rP5B6sdQr1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, shares">437,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_zudb7kxpNvP4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, Value">402,068</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_zpaba9E4mGZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zVTbfqbW6iba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value
                                            is net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees">1,407,262</span> of fees associated with the issuances.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zlejtRyQe31c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zoZjkIOtyHI6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share">197,273</span> broker warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share">180,280 </span>shares of common stock
                                            and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise">1,409,771 </span>shares of common stock exercised as part of the Company&#8217;s
                                            initial public offering.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_z24ejyBVEFq1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zkLhD1kqAUba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock">336,810</span> shares of common stock issued upon conversion of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding">1,213</span> Preferred Shares and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock">100,517</span>
                                            common shares to settle dividends payable balance.</span></td></tr></table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Of Stock Options, Valuation Assumptions</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjFxAl0mLK3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zBaWiW2hUbo9" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zhMcG7Vze4z1" title="Expected volatility">85.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_z7TmHT9meRab" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zj4OzbZ2MUfg" title="Expected life">2.33</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zJiIunAv2NNg" title="Risk-free interest rate">0.73</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zqrSyCvFjEMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zS9WSxHJNIXh" style="display: none">Schedule Of Stock Options, Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Expected average volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zzZd2zSHWZb5" title="Expected volatility">85.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zxheEKRT7OYf" title="Expected volatility">69.8</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zpgZ1YZFEyve" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zv1bW8CFMpw9" style="text-align: right" title="Dividend yield">8.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zlNTKtD2QOnj" title="Expected life">2.33</span> Years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z59ra0LR6fpd" title="Expected life">3.33</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zlxJazmtaUHj" title="Risk-free interest rate">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zZ9jfDpLPPI5" title="Risk-free interest rate">0.17</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zykKzq1xTiEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zAI1VcyQekT9" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlqKbqQNTHXh" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHSY18pcFCve" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc0uoL4xYoje" title="Weighted Average Remaining Life in Years Outstanding">3.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEgcPNiFzEod" style="text-align: right" title="Number of Warrants, Issued"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWGdzP4hgfd5" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDJ8BkLCpngh" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcMdvhnPUqSl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Z2V48oZPpc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXVFuH1uPzt8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z21PCphyMc5g" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze8hCGHfFJ8a" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5ZW4uR86yU8" title="Weighted Average Remaining Life in Years Outstanding">2.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAd8zJkaU7dg" style="text-align: right" title="Number of Warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcgLjEuctt5e" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCfXWpepbsC" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zREYA2RzJlWi" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrJXH3EJHUl4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(48,532</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxVBHHEKMvKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0MKUidIv8Zf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7GPzqiGfWx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the common stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfwUq0E6s3c" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCQq5BYydFa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0KcnPEUWxa" style="width: 12%; text-align: right" title="Number of Warrants, granted">2,304,544</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOnBZehpQzm2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, granted">2.89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxqi6r40Aq1" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOOZUfB75Rua" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup id="xdx_F45_zMhcIcLQEOg3">(1)</sup></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zPAiB1fqCrda" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(2,284,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z3Jr1f2NZ178" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">2.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding and Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAPnlh9J9We" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DbtcWe9i2d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">2.50</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zPB1oqRtX8Ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zZ50IP42y1W5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants">180,280</span> common stock.</span></td></tr></table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zTzjVKqsXQ0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zoAtzKTNqnb4" style="display: none">Schedule
of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average Life <br/>
(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br/>
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGJXH4vqT4g3" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxacmSgngLd1" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUF19Q2fWyOb" title="Weighted Average Remaining Life in Years Outstanding">4.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwXUtfIylJwe" style="width: 12%; text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCpyCdI6bKig" style="text-align: right" title="Number of Warrants, Issued"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziER2wFJ8At9" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCI3PYy22nyk" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3FRt72pUq7k" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhjBy06R5li3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2239">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zggVAJWPLXyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZXwl3qiVQUh" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">48,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1UF2OS1H3h7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">24.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyYeEN31fxOc" title="Weighted Average Remaining Life in Years Outstanding">3.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCv4qGki3iv4" style="text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyUcgegtfU0d" style="text-align: right" title="Number of Warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl2251">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoTiqWpp5v77" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2253">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjyGRJa1HEhf" style="text-align: right" title="Number of Warrants, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8gAZuUdIi3f" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg3J5QbCGnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2259">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTvaRVkvP63a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding and Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zciR8WEnUiXh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance">48,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cSpiTgKCcd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">24.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5EEhfd6Lr21" title="Weighted Average Remaining Life in Years Outstanding">2.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4uV5MkPbHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units (RSUs)</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zQUTKItLSwyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSUs) is set forth as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zEPSKpTDUEX2" style="display: none">Schedule
of Restricted Stock Units (RSUs) </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
RSU</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise <br/>
Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zucGsO7jApGk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">61,884</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh2nhdHl9H4d" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">23.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxjCwRdW8aBh" title="Weighted Average Life (Years)">4.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVwpB3WDjyb" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaC85nk4TjE9" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8IQpkJhHpBk" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAkqKJsJkf35" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNTQQ0pKQNEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoTwwRxCwFd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">59,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqJQarbmomS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">23.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRzMbmLfLjD" title="Weighted Average Life (Years)">3.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0yYtPiigZh7" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwpyGG1LxO97" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLRpATl7oARd" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMSs7ioeWlI4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKNoINGNfkac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZdWes1Tiv1k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjVqgVvh1vkl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance">59,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm4QxHnPnqtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance">23.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk6uMcKKK4p7" title="Weighted Average Life (Years)">2.58</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Exercisable, September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFSAFrLb73b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable">58,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1SVsH5cj8Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable">23.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs5wrkCUxacl" title="Exercisable Weighted Average Life (Years)">2.58</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z7J26BhMgTZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSU) follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zD2cjcYwwuee" style="display: none">Schedule
of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, December 31, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGy8hGU7H6Xk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">60,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfV9RQHPHnO" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">24.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28RkmioCX4d" title="Weighted Average Life (Years)"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN4n3nTXpXob" style="text-align: right" title="Number of Stock Option Outstanding, Granted">4,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8Xq9TXq6oca" style="text-align: right" title="Weighted Average Exercise Price, Granted">22.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOH1D3MKKA46" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zebTa7ZZJWMg" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjwYmKlTdna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlNxm3U5p3jj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhYdez79ua7j" style="text-align: right" title="Number of Stock Option Outstanding, Beginning Balance">61,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EEh9u8Rny9" style="text-align: right" title="Weighted Average Exercise Price, Granted">23.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcTHzBsvqd9" title="Weighted Average Life (Years)">4.33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvGxO5u1nf9" style="text-align: right" title="Number of Stock Option Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQZHtFixO4o1" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited">(2,702</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfMc4kDyj2b2" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">27.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztWDydoEqsd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJkxxHKumOpe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmHKnly3tlMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance">59,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJO11isFw8pk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance">23.57</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc9pi5v9Xl3g" title="Weighted Average Life (Years)">3.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZO4vwClYXi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable">43,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTf5l0KEVdf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable">23.93</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoj6q8oIA391" title="Exercisable Weighted Average Life (Years)">3.33</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales of stock or previously unissued stock made by subsidiary or equity method investee to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908146880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Restated) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock', window );">Schedule of Reconciliation of Income Tax Benefit</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zfpTJrpMXd9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcC0lCcc0xA5">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z0l80A5F9c28" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zjx3wEimIymc" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20201231_zmrMSFl6fEi8" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zMQzg6FtDgxl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(241,948</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(21,111</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zEsuz5Cwkrxl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(95,051</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,293</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_zgPBp4WFMv3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,381</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zMNAxT1v2cy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317,618</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zEOpZnHn4vZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense (benefit)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2354">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2355">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVqWKqV9sse3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z3jVIxUWCK47" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zm8TRJoHJWl6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20201231_z62SpSjAcV7k" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Restated)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred income tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzOFC_zzmIcFjC0vv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operation loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">890,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">587,699</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzOFC_zg6BYHQ13JA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzOFC_z6hOw8owWjlf" style="vertical-align: bottom; background-color: White">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetInterestCarryforward_iI_maDTAGzOFC_zFYATNHgeXYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,574</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,596</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzOFC_z4t5PiJIEgv1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,801</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,801</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzOFC_maDTANzoN8_zQdjZxKskwAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,039,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,994</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoN8_zzcDn27G6w6a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,039,612</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(721,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoN8_zb7Vji106gv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred income tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2380">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Pretax Income From Continuing Operations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908156112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zrQCbsF8GlR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zHqsuMlFkPke" style="display: none">Schedule
of Error Corrections and Prior Period Adjustments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7rhXTFinxua" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Originally</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reported<br/> ($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zA3FNhfJBlJa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zcqwd6LQgrzd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zDBaXJwDx9Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_zln5uBsBYHn5" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Additional paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">3,730,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">420,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,150,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zMPE94sVvJVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,375,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,795,432</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPifdA6smGZ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br/>
Reported <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zws6ZyNjQgkd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_zTZDMpCuETek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As <br/>
Restated <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zPrs4NLrg89i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LegalFees_i01_z0Hbf5NRlM45" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Legal and professional</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">264,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">420,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">684,684</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01_zAJ0lsN7xFVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,322,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,742,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zMIZK59m6f5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,322,992</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,742,992</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zSedjX2VsXOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Loss before Income Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(732,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,152,134</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zlloZelMBcB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(732,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,152,134</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJhHtr5hWeEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(835,196</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,255,196</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zKPH6nydBU59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss per shares - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.08</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeVIxtMrSjn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Originally <br/>
Reported <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyfQ25RK6Ach" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restatement <br/>
Adjustment<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zfIlx8K5HED8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As<br/>
 Restated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zs4cRQ0OtDG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zIkx9Tj0O3gk" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(732,134</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(420,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(1,152,134</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zdOSwsZHODke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910,067</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904493600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Aug. 12, 2016</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of convertible shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">2-for-1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Awarded contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,531,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,143,980<span></span>
</td>
<td class="nump">$ 5,795,432<span></span>
</td>
<td class="nump">$ 4,540,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of convertible shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock membership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906726640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Useful Lives for Property Plant Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733994626464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value by Liabilities on Balance Sheet (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 94,025<span></span>
</td>
<td class="nump">$ 673,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,025<span></span>
</td>
<td class="nump">$ 673,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904695808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">145,594<span></span>
</td>
<td class="nump">145,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,062<span></span>
</td>
<td class="nump">97,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">48,532<span></span>
</td>
<td class="nump">48,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733900437312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Nov. 16, 2021</div></th>
<th class="th"><div>Dec. 06, 2019</div></th>
<th class="th"><div>Dec. 05, 2018</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 18, 2017</div></th>
<th class="th"><div>Sep. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromContractAwardsForResearchAndDevelopment', window );">Proceeds from contract awards for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 791,017<span></span>
</td>
<td class="nump">$ 354,829<span></span>
</td>
<td class="nump">$ 282,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ResearchAndDevelopmentDeficitNet', window );">Net deficit on research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,868<span></span>
</td>
<td class="nump">$ 1,021,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 25.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember', window );">TCG Green Chem Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Project cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_SBIRMember', window );">SBIR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Project cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527,185<span></span>
</td>
<td class="nump">$ 505,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 1,411,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,467<span></span>
</td>
<td class="nump">412,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_PhaseIIMember', window );">Phase II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds for research and development from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,484,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Business development new establishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_SubcontractPhaseIIMember', window );">Subcontract Phase II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,866<span></span>
</td>
<td class="nump">292,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=SHPH_OneQuarterlyPaymentsMember', window );">1 Quarterly Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromContractAwardsForResearchAndDevelopment', window );">Proceeds from contract awards for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=SHPH_TwoQuarterlyPaymentsMember', window );">2 Quarterly Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromContractAwardsForResearchAndDevelopment', window );">Proceeds from contract awards for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember', window );">Additional Funding Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds for research and development from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795,248<span></span>
</td>
<td class="nump">$ 742,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,502<span></span>
</td>
<td class="nump">$ 1,903,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="nump">$ 211,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInvestmentIncomeReceivableOutstanding', window );">Research and development invoice receivable, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,231<span></span>
</td>
<td class="nump">$ 4,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccruedInvestmentIncomeReceivableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development invoice receivable, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccruedInvestmentIncomeReceivableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to invoices in research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentsToInvoicesInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromContractAwardsForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from contract awards for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromContractAwardsForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ResearchAndDevelopmentDeficitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deficit on research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ResearchAndDevelopmentDeficitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_SBIRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_SBIRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_PhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_PhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_SubcontractPhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=SHPH_SubcontractPhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_OneQuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_OneQuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_TwoQuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_TwoQuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906515456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 127,466<span></span>
</td>
<td class="nump">$ 127,466<span></span>
</td>
<td class="nump">$ 127,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(113,386)<span></span>
</td>
<td class="num">(108,902)<span></span>
</td>
<td class="num">(102,684)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,080<span></span>
</td>
<td class="nump">18,564<span></span>
</td>
<td class="nump">24,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,861<span></span>
</td>
<td class="nump">8,861<span></span>
</td>
<td class="nump">8,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SHPH_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 118,605<span></span>
</td>
<td class="nump">$ 118,605<span></span>
</td>
<td class="nump">$ 118,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SHPH_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SHPH_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733907544928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 4,484<span></span>
</td>
<td class="nump">$ 4,050<span></span>
</td>
<td class="nump">$ 6,218<span></span>
</td>
<td class="nump">$ 5,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904475696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Right of Use Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_OfficeLease', window );">Office Lease</a></td>
<td class="nump">$ 265,207<span></span>
</td>
<td class="nump">$ 265,207<span></span>
</td>
<td class="nump">$ 265,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccumulatedAmortizationOnRightOfUseAssets', window );">Less accumulated amortization</a></td>
<td class="num">(193,237)<span></span>
</td>
<td class="num">(148,225)<span></span>
</td>
<td class="num">(93,609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use, net</a></td>
<td class="nump">$ 71,970<span></span>
</td>
<td class="nump">$ 116,982<span></span>
</td>
<td class="nump">$ 171,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccumulatedAmortizationOnRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization on right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccumulatedAmortizationOnRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_OfficeLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_OfficeLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904695440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Office Lease</a></td>
<td class="nump">$ 80,378<span></span>
</td>
<td class="nump">$ 129,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(73,707)<span></span>
</td>
<td class="num">(66,934)<span></span>
</td>
<td class="num">$ (58,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term portion</a></td>
<td class="nump">$ 6,671<span></span>
</td>
<td class="nump">$ 62,442<span></span>
</td>
<td class="nump">$ 129,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733994641808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule Of Operating Lease Maturity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 19,440<span></span>
</td>
<td class="nump">$ 76,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">64,800<span></span>
</td>
<td class="nump">64,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">84,240<span></span>
</td>
<td class="nump">141,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(3,862)<span></span>
</td>
<td class="num">(11,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PV of Payments</a></td>
<td class="nump">$ 80,378<span></span>
</td>
<td class="nump">$ 129,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904434048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Right-of-use Asset And Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription', window );">Interest rate used to lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,631<span></span>
</td>
<td class="nump">$ 52,445<span></span>
</td>
<td class="nump">$ 74,028<span></span>
</td>
<td class="nump">$ 71,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_OperatingLeasePayment', window );">Lease payment</a></td>
<td class="nump">$ 6,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">Oct. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 6,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="nump">$ 6,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_OperatingLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_OperatingLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee to determine discount rate for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733893998064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Aug. 24, 2019</div></th>
<th class="th"><div>Jun. 24, 2019</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>May 30, 2018</div></th>
<th class="th"><div>Apr. 04, 2018</div></th>
<th class="th"><div>Jan. 25, 2018</div></th>
<th class="th"><div>Dec. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt maturity, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July of 2022 the notes were extended to June 30, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021<span></span>
</td>
<td class="text">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021<span></span>
</td>
<td class="text">December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021<span></span>
</td>
<td class="text">In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the
notes were extended to June 30, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">83.40%<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_RelatedPartyTransactionAmountsOfTransactions', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2022<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 424,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,592<span></span>
</td>
<td class="nump">$ 31,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,835<span></span>
</td>
<td class="nump">458,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable, Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,491<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,491<span></span>
</td>
<td class="nump">124,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables One [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 25,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables One [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 25,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  04,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  04,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Three [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Three [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 23,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member] | Notes Payable Other Payables Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 22,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember', window );">Related Party Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_RelatedPartyTransactionAmountsOfTransactions', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Notes payable related party transaction rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Notes payable related party maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Notes payable related party debt principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,150<span></span>
</td>
<td class="nump">10,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Notes payable related party debt plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,379<span></span>
</td>
<td class="nump">$ 149,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_RelatedPartyTransactionAmountsOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction amounts of transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_RelatedPartyTransactionAmountsOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NotesPayableOtherPayablesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906521008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LoanForgiveness', window );">Loan Forgiveness</a></td>
<td class="num">(73,007)<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember', window );">PPP Note Payable One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember', window );">PPP Note Payable Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733905783968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Notes Payable (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember', window );">PPP Note Payable One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 15,  2020<span></span>
</td>
<td class="text">May 15,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember', window );">PPP Note Payable Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  09,  2021<span></span>
</td>
<td class="text">Mar.  09,  2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PaycheckProtectionProgramNotePayableTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733900278256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Promissory Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Promissory notes issued on December 28, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less unamortized discount on notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(408,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember', window );">Promissory Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Promissory notes issued on December 28, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember', window );">Promissory Note Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Promissory notes issued on December 28, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember', window );">Promissory Note Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Promissory notes issued on December 28, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember', window );">Promissory Note Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Promissory notes issued on December 28, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733905847008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Promissory Notes (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember', window );">Promissory Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 28,  2021<span></span>
</td>
<td class="text">Dec. 28,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember', window );">Promissory Note Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  08,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember', window );">Promissory Note Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 11,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember', window );">Promissory Note Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_PromissoryNoteFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733899910400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>May 15, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MediumTermNotes', window );">Term notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtDescription', window );">Term note description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.<span></span>
</td>
<td class="text">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants exercised to payment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(112,797)<span></span>
</td>
<td class="nump">$ 26,685<span></span>
</td>
<td class="num">(94,025)<span></span>
</td>
<td class="num">$ (30,971)<span></span>
</td>
<td class="num">$ (579,146)<span></span>
</td>
<td class="nump">$ 256,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 224,985<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt instrument conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,250<span></span>
</td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesGainLoss', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,625<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 408,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_AccreditedInvestorMember', window );">Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">83.40%<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_UnsecuredPromissoryNotesMember', window );">Unsecured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SHPH_NoteTwoMember', window );">Note Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt remaining amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value at the balance sheet date of a financial instrument used to receive debt funding on a regular basis with original maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information about borrowings which initially required repayment in less than twelve months (or normal operating cycle, if longer) after its issuance and that does not otherwise qualify as long-term debt. It typically is comprised of borrowings under letters of credit, lines of credit, commercial paper, and notes payable of short duration. Disclosures include amounts of borrowings under each arrangement, description of underlying arrangements, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements such as the effects of refinancings and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SHPH_NoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SHPH_NoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733899879600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Sale of Equity or Issued (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,031,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,031,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_NotesPayableMember', window );">Notes Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember', window );">Note Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,267,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_CommonStockPayableMember', window );">Common Stock Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember', window );">Preferred Stock Dividend Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Value
                                            is net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees">1,407,262</span> of fees associated with the issuances.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share">197,273</span> broker warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share">180,280 </span>shares of common stock
                                            and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise">1,409,771 </span>shares of common stock exercised as part of the Company&#8217;s
                                            initial public offering.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock">336,810</span> shares of common stock issued upon conversion of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding">1,213</span> Preferred Shares and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock">100,517</span>
                                            common shares to settle dividends payable balance.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_CommonStockPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_CommonStockPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733904402048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Sale of Equity or Issued (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance fees | $</a></td>
<td class="nump">$ 1,407,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, share</a></td>
<td class="nump">197,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued for common stock, share</a></td>
<td class="nump">180,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of common stock</a></td>
<td class="nump">336,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember', window );">Preferred Stock Dividend Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of common stock</a></td>
<td class="nump">100,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercise</a></td>
<td class="nump">1,409,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">1,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_PreferredStockDividendPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908979824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule Of Stock Options, Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733893912064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,304,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,284,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,532<span></span>
</td>
<td class="nump">48,532<span></span>
</td>
<td class="nump">48,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.98<span></span>
</td>
<td class="nump">$ 24.98<span></span>
</td>
<td class="nump">$ 24.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted Average Remaining Life in Years Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,532)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.98<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,532<span></span>
</td>
<td class="nump">48,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24.98<span></span>
</td>
<td class="nump">$ 24.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life in Years Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants">180,280</span> common stock.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments cancelled in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exexcises in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733908930112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">197,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants</a></td>
<td class="nump">180,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember', window );">Common Stock To Be Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants</a></td>
<td class="nump">180,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733893923456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (RSUs) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercisable</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Option Outstanding, Beginning Balance</a></td>
<td class="nump">59,182<span></span>
</td>
<td class="nump">61,884<span></span>
</td>
<td class="nump">60,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 23.57<span></span>
</td>
<td class="nump">$ 23.76<span></span>
</td>
<td class="nump">$ 24.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Life (Years)</a></td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Option Outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Stock Option Outstanding, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27.76<span></span>
</td>
<td class="nump">$ 27.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Stock Option Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23.76<span></span>
</td>
<td class="nump">22.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (27.76)<span></span>
</td>
<td class="num">$ (27.76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Option Outstanding, Ending Balance</a></td>
<td class="nump">59,182<span></span>
</td>
<td class="nump">59,182<span></span>
</td>
<td class="nump">61,884<span></span>
</td>
<td class="nump">60,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 23.57<span></span>
</td>
<td class="nump">$ 23.57<span></span>
</td>
<td class="nump">$ 23.76<span></span>
</td>
<td class="nump">$ 24.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Stock Option, exercisable</a></td>
<td class="nump">58,813<span></span>
</td>
<td class="nump">43,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercisable</a></td>
<td class="nump">$ 23.74<span></span>
</td>
<td class="nump">$ 23.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable Weighted Average Life (Years)</a></td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733896301088">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Jun. 04, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60<span></span>
</td>
<td class="nump">3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,586,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="nump">9,291,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,031,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise low price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Common stock, Conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Increase in common stock conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,025<span></span>
</td>
<td class="nump">$ 673,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(112,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,025)<span></span>
</td>
<td class="num">$ (30,971)<span></span>
</td>
<td class="num">(579,146)<span></span>
</td>
<td class="nump">256,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,667<span></span>
</td>
<td class="nump">$ 166,533<span></span>
</td>
<td class="nump">$ 166,533<span></span>
</td>
<td class="nump">$ 122,517<span></span>
</td>
<td class="nump">$ 122,517<span></span>
</td>
<td class="nump">$ 122,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,067<span></span>
</td>
<td class="nump">459,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,733<span></span>
</td>
<td class="nump">367,551<span></span>
</td>
<td class="nump">910,067<span></span>
</td>
<td class="nump">459,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.74<span></span>
</td>
<td class="nump">$ 23.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share granted under equity incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,733<span></span>
</td>
<td class="nump">367,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,334<span></span>
</td>
<td class="nump">$ 8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share granted under equity incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,031,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Increase in common stock conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PercentageOfVariableExercisePrice', window );">Percentage of variable exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SHPH_MembershipInterestHoldersMember', window );">Membership Interest Holders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficerMember', window );">Directors And Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,626<span></span>
</td>
<td class="nump">$ 21,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficerMember', window );">Directors And Officer [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,067<span></span>
</td>
<td class="nump">$ 459,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
<td class="nump">7,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,626<span></span>
</td>
<td class="nump">21,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offerings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Purchase up warrants shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DebtInstrumentConvertibleConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember', window );">Common Stock To Be Issued [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted into common stock, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends on preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Dividends total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Commons stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offerings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Common stock, Conversion price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,025<span></span>
</td>
<td class="nump">$ 673,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,025<span></span>
</td>
<td class="nump">$ 30,971<span></span>
</td>
<td class="nump">$ 579,146<span></span>
</td>
<td class="nump">$ 256,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,059<span></span>
</td>
<td class="nump">$ 227,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Value
                                            is net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees">1,407,262</span> of fees associated with the issuances.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DebtInstrumentConvertibleConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DebtInstrumentConvertibleConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PercentageOfVariableExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of variable exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PercentageOfVariableExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_MembershipInterestHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_MembershipInterestHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_CommonStockToBeIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733893987280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (241,948)<span></span>
</td>
<td class="num">$ (21,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,051)<span></span>
</td>
<td class="num">(8,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,381<span></span>
</td>
<td class="nump">19,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,618<span></span>
</td>
<td class="nump">10,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733907107200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operation loss carry forwards</a></td>
<td class="nump">$ 890,970<span></span>
</td>
<td class="nump">$ 587,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">7,479<span></span>
</td>
<td class="nump">8,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">7,788<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest</a></td>
<td class="nump">45,574<span></span>
</td>
<td class="nump">30,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D tax credits</a></td>
<td class="nump">87,801<span></span>
</td>
<td class="nump">87,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
<td class="nump">1,039,612<span></span>
</td>
<td class="nump">721,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(1,039,612)<span></span>
</td>
<td class="num">(721,994)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733906823808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Restated) (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733892070704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">$ 16,548,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,548,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150,867<span></span>
</td>
<td class="nump">$ 2,833,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,143,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,143,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="num">(4,540,236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="nump">70,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,958<span></span>
</td>
<td class="nump">$ 154,886<span></span>
</td>
<td class="nump">684,684<span></span>
</td>
<td class="nump">261,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">821,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,490<span></span>
</td>
<td class="nump">754,453<span></span>
</td>
<td class="nump">1,742,992<span></span>
</td>
<td class="nump">509,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(821,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,813,490)<span></span>
</td>
<td class="num">(754,453)<span></span>
</td>
<td class="num">(1,742,992)<span></span>
</td>
<td class="num">(509,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before Income Taxes</a></td>
<td class="num">(998,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,277,539)<span></span>
</td>
<td class="num">(693,086)<span></span>
</td>
<td class="num">(1,152,134)<span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(998,425)<span></span>
</td>
<td class="num">$ (597,275)<span></span>
</td>
<td class="num">$ (681,839)<span></span>
</td>
<td class="num">(216,961)<span></span>
</td>
<td class="num">$ (346,801)<span></span>
</td>
<td class="num">$ (129,324)<span></span>
</td>
<td class="num">(2,277,539)<span></span>
</td>
<td class="num">(693,086)<span></span>
</td>
<td class="num">(1,152,134)<span></span>
</td>
<td class="num">(805,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,017,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (242,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,348,548)<span></span>
</td>
<td class="num">$ (770,390)<span></span>
</td>
<td class="num">$ (1,255,196)<span></span>
</td>
<td class="num">$ (908,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - basic and diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,733<span></span>
</td>
<td class="nump">$ 367,551<span></span>
</td>
<td class="nump">$ 910,067<span></span>
</td>
<td class="nump">$ 459,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,730,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,375,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,322,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (835,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139733893846080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Financial Statements (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,566<span></span>
</td>
<td class="nump">$ 48,736<span></span>
</td>
<td class="nump">$ 659,958<span></span>
</td>
<td class="nump">$ 154,886<span></span>
</td>
<td class="nump">$ 684,684<span></span>
</td>
<td class="nump">$ 261,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Post reverse split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,733<span></span>
</td>
<td class="nump">$ 367,551<span></span>
</td>
<td class="nump">$ 910,067<span></span>
</td>
<td class="nump">$ 459,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,031,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Post reverse split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument decrease forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,985<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,250<span></span>
</td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DebtInstrumentConvertibleConversionSharesPercentage', window );">Conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentOfInvoice', window );">Value issued</a></td>
<td class="nump">$ 211,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DebtInstrumentConvertibleConversionSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible conversion shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DebtInstrumentConvertibleConversionSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentOfInvoice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of invoice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentOfInvoice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>forms-1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SHPH="http://shuttlepharma.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="shph-20220930.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SHPH:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2016-08-112016-08-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-11</startDate>
            <endDate>2016-08-12</endDate>
        </period>
    </context>
    <context id="From2022-03-282022-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-19</startDate>
            <endDate>2017-09-18</endDate>
        </period>
    </context>
    <context id="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-17</startDate>
            <endDate>2020-09-16</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:OneQuarterlyPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:TwoQuarterlyPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-252022-04-26_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-09-172020-09-16_custom_PhaseIIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-17</startDate>
            <endDate>2020-09-16</endDate>
        </period>
    </context>
    <context id="From2021-11-162021-11-16_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-16</startDate>
            <endDate>2021-11-16</endDate>
        </period>
    </context>
    <context id="From2021-12-022021-12-03_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PhaseIIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-05</startDate>
            <endDate>2018-12-05</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_SubcontractPhaseIIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:SubcontractPhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PhaseIIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:PhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SubcontractPhaseIIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">SHPH:SubcontractPhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SBIRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:SBIRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SBIRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:SBIRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SHPH:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2018-09-292018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2018-09-29</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="From2021-06-212021-06-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-24</startDate>
            <endDate>2018-01-25</endDate>
        </period>
    </context>
    <context id="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-24</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-24</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="From2018-01-242018-01-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2018-01-24</startDate>
            <endDate>2018-01-25</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-04</endDate>
        </period>
    </context>
    <context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-30</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-30</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="From2018-04-032018-04-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-04</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-29</startDate>
            <endDate>2018-05-30</endDate>
        </period>
    </context>
    <context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-30</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-30</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="From2018-05-292018-05-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2018-05-29</startDate>
            <endDate>2018-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-23</startDate>
            <endDate>2019-06-24</endDate>
        </period>
    </context>
    <context id="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-24</endDate>
        </period>
    </context>
    <context id="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-22</startDate>
            <endDate>2019-09-23</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NotesPayableOtherPayablesSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="From2021-03-092021-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="From2020-05-152020-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="From2021-12-282021-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="From2021-12-282021-12-28_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_NoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:NoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2022-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="From2022-02-082022-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="From2022-03-112022-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="From2022-02-082022-02-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="From2022-03-112022-03-11_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PaycheckProtectionProgramNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PromissoryNoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PromissoryNoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PromissoryNoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PromissoryNoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SHPH:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-06-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2018-06-04</instant>
        </period>
    </context>
    <context id="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-04</startDate>
            <endDate>2018-06-04</endDate>
        </period>
    </context>
    <context id="AsOf2018-06-04_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-04</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:MembershipInterestHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="From2019-08-162019-08-16_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_NotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_NoteWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CommonStockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:CommonStockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:PreferredStockDividendPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember52285984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-212022-01-22_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-21</startDate>
            <endDate>2022-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-22_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-22</instant>
        </period>
    </context>
    <context id="AsOf2022-02-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2022-03-11_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="From2022-02-072022-02-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="From2022-03-102022-03-11_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="From2022-03-292022-03-30_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="From2022-04-052022-04-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-09-30">0001757499</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-09-30">false</dei:AmendmentFlag>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0039"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockToBeIssued
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForConversionOfConvertibleDebt
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForDividendPayable
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0823"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0990"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_custom_PromissoryNoteOneMember"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_custom_PromissoryNoteTwoMember"
      id="xdx2ixbrl1080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2021-12-31_custom_PromissoryNoteTwoMember"
      id="xdx2ixbrl1081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_custom_PromissoryNoteThreeMember"
      id="xdx2ixbrl1085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2021-12-31_custom_PromissoryNoteThreeMember"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_custom_PromissoryNoteFourMember"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2021-12-31_custom_PromissoryNoteFourMember"
      id="xdx2ixbrl1091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl1095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl1098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl1101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1265"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1267"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1269"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1271"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1273"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1275"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1283"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1285"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1287"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1289"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1295"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1297"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1299"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1301"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      id="xdx2ixbrl1307"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      id="xdx2ixbrl1309"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1346"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1352"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1354"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1362"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1364"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1366"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1368"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1370"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1372"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:CommodityContractAssetCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl1463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl1464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseCustomerDeposits
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseCustomerDeposits
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1783"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1784"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1870"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember"
      id="xdx2ixbrl2089"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:LoanForgiveness
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl2094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2231"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2233"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2235"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2237"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2239"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2241"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2251"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2253"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2255"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2257"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2259"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2261"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl2269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2295"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2305"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2307"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2315"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2321"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2323"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl2354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl2355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl2381"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-09-30">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-09-30">SHUTTLE PHARMACEUTICALS HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-09-30">82-5089826</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-09-30">One Research Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-09-30">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-09-30">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-09-30">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-09-30">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-09-30">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-09-30">403-4212</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-09-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-09-30">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">9120390</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">504749</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">163142</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4866</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5954</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">9289486</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">509615</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">14080</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18564</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6480</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6480</us-gaap:OtherAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">71970</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">116982</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">9382016</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">651641</us-gaap:Assets>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">107153</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">828313</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">18904</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">552</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">85233</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46947</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">331059</us-gaap:DividendsPayableCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">685473</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">685473</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableToBankCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">91021</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73007</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">73707</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">66934</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">970470</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2217331</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6671</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">62442</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">977141</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2279773</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1212500</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1212500</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">13586393</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">13586393</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">136</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">93</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">16548719</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4150867</us-gaap:AdditionalPaidInCapitalCommonStock>
    <SHPH:CommonStockToBeIssued contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16340</SHPH:CommonStockToBeIssued>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-8143980</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-5795432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">8404875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">9382016</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">651641</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">669038</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">186958</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">1048821</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">579684</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">81864</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">6422</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">104711</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">19883</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">70566</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">48736</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">659958</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">154886</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">821468</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">242116</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">1813490</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">754453</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-821468</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-242116</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-1813490</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-754453</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">13725</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">10547</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">39108</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">31641</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">604716</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">113</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">920660</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">463</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-112797</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">26685</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-94025</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-30971</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">328687</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">328687</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">62500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">73007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">62500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-176957</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">25155</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-464049</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">61367</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-998425</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-216961</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2277539</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-693086</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-998425</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-216961</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2277539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-693086</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">19473</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">25768</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">71009</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">77304</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-1017898</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-242729</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2348548</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-770390</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">10164979</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">9291526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">9723510</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-09-30"
      decimals="INF"
      unitRef="Shares">9298332</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9312152</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4150867</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5795432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">319643</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">319643</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">839</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">-16340</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5104</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">166533</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">166533</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-681839</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-681839</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9318095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4653383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6503039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-1849563</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5104</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">166533</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">166533</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-597275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-597275</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9323199</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4819916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7126082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-2306073</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10031401</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">10031415</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14084</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">14098</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">92598</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">92598</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">147500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">588523</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">147500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">588523</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">857780</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">576467</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">576476</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1045</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">23667</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">23667</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">19473</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">19473</us-gaap:DividendsPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">-1213</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">437327</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">402064</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">402068</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-998425</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-998425</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13586393</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">16548719</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8143980</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">8404875</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9291526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2833507</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4540236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-1690296</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-129324</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-129324</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9291526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2956024</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4695328</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1722871</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7738</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-346801</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-346801</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9299264</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3078541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5067897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-1972923</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9299264</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3078541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5067897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-1972923</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9382</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">122517</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">25768</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-216961</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-216961</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9308646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3201058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5310626</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-2093135</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9308646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3201058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5310626</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-2093135</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2277539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-693086</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">4484</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">4050</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-94025</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-30971</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">45012</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">40408</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">885505</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">328687</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">73007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">62500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-12625</us-gaap:DebtSecuritiesGainLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">356733</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">367551</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">5954</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-211455</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">158276</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-5281</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-392473</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">3646</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">5727</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">270</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">38286</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">31641</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-48998</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-42930</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2030587</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-165185</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">10045513</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">120000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">73007</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">600715</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">10646228</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">193007</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">8615641</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">27822</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">504749</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">117153</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">9120390</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">144975</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">17489</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">293</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockIssued1>
    <SHPH:CommonStockIssuedForConversionOfConvertibleDebt
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">588524</SHPH:CommonStockIssuedForConversionOfConvertibleDebt>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">576476</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonStockIssuedForDividendPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">402067</SHPH:CommonStockIssuedForDividendPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUWPhsGrtOBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span&gt;Organization&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_82F_zvrcvWircP1h" style="display: none"&gt;Organization
and Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Line of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#x201c;Shuttle&#x201d;). In connection with the conversion the Company issued &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkO5fO6ylmb" title="Number of convertible shares issued"&gt;45,000,000&lt;/span&gt; shares of common
stock in exchange for &lt;span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxJA6Qa3Ja8i" title="Sale of stock membership percentage"&gt;100&lt;/span&gt;% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#x201c;Company&#x201d;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#x2019;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#x2019;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#x201c;SBIR&#x201d;) contract provided
by the National Cancer Institute (&#x201c;NCI&#x201d;), a unit of the National Institutes of Health (&#x201c;NIH&#x201d;). Ropidoxuridine
has been further developed though the Company&#x2019;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, the Company has been working on developing products through NIH grants,
including a product to predict late effects of radiation with metabolite biomarkers and develop prostate cancer cell lines in health
disparities research.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
production and marketing of the Company&#x2019;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#x201c;FDA&#x201d;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 1, 2022, we effected a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zSGzuPRKQiHh" title="Reverse stock split"&gt;2-for-1 reverse stock split&lt;/span&gt; of our issued and outstanding shares of common stock (the &#x201c;Reverse Stock
Split&#x201d;). All references to shares of our common stock in this report refers to the number of shares of common stock after giving
effect to the Reverse Stock Split (unless otherwise indicated).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-03-282022-04-02">2-for-1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zh8HybQdj397" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_823_zZWvXrhpJe05"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhSeyCkF9SFi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z0W8FiA8tXZh"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX3kHkk5xqEg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zkpAz40vtY5g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zPEiyQuA66c7"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFFpvu1BVnNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zPpD978nUCdj"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zrejJygRHQC4" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life"&gt;10&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zrSjsjleiadg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqDNlRLgmH2b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zoyPOKzGk12h"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#x201c;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#x2013; Moonshot Project&#x201d; and (2) &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
Contract #HHSN261201600027C/75N91018C00016 supported &#x201c;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#x201d; This $&lt;span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zAX85jorC2o8" title="Proceeds for research and development from collaborators"&gt;299,502&lt;/span&gt; Phase I award includes funded research from September 19, 2016 through September 18, 2017
and was advanced to Phase II of the awards with funding of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zrl1OPzzKA4k" title="Proceeds for research and development from collaborators"&gt;1,903,095&lt;/span&gt; with a fixed price contract period of September 17, 2018 through
September 16, 2020 and subsequent no cost extensions through September 15, 2021 and then March 15, 2022 (Reference 75N91019C00031). The
Company received quarterly payments of $&lt;span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zLUMgHUOD9v2" title="Proceeds from contract awards for research and development"&gt;211,455&lt;/span&gt; for a total of $&lt;span id="xdx_902_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zHVzt4MlVLvc" title="Proceeds from contract awards for research and development"&gt;845,820&lt;/span&gt; in 2020; and 2 quarterly payments related to Topic 345 for a
total of $&lt;span id="xdx_901_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_z5byWYRT12H5" title="Proceeds from contract awards for research and development"&gt;422,910&lt;/span&gt; in 2021. On April 6, 2022, the Company submitted the final invoice for &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects,&#x201d; for $&lt;span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220425__20220426__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zdHXKcE9yNBg" title="Payments to invoices in research and development"&gt;211,455&lt;/span&gt;, following the completion of the Final Quarterly Progress
Report to NIH covering the performance period of September 16, 2019-March 15, 2022. The invoice was paid in full on April 27, 2022. In
Phase II of the SBIR effort, the Company completed an analytical validation of the metabolic test kit, extended the option to license
the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#x201c;kits,&#x201d; test and developed
plans for a multi-institutional clinical trial to be implemented in the Phase III effort. This contract included a subcontract to Georgetown
University (&#x201c;Georgetown&#x201d;) for use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended
to complete the milestones which were delayed due to the impact of COVID-19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 6, 2019, the Company engaged Georgetown to perform the $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZDynIs5qjMc" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt; subcontract of its Phase II contract #HHSN75N91019C00031. The
Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zD1dF4GG7wYc" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt;. Georgetown invoiced the
Company for a total of $&lt;span id="xdx_90E_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zk3255qtn7m3" title="Payments to invoices in research and development"&gt;791,017&lt;/span&gt; as of September 30, 2022, leaving a balance of $&lt;span id="xdx_907_ecustom--AccruedInvestmentIncomeReceivableOutstanding_iI_c20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zbLnUtrmaXe5" title="Research and development invoice receivable, outstanding"&gt;4,231&lt;/span&gt;. Depending on the resources it uses, Georgetown
may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable amount, the
Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $&lt;span id="xdx_902_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220401__20220430_zE9fjBl3FtLl" title="Payments to invoices in research and development"&gt;791,017&lt;/span&gt; were made to Georgetown, including
an additional invoice for $&lt;span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220701__20220930_zPTpk6s8LFmj" title="Payments to invoices in research and development"&gt;282,643&lt;/span&gt; which was received but not paid until the second quarter of 2022. All invoices have now been paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#x201c;Topic 352 &#x2013;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#x201d; and was awarded to provide $&lt;span id="xdx_90A_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zanyYyghAh34" title="Proceeds from contract awards for research and development"&gt;1,484,350&lt;/span&gt; to fund research
from September 17, 2018 through September 16, 2020 and was extended without cost through November 16, 2021 due to delays caused by the
impact of COVID-19. For the entire contract period, the Company invoiced and received a total of $&lt;span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211116__20211116__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVAJShB1sPPd" title="Payments to invoices in research and development"&gt;1,411,883&lt;/span&gt;. The final draft report was
filed with the NIH along with the final invoice for $&lt;span id="xdx_90B_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211202__20211203__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfrcR6AlrTFj" title="Payments to invoices in research and development"&gt;10,000&lt;/span&gt;, which payment was made on December 3, 2021, and no additional payments are
expected. The Phase II contract also includes a subcontract to Georgetown University for $&lt;span id="xdx_906_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zeOLO5T65Yv7" title="Business development new establishment"&gt;742,002&lt;/span&gt; to establish prostate cancer cell lines
from African American patients undergoing prostate surgery for cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2018, the Company engaged Georgetown University to perform the $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z2CdTdQbva21" title="Proceeds for research and development from collaborators"&gt;742,002&lt;/span&gt; subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $&lt;span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zMG2pQQCfA07" title="Payments to invoices in research and development"&gt;305,866&lt;/span&gt; as of September 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the quarter ended September 30, 2022, the Company recorded a
net deficit of $&lt;span id="xdx_90C_ecustom--ResearchAndDevelopmentDeficitNet_c20220101__20220930_zoT3CbZyLPwk" title="Net deficit on research and development"&gt;83,868&lt;/span&gt; with the Company funding the NIH no-cost extension along with other R&amp;amp;D activities. The NIH made the final
payment of $&lt;span id="xdx_90F_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zor9EaiE5Fu5" title="Payments to invoices in research and development"&gt;211,455&lt;/span&gt; in April 2022 for Topic 345.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September of 2022, TCG GreenChem, Inc. (&#x201c;TCG GreenChem&#x201d;) was contracted for process research, development and cGMP compliant
manufacture of IPdR. The total project cost is $&lt;span id="xdx_90C_eus-gaap--CapitalizedContractCostNet_iI_c20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_z0ryukO7eiIc" title="Project cost"&gt;1,500,000&lt;/span&gt; based on four milestone payments, the first payment of $&lt;span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zYKX6wr2MDMh" title="Payments to invoices in research and development"&gt;450,000&lt;/span&gt; was paid during
the quarter ended September 30, 2022, pursuant to which TCG GreenChem commenced work on the project.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#x2013; a reduction of costs, a deferred
credit to be amortized, revenue or other income. Due to the terms of the contracts we have entered into, the Company concluded that the
reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zPlBfuV8LKl9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_za7MJc2KLRf"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of September 30, 2022, the Company had no derivative instruments. As of December 31, 2021
the Company&#x2019;s only derivative financial instrument was an embedded warrant feature associated with its Series A Convertible Preferred
Stock due to certain provisions that allow for a change in the warrant value based on fluctuations of the Company&#x2019;s fair value
of common stock at the date of issuance of the warrant based on certain contingent call features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVgFsM34CXt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zOeVLCJpuOoc"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and FASB ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
established trading market for the Company&#x2019;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company utilized $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GTWgulRiA7" title="Share price"&gt;25.22 &lt;/span&gt;(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FYyHnhqDba" title="Share price"&gt;5.00&lt;/span&gt; in 2021, $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLPlikArwB8" title="Share price"&gt;4.00&lt;/span&gt; through March 31, 2022 and $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUXJKtHAQEP7" title="Share price"&gt;6.00 &lt;/span&gt;through June 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2022, the Company identified &lt;span id="xdx_904_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_do_c20220930_zygmAQg0VFEb" title="Financial liabilities fair value"&gt;no&lt;/span&gt; liabilities required to be presented on the balance sheet at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGngUoQuWHod" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Warrant Liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zsd9NRdAjIL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSMPJgjkKtRe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zGDBm12N3Bgh"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from providing research and development is recognized under &lt;i&gt;Topic 606&lt;/i&gt; in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;executed
    contracts with the Company&#x2019;s customers that it believes are legally enforceable;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification
    of performance obligations in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determination
    of the transaction price for each performance obligation in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocation
    the transaction price to each performance obligation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognition
    of revenue only when the Company satisfies each performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from NIH contracts is received in accordance with Federal grants and contracts policies. Research and development expenses
are posted against revenue and recorded on the statement of operations as &#x201c;Research and development, net of contract expense reimbursements.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zcExFdFHdFK3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z6PnT83yyhM"&gt;Basic
and Diluted Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share (&#x201c;EPS&#x201d;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
shares of common stock outstanding during the period using the treasury stock method and as if converted method. Dilutive potential shares
of common stock include outstanding warrants and Series A preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu2C2gyHdXxj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Anti dilutive securities excluded from
    computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zXv2XedQLmv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9PcSCc4vTKf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z0Lznkh5Cw24"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#x201c;Debt&#x2014;Debt with &#x201c;Conversion and Other Options&#x201d;
and ASC subtopic 815-40 &#x201c;Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity.&#x201d; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_855_zOFftms3vb0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhSeyCkF9SFi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z0W8FiA8tXZh"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX3kHkk5xqEg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zkpAz40vtY5g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"/&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zPEiyQuA66c7"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFFpvu1BVnNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zPpD978nUCdj"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zrejJygRHQC4" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life"&gt;10&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zrSjsjleiadg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89C_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zuAs3MB2DJF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zrejJygRHQC4" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaYBBgBnVnJk" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zC70WInU1Ywh" title="Property plant and equipment useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zTeOVBo65OE6" title="Property plant and equipment useful life"&gt;10&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_us-gaap_ComputerEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_us-gaap_EquipmentMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqDNlRLgmH2b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zoyPOKzGk12h"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#x201c;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#x2013; Moonshot Project&#x201d; and (2) &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
Contract #HHSN261201600027C/75N91018C00016 supported &#x201c;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#x201d; This $&lt;span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zAX85jorC2o8" title="Proceeds for research and development from collaborators"&gt;299,502&lt;/span&gt; Phase I award includes funded research from September 19, 2016 through September 18, 2017
and was advanced to Phase II of the awards with funding of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zrl1OPzzKA4k" title="Proceeds for research and development from collaborators"&gt;1,903,095&lt;/span&gt; with a fixed price contract period of September 17, 2018 through
September 16, 2020 and subsequent no cost extensions through September 15, 2021 and then March 15, 2022 (Reference 75N91019C00031). The
Company received quarterly payments of $&lt;span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zLUMgHUOD9v2" title="Proceeds from contract awards for research and development"&gt;211,455&lt;/span&gt; for a total of $&lt;span id="xdx_902_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zHVzt4MlVLvc" title="Proceeds from contract awards for research and development"&gt;845,820&lt;/span&gt; in 2020; and 2 quarterly payments related to Topic 345 for a
total of $&lt;span id="xdx_901_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_z5byWYRT12H5" title="Proceeds from contract awards for research and development"&gt;422,910&lt;/span&gt; in 2021. On April 6, 2022, the Company submitted the final invoice for &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects,&#x201d; for $&lt;span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220425__20220426__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zdHXKcE9yNBg" title="Payments to invoices in research and development"&gt;211,455&lt;/span&gt;, following the completion of the Final Quarterly Progress
Report to NIH covering the performance period of September 16, 2019-March 15, 2022. The invoice was paid in full on April 27, 2022. In
Phase II of the SBIR effort, the Company completed an analytical validation of the metabolic test kit, extended the option to license
the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#x201c;kits,&#x201d; test and developed
plans for a multi-institutional clinical trial to be implemented in the Phase III effort. This contract included a subcontract to Georgetown
University (&#x201c;Georgetown&#x201d;) for use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended
to complete the milestones which were delayed due to the impact of COVID-19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 6, 2019, the Company engaged Georgetown to perform the $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZDynIs5qjMc" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt; subcontract of its Phase II contract #HHSN75N91019C00031. The
Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zD1dF4GG7wYc" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt;. Georgetown invoiced the
Company for a total of $&lt;span id="xdx_90E_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zk3255qtn7m3" title="Payments to invoices in research and development"&gt;791,017&lt;/span&gt; as of September 30, 2022, leaving a balance of $&lt;span id="xdx_907_ecustom--AccruedInvestmentIncomeReceivableOutstanding_iI_c20220930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zbLnUtrmaXe5" title="Research and development invoice receivable, outstanding"&gt;4,231&lt;/span&gt;. Depending on the resources it uses, Georgetown
may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable amount, the
Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $&lt;span id="xdx_902_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220401__20220430_zE9fjBl3FtLl" title="Payments to invoices in research and development"&gt;791,017&lt;/span&gt; were made to Georgetown, including
an additional invoice for $&lt;span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220701__20220930_zPTpk6s8LFmj" title="Payments to invoices in research and development"&gt;282,643&lt;/span&gt; which was received but not paid until the second quarter of 2022. All invoices have now been paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#x201c;Topic 352 &#x2013;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#x201d; and was awarded to provide $&lt;span id="xdx_90A_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zanyYyghAh34" title="Proceeds from contract awards for research and development"&gt;1,484,350&lt;/span&gt; to fund research
from September 17, 2018 through September 16, 2020 and was extended without cost through November 16, 2021 due to delays caused by the
impact of COVID-19. For the entire contract period, the Company invoiced and received a total of $&lt;span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211116__20211116__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVAJShB1sPPd" title="Payments to invoices in research and development"&gt;1,411,883&lt;/span&gt;. The final draft report was
filed with the NIH along with the final invoice for $&lt;span id="xdx_90B_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211202__20211203__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfrcR6AlrTFj" title="Payments to invoices in research and development"&gt;10,000&lt;/span&gt;, which payment was made on December 3, 2021, and no additional payments are
expected. The Phase II contract also includes a subcontract to Georgetown University for $&lt;span id="xdx_906_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zeOLO5T65Yv7" title="Business development new establishment"&gt;742,002&lt;/span&gt; to establish prostate cancer cell lines
from African American patients undergoing prostate surgery for cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2018, the Company engaged Georgetown University to perform the $&lt;span id="xdx_906_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z2CdTdQbva21" title="Proceeds for research and development from collaborators"&gt;742,002&lt;/span&gt; subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $&lt;span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zMG2pQQCfA07" title="Payments to invoices in research and development"&gt;305,866&lt;/span&gt; as of September 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the quarter ended September 30, 2022, the Company recorded a
net deficit of $&lt;span id="xdx_90C_ecustom--ResearchAndDevelopmentDeficitNet_c20220101__20220930_zoT3CbZyLPwk" title="Net deficit on research and development"&gt;83,868&lt;/span&gt; with the Company funding the NIH no-cost extension along with other R&amp;amp;D activities. The NIH made the final
payment of $&lt;span id="xdx_90F_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zor9EaiE5Fu5" title="Payments to invoices in research and development"&gt;211,455&lt;/span&gt; in April 2022 for Topic 345.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September of 2022, TCG GreenChem, Inc. (&#x201c;TCG GreenChem&#x201d;) was contracted for process research, development and cGMP compliant
manufacture of IPdR. The total project cost is $&lt;span id="xdx_90C_eus-gaap--CapitalizedContractCostNet_iI_c20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_z0ryukO7eiIc" title="Project cost"&gt;1,500,000&lt;/span&gt; based on four milestone payments, the first payment of $&lt;span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20220930__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zYKX6wr2MDMh" title="Payments to invoices in research and development"&gt;450,000&lt;/span&gt; was paid during
the quarter ended September 30, 2022, pursuant to which TCG GreenChem commenced work on the project.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#x2013; a reduction of costs, a deferred
credit to be amortized, revenue or other income. Due to the terms of the contracts we have entered into, the Company concluded that the
reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">299502</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">1903095</us-gaap:ProceedsFromCollaborators>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember"
      decimals="0"
      unitRef="USD">211455</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">845820</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember"
      decimals="0"
      unitRef="USD">422910</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-04-252022-04-26_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">211455</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">795248</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">795248</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">791017</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:AccruedInvestmentIncomeReceivableOutstanding
      contextRef="AsOf2022-09-30_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">4231</SHPH:AccruedInvestmentIncomeReceivableOutstanding>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-04-012022-04-30"
      decimals="0"
      unitRef="USD">791017</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">282643</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-09-172020-09-16_custom_PhaseIIMember"
      decimals="0"
      unitRef="USD">1484350</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2021-11-162021-11-16_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1411883</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2021-12-022021-12-03_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">10000</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2021-01-012021-12-31_custom_PhaseIIMember"
      decimals="0"
      unitRef="USD">742002</us-gaap:BusinessDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">742002</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-09-30_custom_SubcontractPhaseIIMember"
      decimals="0"
      unitRef="USD">305866</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:ResearchAndDevelopmentDeficitNet
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">83868</SHPH:ResearchAndDevelopmentDeficitNet>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-09-30_custom_PhaseIIMember"
      decimals="0"
      unitRef="USD">211455</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2022-09-30_custom_TCGGreenChemIncMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:CapitalizedContractCostNet>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-09-30_custom_TCGGreenChemIncMember"
      decimals="0"
      unitRef="USD">450000</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zPlBfuV8LKl9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_za7MJc2KLRf"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of September 30, 2022, the Company had no derivative instruments. As of December 31, 2021
the Company&#x2019;s only derivative financial instrument was an embedded warrant feature associated with its Series A Convertible Preferred
Stock due to certain provisions that allow for a change in the warrant value based on fluctuations of the Company&#x2019;s fair value
of common stock at the date of issuance of the warrant based on certain contingent call features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVgFsM34CXt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zOeVLCJpuOoc"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and FASB ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
established trading market for the Company&#x2019;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company utilized $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GTWgulRiA7" title="Share price"&gt;25.22 &lt;/span&gt;(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FYyHnhqDba" title="Share price"&gt;5.00&lt;/span&gt; in 2021, $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLPlikArwB8" title="Share price"&gt;4.00&lt;/span&gt; through March 31, 2022 and $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUXJKtHAQEP7" title="Share price"&gt;6.00 &lt;/span&gt;through June 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2022, the Company identified &lt;span id="xdx_904_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_do_c20220930_zygmAQg0VFEb" title="Financial liabilities fair value"&gt;no&lt;/span&gt; liabilities required to be presented on the balance sheet at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGngUoQuWHod" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Warrant Liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zsd9NRdAjIL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">25.22</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zDAl34hW7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zGngUoQuWHod" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrkIgUG3xWEi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcmkjHChhcv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw7gllJtMcf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zL2j3vM3T0r2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zII3YXD1Bdse" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Warrant Liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSMPJgjkKtRe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zGDBm12N3Bgh"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from providing research and development is recognized under &lt;i&gt;Topic 606&lt;/i&gt; in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;executed
    contracts with the Company&#x2019;s customers that it believes are legally enforceable;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification
    of performance obligations in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determination
    of the transaction price for each performance obligation in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocation
    the transaction price to each performance obligation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognition
    of revenue only when the Company satisfies each performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from NIH contracts is received in accordance with Federal grants and contracts policies. Research and development expenses
are posted against revenue and recorded on the statement of operations as &#x201c;Research and development, net of contract expense reimbursements.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zcExFdFHdFK3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z6PnT83yyhM"&gt;Basic
and Diluted Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share (&#x201c;EPS&#x201d;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
shares of common stock outstanding during the period using the treasury stock method and as if converted method. Dilutive potential shares
of common stock include outstanding warrants and Series A preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu2C2gyHdXxj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Anti dilutive securities excluded from
    computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zXv2XedQLmv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znLEUApGv0Zc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from
the computation of diluted net loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zu2C2gyHdXxj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220930_zXH2zRI9VAW2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zrXusRHDnfXf" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zdlB2SaSzU19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoknrc1qtBT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zj74MWgB5LZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Anti dilutive securities excluded from
    computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">97062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">145594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9PcSCc4vTKf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z0Lznkh5Cw24"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#x201c;Debt&#x2014;Debt with &#x201c;Conversion and Other Options&#x201d;
and ASC subtopic 815-40 &#x201c;Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity.&#x201d; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxAmmBNyUPr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_820_zzo393qkBFad"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHw4g6hhBnUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zgIcSqP1GQel" style="display: none"&gt;Schedule
of Property and Equipment Net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220930_zIuASPNq3qll" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zr4QYBfzAWEd" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zU5MxQUAw8E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zwWSOCdm4pAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzwPA_zbpLEntztHr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzwPA_zk6WVvG8Nbf5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzwPA_zAsg6aOTm5zl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,080&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zPydfRBEeKO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the nine months ended September 30, 2022 and 2021, were $&lt;span id="xdx_908_eus-gaap--Depreciation_c20220101__20220930_pp0p0" title="Depreciation expense"&gt;4,484&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20210101__20210930_pp0p0" title="Depreciation expense"&gt;4,050&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHw4g6hhBnUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zgIcSqP1GQel" style="display: none"&gt;Schedule
of Property and Equipment Net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220930_zIuASPNq3qll" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zr4QYBfzAWEd" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zU5MxQUAw8E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zwWSOCdm4pAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzwPA_zbpLEntztHr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzwPA_zk6WVvG8Nbf5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzwPA_zAsg6aOTm5zl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,080&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-09-30_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">8861</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">8861</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-09-30_custom_LaboratoryEquipmentMember"
      decimals="0"
      unitRef="USD">118605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember"
      decimals="0"
      unitRef="USD">118605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">127466</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">127466</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">113386</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">108902</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">14080</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18564</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">4484</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">4050</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zuv0V6rq4jj3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_825_zMjBSD57lQej"&gt;Operating Lease Right-of-use Asset and Operating Lease Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. &lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20220101__20220930_zIbc0fPlyQ28" title="Interest rate used to lease, description"&gt;The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.&lt;/span&gt; Operating lease expense is recognized on a straight-line basis over the lease
term. During the nine months ended September 30 2022, and 2021, the Company recorded $&lt;span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20220101__20220930_zPsAhOsQYJ41" title="Operating lease expense"&gt;52,631 &lt;/span&gt;and $&lt;span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20210101__20210930_zEQJOlnYwN2" title="Operating lease expense"&gt;52,445&lt;/span&gt;, respectively, as operating
lease expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $&lt;span id="xdx_90F_ecustom--OperatingLeasePayment_c20180929__20181001_zHIwK06J5LAa" title="Lease payment"&gt;6,291&lt;/span&gt;, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on &lt;span id="xdx_906_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zGzBQnCk7Hd9" title="Operating lease expiration date"&gt;October 31, 2023&lt;/span&gt;. A security deposit of $&lt;span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zSUIHXH46n4h" title="Security deposit"&gt;6,480&lt;/span&gt; is being held for the duration of the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#x2018;package of practical expedients,&#x2019; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of &lt;span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20220930_zyxAeXkmYHJl" title="Lease term"&gt;12&lt;/span&gt;
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zWm8Fs7Ed7R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Right-of-use assets are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zAImY9PDHMUg" style="display: none"&gt;Schedule of Operating Lease Right of Use Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220930_z1midZtHPzW3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zAPSmuBNbsTj" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfficeLease_iI_zj9387NWMqbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_ztbnQ85VGf8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(193,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zYVRdiQfZ24a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;71,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zyzsMs5EExFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
on the right-of-use asset is included in rent expense on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zxqoKB1Dwu8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zH01tCtnTGW9" style="display: none"&gt;Schedule
of Operating
Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220930_zOkTDA3D9pE3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zf8g6zEjZ5V8" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zPgpaBsyNEYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;80,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zuhPVK1tOQza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,934&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF267iEwqDW" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zgOSKTLN20g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI3LHmxEst4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Maturities of lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zeTus9Yk7gqg" style="display: none"&gt;Schedule Of Operating Lease Maturity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220930_zdlre74HLWW3" style="text-align: center"&gt;As of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz4Xq_zApK0lBgQLz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 75%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;19,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz4Xq_ztBHxWzLa5Da" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz4Xq_zmHWBOXUo113" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNs3XD3FUEd1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zCqRaCFYxwo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left"&gt;PV of Payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;80,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z8DNgHe4XlDi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription contextRef="From2022-01-01to2022-09-30">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">52631</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">52445</us-gaap:OperatingLeaseExpense>
    <SHPH:OperatingLeasePayment
      contextRef="From2018-09-292018-10-01"
      decimals="0"
      unitRef="USD">6291</SHPH:OperatingLeasePayment>
    <us-gaap:LeaseExpirationDate1 contextRef="From2018-09-292018-10-01">2023-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:SecurityDeposit contextRef="AsOf2018-10-01" decimals="0" unitRef="USD">6480</us-gaap:SecurityDeposit>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="AsOf2022-09-30">P12M</us-gaap:LessorOperatingLeaseTermOfContract>
    <SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_898_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zWm8Fs7Ed7R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Right-of-use assets are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zAImY9PDHMUg" style="display: none"&gt;Schedule of Operating Lease Right of Use Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220930_z1midZtHPzW3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zAPSmuBNbsTj" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfficeLease_iI_zj9387NWMqbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_ztbnQ85VGf8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(193,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zYVRdiQfZ24a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;71,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock>
    <SHPH:OfficeLease contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">265207</SHPH:OfficeLease>
    <SHPH:OfficeLease contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">265207</SHPH:OfficeLease>
    <SHPH:AccumulatedAmortizationOnRightOfUseAssets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">193237</SHPH:AccumulatedAmortizationOnRightOfUseAssets>
    <SHPH:AccumulatedAmortizationOnRightOfUseAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">148225</SHPH:AccumulatedAmortizationOnRightOfUseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">71970</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">116982</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zxqoKB1Dwu8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zH01tCtnTGW9" style="display: none"&gt;Schedule
of Operating
Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220930_zOkTDA3D9pE3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zf8g6zEjZ5V8" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zPgpaBsyNEYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;80,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zuhPVK1tOQza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,934&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF267iEwqDW" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">80378</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">129376</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">73707</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">66934</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6671</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">62442</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI3LHmxEst4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Maturities of lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zeTus9Yk7gqg" style="display: none"&gt;Schedule Of Operating Lease Maturity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220930_zdlre74HLWW3" style="text-align: center"&gt;As of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz4Xq_zApK0lBgQLz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 75%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;19,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz4Xq_ztBHxWzLa5Da" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz4Xq_zmHWBOXUo113" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNs3XD3FUEd1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zCqRaCFYxwo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left"&gt;PV of Payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;80,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">19440</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">64800</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">84240</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3862</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">80378</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaMZoFHT4i5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_826_zfGWuPdewMyh"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $&lt;span id="xdx_90C_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZOFY1AwSQg1" title="Notes payable related party debt principal balance"&gt;426,243&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCy9ehTHkvwa" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum, with a maturity date of &lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zRLDPj45LaN3" title="Notes payable related party maturity date"&gt;December 31, 2021&lt;/span&gt;; and (ii) a single loan
owed to an officer of the company in the principal amount of $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zzor0xXKoNrk" title="Notes payable related party debt principal balance"&gt;139,229&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z486baGpwzp3" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum, with a maturity
date of &lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zYNOE6FGcfVe" title="Notes payable related party maturity date"&gt;December 31, 2021&lt;/span&gt;. &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211230_z0tSNlGSIn2d" title="Debt maturity, description"&gt;In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the
notes were extended to June 30, 2023&lt;/span&gt; (Note 8). As of September 30, 2022, the accrued interest was $&lt;span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zmlntEGsiPUd"&gt;55,592&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zlw8S2lqMxM9"&gt;18,150&lt;/span&gt;, respectively,
and the total balances with accrued interest of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwYaXOagoI5" title="Notes payable related party debt plus accrued interest"&gt;481,835&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zsYOz269cZih" title="Notes payable related party debt plus accrued interest"&gt;157,379&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zN6ODjJNjKrh" title="Notes payable related party debt principal balance"&gt;120,000&lt;/span&gt; (principal) with
an interest rate of &lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWb90yOLkMD7" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum due &lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zZ5YMQoAWv1e" title="Notes payable related party maturity date"&gt;June 21, 2022&lt;/span&gt;, due at maturity. &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20210621__20210621_ziq4T2WoR643" title="Debt maturity, description"&gt;In July of 2022 the notes were extended to June 30, 2023&lt;/span&gt; (Note
8). As of September 30, 2022, the accrued interest was $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ze5eZcGl12lb" title="Accrued interest"&gt;11,491&lt;/span&gt; and the total balance with accrued interest was $&lt;span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zc88cZ7OnoLl" title="Notes payable related party debt plus accrued interest"&gt;131,491&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2022, in conjunction with a private placement of 10% notes and warrants (as detailed in Note 6 below), in exchange for a $&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zBRBBQsMjfI5" title="Notes payable related party debt principal balance"&gt;50,000&lt;/span&gt;
payment upon subscription, the Company issued a note to the spouse of an officer of the Company in the amount of $&lt;span id="xdx_90B_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zEG3d94KjpQc" title="Notes issued"&gt;50,000&lt;/span&gt; (principal)
with an interest rate of &lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zQQSHlaQcnn4" title="Notes payable related party transaction rate"&gt;10&lt;/span&gt;% per annum due &lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionDate_dd_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zag9YEyK59ji" title="Notes payable related party maturity date"&gt;August 31, 2022&lt;/span&gt;, with interest due at maturity, and warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zzynqJftCic3" title="Warrants to purchase of common stock"&gt;20,000&lt;/span&gt; shares of
common stock, at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_ziRlJzGF9Ht7" title="Exercise price of warrants"&gt;2.50&lt;/span&gt; per share. The value of the warrants was determined using a computed volatility of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zuCupUQpvt75" title="Volatility rate"&gt;101&lt;/span&gt;%,
&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zsOSczY4n4h9" title="Dividend rate"&gt;0&lt;/span&gt;% dividend rate, and a risk free interest rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zdp2m5tb6USa" title="Risk free interest rate"&gt;4.25&lt;/span&gt;%, and was applied as a discount on the notes payable. The loan was fully repaid
including $&lt;span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zLnGUxarbx43" title="Repayments of accrued interest"&gt;822&lt;/span&gt; of accrued interest in September of 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SHPH:RelatedPartyTransactionAmountsOfTransactions
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">426243</SHPH:RelatedPartyTransactionAmountsOfTransactions>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">139229</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2021-12-012021-12-30">In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the
notes were extended to June 30, 2023</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-09-30_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">55592</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-09-30_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">18150</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">481835</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2022-01-012022-09-30_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">157379</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember">2022-06-21</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2021-06-212021-06-21">In July of 2022 the notes were extended to June 30, 2023</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">11491</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">131491</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:NotesIssued1
      contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:NotesIssued1>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember">2022-08-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-08-01_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="USDPShares">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-09-30_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">822</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_ztol0MmZp7kf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 - &lt;span id="xdx_826_zd1TOgmUHXV6"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 9, 2021, the Company obtained a $&lt;span id="xdx_908_eus-gaap--MediumTermNotes_iI_c20210309_zNsNktLppFdg" title="Term notes issued"&gt;73,007&lt;/span&gt; term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#x2019;s Paycheck
Protection Program (the &#x201c;PPP&#x201d;). The note bears an interest rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zlZhTSb6ols2" title="Interest rate"&gt;1&lt;/span&gt;% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#x2019;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. &lt;span id="xdx_901_eus-gaap--ShortTermDebtDescription_c20210309__20210309_z3rNThwCFcHg" title="Term note description"&gt;No more than 25% of the amount forgiven can be attributable
to non-payroll costs.&lt;/span&gt; As of December 31, 2021, a &#x201c;Loan Forgiveness Application&#x201d; was submitted to PNC Bank along with the
requested documentation and during the quarter ended March 31, 2022 the note liability was reduced in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2020, the Company obtained a $&lt;span id="xdx_90C_eus-gaap--MediumTermNotes_iI_c20200515_zI4nrf1tdYpk" title="Term notes issued"&gt;62,500&lt;/span&gt; term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#x2019;s Paycheck
Protection Program (the &#x201c;PPP&#x201d;). The note bears an interest rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_z3dN2O76sNLk" title="Interest rate"&gt;1&lt;/span&gt;% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#x2019;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. &lt;span id="xdx_903_eus-gaap--ShortTermDebtDescription_c20200515__20200515_zF98mIUB8pni" title="Term note description"&gt;No more than 25% of the amount forgiven can be attributable
to non-payroll costs.&lt;/span&gt; A &#x201c;Loan Forgiveness Application&#x201d; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zBuehpHgeOmh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span id="xdx_8B7_zh3WL2OqTeea" style="display: none"&gt;Schedule
of Notes Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220930_zCOLUnMIYUub" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zhTWY6hOtPcj" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;PPP Note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zV3AXygSN6yh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zLqQeYshslhh" title="Debt maturity date"&gt;May 15, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zgEHevVdpow9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zyRSdphG0GA7" title="Debt maturity date"&gt;March 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LoanForgiveness_iI_zyqQSYNNAWZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_zSmWxVZcgvbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zv7ZlW0MOIk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2021, the Company issued $&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_c20211228_znE5S8lRaJTi" title="Notes payable"&gt;500,000&lt;/span&gt; note units, consisting of two $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zbghPOeTdQW7" title="Notes payable"&gt;250,000&lt;/span&gt; notes, for a total of $&lt;span id="xdx_90B_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zmc9hJwVpeKb" title="Notes payable"&gt;500,000&lt;/span&gt; &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_z1pVK4Psebo9" title="Interest rate"&gt;10&lt;/span&gt;% unsecured promissory
notes with a maturity date of &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_zCZuBWQ4Wiuh" title="Debt maturity date"&gt;December 28, 2022&lt;/span&gt;, and warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zlUonDf1vJfd" title="Warrants to purchase of common stock"&gt;500,000&lt;/span&gt; shares of common stock exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zaxpfbxbx4D8" title="Exercise price of warrants"&gt;1.00&lt;/span&gt; per share
with an expiry date of December 28, 2026, and fees of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zi4Ukw48HLJ2" title="Debt fee amount"&gt;5,075&lt;/span&gt;. The value of the warrants was determined using a computed volatility of
&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxiYBqqVCKba" title="Volatility rate"&gt;85.5&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IYQPeqxcAa" title="Dividend rate"&gt;0&lt;/span&gt;% dividend rate, and a risk free interest rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqPoFqdf29rk" title="Risk free interest rate"&gt;1.27&lt;/span&gt;% and was applied as a discount on the notes payable. In September 2022,
the warrants were exercised fully reducing the principal and the Company paid $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20211228__20211228_zP4GuXcpTjIj" title="Warrants exercised to payment of debt"&gt;16,667&lt;/span&gt; of interest in cash. As of September 30, 2022,
$&lt;span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--NoteTwoMember_zhv9jfCzr4ue" title="Accrued interest payable"&gt;18,904&lt;/span&gt; of accrued interest is payable on the second note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2022 and March 11, 2022, the Company sold $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220208_zaZ8Z5J146o" title="Convertible notes payable"&gt;365,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220311_z1bi1WgRaY9k" title="Convertible notes payable"&gt;224,985&lt;/span&gt;, respectively, in &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208_zOOSldRDENG8" title="Interest rate"&gt;6&lt;/span&gt;% convertible notes (the &#x201c;Notes&#x201d;),
which notes bore &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311_zlGt98vomy9c" title="Interest rate"&gt;6&lt;/span&gt;% interest, were repayable three years from the date of issuance, and, upon completion of the Company&#x2019;s initial
public offering, converted automatically into units, with each unit consisting of one share of common stock and a warrant to purchase
one share of commons stock (the &#x201c;Conversion Units&#x201d;) at a conversion price equal to &lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208_zEMYxukktWoh" title="Debt instrument conversion rate"&gt;&lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311_z0awGhG58UX8" title="Debt instrument conversion rate"&gt;50&lt;/span&gt;&lt;/span&gt;% of the per unit offering price upon
closing of our initial public offering. Boustead Securities LLC acted as placement agent for the convertible note offering and received
compensation of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20220208__20220208_zoUoxSp0kmO6" title="Proceeds from convertible notes payable"&gt;36,500&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220311__20220311_zliJ0BM2kW3f" title="Proceeds from convertible notes payable"&gt;22,250&lt;/span&gt;, respectively, and warrants to purchase shares of common stock equal to 10% of the Conversion Units,
exercisable at the conversion price of the Convertible Notes. The value of the warrants was determined using computed volatility of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0ifbTPrWJ64" title="Volatility rate"&gt;83.4&lt;/span&gt;%,
&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY9QrLuU5egl" title="Dividend rate"&gt;0&lt;/span&gt;% dividend rate, and a risk free interest rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220208__20220208__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdYbIRrp4jI9" title="Risk free interest rate"&gt;1.27&lt;/span&gt;%, and computed volatility of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze5AjFzg6tU4" title="Volatility rate"&gt;85.5&lt;/span&gt;% %, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGEOPUhsgM2f" title="Dividend rate"&gt;0&lt;/span&gt;% dividend rate, and a risk free interest
rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220311__20220311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEW2I5goaJ04" title="Risk free interest rate"&gt;1.96&lt;/span&gt;%, and was applied as a discount on the notes payable. In September 2022, the notes were fully converted,  relieving the
Company of $&lt;span id="xdx_906_eus-gaap--DebtSecuritiesGainLoss_iN_di_c20220101__20220930_zftj2yXZnIh6" title="Gain on interest relief on conversion of notes payable"&gt;12,625&lt;/span&gt; of accrued interest recorded as a gain on settlement of debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2022, the Company issued $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20220801_zB7CTt40IFq1" title="Convertible notes payable"&gt;125,000&lt;/span&gt;
in &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801_zzvCTmDcnWj3" title="Interest rate"&gt;10&lt;/span&gt;%
convertible notes payable and warrants to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zNOFTL3lMIHi" title="Warrants to purchase of common stock"&gt;50,000&lt;/span&gt;
shares of common stock to three accredited investors (which amount includes the $&lt;span id="xdx_90A_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zCc08vTUCt65" title="Notes issued"&gt;50,000&lt;/span&gt;
note and warrant purchased by a related party as detailed in Note 5 above). The warrants issued in this transaction were exercisable
at price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zEWdjNy4L0df" title="Exercise price"&gt;2.50&lt;/span&gt; per share. The value of the warrants was
determined using a computed volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbl3f0ru4UCh" title="Volatility rate"&gt;101&lt;/span&gt;%, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zZzDMYWjaf9i" title="Dividend rate"&gt;0&lt;/span&gt;%
dividend rate, and a risk free interest rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zbdAG69gbbfd" title="Risk free interest rate"&gt;4.25&lt;/span&gt;%
and was applied as a discount on the notes payable. In September 2022, &lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220901__20220930_zakHV9tn7kV2" title="Warrants exercised to payment of debt"&gt;30,000&lt;/span&gt;
warrants were exercised in exchange for cancellation of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7HMePc1r7oh" title="Debt forgiveness"&gt;75,000&lt;/span&gt; in notes, thus reducing $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_znfSheCRRF33" title="Repayments of notes payable"&gt;75,000&lt;/span&gt;
of the principal. The remaining $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zv2sMilMt14a" title="Debt remaining amount"&gt;50,000&lt;/span&gt;
note owed to the related party was then paid off in full.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYzIEK2eVmQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zwWGyadF88hh" style="display: none"&gt;Schedule
of Promissory Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220930_z8sz6rbUuhP7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zGN2XUdpFHY8" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z8rCGaaJjyP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zw3T5TSJyY52" title="Debt maturity date"&gt;December 28, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zVhNOEpSV6nf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zrdUXY9T00Y3" title="Debt maturity date"&gt;February 8, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zw5zFEWoegz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zvymj71KTPZa" title="Debt maturity date"&gt;March 11, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zcRQi5sCgQ57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zXkxFE5K93x1" title="Debt maturity date"&gt;August 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzxfV_zaBoiXSvwhI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zxwXaJH3mH72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(408,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zHKNNzyBPYGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total outstanding notes payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zkicrC7Cmmv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ending September 30, 2022, the Company fully amortized the debt discount and included $&lt;span id="xdx_905_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220930_z0kIM3m07Bf" title="Amortized debt discount"&gt;408,979&lt;/span&gt; in interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:MediumTermNotes contextRef="AsOf2021-03-09" decimals="0" unitRef="USD">73007</us-gaap:MediumTermNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-03-09" decimals="INF" unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermDebtDescription contextRef="From2021-03-092021-03-09">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</us-gaap:ShortTermDebtDescription>
    <us-gaap:MediumTermNotes contextRef="AsOf2020-05-15" decimals="0" unitRef="USD">62500</us-gaap:MediumTermNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-05-15" decimals="INF" unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermDebtDescription contextRef="From2020-05-152020-05-15">No more than 25% of the amount forgiven can be attributable
to non-payroll costs.</us-gaap:ShortTermDebtDescription>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zBuehpHgeOmh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span id="xdx_8B7_zh3WL2OqTeea" style="display: none"&gt;Schedule
of Notes Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220930_zCOLUnMIYUub" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zhTWY6hOtPcj" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;PPP Note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zV3AXygSN6yh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zLqQeYshslhh" title="Debt maturity date"&gt;May 15, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zgEHevVdpow9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zyRSdphG0GA7" title="Debt maturity date"&gt;March 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LoanForgiveness_iI_zyqQSYNNAWZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_zSmWxVZcgvbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember">2020-05-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember">2021-03-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-09-30_custom_PaycheckProtectionProgramNotePayableTwoMember"
      decimals="0"
      unitRef="USD">73007</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember"
      decimals="0"
      unitRef="USD">73007</us-gaap:NotesPayable>
    <SHPH:LoanForgiveness contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-73007</SHPH:LoanForgiveness>
    <SHPH:LoanForgiveness contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-62500</SHPH:LoanForgiveness>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73007</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-28" decimals="0" unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-12-28" decimals="INF" unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-12-282021-12-28">2022-12-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-12-28" decimals="INF" unitRef="Shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-28"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2021-12-28" decimals="0" unitRef="USD">5075</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-12-282021-12-28"
      decimals="0"
      unitRef="USD">16667</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2022-01-012022-09-30_custom_NoteTwoMember"
      decimals="0"
      unitRef="USD">18904</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2022-02-08" decimals="0" unitRef="USD">365000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2022-03-11" decimals="0" unitRef="USD">224985</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2022-02-08" decimals="INF" unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2022-03-11" decimals="INF" unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-02-082022-02-08"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-03-112022-03-11"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-02-082022-02-08"
      decimals="0"
      unitRef="USD">36500</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-03-112022-03-11"
      decimals="0"
      unitRef="USD">22250</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-02-082022-02-08_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-03-112022-03-11_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-12625</us-gaap:DebtSecuritiesGainLoss>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2022-08-01" decimals="0" unitRef="USD">125000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2022-08-01" decimals="INF" unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-08-01_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:NotesIssued1
      contextRef="From2022-08-012022-08-01_custom_AccreditedInvestorMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:NotesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="USDPShares">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-09-012022-09-30"
      decimals="0"
      unitRef="USD">30000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember"
      decimals="0"
      unitRef="USD">75000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-012022-09-30_us-gaap_ConvertibleDebtMember"
      decimals="0"
      unitRef="USD">75000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-09-30_us-gaap_ConvertibleDebtMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYzIEK2eVmQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zwWGyadF88hh" style="display: none"&gt;Schedule
of Promissory Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220930_z8sz6rbUuhP7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zGN2XUdpFHY8" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z8rCGaaJjyP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zw3T5TSJyY52" title="Debt maturity date"&gt;December 28, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zVhNOEpSV6nf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteTwoMember_zrdUXY9T00Y3" title="Debt maturity date"&gt;February 8, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zw5zFEWoegz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteThreeMember_zvymj71KTPZa" title="Debt maturity date"&gt;March 11, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zcRQi5sCgQ57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Promissory note issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteFourMember_zXkxFE5K93x1" title="Debt maturity date"&gt;August 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzxfV_zaBoiXSvwhI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zxwXaJH3mH72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(408,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zHKNNzyBPYGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total outstanding notes payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PromissoryNoteOneMember">2021-12-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2021-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PromissoryNoteTwoMember">2022-02-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PromissoryNoteThreeMember">2022-03-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-09-30_custom_PromissoryNoteFourMember">2022-08-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">408979</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">91021</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">408979</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxRJE3vYPZJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_821_zhYyZ2od3pAb"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Company&#x2019;s amended and restated articles of incorporation, the Company is authorized to issue &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zD7b65CwANT9" title="Common Stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of common
stock, with a par value of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zwHgHRxOgj99" title="Common stock, par value (in dollars per share)"&gt;0.00001&lt;/span&gt; per share, and &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_zpdqMosGBgg9" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; shares of preferred stock, with a par value of $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zjBTp9hZfGX3" title="Preferred stock par value"&gt;0.00001&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
A Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#x2019;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#x2019;s common stock on a national securities exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
September 2022, the Company converted &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zysPduE62CKh" title="Converted shares issued"&gt;1,213
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Series A Preferred Stock into &lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGqislf6LlI7" title="Converted shares issued"&gt;336,810
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock and warrants to purchase
&lt;span id="xdx_905_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMvG6hvR7ng" title="Purchase up warrants shares"&gt;336,810
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, which conversion shares
and warrants were calculated using a conversion price of &lt;span id="xdx_909_ecustom--DebtInstrumentConvertibleConversionPricePercentage_iI_pid_dp_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFqdTaco7AF8" title="Conversion price percentage"&gt;90&lt;/span&gt;% of the IPO price of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYZ0SOMJSdT5" title="Conversion price"&gt;4.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, resulting in a discounted conversion
price of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930_z8Z9SpoKwDYb" title="Conversion price"&gt;3.60&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. The warrants issued to the Series A Preferred Stockholders are exercisable at $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930_zpUsyRLcr86l" title="Exercisable"&gt;4.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share for a period of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dt_c20220101__20220930_zcseRHSywJsi" title="Remaining contractual term"&gt;three years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2022, the Company accrued $&lt;span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztK97ATl9iCl" title="Dividends on preferred stock"&gt;71,009&lt;/span&gt; for the &lt;span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoOPrvkdYbN1" title="Preferred stock dividend rate"&gt;8.5&lt;/span&gt;% cumulative dividends on the Series A Preferred stock
and $&lt;span id="xdx_900_eus-gaap--DividendsPreferredStockCash_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWqcisRwodE6" title="Dividends on preferred stock"&gt;103,062&lt;/span&gt; for the year ended December 31, 2021, for a total of $&lt;span id="xdx_90F_eus-gaap--DividendsShareBasedCompensation_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1YIxjGJzwg" title="Dividends total"&gt;402,068&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DividendsShareBasedCompensation_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHpH2VNhCRA9" title="Dividends total"&gt;331,059&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
September 2022, the Company paid the dividend payable balance of $&lt;span id="xdx_90F_eus-gaap--DividendsCommonStock_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLxXy8ZdoY7j" title="Commons stock dividend"&gt;402,068&lt;/span&gt;
to the Series A Stockholders through the issuance of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220901__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlRcBiJtDOLg" title="Common stock issued for cash, shares"&gt;100,517&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2022, the Company had &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znMFb6GdN5q" title="Preferred Stock, shares outstanding"&gt;no&lt;/span&gt; shares of Series A Preferred Stock outstanding, and &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRzGJoa4QEp2" title="Preferred Stock, shares outstanding"&gt;1,213&lt;/span&gt; shares as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2022 and December 31, 2021, the Company had &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20220930_zyK4ucXu9E02" title="Common Stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20220930_zAVlHx39w4v8" title="Common Stock, shares outstanding"&gt;13,586,393&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20211231_zWDNxwbzx2Vd" title="Common Stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zSlmTeZoglFe" title="Common Stock, shares outstanding"&gt;9,312,152&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding,
respectively. The balance includes &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOoy8zoPAyhd" title="Common stock issued for restricted stock units, shares"&gt;20,626&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5jxBFcjiqj" title="Common stock issued for restricted stock units, shares"&gt;21,530&lt;/span&gt; shares of restricted stock issued in 2021 and 2020 respectively and &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNPfk1gGbaD2" title="Sale of stock number of shares issued in transaction"&gt;839&lt;/span&gt; shares of
common stock issued to settle shares of common stock owed to Shuttle&#x2019;s original membership holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_zoIvY7momya6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2022, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B2_zlcBSojejxUa" style="display: none"&gt;Schedule of
Sale of Equity or Issued&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value $&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span id="xdx_F4C_zVQnroxtrN48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public offering&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zGz90CtsNEja" style="width: 12%; text-align: right" title="Stock issued during period, shares"&gt;1,409,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zVMczMb85TE9" style="width: 12%; text-align: right" title="Stock issued during period, Value"&gt;10,031,415&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zI1ZZDkuYRll" style="text-align: right" title="Stock issued during period, shares"&gt;147,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zfUkLCAktb1c" style="text-align: right" title="Stock issued during period, shares"&gt;588,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F49_z4m8t1dYYtpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant exercises&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_zOLfHvinhUdc" style="text-align: right" title="Stock issued during period, shares"&gt;2,267,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_ziQh59zpa9Pc" style="text-align: right" title="Stock issued during period, shares"&gt;590,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Common stock payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_zh3yWT2pEEAl" style="text-align: right" title="Stock issued during period, shares"&gt;839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_z0haD5Kr4GCl" style="text-align: right" title="Stock issued during period, value"&gt;16,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F42_z27rO27rUT38" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preferred Share and Dividends Payable&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_z5rP5B6sdQr1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, shares"&gt;437,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_zudb7kxpNvP4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, Value"&gt;402,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F02_zpaba9E4mGZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zVTbfqbW6iba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Value
                                            is net of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees"&gt;1,407,262&lt;/span&gt; of fees associated with the issuances.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F07_zlejtRyQe31c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zoZjkIOtyHI6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share"&gt;197,273&lt;/span&gt; broker warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share"&gt;180,280 &lt;/span&gt;shares of common stock
                                            and warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise"&gt;1,409,771 &lt;/span&gt;shares of common stock exercised as part of the Company&#x2019;s
                                            initial public offering.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0A_z24ejyBVEFq1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_zkLhD1kqAUba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock"&gt;336,810&lt;/span&gt; shares of common stock issued upon conversion of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding"&gt;1,213&lt;/span&gt; Preferred Shares and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock"&gt;100,517&lt;/span&gt;
                                            common shares to settle dividends payable balance.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zjCfC19j6Sl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock to be Issued&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 4, 2018, $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zwHhIwAEzAuf" title="Convertible notes"&gt;120,250&lt;/span&gt; outstanding convertible notes were converted to &lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_ztKaKDNIn7Y8" title="Debt converted into common stock"&gt;6,182&lt;/span&gt; shares of common stock of the Company at a price of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z6asrYHk8upb" title="Conversion price"&gt;19.44&lt;/span&gt;
per share. The Company recorded $&lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zdsTjGnoIQKj" title="Debt converted into common stock, value"&gt;16,340&lt;/span&gt; of common stock to be issued for the accrued interest. As of September 30, 2022, &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_z2ZquAj5Eolg" title="Stock issued during period, shares"&gt;839&lt;/span&gt; shares of
common stock were issued to settle the $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--MembershipInterestHoldersMember_zSRH7R6eSTxd" title="Stock issued during period, Value"&gt;16,340&lt;/span&gt; of common stock to be issued to Shuttle&#x2019;s original membership interest holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock sold in the Company&#x2019;s 2018 and 2019 private placement offerings included warrants to be issued upon the
earlier of a closing of the sale of shares of common stock to the public at a prices per share of at least $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20220930_z1tTtPcgJDxd" title="Share price"&gt;13.88&lt;/span&gt; or in a firm commitment
underwritten public offering pursuant to an effective registration statement resulting in gross proceeds of at least $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB2KU2vdlv3" title="Proceeds from initial public offerings"&gt;15,000,000&lt;/span&gt;. The
warrants shall be exercisable for a period of three years after the date of issuance. The warrant exercise price is contingent on the
terms of the public offering. If an initial public offering occurs at a price at or above $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRR6lqHIg3yl" title="Share price"&gt;13.88&lt;/span&gt; per share, then the exercise price shall
be set to the issuance price of the common stock with the number of warrants determined based on a 10% discount to the per share common
stock issuance price. In the scenario where the common stock is listed with the common stock issuance price below $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_c20220101__20220930_z5P9n8rrD4Kl" title="Warrant exercise low price"&gt;13.88&lt;/span&gt;, the exercise
price will be set to $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930_zzdRjpgjWnri" title="Warrant exercise price increase"&gt;20.82&lt;/span&gt; with the number of warrants based on a fixed conversion price of $&lt;span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20220930_zqFHOFxm4Owd" title="Common stock, Conversion price"&gt;12.49&lt;/span&gt;, which represents a 10.0% discount
to the $&lt;span id="xdx_90D_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930_zhRwRdpzY0Ve" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt; threshold. The warrants also have contingent call features based on the terms of the public offering. If an initial public
offering occurs at a price at or above $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjKtYc3NwVd7" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt;, then the warrants are callable if the 20-day VWAP of the common stock in at or above 150%
of the variable exercise price. In the scenario where the common stock is listed with a common stock issuance price below $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbtx0LXUF6T" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt;, then
the warrants are callable if the 20-day VWAP of the common stock is at or above the $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztYOrsqyePJ4" title="Warrant exercise price increase"&gt;20.82&lt;/span&gt; exercise price. The detachable warrants contained
terms and features that gave rise to derivative liability classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 6, 2022, the Company amended its certificate of designation for the Series A Preferred Stock (the &#x201c;Amended Series A
Preferred Certificate of Designation&#x201d;) in order to modify the conditions pursuant to which the Series A Preferred Stock would
automatically convert. Under the Amended Series A Certificate of Designation, the automatic conversion feature was amended so as to
allow for conversion upon completion of a $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrVPdWFRuO2j" title="Proceeds from initial public offerings"&gt;10,000,000&lt;/span&gt;
public offering or the listing of the Company&#x2019;s common stock on a qualified exchange, in which case the Series A Preferred
Stock would convert at either 90% of the per share IPO price or $&lt;span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220406__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziRG45hYCN92" title="Common stock, conversion price"&gt;5.00&lt;/span&gt;
per share. As a result, upon completion of our initial public offering, the Series A Preferred Stock was converted and warrants were
issued in relation to the conversion, with each warrant then exercisable at the equivalent of the per share initial public offering
price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative warrant liability linked to the Series A Preferred Stock as of September 30, 2022 and December 31, 2021 was $&lt;span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_dxL_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgFf9ljfN3j8" title="Derivative warrant liabilities::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkf9RBW6mOGd" title="Derivative warrant liabilities"&gt;94,025&lt;/span&gt;,
respectively. For the period ended September 30, 2022 and 2021, the change in fair value of warrant liability was a gain of $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTxTNHtR5OCk" title="Fair value of warrants liability"&gt;94,025&lt;/span&gt; and
a gain of $&lt;span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1DELF0Ddi9l" title="Fair value of warrants liability"&gt;30,971&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjFxAl0mLK3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of the liability measured on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zBaWiW2hUbo9" style="display: none"&gt;Schedule Of Stock Options, Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Expected average volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zhMcG7Vze4z1" title="Expected volatility"&gt;85.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_z7TmHT9meRab" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zj4OzbZ2MUfg" title="Expected life"&gt;2.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zJiIunAv2NNg" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zDgPwOwoBaI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zykKzq1xTiEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Series A Preferred Stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zAI1VcyQekT9" style="display: none"&gt;Schedule
of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlqKbqQNTHXh" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHSY18pcFCve" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc0uoL4xYoje" title="Weighted Average Remaining Life in Years Outstanding"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEgcPNiFzEod" style="text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWGdzP4hgfd5" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDJ8BkLCpngh" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcMdvhnPUqSl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Z2V48oZPpc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXVFuH1uPzt8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding and Exercisable, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z21PCphyMc5g" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze8hCGHfFJ8a" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5ZW4uR86yU8" title="Weighted Average Remaining Life in Years Outstanding"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAd8zJkaU7dg" style="text-align: right" title="Number of Warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcgLjEuctt5e" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCfXWpepbsC" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zREYA2RzJlWi" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrJXH3EJHUl4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxVBHHEKMvKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding and Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0MKUidIv8Zf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7GPzqiGfWx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the common stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfwUq0E6s3c" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCQq5BYydFa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0KcnPEUWxa" style="width: 12%; text-align: right" title="Number of Warrants, granted"&gt;2,304,544&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOnBZehpQzm2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, granted"&gt;2.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxqi6r40Aq1" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOOZUfB75Rua" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup id="xdx_F45_zMhcIcLQEOg3"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zPAiB1fqCrda" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(2,284,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z3Jr1f2NZ178" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding and Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAPnlh9J9We" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DbtcWe9i2d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zPB1oqRtX8Ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zZ50IP42y1W5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants"&gt;197,273&lt;/span&gt; warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants"&gt;180,280&lt;/span&gt; common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A9_z4f0j9hJ2Zs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#x2019;s compensation committee. We have reserved &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxdfGHb6KhW1" title="Common stock reserved for future issuance"&gt;3,000,000&lt;/span&gt; shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of September 30, 2022, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzL6U5wIodUi" title="Share granted under equity incentive plan"&gt;384,167&lt;/span&gt; shares have been granted under the
2018 Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement outlining the terms of their service as a director and pursuant to which they would each receive a grant of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCPIhiIAP2p" title="Share granted under equity incentive plan"&gt;75,000&lt;/span&gt; worth
of Restricted Stock Units (&#x201c;RSUs&#x201d;) issuable under the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;).
The RSUs vested annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z5ooPFBxfCBf" title="Restricted stock value"&gt;25,000&lt;/span&gt; per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2022 and 2021, pursuant to the agreements with directors and officers, compensation expense for the
RSUs of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVM5fAAQtaok" title="Share based compensation"&gt;356,733&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHaDH6jUr0h" title="Share based compensation"&gt;367,551&lt;/span&gt; was included in compensation, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2022, there was $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VSL6Fw3YDf" title="Unrecognized compensation cost"&gt;8,334&lt;/span&gt; of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the current year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zQUTKItLSwyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Restricted Stock Units (RSUs) is set forth as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zEPSKpTDUEX2" style="display: none"&gt;Schedule
of Restricted Stock Units (RSUs) &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
RSU&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zucGsO7jApGk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;61,884&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh2nhdHl9H4d" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;23.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxjCwRdW8aBh" title="Weighted Average Life (Years)"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVwpB3WDjyb" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaC85nk4TjE9" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8IQpkJhHpBk" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAkqKJsJkf35" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNTQQ0pKQNEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoTwwRxCwFd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;59,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqJQarbmomS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;23.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRzMbmLfLjD" title="Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0yYtPiigZh7" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwpyGG1LxO97" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLRpATl7oARd" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMSs7ioeWlI4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKNoINGNfkac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZdWes1Tiv1k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjVqgVvh1vkl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance"&gt;59,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm4QxHnPnqtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;23.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk6uMcKKK4p7" title="Weighted Average Life (Years)"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFSAFrLb73b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable"&gt;58,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1SVsH5cj8Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable"&gt;23.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs5wrkCUxacl" title="Exercisable Weighted Average Life (Years)"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zYGyYMXhjXe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">336810</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">336810</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <SHPH:DebtInstrumentConvertibleConversionPricePercentage
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.90</SHPH:DebtInstrumentConvertibleConversionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">3.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-09-30">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218"
      decimals="0"
      unitRef="USD">71009</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281"
      decimals="0"
      unitRef="USD">103062</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsShareBasedCompensation
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218"
      decimals="0"
      unitRef="USD">402068</us-gaap:DividendsShareBasedCompensation>
    <us-gaap:DividendsShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281"
      decimals="0"
      unitRef="USD">331059</us-gaap:DividendsShareBasedCompensation>
    <us-gaap:DividendsCommonStock
      contextRef="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">402068</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-012022-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">100517</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">13586393</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">13586393</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20626</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">21530</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">839</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock_zoIvY7momya6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2022, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B2_zlcBSojejxUa" style="display: none"&gt;Schedule of
Sale of Equity or Issued&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value $&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span id="xdx_F4C_zVQnroxtrN48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public offering&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zGz90CtsNEja" style="width: 12%; text-align: right" title="Stock issued during period, shares"&gt;1,409,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_fKDEp_zVMczMb85TE9" style="width: 12%; text-align: right" title="Stock issued during period, Value"&gt;10,031,415&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zI1ZZDkuYRll" style="text-align: right" title="Stock issued during period, shares"&gt;147,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--NotesPayableMember_zfUkLCAktb1c" style="text-align: right" title="Stock issued during period, shares"&gt;588,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F49_z4m8t1dYYtpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant exercises&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_zOLfHvinhUdc" style="text-align: right" title="Stock issued during period, shares"&gt;2,267,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--NoteWarrantMember_fKDIp_ziQh59zpa9Pc" style="text-align: right" title="Stock issued during period, shares"&gt;590,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Common stock payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_zh3yWT2pEEAl" style="text-align: right" title="Stock issued during period, shares"&gt;839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockPayableMember_z0haD5Kr4GCl" style="text-align: right" title="Stock issued during period, value"&gt;16,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F42_z27rO27rUT38" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preferred Share and Dividends Payable&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_z5rP5B6sdQr1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, shares"&gt;437,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_fKDMp_zudb7kxpNvP4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock issued during period, Value"&gt;402,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F02_zpaba9E4mGZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zVTbfqbW6iba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Value
                                            is net of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da" title="Stock issuance fees"&gt;1,407,262&lt;/span&gt; of fees associated with the issuances.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F07_zlejtRyQe31c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zoZjkIOtyHI6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52" title="Warrants, share"&gt;197,273&lt;/span&gt; broker warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl" title="Warrants issued for common stock, share"&gt;180,280 &lt;/span&gt;shares of common stock
                                            and warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5" title="Number of shares exercise"&gt;1,409,771 &lt;/span&gt;shares of common stock exercised as part of the Company&#x2019;s
                                            initial public offering.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0A_z24ejyBVEFq1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_zkLhD1kqAUba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf" title="Conversion of common stock"&gt;336,810&lt;/span&gt; shares of common stock issued upon conversion of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC" title="Preferred Stock, shares outstanding"&gt;1,213&lt;/span&gt; Preferred Shares and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6" title="Conversion of common stock"&gt;100,517&lt;/span&gt;
                                            common shares to settle dividends payable balance.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_IPOMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">10031415</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_custom_NotesPayableMember"
      decimals="INF"
      unitRef="Shares">147500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_custom_NotesPayableMember"
      decimals="0"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_NoteWarrantMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">2267551</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_NoteWarrantMember"
      decimals="0"
      id="Fact001176"
      unitRef="USD">590574</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_custom_CommonStockPayableMember"
      decimals="INF"
      unitRef="Shares">839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_custom_CommonStockPayableMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember"
      decimals="INF"
      id="Fact001182"
      unitRef="Shares">437327</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember"
      decimals="0"
      id="Fact001184"
      unitRef="USD">402068</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">1407262</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">197273</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">180280</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      decimals="INF"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">336810</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-012022-09-30_custom_PreferredStockDividendPayableMember"
      decimals="INF"
      unitRef="Shares">100517</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2018-06-04" decimals="0" unitRef="USD">120250</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      unitRef="Shares">6182</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      unitRef="USDPShares">19.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember"
      decimals="INF"
      unitRef="Shares">839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_custom_MembershipInterestHoldersMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-30_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:SharePrice>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">20.82</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">12.49</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2022-01-012022-09-30_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2022-01-012022-09-30_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">20.82</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-04-062022-04-06_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_SeriesAPreferredStockMember52284218"
      decimals="0"
      unitRef="USD">94025</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">30971</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjFxAl0mLK3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of the liability measured on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zBaWiW2hUbo9" style="display: none"&gt;Schedule Of Stock Options, Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Expected average volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zhMcG7Vze4z1" title="Expected volatility"&gt;85.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_z7TmHT9meRab" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zj4OzbZ2MUfg" title="Expected life"&gt;2.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zJiIunAv2NNg" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31">P2Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zykKzq1xTiEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Series A Preferred Stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zAI1VcyQekT9" style="display: none"&gt;Schedule
of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlqKbqQNTHXh" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHSY18pcFCve" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc0uoL4xYoje" title="Weighted Average Remaining Life in Years Outstanding"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEgcPNiFzEod" style="text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWGdzP4hgfd5" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDJ8BkLCpngh" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcMdvhnPUqSl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Z2V48oZPpc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXVFuH1uPzt8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding and Exercisable, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z21PCphyMc5g" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze8hCGHfFJ8a" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5ZW4uR86yU8" title="Weighted Average Remaining Life in Years Outstanding"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAd8zJkaU7dg" style="text-align: right" title="Number of Warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcgLjEuctt5e" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCfXWpepbsC" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zREYA2RzJlWi" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrJXH3EJHUl4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxVBHHEKMvKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding and Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0MKUidIv8Zf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7GPzqiGfWx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the common stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfwUq0E6s3c" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCQq5BYydFa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0KcnPEUWxa" style="width: 12%; text-align: right" title="Number of Warrants, granted"&gt;2,304,544&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOnBZehpQzm2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, granted"&gt;2.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxqi6r40Aq1" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOOZUfB75Rua" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup id="xdx_F45_zMhcIcLQEOg3"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zPAiB1fqCrda" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(2,284,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z3Jr1f2NZ178" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding and Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAPnlh9J9We" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DbtcWe9i2d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zPB1oqRtX8Ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zZ50IP42y1W5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk" title="Warrants"&gt;197,273&lt;/span&gt; warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2" title="Warrants"&gt;180,280&lt;/span&gt; common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">P3Y3M29D</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">P2Y3M29D</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      decimals="INF"
      unitRef="Shares">2304544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      decimals="INF"
      unitRef="USDPShares">2.89</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">2284544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember52285984"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">2.89</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.50</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">197273</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-09-30_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      unitRef="Shares">180280</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">384167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2019-08-162019-08-16_srt_DirectorMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">356733</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">367551</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">8334</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zQUTKItLSwyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Restricted Stock Units (RSUs) is set forth as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zEPSKpTDUEX2" style="display: none"&gt;Schedule
of Restricted Stock Units (RSUs) &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
RSU&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zucGsO7jApGk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;61,884&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh2nhdHl9H4d" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;23.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxjCwRdW8aBh" title="Weighted Average Life (Years)"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVwpB3WDjyb" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaC85nk4TjE9" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8IQpkJhHpBk" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAkqKJsJkf35" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNTQQ0pKQNEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoTwwRxCwFd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;59,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqJQarbmomS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;23.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRzMbmLfLjD" title="Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0yYtPiigZh7" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwpyGG1LxO97" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLRpATl7oARd" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMSs7ioeWlI4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKNoINGNfkac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZdWes1Tiv1k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjVqgVvh1vkl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance"&gt;59,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm4QxHnPnqtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;23.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk6uMcKKK4p7" title="Weighted Average Life (Years)"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Exercisable, September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFSAFrLb73b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable"&gt;58,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1SVsH5cj8Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable"&gt;23.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs5wrkCUxacl" title="Exercisable Weighted Average Life (Years)"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">61884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">P4Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">27.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">59182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">P3Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">59182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">58813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zUvfGAU5tdAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_821_z3MypG20efs4"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluated all additional events subsequent to the balance sheet date through November 14, 2022, the date the financial statements were
available to be issued, and determined that no items were required to be disclosed.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">504749</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">117153</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4866</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">12579</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CommodityContractAssetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">211455</us-gaap:CommodityContractAssetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">509615</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">341187</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18564</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24782</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6480</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6480</us-gaap:OtherAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">116982</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">171598</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">651641</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">544047</us-gaap:Assets>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">828313</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">516966</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">552</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">392</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46947</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">331059</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">227997</us-gaap:DividendsPayableCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">685473</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">565473</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableToBankCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">91021</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73007</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">62500</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">673171</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">66934</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">58468</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2217331</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2104967</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">62442</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">129376</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2279773</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2234343</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1212500</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1212500</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">9291526</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">9291526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">93</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">93</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">93</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">93</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4150867</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2833507</us-gaap:AdditionalPaidInCapitalCommonStock>
    <SHPH:CommonStockToBeIssued contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16340</SHPH:CommonStockToBeIssued>
    <SHPH:CommonStockToBeIssued contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">16340</SHPH:CommonStockToBeIssued>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-5795432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-4540236</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-1690296</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">651641</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">544047</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1021808</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">161772</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36500</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">85927</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">684684</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">261823</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1742992</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">509522</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1742992</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-509522</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">46947</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">36771</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3841</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">2859</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-579146</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">256580</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">62500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">590858</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-296210</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-805732</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-805732</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">103062</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">103062</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1255196</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-908794</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">9301750</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">9291526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9269996</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2373918</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3631442</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-1241091</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">21530</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">459589</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">459589</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">103062</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">103062</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-805732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-805732</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9291526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2833507</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4540236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-1690296</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">407293</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">407293</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20626</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">490067</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">490067</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">103062</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">103062</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9312152</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4150867</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5795432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9312152</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4150867</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5795432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-805732</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6218</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">5782</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-579146</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">256580</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">54616</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">49169</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3389</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">62500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">910067</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">459589</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-211455</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-164927</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-7713</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">586</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">311347</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-51127</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">160</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">392</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">46947</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-54959</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-58468</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-50866</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-300336</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-26831</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">10818</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-10818</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">120000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">7573</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">73007</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">62500</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">494925</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">687932</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">70073</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">387596</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">32424</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">117153</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">84729</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">504749</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">117153</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">293</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1886</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zfW6OIA38t38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_828_zA3NBGJxSpV9"&gt;Organization and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Line of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a corporation and the Company changed its name to Shuttle
Pharmaceuticals, Inc. (&#x201c;Shuttle&#x201d;). In connection with the conversion the Company issued &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z980VB5bNKS6" title="Number of convertible shares issued"&gt;45,000,000&lt;/span&gt; shares of common stock
in exchange for &lt;span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160811__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQh8FlUdslqc" title="Sale of stock membership percentage"&gt;100&lt;/span&gt;% of the outstanding membership interests prior to conversion. On June 4, 2018, Shuttle completed a reverse merger
with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp.), a Delaware corporation (the &#x201c;Company&#x201d;),
pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies which has produced a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#x2019;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#x2019;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (SBIR) contract provided by the
National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH). Ropidoxuridine has been further developed though
the Company&#x2019;s collaborations with the University of Virginia for use in combination with proton therapy to improve patient survival.
The Company is working on developing products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
production and marketing of the Company&#x2019;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&#x201c;FDA&#x201d;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 1, 2022, we effected a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20220328__20220402_zt1vsqnk4tA5" title="Reverse stock split"&gt;2-for-1 reverse stock split&lt;/span&gt; of our issued and outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;).
All references to shares of our common stock in this registration statement on Form S-1 refers to the number of shares of common stock
after giving effect to the Reverse Stock Split (unless otherwise indicated).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&#x2019;s only revenue source since inception has been government awarded contracts totaling
$&lt;span id="xdx_900_eus-gaap--GovernmentContractReceivable_iI_c20211231_zQhXS9JD3uvf" title="Awarded contracts"&gt;5,531,722&lt;/span&gt;, and the Company has incurred losses since inception, having accumulated a deficit of $&lt;span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_zRDBDopnla4g" title="Accumulated deficit"&gt;5,795,432&lt;/span&gt; as of December 31, 2021.
The Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient
to cover operating costs over an extended period. These factors, among others, raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing
through debt or equity financings with an aim to continue progress toward commercial viability of its products. The Company continues
to submit Federal grant and contract applications which have historically been the primary source of revenue. The financial statements
do not include any adjustments that might result from the outcome of the uncertainty of raising additional capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2016-08-112016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-03-282022-04-02">2-for-1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:GovernmentContractReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5531722</us-gaap:GovernmentContractReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-5795432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zaCWCeJJoHH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_829_zDwoeqdcnG92"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzSeCibrySFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zHFk2Mm9gwU8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConsolidationPolicyTextBlock_zpCW6ei1Xrg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z9MlYvZzbJ37"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zeUqtynLxD3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zHxcJoKlrWk3"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_z1VY8Pmu6GNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zUGWDSisXQa6"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounts receivable consists of amounts due from the National Institutes of Health (&#x201c;NIH&#x201d;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on research
and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and payments
from the contracts are generally collected within 30 days of the Company&#x2019;s submission for reimbursement. The Company currently
does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection
information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance of the invoice and typically
would be considered past due when the term expires. The Company&#x2019;s allowance for doubtful accounts was $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zkVwpc8cgnp9" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zBypMpqdf6y2" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; at December 31, 2020 and
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeRTsuUFY894" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zy1ME33lauv2"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zqvG7r2Lue0g" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zoq40ARkvugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGp2dE9hhrRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zgQsodqcjYxk"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#x201c;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#x2013; Moonshot Project&#x201d; and (2) &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
Contract #HHSN261201600027C/75N91018C00016 supported &#x201c;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#x201d; This $&lt;span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zaeusPjbqBc2" title="Proceeds for research and development from collaborators"&gt;299,502&lt;/span&gt; Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $&lt;span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZxtPV2c0e48" title="Proceeds for research and development from collaborators"&gt;1,903,095&lt;/span&gt; with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $&lt;span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zUPYw14OkS5l" title="Proceeds from contract awards for research and development"&gt;211,455&lt;/span&gt;
for a total of $&lt;span id="xdx_90D_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zRHHZEcba5ki" title="Proceeds from contract awards for research and development"&gt;845,820&lt;/span&gt; in 2020; and 2 quarterly payments related to Topic 345 for a total of $&lt;span id="xdx_909_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_zP3SGc96Lxwi" title="Proceeds from contract awards for research and development"&gt;422,910&lt;/span&gt; in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#x201c;kits,&#x201d;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 6, 2019, the Company engaged Georgetown University to perform the $&lt;span id="xdx_903_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zM0qWX69QD7a" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt; subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $&lt;span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z3cnkMBBBhNf" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt;. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $&lt;span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211201__20211231_zDFLz35b8ZD" title="Payments to invoices in research and development"&gt;354,829&lt;/span&gt; were made to Georgetown,
and additional invoices for $&lt;span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231_zdbj5Zip7kb" title="Payments to invoices in research and development"&gt;436,188&lt;/span&gt; were received but not yet paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#x201c;Topic 352 &#x2013;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#x201d; and was awarded to provide $&lt;span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_z3qXOJD0BmS" title="Proceeds from contract awards for research and development"&gt;1,484,350&lt;/span&gt; to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $&lt;span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zajbxohgsNr4" title="Payments to invoices in research and development"&gt;412,321&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0Q4mmcdceZb" title="Payments to invoices in research and development"&gt;82,467&lt;/span&gt; in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $&lt;span id="xdx_90C_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zjZOQRhRSoT5" title="Business development new establishment"&gt;742,002&lt;/span&gt; to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2018, the Company engaged Georgetown University to perform the $&lt;span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z9lcD8RCIC0j" title="Proceeds for research and development from collaborators"&gt;742,002&lt;/span&gt; subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $&lt;span id="xdx_903_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zG9gSpfZ7Rp8" title="Payments to invoices in research and development"&gt;292,252&lt;/span&gt; as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $&lt;span id="xdx_908_ecustom--ResearchAndDevelopmentDeficitNet_c20210101__20211231_z4cRZ85dT5Ai" title="Net deficit on research and development"&gt;1,021,808&lt;/span&gt; from these two SBIR contracts which is the result of recording $&lt;span id="xdx_909_eus-gaap--CapitalizedContractCostNet_iI_c20211231__dei--LegalEntityAxis__custom--SBIRMember_zgGdHtrh81Xk" title="Project cost"&gt;1,527,185&lt;/span&gt; in SBIR contract related expenses
on revenues of $&lt;span id="xdx_908_eus-gaap--CapitalizedContractCostNet_iI_c20201231__dei--LegalEntityAxis__custom--SBIRMember_zoZGhm200M6h" title="Project cost"&gt;505,377&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#x2013; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--DerivativesPolicyTextBlock_zDJe5Tlsf9bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zCUUvceE5Y19"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&#x2019;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&#x2019;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKwi81zQZRlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zKgD4N7HXxc5"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 inputs to the valuation
    methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets
    in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially
    the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 inputs to the valuation
    methodology us one or more unobservable inputs which are significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and FASB ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
established trading market for the Company&#x2019;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company utilized $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8I5At1BUld" title="Share price"&gt;25.22 &lt;/span&gt;(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY7PlvqW9iE8" title="Share price"&gt;5.00&lt;/span&gt; in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z5wlC8g4VNF4" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1870"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1875"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;673,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zMFIwN4l8G2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zF0u8ua9DnYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z4tzmmsrb0zi"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from providing research and development is recognized under &lt;i&gt;Topic 606&lt;/i&gt; in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;executed contracts with
    the Company&#x2019;s customers that it believes are legally enforceable;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification of performance
    obligations in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determination of the transaction
    price for each performance obligation in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocation the transaction
    price to each performance obligation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognition of revenue
    only when the Company satisfies each performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &#x201c;Research and development, net
of contract expense reimbursements.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zPau7tRPvDne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z6G31CPqBJC7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9PNW0W5dLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zjn1rBexH1P3"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMMOgYBJyl01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zbbuukvDA6n5"&gt;Basic
and Diluted Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share (&#x201c;EPS&#x201d;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zLrPHxK3r8ik" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zmayAC6bl05j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3igIdv3U6A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z20jsWIwjfHk"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#x201c;Debt&#x2014;Debt with &#x201c;Conversion and Other Options&#x201d;
and ASC subtopic 815-40 &#x201c;Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity.&#x201d; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85E_z3agHB8KBysk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzSeCibrySFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zHFk2Mm9gwU8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_848_eus-gaap--ConsolidationPolicyTextBlock_zpCW6ei1Xrg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z9MlYvZzbJ37"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-012021-12-31">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zeUqtynLxD3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zHxcJoKlrWk3"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy contextRef="From2021-01-012021-12-31">&lt;p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_z1VY8Pmu6GNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zUGWDSisXQa6"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounts receivable consists of amounts due from the National Institutes of Health (&#x201c;NIH&#x201d;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on research
and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and payments
from the contracts are generally collected within 30 days of the Company&#x2019;s submission for reimbursement. The Company currently
does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection
information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance of the invoice and typically
would be considered past due when the term expires. The Company&#x2019;s allowance for doubtful accounts was $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zkVwpc8cgnp9" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zBypMpqdf6y2" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; at December 31, 2020 and
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeRTsuUFY894" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zy1ME33lauv2"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zqvG7r2Lue0g" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zoq40ARkvugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zO5AsD8FQ1O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zqvG7r2Lue0g" style="display: none"&gt;Schedule
of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhjZhxtNSynj" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLUWdrFaw3Cl" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYyQqvMkDIqi" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;
</SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_us-gaap_EquipmentMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-012021-12-31">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGp2dE9hhrRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zgQsodqcjYxk"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &#x201c;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &#x2013; Moonshot Project&#x201d; and (2) &#x201c;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
Contract #HHSN261201600027C/75N91018C00016 supported &#x201c;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&#x201d; This $&lt;span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20160919__20170918__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zaeusPjbqBc2" title="Proceeds for research and development from collaborators"&gt;299,502&lt;/span&gt; Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $&lt;span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zZxtPV2c0e48" title="Proceeds for research and development from collaborators"&gt;1,903,095&lt;/span&gt; with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $&lt;span id="xdx_904_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231__us-gaap--AwardDateAxis__custom--OneQuarterlyPaymentsMember_zUPYw14OkS5l" title="Proceeds from contract awards for research and development"&gt;211,455&lt;/span&gt;
for a total of $&lt;span id="xdx_90D_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20200101__20201231_zRHHZEcba5ki" title="Proceeds from contract awards for research and development"&gt;845,820&lt;/span&gt; in 2020; and 2 quarterly payments related to Topic 345 for a total of $&lt;span id="xdx_909_ecustom--ProceedsFromContractAwardsForResearchAndDevelopment_c20210101__20211231__us-gaap--AwardDateAxis__custom--TwoQuarterlyPaymentsMember_zP3SGc96Lxwi" title="Proceeds from contract awards for research and development"&gt;422,910&lt;/span&gt; in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &#x201c;kits,&#x201d;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 6, 2019, the Company engaged Georgetown University to perform the $&lt;span id="xdx_903_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_zM0qWX69QD7a" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt; subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $&lt;span id="xdx_905_eus-gaap--ProceedsFromCollaborators_c20191206__20191206__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z3cnkMBBBhNf" title="Proceeds for research and development from collaborators"&gt;795,248&lt;/span&gt;. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $&lt;span id="xdx_906_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20211201__20211231_zDFLz35b8ZD" title="Payments to invoices in research and development"&gt;354,829&lt;/span&gt; were made to Georgetown,
and additional invoices for $&lt;span id="xdx_907_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231_zdbj5Zip7kb" title="Payments to invoices in research and development"&gt;436,188&lt;/span&gt; were received but not yet paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &#x201c;Topic 352 &#x2013;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&#x201d; and was awarded to provide $&lt;span id="xdx_908_eus-gaap--ProceedsFromCollaborators_c20180917__20200916__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_z3qXOJD0BmS" title="Proceeds from contract awards for research and development"&gt;1,484,350&lt;/span&gt; to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $&lt;span id="xdx_904_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zajbxohgsNr4" title="Payments to invoices in research and development"&gt;412,321&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0Q4mmcdceZb" title="Payments to invoices in research and development"&gt;82,467&lt;/span&gt; in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $&lt;span id="xdx_90C_eus-gaap--BusinessDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--PhaseIIMember_zjZOQRhRSoT5" title="Business development new establishment"&gt;742,002&lt;/span&gt; to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2018, the Company engaged Georgetown University to perform the $&lt;span id="xdx_90C_eus-gaap--ProceedsFromCollaborators_c20181205__20181205__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--AdditionalFundingAgreementTermsMember_z9lcD8RCIC0j" title="Proceeds for research and development from collaborators"&gt;742,002&lt;/span&gt; subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $&lt;span id="xdx_903_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--SubcontractPhaseIIMember_zG9gSpfZ7Rp8" title="Payments to invoices in research and development"&gt;292,252&lt;/span&gt; as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $&lt;span id="xdx_908_ecustom--ResearchAndDevelopmentDeficitNet_c20210101__20211231_z4cRZ85dT5Ai" title="Net deficit on research and development"&gt;1,021,808&lt;/span&gt; from these two SBIR contracts which is the result of recording $&lt;span id="xdx_909_eus-gaap--CapitalizedContractCostNet_iI_c20211231__dei--LegalEntityAxis__custom--SBIRMember_zgGdHtrh81Xk" title="Project cost"&gt;1,527,185&lt;/span&gt; in SBIR contract related expenses
on revenues of $&lt;span id="xdx_908_eus-gaap--CapitalizedContractCostNet_iI_c20201231__dei--LegalEntityAxis__custom--SBIRMember_zoZGhm200M6h" title="Project cost"&gt;505,377&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &#x2013; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2016-09-192017-09-18_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">299502</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-09-172020-09-16_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">1903095</us-gaap:ProceedsFromCollaborators>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2020-01-012020-12-31_custom_OneQuarterlyPaymentsMember"
      decimals="0"
      unitRef="USD">211455</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">845820</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <SHPH:ProceedsFromContractAwardsForResearchAndDevelopment
      contextRef="From2021-01-012021-12-31_custom_TwoQuarterlyPaymentsMember"
      decimals="0"
      unitRef="USD">422910</SHPH:ProceedsFromContractAwardsForResearchAndDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">795248</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2019-12-062019-12-06_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">795248</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2021-12-012021-12-31"
      decimals="0"
      unitRef="USD">354829</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">436188</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-09-172020-09-16_custom_PhaseIIMember"
      decimals="0"
      unitRef="USD">1484350</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">412321</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">82467</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2021-01-012021-12-31_custom_PhaseIIMember"
      decimals="0"
      unitRef="USD">742002</us-gaap:BusinessDevelopment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="From2018-12-052018-12-05_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      unitRef="USD">742002</us-gaap:ProceedsFromCollaborators>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2021-01-012021-12-31_custom_SubcontractPhaseIIMember"
      decimals="0"
      unitRef="USD">292252</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:ResearchAndDevelopmentDeficitNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1021808</SHPH:ResearchAndDevelopmentDeficitNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2021-12-31_custom_SBIRMember"
      decimals="0"
      unitRef="USD">1527185</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2020-12-31_custom_SBIRMember"
      decimals="0"
      unitRef="USD">505377</us-gaap:CapitalizedContractCostNet>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_841_eus-gaap--DerivativesPolicyTextBlock_zDJe5Tlsf9bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zCUUvceE5Y19"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&#x2019;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&#x2019;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-01-012021-12-31">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKwi81zQZRlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zKgD4N7HXxc5"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 inputs to the valuation
    methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets
    in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially
    the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 inputs to the valuation
    methodology us one or more unobservable inputs which are significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and FASB ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
established trading market for the Company&#x2019;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company utilized $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8I5At1BUld" title="Share price"&gt;25.22 &lt;/span&gt;(post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY7PlvqW9iE8" title="Share price"&gt;5.00&lt;/span&gt; in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z5wlC8g4VNF4" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1870"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1875"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;673,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zMFIwN4l8G2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">25.22</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89D_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zTtdoGtWsxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z5wlC8g4VNF4" style="display: none"&gt;Schedule
of Fair Value by Liabilities on Balance Sheet &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfDjThbGKyQi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsH0xkPB586e" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6E7gK7WMil" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zxom4qocKbE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1870"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2020, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRBcgXJT7eaf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJTHYasJdLe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnsBI9f4lfj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_zB1VAnqFeFrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Warrant Liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1875"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;673,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">673171</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zF0u8ua9DnYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z4tzmmsrb0zi"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from providing research and development is recognized under &lt;i&gt;Topic 606&lt;/i&gt; in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;executed contracts with
    the Company&#x2019;s customers that it believes are legally enforceable;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identification of performance
    obligations in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determination of the transaction
    price for each performance obligation in the respective contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocation the transaction
    price to each performance obligation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognition of revenue
    only when the Company satisfies each performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &#x201c;Research and development, net
of contract expense reimbursements.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zPau7tRPvDne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z6G31CPqBJC7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9PNW0W5dLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zjn1rBexH1P3"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMMOgYBJyl01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zbbuukvDA6n5"&gt;Basic
and Diluted Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share (&#x201c;EPS&#x201d;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zLrPHxK3r8ik" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zmayAC6bl05j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJUeYygdkaNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zLrPHxK3r8ik" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zusTLYIRJP46" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200101__20201231_zI4TBuEO233b" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_z0AxrbB5zxwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;97,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3cufV5qVA02" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ziO7LLJWvxWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">97062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">97062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">145594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">145594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3igIdv3U6A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z20jsWIwjfHk"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &#x201c;Debt&#x2014;Debt with &#x201c;Conversion and Other Options&#x201d;
and ASC subtopic 815-40 &#x201c;Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity.&#x201d; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z7xeq4BqZwSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_828_zPZ4ViShhbq5"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z293shVBnX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following as of December 31, 2021, and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zUr4lrOJYvF3" style="display: none"&gt;Schedule
of Property and Equipment Net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zSEQkOppiO5i" style="white-space: nowrap; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_zkJJtHp8oFWl" style="white-space: nowrap; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOKWx4HrW392" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Office Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zLyb9JAYDobb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_zMWGxtXnHRM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zwkuXQRcad9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(102,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zc6buQvCEHzk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zoUlaKjS5kU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the twelve months ended December 31, 2021, and 2020 were $&lt;span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zru2PqkqicX1" title="Depreciation expense"&gt;6,218&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zXK7hqXRAlZj" title="Depreciation expense"&gt;5,782&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z293shVBnX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following as of December 31, 2021, and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zUr4lrOJYvF3" style="display: none"&gt;Schedule
of Property and Equipment Net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zSEQkOppiO5i" style="white-space: nowrap; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_zkJJtHp8oFWl" style="white-space: nowrap; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOKWx4HrW392" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Office Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zLyb9JAYDobb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,605&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_zMWGxtXnHRM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zwkuXQRcad9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(102,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zc6buQvCEHzk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">8861</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">8861</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember"
      decimals="0"
      unitRef="USD">118605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentMember"
      decimals="0"
      unitRef="USD">118605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">127466</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">127466</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">108902</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">102684</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18564</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24782</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6218</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">5782</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zyBTUAHGSRD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_829_zco7edg7vAk7"&gt;Operating Lease Right-of-use Asset and Operating Lease Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20210101__20211231_zP1K07qIF6Q8" title="Interest rate used to lease, description"&gt;The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.&lt;/span&gt; Operating lease expense is recognized on a straight-line basis over the lease
term. During the twelve months ended December 31, 2021, and the year ended December 31, 2020, the Company recorded $&lt;span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zyxBDvt1RKC" title="Operating lease expense"&gt;74,028&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20200101__20201231_zTvLFQFhMsn" title="Operating lease expense"&gt;71,872&lt;/span&gt;,
respectively, as operating lease expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $&lt;span id="xdx_902_eus-gaap--OperatingLeasePayments_c20180929__20181001_zBlZi2wzv0B8" title="Lease payment"&gt;6,107&lt;/span&gt;, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on &lt;span id="xdx_90F_eus-gaap--LeaseExpirationDate1_dd_c20180929__20181001_zsuGo17UZjf" title="Operating lease expiration date"&gt;October 31, 2023&lt;/span&gt;. A security deposit of $&lt;span id="xdx_908_eus-gaap--SecurityDeposit_iI_c20181001_zwDFKEoT6KKi" title="Security deposit"&gt;6,480&lt;/span&gt; is being held for the duration of the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &#x2018;package of practical expedients,&#x2019; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of &lt;span id="xdx_909_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20211231_z8MnUaYYMk5c" title="Lease term"&gt;12&lt;/span&gt;
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p id="xdx_890_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zGNZoOUwWE2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1CVxMNAGGw7" style="display: none"&gt;Schedule of Operating Lease Right of Use Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zIPeQCOX6197" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zGRdq5m7ruo" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfficeLease_iI_zByLv4uguS7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_za6ldmTid0xk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,609&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zQxRuTcj6KK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;171,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z42s2REETpNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Right-of-use assets are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
on the right-of -use asset is included in rent expense on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRhltcKRLqyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zZms85qMdgaf" style="display: none"&gt;Schedule
of Operating
Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zdZcv5DI5bpg" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zSX1D7qU6WY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zeMS8XHFzwh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,934&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_znebceF7M491" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zZTR5TCyHSN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z98Fy6YXydx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Maturities of lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zMMRA9wuYNOj" style="display: none"&gt;Schedule Of Operating Lease Maturity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231_ztevs8lGFSs" style="text-align: center"&gt;As of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zHj2r2sgCHW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zMl8VEXKF1s5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zzzVCxMlgfGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQoP45FoKrEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zuRGKEbQQBi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;PV of Payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z7JAV7O5pPTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription contextRef="From2021-01-012021-12-31">The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">74028</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">71872</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="From2018-09-292018-10-01"
      decimals="0"
      unitRef="USD">6107</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseExpirationDate1 contextRef="From2018-09-292018-10-01">2023-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:SecurityDeposit contextRef="AsOf2018-10-01" decimals="0" unitRef="USD">6480</us-gaap:SecurityDeposit>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="AsOf2021-12-31">P12M</us-gaap:LessorOperatingLeaseTermOfContract>
    <SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock_zGNZoOUwWE2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1CVxMNAGGw7" style="display: none"&gt;Schedule of Operating Lease Right of Use Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zIPeQCOX6197" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zGRdq5m7ruo" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfficeLease_iI_zByLv4uguS7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;265,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccumulatedAmortizationOnRightOfUseAssets_iNI_di_za6ldmTid0xk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,609&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_zQxRuTcj6KK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;171,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock>
    <SHPH:OfficeLease contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">265207</SHPH:OfficeLease>
    <SHPH:OfficeLease contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">265207</SHPH:OfficeLease>
    <SHPH:AccumulatedAmortizationOnRightOfUseAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">148225</SHPH:AccumulatedAmortizationOnRightOfUseAssets>
    <SHPH:AccumulatedAmortizationOnRightOfUseAssets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">93609</SHPH:AccumulatedAmortizationOnRightOfUseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">116982</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">171598</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRhltcKRLqyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zZms85qMdgaf" style="display: none"&gt;Schedule
of Operating
Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zdZcv5DI5bpg" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zSX1D7qU6WY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;Office Lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zeMS8XHFzwh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,934&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_znebceF7M491" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">129376</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">66934</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">62442</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z98Fy6YXydx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Maturities of lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zMMRA9wuYNOj" style="display: none"&gt;Schedule Of Operating Lease Maturity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231_ztevs8lGFSs" style="text-align: center"&gt;As of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zHj2r2sgCHW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zMl8VEXKF1s5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zzzVCxMlgfGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQoP45FoKrEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zuRGKEbQQBi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;PV of Payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129,376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">76248</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">64800</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">141048</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11672</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">129376</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgV7cbTOJVHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_82B_zue1ELM5AIeb"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 25, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_ziaj3PvHRAmb" title="Notes payable related party debt principal balance"&gt;300,000&lt;/span&gt;. The loan bears
interest at the rate of &lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180124__20180125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zxv3KbgJXN33" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum. The loan plus accrued interest was payable in full on January 25, 2019. On January 25, 2019,
the Company amended the loan for purposes of extending the maturity date from &lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zc013yLOUBOe" title="Notes payable related party maturity date"&gt;January 25, 2019&lt;/span&gt;, to &lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionDate_dd_c20190124__20190125__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_z9D8xe0Q60Rh" title="Notes payable related party maturity date"&gt;October 25, 2020&lt;/span&gt;. On &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20180124__20180125_zkIxMRnmJS55" title="Debt maturity, description"&gt;December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021&lt;/span&gt;, bringing the total amount owed under the loan,
together with accrued interest of $&lt;span id="xdx_907_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zD63Fsdxwbsi" title="Accrued interest"&gt;64,084&lt;/span&gt;, to a total of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zcNp4SbZ0cH2" title="Notes payable related party debt plus accrued interest"&gt;364,084&lt;/span&gt;. This note was rolled into the note referenced below with a principal
amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesOneMember_zH39XI1L8eIl" title="Principal amount"&gt;424,056&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 4, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zTiCpL3U3hlb" title="Notes payable related party debt principal balance"&gt;50,000&lt;/span&gt;. The loan bears
an interest rate of &lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180403__20180404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z69480AXTxgf" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum. The loan plus accrued interest was payable in full on September 4, 2018. On October 31, 2018, the
Company amended the terms to extend the maturity date from &lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z6RsAiK6BqMh" title="Notes payable related party maturity date"&gt;September 4, 2018&lt;/span&gt;, to &lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zqvxRWSCRsff" title="Notes payable related party maturity date"&gt;April 4, 2019&lt;/span&gt;. On April 4, 2019, the Company amended
the terms to extend the maturity date from April 4, 2019, to October 25, 2020. On &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20180403__20180404_zZXawIIW4KW4" title="Debt maturity, description"&gt;December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021&lt;/span&gt;, bringing the total amount owed under the loan, together with accrued interest of
$&lt;span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zf0XvZ6quGL5" title="Accrued interest"&gt;9,972&lt;/span&gt;, to a total of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_zpArJH6UU8fi" title="Notes payable related party debt plus accrued interest"&gt;59,972&lt;/span&gt;. This note was rolled into the note referenced below with a principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesTwoMember_z3dN2qTgVwl9" title="Principal amount"&gt;424,056&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30, 2018, the Company entered into a loan with an officer of the Company in the amount of $&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zCAgiurrO8rc" title="Notes payable related party debt principal balance"&gt;25,000&lt;/span&gt;. The loan bears an interest rate
of &lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20180529__20180530__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zHMFD4PKABwd" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum. The loan plus accrued interest was payable in full on July 15, 2018. On October 31, 2018, the Company amended the
terms to extend the maturity date from &lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zllr31sa1F9" title="Notes payable related party maturity date"&gt;July 15, 2018&lt;/span&gt;, to &lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionDate_dd_c20181030__20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zzX8SlZEoREc" title="Notes payable related party maturity date"&gt;November 30, 2020&lt;/span&gt;. On &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20180529__20180530_z5uXZGEZvGFc" title="Debt maturity, description"&gt;December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021&lt;/span&gt;, bringing the total amount owed under the loan, together with accrued interest of
$&lt;span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zuJ3zeqqiY8g" title="Accrued interest"&gt;4,698&lt;/span&gt;, to a total of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_z4R4JbzIWDz" title="Notes payable related party debt plus accrued interest"&gt;29,698&lt;/span&gt;. This note was rolled into the note reference below with a principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesThreeMember_zXw7NUwGwtDf" title="Principal amount"&gt;138,448&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zAtaw5etE5sd" title="Notes payable related party debt principal balance"&gt;70,000&lt;/span&gt;. The loan bore interest
rate of &lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zdzVaV8LZCL1" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum and required monthly payments of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_zuYg1aef7bH4" title="Monthly payment"&gt;6,073&lt;/span&gt;. The loan plus accrued interest was paid in full on &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20190623__20190624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFourMember_z5PhWEq2L4rl" title="Debt instrument, maturity date"&gt;June 30, 2020&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zhB7TV86pA67" title="Notes payable related party debt principal balance"&gt;70,000&lt;/span&gt;. The loan bore
an interest rate of &lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zGlhPkLe7MD2" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum and required monthly payments of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_z1jrzoeS9Yh5" title="Monthly payment"&gt;6,073&lt;/span&gt;. The loan plus accrued interest was paid in full on &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20190823__20190824__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesFiveMember_zrYsvyir1byk" title="Debt instrument, maturity date"&gt;August
23, 2020&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zde2Jp2Lp7e9" title="Notes payable related party debt principal balance"&gt;100,000&lt;/span&gt;. The loan
bore an interest rate of &lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_z5zZGaYsHaw1" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum and became payable in full on &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20190922__20190923__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zQF7WgHVecC" title="Debt instrument, maturity date"&gt;September 22, 2020&lt;/span&gt;. This note was rolled into the note reference
below with a principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__custom--NotesPayableOtherPayablesSixMember_zi6mQafHA2Jj" title="Principal amount"&gt;138,448&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zvSTsmjveRp2" title="Notes payable related party debt principal balance"&gt;424,056&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z1qcw8IFirVd" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum, with a maturity date of &lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCKaR0uOZh5b" title="Notes payable related party maturity date"&gt;December 31, 2021&lt;/span&gt;; and (ii) a single loan
owed to an officer of the company in the principal amount of $&lt;span id="xdx_908_ecustom--RelatedPartyTransactionAmountsOfTransactions_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zLUZIfTwEEck" title="Notes payable related party debt principal balance"&gt;138,449&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zvBk6xrXF8gc" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum, with a maturity
date of &lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDate_dd_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zviIvjcujOa1" title="Notes payable related party maturity date"&gt;December 31, 2021&lt;/span&gt;. In December of 2021 the maturity dates of these loans were extended to June 30, 2022. As of December 31, 2021,
the accrued interest was $&lt;span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zjRZs7A3t3j" title="Interest payable current"&gt;31,804&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zbWGQaY9snX6" title="Interest payable current"&gt;10,384&lt;/span&gt;, and the total balances with accrued interest of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zIP9oj6WWQvj" title="Notes payable related party debt plus accrued interest"&gt;458,047&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z5po8X8hcDjj" title="Notes payable related party debt plus accrued interest"&gt;149,613&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zDHoYtcfSsrb" title="Notes payable related party debt principal balance"&gt;120,000&lt;/span&gt; (principal) with
an interest rate of &lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zOUt5WlmIToe" title="Notes payable related party transaction rate"&gt;7.5&lt;/span&gt;% per annum due June 21, 2022, due at maturity. As of December 31, 2021, the accrued interest was $&lt;span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zZTGcwZ2cfg" title="Accrued interest"&gt;4,759&lt;/span&gt; and the
total balances with accrued interest of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zoPLNMS0oK63" title="Notes payable related party debt plus accrued interest"&gt;124,759&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2018-01-242018-01-25_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesOneMember">2019-01-25</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2019-01-242019-01-25_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesOneMember">2020-10-25</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2018-01-242018-01-25">December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember"
      decimals="0"
      unitRef="USD">64084</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember"
      decimals="0"
      unitRef="USD">364084</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesOneMember"
      decimals="0"
      unitRef="USD">424056</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2018-04-032018-04-04_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesTwoMember">2018-09-04</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesTwoMember">2019-04-04</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2018-04-032018-04-04">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember"
      decimals="0"
      unitRef="USD">9972</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember"
      decimals="0"
      unitRef="USD">59972</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesTwoMember"
      decimals="0"
      unitRef="USD">424056</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2018-05-292018-05-30_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MinimumMember_custom_NotesPayableOtherPayablesThreeMember">2018-07-15</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2018-10-302018-10-31_custom_OfficersSpouseMember_srt_MaximumMember_custom_NotesPayableOtherPayablesThreeMember">2020-11-30</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2018-05-292018-05-30">December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember"
      decimals="0"
      unitRef="USD">4698</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember"
      decimals="0"
      unitRef="USD">29698</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesThreeMember"
      decimals="0"
      unitRef="USD">138448</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember"
      decimals="0"
      unitRef="USD">70000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember"
      decimals="0"
      unitRef="USD">6073</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-06-232019-06-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFourMember">2020-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember"
      decimals="0"
      unitRef="USD">70000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember"
      decimals="0"
      unitRef="USD">6073</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-08-232019-08-24_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesFiveMember">2020-08-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-09-222019-09-23_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember">2020-09-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_custom_NotesPayableOtherPayablesSixMember"
      decimals="0"
      unitRef="USD">138448</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">424056</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <SHPH:RelatedPartyTransactionAmountsOfTransactions
      contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">138449</SHPH:RelatedPartyTransactionAmountsOfTransactions>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">31804</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">10384</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">458047</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_RelatedPartyOfficerMember"
      decimals="0"
      unitRef="USD">149613</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">4759</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_OfficersSpouseMember_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">124759</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zeswcbZw9T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 - &lt;span id="xdx_828_zF9fjtDCFVra"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 9, 2021, the Company obtained a $&lt;span id="xdx_90D_eus-gaap--MediumTermNotes_iI_c20210309_z1t8aWehYrWh" title="Term notes issued"&gt;73,007&lt;/span&gt; term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#x2019;s Paycheck
Protection Program (the &#x201c;PPP&#x201d;). The note bears an interest rate of &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_zBkMzrjwAEE1" title="Interest rate"&gt;1&lt;/span&gt;% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#x2019;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. As of December 31, 2021, a &#x201c;Loan Forgiveness Application&#x201d; was submitted to PNC Bank along with the
requested documentation and subsequent to the close of the December 31, 2021, reporting period the note liability was reduced in its
entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2020, the Company obtained a $&lt;span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20200515_zWqO2LbvoP6a" title="Term notes issued"&gt;62,500&lt;/span&gt; term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#x2019;s Paycheck
Protection Program (the &#x201c;PPP&#x201d;). The note bears an interest rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200515_zQqWltLwz2Ic" title="Interest rate"&gt;1&lt;/span&gt;% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&#x2019;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. A &#x201c;Loan Forgiveness Application&#x201d; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zEJQH7FsQBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z7x0Bf5QV6J7" style="display: none"&gt;Schedule
of Notes Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zs8ZjEzR5as6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20201231_z5ddmsxg9gG3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zlKWCVwANhc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zAwg53kad8Uj" title="Debt maturity date"&gt;May 15, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zKIGQqEGOeIc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_ztFm5G3svYx7" title="Debt maturity date"&gt;March 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LoanForgiveness_iI_zed16WxGRXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NotesPayable_iI_zCp6BUuAMjk8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z3EMa0tpeiZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2021, the Company issued $&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20211228_zcmhoubBafya" title="Notes payable"&gt;500,000&lt;/span&gt; note units, consisting of two $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zUFrLFDAvifi" title="Notes payable"&gt;250,000&lt;/span&gt; notes, for a total of $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211228__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNotesMember_zZlcggDXmFga" title="Notes payable"&gt;500,000&lt;/span&gt; &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zrCIkl2P8ikd" title="Interest rate"&gt;10&lt;/span&gt;% unsecured promissory
notes with a maturity date of &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z4Dxj02eBRtc" title="Debt maturity date"&gt;December 28, 2022&lt;/span&gt;, and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zXo1AtI4bHj4" title="Warrants to purchase of common stock"&gt;500,000&lt;/span&gt; warrants exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_zXs4eR6Ol0ta" title="Exercise price of warrants"&gt;1.00&lt;/span&gt; per share with an expiry date of December
28, 2026, and fees of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_iI_c20211228_zcE58aOZgKAf" title="Debt fee amount"&gt;5,075&lt;/span&gt;. The value of the warrants was determined using a computed volatility of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSx2U7ZLDDt5" title="Volatility rate"&gt;85.5&lt;/span&gt;%, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF8MylifPkUj" title="Dividend rate"&gt;0&lt;/span&gt;% dividend rate, and a
risk free interest rate of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211228__20211228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMlII9Z5iwQg" title="Risk free interest rate"&gt;1.27&lt;/span&gt;% and was applied as a discount on the notes payable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4nwu7JkSlxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zF9q91NBsww7" style="display: none"&gt;Schedule
of Promissory Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zScL1QxrrD58" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z7eF9AhBvJH" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;Promissory notes issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zEYM2T1Dfl7c" title="Debt maturity date"&gt;December 28, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zwVIHIq0ckw6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less unamortized discount on notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(408,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zRjlbHqT2Zb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zAIXs23KZWDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:MediumTermNotes contextRef="AsOf2021-03-09" decimals="0" unitRef="USD">73007</us-gaap:MediumTermNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-03-09" decimals="INF" unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MediumTermNotes contextRef="AsOf2020-05-15" decimals="0" unitRef="USD">62500</us-gaap:MediumTermNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-05-15" decimals="INF" unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zEJQH7FsQBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z7x0Bf5QV6J7" style="display: none"&gt;Schedule
of Notes Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zs8ZjEzR5as6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20201231_z5ddmsxg9gG3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zlKWCVwANhc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableOneMember_zAwg53kad8Uj" title="Debt maturity date"&gt;May 15, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NotesPayable_iI_hus-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_zKIGQqEGOeIc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;PPP Note &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramNotePayableTwoMember_ztFm5G3svYx7" title="Debt maturity date"&gt;March 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LoanForgiveness_iI_zed16WxGRXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loan Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NotesPayable_iI_zCp6BUuAMjk8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember">2020-05-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableOneMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-12-31_custom_PaycheckProtectionProgramNotePayableOneMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember">2021-03-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_PaycheckProtectionProgramNotePayableTwoMember"
      decimals="0"
      unitRef="USD">73007</us-gaap:NotesPayable>
    <SHPH:LoanForgiveness contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-62500</SHPH:LoanForgiveness>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73007</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">62500</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-28" decimals="0" unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-28_us-gaap_NotesPayableOtherPayablesMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-28_custom_UnsecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-12-28" decimals="INF" unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-12-282021-12-28">2022-12-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-12-28" decimals="INF" unitRef="Shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-28"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2021-12-28" decimals="0" unitRef="USD">5075</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-12-282021-12-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4nwu7JkSlxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zF9q91NBsww7" style="display: none"&gt;Schedule
of Promissory Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zScL1QxrrD58" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_z7eF9AhBvJH" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;Promissory notes issued on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb21pc3NvcnkgTm90ZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteOneMember_zEYM2T1Dfl7c" title="Debt maturity date"&gt;December 28, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_msLTDzxfV_zwVIHIq0ckw6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less unamortized discount on notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(408,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_mtLTDzxfV_zRjlbHqT2Zb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-12-31_custom_PromissoryNoteOneMember">2021-12-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2021-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">408979</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">91021</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJOFMLgMcr2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82F_zYWN4IZTowha"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Company&#x2019;s amended and restated articles of incorporation, the Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zqmLmrckmf51" title="Common Stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of common
stock, with a par value of $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zmu3E0EDFesh" title="Common stock, par value (in dollars per share)"&gt;0.00001&lt;/span&gt; per share, and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z2Y5sNmXI658" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; shares of preferred stock, with a par value of $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zdNWjXHIUN8l" title="Preferred stock par value"&gt;0.00001&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
A Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#x2019;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&#x2019;s common stock on a national securities exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, and 2020, the Company had &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOTJy3GY9uFa" title="Preferred Stock, shares outstanding"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsjVxLIUMvzd" title="Preferred Stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJgeknCVqbCf" title="Preferred Stock, shares outstanding"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zE0wdkBs3Ue7" title="Preferred Stock, shares issued"&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Series A Preferred Stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, and 2020, the Company had accrued the &lt;span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zj8eEaa8Nol4" title="Preferred stock dividend rate"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHD9RT1BBwDe" title="Preferred stock dividend rate"&gt;8.5&lt;/span&gt;&lt;/span&gt;% cumulative dividends on the Series A Preferred stock of $&lt;span id="xdx_90D_eus-gaap--PreferredStockValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUPcQNVJm4M3" title="Preferred stock value"&gt;331,059&lt;/span&gt; and
$&lt;span id="xdx_90F_eus-gaap--PreferredStockValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFisKpopTzcl" title="Preferred stock value"&gt;227,997&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, and 2020, the Company had &lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20211231_zDdr296UZk3b" title="Common Stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_ztynPIhxgAsf" title="Common Stock, shares outstanding"&gt;9,312,152&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20201231_z6RWhStahwGh" title="Common Stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zEAN0207Spo2" title="Common Stock, shares outstanding"&gt;9,291,526&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding, respectively.
The balance includes &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofyvVudYVxc" title="Common stock issued for restricted stock units, shares"&gt;20,626&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoj8d0RhakV5" title="Common stock issued for restricted stock units, shares"&gt;21,530&lt;/span&gt; shares of restricted stock issued in 2021 and 2020 respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock to be Issued&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 4, 2018, $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20180604_zU2hW2gE3742" title="Convertible notes"&gt;120,250&lt;/span&gt; outstanding convertible notes were converted to &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z3u4hGHNlJD4" title="Debt converted into common stock"&gt;6,182&lt;/span&gt; shares of common stock of the Company at a price of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zJ12HcFHlna4" title="Conversion price"&gt;19.44&lt;/span&gt;
per share. The Company has recorded $&lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20180604__20180604__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z5OcV4XFuU01" title="Debt converted into common stock, value"&gt;16,340&lt;/span&gt; of common stock to be issued for the accrued interest. As of December 31, 2020 and 2021,
the common stock has not been issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock sold in the private placement offerings, included warrants to be issued upon the earlier of a closing of the
sale of shares of common stock to the public at a prices per share of at least $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20211231_z8xagu8x2f2a" title="Share price"&gt;13.88&lt;/span&gt; or in a firm commitment underwritten public offering
pursuant to an effective registration statement resulting in gross proceeds of at least $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zycRFeTR9Urg" title="Proceeds from initial public offerings"&gt;15,000,000&lt;/span&gt;. The warrants shall be exercisable
for a period of three years after the date of issuance. The warrant exercise price is contingent on the terms of the public offering.
If an initial public offering occurs at a price at or above $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z62X2QT8yqFe" title="Share price"&gt;13.88&lt;/span&gt; per share, then the exercise price shall be set to the issuance price
of the common stock with the number of warrants determined based on a 10% discount to the per share common stock issuance price. In the
scenario where the common stock is listed with the common stock issuance price below $&lt;span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20210101__20211231_zaNFx9nt96Lb" title="Warrant exercise low price"&gt;13.88&lt;/span&gt;, the exercise price will be set to $&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231_zIDoOwqh0cn6" title="Warrant exercise price increase"&gt;20.82&lt;/span&gt;
with the number of warrants based on a fixed conversion price of $&lt;span id="xdx_90C_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20210101__20211231_zZYrxwzjqw86" title="Common stock, Conversion price"&gt;12.49&lt;/span&gt;, which represents a 10.0% discount to the $&lt;span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231_zPoS7a33NwV" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt; threshold. The
warrants also have contingent call features based on the terms of the public offering. If an initial public offering occurs at a price
at or above $&lt;span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVTqfcwTRkZk" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt;, then the warrants are callable if the 20-day VWAP of the common stock in at or above &lt;span id="xdx_90F_ecustom--PercentageOfVariableExercisePrice_pid_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs0BeknGg207" title="Percentage of variable exercise price"&gt;150%&lt;/span&gt; of the variable exercise
price. In the scenario where the common stock is listed with a common stock issuance price below $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zhTBmM4kryXf" title="Increase in common stock conversion price"&gt;13.88&lt;/span&gt;, then the warrants are callable
if the 20-day VWAP of the common stock is at or above the $&lt;span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za22Npow9PX7" title="Warrant exercise price increase"&gt;20.82&lt;/span&gt; exercise price. The detachable warrants contained terms and features
that gave rise to derivative liability classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liability linked to the Series A Preferred Stock as of December 31, 2021 and 2020 was $&lt;span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwaJvWUkYSz7"&gt;94,025
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_909_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZ7vcqJAGOWd"&gt;673,171&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. The change in fair value of warrant liability was a gain of $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBi59iJAXl"&gt;579,146
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as of December 31, 2021 and a loss of $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znbzoMXbSu3h"&gt;256,580
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zqrSyCvFjEMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zS9WSxHJNIXh" style="display: none"&gt;Schedule Of Stock Options, Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;Expected average volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zzZd2zSHWZb5" title="Expected volatility"&gt;85.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zxheEKRT7OYf" title="Expected volatility"&gt;69.8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zpgZ1YZFEyve" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zv1bW8CFMpw9" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zlNTKtD2QOnj" title="Expected life"&gt;2.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z59ra0LR6fpd" title="Expected life"&gt;3.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zlxJazmtaUHj" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zZ9jfDpLPPI5" title="Risk-free interest rate"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zeDQOtB9mNm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zTzjVKqsXQ0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Series A Preferred Stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zoAtzKTNqnb4" style="display: none"&gt;Schedule
of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average Life &lt;br/&gt;
(years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic &lt;br/&gt;
Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGJXH4vqT4g3" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxacmSgngLd1" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUF19Q2fWyOb" title="Weighted Average Remaining Life in Years Outstanding"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwXUtfIylJwe" style="width: 12%; text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCpyCdI6bKig" style="text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziER2wFJ8At9" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCI3PYy22nyk" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3FRt72pUq7k" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhjBy06R5li3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zggVAJWPLXyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZXwl3qiVQUh" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1UF2OS1H3h7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyYeEN31fxOc" title="Weighted Average Remaining Life in Years Outstanding"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCv4qGki3iv4" style="text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyUcgegtfU0d" style="text-align: right" title="Number of Warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2251"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoTiqWpp5v77" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjyGRJa1HEhf" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2255"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8gAZuUdIi3f" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg3J5QbCGnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2259"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTvaRVkvP63a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding and Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zciR8WEnUiXh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cSpiTgKCcd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;24.98&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5EEhfd6Lr21" title="Weighted Average Remaining Life in Years Outstanding"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4uV5MkPbHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zNG4gJ7WsYa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#x2019;s compensation committee or,
alternatively, if there is no compensation committee, the Company&#x2019;s board of directors. We have reserved &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zC4rmGYlSjsc" title="Common stock reserved for future issuance"&gt;3,000,000&lt;/span&gt; shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of December 31, 2021, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zGVxAssdvL8l" title="Share granted under equity incentive plan"&gt;384,167&lt;/span&gt; shares have been granted under the 2018
Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement pursuant to which they will serve as a director and pursuant to which they would each receive a grant of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190816__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFeLlgpGRcM5" title="Share granted under equity incentive plan"&gt;75,000&lt;/span&gt; worth
of Restricted Stock Units (&#x201c;RSUs&#x201d;) issuable under the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;).
The RSUs vest annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20190816__20190816__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RZrX46Zjme" title="Restricted stock value"&gt;25,000&lt;/span&gt; per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2021 and 2020, pursuant to the agreements with directors and officers &lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zhzvnX1ARNmj" title="Share based compensation"&gt;20,626&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember_zRYz075b8zUk" title="Share based compensation"&gt;21,530&lt;/span&gt; RSUs were issued
with a value of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8ylF59eZsg6" title="Share based compensation"&gt;490,067&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQdA6Nr8en2c" title="Share based compensation"&gt;459,589&lt;/span&gt; included in wages, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, there was $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuaVhtPSHXPg" title="Unrecognized compensation cost"&gt;390,067&lt;/span&gt; of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the next two years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z7J26BhMgTZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Restricted Stock Units (RSU) follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zD2cjcYwwuee" style="display: none"&gt;Schedule
of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSU&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGy8hGU7H6Xk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;60,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfV9RQHPHnO" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;24.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28RkmioCX4d" title="Weighted Average Life (Years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2295"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN4n3nTXpXob" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;4,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8Xq9TXq6oca" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;22.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOH1D3MKKA46" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zebTa7ZZJWMg" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjwYmKlTdna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlNxm3U5p3jj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhYdez79ua7j" style="text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;61,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EEh9u8Rny9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;23.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcTHzBsvqd9" title="Weighted Average Life (Years)"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvGxO5u1nf9" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQZHtFixO4o1" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfMc4kDyj2b2" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztWDydoEqsd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJkxxHKumOpe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmHKnly3tlMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance"&gt;59,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJO11isFw8pk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;23.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc9pi5v9Xl3g" title="Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZO4vwClYXi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable"&gt;43,056&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTf5l0KEVdf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable"&gt;23.93&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoj6q8oIA391" title="Exercisable Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1213</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">331059</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">227997</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9312152</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">9291526</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">9291526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20626</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">21530</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2018-06-04" decimals="0" unitRef="USD">120250</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      unitRef="Shares">6182</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      unitRef="USDPShares">19.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2018-06-042018-06-04_custom_CommonStockToBeIssuedMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:SharePrice>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">20.82</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">12.49</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2021-01-012021-12-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <SHPH:PercentageOfVariableExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Pure">1.50</SHPH:PercentageOfVariableExercisePrice>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2021-01-012021-12-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">13.88</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">20.82</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">94025</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">673171</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember52284281"
      decimals="0"
      unitRef="USD">579146</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember52285078"
      decimals="0"
      unitRef="USD">256580</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zqrSyCvFjEMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zS9WSxHJNIXh" style="display: none"&gt;Schedule Of Stock Options, Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;Expected average volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zzZd2zSHWZb5" title="Expected volatility"&gt;85.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zxheEKRT7OYf" title="Expected volatility"&gt;69.8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zpgZ1YZFEyve" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zv1bW8CFMpw9" style="text-align: right" title="Dividend yield"&gt;8.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zlNTKtD2QOnj" title="Expected life"&gt;2.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z59ra0LR6fpd" title="Expected life"&gt;3.33&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zlxJazmtaUHj" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zZ9jfDpLPPI5" title="Risk-free interest rate"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31">P2Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31">P3Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zTzjVKqsXQ0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Series A Preferred Stock warrants is set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zoAtzKTNqnb4" style="display: none"&gt;Schedule
of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average Life &lt;br/&gt;
(years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic &lt;br/&gt;
Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGJXH4vqT4g3" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxacmSgngLd1" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUF19Q2fWyOb" title="Weighted Average Remaining Life in Years Outstanding"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwXUtfIylJwe" style="width: 12%; text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCpyCdI6bKig" style="text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziER2wFJ8At9" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCI3PYy22nyk" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3FRt72pUq7k" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhjBy06R5li3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zggVAJWPLXyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZXwl3qiVQUh" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;48,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1UF2OS1H3h7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;24.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyYeEN31fxOc" title="Weighted Average Remaining Life in Years Outstanding"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCv4qGki3iv4" style="text-align: right" title="Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyUcgegtfU0d" style="text-align: right" title="Number of Warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2251"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoTiqWpp5v77" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjyGRJa1HEhf" style="text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2255"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8gAZuUdIi3f" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg3J5QbCGnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2259"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTvaRVkvP63a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding and Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zciR8WEnUiXh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;48,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cSpiTgKCcd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;24.98&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5EEhfd6Lr21" title="Weighted Average Remaining Life in Years Outstanding"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4uV5MkPbHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">P4Y3M29D</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">P3Y3M29D</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">48532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">24.98</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_SeriesAPreferredStockMember">P2Y3M29D</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">384167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2019-08-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2019-08-162019-08-16_srt_DirectorMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember"
      decimals="0"
      unitRef="USD">20626</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember"
      decimals="0"
      unitRef="USD">21530</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">490067</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_DirectorsAndOfficerMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">459589</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">390067</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z7J26BhMgTZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
continuity schedule of the Restricted Stock Units (RSU) follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zD2cjcYwwuee" style="display: none"&gt;Schedule
of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSU&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGy8hGU7H6Xk" style="width: 12%; text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;60,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfV9RQHPHnO" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;24.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28RkmioCX4d" title="Weighted Average Life (Years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2295"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN4n3nTXpXob" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;4,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8Xq9TXq6oca" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;22.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOH1D3MKKA46" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zebTa7ZZJWMg" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjwYmKlTdna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlNxm3U5p3jj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding, December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhYdez79ua7j" style="text-align: right" title="Number of Stock Option Outstanding, Beginning Balance"&gt;61,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EEh9u8Rny9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;23.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcTHzBsvqd9" title="Weighted Average Life (Years)"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvGxO5u1nf9" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQZHtFixO4o1" style="text-align: right" title="Number of Stock Option Outstanding, Forfeited"&gt;(2,702&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfMc4kDyj2b2" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;27.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztWDydoEqsd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJkxxHKumOpe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmHKnly3tlMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Ending Balance"&gt;59,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJO11isFw8pk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;23.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc9pi5v9Xl3g" title="Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZO4vwClYXi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option, exercisable"&gt;43,056&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTf5l0KEVdf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, exercisable"&gt;23.93&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoj6q8oIA391" title="Exercisable Weighted Average Life (Years)"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">60169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">24.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">4417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">22.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">27.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">61884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">P4Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">27.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">59182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">P3Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">43056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">23.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">P3Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zKgTM9QEZJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82C_zRXUrVVPJdTl"&gt;Income Taxes (Restated)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not made provision for income taxes for the years ended December 31, 2021, since the Company has the benefit of net operating
losses in these periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zfpTJrpMXd9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcC0lCcc0xA5"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_z0l80A5F9c28" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zjx3wEimIymc" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20201231_zmrMSFl6fEi8" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(Restated)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zMQzg6FtDgxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(241,948&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zEsuz5Cwkrxl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(95,051&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,293&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_zgPBp4WFMv3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zMNAxT1v2cy8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317,618&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zEOpZnHn4vZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2355"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zxVODHcZRn3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVqWKqV9sse3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z3jVIxUWCK47" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zm8TRJoHJWl6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20201231_z62SpSjAcV7k" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(Restated)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzOFC_zzmIcFjC0vv5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Net operation loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;890,970&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;587,699&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzOFC_zg6BYHQ13JA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzOFC_z6hOw8owWjlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetInterestCarryforward_iI_maDTAGzOFC_zFYATNHgeXYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzOFC_z4t5PiJIEgv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzOFC_maDTANzoN8_zQdjZxKskwAi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoN8_zzcDn27G6w6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,039,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(721,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoN8_zb7Vji106gv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2380"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2381"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z0qYBc8kUl23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has approximately $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zQSm8R518ktg" title="Operating loss carryforwards"&gt;3,000,000&lt;/span&gt; of net operating losses (&#x201c;NOL&#x201d;) carried forward to offset taxable income, if any, in
future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on
the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs for every
period because it is more likely than not that all of the deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zfpTJrpMXd9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcC0lCcc0xA5"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_z0l80A5F9c28" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zjx3wEimIymc" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20201231_zmrMSFl6fEi8" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(Restated)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zMQzg6FtDgxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(241,948&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zEsuz5Cwkrxl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(95,051&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,293&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_zgPBp4WFMv3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zMNAxT1v2cy8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317,618&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zEOpZnHn4vZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2355"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-241948</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-21111</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-95051</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-8293</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19381</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">19381</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">317618</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">10023</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVqWKqV9sse3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z3jVIxUWCK47" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zm8TRJoHJWl6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20201231_z62SpSjAcV7k" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(Restated)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzOFC_zzmIcFjC0vv5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Net operation loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;890,970&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;587,699&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzOFC_zg6BYHQ13JA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzOFC_z6hOw8owWjlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetInterestCarryforward_iI_maDTAGzOFC_zFYATNHgeXYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzOFC_z4t5PiJIEgv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzOFC_maDTANzoN8_zQdjZxKskwAi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoN8_zzcDn27G6w6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,039,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(721,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoN8_zb7Vji106gv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2380"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2381"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">890970</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">587699</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7479</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8110</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7788</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7788</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">45574</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">30596</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">87801</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">87801</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1039612</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">721994</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1039612</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">721994</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ErrorCorrectionTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_805_eus-gaap--ErrorCorrectionTextBlock_ziNNLYktv2F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_823_z3AQT96MY1i6"&gt;Restatement of Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial statements as of and for the year ended December 31, 2021, contained an understatement of legal and professional
expenses of $&lt;span id="xdx_90D_eus-gaap--LegalFees_c20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zwd2SFrgbQHj" title="Legal and professional"&gt;420,000&lt;/span&gt; for the valuation of a total of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231_zPA07Qu17mz2" title="Shares issued"&gt;210,000&lt;/span&gt; shares (&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20210101__20211231_zXbkI9X12ch4" title="Post split"&gt;105,000&lt;/span&gt; shares on a post-split basis) of incentive stock transferred
from a significant shareholder of the Company , who is also the wife of our Chairman and CEO, to a consultant for the Company in a private
transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zrQCbsF8GlR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zHqsuMlFkPke" style="display: none"&gt;Schedule
of Error Corrections and Prior Period Adjustments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7rhXTFinxua" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Originally&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reported&lt;br/&gt; ($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zA3FNhfJBlJa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zcqwd6LQgrzd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zDBaXJwDx9Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_zln5uBsBYHn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,730,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,150,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zMPE94sVvJVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,375,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,795,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
Ended December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPifdA6smGZ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Originally &lt;br/&gt;
Reported &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zws6ZyNjQgkd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_zTZDMpCuETek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As &lt;br/&gt;
Restated &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zPrs4NLrg89i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;OPERATING EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LegalFees_i01_z0Hbf5NRlM45" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;264,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;684,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingExpenses_i01_zAJ0lsN7xFVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,322,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,742,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zMIZK59m6f5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,322,992&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,742,992&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zSedjX2VsXOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Loss before Income Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_zlloZelMBcB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJhHtr5hWeEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(835,196&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,255,196&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zKPH6nydBU59" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss per shares - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeVIxtMrSjn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Originally &lt;br/&gt;
Reported &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyfQ25RK6Ach" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zfIlx8K5HED8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As&lt;br/&gt;
 Restated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zs4cRQ0OtDG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash Flows From Operating Activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zIkx9Tj0O3gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zdOSwsZHODke" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zV1WtBGFe06a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ErrorCorrectionTextBlock>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:LegalFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">210000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">105000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zrQCbsF8GlR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zHqsuMlFkPke" style="display: none"&gt;Schedule
of Error Corrections and Prior Period Adjustments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7rhXTFinxua" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Originally&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reported&lt;br/&gt; ($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zA3FNhfJBlJa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zcqwd6LQgrzd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zDBaXJwDx9Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_zln5uBsBYHn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,730,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,150,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zMPE94sVvJVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,375,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,795,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
Ended December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPifdA6smGZ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Originally &lt;br/&gt;
Reported &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zws6ZyNjQgkd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_zTZDMpCuETek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As &lt;br/&gt;
Restated &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zPrs4NLrg89i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;OPERATING EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LegalFees_i01_z0Hbf5NRlM45" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;264,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;684,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingExpenses_i01_zAJ0lsN7xFVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,322,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,742,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zMIZK59m6f5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,322,992&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,742,992&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zSedjX2VsXOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Loss before Income Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_zlloZelMBcB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJhHtr5hWeEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(835,196&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,255,196&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zKPH6nydBU59" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loss per shares - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeVIxtMrSjn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Originally &lt;br/&gt;
Reported &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyfQ25RK6Ach" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restatement &lt;br/&gt;
Adjustment&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zfIlx8K5HED8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As&lt;br/&gt;
 Restated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zs4cRQ0OtDG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash Flows From Operating Activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zIkx9Tj0O3gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(732,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(420,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(1,152,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zdOSwsZHODke" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">3730867</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4150867</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-5375432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-5795432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">264684</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">684684</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">1322992</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1742992</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-1322992</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1742992</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-732134</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-732134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-835196</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1255196</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="INF"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-732134</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">-420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1152134</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">490067</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_srt_RestatementAdjustmentMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">910067</us-gaap:ShareBasedCompensation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-012021-12-31">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z343XKlw7CQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_82B_zWuhxLDwk3wj"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluated all additional events subsequent to the balance sheet date through June 3, 2022, the date the financial statements were available
to be issued, and determined the following items:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 22, 2022, the Company received notice of forgiveness for the PPP loan entered into on March 9, 2021 for $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220121__20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzkm1op1Eps9" title="Debt instrument decrease forgiveness"&gt;73,007&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--InterestReceivable_iI_c20220122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpcJCURlSL3a" title="Interest receivable"&gt;641&lt;/span&gt; in interest
that reduced the note liability in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2022, and March 11, 2022, the Company sold $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGm5pZdmdnG1" title="Debt instrument face amount"&gt;365,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkYdx1sLJb0i" title="Debt instrument face amount"&gt;224,985&lt;/span&gt;, respectively, in &lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwn4ary0nN99" title="Conversion ratio"&gt;6&lt;/span&gt;% convertible notes (the &#x201c;Notes&#x201d;),
which bear &lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztLohKgLkqY4" title="Conversion ratio"&gt;6&lt;/span&gt;% interest, are repayable three years from the date of issuance, and will convert automatically into shares of common stock
(the &#x201c;Conversion Shares&#x201d;) at a conversion price of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9ZVzY2PLokh" title="Conversion price"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zea8xCWlhm7e" title="Conversion price"&gt;2.50&lt;/span&gt;&lt;/span&gt; per share upon closing of this offering. Boustead Securities LLC
acted as placement agent for this offering and received compensation of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9q7eG1gwJUl" title="Share based compensation"&gt;36,500&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXkEALhBootf" title="Share based compensation"&gt;22,250&lt;/span&gt;, respectively, and warrants to purchase shares
of common stock equal to &lt;span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220207__20220208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxh0jNKYsmT2" title="Conversion shares"&gt;&lt;span id="xdx_90E_ecustom--DebtInstrumentConvertibleConversionSharesPercentage_dp_uPure_c20220310__20220311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWXIjTdDQ05f" title="Conversion shares"&gt;10&lt;/span&gt;&lt;/span&gt;% of the Conversion Shares, exercisable at the conversion price of the Convertible Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 30, 2022, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwZ9OkBXUNz8" title="Shares issued"&gt;1,678&lt;/span&gt; shares (&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQeN58VOlfrf" title="Post reverse split"&gt;839&lt;/span&gt; shares post-reverse split) of common stock to correct an issuance error on completion
of the 2018 share exchange which is valued at $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220329__20220330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO0sgTPNFE9l" title="Value  issued"&gt;16,340&lt;/span&gt; common stock to be issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 1, 2022, pursuant to the consent of the Company&#x2019;s board of directors and a majority of its common stockholders, the Company
effectuated a two-for-one reverse split, pursuant to which each stockholder received one share of common stock for every two shares held.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 6, 2022, the Company submitted the final invoice for &#x201c;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity
for Radiation Late Effects,&#x201d; for $&lt;span id="xdx_904_ecustom--PaymentOfInvoice_c20220405__20220406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQ4Xvb2fA5" title="Value  issued"&gt;211,455&lt;/span&gt;, following the completion of the Final Quarterly Progress Report to NIH covering the
performance period of 9/16/2019-3/15/2022. The invoice was paid in full on April 27, 2022.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2022-01-212022-01-22_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">73007</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:InterestReceivable
      contextRef="AsOf2022-01-22_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">641</us-gaap:InterestReceivable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-02-08_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">365000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-03-11_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">224985</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-02-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">2.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-03-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">2.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">36500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">22250</us-gaap:ShareBasedCompensation>
    <SHPH:DebtInstrumentConvertibleConversionSharesPercentage
      contextRef="From2022-02-072022-02-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.10</SHPH:DebtInstrumentConvertibleConversionSharesPercentage>
    <SHPH:DebtInstrumentConvertibleConversionSharesPercentage
      contextRef="From2022-03-102022-03-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.10</SHPH:DebtInstrumentConvertibleConversionSharesPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">1678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">839</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-03-292022-03-30_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">16340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SHPH:PaymentOfInvoice
      contextRef="From2022-04-052022-04-06_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">211455</SHPH:PaymentOfInvoice>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001166"
          xlink:label="Fact001166"
          xlink:type="locator"/>
        <link:footnote id="Footnote001185" xlink:label="Footnote001185" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Value
                                            is net of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20220930_ztb990d1z0da"
  title="Stock issuance fees">1,407,262</xhtml:span> of fees associated with the issuances.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001166"
          xlink:to="Footnote001185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001168"
          xlink:label="Fact001168"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001168"
          xlink:to="Footnote001185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001174"
          xlink:label="Fact001174"
          xlink:type="locator"/>
        <link:footnote id="Footnote001188" xlink:label="Footnote001188" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
                                            <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zxJWTf8Slc52"
  title="Warrants, share">197,273</xhtml:span> broker warrants exercised on a cashless basis for <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930_z05yHoofofdl"
  title="Warrants issued for common stock, share">180,280 </xhtml:span>shares of common stock
                                            and warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTF3d7cbMim5"
  title="Number of shares exercise">1,409,771 </xhtml:span>shares of common stock exercised as part of the Company&#x2019;s
                                            initial public offering.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001174"
          xlink:to="Footnote001188"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001176"
          xlink:label="Fact001176"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001176"
          xlink:to="Footnote001188"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001182"
          xlink:label="Fact001182"
          xlink:type="locator"/>
        <link:footnote id="Footnote001195" xlink:label="Footnote001195" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
                                            <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930_zYRIFGjkcIbf"
  title="Conversion of common stock">336,810</xhtml:span> shares of common stock issued upon conversion of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt8xtp2ChpC"
  title="Preferred Stock, shares outstanding">1,213</xhtml:span> Preferred Shares and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNhbGUgb2YgRXF1aXR5IG9yIElzc3VlZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20220930__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredStockDividendPayableMember_zbhUviJ381j6"
  title="Conversion of common stock">100,517</xhtml:span>
                                            common shares to settle dividends payable balance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001182"
          xlink:to="Footnote001195"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001184"
          xlink:label="Fact001184"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001184"
          xlink:to="Footnote001195"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001311"
          xlink:label="Fact001311"
          xlink:type="locator"/>
        <link:footnote id="Footnote001318" xlink:label="Footnote001318" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
                                            <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zHCDdSOzDVRk"
  title="Warrants">197,273</xhtml:span> warrants exercised on a cashless basis for <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zLT8TIqWCuN2"
  title="Warrants">180,280</xhtml:span> common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001311"
          xlink:to="Footnote001318"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001313"
          xlink:label="Fact001313"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001313"
          xlink:to="Footnote001318"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MK]RBFR414*@,%$T(NT4?T=,J1C<_WDY=I0=DTKI)T_ECW;G_2N<K*.]0X'U
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M>D=9'69 4A!&H*]O.%<O#;.M;/]WF/\+4$L#!!0    ( /B(.5:"[5=-'@@
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M%NN=D"*B9\1MG2WKMK8S#;K"_E ::]/#,2E(JQ>+?%>=^F_U5SU/\9SUS5_
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ME'=X<=7K/S7;S_L^KO\'4$L#!!0    ( /B(.5;-=O,MH@D  .<W   8
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M3[]<SUIY*PIPMCQT>[_O%H]T&WN_5V6[;KQ4=I\![1-[>X0M #,9@V,@\(]
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M'!F@O1! =B6PJ,66YYDG7M7$%*" 128_GR(6X3#0O0:(/(Z,26E:A2$BNL=
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M1WQX[@HH<064.@ :!KVGTR2RSO&'W7:[/U3""\F/RFFWUT/[.[P 6,GZQ0N
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M_U4E)]GAA^K@^&[?[?\ 4$L#!!0    ( /B(.59QU%:<H@D  /<A   8
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M#L51(!Z]T=!M"2[NEK^KZ ?U*5"FK%7F5-G5T71 V70@=$K3$L%RAB11"G<
M4;(C%6& (@!<7(N1R]=.$^';'4L.+03PJ?9MX=(;EFWQFA*J!T%#!9PRUY56
M.%U:5@]QS.%M)ICOT&X@G1_%DC0\K;I&FD?@<L_JT$M4ZL%PD0P'=Q'9 IRH
M/?C(B0^ UIJ[RJT^KZPM6,A+U#=Q66#LT-1NLA5]BKYZ>3E0!>L\;!W'?21@
M83WPI7-QF0=&@V,4480,>@A4/T>8RD*5$G#HE2B.*!%"F=QV4,Z1^Y;0E,,R
MF!X<B)W2@MH/VI-+2M1=4:DZ0]]8TVO)SWSG,0D7_R[JZ&!_X+N<G<5'H)8J
M)GID.!HC^(10*I>Z)M[ &789)+\-7*13^>>\1,U 3!1%MT+N"IJS>3'<6U +
MD3L5&#M%!H@X2CM*4W0!5%D<PIO8@6S:+>11(B45%U;(6.+B(#19(UXEV+D0
MX?\T.KTUJ:DB,UUOSATD#^&#*+1_=:VH Z0R"NAQE2YH>ZY=WC5K!M\X!BKA
M(%G#%,?$#MT891F+3B5ISP&['189UK1 'G<CLEA#C"P5=W6[>AK,(UB<G+3J
M0N<4"HZB(J"RFV#S#^(&W4D0/S*!$HM<XL1:Q($0S?:F)U=JZ\7\>]2*[V?(
M.!:!EII$>!9Q:+KZB^>5AQ%E;T39&5#8-?=-)6([E60/4\G_W%22VF:2&KF6
MT_%A.OE_F$YH+#DPCZ2BD]TSCV 0^=H)!)WUG9E#_.G,D7WIS/'54X;XVBEC
M%Z,4J*^?*,1?-5%D_\5$(1XFBH>)XF&B>)@H'B:*STX4W.IG?:M/,)-Y'A6A
MF*Z&KX[\]JNC2D)_KF6@ <!-%;'@&.I>"&[,X:4R@$I=([V!TY95R3FTL7B@
M0FADN>\; BK.JFFY,M"U-ET<.?8IF:8**2+YYE'MP^V'-3B:3#9H:+WM7(X/
M'$K5D?2AF Q%>4NW0FZDH]:@;Q8H/B!A<M/?Q.GX]'@V?C*?X^K)#Z?CD^/Y
M_O3#&%,1BTZB/P)X6TTDC@?4M<3JP5G$_:!X#U07A6/:PZOD<2XM'SOMHL_W
M!QVD)Y+=QR9)?=CNR?I27*AE(!"1B'"[79!:".23U$T:?,C3C-J2E0B6'+ S
M%XBU[GF$&OBPK89[CA]$>6JX4>L !?%*%02"F#-IWD@]V&Y7/+3> %:U\S^<
M,3B15>(@DP))+4,,;=3A$$ZSPG*ZQU9$<>F3Q>^H9Q'&G-<-Y315\:Y.TQ^=
MEF:3OAOH"&;$B-$%%%<N:46A4R.8@GPD#GUE.=GY;AT^+?DG!S[27/R:?7@Z
M_*KADK_,GVR7QY]$8&8%UWI1JQ6V3H^>G(XB+?4WP;;\33UX-MB&+]$,(0BT
M .]7%H24;NB X;<>%_\"4$L#!!0    ( /B(.58^0P,;H1H  /9Y   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL[3W9<MO&EN_]%5U*)I5401)7+7;B
M*EER8M^*$Y45WSQ,S0,(-,F^!@$&#4ABOG[.TANXV7$<3VK"!UM<&J=/GS[[
M(GW[4-7OS%RI1CXNBM)\=S1OFN63TU.3S=4B-2?54I7PS;2J%VD#;^O9J5G6
M*LWIH45Q.NCUSDX7J2Z/GGU+G]W6S[ZMVJ;0I;JMI6D7B[1>/5=%]?#=4?_(
M??!&S^8-?G#Z[-ME.E-WJGF[O*WAW:F'DNN%*HVN2EFKZ7='5_TGUR-<3PO^
MK=6#B5Y+/,FDJM[AFU?Y=T<]1$@5*FL00@H_[M6U*@H$!&C\9F$>^2WQP?BU
M@_X]G1W.,DF-NJZ*7W7>S+\[NCB2N9JF;=&\J1Y>*GN>,<++JL+0__*!UXZ&
M1S)K35,M[,. P4*7_#-]M'2('KCH[7A@8!\8?.@#0_O D [*F-&Q;M(F??9M
M73W(&E<#-'Q!M*&GX32ZQ%N\:VKX5L-SS;,[OCU93>6=GI5ZJK.T;.15EE5M
MV>AR)F^K0F=:F6]/&]@/GSK-+.SG#'NP _:E?%V5S=S(%V6N\BW/7^]_OC_8
M ^ 4#NI/.W"G?3[8"_%.+4_DL)?(06\PV(;0_L=O5 :/]^GQ_AYTAI[X0X(W
MW %O"Y7E?U]-3%,#=__/-H(SO-%V>"CQ3\PRS=1W1R#21M7WZNC95U_TSWI/
MMQWV$P'K''WDCS[:!_U/\MU>V-LQ_ZEJE!C(K[ZX&/3[3^6'[R^?IT8; 0MO
M$5C9I*1_?IG#&S'595IF.BVD@<\5J+?&R+3,0<$5\#Z7N39949D6'I7S]%[)
MB5*E!+26:0U?+]O:M+AQ4\EFKF3=%LH!F+4%;6402?SR3F5MK1MM5[QXS.9I
M.5/BNEHLM"&]^C6>;]![>O?BFE[UGWYS@JC*K8AN0:@U>';<+<VRNH7U$SP^
MHI &VNB2WM4YP%2@L9JY^$&5JDZ+8H4T5$L\>TS,6L/N2SR</<S;4N.:.\3&
M>+Q_N+JZ#8A[RE\#%> Z<D_Z[83?<AZT%#+SC\,G?![$&?"HC'(( 167:;DB
M!CE_"BOF%9SFN'HHX2'33HS.-7!,(N_F;=,42M[.4[ CF6H;X)W").)5">KA
MJBB /(VJ,X8G09A+DV9\DWAOD[1 LL7HJD*#;D?T3N1;8"M Z85I]()H@\?E
M\_#QX<O.@;:2 FX(%J&5U\V*3XNT!;;ZK=7(C(NT!"N-BY'W%ND[)97?$M%,
M#5CV):/=S--&IM,IV%Y!;*J658U[IPN\868/8Y1E_D*G$UT$3@U"8)%'GL"=
M=SW3T(W@\=SM;#^Q6).Z7;C5ZEZ5K<5&/8(+9.!-#M)DF9T?PG=+5>LJ9Z&Q
M+&%EL0;>5O=IT1*).L02$;&ZCZ*+ ;?1F#W4A3L%P:Z1(%-@%)/(N0;#7R-;
M$;:U5L P"3UXGP)^+3P$:->TOJKY@H1N@)L*#6<U>*<3/%9JJC*= +>V8$)K
M)J6NLW8!E$,F3.SQ#;@]1*J'N<[F$AF'OF%I@;?((DB?_[3YS!)\ EXA0TSK
M>H5?(G442>P>;HB5"[&#:=8NAMD-N*6L&CQ#KH'TZ1(E&FE45PM[?%.U-1R"
M20ZD0)#V+"(0#D1N%8LX'&4%/ GLC*<"4=6DM^A:\GM5@Y.YXEVVZ05_C[ K
M*VWUV) 8 4:*T'9 [2:(@Q$3U3R@K-,3'5YH-I!/Y+1M4%RBBP''O;;VX$&#
MDH'K98E$I1';L !<EX[8? :XHNV*$Y1ST>; )$9-VP)N[)X5];+&71NF#6J.
M):Y/)$N!54; 5_H^16_<)/X\8070MGH@.P%OP,%6P.FY:-)'RR,G8!QX%T%6
MS>W2_=AO3@0FU'/4$\@])V *@7-RW9"9969%'5S2MFQ-EZD&.<&'P6K6,W@:
M1$2E=0E$@<^)!BB$^5-@ @"%A$[@N5(]@'(G(8<;A'NUS(^ TJ5NTD+_CC?P
MZYS,SC9ZT>):-9H,4LV\^Z#!](!B7(()@D^G3A#9;<!C,4-F(*NM]244F &X
M.L1-,,Q%=8_ZT/$J''^I*#!RUMI>"7+]#&B"VX,FAM/Z2\^130)SG<B;:)O=
M3( 0X)M[#1!$\!K0=\7(Z1B=,KE08&)SNA&TH*!R&BMKP,!619!M<CR;6]Y+
M\1J1<<P3>0>1:PY^$:J5M\R@/](B!.N81-X6R/N>>\3W+5PMR= 8':1E"U=G
MUEAI+-Z $Y?6V5P$MNOWI/\4E]^ /BTJ_NZ%TU"=%7FTPNNP=4[CSV-&._%0
MY$XH]HX2.6F#1D1GH2&P"5Y!WH)5CIY.9 ;$)^,1.9(5.+L.+#R6KNJJX 6L
M2H&*8"I*542KG!Z#EZ9=+L&TD$@P-\*%HB7'4"4\0O1 6PU:"UF"E#NKYT 9
M<%5G)9/EIU<OY=WS5V\DR $8>!20VA.E#O+05$_DU_UOI'43?ZF6.I/#\>")
MQ S ,3B*L.AUE:N"V$( 6Y".D->H FKY4J4%L-D-R!O83V 73WH7$+RN (%Y
M16KG/R!#U@LE"GT]6-]Y-'Z"X4"N6=B>ZPJBB7= 0DEQ F\N[.:W($IXJW>8
M_(#UN#_R[ALP;"QE/R*J+TB;FQ.W,_I]GA@=OHHI:,6>5RT9=S+_.2B'$L41
M0,/G:$%0EJT?CD*_9+RL""X=R3+&FHPP6DJ\>G".8A:3?,V+!;BY&C6@5Q83
M1PG'F=;$5:!^F,_6MLG@_B0J"S)75U/T>N G0*87"[28E:0@#LY-WJ>%3#0$
MBX7/S?E^<WN_Z&HXHIR !4</H^-49* WZ^ 8$ MZ;D:X( [D/%NU!KX^;/3*
MKQ%$8+0&J.8V*3$%QTN3U[,*>A90:\CP0@!0>[K2M7CA(V7M),@&AI;P]/G:
M1F():F_O":T/8 \03N!M_@25MP*3L'Z_V]$-6DMXG@Q2*L%<RKQN9^3S(PK^
M_ '>EG.#@L& />@9]AS5#-9;'7)#WCKX+P8UVPI0H"Q.TO'LT-$I%.'R4'6O
MU00SB5H'F<HBLBD^+! 5NG6(,3+$!NE/Q"\;G),^I'7.,CK5CW3E*_87%BF2
M>N6WUR49ZPIM J#R6PO$41AAN.A2E_>5SBPAK*&%BRV/P1EN2>E,P:5'@8!+
MSRNZ<T?IE/P=VEE6DT+/&&$P94VJ"PHX$(]F7BL5TX<L[A/9/P&+:4_TQ<N7
M=S\-SOJ#7O^LU^L-SJ]/S\<_7?9[_8MK>-\_<U2$PWZ$BI3[5:1XKXH$+^1+
M.;B\3,:]@>PGE[UATKL<2U#IR6@\EA>C<7(QZ,D1, H@[3__N10W*E.+">Q]
MAOF\_F67D50Y2]%T_Z J,.%-]4!JR&H%6OFE/+\<)X/11?2SG_3ZYW*4#(9]
M_VYP,4C.1D,Y8(;9%,2(Q!=$TFM'4\-AL)<DS(C;6T+%E&ZH)?F%M,#PLH87
MUQL&T]D[08SKD2$K.EFSHANWM-.*QL;R 5P<D@-6"(YUOX3;&5V,DN&XAZ_@
M'BXNAN!L)8"H/!\-X.>@<RUCNI:+]U[+VU)CS(;H;-Z0A3OL 1N<G9%)#4%]
M5D'0]+MB*KML 7RL=,>I#M*-\;FN.<J%0)F#.9!U;>)(&T/[FB(/DLTN"-J%
M CA!\3EOQDZZ=D[UA."P.D<GK6G2;,[N5&E#$Q\#DL;3@"_JK/6TQ?X3=K)X
MPF;$8F0-:1*TM=:ZU^]U6)%1"0KG40P8!%!B!@T(I9F:;&T32M"9E8%0% 0]
M$YQPL(Y-%NP:$X>B.LM9>'+8%/AS\]BHA6NE%Y,6HGG6P%;IV>R;Y!H9'-%C
MPG1!TAO1@F8&WT,US@'(@-_1%R9I; T*2CJ!PTI,<(*-2LV<V8!IZ\P5/6N5
MNV3,[S Y2ASN"A%=%F?T$;XH 4.(F'6FR5I^*2^&P,877HN]*D6 !@L8V"_7
M/\@?0+.7UW.U2"1E)5U^M?.=2[22R#HR* [7@ OQWOR-)QON0?;#ZUO+?>"G
MB$5:MIB-LDF^5[?Y&[Z6IH(8V9E6#FQ):?=!9;/TC\;\\PV8^SI'(^^R%C9[
MW(!T-;0QHM:]UX3SFE;-&!\<S5J=NZS#&C@$,D-&+0GF#(0U%HL)F9YC@#C5
MC>#4B<9TSZ\VBX9Q;!Y$?P%A"_(H2$A)^\"5L"(HX-;+E(UU5:^C$4[E8I U
M:2/N!]40LB89VM/&)O= GL&A^AVUA\UO^N0">@+50B$7*B=+Z*R:*)UJC?Z#
MXCRTPIPU*04,*[L^E7-@G3X3:Z+U@)0@,F".$#?<=A)9<P1 I$+ %A?&."*6
ME?B'JBWR;2JCN[M8TR!REP;IP-BC2VY\/DM\[Y-EKS"4:OFXL14)"6'4U' B
M3/6F,Q Q7MN)$_04+#N<1D? B/A1"DV2KUDVF*R!*()36H0_J)%"3U>HLU#B
M<TR\1 ^>R._AT?!!5!>(]_-!@N5$*^^IB?.TS  1K "!*:=M'L<I*T$:VL3V
MD2P:61YT=8_I0TK9*3!F4<(=4_H)>]Q<S_)YRPB83^K;KZ+<92<U>B*0"*:I
MLG?6G7D?0;J\WE*(#<YJ62UPX9U>V"H<\#?X17B?C-%. F'Y0H#\J26G/TLJ
M0F'Z2_W6(@%#:C2W:61DS *#>LS@;J95N^BRDX^4 P^$L^#K/&7F*#K6P;#&
MI'._DF\<,V'-*L%K<GR<N^*+0KRGZY?EJB,W6UFCD^FOPZ& /_0NZVL+'X 0
M!C?N+=\=$,*=D;YOP)MHCLG6&H51$D<XTSW<FI$2(4I0X2LG/P>PZ0_@1JFY
MP#[?12TG57!%W[[/8L_3')#;<6$.B/=K7?^ V%9<J$H0JO>P+'O8I5<"\+Y&
M$^;4!3J@%>9OK5-(@GF'M1 CK["4"I:OT6B@(#RSAN4.)4;F;"W U2?U0S;5
M1 5 ##Q86UA1=>+H,&#1\)<W+5HL:W2*V.LG#D(NR% L%B@MA,Y:&5 ;+)5G
MOB3H-O7;.;RC F.&6MFI4="0L)GX-R$)0+9K=U @PD':A?-V11(D$UDT\2GX
MR+.,/H0 W7]2MVJC3B9 BNOF&&T'<,2D2;JE-N?-ITNXID=*GN,"74<4->Y&
M^0L"B ;5=A$ /:[NGHNKNVO)\2%$R@G12#*-7D-0 X0+]=6;J)MA*_7$5U]<
MGIU?/I4_HK<H^D"39=MX:QQ4'U<&JJ*:K4A5_-96R*_+FG(>R&/@S94-9[&Y
M4("EBXA$VO6 2<HK@*2M;3[XH,U=SF03 0.>9)'6NTJ9&_LGFS!$.,0F0
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MK=!5MDAOWX2:3W;N09ET#ZP.]RE",QO'"BX+[07"   S14;9 Q];EP2O)#?
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M_Z!Z;P?2BO<8_\+$R:/%.XQ#/X#= ^H=ACBA[)3OEC"VZ[J@OW'550@]=S>
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MPD;QSBC<K9#/C'Z4AFFXH2LZYNS;6\:I81.<*[,:=@T*L&3=,H!]\&#D"-@
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MA3; ]35'(?5 ;]#\Y%K\ U!+ P04    " #XB#E6I<6H$0 -  "+,0  &0
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MFC+7;Y>"(Y'3 CR?EV737= &_>\O3O\'4$L#!!0    ( /B(.5;@?K;Y2@0
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M=H6\@WB"0 @D#.3.*"<22E:J3G+U.TK(KPN*=+K6DQZN9*TH!JI8M^X4Q 4
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MTHYR,[K71VD^GF1+2K FS%]!TYL@MH']3^_>VL >3[7[(_@12&>1KH.5ND1
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MP.^SLJSM!^P [[>CX;W^7U!+ P04    " #XB#E6W$Z:=W($  #&#P  &0
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M_()62%6=&JL'(PMW\%I(0\<X=[NB@S8J.X"^IU*:[8,-T!S=)W\"4$L#!!0
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M7%=0]S>,R=>"#M!]09G] U!+ P04    " #XB#E6%,N]Z?("  #3#   &0
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M#Z@%#31?S*@POVA3S1WV/1270K*L!JL=9"2OKOBE-F('H'C: 5$-B/X&#/<
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MGJ#NIXS);4<O8+]CIG\ 4$L#!!0    ( /B(.59FH3')-@,  *L1   9
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M^\7ZS<#Z0/$LWRN/N=([[[PY1S)!83KHZU/.U>; ;+_+]S/A/U!+ P04
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MBP=,&<CW2TK%=J 6J)M&_Q]02P,$%     @ ^(@Y5D F[3WC"@  M(\  !D
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MDB!>%%.G]V).N"YF>'G+V+\(^RKGJK?9.ICS^]ZZ5--WWGOXRY_H>/"WMNQ
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MY%>>KBY,]J ;(J":#-44J*9"-0VJZ5#-@&HF5+.@F@W5'*CF0C4/JODHK9F
M^PT1[/^W(4+<U=5Q"-T0 =44=KJD?#*3V.CH8\#4MG8M:[4TZ.ATJ&9 -1.J
M65#-AFI.R[%GLYET?.S=EG9T-A@.9D<W_3SH\'R4ULR=_?8$]L=O3V"G[QS>
M=K?T23R4JY,$NO$ JJE038-J.E0SH)K)3C<>M'URK@7MU89J#E1SH9H'U7R4
MUHBNX7[CP5"\\>#KN5E2G6-%ALUY^!Z\1/P7DFSR+ ^J2\NV"!-W=>V4":K)
M4$V!:BI4TZ":#M6,6FO>@1H>O5&&V:F5!1V9#=4<J.9"-0^J^2CM,[[ZV9+S
M7 [RX.%NQ=,W_L2C*"/5YT06J=8[>+0(IM=RX^CM(^OU3Q[7Z*U.6QZWZ*U3
M/=[?\P]WZ^"-.T'Z%L89B?AKT=7@9E+\]4O#M^7NFSQ9W_=HC[PD>9ZLJB^7
M/%CPM&Q0_/PU2?+M-V4''TGZK7HZ#_\#4$L#!!0    ( /B(.5:QWUMW,@,
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MP!P\Z>!:2E 2G26@"&7R' W0TSQ!9Y_/IZ[2C1@Z-VV+WC1%\:&B4%VBP+M
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M=]1VZZ1'^ZBH9J&:C6H.JKFHYJ&:CVH!JH4G7F>?'E8[.W>:#D,?H=L3HYI
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MF!<MSL9%@Y-<'?XFA(NCI+I< IX!E0'B^9R(HE,VY'FR^H<B^ =02P,$%
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MR@[B_9:(_:"NR #-5=/] U!+ P04    " #XB#E6 $?A2&@#  ".$@  &0
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M :J%E-;,#W6!IB8OT*S.0>2KI.A5'U%-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
MU4)*:Z:2NA)4F[*KI&@9**KIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6DAIS;12
M%Y9J\L+2(Z['(!=Z9Y*M=N@[Z/J>=L-1JX3T2,]$[X6%:C:J.:CFHIJ':CZJ
M!:@64EIS7-?%H9J\./3@E1;D\;U']59K? .D/: /-C$.-S'1P[90S48U!]5<
M5/-0S4>U -5"2FMNVU:79P[EY9D]+HP@E_H.Z$IK?\=;G;5W;MG74&M]2]<X
MMJ&)WA$+U6Q4<U#-134/U7Q4"U MI+3F$*^K*H?RJLKV&J'R7Z5OH:6\A]Y#
M'RVT1#4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)*:V8:K<XT;*'E$"VT1#4=U0Q4
M,U'-0C4;U1Q4<U'-0S4?U0)4"RFMF5;>["TM+[0\8@E1+O3.).R.TNR6TNR>
MTNRFTNRNTNRVTNR^TNS&TL.=92EU9[]0'^TS0+60TIH9HBZI'$K+L XO1LKC
M>^<'4M-1S4 U$]4L5+-1S4$U%]6\2I,L6_MHAP&JA9363 YU#>507D/99XD3
MO<HCJNFH9J":B6H6JMFHYJ":BVI>I;47P$<[5ZI NPU0+:2T9K*H"RJ'AS93
M+@NN/V\O9?.#\J_\3J0OOV;R-5*TS!+5=%0S4,U$-0O5;%1S4,U%-0_5?%0+
M4"VDM&:"J<LLAVR9Y1 MLT0U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 LIK9E6
MZC++H;S,,CQT"3YY?.\\@F[.C6K&L.,*HAU?BC/17BU4LU'-0347U3Q4\U$M
M0+60TIH9HB[8',H+-G]:9V+^D(J%\CE-5G&6)>FSLDT;TM,:M(P3U714,U#-
M1#4+U6Q4<U#-134/U7Q4"U MI+1&=AG5=:2C 7I:,T*+25%-1S4#U4Q4LU#-
M1C4'U5Q4\U#-1[4 U4)*:Z:5NG9U)*]=/7A:(X_OG4?0RE14,T9=NWUWG-:@
MO5JH9J.:@VHNJGFHYJ-:@&HAI34SA%9G"/E^WV6&4'Y\2J0G,7*C=Y9 "TU1
MS4 U$]4L5+-1S4$U%]4\5/-1+4"UD-*:N:0N-!T-V9,8M.H4U714,U#-1#4+
MU6Q4<U#-134/U7Q4"U MI+1F6JFK4T?2 K?-M@8/8E&7G\G.9\C*NRM4TU'-
M0#43U2Q4LU'-0347U;Q*:VP!?#X;M"ZIXJ.=!J@64EHS5]3%JB-YL>K;'9<W
MTQ'I:0U:KHIJ.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!926C.GU#6MHPE[6H-6
MLJ*:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH64UDPK=27KZ(BMXV^2]#9^%&N1
M=>Y>("=ZIQ*T>A75#%0S4<U"-1O5'%1S4<VKM+<[]4S'.Y^X^6BG :J%E-;,
M$759ZDA>EOI%W$?/Y:0C.VJ?:+G6.UV@1:JH9J":B6H6JMFHYJ":BVI>I1U,
M%VB-*JJ%E-9,%W6-ZNC 147+*44J5E&\CM>W2K3:MU6TW.F=*-"J5%0S4,U$
M-0O5[$H[L)>-<UPS%STV[[A.?;33 -5"2ML.[;/L3HA<C_+H\F(ETEMQ)9;+
M3-GL[5YV\N;68D#?%$-???]1.SG;N=U1W[MJQ^V>^M[ONCU0WX>;V\_J;B\O
M[J-;$43%J<@Z4Y;BICB$P>FT>+;2^/;N]9<\N?]PHIXHUTF>)ZO-CW<B6HBT
M;%#\_28IYB?5+V4'3TGZ;7,W+_\'4$L#!!0    ( /B(.5:]WOJ_( 4  '(C
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+6:76_B.!2&[_=76-G1
M:D9BF]CY@BX@+26CK32=18-FYJ*:"T,,1$UBQC9E^N_7^6A"()C"FEZ4?)WW
MV$_"Z7D;][>4/?$5(0+\2N*4#XR5$.M;T^3S%4DPOZ%KDLHS"\H2+.0N6YI\
MS0@.\Z D-I%E>6:"H]08]O-C$S;LTXV(HY1,&.";),'L941BNAT8T'@]\"5:
MKD1VP!SVUWA)ID1\74^8W#,KE3!*2,HCF@)&%@/C;W@;(#\+R*_X%I$MW]D&
MV51FE#YE._?AP+"R$9&8S$4F@>7',[DC<9PIR7'\+$6-*F<6N+O]JOXQG[R<
MS QS<D?C[U$H5@.C:X"0+/ F%E_H]A]23LC-].8TYOEOL"VN]7L&F&^XH$D9
M+$>01&GQB7^5('8"H'TD )4!:#_ /1)@EP'V6P.<,L#9#_".!+AE0#YULYA[
M#FZ,!1[V&=T"EETMU;*-G'X>+7E%:?:@3 639R,9)X93^>2%FY@ N@!37'P&
M/S>1> &4@7O.-R0$[\=$X"CF'\"?X.MT#-Z_^] WA<R>:9CS,M-=D0D=R62#
M!YJ*%0=!&I*P)7ZLCN^=B@_4\1 I!$R)K6*'7MG=(:7BE*QO@&UU +(0:IO0
M_PL/U.%C,I?A, ^'BMG8U9-@YWKVL>%L9CP*(UDM.M63,!5T_@0>/\E+P;T@
M"?_1=M\+7:==-ZMTMWR-YV1@R%+&"7LFQO"/WZ%G_=7&3*=8H$FLP=.I>#HJ
M]6'!+BJ^0>&&1>D2K F+:-@!?(5EPC:62LUS6>H4"PHQ+Q?+_OP\#Q&TY$_?
M?&ZAY%:4W(LI?</QAK1!*B3=G:'(D=C0@6XUF * ,O>Y #2)-3!Y%29/B>E^
M\B]X?"#)C+#6KZ R^MS'1J=8H$FL0<VOJ/E7*FF^3IXZQ0)-8@V>W8IG5W])
M&ZDU'V'K#5 &G7L#N@>E"SI6S_=ALUP$FI(VV/8JMCWMA7"DECR"5AET+MK>
M&TMQH"EK@RVTZB[74J+X3 7A8()?\$R6 54E50N=BT>K6J!+K0EQQRK *Y73
M4E@75)UJ@2ZU)E140T57:!/5HF<#12T%TG=W>KL2E::L352U08'*?OVR7E&M
M>38I^Z#>N=VNBYQ]4M=P'K"V'E#M/;)R![YCQG JU-5.J]_0JA;H4FLRK(T)
M=*]5[73:CK%6M4"76A-J;6.@VL=<UD&>$'U$[;=!JRDJU1K^%WF^Z^XWD;K2
M-@G7E@<J'<!E?>0)S6. M;JD4JU16GN6ZQ^4UFLX(%A;(*CV*W<T26A:5H(W
M-91:K8Q6M4"76I-E;7E@[UHE5JN)T:H6Z%)K_D^ZMCI(;74N:RC5HN<"+=5V
MBV77[NU]D76E;'*JW0Q2-O:7=9-JS;,QP4/W[-G.?MNM*VD35.U0D-JA3!A9
M$,8DI0+9.'J.0I*&;ZI^:NVS@>E4"W2I-;G6=@9=ZX4+TNIIM*H%NM2:4&OG
M@Z[PUF5T0O31;K\-6LT3.GS!XMB^C?S]:G -6X1J6X3TO[ 9G= \QE>KCT*'
M;XT<"UE>=Y_O-1P2RAQ2\TC=T:,3W3?\D8/]+>(@)2(K$^\ [#B6WT$> K G
M/WT;P*[505TK/]/K^#X$MNUUNC [@J \;UD=%_IM@S1WU@\DA"WSA1L<S.DF
M%<4+Y.IHM3ADE"^)V#^.O-NQG&O;&5^>R=>3F'6*8C7* V;+*.4@)@N9SKKQ
MY1U@Q0*/8D?0=;Z"84:%H$F^N2(X)"R[0)Y?4"I>=[($U3*;X7]02P,$%
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M'825"V+ECJ"[8CUF386@>;&Y!2Q?&U0'>3RA5)QV5(%Z57+V/U!+ P04
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M>?ZX9A_??@H^> K[SS7[<,-N1&%L(M<Z2-@<"6-(F(N$>4B8CX0%2%B(A"U
ML%9:68>TLJ33PS_Y?;G,J3X+V&;I'<_S_;I'E%I6+[$MU3#-SO0@]38V9Y P
M9O7G8=NBG?Z[2)<>$N;WS[]I.(YA=^[Z_6%JY1K'[HPS%-!LO?S;N9OWFQ%3
MLPD5W\OM0]#9TJ#[E)9K:27=\BPJXLV]PK]L^2;GN2CL[%X/RN?=LJ>=N),Z
M'!MW2!CK#X#H1-.Z@8?TZ2%A?G\ FJU1W>FN-_KM+$/7#=J)/ '.THGC=!<2
M_7:&ZAB$B$//.82>([_?I7FNW&7I^B7\THTP[!S!*DL4=U)O8^,."6."$0@#
M#^G40\)\P0C$D2=H* P]$5 8>X*&LN#3U.83>?7;X7?+[]*,*\%FF:ZY\BGZ
M(K[SU:A6+QS'UHG1B4&YS[%!"*4QT2"(9CJFU@E#J%L/2O.%@R"69=#N)P>B
MEJ9#U=[\*VJH:08IP[L3BZ*6MFI8]%0P'I6'-&DP?N"%DI0!*0P^;6CP:;T%
MQYGA6,3J-)R+&IJV9G?/(1.Y%H>,@$C+6[3::>B)&FK$H:1SKGVA:_&%%K04
M7VA!PQ,76M!2>J%)<Z')H NM1$61Q;>[(KI-N%*D2GD#6J<;)3^J)PB#@0C.
MGZI9MM.=#N4=&7TK0M*8:!3EC&@1IQM72+<>E.8+!T%UNUSC=R-4T-*R5-J=
M/4/AU26&H3EF-T(%+1W5MAS]1(0V!2U-^H%^$Z'EHDS)'Z+R3"AGE9XB7NX?
M3E=QLBN$->!W-=D^[I3Z1NL&)K1P!:4Q\0A4T@U+:%$*2O/%0R"T&Y/BD5IJ
MZX_6#5#Q%>XNVD[ G1.QV52#-%WZR>-5E#\H;I(^Y8I;/3C\<7AN?5MIAN(B
MYOFY,#*1=80K*&T.I3$HS872/"C-A]("*"V$TA8H6COKFK*5)J];[34.9Y6B
M;E4M4ZH/B/9/Z\)$0Y8ZKJ"T.93&H#072O.@-+^F':\UJ&%:M#>E"-J95KEZ
MZ4XB_7:.IJJ],JR@G6XXAGUJ&FGJ5YKT<_S9=<8?XW27)U^5CWR;9E5!]K_O
M^?J69_\3!C6TE@6ES:$T!J6Y4)H'I?E06@"EA5#: D5K)UM3U=(LZ9IMG$).
M0Q9JKJ"T.93&H#072O.@-!]*"Z"T$$I;H&CM5&MJ>9J\F#=.+2>'C4XU:-D/
M2F-0F@NE>5":#Z4%4%JH]<N(U*("^1W*;3N+FK*D)J]+#I3IR2FCTP=:O832
M&)3F0FD>E.9#:0&4%FJB2BBU!+H_E-_V]W*:PBI1I0N^8?) @BP+7D%I<RB-
M06DNE.9!:3Z4%D!I(92V0-':*=:4BXF\7#Q<*B@'C4XS)&T.I3$HS872/"C-
MA]("*"TD_<HY,05J1I37=@(U97@B+\./D3W*4:-3"%J6A](8E.9":1Z4YD-I
M 906UK26+),2@30.Y;:=0XU0@,B% D/UFW+,Z/R!J@>@- :EN5":!Z7Y4%H
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MG)33]VU:%.EZ__*!1^4C7=6@_/U=FA8O;RH'3VGV>3_,V=]02P,$%     @
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M^/DZ38O/)^4 QQNR+_X/4$L#!!0    ( /B(.5;"C[X1, ,  /(2   -
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MP .&)(G;!_?VHWB]3\6;7[E&CU!+ P04    " #XB#E6EXJ[',     3 @
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MLG_NV#BA+)(<4B,='R>41Y+#B80=/7",2=DD.:1..I6>4CI)^]1)B!\L''[
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M]?&7Y??)T:MRP3G ;_O'+U!+ P04    " #XB#E6*F32ILH!  ";'P  $P
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M4$L! A0#%     @ ^(@Y5M)>@T/N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ^(@Y5IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #XB#E67%>Z@?\#   Z#@  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ^(@Y5BIT]J F!P  D20
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M965T-BYX;6Q02P$"% ,4    " #XB#E6<=16G*()  #W(0  &
M    @(&W.0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M^(@Y5CY# QNA&@  ]GD  !@              ("!CT,  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /B(.5;/,_U06P,   (*   8
M          " @69>  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " #XB#E6=@6VH?L%  "&%0  &0              @('W80  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /B(.58$]<H*T@0   D1
M   9              " @2EH  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ ^(@Y5O1HJ4%B!   ?@T  !D              ("!,FT
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #XB#E6I<6H
M$0 -  "+,0  &0              @('+<0  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( /B(.5;@?K;Y2@0  *H*   9
M  " @0)_  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M^(@Y5B9MB744!   /@D  !D              ("!@X,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " #XB#E6X_#7Z @$   \"0  &0
M            @('.AP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( /B(.58%15YW!1P  &:$   9              " @0V,  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ^(@Y5MQ.FG=R!
MQ@\  !D              ("!2:@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " #XB#E67ZQ\+1<#   !"0  &0              @('R
MK   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /B(.5:B
MY1A+[P,  *P-   9              " @4"P  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ ^(@Y5G*AH5]E P  @0H  !D
M     ("!9K0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /B(.584R[WI\@(  -,,   9              "
M@0G*  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ^(@Y
M5F:A,<DV P  JQ$  !D              ("!,LT  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " #XB#E6!",K1SD#  ! #@  &0
M        @(&?T   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( /B(.59 )NT]XPH  +2/   9              " @0_4  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ^(@Y5K'?6W<R P  B0X
M !D              ("!*=\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " #XB#E6J,@I;J "  #-!P  &0              @(&2X@
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /B(.5:Y^1N>
MH (  *T'   9              " @6GE  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ ^(@Y5KSG78.; @  O@<  !D
M ("!0.@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #X
MB#E6)-QMIKP"  ">!P  &0              @($2ZP  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /B(.59H$I*2*@0  -,4   9
M          " @07N  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#
M%     @ ^(@Y5AU2%,+H'   G4H" !D              ("!9O(  'AL+W=O
M<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #XB#E6O0+%EBD#  "M
M$   &0              @(&%#P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;%!+ 0(4 Q0    ( /B(.5:=*WA0"@,  '8.   9              " @>42
M 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ^(@Y5@!'
MX4AH P  CA(  !D              ("!)A8! 'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6Q02P$"% ,4    " #XB#E66%AKO(D#   =%@  &0
M    @('%&0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M /B(.5:D5B1R#@X  .?+   9              " @84= 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ ^(@Y5KW>^K\@!0  <B,  !D
M             ("!RBL! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " #XB#E67"5BEX$#  !X#   &0              @($A,0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /B(.5:>]L :Q@(
M .<'   9              " @=DT 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ ^(@Y5DG,LA.P!0  *R<  !D              ("!
MUC<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #XB#E6
MH0SOLV<"  "7!@  &0              @(&]/0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( /B(.58,+%T<I04  #4H   9
M      " @5M  0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ ^(@Y5I!8X0BA'   ONX! !D              ("!-T8! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #XB#E60]\+-?X#  "A%
M&0              @($/8P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( /B(.5:/*TM6'P,  -P)   9              " @41G 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ^(@Y5M*LRJ *
M @  )P0  !D              ("!FFH! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " #XB#E67MR7SI<+  #7B   &0
M@(';; $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /B(
M.58_1Z.!4@@  )Q=   9              " @:EX 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ ^(@Y5L*/OA$P P  \A(   T
M         ( !,H$! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #XB#E6EXJ[
M',     3 @  "P              @ &-A $ 7W)E;',O+G)E;'-02P$"% ,4
M    " #XB#E6/.\6@Y<$  "W(P  #P              @ %VA0$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ ^(@Y5GQ^Z1O4 0  QA\  !H
M     ( !.HH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ ^(@Y5BIDTJ;* 0  FQ\  !,              ( !1HP! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #T /0"B$   08X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>309</ContextCount>
  <ElementCount>289</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndGoingConcern</Role>
      <ShortName>Organization and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability</Role>
      <ShortName>Operating Lease Right-of-use Asset and Operating Lease Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Notes Payable-Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedParty</Role>
      <ShortName>Notes Payable-Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes (Restated)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesRestated</Role>
      <ShortName>Income Taxes (Restated)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Restatement of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RestatementOfFinancialStatements</Role>
      <ShortName>Restatement of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables</Role>
      <ShortName>Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/NotesPayable-relatedParty</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Income Taxes (Restated) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesRestatedTables</Role>
      <ShortName>Income Taxes (Restated) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/IncomeTaxesRestated</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Restatement of Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables</Role>
      <ShortName>Restatement of Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/RestatementOfFinancialStatements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Organization and Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative</Role>
      <ShortName>Organization and Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/OrganizationAndGoingConcern</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails</Role>
      <ShortName>Schedule of Useful Lives for Property Plant Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails</Role>
      <ShortName>Schedule of Fair Value by Liabilities on Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Property and Equipment, Net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>Property and Equipment, Net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails</Role>
      <ShortName>Schedule of Operating Lease Right of Use Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails</Role>
      <ShortName>Schedule Of Operating Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative</Role>
      <ShortName>Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative</Role>
      <ShortName>Notes Payable-Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/NotesPayable-relatedParty</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails</Role>
      <ShortName>Schedule of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical</Role>
      <ShortName>Schedule of Notes Payable (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails</Role>
      <ShortName>Schedule of Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical</Role>
      <ShortName>Schedule of Promissory Notes (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/NotesPayableTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails</Role>
      <ShortName>Schedule of Sale of Equity or Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical</Role>
      <ShortName>Schedule of Sale of Equity or Issued (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Schedule Of Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>Schedule of Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical</Role>
      <ShortName>Schedule of Warrants Activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative</Role>
      <ShortName>Income Taxes (Restated) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/IncomeTaxesRestatedTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails</Role>
      <ShortName>Schedule of Error Corrections and Prior Period Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative</Role>
      <ShortName>Restatement of Financial Statements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="forms-1.htm">forms-1.htm</File>
    <File>ex107.htm</File>
    <File>ex23-1.htm</File>
    <File>ex5-1.htm</File>
    <File>shph-20220930.xsd</File>
    <File>shph-20220930_cal.xml</File>
    <File>shph-20220930_def.xml</File>
    <File>shph-20220930_lab.xml</File>
    <File>shph-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
    <File>forms-1_002.jpg</File>
    <File>forms-1_003.jpg</File>
    <File>forms-1_004.jpg</File>
    <File>forms-1_005.jpg</File>
    <File>forms-1_006.jpg</File>
    <File>forms-1_007.jpg</File>
    <File>forms-1_008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1347">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "forms-1.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1347,
    "http://xbrl.sec.gov/dei/2022": 17
   },
   "contextCount": 309,
   "dts": {
    "calculationLink": {
     "local": [
      "shph-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "shph-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "forms-1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "shph-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "shph-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "shph-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 478,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 262,
    "http://shuttlepharma.com/20220930": 19,
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 283
   },
   "keyCustom": 26,
   "keyStandard": 263,
   "memberCustom": 32,
   "memberStandard": 26,
   "nsprefix": "SHPH",
   "nsuri": "http://shuttlepharma.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://shuttlepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability",
     "shortName": "Operating Lease Right-of-use Asset and Operating Lease Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Notes Payable-Related Party",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedParty",
     "shortName": "Notes Payable-Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Notes Payable",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://shuttlepharma.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://shuttlepharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://shuttlepharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Income Taxes (Restated)",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://shuttlepharma.com/role/IncomeTaxesRestated",
     "shortName": "Income Taxes (Restated)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Restatement of Financial Statements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://shuttlepharma.com/role/RestatementOfFinancialStatements",
     "shortName": "Restatement of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://shuttlepharma.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://shuttlepharma.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables",
     "shortName": "Operating Lease Right-of-use Asset and Operating Lease Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Notes Payable (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://shuttlepharma.com/role/NotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://shuttlepharma.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Income Taxes (Restated) (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://shuttlepharma.com/role/IncomeTaxesRestatedTables",
     "shortName": "Income Taxes (Restated) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Restatement of Financial Statements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables",
     "shortName": "Restatement of Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesIssued1",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Organization and Going Concern (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
     "shortName": "Organization and Going Concern (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-03-282022-04-02",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails",
     "shortName": "Schedule of Useful Lives for Property Plant Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_FurnitureAndFixturesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Fair Value by Liabilities on Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails",
     "shortName": "Schedule of Fair Value by Liabilities on Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "SHPH:ProceedsFromContractAwardsForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "SHPH:ProceedsFromContractAwardsForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Property and Equipment Net (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Schedule of Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Property and Equipment, Net (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "Property and Equipment, Net (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "SHPH:OfficeLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Operating Lease Right of Use Assets (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails",
     "shortName": "Schedule of Operating Lease Right of Use Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "SHPH:OfficeLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Schedule of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Schedule Of Operating Lease Maturity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails",
     "shortName": "Schedule Of Operating Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative",
     "shortName": "Operating Lease Right-of-use Asset and Operating Lease Liability (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-06-212021-06-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Notes Payable-Related Party (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
     "shortName": "Notes Payable-Related Party (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-06-212021-06-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Notes Payable (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
     "shortName": "Schedule of Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "lang": null,
      "name": "SHPH:LoanForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-12-282021-12-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Notes Payable (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
     "shortName": "Schedule of Notes Payable (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_custom_PaycheckProtectionProgramNotePayableOneMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Promissory Notes (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
     "shortName": "Schedule of Promissory Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://shuttlepharma.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-12-282021-12-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Promissory Notes (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical",
     "shortName": "Schedule of Promissory Notes (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_custom_PromissoryNoteOneMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-03-09",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MediumTermNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Notes Payable (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
     "shortName": "Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-03-09",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MediumTermNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Sale of Equity or Issued (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
     "shortName": "Schedule of Sale of Equity or Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_custom_NotesPayableMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Sale of Equity or Issued (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
     "shortName": "Schedule of Sale of Equity or Issued (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Schedule Of Stock Options, Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
     "shortName": "Schedule Of Stock Options, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_WarrantMember52285984",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of Warrants Activity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "Schedule of Warrants Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_WarrantMember52285984",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
     "shortName": "Schedule of Warrants Activity (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30_custom_CommonStockToBeIssuedMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
     "shortName": "Schedule of Restricted Stock Units (RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2018-06-04",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
     "shortName": "Schedule of Reconciliation of Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Schedule of Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Income Taxes (Restated) (Details Narrative)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative",
     "shortName": "Income Taxes (Restated) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of Error Corrections and Prior Period Adjustments (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
     "shortName": "Schedule of Error Corrections and Prior Period Adjustments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LegalFees",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Restatement of Financial Statements (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
     "shortName": "Restatement of Financial Statements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://shuttlepharma.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Organization and Going Concern",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://shuttlepharma.com/role/OrganizationAndGoingConcern",
     "shortName": "Organization and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://shuttlepharma.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "SHPH_AccreditedInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredited Investor [Member]",
        "label": "Accredited Investor [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_AccruedInvestmentIncomeReceivableOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development invoice receivable, outstanding.",
        "label": "Research and development invoice receivable, outstanding"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivableOutstanding",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_AccumulatedAmortizationOnRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amortization on right of use assets.",
        "label": "AccumulatedAmortizationOnRightOfUseAssets",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "AccumulatedAmortizationOnRightOfUseAssets",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_CommonStockIssuedForConversionOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for conversion of convertible debt.",
        "label": "Common stock issued for conversion of convertible debt"
       }
      }
     },
     "localname": "CommonStockIssuedForConversionOfConvertibleDebt",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_CommonStockIssuedForDividendPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for dividend payable.",
        "label": "Common stock issued for dividend payable"
       }
      }
     },
     "localname": "CommonStockIssuedForDividendPayable",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for exercise of warrants with settlement of notes payable.",
        "label": "CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable",
        "verboseLabel": "Common stock issued for exercise of warrants with settlement of notes payable"
       }
      }
     },
     "localname": "CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_CommonStockPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Payable [Member]",
        "label": "Common Stock Payable [Member]"
       }
      }
     },
     "localname": "CommonStockPayableMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_CommonStockToBeIssued": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock to be issued.",
        "label": "Common stock to be issued"
       }
      }
     },
     "localname": "CommonStockToBeIssued",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_CommonStockToBeIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock To Be Issued [Member]",
        "label": "Common Stock To Be Issued [Member]"
       }
      }
     },
     "localname": "CommonStockToBeIssuedMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_DebtInstrumentConvertibleConversionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price percentage.",
        "label": "Conversion price percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPricePercentage",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "SHPH_DebtInstrumentConvertibleConversionSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument convertible conversion shares percentage.",
        "label": "Conversion shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionSharesPercentage",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "SHPH_DirectorsAndOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors And Officer [Member]",
        "label": "Directors And Officer [Member]"
       }
      }
     },
     "localname": "DirectorsAndOfficerMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right-of-use Asset And Operating Lease Liability",
        "terseLabel": "Schedule Of Operating Lease Liabilities",
        "verboseLabel": "Schedule Of Operating Lease Right Of Use Assets"
       }
      }
     },
     "localname": "DisclosureOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityAbstract",
     "nsuri": "http://shuttlepharma.com/20220930",
     "xbrltype": "stringItemType"
    },
    "SHPH_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_LoanForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Forgiveness.",
        "label": "Loan Forgiveness"
       }
      }
     },
     "localname": "LoanForgiveness",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_MembershipInterestHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Membership Interest Holders [Member]",
        "label": "Membership Interest Holders [Member]"
       }
      }
     },
     "localname": "MembershipInterestHoldersMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NoteTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Two [Member]",
        "label": "Note Two [Member]"
       }
      }
     },
     "localname": "NoteTwoMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable [Member]",
        "label": "Notes Payable [Member]"
       }
      }
     },
     "localname": "NotesPayableMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables Five [Member]",
        "label": "Notes Payable Other Payables Five [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesFiveMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables Four [Member]",
        "label": "Notes Payable Other Payables Four [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesFourMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables One [Member]",
        "label": "Notes Payable Other Payables One [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesOneMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables Six [Member]",
        "label": "Notes Payable Other Payables Six [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesSixMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables Three [Member]",
        "label": "Notes Payable Other Payables Three [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesThreeMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_NotesPayableOtherPayablesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Other Payables Two [Member]",
        "label": "Notes Payable Other Payables Two [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesTwoMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_OfficeLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Lease.",
        "label": "Office Lease"
       }
      }
     },
     "localname": "OfficeLease",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_OfficersSpouseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers Spouse [Member]",
        "label": "Officers Spouse [Member]"
       }
      }
     },
     "localname": "OfficersSpouseMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_OneQuarterlyPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1 Quarterly Payments [Member]",
        "label": "1 Quarterly Payments [Member]"
       }
      }
     },
     "localname": "OneQuarterlyPaymentsMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_OperatingLeasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payment.",
        "label": "Lease payment"
       }
      }
     },
     "localname": "OperatingLeasePayment",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_PaycheckProtectionProgramNotePayableOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP Note Payable One [Member]",
        "label": "PPP Note Payable One [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramNotePayableOneMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PaycheckProtectionProgramNotePayableTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP Note Payable Two [Member]",
        "label": "PPP Note Payable Two [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramNotePayableTwoMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PaymentOfInvoice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of invoice.",
        "label": "Value issued"
       }
      }
     },
     "localname": "PaymentOfInvoice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_PaymentsToInvoicesInResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to invoices in research and development.",
        "label": "Payments to invoices in research and development"
       }
      }
     },
     "localname": "PaymentsToInvoicesInResearchAndDevelopment",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_PercentageOfVariableExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of variable exercise price.",
        "label": "Percentage of variable exercise price"
       }
      }
     },
     "localname": "PercentageOfVariableExercisePrice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "SHPH_PhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase II [Member]",
        "label": "Phase II [Member]"
       }
      }
     },
     "localname": "PhaseIIMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PreferredStockDividendPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Dividend Payable [Member]",
        "label": "Preferred Stock Dividend Payable [Member]"
       }
      }
     },
     "localname": "PreferredStockDividendPayableMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_ProceedsFromContractAwardsForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from contract awards for research and development.",
        "label": "Proceeds from contract awards for research and development"
       }
      }
     },
     "localname": "ProceedsFromContractAwardsForResearchAndDevelopment",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_PromissoryNoteFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note Four [Member]",
        "label": "Promissory Note Four [Member]"
       }
      }
     },
     "localname": "PromissoryNoteFourMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PromissoryNoteOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note One [Member]",
        "label": "Promissory Note One [Member]"
       }
      }
     },
     "localname": "PromissoryNoteOneMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PromissoryNoteThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note Three [Member]",
        "label": "Promissory Note Three [Member]"
       }
      }
     },
     "localname": "PromissoryNoteThreeMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_PromissoryNoteTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note Two [Member]",
        "label": "Promissory Note Two [Member]"
       }
      }
     },
     "localname": "PromissoryNoteTwoMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_RelatedPartyOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Officer [Member]",
        "label": "Related Party Officer [Member]"
       }
      }
     },
     "localname": "RelatedPartyOfficerMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_RelatedPartyTransactionAmountsOfTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction amounts of transactions.",
        "label": "Notes payable related party debt principal balance"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransactions",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_ResearchAndDevelopmentDeficitNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net deficit on research and development.",
        "label": "Net deficit on research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentDeficitNet",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SHPH_SBIRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SBIR [Member]",
        "label": "SBIR [Member]"
       }
      }
     },
     "localname": "SBIRMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Operating Lease Right Of Use Assets [Table Text Block]",
        "label": "Schedule of Operating Lease Right of Use Assets"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Pretax Income From Continuing Operations [Table Text Block]",
        "label": "Schedule of Reconciliation of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesRestatedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Useful Lives for Property Plant Equipment [Table Text Block]",
        "label": "Schedule of Useful Lives for Property Plant Equipment"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SHPH_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments cancelled in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelledInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exexcises in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
        "verboseLabel": "Weighted Average Remaining Life in Years Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life in Years Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SHPH_SubcontractPhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontract Phase II [Member]",
        "label": "Subcontract Phase II [Member]"
       }
      }
     },
     "localname": "SubcontractPhaseIIMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_TCGGreenChemIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TCG Green Chem Inc [Member]",
        "label": "TCG Green Chem Inc [Member]"
       }
      }
     },
     "localname": "TCGGreenChemIncMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_TwoQuarterlyPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2 Quarterly Payments [Member]",
        "label": "2 Quarterly Payments [Member]"
       }
      }
     },
     "localname": "TwoQuarterlyPaymentsMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Equity Incentive Plan [Member]",
        "label": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SHPH_UnsecuredPromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured Promissory Notes [Member]",
        "label": "Unsecured Promissory Notes [Member]"
       }
      }
     },
     "localname": "UnsecuredPromissoryNotesMember",
     "nsuri": "http://shuttlepharma.com/20220930",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r544",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r342",
      "r470",
      "r493",
      "r511",
      "r512",
      "r525",
      "r529",
      "r532",
      "r591",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r342",
      "r470",
      "r493",
      "r511",
      "r512",
      "r525",
      "r529",
      "r532",
      "r591",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r334",
      "r342",
      "r368",
      "r369",
      "r370",
      "r469",
      "r470",
      "r493",
      "r511",
      "r512",
      "r525",
      "r529",
      "r532",
      "r587",
      "r591",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r334",
      "r342",
      "r368",
      "r369",
      "r370",
      "r469",
      "r470",
      "r493",
      "r511",
      "r512",
      "r525",
      "r529",
      "r532",
      "r587",
      "r591",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r214",
      "r215",
      "r231",
      "r416",
      "r417",
      "r572",
      "r573",
      "r574",
      "r575",
      "r577",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r164",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r231",
      "r265",
      "r266",
      "r391",
      "r412",
      "r416",
      "r417",
      "r418",
      "r444",
      "r455",
      "r456",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r164",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r231",
      "r265",
      "r266",
      "r391",
      "r412",
      "r416",
      "r417",
      "r418",
      "r444",
      "r455",
      "r456",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r164",
      "r201",
      "r203",
      "r205",
      "r206",
      "r209",
      "r210",
      "r218",
      "r231",
      "r391",
      "r412",
      "r416",
      "r417",
      "r444",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r586",
      "r624",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r583",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r170"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFundingAgreementTermsMember": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of commitments to provide additional funding under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Additional Funding Agreement Terms [Member]"
       }
      }
     },
     "localname": "AdditionalFundingAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r569",
      "r570",
      "r571",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r103",
      "r104",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation (As Restated)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r76",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Warrants issued for financing costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r176",
      "r256",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r30",
      "r40",
      "r123",
      "r306"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r306",
      "r439",
      "r523",
      "r524",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortized debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r136",
      "r146",
      "r172",
      "r196",
      "r242",
      "r245",
      "r249",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r403",
      "r405",
      "r421",
      "r531",
      "r589",
      "r590",
      "r635"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r167",
      "r177",
      "r196",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r403",
      "r405",
      "r421",
      "r531",
      "r589",
      "r590",
      "r635"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDevelopment": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.",
        "label": "Business development new establishment"
       }
      }
     },
     "localname": "BusinessDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Project cost"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r506",
      "r507",
      "r531",
      "r554"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r36",
      "r42",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r122"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r196",
      "r223",
      "r224",
      "r227",
      "r229",
      "r233",
      "r234",
      "r260",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r315",
      "r316",
      "r319",
      "r323",
      "r331",
      "r421",
      "r513",
      "r553",
      "r564",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Warrants issued for common stock, share",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants, share",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommodityContractAssetCurrent": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the asset arising from commodity contracts such as futures contracts tied to the movement of a particular commodity, which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.",
        "label": "Contracts receivable"
       }
      }
     },
     "localname": "CommodityContractAssetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.",
        "label": "Common stock, Conversion price"
       }
      }
     },
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.",
        "label": "Increase in common stock conversion price"
       }
      }
     },
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r569",
      "r570",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r531"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Number of convertible shares issued",
        "verboseLabel": "Conversion of common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r67",
      "r284",
      "r285",
      "r296",
      "r297",
      "r298",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r1",
      "r137",
      "r147",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r2",
      "r3",
      "r77",
      "r80",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Purchase up warrants shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt converted into common stock, value"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt instrument conversion rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt converted into common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "verboseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r193",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r300",
      "r307",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r1",
      "r137",
      "r144",
      "r311"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Promissory notes issued on December 28, 2021"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r68",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r18",
      "r77",
      "r80",
      "r82",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt forgiveness",
        "verboseLabel": "Debt instrument decrease forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r124",
      "r126",
      "r284",
      "r440",
      "r521",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount",
        "terseLabel": "Debt instrument face amount",
        "verboseLabel": "Debt remaining amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt fee amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Notes payable related party debt plus accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r178",
      "r520",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt instrument, maturity date",
        "verboseLabel": "Debt maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt maturity, description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r20",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Monthly payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r77",
      "r81",
      "r82",
      "r83",
      "r123",
      "r124",
      "r126",
      "r143",
      "r200",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r440",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r125",
      "r296",
      "r312",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less unamortized discount on notes payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Gain (Loss)",
        "negatedLabel": "Gain on interest relief on conversion of notes payable"
       }
      }
     },
     "localname": "DebtSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "verboseLabel": "Interest"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r110",
      "r622"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "R&amp;D tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r110",
      "r622"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operation loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r40",
      "r60"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative liability",
        "terseLabel": "Derivative warrant liabilities",
        "verboseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r84",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Commons stock dividend"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r84",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Dividends on Series A preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r84",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends on preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.",
        "label": "Dividends total"
       }
      }
     },
     "localname": "DividendsShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r12",
      "r127",
      "r567"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued interest payable - related parties"
       }
      }
     },
     "localname": "DueToOtherRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r187",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r220",
      "r223",
      "r227",
      "r228",
      "r229",
      "r231",
      "r417",
      "r418",
      "r488",
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per shares - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r197",
      "r379",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r163",
      "r183",
      "r184",
      "r185",
      "r201",
      "r202",
      "r203",
      "r206",
      "r215",
      "r218",
      "r232",
      "r264",
      "r333",
      "r373",
      "r374",
      "r375",
      "r390",
      "r391",
      "r416",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r456",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting error correction.",
        "label": "Restatement of Financial Statements"
       }
      }
     },
     "localname": "ErrorCorrectionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r40",
      "r72"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Fair value of warrants liability",
        "verboseLabel": "Warrants exercised to payment of debt"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Schedule of Fair Value by Liabilities on Balance Sheet"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r298",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r420",
      "r466",
      "r467",
      "r468",
      "r521",
      "r522",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r298",
      "r335",
      "r340",
      "r420",
      "r466",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r298",
      "r335",
      "r340",
      "r420",
      "r467",
      "r521",
      "r522",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r298",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r420",
      "r468",
      "r521",
      "r522",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r298",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r466",
      "r467",
      "r468",
      "r521",
      "r522",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial liabilities fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r588"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain on settlement of accounts payable",
        "negatedLabel": "Gain on settlement of accounts payable"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r40",
      "r69",
      "r70"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on forgiveness of Paycheck Protection Program note payable",
        "negatedLabel": "Gain on forgiveness of Paycheck Protection Program note payable"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "Awarded contracts"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r134",
      "r139",
      "r153",
      "r242",
      "r244",
      "r248",
      "r250",
      "r489",
      "r519"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before Income Taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r380",
      "r381",
      "r386",
      "r392",
      "r395",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes (Restated)"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesRestated"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r198",
      "r217",
      "r218",
      "r241",
      "r378",
      "r393",
      "r396",
      "r492"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax provision",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r182",
      "r376",
      "r377",
      "r381",
      "r382",
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income tax benefit, net of federal tax effect"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "verboseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r562",
      "r628"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "verboseLabel": "Accrued interest payable - related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Contracts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseCustomerDeposits": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest expense recognized during the period on customer deposits or security deposits held in interest bearing accounts.",
        "label": "Loss on write off of deposit"
       }
      }
     },
     "localname": "InterestExpenseCustomerDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r30",
      "r304",
      "r314",
      "r523",
      "r524"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "negatedLabel": "Interest expense - related parties"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r188",
      "r190",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Operating lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal and professional"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of assumptions and judgments used by lessee to determine discount rate for operating lease.",
        "label": "Interest rate used to lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule Of Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Operating Lease Right-of-use Asset and Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r196",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r404",
      "r405",
      "r406",
      "r421",
      "r518",
      "r589",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r138",
      "r150",
      "r531",
      "r566",
      "r584",
      "r626"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r168",
      "r196",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r404",
      "r405",
      "r406",
      "r421",
      "r531",
      "r589",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r1",
      "r137",
      "r148",
      "r297",
      "r313",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetails",
      "http://shuttlepharma.com/role/ScheduleOfPromissoryNotesDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotes": {
     "auth_ref": [
      "r1",
      "r137",
      "r148",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value at the balance sheet date of a financial instrument used to receive debt funding on a regular basis with original maturities ranging from 5-10 years.",
        "label": "Term notes issued"
       }
      }
     },
     "localname": "MediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r41",
      "r140",
      "r152",
      "r166",
      "r180",
      "r181",
      "r185",
      "r196",
      "r205",
      "r209",
      "r210",
      "r212",
      "r213",
      "r217",
      "r218",
      "r225",
      "r242",
      "r244",
      "r248",
      "r250",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r418",
      "r421",
      "r519",
      "r589"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r209",
      "r210",
      "r212",
      "r213",
      "r220",
      "r221",
      "r226",
      "r229",
      "r242",
      "r244",
      "r248",
      "r250",
      "r519"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r49",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r212",
      "r219",
      "r231",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r373",
      "r374",
      "r375",
      "r388",
      "r389",
      "r390",
      "r391",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r473",
      "r474",
      "r475",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoteWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A note that entitles the holder to buy stock of the company at a specified price, which is much higher than the stock price at the time of issue.",
        "label": "Note Warrant [Member]"
       }
      }
     },
     "localname": "NoteWarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes issued"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r1",
      "r137",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable [Default Label]",
        "terseLabel": "Notes payable",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r11",
      "r128",
      "r567"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes payable - related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:",
        "verboseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r242",
      "r244",
      "r248",
      "r250",
      "r519"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "PV of Payments",
        "verboseLabel": "Office Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability current portion",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability non-current",
        "verboseLabel": "Long term portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Lease payment"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset",
        "totalLabel": "Right-of-use, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Schedule of Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesRestatedDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Going Concern"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued interest payable"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r135",
      "r145",
      "r171"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Paycheck Protection Program note payable, current portion"
       }
      }
     },
     "localname": "OtherNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Stock issuance fees"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred stock dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Dividend on Series A preferred stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r3",
      "r77",
      "r78",
      "r564",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred stock, liquidationPreference per share"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r194",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred stock, liquidationPreference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r531"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds for research and development from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from convertible notes payable"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from initial public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common shares and exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short-term debt classified as other.",
        "label": "Proceeds from PPP note payable"
       }
      }
     },
     "localname": "ProceedsFromOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from notes payable-related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work."
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r169"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r151",
      "r490",
      "r531"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property plant and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r341",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r129",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Notes payable related party debt principal balance"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.",
        "label": "Notes payable related party maturity date"
       }
      }
     },
     "localname": "RelatedPartyTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Notes payable related party transaction rate"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r341",
      "r459",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r457",
      "r458",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Notes Payable-Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of note payable-related party"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of accrued interest"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r105",
      "r155",
      "r643"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development, net of contract expense reimbursements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r84",
      "r149",
      "r500",
      "r505",
      "r531"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r163",
      "r201",
      "r202",
      "r203",
      "r206",
      "r215",
      "r218",
      "r264",
      "r373",
      "r374",
      "r375",
      "r390",
      "r391",
      "r416",
      "r496",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r186",
      "r196",
      "r239",
      "r240",
      "r243",
      "r246",
      "r247",
      "r251",
      "r252",
      "r253",
      "r260",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r421",
      "r489",
      "r589"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of stock number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of stock membership percentage"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r20",
      "r77",
      "r81",
      "r82",
      "r83",
      "r123",
      "r124",
      "r126",
      "r143",
      "r521",
      "r523",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Promissory Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesRestatedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of sales of stock or previously unissued stock made by subsidiary or equity method investee to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Sale of Equity or Issued"
       }
      }
     },
     "localname": "ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r173",
      "r174",
      "r175",
      "r233",
      "r315",
      "r316",
      "r317",
      "r319",
      "r323",
      "r329",
      "r331",
      "r525",
      "r553",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r86",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OperatingLeaseRight-of-useAssetAndOperatingLeaseLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r557",
      "r558",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Number of Warrants, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Warrants, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Warrants Outstanding, Ending Balance",
        "periodStartLabel": "Number of Warrants Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share granted under equity incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of Stock Option, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price, exercisable",
        "verboseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Stock Option Outstanding, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Stock Option Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Intrinsic Value, Outstanding Ending Balance",
        "periodStartLabel": "Intrinsic Value, Outstanding Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Stock Option Outstanding, Ending Balance",
        "periodStartLabel": "Number of Stock Option Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price, Forfeited",
        "negatedLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable Weighted Average Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Life (Years)",
        "verboseLabel": "Remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtDescription": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about borrowings which initially required repayment in less than twelve months (or normal operating cycle, if longer) after its issuance and that does not otherwise qualify as long-term debt. It typically is comprised of borrowings under letters of credit, lines of credit, commercial paper, and notes payable of short duration. Disclosures include amounts of borrowings under each arrangement, description of underlying arrangements, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements such as the effects of refinancings and noncompliance with debt covenants.",
        "label": "Term note description"
       }
      }
     },
     "localname": "ShortTermDebtDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r196",
      "r223",
      "r224",
      "r227",
      "r229",
      "r233",
      "r234",
      "r260",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r315",
      "r316",
      "r319",
      "r323",
      "r331",
      "r421",
      "r513",
      "r553",
      "r564",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r76",
      "r163",
      "r183",
      "r184",
      "r185",
      "r201",
      "r202",
      "r203",
      "r206",
      "r215",
      "r218",
      "r232",
      "r264",
      "r333",
      "r373",
      "r374",
      "r375",
      "r390",
      "r391",
      "r416",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r456",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r232",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Shares issued for conversion of accrued interest"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r22",
      "r76",
      "r77",
      "r84",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Common stock issued for conversion of accrued interest convertible debt, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.",
        "label": "Common shares issued for dividends on and conversion of Series A preferred stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r76",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock issued for cash, shares",
        "terseLabel": "Shares issued",
        "verboseLabel": "Stock issued during period, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for exercise of warrants with settlement of notes payable, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r3",
      "r4",
      "r76",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Common stock issued for restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Post reverse split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r76",
      "r84",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Warrants exercised for cash, shares",
        "terseLabel": "Number of Stock Option Outstanding, Exercised",
        "verboseLabel": "Number of shares exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r23",
      "r76",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Common stock issued for conversion of accrued interest convertible debt"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.",
        "label": "Common shares issued for dividends on and conversion of Series A preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r76",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Common stock issued for cash",
        "terseLabel": "Value issued",
        "verboseLabel": "Stock issued during period, Value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for exercise of warrants with settlement of notes payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r76",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Common stock issued for restricted stock units",
        "verboseLabel": "Restricted stock value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r76",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Warrants exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r58",
      "r531",
      "r566",
      "r584",
      "r626"
     ],
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit:",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r195",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r330",
      "r333",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r436",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r436",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r436",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfFinancialStatementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r235",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant exercise low price"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant exercise price increase"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueByLiabilitiesOnBalanceSheetDetails",
      "http://shuttlepharma.com/role/ScheduleOfSaleOfEquityOrIssuedDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r222",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r220",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "https://asc.fasb.org/topic&trid=2196771",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(6))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55295-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r551": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001493152-23-002473-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-002473-xbrl.zip
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M%A+HW?LN;E7$G.$*$%)"U)@Y6ZWF@3 .IA;[>!>LNA4%K?9)R9;*07IBTKK
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MZ+=[PWP%JF8$+WRV+#$SXW#3XUCD,LPXAU[6W%,PG<,R_P=02P,$%     @
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M1S<]V98IVZK4ZAN-O=G5?HKT+BLR&8F.6RR7Z#'6*:<J\6OY!VV5IJH_9_U
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M07UC0$GOUG>,7__4K8 ]1=)/(_!\V()1[#"O#5H#F":^";Q./N@[&W69FQY
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M0HTPJJ7:A2LC("^X-Y8)+Z9ZBJX8[LH(4,!9"CC*""BS$5 A0"DCH,Q&0(6
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M'=Q;!^$GM>UM]+8GYWN)L$VKT&VO>8)@;QQ&GQ00-QF(<I87,P12-ZW81Z^
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M/10!!MZ:1DY.9BA,YJ7*C$\^EMDI>F]DCM[;VO:6C 0).1%.%9X5HO.A&-H
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MAZ)Y'J8/R]JZ;V19^K?\/)'9CS*H1:KKE[,VU3N+'XYD,Q)IPX,(B2-"477
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MG09S7*OW@$<':9_ [M6)@NUAHR2Z471BHE.=MOEG@ JS/M*\H4Z;A3'4T24
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MS\I45-K_7,2>.G841- UV24SA:=I),*#V<CIZ3QA&?LHV-K ,IVNI5/U9 5
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MM$.?FA_><G* %WC )=[%0NR1 :\VQ.LP(#K#-10>\4W4;4@-!@&(!7P\P2*
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M_FANS=E**^^%="R51)E&)$XLX5H)>4H;QZT528A2VG>YX66V'A[#YARRP*F
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MN(+[63DH7XT;FB'G^F@.?W8-M($@:\>R@:RBY91("-I&!JG]M# P$D1LP3_
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M#[!=)*UK^'CE9/]4MYL_/SK[FC[7;OX\!F2/85IC]/Y+<L*V88\IS$]14KM
MVW?#'!\J99U=Q$]/+^*S\Q>ZY\RTA$F=CTSJB*8U,JG?B4EEZ[5)$6Y'3LH"
M;>Y&?G5G<SU_$E\\O8R?GUWL\JN+D5\=T;1&?G5G*WV=(?_ @?:7>3;?CFSH
MMR:F86Z"ZPK\TVB39&DT3^I5E.IVUSY<XNT_&W921'%T-)AG&X12-LE64*"V
M_6$T/ C=MS:&/3&+%MV<3V06[XV1^*&9<[S&T*!-[HO.[?E';_GH;71MD/3A
MZSDJXA\YY9?CE$=&*G^K]5J7"X$]-ND=^=X.E'+"N,Z]=US_HAE98*LV!U,[
M-/!)^BQV]<S-MLHU\UQRO7PF^AP)K^)^W4DB_:&\ <./IY-LL7< \]%4\XP;
M+C1U]$M2 6 ;C!S-$7SVF)]GV(7LJ_/XXL5Y_.3Y98PZ[W;-26HE"XO':9:W
M$I5/L8F<[#J=(*7 UEAVH^M,&L=SR@/AB2-;H=4M/+!:6XM\+TRS0\V!9<F)
M[RV]<O73Z\<&W3IM'R7;* K_?76UVY1D,0 H']M9V%:>50*K%I17&\ZF_!?1
M^;MRDZ7EQ[9"T:V)HZNWZ;O_^OGME2NI_>'URU<TR"J;,:P!@^A%ZS)'TR=T
MUINOBC(OEW1-\Z1!RDE,"FICI-%3$F;M,&,&S,%C4F(P RR.%)[K3/HF0Z\J
M*^X=97/APZ8H/F=ET])_U9I<&BA@G'3)BE8+K:M*.'5S=Y\MV@\MA+-FZ7Q<
M6;-IC-WMG7VFRYPWJ[)=KB215))F//J^JT<(V!C?Z'Z'0K3;,J:#!TBB"\?X
M5JG#X@#.T$JZT,P=A/:C)Q?T(TTZ9!)';?R,^M]H*7_V2G]*ZC3YITRE <.#
M6-^N9V5^U'K@[T!!DG#ZP]L?E#6==*.NQTQ4Q\^!1F;S[ZST759_D(E\3WI,
M6=U9GL?O+@X.=Z[_BXH\"11(V2892M*?KC))JBU$2)=,.4S3K>:K2=VF?S4K
MZ4MJ52T<FSVQ_7K6V;GH68(-G2L(C93[A!]1$.+!HD,N4F)T",6') UO(1\6
M71'5@W9A=A4:(T_-7'!PN)?@M:G9^A3+USDY^L[)!U\Z_3#AM X:$OF+S5*2
ML.X!#T.EILQ.ZSLJLT$D %7.C[*OHPLB*UM+W92P>_4YU&:*JPM%WTS:W.-9
MBH<L1SD[O72OOPH*OW\B,SR&Q?W5D_CR[#(^/3U5GX O/E*#^67.T(.-'8"'
M?EN1F1X]VH6B)\O6?!UK-0_J- %S#S[UU=G)Q0M4:,JT8V6 LB::X8OXV9,G
M\=/32[LLUXCZ44;[<!:C1NGTV8OA55N7G%VK.N6&>=Z!^+;M3?IMRME=C+*'
MRH.ACS,F<)^4'<G8N@<3_7EE=GG4@#[2R:LQ'UE3JH?Z-7@5)5127*G*3C>A
MARGG68!^,6:P(ZH=Y-&7H,6^)GK^N9HHS>^SZ;MSN4C"W(C(@+M7%G1W_V_3
M5G/V&Y^?0M)&P]GC5FJZB6@?\BA!"U94WQJHU21KG;3;L!@N%W<]X:_.3RY/
MO;#NEW3RG1SOY[^AX?Y^%Y0SYGZ/R_G99N+^R_D2<5!KNG[N_W.70 .O/=4/
M"(M9+:WF$9#)"@$H2DOCRIDA<NR=#*Z_NZ^_;D(=X>;]"S0]DMT":'4R$)%Y
M. ;X,14-OD.: "CD/1_W^TV>-0^Q=O!XUO?=8H$4NVLZTY<D5W,R.8DWG)]S
M0H?A/S(DQOECNM>/SQC1K6+H([[O( "'U@\8ME0Q'+R2VV$0C\"KK-=1APIH
MR8)DG-!L.)>$H<D ,$'\Z1:E>L#3R._6%L%H2#7OYC!R6OLRNV:]G-?-*A%>
M'IAH]*@MN!F>AWP"4B0#8'P]8D$<ZTH_@07Q9,2"N%,LB+/3$0QBQ#KX[6K+
M^[_]^./+=_\[G7Q_]=/+GUY=O?QK=/73]V_>_?CRYZLW/XT*S'U>'^-8+$ID
MK7%J2[M> R#+][U(DR:Q(<69D2!IQA&#?[2%5!<PP-==M;.;3O;VLXM=,UM-
M)?2OOW?=.?B/""C4DE/7E+$/J9J\-C>2:;<+!GL@AWSW5_C8:1@LRIT_MT_W
M-!.])OK][Y%'_0'KVW7=?8;Z]?F3_3Q%[0Z]>K+DW^38^UWO.32\_B1G0)8^
MQ)GZ376]WY_^QT'._?NRTG10DD#_RXCRWP%4^'[N^_V9Z3VED)^RPD0_TB.K
M^TTG=YIR>0>LU"+F64'$;H#[='\.9 &W7JM/.UP.BFPM,K*LZ>(L/JJ3NL_7
MY$ZH[(\G,%@:9M,$1!9:%G?YF8O3N&.TW//S'\7'PQ$?Y_=5?)R?GI\=U>'<
M^P4<&76='M7AW/L%'!EUG1_5X=S[!1P9=1V99#PT??0/OUZ'.,E;K]"A3/O1
M2\U!?6>X75/Z];W;YWLQR7M!#/=T;^_%)$<">."3' G@?BE$WT0S4FN75=D6
M*>+T9?7?4;6</3H_?1*?7SR/SR\OO]ZK-'VF1GFG\!O2;OLWGMV]J#75!-0[
MF^A7=TKPG&]RE]-[?*?3N^O-NQ.6,9+=2'8CV8UD-Y+=2'8CV1V2ROO+*FO,
MG?08?/*?7W:/-&W: MJ:CQM3U*;^S>=Z;]H,GGWA#?[M-]BE-O_G%[[-9_&S
M)^?QBQ>W1Y4.:&_OR/ >:?7^T>KEZ8OX\A/QSP/:V9%2'RREGJ%16?SDQ>V9
M( >TMR.M/EA:?7;Y)'YR>7&/*?70?-I_M WTU[+66#7WL"A=E>1HC1^=-?[H
M[A3X+[F+OS598B2] R2]N]+'1\([L$T[=,*[._5Z)+T#V[1#)[V[TI9_/\*[
M-^[O+^KR!DB,:VQ7KDWT2-W>XRT]OEMZ^>(T?G[Y_* OZ1@?/5+B>W3^XFE\
M?C;J)B/A_<Z$]^3ID_CTR8N1\$;"^UT)[^E9?/'TV4&3W>@U_N06_60:F5E>
MUJ.G^/ANZ:.S^.SR/#Z[>'+0-W44$$=(>L]/+^-G%Z.G>"2\W]L6B\^?/8LO
M+T:E>"2]WYGTGKZXB$^?/[U'A#=ZBFFD7[21FDS/ME>S75"T+4K0N(7QS]$)
M.JFS.:.2IUG>-I\  !WO])=,0_NB%_M%?'%Z%C^[/&P'W^A>/FX:/']Q%E^>
M'[9T&6GPN&GPV?E%?'G@@8Z1!H^;!L]?/(\O#MRS,#J??YWSV3<7'K7KAV0Q
MGYZ<'?9%'OTT1TEUIZ-W<*2ZWYWJSN]3$NE(=4="=:>'G:>QQR&MS6L/H^'=
M'9/U@;;UN[-5<NO13W86W],6/9DW;9+'Z-])(U?K)'I4F46.9NST5S3>FI<%
M^HYS$T@>M&#S"+T(I3THAC0?335'^W%Z B_=)%65H(LH/LM]"[4#>D9OTX0J
MUSBT7"QH7<7RZY/H>(_HW^GB?3EV\?:@G7?1Q?ML[.(]=O'^C<O[TTP'R]+_
M^Q\?DO_O]/2<?I35OKMZ__].)]^_?/7SFW?OQTZY]WE]?\K^_+*83D18H1TR
MQ%795CV16ER7^34D8+2B^4:I65:&16"5U1].HO\M6]OQ>TXR>='F^1;RL\Z(
MI[(T] W#\4:T(&E<5B)1DSSG1THIK,H*EL[<)WRWYW8D'"G:TA=3,Z?Q(6]G
M[79GTB?1U8+&WUI!W9U!'54F!_8^7L>KL[;."E/7JB?DV^FDG,_;BO8N_',<
M-#J?VP[DL05&P.#2ASSFI=EYU]&-;8>>I- Q#.U/0OK G&9P$I%>@[/_8!IZ
M(YOSQOKE3"=R"',>@A:=HT%HVO+*_0)))9&%X<,M\?NJ2;*BR<S>I=*TJ_!O
MN.RWTD$LK=:Q]^MD"P>K(<E0-1@'IT@3V>(=/\K)G_XK&[G#O5T?"8%WH*GI
MY)TGDS=TPM\Z$OK>78=7]CHP!;Y*-EE#O[XC[2.KI-/Z*"KN\_J@$61__M;,
MD[8F.^S&1*LDC?)LG8$P%FV1@E%GQ N4SV0%D0.1P*:=Y=G<V3^Q_C$U&T/_
MAUA-TH)PB'DNLFKM[+=H6>(WXK+$RX@9;6@\(JXN,R..A)=AT3&7WYJDBC!L
M&MG>KFCK&J$?D3*CD0;O[_K>@KZF$S6QYR2!0"(J+O?06_0(SR+\=W[ZS=7;
M-_Q?9]]\'1$QN=ZLT3G3"/U?HNL;0QH&")JH:+8-Q%DM,$A$Y==$@U9MLHK,
MLB317K#P)*)MJ@2"OYQ!#.."X$WN[\VZ#<WSJJ#]:=I&?!@_F"1O5M&CGZY^
M^)K)F50*:$*J5!!=SU<GR'B$BP%*T2JI(77+&V08DF9$FT+">I.;AK2,Z"W]
MV417$;0%V*114V%O,/ [NDII^;&MLA2:!.M@M";S>.!9[.L/KU^^HDU89;,,
M_HP-W3],C+=JE5RS=X0N7C.=V.^GHCITAI,]2DM^^D-1WD29T\_P-.E*:<NJ
M4D:JA*&M)%5LE=%_L X"KPL-=9V1S9MGS5:TIAX%T.GB*T0@]#><7W53$7>J
M./;[[)MZQWN#$\,>BLI3;AKA,%#A:!&D BTKCB)7Y=R8E,_IJ[.S^/3Y\_C9
MTR>T ZMLOL(^)*1IS;,-487,OVXWF[*B+<&T[/')#M"*\G+#'S0+VDA:<K.J
MRI;T:CVT_JGQ=X=.#:<?R=&#7"-5^J*T:I=T/8L6>G9;,3XOZZ-"4GS85S^]
MIMM:,]]E7QD3:H2?H?I5K+F7>JEH6<,$53LJ(9T6OC0Z+M#+4T\P)\?+CHZ=
MW8K(?P,Q6[?S.<PCML8RF@L-&'D17A9\G_0I,@!#.H_I!BQ;8AME16;/AF[3
M-=$/B,[?[.Q?8O)UN0&9DZ14ID1_L*CRG.[30B\=<CHR^2I=+II,W21+8:7!
MIT>9?^_7]PL)6C+$*SI-.F46.&5A/!_B<]\EF,\ACCY3A4AEL;$LF<5&[[^]
M>F<U 6: T\E97Z0F3?37;&&PWO]ZMRI38I)U#N+^@8Q_V$ DM6FPO"YE\C1L
M3Z+6:UC/ZY(8:$O2W0I8$7$D&XR)<D.Z-K-UM\#IQ+Y1V\M ?-U-;H/I[JZX
MP,KV7C*9X5(T%G%)L'RP=Q;,ODYRM[E_*S(N<'C?\-OP T"BPY,#?P4I05OQ
MA)"(I*] ]"_;! $3@Y71UMV80.#SU^6S[+NW.@'M1!EA@E[G$-6+9EFW,\1X
MH/G!::-^""S/2E=\WWMM2!C3'XE+V37LE<Y=!H5C*0JV4E3B*5'N;J,(6Z<Z
M]8XW-3E)2>*$_IQA4A<TB<>DJZR]UR@&PE#><O@*HZGJP^*>UV/XYU>D=6';
M60<U!3Q16!6WIH++AE0J0Q-(:GYZT9)&8*#8W#2K6#9?^'BT,LDUV+HR\PX'
M'R"&7\G 3Z834=F40'O;:P4,O3] E^$TX6&(?!A0?8GA9G7\??]]O*QQF/7[
MN%<8Y^K'P7[U'G3B4G>6<4I;>A>=+DY/+K/B8!-%W"3/[WR6+YX^>_$E\EF^
M +6*A>&:A2R2Z[)B4E6?N6(,$_,06V-'TH+Q7KU-WUG?.FPRONZEMYSP)_N/
M'6/%&FSP7L^,3*.&!5U!=,W+NB$V7;%D*EAD.;7#VW=?,/OZM]V% Z7^ YW6
M[\V;1V+Y_:=UGWACJYB2@8Z7FG59U VK<W6R,(VH>*36$AW,^XZSCJGL3>2R
M$#=Z:J!;DM;(\.VB>^/O-:FEQ-]NLF8E^K!.HVU6986)J*?L^]<O1V(^BFF-
MG.\03^7!<C[8J0JGNQ@.&U3&!3;2&,RH8F<"LBF*DLS:NJW8%F:>IKQ*#,:$
MTU2LGX']!C4QP%I,1O%@.AZK. W*:<LJ8+35P-CP950)8@D%K96#ELBT6":5
M,T%34].NN6R.[KK&"W(4TQJYZ2&>RH/EIC<KX_')$9>L8%YS"@['LBT+XV!Q
MP7HC?$(:D>ZS7GI* YG\HO/\[=4\1SH]BFF-3.T03^7!,C5OE<[G9M.PLA?P
M,L^--F5-;&Z35,D:YJXD)PS$GON!%?=J1HQLGDA.KRG2#9G.&D"R_Y*)K$U"
M6B=G-1*ME;GFV*HS<N2-AT?N(V\<B>6H>2-QM"Q%G5<<I:UT:63&52.RKHX\
M+3Z(4)<!\Q9!YI'2CF):(ULZQ%,9V5)#S^5;4H_F)J-9$1,J#/(\$E+'=G-*
M:I\F/08<CF5:(VLZQ%-YL*QIR$5F@1MJ,V\YW)#GR:S47M=L16H$PKOV.WF"
M,1<S,!-#C.)79,7M(5L'4W+LV6J?P(9X.F)#W"TVQ/F(#?%'84.,>9F')0''
MO,R>KBX>@>S:%)J(S4GGFLJ^*1O#6?:!="RK6DOKO"X?<X& 5OME=5-ELY9%
MH$39EY+$I( )"K6D8E%F$61]NRPE*UI')>\HIC5:!(=X*@^6 ;KD2U?D6$2&
M&%+"ZOYFM:TSTN4+X6D;^I5+P8D%MA(7GQ'#7&0,^I*NLR)C3F?]KVU]2[W5
M2*)',:V1GQWBJ3Q8?N;CY9I,KORG6655^AB(3=L '< H?,4>!0]ND>#AG>K7
M?A7?9I,#<TH^*=,8J.>C02NS!N  0!;*$INH0)U(10^#]K,RS;!:?(FSXMGS
M$D?7M(%<Z(L_8"C&+_!SR;>,%I&;/A*"3@F</M0QV<-#;+Z1&=CJSK]@<C^&
M(T1O >V1H83TD<**S/_RXUN'*Z)SAW([7MFCF-;(WP_Q5!XL?Q\J%@I=SF9O
M75#@I6:OMK/:1]H[BFF-C.H03V5D5 &C,L!W5>0*TME,#MBH%O@:%9R"]!#[
MZ4?5Z3BF-7*D0SR5D2,%'"FY+K.T8QP#YX$AD!M3+4S%$5(@']J?%S #)?M[
MGB?9>F16QS&MD5D=XJD\6&;ERUUDCOMAVY*:ZY8M/H0"<<ZV0;0"WC/@S)N4
MO7>P%]N".. W^--(D<<PK9%]'>*I/%SVI?D<]'M6,*2[\#.XY/])%A_4+^)E
M"R!:[V=MOF^'31(_&2; !Y,R>43K$X#A'Y-BR\B^7&0^*Z_-XSQC<$_7)Z9"
ME'U;:BX2PZN7^4GT<CXO&6\CW\8!QBAC@DB3F%V0T9E/]^VC95H@;@$09Z#3
M_7"6T4M G1862[PV;K; !V4(5/M#FM7SMI8"TYV.-M+71;K!]& ^&5$]<.ON
MAWJ20;+U)MD9! BX=%HMT$R@"]C%<A"NJ9*BEJX=7'F1A)G-%EQ7@-TMQ*B]
MSYU>,MQMA[99\=T53'P -!15:+\6^!FPLA7- F@J&3!9&)(O-7FRE2U-&>*J
M+KN]>N3,9XC_D1TG$<%54JW1<N<7A8-)7 ,+W\*'SD>JA0&)*EBS' PD#NLG
M,)V@OSAM(GW+>;/ WKAV6"%O U3X#AVZ+62 =1H\TL%L&PMDUM;&,)TJ8*M$
M.;=1$4+CTZVI?.R3F6EC ?)'Y.O[OCX@7W/VXR[XOH)>@YR3N6D;J]/S+>7X
M]6V4W6[HP@GC (\$F)*AR]F"4+O-L,(F5B?3R7OZ#[I($-S=3]MK&]9%9+9?
M&/"W-P _3M@L883M)OE@.P\$W<4",.>=)F._6.ZR P>.-0]H#G0CDO0:YE.Z
MVU"AZ@;"P.L]4O7.]0PNOL.+%I3G/F"TB!3)BPBSP6B:YN/&%+CEO7Y</A>6
MN&CA\%@\UK4]2 Q09>R-<KR)]V-KF@Z2%3#& P'@4?D![DSL@PB%LR(<NM^^
MSF&+B@L$L-/T60!Z&P62$5K+9)L+(FGNNU$EFRS%PSA1Z>AC\I1(''ZU#!0
M,'8%WJ[W$5-6I'29JJUGTPP<KL(ZY?.V$GN720LK17,6DGR@<+0$\EQZ0:O@
M/!/ZNVL1='YZ=BXPW*2CMNM6SB<U$)D-(V<O(M\KYN)4FL5$-_27KY['9T\N
MXA?/3WFZ."-D,@O SBUD]$F.?Q)]1TM$R!:21%NA=%B\W4AYGNF%)01MEBHY
M/(^:-G-'/.!=W#8Y7W0&R<JT?FB].CY1??1LK#ZZV^JCB['ZZ(%UIOUB1N-
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M#[WH35G%^PJX]<"EX+BMW=9V=VN?2L=("U(G$C$FP[H$KPR!.<8*D+$"9*P
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MH>T[D6.7)A,9XD'"EH@?+:MD;-1X)-,:N= AGLJ#Y4+)=9+E"BSLXWX6MB!
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M/__/\_/STV^NWGW+_W7VS==NC-A!(X4N2VE2L ?WR&3B!LW+@@VY7<,& .,
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M\HCS";90TZ%)L@M"5?;1CK_WZX,=/T2H2H'23"2D64NH[)^2AZ1;A*4S;:%
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M@=6_=YO_;;#A;*<5GI\5_S,W22H^,*O&VA+?(4!JR6AAEH%>(0'1L\S56N^
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M7JH=&;]5)N7Z8PSE"88HI>$!)96&>B4U00@IT+QX,>Y*5TP(#OV'FU1GUNV
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M_.,UKH[=>-1V:C=(T;"]86J($_FQ%%G(LG>.CF(G D*E= .7I;%C)-;KXOM
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MAFQ0$1!@=AI!(HN<# ,HE>[N[Q*6&P+U"6^QMVK[QB>HO<EPK$?IOP,ZNIA
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MK5V@ [8X02"0 Q 1'0<&^$J++\RZG 0,-S'&72NZ$V0GMPLPVEV2PU:B:+W
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MD^Y?V@\X;W?[ +_61L+^UJGQ3ZJ8,W! &S9R@]Q&6YCY=]:VE1)%DMYG\4R
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M_ZRKEK8!0F82'&Q<V9 N^U<F%:4>V'%Z\I?O+U\F44?6#8T!8Z%C\-H5U48
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M3@Q3/SI9  P>2?VNR)YZX/]PF28C[;[R\TN(U,YQQ"NN;D(,1-EGR8]%44+
M)--C,+\&GEVUZBY(1GR"W5"=6^?D2<$5N/C2:ZE(@B0B,HG0(1@]IR=_ \Q"
MM!^4[:L/<])&9#J^S#:_N9$S148_;OA$F]8#9%?9M6!:O)*W38OC9X-DPBC0
MC95!:B8")UE;CF.F"JJYRAE@IX>QE3Z&O9Q*=#8:TY.VNG)\JG&93<#L2_)!
M^WT\36Z8*&'F2K?,Y\*3 HX6S:LT;))]<?;--P%?L]]2B_*[IR?Y>DUGHI3B
MW.TEQ!P:*$-A@:7UX-G!_^;E'(0(FN]B=!*^^P:#'(2!Y=CGQ_A?^<6:N2@3
M)N%GO-]7%YS10221,SJPX#*M>^(*NZU4FM(MV$YBKEI+@=A3ID3& 6W7/I9.
M5II7B\4I UR"::H*YQ%I8VA*H"TC!I,>JA+"L-QJ-' M*0BZ*^L#CZ+EU)V@
M9;-"A,@#:W4[]6XZ(!X1?*K'I=)M5OF,D7F\1V#H"NYVNZ<0<(BXC=(7 [/D
M__$&^ T7$W<U,+Q&_Y(@<-KL5V/Y<@?XR],]/JK3$U%!4#?T+A??F+)AFI@(
M,;+GI3+^:%C,WG\!O3>;XE=7H'8%TK!CG M&QW?FZ>C=VC.]0A&)2V%=W1 T
MFJ_8&< P/=%+LX,^EI3O55?H]_006<E)1QR0CO A<9:"^PHN38OT[P2<)/D3
MZA)#=:%GJ4IV\AT13&V<0&U)ZAZ8.,:$:#?)K PF WGR,=0F5 "(O94A\"Y-
M.$1SH/S?UT9(SMOC2.BT*,AL:),7YQ)/\I 1<1!%VYC&#9Q[5MEX>M(C>O/\
M%EKWV,OK]/ICF@+3VHB"WJ=7"O#0).2!"S@LE3FZKDC0SF@CAE&&T:B!F@JP
M1DFB$ @@0\3C>,@H )E849@0[8M(L!$.V1Y@?MAL%H&-PPGQ 1UP3K<_0YD9
M98ANH>0HG,U<*(2+V2XLLPDKWG_(O)3D&M=7KA%X&8RZJHZJ ORVTKC=-5)N
M=W!?!'MN5MS(Z"74D@JD3++'LN' [5 OV-@Q4H-]+\_F$9D@J)"8]MD]AEXX
MNL*G/2U16U<3G/W0%%\B:Y2$)?I$#$5V)QW)2K&.(S3>,;I52>[B(GW2*=:6
MPA:#_2X 3N2H[JI!]Z)I/E6%)A_5H)PEB\<5*T\_(7?7GKMZ[TY:\W;74DX"
MR;S%8PU.W1C7$3OC[&.R/SYSKO1 60Z)"??II[RBA-O^$^\XG0GW=R:\C9*G
M@?3HIXWRB 2\\G14W-_P+S6J*\$[C\V+BB)\041/_WN2W!LH:,U4!_*JV5;C
MN)K9]3E>JYF-ZDHE&4M.ET+M/#^A1O<YVA4Q=XW5U29C9;4#LYY/D=V< G_"
MG,[0_C0;<6:!'<5]IP;"WKW(?E0WV^O %N"2$;W7:"T THODM/H3XB-)CG@F
MPKTFI7>?.4B-$DQ*[?Z&_PNX^+2=V(BNB"):RV7.J8EKP2"7,'OP1R#;ZG<N
M(X/2,,O05'I#1!AGI'U*T@.I)AWSIG72]V!)RLF9/JJ=09883SW\7?0EVUY]
M@\I0/Z ,0*PLGW4:!8]AW$WJV4(8Y[,$\1<T=-,X=&6(PW/T[J3RR0+_10G
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MK;0G6A8X.)'Z18'IV"6#/6K1.3FW AU=_ 96]@B+8"1=JD5PT6F7E_W3[=)
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MCTX+**;O?PE.Q=PYPDT%8I;#69^KKGU3#!0UI.-Q(#!""[X$'.UV@9XP,JY
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MB\C&TS9GP^SV>AOFXC;V1K5<;.B:_7:U7(>R7"VPN=I/<$NJY7K>W?6$H_;
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M! @_9H04(TU&IYN%@1-H( NJSL5(!/P$OX1)CFQ9J_N%*&EV)3(+@WVD!V+
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M%-L=L]UJB1EVNF:O=2:Q:QEKN6FV&P.I<]\3\XY:Q["G=!J C[!AZ(\CWYO
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MJ'.)^6L_\W:+X!NED3;D7I27EDZ^E]+A0:.<]1MF)X_,^.H@8EIF"ZOOVA6
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MT@O.G ?'Z!NLKL8#T,BIA0?1 H5, &LX=."0@4D00YYQ:Q'VD "/0U@T[ES
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M:,U!)YP$'*1)6A-_:DN$< MT-=T+2\ \_9O,KM,$8@J\%(NA2:1? HX,:/5
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M(>'??$QGR0.!N2-@0LZ)0>A.)V79,%29D< F]12Z7:OCL6!^'D+2CL>^06W
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M<$5;TN:&;5DBW3LTN:R%<)V;2@CK=Z,+1TB/&NOYHBZJI+3#,MKVQ*4G:9V
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MSVVL07Z%#A:C4@0;/(D0]<7W6.&L[NXJWL36F[?;4N4P*4:-$*[X>Q(F[OC
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M#H&:9H[9TL'*K&DM]64_ 81 V.Z7YE+!F+  ]RW%KTB0D."MC/:FP8.RRX)
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M)">0D<P0CVRDJ);4#JH/0!J]N1$H7$EDB@9RIC3> /^D4Q!NH3F<;\,DDW[
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MY*_LX&[T/;V!?)/9&BVE[>P6,N\F=7)$)T)#SA1\DP\S=ZHGHU%1COF"..S
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MQZ.#=0[9GL=M>K.UAZ%5(:\:+BSQ_-J\UW-E^?VQ0U2:)&&9Y0GB#J+*G!0
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M##OF*P(9$I1#OKZ2VN\EPCLSU$3/@DY#MJ.(+65FW]6JGM[25&/5FS5S"?_
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MHV7:A&P[!5$-?(T]JU^(WD@S 2W\C5JI$GTYR;X"3$3,:IY$!V];!Q;MU*E
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M1]M,!NZE>=@+6 4U&\+ MM'-POZ(T2LUD^$7U>O8H51;"E>Q!L?\VRR7')'
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M2<+*U:#MAV+ZZ33-X.,E_?P\8\U-5+8SY!L@);%:<+H#!&W%%TW#C(CPV,H
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M24/CT6K6T.0GV?MI\7!>"/*T;OVAXDA*P6K%!=RH%ZNBS\X"0?]UA9+642V
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MEAK_YP/0,O%8U[+6H0W\TW)^:&JXUX*];(7T@R?7G]M8Z-"&8\8'],7EQV&
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MRX8K-;;HECK(]RH>]@2H7;)J$*%&]G>:P8W\/IU*?WBG(K((2<XP0R^"PC:
M04I-0F<K.<%PH;D:+4V!(H\511,S"J59;!L,<VI8*^<IR+4)%4T7_VVISA<D
MNG6GR=LR=TX?&6]K5?]V24MQSRB;[1WP+EM2&>C$V'0G_LQOA[\>(-;Q3'Y+
MIM.BX8Q!)>,C6J.:EN7-&@B/"3WD\/U!E!%M[#0/-(Y%N]Z!_3Q37H@@<RST
M%(8?#_4(SK"3]H>V9:Q<P^,FG7F?O],L?+>[\ K?,SWB[I#/ ;:,':A]H!#]
M%67=6-LI+ 4;;)M=*=C&Q2*P0;JVA[#?E;A;FZM+CLP9_J\TZ_-CQ*9WV2T[
M.^+:Y(EV*Y3<)7YNV#<;E G1%7Z1B +OW*P=YU P;E#N0X2P"-AZQ)[3]#3)
M\Q7[%-?;#OM01,PD+=I:OCC&((."ALN<.)A64]RM\V[79>^NKT[ BS6L9]0!
MQN-6_5[.7',YQ7='MGI26=8G_L; 6;*RHJMU!L[/C8#8<T>O]<Y=L4A/HG(N
MP,#>#Q?H$P^PENG1TIS"XCY.PJ*VUZ_^"SF_&A)TI4K/W?<"]_*DY!9[Q-UM
M%M;VWIIPJ<;Y_#;X$.O3GKBB81:X/K+HQW';UXV.VMM2GQ41OEW9EJ0H":53
MT?%X=_WE)"J/\85<K7=DO]?&A-:]KE?T@B=Z(GUK/X;'YJAN9N?$4J92:6!?
M:.^P>!Y\>%&/O=C0K1&"B'O@J8:PJ=B0UWRFWS:/X#&8EJ9.9(5L:GMP!+52
MC=D7+DEUGM.[1#4=7LMR5+2V#/^#+)DD)^*&9F'\?%T8U-Y56S/88Z5+T31B
M .C52E2T#\EX=))\,A57Z35Y2D8/\4ZM.1-=5TLP^CQJG?-&DO>X)"6*[P>V
MV')?RRP'R?IYY-^Y92()SD@SG$C?AIJYDB'55_VVSI#:V;[ D/IX^'/T<TG\
M&-PU1J;C=!/"[;>CJ&HFI!BG>FWQX*_IW%0VX/K^M-Z,?JUG_+C-S5#7,2>9
MDP$1?0BKJ-XD>3-/H$_C49=]O7'XX>#-T0-GL8%!<P@.7F],IW5YXG:O\GP6
M&%3I?]1Z &_Q"\NLU%LKNT$:S3H?J^<+,5]\$(R;C]:*^6F2-=)DN:I,'8H<
M89=N1XAS55K,VZKGET@F;4]==2D@83U+83[RYG7EPG@D&\GIKKJ)%U7];]".
M/UC99D0*-H/W>K2]G@V/_8XS&2X#N.7G5\?ZD2W'@Z[PG,P&*[QC=9?KL= *
M9RZN*:>?G%,Y%AJ=.M+NE/@\K,;F-LADKX::WY%9TO&#EYZ'V>#*%C'\=A[$
M[>BWTRHZQZH3G%GW*%NYSPJSP*&FE7M-_W^V,'165E1&ID6RA9_&JX6H]I30
M)85LJ^HDN)EX.5) X9,"Y!U(G1+*[0S->H,>RX]GS0.BIJN)5NQ\WY1Z;[(4
M?;$_UU,)U[!76'32#-*3;4.2SZ0 11+D_0/R].#]Z\K6,OD+W;UUX]&2X];I
MDM.2(5##%?;>!;@2<"U8,6K5 R+N\' B58 /9_"8DF&1%=-/DP::O7VC:K#K
M%0IB_H"Z'D>_-CEIDZ08_(+2UT2N\4NR. K:=235/3?5J<FS9)[\8=/S.,E!
MF(V_A)9SDBDE87I0^VAG[\(R?WD^U<K\EJMD/-K>V[)*9-NVUY[L8I6;"$R&
M?4A-A8!*BJJ=60._,ETXO YC_U]<&Z\YX1'6.Y>2&=CK;.V3[;& 9T"M?&?2
M@\5*]@B<"BDMKUG66HR+I#;Q"\R]5N1"&:RW=XZ7Y9N#WN+)7T?RI!\W:Z(D
MM'@"[=*?$/WOZ+_$KMY1*!?Y9ICPPMLZ<XF87"P?5O)IIHDZ!<\P8V^["*X"
M> 98R=)E'/66$4MXTU71)>V:J[4F):OVC(V$HN+\N$FKA11\D]F0E#8B^$[7
MXJW!)0KJ-8@<!YS!Q;VBH6C&U:_)66MEU <'QQ_K8FO,"4EYXJ6AM<R+6@L]
M\** -7& @PVS,LDK:"_IDH1YHD;_M"RJZF$E4@AQ8#%[9&FDE'&3>#M-^[1@
MYUUG_^E#Q2=C,4&(N55J6I,Y8KB(E]A/D9U*O)?&-O]N0+M:'H%%"JN;+1@)
MQD!U.Z;34+&D0F!+,G *M]>HA"2&57(84^OP^/Q5FD2G2RG.E%D'_:5(LM16
M&+ZH%Z3=1&_2G-,!HK<H;W0EI5+\ZK*!K;WJAO)[S' ZG AD'1#(.A&M91-E
M0V*.8G/TZ&JHM%WG7+4<S#/CP\W!R53/!J+.1*V5ES9_CPSD%+R P4:65G=@
MB*7H%4GM)"RL;*G#X-FVE'86J"><AQ9<4,Z(/'@6'4)Z$H6O)<5*U\3I0#8;
MDF^/)"5C0JPPN62P2LBU4"QN?!\;0>9G;5I5\$>A#R?1<F,>XI2+-"&??.ID
M7[C^W1\T^$Q3G.&A!IH-G8/CALYBY.XU_0HP'"[=IW'LF4NFTRQ)X3IL[*B8
M ]VA;(82?$ALNE*R(2N)\G::<8?_"#7!$9<3#7_&$E5<["'" 1+3OXO*AD*M
MI<674#\!_(BTYHCR5 Q2$5ZBGDH%!J'9O!;1$\9(OYWU?4D<?G^(PU]O''YO
MB,/?0K7OF\?AG2$R'AW,B =+*;^ZB%OMCN_:[.[^YGQ<F&)6(*'O5U)$%K!D
MEU50 K*:$R_PA"H2 L?,ZM;ZR,I3L>?ABV'CS&)1L<LBJ"(9C\(R$M<DQCM9
MZHXCRQMXMNS9X]#@J]#V[*Q4_VZKZ1&R&>E[F*>%@!B/6@XC-^'5LHH>',8-
M$+*]_^2I0E \?:!>D"ZTDCP96<</_>_^ U>^<'CT<CQJ%X?W:BJ!(H2UH7/Q
M$DDG<$5:QP!\(]EYRY:"FM&%R#SONO+8(CI?%G_@WOK'6[4YX?*NE$Y<%#@[
M>O;Z Y(\Q0=KXX6TIZ1>O^YB%&&ABV4Z*_X@193DIQ'W7F^$N&>=;:P.&9,(
MM@9KYG;M9]*4EJYP9?<AT$EBKQ_;,50Q)B6;/F)J 3CLUM9T*Y"JL" &&_UT
M+[9>&!BYF2"7M>VGENT0 A2NQ5E4>Z*S*0YC\2@*$1"?IU.R_;@,1G$0X7E+
MRBRM,KCY QQ%A1%9'[D*'[8[PQXBF-!L9VBD+<!7Y0P=MGBRI5J3;?2JOM/8
M4V[1*L*P99R^+E+BJ$-QX0T*F ])M@0X*ER)Z711F6R2-"<B87H 358%RFKT
M(F#Z^!GNB\S>"&<E.@RD,)4!,*"M7(9UAR<U+AV$!,FN7*IP C;&\1SH05GT
MC\WHUX:LN^,K5^5U<'SY8;((.*;]SN'9]7#\!4W]N+@$TA%,QE6.(1ME':,)
MD4-:Z%9='A. L_KH/ZTF>Y;@H55!BKO>OR.(%HE$8UMU6IQ,4L!AE4']GEBY
M7*M66^C4E:6WR?"PC$P"HQRB1'/U%3/OV.0(S[<&5PR],*?%P"E0,F ?+4/9
M3.M*XB6-1-@]%VI.BK!VW8I!#>>1#*@T;2@,]LF9_OCV)7U_9J*-GTW^3S.5
M.(OH!?!NB41.5L3?>"3R3S+A.(QB5] 67_,+KU<D)@[_2BGAP 5OL-1L$Q4\
M9)6[)DD^$VZEEOG:6:#G><QU5*OK.<TMKO<DS(!IU<(P[:DKH;5E,*P?B.\L
M9%I<#?3XJ4O':<5&F2FF<,R).=#AB.T/0,6MD[S[@99ZA;2XM36SJ]@3R,B3
M]4@\@_+.YS FCQ1B4SZ4 E<D6B&JQC:$K7YU?-&M5G+&3CKVZS$LI#5[L(SP
MJ@?11,DI^)D4-K!A!**[ZB;OZ!5*N1%-WH\5<HH40>05TDS &0[.&++:+[-S
MR#J5=@/)QP_D=>*[5>7(\7[O#LRU&P3O;C]PH!BO3$Z"]V@S^D>RS&@>SUNF
MEP_!*U4M5_%X=,7O/7G Z^XYNJ$SDLZ2_Q1099,+C[LHXC6)@&7R'[K>>>N-
MZ7E=U&( 08_4RO8)R< %CEHW]^'.,JB[SU\/,O,OVLFR & #'?CC,KD^%BO5
M%&'BW=1J:C!<:&((*23UXBPY)S+-,E7M0_&$TY.31HO\NLS5$MO#7QE6Q:4Y
MMGALCU8(_6<YY;Q)R:'(C$L2[I3 D]I8/W0A%M\30W$R2),E*_$-LO3KN@-0
MU\J,:>%E?$Q.EK3D+S-B,[.D3?MK-W].)96*7.7( ;HGXFU$4SFCG:!K=Y*<
M(SWFS7.^W<@CZ,"EJO3X'$HY[R 9CYR(=*#<#O-OWX%6H!Y:%"V'ZU" !S*D
M3MV&K[#6_K2M(T_,- %<<=[WG@,1;ON4:*=]2FD[U_5- %)P&1X>*9N___8@
MB :VD)Y6X#RDIF@O[L9]^#.__[:"EI%6@6(/+63:5)('[)&>6)6W-\7A,M$!
M)TK!K^F*T>WG-/ -Y"-7#V1)6-4.+HT-L,_^U=!&B(:NOP<P%A8OX\ZRL;O/
MA7\I*@-C_Z \08TZ8L9DG(2,6*_Q%S!A312-5PJSUZ9!L'YY2$>(6%TA6NC3
MIW'D&2'>9F8X*Z"/DB#G/(>+@7 2;M!39D5-IMLIL6\3E$;U.K?[:MV2NI/J
MP;DQO:@.[?Q72=$+?6P]&:$LHGPEC*2GAD: HH%Q5J(/."^24PF..[]J)WMR
M)0ER4\A!UE\"Z1=';S=_L85=DES_CTVQ0\Z*J+_X1)%8;#XM\XCVYK=S=-M(
M!=C",CWAK!7[-C,C:5S#.0 NV6?5S:BA=43AL3.IX. CMY_8M4OM#5)>B9WG
M',ZEHTILC;AO112:H&90!+N[ E&F8BOT/(G[$T6=%A0\]OJK51J41'V]E<GH
M-L^:>&A-X:MMV$PX7\(U$)'..Z'37B'3,&].Z01_?"/KQD1P,A>T;_W,49'1
M,X +I*MMQ?6C:.,9L6DR 8Y(%R*UF73YF5H(KW$L7T0'_R%%XN'_3WK/-!%U
M7AH)X.#ZJBS)D@WZ^,CX>]'&KT4^@_)"/^K@K544^+VP.<1J4J-<P6V?O'AG
M6>D7@ CL;PW)"]>;O/!X2%X85)J?7O*KJ-H4_QJB5]60LW!SY)-8( 53FE6&
M\.(,SPC$_-8?4<:;<-H\9\^IJ[YD52/*"TVI%UJDM8/=8Y+TA::DKVE;"K5A
MZ%MZ,?D^"Q%"H2C_AGXFM;GF2_K,02B[]GA?]XI^@VG=\6OZ#ATC^I+^5Z%A
MN>+#&%LCO%(Y8(TBA.A(BQ3 J7K!M6GS%!4GT/YG#1EJFFA0U<7T$]1!W,WQ
MZ",W6*29<O-%[N$2](/!O6=8,)<J4WV"60<;AN0N?<#Y "UX&1?5UIQ'G=1U
MF4Z:6I.4-;%8 C'>(%.N0YH]L9UCS037STKG(^ZAI#T@%<E:5D^014N']ZFV
M1YLGU8ZG"4/C&5AVY:Q"'JI:%$V&@@F8T0IH;F;M;[)Y?K9 !CI-#=4#9&#
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M8:"Y5Y^U"C;IF67-K>V:7-_J?X&5VQ/?*\\.T,=P@\Z\)BTM%9DT6Z%AU',
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M?I U,,7;N"O?.U,45*7LW$7S7.,FU5+7L#KUSO2YWJ49P7\NZ&@R'-)[0=;
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M+UJ(?BFW==%C?<-]+5IV]^+M1X]N"S4K9WH@9"!D(.0KW.$_Q4)_7Z2UZ3%
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MCRMSD%]_DI"V3Z8 'IQ%S9+^/#GO^$]!12*>580 >$QN?O'O)H5/E5/K::P
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MEH57*C&RI".O5+(L- ]J;(Q(XD""SN+?D:I@\Q5%&&:?1?893R<;(]=4 <]
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MJL='&TJ#J23H@$ 1L!$ODPF'46G0S\OA9.@\$4LC)'UR^!LNMTL+MA.D360
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MP#JG(5_OU5^'J'O?JG8L&TVO:JNGF0I^)XM;#TT$2. @BW)[*CB)<CLE0$J
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M$ZJ]C$R&W:%?XN*20"T1C'JI/XQ1QIBBE,G!@T.L,O"?C*)J(_C5] <H-JW
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M*NQI-$:BPI["R0SQ;K8),9#B71/$5UAQFY&"V43FOK 5K&\79I^'&!WND6^
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MH2X.135]!+VO*N5]4&L<16IQX6^3DN-#P5E"]<.50I'E(A@B64?CWHN!]X#
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M0=64.JK\B;F""H=@]LI *"SZO_2O^RWTEZD,<N7/YW\AIH.0;@+I*=<!4.G
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MSW]B\,._^)'G444ZB#\)-'BZ I.1T&A/GDWY^4$UY1;?]^Y:4:VA)L'G0Z8
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MX)KT@D*>/@%Z?(0>QSARSQ%@KMQCF>'(1 .Q;71((F:=U[$045!D>.OR( 5
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M*=&BG^,C?(B%"T8G=VD.N,C%47*66-HCW9D\*#&WD-PTS]."<AC>+WG8#8
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M&%!W0)7B:%Y<4#A4;=P0!67_0Q_'Y(($-?ZP"6S5)*6!TY(*!>^90[_MNE8
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MP!.A9?!XC?[F_:_.Y?^%IA( UX& \X&#FH.[3<C+=W?HVUL"@0&Z)I!-;S
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MKH6>VGQG<O]X=</QQ_G/(@.<+0.<]]2&SW-9*<DA-[?,S9,2CC"888S*0B;
M.4:7RE V*5XN;D!4+"\3+^?Z,A,9RZZ'C\P(IZL"W%J_&ZU!W>&&&B&3/)OC
M\Q9^)K\%-I5X_'#:K94G%P=]1ZZMHPO\#I:33\(!2TAS[ 4*%&(,!<KG[9_6
M9%G-N88R-!!AQ=)I5(=F## J.Q9>^YB!/*+A&09R) FR)\T)XD"C]1@:H<<=
M+8'6&3XU7'G/:SN1M*-U4,!1& DR#I+WQHH"H11RYOBB]?F&BIF>/0X$CA-)
M/30 ,RQD)0#;@:!,<+$:0Y&P79.VZ6(P9C_S(J,G8:M0I$=:&Q%N%\T"WB;9
M#Q<K!^2!!-+C\S>T]RC M0/MFE9_RC]$VQY)&M#A ">70V0"F5QU#,VZT-"9
M9UE+8Z"1.$<:C\TEPM#9 AD'@QH70TCI[LF4M(50N'C!]&G7KYMBP)>1:-"5
MW">! 7]^ O(A[KPR>IXSH=T=%S6+C5=F_]EF)[!R19C(T3"8:V@*0FLCF3IL
M&D3XA*[5#PQ4CK!U0*)CS<408 (T:VV/!>3'VC2<$[+VGVRQC+YA:I#<(AW,
M[]"*B\D'H'EI+%DI/+0X\#3 K6K>-0Z1P_X3!]_TK).<7!/)J4U12O625V](
M:E^ LA#7406B'J+C\"=G+M9"[.!$&=DU!1POHS]M^B)].IRH#2/_^GP>Y"1L
M,CA1!NN/+3@_K><*+9;S&3Y7"B<!=>D_X()#]L9L/A='?;WQ %\X0( A8^]"
ME^1A9PP0URZ)@Y7'_!:X,QYWBN&T,N0B<+U25Z)W4U="NA)H9C"@1:!3\HG%
M\Y 3Z[FCH^+[XX]XQA'/?;<04=,*RXDC>?-"$;45O(2P,NX-2<]+EL_G7TVU
M.,QNJY<04CZ>L@QQ&98KAJHXP?#:[UG6\GH527@C''841#%0@HJ.!%4 QT42
MT>H@\PN&WU"!,/,*!T-!KS4=RH*VW*!BM!7"TSE3;TVTO ]2WD41$:)M+"]&
MMR>6<;,Q1 K1(FOD%:.*T>RM6WAR&3[+A:N?0TS3Y")+0N>*@/"@^PSL?F2;
MN7V&(6'_@O\A>78G;((3Z5A-N>]<<L]AJG6,DP,L1FZE)VJ2$?$HYT(E#\IX
ME:-,ODM3^^2"'@F3@)MVGZG@8T)]5'P\*!R"C(DE(V+[_"J!&%O%YM"63VOE
MWO.!DJV;9\JVJKB<K>)RN%DB':6%'3I<#.+Q2KV,L:H-H.$+T47IL(6WJ.BY
M!:>MF]%+P2B=U8?/V[I%1<\MM'3TJ<1G"KEL^!81SULPG&08%,[#@<.1'\!"
M5RA=<Q=(?VE8'LX0"0 1<%^Z7!B^%XC$".0P>L(VN>K;!-3+L3] O0D#]99^
M@'I_@'H#EO$;*: O'PCE:2EJ2'R'5/65<!5?U2KC,P@ZJ5V*#5SAKJR+,-._
MP/P?ACX,Z@.SI>I,#Y75 ;6[@W,=]FAP9U7'UUDU4QD8VECE[I_"55J0JZ46
M+ZV*G;&**@E4854=9#+<*M'LW:J8C%VDO<^R9-2(%A#AV94A@*^2VN"#B=4?
MW=1I&Y@W%XX7I]&PL5[4R>.D/Z@,LKD4T]])%5_1/+=G#LO76.5*N4PV'Y[<
M1OL,!7?V;'=W_#5^OJ*JF8P>K:ER9UYLUEQ<6F5]\0+MKOM[G)5QP0D8@Y!$
M6RU NSL!.1BF3KTXJ!S79ZK!O!%\.^Y%^BNIJ1D5\ZHL;>USZ#\%6JW!>>2<
M>/'7%H+JF=;%(NP+1D3V=UMB?%<YN1X<<$:K)6ZE!\'M<>C_"LY/=B@BQO16
MD'".RY1*H?Z&P^RD,*(N]$R+G?(=VM=ZLD+%U6X=$!0-J6C[5[.%'$%5J4O+
M#?I_5I4/FTU';GIZ]ZI04?2;^G9ZGKC !_QD^E-V+7+#9M!%&UXB0;Q4J\D#
ME!N.*J")VWG#+-%B!+T2.+N=H((=]Q%TB?1K$?CE8#L"C5!S:JXCDNNN:H%@
M273G> YH%V'\RK)UWLE2\ZR9ORGD']^*ME >!/4]0F.;9(#S(!N#./=OP+P7
MJS!+Y.8MYG@D8.$%]Y"^LV85T81+K^.9/ER[61@CMO<U#$MO/<48(WG1B8B0
M)_ZT\6U\UJF5+^2)?3:W?,&E.Y*K9"BA\X-+ JV?-IVOX:OBC7C9>1-X;LM2
MQ25\N>6=G]:4YINCB.)7,G@\W7V0P$62/$PJ.9[=G063/,PR.1XW60=:&Q)J
MMOV+S@1X/>UA@5P-K#)&]^\C/(]""MGV5&_S:V>??!?[^1$_NKRL]BIL<2NM
MS=EL.[WVPZ:T[,'+LOE,J5!8.+^^35?USXV\"#R,J\E+ZZOHKR0,:)$,V3$(
MNU/>477 ZB/KA!H'&4.$_D670$NYZ'F $$C'!1>X*]W["%+Y!90OP -@OXVX
M)[(%AM_!#R*X)  M99I"=T PH%1**F#3QN#:69GZQWZZH^@I>KB/=W=L;]H9
MKH&[Z $WAM9@AU[,-MP%Q%*M4G-90_>YBEYG& "%@AFJS*[O)9AWU)@8Z(0A
MM=9%ZX*)BFB1;]>!:"'+@QD9:/ 3YH[>BFZ&V8E#A-"NUZ/Y?942(9%Z&&,@
M27B.]E"<DA!T9XU'&D#I2*9=@J_+&,0+AXS'!H3!D#'Q)M%D:%= 3H+L+.\^
M<^CP4EGI43+TH'H=<V;\\'QT=:(QBE)/[LK!%8.N3I%@!7M(OGPA!=]%4^TF
M6^T\3<Y:[T[/ZX7[I4M> ?-&$Z7XO9"-2_:599%F#R\.M:7=+K:C+<U6B$G5
M]KQ-I^Z@$T%ZN_J_PG#T^Q#XGJ#=1[8JW>'KI+[!BDWM[MA0% %[6/]LEH7/
MG-#T<DV0:_GZ./^YS(E$;(AY#:6RZJH\PN:OW5[V8T9\PLE!:Y.CP6G!"_I6
M]8@Y0BZA6AU(PPR#&:ZMWAK/W^SVFG?7W2,1<IL1>*N&@\.6F8$7ZQZ=M^BE
M+Z@F5.4Y_4AH+(V6>$64$'%D*)X/2?($ 8BX@: ].H.,"W0'7!W>@D]1DO?V
MS@" JH;N/G/BZW*M'MF31<M@:0E6GXQ?FD5);G@*Q.WAS?/DPT<766IIM:0&
M#6KYA$:>C8Q-,R39"YAVR-MV>IKLH'.&W@VZ83)15T,NN:MAJ4U[/'THO.O\
M^>'YX'.I]D3W.Y>/WFV[(U*D$%WQ;+X1LDW'%*Z0Y#(\BH( ;F$X%ER;0.U7
M>J1_[HZO% J_0N=2%VW9H:QKV!Y%OJ5)@I\X,NIV:3*$#I@6@1@VH'%_+(L6
M2:?O<?"0/CAI*GYF'[FJ;I^P@S,2>^B)/1G=+H1K%!NV]Y1Y%M>W.Y[O$-I
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M9#QX<N,.5 S0U 7V.  R'+NYE@L28.QNK7K_.;%?9JP_8K6U8_V<%T$VUD6
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MW#H\/K_MQT&]#\P'P!]NK7R $=)8^6TZ$(NN4!TWE,4G\[@UO<^NM0.QX.I
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M&D9[U- A8K1W@NPL /(5%./IUF>M9P'(&?K 0#888Z3A)E!D)HX54A4LDZ:
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M.21-UA7[ =X2_>EAL5/(5]\K%S=E%ZH+QF3 7\]8L,+.$.9CNX2^/*K@?B7
M"8Z$?18B3]W=,<@,*4'P2-"=]O+(>]XUPY:@-W6"P((;JUJ2CL?D6^;WX_[Q
MU4>S_UR>668Z".?M?Z-K480*:]UPNM__66#5P\:4^.J[F_C9?;3VX6W-SDQ(
MYVB4]+9TJ2?INB3&$>"1^'JN&4<'_7[9!0A.'V M[L(R'#V$U,287T2*1_Y9
MQI)C/G2A8XKR\\'-J#QXZAT]9,,6W!G"8NN\W8*[3:;I6FZUP+N<]!9)']@?
M^O/?_]G;8^JRI(C_,BVA+_U&#WL=2VH7'L+E?S-X']'/S-Z>%?(0Y;?X 4K?
M^A2P2;90G\O\[A5T>?P59/F%=SV@_0L*/(3$W4GEO>=UO_[4]]QK9ZW:;P:2
M[?\R%5WHR-W?S 4Z+61E+S180B[K_M9_K*_!GYQXAQ7K^.]_T%('K;HN"2][
M'0D='/3P$=XVMV!^FD7V+*@_ZA.X"N[%@U4E"^<2Z#4>[!^S>V7?;$8U)3AC
MG4360Q<A0#*3=#K_*_^!OTK&[DZ%<>Y7<FLAD4W6B<1S<OZ[97?.%YC7#>#?
MD@UE//M)3#=D\@M=@&F%7!DQY&2 #I3T(7HH\0!=O&9NC$7,<28P*D8%!)//
ML1"#/%&/[T.8US#7B\/!A.E.!47R/FL6J$^R&)I@\ RPS,@]P-"PR97^%@R
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MS_[Z\S?W#UJ3\<A?W[W6W/]G+Y[IG1[61NUIJR(?<+W7JBY&&[??N_#%,01
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M[LK\";)JX@T\$?OPX 5WB+JESHX.KILV0+?.HJ)+D"T0;C8Q>ZH.9^X[IN4
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M[1Y1J.HM$)7-+SMX[I. #C@\\.(;%FJ)$]GJ"F>:\6KMXN%VE!3'X(TFW]P
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M6H*L*YZGOP]X+D\(I[,)P>X2\Y:TB/J"BM?R385LU[%_-*O&L[+,%-/E C_
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M\GT%[FSUD5GDK"E?'E">-,Q1YI_8ON#EG[Q)YZ-SK0&@CLPDP,R9Y^4VUOK
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M_(._=)$..Y=9F\%'[#"@S8/8YN^6R']BMW).#%Q0BHN-_964F)70'1SR@(,
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M^SS-8S@61FW!WG_!M4.VBONPK2XC!8;>ST+%W[XDI84>O*5K"0SXD.RO/7$
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M[3A7S)-84)[>,,I+B:$\$Q?*R_G30N=;X>%*U6)!>68)E >3N![R4NG0UMJ
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MBT]ZL?FZI8U.?EPF.IG:%:8*.3KI9*K)2^Y>>2NJM6(P=1Z_^&1$7'6K#HW
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M(AI34!33V%4'?;TO4"!SL$1T6J(-)K.G80QJ!'\ Q .UHQ-8$.@#!2;YP"
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MO_4"NK-ZB?<(ZM(B0+_6LE,(G%>:SX*F"=U^1:N!=X6?@A]>:1I%@S+23P4
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MJ23(&G':"]@:[Y#B4[WX!=@;2'JR7N_1=S\C_VW;AVA&>$?Q<X"_#FM2NU"
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MT !*B?] O'NL;5LR5B:D/IO136T(_O] (37>^&58JNDZ ..*"$EZ\'.H&M\
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MTLP1<V9);BKE+Y#4@B=H^ +(&G)*]J;<Q98@N)BR/93#R/"9LAY)V'[H6DI
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M\]3ZI-E[N-1Z-R]2OA&!6;,Y[0A UEU15F2*?HUUEJT,+4TF](EB>SR^/V;
MQ!GT56W,:,8$K%E_SYEE+C:;%$+?,A)K^%NUJ9<6^B6$[ZN@W)N/GOIPO2=+
M=:E7'U2Q8>GJR$W$4U8Y%47VJY!>")2^_H*"%?0M$UW C$_*2'A'H %V"Y-+
MO/#/_S''_LS.0H.# [3RKDX&9POFS*CP89\W9U', $#GZA-6R;&%="DO\KF
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MR'H;DL%X#?A\7'P01F@)<E?O^Y\O/C^%LCCF6\S6%+(/R# ^/* D!V(* P#
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M)XDAJKIV,X2HVHK* 43E5A1 -%'?;N=+JXU.C_]<^]OM;>>A<FX@)O&QU>L
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MJ,/9[3W/=BPZG55 #!E=$(<@0PFG!!:!)"BJ$X\DW2"25&KZV2@?Y8GJ*$Z
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M [$#8I_U[,$4L7\V\L8F_.7_ 5!+ P04    " #XB#E6C%EZA'\=  #%(0
M#P   &9O<FUS+3%?,# Q+FIP9]5X9U137;=ND!(5$*1+?P%!"$6Z-!$1D&[H
M'>DE(+V7*$4@@ A(E2*]AH@0:@"E@_1.Z%UZA]"2PWO&*7_NN.-\W_E^W#OW
M>'[L,>?8>S_K67.N.3=N"K<((%=15%8$X.'A =[>7@#<#$ ><)>("$A$>!<(
M!-Z[=_<^"14I"3$QR2,*2C(J)GH69B9Z1D96#GXN5C9>=D;&)^+<O$\%141$
M6+@D9)X)2?,+BPC]_1"\>_?ND1"3T)&2T@G]Q?B7T#]LN)^ AW<!&W@Q^'AL
M@#L/\? ?XN': 2P  !XAWK\;X#\,[PX^ 2$1\.Z]^\2W 4ARP!T\?/P[!/B$
MA 0$M]Z@6S^ X"$AQ5^"<D248 L@FQN5T(?XG+OL+RM_46L-'W (6[J'W+M/
M0TOWB/XQ)]<3;AX143'Q9Q*2\J\4%)5>*ZMHZ^CJZ1L8&EE9V]C:V3LX>GAZ
M>?OX^OF'AH5_C(B,@B4D?DE*3DE-2\_-RR\H+"HN*?U158VLJ:VK;VAM:^_H
M[.KNZ1T9'1N?F)R:1B\MKZRNK6_\V=PZ/#H^.3T[QUQ<_LT+#X"/]Y_V?^3U
M\);7'0("? +@W[SP[OC\'?"0@/ O02(*.3#0PHV23>C#7:J7\3F5O^ZQ"VL=
M4%NZ#]^GX1!9>GSX-[5_9_8_(Q;R3S'[+V+_S0L-(,''NQ4/_R% %G!^^23W
M_?W_9U"\GO0V?/4=3,A!W,:;R!9>^O4E:RB1U:4^:06F2VV8_Y5116F/NY^@
M(K'0C=L(8JNAU:%&_W*MAX%OZ$?HM4;P'T3J_K[MF,L&JL[]J&]M*G$;G+RV
M+^B.,%*7S]7H'-_FE=191&X-EH@(4"GY.-5ZZT?[V&N022,P]+M\&ZJI>@8#
MNN&!.0<K[9IYON%\-AYG4FUKK^\M4@YAO4YJ(_B?*_.E'A6Q%3U\Z<MHE+LZ
MRU'=?+[S\ M$RP.97RM>G N;:G^2"P/\JP$B:Q>WL52UEA4^"DZJV7E(3/F>
M2-U-\F,!E;I?F2DYW^Z;;H_=H6"OCM@O&;IT@=K>.(!P'AFUCX0SDR8?IJOB
M CR-<0=>Y0W6_\*R#]$?\;3 '1,A1OT3>:[M/=+A P$/6ANR[P1*H@[#Q'VL
MJ\4^YZ Q5_M3]Z](9"1]&47>GB@S.ZWQ(!GVW 0;%=BZ(TCRR8,Z@L07;_Q$
MF80UQLEQ@/(7"7&*C/07C3JC[T1B%2&@?!"''7!AOHERB;GV!P1.H;<,WI#/
MWG^0=X20E6EKP&A"-)<C4"WF/Q<(M1.*>&O\651"[A)XBB S<^>""G_)27A>
MJ-M/QJODEA"*CDVXN25&W^Z0:HY_[<J&N K9XW.9-1[Q7A?(2F<$4R\OT'KM
M?]\40Q.0154(R@Q("1S 3N;TL%P-=:C,&C0ZQYOK*N\:LLY"L:V%"6VG]?^2
MOVXGI72N__VZN*<X"/*(5ZV9SCY64.M,)^EQXWC229"0LYT^<A3^2\CD-7F
M75-0]-(-Q4P;FJDBS?&#53A =I=Y=7)0%M]S%74X7.=*-OV67WC+E_JDWS\M
M4V^+)^CA;P4'C]9F$5_=I^B,A^__B"< =?<O]&,WZ6,:%!$0Z+VV7ZPNQ7N@
M+42DMX/'T@4QR75,T2'UD6K%I,W)LXJ8FL"33 G/F]?EY7MQ<&GA4@5A.6DU
MTJ99B[$;2"4B&TL)6=]725&.QP&@MH%3[GY/_.-^3C8:F$0W/EO;4R2;:'XG
MDD7[4!HT[=C$<L%TG%(=YGB=7>((>U(12IX+>P+X5Z%\U_9XIT8-[V)AS6BX
M0EZ_^1.DWC;I##W#;6<UA#=1+YCTF#[P,Z8@]^+K&Y@[JL8H"W)H;([M&V(;
MS@DT60@\?GO$S@1<A@QB&7TM G67MP,DQI#E4%2J?_&N81;/I/4A;63%*2T7
MI)G=?._;XOU3END] O%+U"KILLB;( E$05[$Y4?\!(8"3!7,2P:IS^G=3'&0
MB8AH9MU*F'KU&=T#T(V"AJTWT7_G U[KUD)/^_0RYPX_I%G%]3UI7,@*044-
M:/O$_]";ZCU,?R0MR_.@W%66YVA7?BDH@X4TUX\57$HQ4MU6H<D:!!I#J?,,
MYG!$NE=L*=!?DF%>=9\H8'4]MS6R6R^C.F0&OUP+EO<L+5#,F!W1B,_P7)8L
MPBZ_MDV6K-\=;I.7C&)S.@6F7] ?6%XN0D?UL%Z["\32+[U8R/CRFM^=3##<
M%L>L["3/C6H6#D%7HS:H4MW;#>_-YRUI>R(Z8BG$7DX)"$5J4;_-$E NNJKJ
M-J=20V!/OMWYWX,+G_.],#)Z\(>AV.AQ2R]R&0>@#I2[2?G6E?<3T]!\L=ZE
M&^/)$NNOB"AN'1WT<[URVB5OI/PCV]EL<2C6*!YY+>=5HJ:YS[)JOE?\1Y9'
M*)W%N /UZC:;FORKU%XU)3U6?W=JJQ"0LG/RW-GZBA5!BO"ZR5+:.TW<2SKQ
MB[A"-2L1"D0Q%T&Z8/O*N^1%\L6_&#V$\Q-ZN!^W0S++AFQ+4<ND+KI?<  2
MZJJ"SNBBE[W?:%\8,_4'+DVX)\S=NY:V>-3N0P>XM(.A#\F8Z2RPO3@ S[J
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M$BXV48_O&#:]7@P"Y82T@NS#7#L? M_R:+)>ZA?U^8Y7:F7%#U.=78%K*OR
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M[3!$T+GTL=(GN\./+:M_#K:>I<2SX]5F31=MUFRT9PE^@.\XGT2,9@LK%CW
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M2%L" &^#')GD>/,.9- .:Z2E,T]C<KH[>1JN98?E&-!'!EW750E+,*QNC6>
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MCQ'?IC'!/7#>P%\/+3'>@YR5L=[%O;0^#?PZH^E)U6,K6#:VKA)?-RH+O54
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MY=1=W)R<W'P\NWGX_M,;^Q,@Q,NQS:W$R7$$V"7$P2G$P6X%8 # P?T/\3B
M_V?CV,7)Q;V;!Q*#'_I ]7Y(?$Y.2&AN2&+H:#AT'. 2XCYP^-BYW<)6UWB.
M!(@<?Y#RBE?N?$63J'4O6?[$]=L1>_C$Q"4DI104E9155+5U3NKJG=*_<-'(
MV,34[)+-%5L[>P=')_<;'IY>WBB?P#M!=X-#0N]%/HR*CGD4&Y>:]B0](_/I
MLZS<O/R"PJ+BUV_>5595U]2^_U#7W-+:UM[Q^4MG7__ X-#PCY%1(FEJ>F;V
M]]S\ F5M?6.3ND7;WOFC%P? R?%?M[_52PC2:]<?'_#\T8MC5_"?#PAQ<1\^
MMOO .2N>:P'"1XX_X!4YG_*JHFF/W EKLNCUV[U\8O+:1 7*']7^H=E_3+&(
M_U>:_3?%_KM>H\!>3@[(>9Q" !Q@,G+CE(%_CO_=XPL%3#)0F!38AQ8)F6K3
M]X\O="K6=4HJ"\D8HNRZQ6]VF*_^\:DS%MH%*HYJ[SR4FS6M[YH.Y39Z4009
MHN[4FWYWT7P,R5X#%,7F2G5*QDX7$?_P]X#A-X[VM26YQ.\YG,;?!.&)ON"8
M,'6)(B5SX1,;(/]E<=UWCP0SRR*,9)==Z'(<W!,6:OGN@/YK)<EVBWOP$<D(
M^^<B\ [E%G+V7VN$VG<URY?]P<F$-]BC":G;E0M2:K,AH#>2IF+4%[K,!KC6
M>\N"A6OV-&HZGBAF ][Y1H$;VJLTY 39&KES5(.'#>QK*V(#DF]87_!L *["
M!B8_@VL7V8#_-3;P>Q#)$+5A RF&&;F-*#80Q60#W IL(&_7=Y"\Y 12LN!$
M$&PR ^<^5<$8I\5P#,_DI2PVL+Z&8^V-80/RL+&GX/:F/736%38PC2@HQF>!
M_^:,?RM,'EV1P&! >Y&'V< 7'NHLC!5NRP::;.';PO,^:K.XOSF%);[%$,ED
M)?"?8P,M%9"P[=[_2J5SS ^01#A;D&R+8%W<<8K;+OJ;4_Y6QW>^;*"G$Z0=
MAS$>@_^TRS_M\G^#79RG(&&R85I+W"]_3Y#:\']B&$^'#C<9J>?J2L4PA'=?
M..C[3&IB2NS)<C_-TM@\7+^7F?9H7A_-(O4S;\"7OVHY!=DSFTIVSN$LK9#J
M'=#L5F2>2#=E DIP9)T4T\*[%6KOU!&+@6G7^?2P 8.I][7CGE\FCR9P+KO-
MD].H#V@ZE'XCU@3-A*)[@2)0E^]W N44<6F(WF[K<3;X8BO('W4SLBUPN(OR
MPSMPH' @;!7&V..*53*6UNZBI$T76)T"-?O8P"=7W.3=*Y82LM%Q4V?^_5P<
M?=IXRBV ,D6M8;Z >\;SKK!T&$Y]=TYYVGJK*Z84UC\S%QW/Z-W];%B..YTO
M:=KN2?$0WNK\<Y?L$87@+3DI6IR$DW\!2KG-?\PL?&GC'CKK6;OOS%,HT;&!
M47O2&IJ9S@:NXL1\[ ZT/&*84/@M8UJHG5^Q9GG1YWN"=O->=[_:\1@X\MP
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M8V0HC+%@1C8*8$*8M6S >R**Q449;EW>;?YCXX5S:TW6\?&Z<7.>'75QF]6
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M?&&5=K6E/Q:=.%4H/)$,VVLRY47NTI7J@>EQ9M=3E51O43X3;[^B'N.W)]Q
MTE17E];I7@PT;9,L3 0CZ[VNE6*_L>32C"AEWPA%HT9^X;<R=8=F2K.D7SM=
MG"CZ&JAZ\58O);4IJ/'/_0]-^'7<R!3U(Z5HN9><353S9@,',/<J._ ^0_>Z
M!^ZN[F4#7F&/HK),:R8:<D;\74=/IA0&AS,FL7>@DP$M3>U5FDH10V3+LO))
M_A ;D-!4B.H@OULT5#C$NHZKZP_/G>@Y2\-LFD_W?%^E*?(P1'DF80S1Y$G-
M"OI%[+?Q_93H^-RY1DU<2Z9=HT[_LE]YSH*:LW/&'6??[(?'ECXF['(Y.7.S
M&!#>B"8N(I.@7M*40%/!+Q/H$(EHXH3["(ZI38$=*M4]L6X<;.!A#TL()GPR
MLFBL!D>%\8^,CY)X-?KV&'R,=4.,&X_57JM5!C!T<E@'G.SVI_5G'.!Q^5,A
M:&DLOGC=EE]:1+O(<M\LL4@B8D^35^@4<BFXOBYGEK72^VKMGDZ6<RD"K3IB
M?./A"3/M=(4NI>DT^G<3Y]":%+H7'<WZ 1> 7TT>0;?AJ@EM3&&7@7K=R3'?
MT$USF,#8!9V-$HVO=IU'S&;BCE_XFK^2@K6\]WS7ZH\\ZD<:FA[,ZF(),4L;
MA>;J9K.)$Y*.74$%(R&IHQ+HZQ??I^Y2,/7(T#F=>_WDYQ:NP.</MI/)$RR^
M+;H[Q@-B,=<POG2L;JO>QD1"SM[G\]8AS3U&E6,! ;)XE,0'NMK%(6+.Z(S5
M<-=8_0G5\BN:/,M08\+=SWS#!CRU:+K@9.WR%99:/\:(TC*E77M/AQ"KDV@X
MI%/!K\,&7KSAUR,ZA^9($"/D'[WIF$5(?W[WQN!X5[)J^HX>OI&43/"LA_H3
MUA2U$BH%]Q*&IS!@A1+CX&LZ'RVRB5!5U P?BUZGY@P:&)4[=5'")ML_A***
MYJE6V\9F:19U RL&Q5?WW7ATYHV3GCMG>([I5CYV"Q(NA8QCB,)(,:WX/33S
M29[E/"(X0J &9[>LMU$0I,$9YA.I0ESX(=Q5@0!U+1'?&6>C@QFU^[_,NIDZ
M/G.W+F(<'2($]?3JNK</X2'F=1U/4T5\TAJKI4;0B'1=C!PY,T%[.7!2'**
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M;\%59BY!>&8#<?JU'8)[, +DI,PIBU!1G0GQ^7&IJL@K ^EG.?PU4X^I?P*
M?:W ;OV]XK_.9"-6OC],K0T"VR;(< GXY-R$3,C'LQ3"$@?=@A%*"PP@2FS
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MM;!Z<%&K:#E,8D4!78P5CA?<7'-!VQ$YH4;25NQJ-HD;U)9XT>E:?M9#:*U
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MM MR0P.0!,9N 6Q$PWN8?U-L!.R<ELR@6ZP*Y&8_DQC4$CJ[P$,\/&:C]QM
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MN?C6$E'?X17@%J>/C5#QHOT/?X)O@HR)Q8$O:U]SM9^P<BHW6_M)DT;CK4^
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M;G/?-$CI6AG+(/,Q&^%*%R*[L)3:VMZ,KK%\.Q^U.;&L6=$D>V-0#F *79G
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M [8K0K-PWA1L0+4C&(%-KN3Y6^&W^WVR^Z^BJB+S_Z=ED4['B0@'1G8$G(9
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MQ;R,&,>1[S L!M*Z$.P LNQ[(S:KJ_O*\-0'A*HR;#JC=9$FT)LRNRV;8A(
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M[/'%S;V3\WVE@E]/)KYP]9@5RPY+OCO0."R-:(G0(*OU\<YV4_\TD'F[K>+
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M4V]6TM]"/92=):&*I@13U0[)E?/ME%V6.%M;7&.A*AE])E(^0&6WCM/V,5J
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M2I''R:>SJ%*,(=D/J)8T/G+97#"2[^2"[2FR8XEP2,:4I7&7R80'C*V\N'9
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MV3&/.HO< 8AGLN*892&6_SA?E"+<>,(>O0X-'^&U2HX\U3]M<V5VW-9UX60
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MEU[22OFS9UYM_D0NO,4&BD/..Z6^*WUN)V5CB\.8J%3I.'J/0 48"E":; 4
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MP>$Y!68K1&P"Y.R_@4(]:8XF0"3IW.X_,0BF) QEN!SV@ ):!!4FJ'TH\*]
M%!K]!X1"_Z_@\SE,T&.[@^BI-_@]<DR0EB8+![<\*S +=89'-[-)? RN2L"
M='@&\12EY PM]<WU\2'('I[?^JP$)[S(L$XJJXKQ.'173O)86^DKGAW=J,23
MB4*O1CK(IR'L,;FZA.^?W[U>@_G-V8UVWJ^,4G!:-L4@Y :-M)"CB[^Z*0!R
M>^/C7A8 @]%+WV@F3%!YV=KRK]R<)Z"_68<Q0160M8RV5G3[& <3Y %92YC'
MG7E7V_3U[WH6_]>N5>P8FG']YW0%/>$UC FZYHBYA9&BLVK5;[T:4NA1U6'L
M6HCKPB<F:'N1^1'T6N;]V?15&0QC'^HZ"0N(86EQ:$XFZ"O6@0G*3%JG:"$1
M+'58XO&RA'0JWQ)V+7ZROCVW%5U_BPDZ3.L^!UE1P#:!MQ==S%UX'''FS9Z.
M#2YDU[8)YLE41H]U"X0*AQKH_N5-VS0^AE9E+-7KISK2B19SKCX1(AJDJG7$
M_$7@7UWP_W=>[*UXDC5X\SCZ 'JI9!ZRI1MDVT450[='L@QTVYP)NA11"V-P
MV#%!HMR$7GI2D#@3I"N;-XJVQVP>@J,7(YB@'X?,<\.9H#@S,,T40FEJ:6!%
MS$\^A@"4&K#TW$@KP*ET^\$!LH(JRP1U7H>X$+<V2 A&2DI])B:)"6+9<E,W
M=/LP!EL&%Q,T8&(^F+CH!";>9((PWMBU06X^EM][I=.#6'B9_9[54H!XZ3_[
MH<91DO+R$R9(PHK$!-'CI0SIZAU0Y,@G?#DW+0O&"B/*M0+(VD^Q!R\135!&
M'98N*1Z;BC[,<E2HW>8UJA]A@Q;)BUUOVTH9SX>$XE>EK9B@$? "S+.VY+?Y
M[V8D8U_Z!D.#"1KM +*9(#AL'O>7]P8:68:M^,-RG'F=V"B6Q<OY&-/H>?&!
M4I950C_^4RWR'5W.!-%>SK4@J.(71AC/NFUS;<VI+'_O2$.:,4'%7@7H><ZA
MH4=,$"J+<88)FK]&Z(9\LX;2>&@O"6B2/GKS)(.?"2I"L3Q;5V9Q*0+ ,_:Q
MQ$6A31"*["AZ7JPN*,Z$I00RER&^F7('/>Z"#H%L/][K\=G.'UP)*P*;R2P3
M#,QLT%]51* IN/J4O[Q7IRY+B_0 4^9F_8'>3:&[09*H:UN>$6<PYRA_<YW+
M[[RXH[%3Y9#52PPAUI X]:/7XK?JDBEZK&'@'6%48AB/COJ/T'C;&-? 3>E4
MZ2U#1CS4O)C1 5T]B6.YPU$FZ,M)C,EA)NAD/@3X@%X.C61Y7-RL+$T!2_DY
MRDH1J[W.VWO0;B(H4";H^0O4 'Z=.(6G*RH&Z4)E&"PSKB9PXP(9==LK6]^_
MQ^1*#?= )M^RPF8>/9\C<E:3,0?9VGZ[V?#Z=F.&SK_<W/8?O:2F$&/L#.,R
M A-$%35+WPJ(K]_$/,*Z@3?U1D*9H*4X*_3\K-ZZ/#X$2P]$;]TR!"LQ3O,Q
MZMM6XRC$)N(FKPQZ,79=L<H"S8W]9E'&!!5"!H>_!SC]NM\:0R8PW[A;4-(C
MI4S0P=N6EI-/8RZ^->_0C'IS\=JZXLJW*FDO!Z/.;'&Q^EY%(EH1'JM\[K,(
M>U+?["S6&HX0'V=@G3$S;8S#Z4?07ZZAI]31- ,PZ160P7BLR03MF&&"IF%C
M3) )JU#\PKKQ"4+UZF5,IM.V6!Z.I9I0#[S#QH*!&^JL2O$R*P$]9/%RL@*Z
MT6LZ=FL?-XT]E@D*SZ ;9K#^RD)C$!.TW$1]@/ZYR 2=9OUNN'0A@J&.)JB2
M=>ALH8Q=+%+3W,<$[6N+@/P0A9!$((S3L>L:L70V"&T7"_FXE^>9H%X,+94)
M*H-\7/C+R-^,8=4*<RW@-1XPP UF88L.35R#%71OGK%Z[L\$ 2D+68UK+H0/
MQA0B_OM( DR-"8*8Q)2[7/A:;;HIT]&=M3%KAD_61_;^6\=4?M&QWO_H6!5Z
M< NR=I )(G$SQI=^Q23(7YC$X_>;Q/S?1L#YEVIMI>LP'H,9.YB@L5#*&A,T
M-\(P8()PZ5]]CM)8>OZY^1F'8_]D;!>"P%M[T0 [*SV"QP98!15T4YD)<D7?
M'30GS_RYBK%_H43N&OH'Z],4F%Z)1A@R@M#?\/1<>J@1M"V6)B[R9Y:&_/FH
M,K)9]GO#\O^': J!7@?97&>"$M"4;(JP%EH$\N<.MZWNS#^@;OKO4+?M[U;W
M#X[%@O5?"QGG/XN8^[_!.[95V(OY.XWUC_C&MK&TT'\KUJ0 \M\*+<B?Q .D
M@A6/&MA5!&.0T93SQ_SR[]_S=QCZEWYE_@]9^G\H#G^/8V['X4GL[[5U7B<K
M#[*8XOG>"#SEA@^&?B(%^QSZ:\D(_4=W&_Z*.IRA7>L:=+?>++UA-)LVIR&E
MDB;.<4&C9[PC[R?<!_$=DHGX%5K_-WW1Q/KIC^$"R70+UV7L$RR]WI1SP=NY
M,;T$*ZD_O81M_&VZ]O[9&'5C?]VU_ARZI/Z&9X7\2BT!_8SX2U_[4P 8,3W+
MEV'(99Q<@:*7?</U,$$]'L.?Y\SY];!B5:JE];0.F4WOLMB_@FF_!SK^N6C:
M^YO0]/]&^,P_&.'_,0S^_WWIT/^?F [_>Z#R/W.S_]KL[_&/9:1_CKK_;V?P
M_RZT_'TI[3\S]>_Q+*G?;>=YOK\Y[[&:MTVUPEF__S+-_SN!\KE%B% \5_J#
MZK>BJK:*Z.ZB,Y)4G&=-,F+RPKYA2V^:U8_73L +-FND+/ZZC?Y8L23_66][
MB']M> Y!?U<D&$"+6<5^9A,EC0G"H/>PJOG<O 6]OY%SJ\FOSNOPF9VG+%N=
MBVU /Y94!JIQ#&O7^U/G)::<.]/%B*I=@4BOY\LE8RDCB[!1M]\&B]_^O"BK
M^8U \,?V_E?FQ?\?2XA_1%W]_]Z*^Q_/:[%_-69_/PS\'07UW\F*?J&QR/]@
MW?-?F\K_"Q+';XJDH5^96.XU_\]K;%@>5].1^^2<NAIDGP>@5'.#"0+'M45^
MGHM(%.]PU\U%!(XJ(D(--FC<BUU_,O/\-^!5L>M/+3OG]%]0U?TB5QS]NRG!
M;PN=D^BI(;7% ITK0'=@X-E-(7\O+_@NB%+^!<X#B5O+4)F4.TDV,6G"^JE)
M.-Q(M2&L!C%.N>\?6W!WR-IJ8R#H=>WV$=6[,F%KF)G>-O"JHBVZ-GUKYPCE
MV"]>C-T0 M/4=>A5K" "JZ4C;V&7B?32CG<14DO<;/_L.=;_GRYZ+A/TQ C[
MS0+H8!!#(6L7;;&VBZN'&5S:3%"<W8PXM5Z(-?;K#^B!F,] ,D/'-.@4JSZ_
MNK64P= B;3+<6&V0>J_]4X=O&>(D^TA$GIZC<0& 4H* H!R7\I212$6MCP,K
M9>&9,<,2QW@XHP74@F< H]@R&&H$7=S;#/[:1(D@<R]UD-4L^M:YT$V.7Z V
M/Y1Y.IQ.5):%S"LI%&D#AWH>?M]S3$G^G&$&NN&X#LUM9*H-_%/M,BL@+Z+"
MT TW4+N9H 9.Y%VJE_],,[Z<>SF5?+X1?_BLZ$!LF#J$,''617K9=[X\U_U0
M2/3][*#J3W,\]?R]$ZU#JQX6"R]N-YXK>7[;NM3.+[# >QCW^OE]<D'P\\($
M ]>)Q-?$GU\ \VENVJ%4REL 3O4&9!G[J!B ^$G>OZO-5C (IC.XM*X_/'#O
MD=EFA,$IR_P/P,!WPKV[/[/57]>7P9F@/4.,KULA-9"G:QB<R93,;!&L9EE
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M'M4&*<E^BIYZBMZ+=:OC(! 3R%+-3-"AL]YU7LWIN)%H2IYIU;"1'57M.GR
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MH65=D)]P4=R\0%OC#_R))?WOS<(Q[MA!$E8 H]]&(OF_,;]$X$$"[=S:AIG
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ME(Z2B4;.*YX_?)SN#GD*Y!4E43T,J6:0=78@7']/\LX;>FBQJQ/KX>TAT\*
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M),M$SBL=# :^+0=-^"D=23][/1U"R;)T6%*]>WR*4VS4+7SZLZP*]IL@\PO
M3"O2872SFS@3TZ&[EQLR8*J!.L=J6?G!]7@_SLN]/GTST_Z%M8&7B@U#OE-_
M5<SRJWIW_13)^T,YIKD<5R5N1CW!O5?Q-[@)[,\<YW[BE7E%DF@4_'A96#1C
M&R1R8T5+*4(<> ZZ$ OJ_*]L*>(+*LA*O[@G\P8T1JM(";&%U\WM,<7'%D,M
MQK^>"_SC-\&"7.!+N*(NE .E,X*:F42Q&=D&/0_@7O$Q2OQR7^'+^F*)GF%/
MT(NN*U67FHRS=V](\2310Z-$,0!2 )!;J=6D&+3H+P$8]A):HR),C-Z5)088
M.HR"55PF+N^S/5'PL %MU7F\$A9Y!15\GG])D$*[=2 ^""2@"7]6P'N?/L2_
M4";TY.=PSFD_<+PIM,* Z#Y1C\S]N8&L>A.-,QV$W#(5XBKS:I#55*S;3D'2
M-)G37#%L#-E0.-1:,;A-22U6'F9@^:)-^U80POJJ!?VN6H2;YKU#,>,_7_P.
MDKIQ_^K1J9?VFR-3$Y.P8"VWS26_3+,?+],;IQI/XO&;;CW\R..>]YI5M*OC
M_\9_VYIMC#879#9/T(X=%R5X3XV MYNJ .KT_H-.F!:M8C]V=A9EHVW  .>O
MRVG7E$])^W*_EWOUP(GRI@M%7)D2-KH"$.)$3K7.0/<"0JUH<3(7XA%-:Q1I
M<F"'E5^Z*]'EIT8@)!ZOL Q2^!V97';DE'UFFZ=Z%:993D>E6M#@;?1$\.49
M./^P;*8E(U?93NB/X?*]X/V9>IC2FP-$6&CUSPQH8]GJ0]N63LZ5L>$1Q-P
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M%,%;(>:E@YL7S.&\'.1S$I4""O@?I@.1Z0O48;A*Y<2]J)M U6$CD,/V973
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M%QG\[?TK63^B+T-I@[CN39H\>FC'H= 9LPXIX86]05U9[2I,#^A X_Z48SS
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MOOZ1YE[EETO9&K%6TM9IERZF'W?T387Q:1\7788N4HSO.NV7EQF8D"*?4?#
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M""&9O//-FIG_>^\WWYW_)"MKY9RSL_=YGOT\OW)6>.]Y\R Q6RL;*]"N7;M
ME_EO$&\&9/FOH_^GU[\F^7^=8Q?O#4C\P"Z=W9?V[%("[1;?M4=\%X\* H-
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MV9I.>!E6&^,#C1?U?MW4.O+4.[0D^PP/A&@;N]R8-;/_'B2KF>&Z=1+I9VE
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M]0^)B":^ROFO.^W.2[5<TFX65]4CBYS6EEFT?.*-8]?D6ZTAH90*=YFD7D9
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M:$4,Z&#L$*SP.DXFHFEMIV!MZA4/Y%B7&;/1(<P#J>@*<3NCPG=<KPPACO%
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M\47M'J*^D2%2[ ?4H_M;<W02O!H:GZ@=+WXA@K2@2#J9$G<K:,F)]0NA0W7
M"1%D?*A8ZQ6?Z?BJOZ)Y+Z5U& AA)AX5H'%:#/QMB7ME%*[$  $KL X(*Q[#
MI5R<>C55[T(-E!XK9YCQ'*#DS]H3F"C!NB*B",)T7VY7 *TEVOULERTC'6Q0
MJI,L4\]AH(8>2\ E2C@.WEA\'>][D]C2>(B^)-1E %IU 7[> 2*(I-ISK>E%
MRD9*BP5A2_DU(+F=(3V";88/()V*1G!>A\'R\8 ",- 3U+]4!C+:EQYXV6,I
M6FD5 D1?F5)G1K?W^HL^#V::95FS6N'6;::D6V$8ES<FS@:PCH&E6]G;?>H=
M(Q[I])?OMR\[Z6PZ,,4ZK_5HVLIP<)-CZW/<T;4AM0J/<_=T+A_IB>.#2:=*
M/A.OD2[%)ZDQ#'4&"A9+D'XG$K&]/\YG^YZ-.EIYS<#=_C0 K"IU%2!:Z'\]
M5%1G1_<5;CJ5.Z9BQW>(-=A;4PTT9X^;K?FCE<!XLX0$S.:+D\%D5)^?(6+.
M_M!W3GOB-:*^_1UA3\1,]EH^VALJ+=C=AZBA;,6Q]PZD,KU0?,H=I(T:0S]!
M)6M>3;"#O]R^IN+4FY2-\P%&3XS$Q-/\3DCUZD7OHV6]_?8;,?\@7+T,E!=N
MW9$95%]1#.#LPZAROIE7Z3#RJPG*5B8Z$>F<AXXK ,,O<0\,941VUK?_O#O>
M,.;TYMSC67)7OKM/*.%^;>):MC+(Y"W'HQ S)C#X'90>D<&DFV8G-?F531\<
MXUQPYTS5_X@5'.9ZX.PQO.NEV&MR[0:)7->^H'9<#ZV+FV5F']P]EU=GUX+6
M0D C<F/*)5)X+VMTK#)S/>1AB'32P\2G:5AW9]^C+KB'FALG7[RVO(S9[!?+
M_(=_*]VSO=$ZN>U]4.Y6!?Y3IS2K'5]@V<X)'0'!AU(#GE[1M)@&GG)1%XYT
M/"H4DD<@NQ4A$[O-[G,?WCWBGYL7=W<:MN]Q($QA_=V[Z6_6'?OR>:MLOM3]
M"9^XS-U-R,*#$Y=TR)P!QB7&SJF5F/9L8U:G4!DP%"<=ON;MHEF/Y&3H4FD>
MQ\=+'G1[)K@$P!/P1G:11?2H()7D+3/)^'$WPNH13F?.[CZ"JE;/ZL'\WZXP
M_#"NU66E79@<"'RZT)TOV!2Y% WLJH]IA<IY6(]SMDS#SN%@B@D3&LGM2M#G
MQ-*VX/J,>WF]M-+C)4AZLS%_+>T-_2E;3XU41;I!1NKM*8W_D0.3?'^X7'+?
MNY[T,X>90^>^/7T4GO7HZ14L_*@>7@:G_/U)ZQG ]_:0=Y=FZ(-'X;/?.NS&
MBI41H<C&+UUI#8(02R.;:^?>GWT@:=7Q31L\(ZFLNEU2>=+>]#5TI^Z*NP@2
M&4[YZKY61)FM)'=S5A))'I7?TQD%E: )2VA9.1(B?+\\.R:"O&"UUZ^PQ0*;
MDK%)W*3JZ,*25]Z5#T20MWTQ:Z'M(LBTYI6E_(F066]N3])?!LE>/3=-42(?
M  ]?7$OQ%V!N/R,9\ET:O"_Q.WFIQ.8C^3GP^,R32[\\?8$I+Y<@ZJMN_T_S
M#Z\:)+DTH$=^C]/CT3Z881&DG2'9J+SV@*W.0EKRF9Y5M2Q"$X5I>CT?/PZ/
M1VT'EHJ?V_$P4FZ^J+W\N8Y7!43?Y=,O689A^^>#2E=+<9];MYQ.>$?"#8D@
M_E+0$?S2^3[R.A Q+FQ8U9Q1:M:%UZ+C&W$OK/T DU:7 VU4?C2]M<L$V)RE
M^27CEK**\T&?>L S3D6SJN'42S(G$W_?J'(8TY%I<F?6R-ZU;8211-Z(35]Q
M20OCA1O;.]@U@_-\WFA;*+FHF&APM-&I"+S^F]DW?9-8OVH5[9& V=9<BGS8
M5'^Z:.E%W>]+E>=@'L,SRF&:<QIK8($BU>@'UH:NF)EBK[DTD[F /S(RDW'^
MCY+)B(TN+N3Z_)4)C)Q8I@\+U<$2?+Q)'YC<"I>N$!#&'4:\3_.UDA'QI
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MA$=12!J@Q'2('E&*6_2TQ8..5.CB:C>:^V-6R,IDM>J?(K*XJ,I ?M6/<PV
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MKA.N,=R!L@K!)7Z&>U9;%3:3G,UK*.4H067(/>7/2<?YT*3K8@-\2_'3L+^
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M,GK;QG^LUFW<N XUN3Z;?N$MGN;P>O\Q,KMN2T":Q)SRR,U#3=LW6RM\;58
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M<.=/A&+D/[T7/H.(&/0_R2-AQP8)2X,D:RY\YXQP-Y">6@$>GC!DR!@EPKU
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MS*VG$ENL"18,EM&M]@0;(#,#[&?%+P0,U$)3Z\4JPOAL8,$5I*XY@^6GP<!
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MH]8V<HG?"GW88@7BZ@^IAYX>5&K^59R:N/IG]VO._Y[0+/H ;/Q_]Y+$D_'
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MF]VAUL.-QAYW/>73]^RX;F>P-,+'SKFM66.(V\7&0R<$J/OJ35V3]PE&P2B
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ME7V'KS]3EMOS-*Y%&R+8G'JA__2#?Q[5--H]&5*[Y&8>,Y?L,MB-WY"_^/[
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M.XF+)Z]((#LI;<A5HULDAKP$\H&R !,A%EJDNR>Y^Y/T@VTQ< GD[R@D;X4
ME4"*/ EO4:#-%%'$Y(SS]FUT> M)=_U#1B?CTX9WUB^.E<1'P+=7G?XKTT@I
MZ5"\YKGJHQ [.[N;1XY-D):.)A"_R2M+PWWE?JDDOH_DFX 4"<2V$KO"(_Y\
MO#XI_6841(H?^:QM(/*@TIWY WJ*"_B1M]:-<@%'QJ?-<Q=FR)O009CMO 31
M&='O[UKVII)]17NW%R?'GWV_X<IFE3-#PSZW'FK(H/=MBDT=[^L5EUQ?6-_
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MM8C!#!$XA00-:5)N%BSN)?X4]A$!'ZESLS@=*#5D*/&N!+(1B88/12^?%?X
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M3OM0^;'S1Q=AM>:SHSSBL-TD#_%$\.9:F$AVG+A3],< _2+/H-.GB-R>8_Y
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M7RIT]-%^\M9<"2S$OO4B@B6XB;^WV0I(N&>E_ SG?AY(2(H@*N#\_'N1P?I
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M6D<Q)X[X]L1$5O97N/:%A!4;E[LZ]Y\$F!3^P<>9"OL:6!E97?[[G!<=\O<
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M/,88N,<BN,<QPKK:))EYR4VQ[><Q!UE;596HR1/IW4$+-(^5;]O]J[E\>9(
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M?PDLI9GP=+SG9[[A8+"5&.#OU##4 -NS@)48XDMQ=5O:1K@'&36J?O?JDUR
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M'QV !QR%]&<V_0>^8DH(')(B M"3M_Y\+R@.B< -X+C1_@)0CS=_J%T RA>
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M!2 - 4A:&#^GIQ$<>2[R/W:3<Y(B,>F_3F!0 M ]4C)L4VUD:1>I7P_?724
M(7P$H(7%WJT&HP,X:C-NV^=O:Y/SWU,,_$/@73'?WON=E/ACP 9T9OK5GN&C
MSL2W:9]7/V[+MV/QD1[E5UK]4E>D9:S=K\QJ7@=:YR4_W:S=^-:2=1E2)/0Y
MXMQ*/5NQ)Q,B=0H(\JI>PHJF3N-2,M>, 8L:BQ+G!1)1-UI3"RJ/DFD<1%@.
M+43@8QHX_:8=/9>3G(R]@JI-> 5>(F_X]V]G1#H_;O[MS,WRF?=7_[*I6/<Z
MYOGG;Y_%T/W8YVCZM,Q[?+R,!+P&8\Q&Q 3WZS+E"3W0WYRX^GB[H9 6D1JO
MJ8''!GMQ+'I7<]Q6H! -E0*FVJPZ0G7T]B=PSVE_D#1MI5;[!O^M6>,W/A^H
M-X*D=/?D![AJI!K)OBFRD(PCGX/[8(?L?"QKE:54NQG?HGH_Z'Z>%K-?07XV
M<'K:7'LOGCQ$GM%:UYOLDR!<ZK2, 4]4#B;F7_Q-NE+MV5Q2E\G;R^;G\6\J
M)#]K(8"SIBLJC'Z_]:Y)N1&#4T6HYO>\_!)?R[Z."O5^%.<\<%=(87!BKQ+E
MJOIR7-LT!2!R&"TE:SK'F=%<SS:0N:@HLN?4WCXP<!;1.Z&P.@LY[(T_B%%D
M/ ?"2[A" 4GV/\35]55D",OQE'N9)H3N-NAMEF6T=.U/E[ D$L.S&\EDU"YF
M9]9"0Y0>'UQ1?NVTW#L: 5DAL"YVYH-8O;%<%8+/E@O_\?;AW>[-;E9V;4,;
M?1:$)^"=%2#(2252?=L(413:)<*B=/]^-7,;%Q/<0#$P9O0; *'@1I\L&PM?
MCA?W1'IG5EAV5BK1K-4S7VV8*-)_)/C#O@2VKGES/4#U9[2),#4)FH]#CK6>
M8AQH5P;T)C]K&-'XS$[</KA2\M-0VO5T+9C507OK)X[QDD\S8-5FU^UX>9<_
MYN29WZI0JWM>&6D^$LXXUI.'O X=&^ZR+3@',WB+NN0'9\FB\JQO?ZTFY ?8
MS#R9.3!G8QVGH1;PM'A&S]SF]I<"M<&:=9EDTM0K7$.& )3"]:%+&$BR\G_
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M4P?*R?HW.-!XZZTEB;+8&7S750:TH2^IQKW7OFXXV-L@3(A0CVL WW-<E2J
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M'>H)0C0)-?#0" HHW>-<,YONU^U$'-CT/P;TOM^&);;^N53:48TR$F'C$PS
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M%( 6;@BIPZ<O._PA$.1F[$=S-O:5R]GS,)3 UM$3FTOD)C;PJMHO(6%R))0
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M!5J[L^G$""O@NN>AP>)/W6X5-H+=5^;>U%_Z=-^):U^SQV[;-_;@Y'''DI/
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MY91YD,N<:=:QFMYRGLEQ<]?$K^G&IML<C6.N-;.G!'"5HX=Y@"WAPYY'*\Y
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MQYE@6TGJE#.8?: <^),_][I8VIZPP"EV1TG57SS< 4B3'_HZN]U0CVG]</;
MJYN$VXP.>1*Y!Z%L!D49S+R'IA90L"#U=0\22NH,U^R);X(;IS6953(3I)ID
M&K\CKV"6:\A(;-*,_-F\"'H>Z?!VK<?5Q6;LY-6LR<O:E C$?R^<-"_E<_*$
M]?%'OY=TYI9E71J\LD/OL-ZMXC=TS8?AFSX-C6O#2VW/W0K*U'-3IBQ\/^7A
M8FNTTH U;2+)8.N_(K?-B[WIY+3IPA(ONE_47J@3=&DA $D4[$!P2JA<RFT
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MJE 3@@MH2I!+JW1_NJ"NWFLJV];1%JB0EH&D]M"UQ:1\WB2DX?BBU]_0IN3
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MW&49>D"9[4P'-_%AH RRX0QG+778>TU3=XNQPTMH6"8>E=JJB-PZ)V]^%)?
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M"2+E[@@F18R*48 #V1H91U 9X7!UVHCTD9 >3<B;T^!]_VIFIQJ7>5\NN\V
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M[L F;)Y5'ROIQ"M,95=78+A(30GQBBT^O1H:Q$,SX;N@38.N7Z3GOJQ=%#B
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M^+51D)>9)"E.\E@3NBEC7D:TA^]PAVK!6;BG)<^;[$1J3HL!!=5VTR?]86*
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M'.#A)SP?H&.4P=V\J(GA'#Z!$Q%W2.!4'<24)ZS9N(V"I(F26('N\YD^[_$
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MU>L#W)Q4*!>0MXNW'$NJ*D!F#\=Z]A\B.P;U/TI]'1S'NG_E<">J>]QQRT'
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M(0BS5#U)"'_[0PQ\^R:8;VN*'&VL[S/3MUXN +<8I543T!4>=D46^M35H8H
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M]5"&V6^9PP\H-IJ/[YVW>LM_LSVM\/SO4R=M]F0<<^9F&#M?"?,+NV)U7N:
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MB6D1(78QJB%^R/]%W^Z7"D_T*^?F[+H_I<A>O'9/UKM+4EO%(_\%4$L#!!0
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M?E8E@)SQ=1% =GF0N)CG(];_^5J0+P7?[020[7@!Y*@??WP"^U6S$CLW\$,
MP8WP*BH%D \>K@)(5]ZZ  *KU'<:A,WC^#N@_%^-R[FC LAK@@#RMN ?H,G<
MZO_I+X#\3A9 _I#\-[!_ _N_#HQB'U>QA 524-&DADWM_DLLYWS%Q+GK;DW
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M*2SN-R67\3_C[[DDC<,5KOEZ12:</+ \W%+KT,PU%@*AP#;I<'[>E(=DH((
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MZZJ:UZP-?SV/*NF,'#-M?8:3Z*VI#XT]4.1D\V6T5+&OF.35U'3Q^VS02./
M8.4465KUVXRG*M"[,U6_]D%K'2&,X;C7[TV=%ZJJN^!E1^;[9W],H?!GVO+M
M=88(=C-.AYO&U1YL#*HWMMH-6;I.40UJ1C\Y*ODX'.&[\)6XM\80P7@J@;][
M,!18H#OV5RGKL2-YN0)(,#8)*XVV9)+N8<P!Z^0H;*H'?CL:'A _-V3D1HGR
M"37S_FYIKSAK-V3MF&]_-)HEAPOUC[D9HP]8LD@K4QP1M'D'*"Z ['1CN3<"
MTOV&&$.0R?'DC\Q*\)Y'6]:!#^DS<7Z@IBB.&_WL(RC>7S<U1!BD#R?&-N'#
M9!23,K4[,TN7)TUFV]@+K0G>G=D.UL7C10)(8'=W@TY.48W[_F!AR9YY)8#4
MVSWLJ[TZMV%7(.%NTQRMTICCDL;C:[@2!JCWRFW##'CEJF6=+ZO+[> N[F'?
MKP;WO?4:Y"0DN(WJ-'R9##,H5ERW/*^C@[S4,+$Q72QU.M2>%MJ2XW5OR5[W
M=)P]CMTRNWBUZ>-L7'\#0V%S'3I8WM0&36D_;9Z@=#X[% C=,J7N=)36&,A>
MONG7F2?=\SY=P^9VC9*)9J+68P%$*9;XFI;N)\U[@+B!O#^[ [S"*N4?D*;#
MN')7[5V8B-<"2/)61*;69K$U6Z$^;L:BWUN4'&\8Q)AHQ">-W@W3>>)/7VY+
MM_?%D&]]0_:&QAW#]L*2\C&'>27"/NQ%R3%>4J<H]PH8*0ST#Q;I]7 "Y@#H
M!E!\ =$>[)[@$DU>:4.$5% VVH+2N1^MSBK\A");U36-?<Z"[[]T]$%(03/F
MW*B>V@NYQ84\J;:NTY6R&J<T\N[,:_S6;^M<UED3?.6)J52Y>W7YGC]*#J>Y
MELT\TRK,+?FS=V#Y;&%1HL[YOLC7?2<J^?6HJX%[0ZL<<OU-;B6IU$?[AY(Y
M1^LF-N(]AOEO)Z/"_%>R=X>_QU4M4I\W/*IEB4R-K85;5L^?8!QX=ROW4'?8
M+Q-;/S791WE_=N[B#\+JUX5=J1A:$D26HG7K61'W^"H@I7_PBMS3:*(\]]=Q
MTQWT-P;#,JA6CD=+VSBQW3)27UOB1['JR>FA@W7:95(_.9V-Q-NYE;9YQFX9
MAYR=,LIWV[ID7,HNT,@M%;-]6]6\>SE.TY,5TK>_XM18+F'W@%,&0:';V2G<
MZ.9]@L(,X5JYMG;,[14G2]DG?SI9RD#^V^'A*.3RP]ADQ,II!HEW%.B-E/WO
MNE%/=Q @L:5(&WVJ5!PY10!Y$2. $%XLG+24<?]RR$^:<Y;&'U>,N;LRS\M&
M'P+@?23ISY25N;91;!!"'C7<A=F53H:+='6V-T^@Q<N7J.]:/\><'3WM8ZS-
M?)DMIG,M_XJJ4RFGT6Z'AKUT77=UVKO?'""7'7?D@*[O38%<XP7):Q0SXV/C
MN$>J3/WRJ5=V,820^RWJ!TZ=1==R\Z1SU3JSTW*5O%<(ROE"22G!3?GSQ458
M_;U8L0T2E<(>!W KZ1QC3)\'0@Z-!* 76<,)7!<6I1<KJ\W7#I(O:/7+"X3>
MQR5SSSPAT[4=G<>(*LL]L?FEP1)9>>*S,_&9KU,[UUCR7%D*7VR3CH"@34 A
M;6<I=A;1<6G+##O\#A]2UW"F'DAR&FD_(A31J\NSFN/<;:%S8NUA=/S.Z9!N
M7Y/IOA*U#U'XO2$>MYL?!%/+1QI>G>2[@H%\L72.S[10B0T[)?CO^+^ @?1T
M?*J*4+[NX1=A#?@,]/%(YO!V6E#_'!JY?Q.^;\F[O;4JY-M7Q;+1K\VV 4![
MC-ZRT?XW[ 6'.S^FH4*=OO<8VR44PR!D!JFIE#^!%S.'TOAC*G*L'RN4"$#>
M%[SY%$-1_+&26(LV8QDE13PK^I7EU\(PTUUZA[8" VJF0F).+/.W-;2D.[6W
MU.=(!U_1UEDW#RDY8O+DOK/K@E](B:3+UI!BHV;<A;,]IN>RGU;,EAP8*87Z
M[]%]%)"RD/O)K6#$$9HSV7NK]8\GHBX*I9LAXW2[*?JL\A5F;&UYY56SFF!.
M\&2&FN+!%\EZ+5O%K._\/68<&2'Z@R"204K'*NNGV\LSK1)N,H83B7-82=0@
MH_,)$RY*];:.BV::Z5F"_G0!1"Y4?&X9I989R+*<R.Q,E1A4,H:[+ZJH_3S-
M_ET8A6'^$$V4?YK?3=O3#H\3[8'OP'S<BL(8M8 M9<%^QA-1N-UH_<GP\ WH
MCB5OE0?"!??ZS:!R>C!:K,3B-5S,L^H^[$Z?18\8/YW1ZD,=8VNA##@."3C
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M>K!J=UES(=7N%.+7Y6_?^6+; "S[ :^(=!6WC3^$;"!UAZG3"U+-19&AG?)
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MVP9M^2Z_XQ1$.(*J.\R<:"SH@8O9RPN;K"M07 D<@*5O]K6VCC4&'YJ$JW<
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M#%)1PO=N3;"?&"6:BE9[UF824+<FEYU?4:06&Q[G-Y^HF;[4I:H)ME1A7M,
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M.S8NDG5JPDE&Q'(/1/)I&N0?&8O^3@#Y[(,3!L74FE\4>-M# #FB)<I+_""
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M_(&E>'FRXN3S!0>2K[\OBY"R:G!,OT-D+2IHE6OV&$SN:59\D'Q!+J<S</!
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M(GA7O_WZG8MIC8V=LZWJZ]B_HW5_M(4D[R@+'GD+L&=61G^XAOH@5\7_T%Y
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MCH@10'Y]!>/^(K00WQ*L_T'>JY>.S5<((&=0 @CWE#_V)PJSSK_[&P(\DR"
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M>+_(<+5 I 5HLP9@Q R2T$8JRNN"VF]:NO&A'>6 6XNY!-("2]3<#+848TX
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MKA@*XI7R.IF*ON P)^\V*0[E ="2(PRVBRR',9Y61<W^[$(47:6;O>IRIM>
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MR2,)!-Y($*?U'];>-8%O@G(,ZJ"?*E?[..-EE6+U60FD"/_(\9\XT?/?!^C
M?VS)C,TX>\^6IF?V$'EB]\"2V+S:)7/U"FZ1(+[[[SY%CDH'0'P6G&Z' JZ9
M'WM:_/;S,Q,LW81VP=]MZX"O;>9)"988'RF&*Q.6H!O S+-?MM66@,4=WBZW
M42*E9]W%>G_M##6$HQ/5K0[*>G!=&^KCCVVA*<!83YBOH"TT91]0G1/-6Q?
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MLDD*4X1H]M ^H2VI@ZI(1( 6?0.MB^0F/J0?-MO H:PGVKZHJ\X:L@6MK%7
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MD(EX3;Y5.WE+@I!T474DNH&U9M5@L" &C+J#)'.T,T[7 0MW)!M%NWMH5I8
MA?,U-KSX;$!ZXL?4?O?%25E("3.*K#2W-@&O5RC\3CW9,S<3:UWSMXXS<I4Z
MX7W ]P-3%B>^!10@RDKUNQD#US%W<?F9%WO<^DUUTIS+>XY.)%_O^U9<[;,S
MKN]O1ZO\G"9:3)/(.8C^^$01B2B292ZBA")#]Y\N^HO0#RR5:92UV[*@OOO_
MN==?ZK#]U71+#?B\UN0"<\&Q)T>\ W_=:A'5N]6$ZT'N6;@2\=KL+.V/.M=3
MW*X#)^:DL# D%UGM\&/GC[1-K3WB"7*4I 7]N>"3^-SG':78O[.;G3_^Z=[V
M'O"1PE#;_V<*YO9_3W[W \B=A>2Q$.:??^DVK+[UH05T\\WO"5%KBU*V]^YF
M-NK\:)&_IGVD('HV\]1O;].+#1H;&]4G-F^P:9S>8V?"G.QE A;8SYM?RJ#2
M@W\DC3Z(M0TR%:UI\3S:X_IPK%C[Y&[K>]J'-D0D(OX/0=D+Y(4M&Y\&3*@:
MK]%\O$J%\PC.6^^*7E6[HM&$7=U862W0SZC<(._G/+1V8CFY<D_2LBVAW'^Q
MHE[9BO3C/GA^H&J9'#Q8;=8W9&KV\<.[KL1#GUZ^D]L_J3)9>_Q6@(G\IMXG
MRV>*MB!6CJDQ84^67QV =?T;R(S>19Z<( /KJ!,7NC!_&Y2<_D4?7Z?_^S[R
M4M@6 ^;L/KP4EJONFN)EP?Y'-K@4-JAY977I\D??G^-T/WQ\L!6%9S<<VKE[
M^'J%K\/Y*/S/HCVJ9]@K_LB,73*L@!]I.]H^R@PK&O[2I0'][]H&+1W[?1H+
M:2._;T]%??^&@E:AO^U]_O>FN./?]B/KOW*?\\\]JZX^FRJ )=\MW S;:]_Z
M]/6*I)O+WA0J\;0=\F]?^+(OS;9/X]CJ4V>QO^\^8 7\JV'V^/^G7N)_WCY%
M/Z5Y!_]DL]D-O3AR1:B^A7%J(X[S=E]@^#GMP\WGJZ9/?%@9K756^VV-99CA
M^=B'C-(8\<>TKSMG.M'HJS,YS)'"*IT]BRV*HW90[]Q$(:VAJFCHQT/_9W'3
M!YKB=F0O_X^TO]3??UOJ2?DA6^B\L$@*^]*P]UEXCQ1&DWG+[ITIV@4R"LR6
MI)U\^X]O1XF_:FS8^+N7C=Q3C<V:OCOTCF]_OH7R_(#*,A&#> K*X/#DCXAK
M1 $@DL,6J<@U9YF3AWW&U5_3[C KS5GD(?,V;SEH%5#=,K0(86T@@V<S'>H\
M0XX4)B\R <CW1 %%@XGX9@8"TBLD*)^4=%57R3QDM>.<Q64I[#*ICUHQWT>-
M98X],4<I$X/!JQ)CT07Q,\DF(D)<,(^/(E<6\#0 X6L9+-*K$*=+$(&,/55=
M(O@8)4Y'$Z!&51IAVZS7]] A72#_-F>F)KU;X^+O\L6]K\1;*0(7:!-;@60M
MVM);CT#%,#9+>K(04,K2BP"&!FA<'%PR1*"<A>@%@U-9)FI(BY):O02!0"WI
MBZ#_%UHVVT;G:7ZGZL15QTTH7W9D#^0GN )45=P Y5MD(*V<$A<"UR1N&[!R
M'^]P.0>>!]6CB.I<=/20*?]^O:V50=CX4SP'JSK=KVQ<5JPWT>X3'KJK^OH%
MC_U]:\M\C3T,=/NK/B71WO%I]1]UDJ\'>&>F^T^E^#/<=?P'WUA7Q^?\44J.
M-"A^59S/<S+I03-KA<A&;-0B+NTN25OD A44$"P4X$>Z1')C'8'#K5*8BFFF
MA==AP\/G9:P;"?^"HXV<M;VJ]S6G"*IKZRAL>*BT]R/[HYU"A2A31B&FQ442
M?5(_%18"CR&K,#9 PM<ZV[)F6AYT<AOP+,ER8.%6_:^U6 K1B3-LB5Z%(<AX
MU7WZ@_"G 4,'\PIBR=4A(^OE^M1NA S2.+];B!=+WC;VQ=6^\/75\SB[.<I9
M1BHN;KRCN*T\Y*"<#? N _^,@#_:)3KP#'.0-?1E%-Y=8N*EWU?V5:^N+MQK
MW\EJ^LOJ\.*:R;H:_^PC5T--!I35TSVT:P_H\;;K6;J<OAHR6S+R-2^B+Y5J
MW/$HV"[)OO7[-6>7NEI[R^++7T?X"W.H]9)=(@>()M=&'C)TZ+;>"@D&3@ +
M(M4<R=KYL0QML_:6VI$R:H[( L2^IJR?MC8&?"-SP\#&  Y<>4;=[S0H%VWD
MX[@/TWM%Y^OBN\^<H2-SZKPTX<EI<CF?AY=KSCR%5H.B.0,L-H08:,/'+,B,
MVP1W??S4>Q%V/ .>:/T+P+ZK\_FM>_+1RGYC/'U_I3Q>!?NAPYA2X.4]F_R'
M_7G\*7!RMDFR.TV0W$UCK/Z":<T0.A#830Q]L)]IWDI1\E],AV28A %_+T.^
MM'$YU@^38?]09)1 "EM?R98GR,C?R^XKPRU)A"$6;]&D.V TV/O;$'PVK;2T
MH&4_8XO(H 82EA)Q4#"B$:\)L00IXJ?TSCAK PK'./,@[^M+X)LVIO/0>_4C
M #*>;CG<X-=8E;7AQ8N!DGI[*^OMX&C.5=-,^D,4:E?WZ<RS;<LRW\Y/FIH^
M'/?=],KB1<)Y_K=W2E?V)CQ\J%O"^Z.WDYGW^E%MY7-7HAUG=JN%2MX;=\JK
M:XFNZWJ!>2R]8*=SX;'2'0?",<[WBEV2,BTM@$);TF^2$92:%(9#K@EB5[4F
M@V'--Y&W3*4P!7+C'H8ZH:=),VRV!MS.O9_!N4H+HM+1,2;P#3.8E21$KTE$
M&(NI;%2:-,D1$FK?+: SSG675L[$>_(T7Y>64KOART+C/<AC3^&*)&61'!0J
M/"_I^"Y"0B[CR!@R'7]+YF<4$TD&X+MXT&%,"J-45KYG*#L"\4VD7>)LE+\6
M7I40;PM5Y ]YS\ W$-<60J0>SJ?(J&(.?M/'$2^H MWEQU<4*7>S3E= &<A$
MZ\W$,U#!<Z(7=$ VVEW2_GX&@O1!!P&2[W^5R!.46_Q:1G^!L#DS81@C1L8S
MD>U[J^,=ST<)C#49K)OYD4Q'YJO>^;H:NC\C%[H+9+2Q-TH,11N@/B[VKHYF
M-50@M)S.VH9> ?6\9FJ8TN3M"Z>H&TU:NN=E1C?SNW7*'M"N,>KE_59\S.@*
MT,*>7 )13_2$=J[J.*^?MK+Z,6M?A3/AE_DAIR3GMWO*DRF5UX*&#B#4WW)'
M"H?L]]L;I?:,6>$-X[BH]2Y.3S#>6X _(^8=;<-3GURJ&=]?W!^XCW[\E-.G
M)Q+VL_0, >+1Z?9/;9\?W2TYYA7_^5'JL8"5QQQ'3S](M]%Y/^NIGXEU$I.Q
MR>PS\^',=YH5@5.#]-"BZS@O2\."H +?D)[RA@>V*J=7RR+0'^OPPE]DB')J
M59^OVU_^GSERDSK_#;OHN#=/@)KY2+:X;:OBFJ3B9 O[:R/]2FZT-6;Z'URQ
M]#1:"HLC+@/?X:.H<FD"ECBE'C[.C_96 GY06K'J>)$/>)/MV#N'5X,DX1,X
M=<YE'1WA;FI3ELX+S>@X4XHU?,.T0K;BK)"J)'[^&4H>0PUA!??%^21SHAS4
M,=[Y00H;8SP 5@^P2'L@/^$EB,7!B[:,ZG3CN RH#I1W%#\A;8981RC<E-%8
M+GEC&RJVLE,3^T4SOY33L%K+R/!4OU%NY!6R&V,741- M#:8-]Y$4WBFGNU(
M&-$9B@ I+(?<Z04+D]\)?$Y4G7J,:'M8N%%Y!7;J^F*N@?[37,=XW D8;O+7
M>^D /X;Y@O8:%0??2,2"RLW17-Q#K#(=OG(&KB'91,!RW>@<]AVF-IT2[7V8
M<.0,U 9P^S5VU6/#"H;.3EGX+CP@YWI"T?9=)CC+YM.!50*;BQ.E)TIJ1LR&
M'TZ=,,^*3]V;D!'ON+_ [VT-GE'V>6[:YIJ!X8[6JS@[M[S][?:V+=]-TEV(
M'VOU:ZY07C1W?2SRLMT5S K=''8:K;2)FR7_T(.3OG]PF_]XNH'2T6-Q9K:_
MEFIN.*U2TA+KDT"U=77ZHGIF9]'MIJ*BHENJAV#K3LQX(H_\R_27_\!1F]N/
MS+I3OT\%2V$DO:4S/82JDZ+%<U(8.Y8,Q8&!AF\E@^2Y7YA D(R@^.6)DYA?
MMLHT*T-_;[)Z!(:=/^9JI#"FDA0&JD3$?9=$&)/YS4R1+8&N0K[,7%R-A60N
MZML+R1OLW 8I#)"QG(G.@)^FL&ZY(:/#::@%+E:RK1X3AZK"BE<@19I2V(^S
MY(NTQ35DR(#\S:]2_$^CPR_4RSBH U4((J6PC=Y&MO!AI.1VFD2!+"I!E;N+
M5Z)$*LP?^X9(_SPVY:4WN3.O4PS)H&H,3>T9A2?[<:A="EO-E+C!!PTE=^"2
M=5C18Q[JI]'M/M!0D]V3$I&,"#:[QSO9"61=LGUEC@LKA1DJSJ9(83:*4M@J
MI.2D@/K/4^3\)%?#EN<Y0EFO]WNEL$;:4B4D@8P<9D=+87=D%^N'H_]Y&J>?
M!*O*[742E\M0J 9Y;&"IZI)0C_Q^J1ZR[-+D@P5_J[X=_Z2]\_^MO/\?RG/+
M%:3YV?4<HM?\T="WURKVVC**8^/V2[_]]MO-S9M#3,=<*ZY*8=LD#Z2P\P=E
M$]CZ]^U]M_3RTL][MI<9-U]YJ10( +$39Z[EUC!)\_%8%B;\?9@,V]1!64__
M3F>JV/\M1^I_F^5_*K/D%P>$BF-WBE/'PP0M-<,3#D\B[LP\N3R5M?;+VA6%
M)<R?AC'"_E#WD\7GJ$XIS-%\_H'+9DX97A#*=VR': [/#8GP$?:?A;[VWR3B
M*54XI_3R)UJ;F%=/^7L1T/[YSM#_K>3_FK[GO[3R;"+\;H@?%U+*STT,V]PR
M^J0K6_!;5KYR#S4;D6TZ3N\B>$J.;)3"!AK:OIUX6W5EVKD8/3T5W/,0R?.L
MWDOG_4$+X@6?\+@0B0D6\+Z=VEM=<4)4)F!:TL6*TL'_ 5!+ P04    " #X
MB#E6>Y^S?1RL  "7S@  #P   &9O<FUS+3%?,# U+FIP9^R[9U13:]LN&A5$
M0$&Z@! 5D":@4@4DKP40$"(@79*%+&J$B(!$"8F*])(E=0E"E!8!(2I-:H10
MEB(BA(Z2@H@T213"A+23]>UROG?O,[YWEQ_GC'%V,IXY,D=FGOE<=[GNZ\Z<
M4S EH($..MHYV(%V[=H%^DWX!@EF01?^WOO?>OT]R?_N'+L$;T$R^T!_[8[8
ML^L8:+?,KCTRNP2](# (M$OT/QT ^L^O7;OWB(CN%=LG+B$I/*#I(&CWKCU[
M=HOL$145$1%^FR#\'B0B(RI[]-2YO7*N 6+'HN1/WW_T;)_&^5?="FXC3$WC
MZ[<>B$LH*AU25M$ZKJVCJV=B:F9N<<;RPD5;._M+#H[N5ST\O;Q]? -_#PH.
M"0T+CXZ)O1V'NG,W\6%2<DIJ6GI.;EY^0>&?CXO*RBLJJPC/JVM>-S0V-;>\
M:6WK(??V]0_\]>[]*&5L?&)R:GJ&SIC_NO!M\?O2,NOGKXU-]A:PO?,WKEV@
M/?\5^O\C+ADAKMTB(GM$Q/[&M6MWW-\'R(B('CVU5_:<JUA E-RQT_?WR9]_
M].Q5M[B&L1M3X?JM$0E%31.Z%NMO:/^&['\,V(/_)63_%=C_C6L&M'_/+J'S
M]LB ("!^(U\'9.T.VK.'+P/?>]/B, KALN?^ .BWNU*B=Q;N:O>!MU5^$X!>
M>763=K+"QA=C.?;2%:\OOWZG3[_^)<<KLC*^4W9\,[ZK#H\+&>I8/-6.Y%4Y
M><ZEEZ@:^(W$^!FFB<J[PKJ_"K?_^!\=*I;FW.08.&?_$F0GJKG:='U;>D4
M8JM-8#<68UV_4W\JCV!7C2L$H*7^F8I)TE<(40":BO,1@"@EXP$"T"GLEJX
MU'YIEA] ^A$B ,4^SK>5]_QVU%;^RBY;!1//7Q^]SXE0%+H#Y)%'KT0_F%5X
M]>1PB'+W@",H.;W4S^]/4-C:8I(W_?(KAT/:RF\-G\IEWSS3=TZX,O?FYB\<
MO^"U8N;M]2,O_:?Z&4]+6C_NLGC[=.^C1XE/0BS>]2=$K=@_W:!%EYX]4Y:>
M?ZCZC$Z?0^W?FSJ36ZYN"-OR7%\#$\_Z,(OGK0Y]X64+VO*<YZT6A-IQV[.P
MMO8\5Q>/D-]27_P8D*B1-%9_([%+<_[)KJN79G3*[DG\YV$9#]Z6X]H+0 &D
M_4(+V+1?ZXMA0WYJ S@^&:,L (TFW&Y-[TD92!. 7C[&+CTYTX1,D1: ?F,)
MS?/F7EFZ?O3!LKS=ET"R#F_WY#A\!_UP/C./*BG/5S>'*:LY6N;LVI5_3^-(
MXE_?SSW=ZVHK#W*U/5O^2$%M/L9GUZD&?;V_Y.GIIT 6(O<<<W99F(#>_]NJ
M"*+!^SU\'N@&'Y%5L-L5_)9^3D.3=NO,T[TCMCJBJ1XBKXZ =FGFW 0)3TC;
M]<X$E.=>HF[V^R,5<_=D>[<7A)'\>T<X,LY/=Z='ZQ_=E9^7[[GKOIM'LL>]
M(T'>MPC/#B>Z)91B=:!?G;^JB\SY;5_\6B]2?#N!9@][FMVXZ\!_&T#Q(=VE
M02R;.SVA]T*>[%\1V_/I]]Q-S<FTR6;T(0'(CX'=BH'P!B>'HF[!IRPZ%?-O
M9H4V8KW3VRCV$88OUBI79[#V/1$"4&1 [-W1/K@7D6-U=Z6^;24AENI>")0+
M0!J7P6P]P%P <JVS[/C1*<? <;-.8J=J:52>7>/RK[8?= %H6S8(SQ8'\\Y<
M8PR3OD8_QDY=)FVD"R/0J_[.?XK#_S1$$;.S9\W>;[F-10:\IFRL.!5S.+.%
M,K,^4]/GM(86OO2FI*ZMU3%R[E18:[HVE.XB/LCE2[0+0"(#CR8T>5V0H/Y'
M7USET2X43,AUA:NG4K5/_$/D)>R6MQ1B?>#2@GVZ]WR!KFNY<&BE>W]UR[$_
M$:FLF7U12]W<T][-(Z_ZB !TABK7(4G+,N9+>G$<EOBJP!V:ZIE&+*#!;F+@
MI<)4H/>LCQVE=,!#B'/#!%3NI9$C(RH?P;)^G_OD9I8G)N SY^9M??[:A1C^
M<,KBR6GR^P?D=QZ]%Z1-?3PC+!_56;Q7?Q_E\OYA;F93I&N#@]46[22 OM!K
MUUY?HB='5'*\>KWHX?/N?LR$W-VVD7#7UXZGG<W&267 \?1O^PPCOCJL_?@M
M^=L<ZN/W;RUOLHX_0$W='!F23].\8?%[K$:=4^)WQ+8W !: 1*4GNXZB]06@
M!WM1^N=X1$-T$*N%,3SP!7*15X,V+D<[)_JRJ.GH4P%2I,#J[W"5QG;]Z4V+
M%ZINK9_JZAK7Y<DW8K5DG D#,04Y4+%!F"PPPKD)XVKS\@6@4%4LH..U=BZ(
M892-9WH053&].2B[13BS);5+#86@*Z5;1YLG>GE ]P.)Y)9A!E(-%0.?6[91
M&.MP>+[LZ_G@42A[!_8H?.9W<[&TQ;$S@7JHNTVY27HY,<OT.E&W;(D&Y];&
M1;'L<I<KSDXECMQJM5J-%T_R6/+5II8OTTM.V'Y;FNAW<]82&0M^Z1%N%V'Q
MTP+MC)^!25^.7OHW"YBS\&LA'!C_@P#4$,*5CZ;;%7*<T9ZL3=(J1V@:2<"#
M8QH&;H+T+6T,'^;"  .F!B.B( V<91U;BV"%>=Z^F\5.TB(?Q]7X+U4KI1!C
MQ5HI.2-N<_M.8PPQ8R05&Q' GB^1PD2P;_"ZN@PQ4\))^=+\7NJ!KK, F%T[
MB=$ XAA*O? ' I :UX/EU=TEW\4\GL\BOVVVQ)0D((C /]1N#_<4_-#^I#%!
M/)9VK+.!=:!OI33^O,1/\H2+R8+>(_:?&)0+!.;X).!CI:?YX$JU5Z6276Y,
M9V5G9?FI=_H.,Z9+5A]EJG@EL<J4W+<$-_>%FY5:O&?G>I)\],;=:E>W6XV,
M5FZG X-L&<!^WBB)!$+KUJ O\,KX9_BC7>8 D;XNPKW,LL\0?JX:[-4^-\$]
M1U<SVW)G;I$3C*&C&^U0,4 <230T?&%M39J1.^][U*S\YE$<<KIIU>U)C1O!
M[>H771>]R.(GQVD5>3FW"#_,WS.H!J,1M2V*U%Q/&8);S+RIQWD7O;+,IQ6,
MF0@[S,ZU]P[1X:-NK]T<Y%UM0X.%&]!_&:'_<0FS+\?^%6(KI.^/N0(0034\
M%R8 _<$G"1G_B[":N<1YI'#[!*#/!/Z:!G([60!JQ?,F@CWD7?W^3/J;_]"2
M0@<I\DJLM5ED-IHUG!&[KLY%,=4[F4YT?!]2%=!;I^'ZB<I<L-+=#8P\8B5Z
M?A]7(_J&M5] 2&R9CT-@8'5),RQH9];A(.G-EZWQ6^"#:(5*M -3.MOF\ J%
MZA>*@3 +4]'*+SXOW2+O)2 K@4*GUE&C10KAS8/E.=7O=?45\3XAS6^2CN\;
M/:?W(.6PK<[D,\^\LLIAES [Y\KA04.[F3S?QFVU'W6(Y?S2J;NORWWSO=_U
M]52HYKDA"XNLE[25M5'1M28_2AH[)W]V<@S0;@"+<P)]4)C@7JAR=E1&+[4Q
M9<U8B-,&B&=@#Z!&H;/2[$)@DH%+4I>?Y&K=;%L@I%M;E9W#/N^C2^YC^/S.
MDI\PNUM*C*[R/6#E>&KHCB[R=]XS 8C6!FD$OR7BU(T Y0".%=< R& 838_8
MJ !Q[(Q1:ZURS.@._Q5+E6&4%I-@#&=]+.28AL_),HW2N&ITO!3@V[.#VD!0
M<44?,VH0ZX%G%SKS6$;3N!7H0PBM&+^[0R&$LV=J":8%X*TA3)<,I+PO5QJQ
MAB#7\S5P?6WHML@*S/$[ZDKW30N2Q7U6270P?'^%6]+I$W^9>6FP:OGB?DR-
M>?M^TF%TF "45,>Y@CX&.41@GIU<DV22:"'])>[TEI[AF6/K]-E9G"0,?76D
ML5ULXENG4 \V4TJW>N:.,,<_%[Q2^E6P[%.ON0TL;/?M/Q%&?V68-V]MXF'J
MF_>T>D <NB*76>M6O3ZL-FR9'5U<;7N+DBG?"F]C37O<N%AS_7F\]QM&<7&E
MIW%TP>ER<H]C_J7X/]Y:N%<\<Y'(1YQY?ZUCD 8!=,RYBBT,PFHQZ_A/Z23J
M 0$H!*O(-6(.)-D<1.'A3 $(APYDJ5[EE5F? _?R3@_T%IZ7%N'JOISH@##/
M#]A]VM3W4W42@&8D?O4@7B 0&DNNR_']N4K&C/5923:=">7*S[.G6&:E I!$
MQP6F/LV+*Q> #85+<758]IE=QPZ8VS(5)@JK4(MDE:Z2LM")@KO.B_T'L/T%
M,Y&)\^T9U0&4"&L%FYHYE?%G[456QSF%[/O"<#K-_T!MM,>10J$J"+R\ !0.
M3MD!KSD0@*OH" #*;&&,J:L 'O-8>4"JY_W@VSGKB8ZS<?0A7P'(DR7V,)CR
M(M9?SGE\,^%"SY7E"0$(44QNN+,E;E2&]A!.?HVK!!!9B"O NSA6"#N%"4^S
M=N48X::5&+!'-,CA4!7(0[X!5S.C9P>?M%H.I)3!4!?<G-V]*;FN&?Z-\>(;
M7S3XL@;:#F-5HT&*1)%Q+\F2L5HWEX:OR7KY-ZR/IA%$RD4S"0;/CS^==Y?T
MFAI;O/:I5O7=\_?N4+E<=X*C7OIB@6+EB8N+R=5F"]J)STD+_ :74KV<.FCN
MEQ)=D]PG&MO33"I?0D@]HL> %,;P-/:M)_8U=O6^M% \"B70=(8WKPP;4AT"
MO&-YDAV8MPOIDG()#*?UK+G@I(28&[&U$9 K;4QBLK4DN]-W]&P(^?;.0)IV
MSJQ_ 55C ,Z$X93#P*]QJ_$L5;)0LW ER_F?\$U*:3860)SG*/H:7HD;R RA
M[V ^VN@)0 _M&8J-)M1$]<,L8K_103\ YUGTWFB?=YBEY].=J[+^5""'[^3D
M$4;R1(L+9UL U)A; Y#72KT'Y'KQ<I&QQ*E:=MRD !2,3#+;*6B@+S6N(=_"
M-$:I#EWCUK'RZLHM;\:X[FH-A<V=(_4Q!J8AY,'*RS7/K9,A@(8 M+I0*?26
M%K.X&RY'"EU/MM'A/<%HHMT!/-.=G0:$L>0N,5/6]M ,X//VJ4;H"RQ5NU&N
M#P&X$NJ.0O3*P0[8))C](BO)2DHZG8^$L33;\CO,$E3<7?O/C,5\S:WV3&QH
MWHUX],)$7L_1Z21!)>=;YF]+,(A(68&V9OZE,W2-0[I5XY:QC*(N&[,B5%JK
M>R;,_\QYL[RJ6E/]ZG[XL5 2TUMZ)HX1(C3DE -&EC^( 34#\QPO]'7@'7-/
M'U\"(->@787J;6U//TF2JU&%2B</\*7'-@T4!_I/H0TG5IN*(4K.4B1Z@E?O
MNZ?="72G*W/:29N'^/Z\1BRM#-]"Q)$"X#/&3DW,K1[(/:HZ-@0R2Z"35HFL
M13_ G27&.,BDIG(A#(0 ) U'W>$KKIB;U3%J]<$'EW>22C/FJV.M9M7^@7)S
MRKIPP4RE^%VE]EK*0R'#%@E NZU5(:O(A #&>I;OQSJ./(H\@#V(%B<"PXS]
MI:8LI5ZD*M=I)-($J2RDWV_MC 0K]W'3]BSHFONR(ANFVL9L+JR\UGC[KG]^
MU:/]OK>BX0>QM'Q\0V$O*8741"3C#J**&9O-A9SKW%CFP)K2_)? BRR;E"I4
M1C=$SOKPC'676A<0A@4GP]3TH90?)DY6^8TL46+JUQQWG1S:P(*]:FWBQ_!/
MU>+7ORVZ/:RVZ&_2BVI_Z^;H0'GZ)'Q03;EZ+',LX0E!ZQ#E^9B_-<S5L>G,
M@*2H2FRYQQG76C?/G4U/QMA*DV54MZ/4R;S#K?/[6L_TK*_C4]RXY_#TK?N+
M0$,(;0W"R)R3']$"D@*8/W_YC*'%0AB+K]*::K%BX>H:#V9[E;K4LK^_I$3&
MUJ),=9^1OUS,D=5_7:]/;TD,!F*9O[K506]8A"R^QC"-M'\)IEK,$.OMA$D?
M%$9B\=+ME4BT_7S$K8F!R\WC7*=J4=GE./9.;*:7'/I=Q,%M1!/QZ8/P@]#'
MIONJ*K7.^-N9?\N[&J@+XXYF!BI;O3_E4-$A/OTQTFPA.O?:JZBLULI([W>M
M=F9-9;-1GAD15=.V\AZR?^N6_[[/7%K%?H6RP+QDKK 85^RL12LD2>/DA$KE
MM%#)6$2'4Z7 _.YYH8J)VO5W"ZZ]AP5C,(;I7GV2@U9I:X9K-H=1WY9'?TR$
M&?R(B(S@&M4X(:,CHB0U/UT[IZ?Y<DBNXM6E6LT;]4]QP]+ ,6RFM>L\'M B
MKA;.0U+53[# &5R'&L"^?VON""LN8[/.KY=_=$P4WTM2O1C9Y!SBV4H:;U)J
M?-F4O0_-25MP\@N-^&VW!2,34X3"76A@V:=87Z!GG7=*;12 9+_[DE*("XTQ
MV3_T#1#0-Y3(KTTYW@MIAFZ2CU7$<G0#?<X;]QU[D/*3R(X6$KO]=\CK6>[I
M4;X\A@IFNA:#D_$2IH,&<#)^SSK? CC%E_HR/8NXA=@J59I @P.876_]47[7
MQ@R-I%HJ9^=FBJ>(Q(-0N<O>-[V2CUNLGKU[M;-)*YEXOL+C;DRKMEN7>E3U
M.U=35SOY1<Q5 OOZY"GJ>53<@]XKM5[3'@7'DL)OQ>AYN&7I6:0ZXDW-2LQU
MQY)?=]A0H'G;V9-\B76.\Q"M&#OK IW&TW:PW>9(4I@FK\3 =!WPYNM#9YH4
MH6KF/95 =10=N;J-.6R>E()[VN;%7'8&ITY>QJWVYM36#?\H/<1KAT3B<"0U
M&\MNSE'^>[QHEQY_"-( 69-$<BS1%^%*7(\)KC+''L6!C6@FV6BB6N@)23^G
MT"<H,4;B6I]:FRG6(=4#U<M_>+^>@F)MJEZ%^9?@N#(-; \*_[BT0O>\T<Q1
MOI1VWSSK)Y5MAF?T]9)>^Q/[-?3@Q.SKP,T9*)OL/T#4YFJZAAFCJISWGG7(
MU*TZ8.K6%X<Y)@!U:V%#AE,A*AUQK,A)!F$-PASN$8"4T+%T7!I5%1N"?(@_
M5-\AR8&@?P=2Z,%9:US_>;A$6)L#:[]E5;6F8L-*(-E&[U,$\4?=S.K;0J7"
MT6MW6.4EE>IW/SIX9%0?NG[S4[79,P_'2KW7W1_E7V;75IHFEIR99$?EG6VB
M=G[1FS9&YF1>Y^7E:5F;'8MAM"Y94*I=+/[Z6*\_7?-JY[.>>_FPSN!417W7
M$9XPO&B-<$4!* @_0W(%W.GK*9 &KZPN.53@O/F]+AG$C"-* &(8I6-#5<=8
M:EO)JTTD13@^Q=*EE8FC]>Z&RCQGXI-L3!"6TIF;"Z--RC<:G2_;F]PF>6.[
M;;@A\V!9_A<\TP<LC4KLF]-E2:=TR' N\(=50NXWGHV#C\?Z:W3OP&J9\?"Q
MV -6/3/^O(6AE)0;FY(C:G//PLK)(<BX6'GWSYHYMJH&R'0PTQ8WC6?@,KM.
M @7SC/4U=]KP?O0-@/"4&R/L[*A[T#XO1_E2,UP$<^T'[DX5%]K C!5*TUCC
M:B!;?J0O[R"J2@""C\2L.''(E4L%7J>\H2%;X&[P-)2^^!:> 6]<[T?N6[$Y
M-6[MQ_$&!MYB+(!\),.)=WS%GM)$3.F2;V=BLKODFBF-$:>7>T:W7#J*5CQP
M[AWCE<(Z@I@9"KM1-D.43AF"G?+H<SE-IO1=K7;4:]0:=/2^X2^?%^!2''6K
M5,7QR7:K2EYNAU^>5V]0QMZE@*?SJ:4J)9:Y,2'J=Q_U!B#..+ROO%2M0Y91
MLKA5K2V*<"J B .);"JOM4N'3X$W8GO6IPAL/T";A:3C5N_,#XN@38%>JKR-
MWDKI7J"5!>F;._JZF266>L-&K%OD-G_7Z#'F5HHAX]07K@.II;F#E.[SM.#;
MF4!*;BY %<JK0SQB)/\T9K)K/P]'"A8RR)P%4YHK-]]=JLR"K]E7<^. - 9>
M'*#T[G0UT88N,%R(-/ #19C4@U\7++=2K,%/4<F262']QN_H'%[P7PY!QK,9
M?LY^<Y@SV&Y=FSUH)/!N?CC3E>O#>VZSOZ7_CK4N9.T DT(S[[<BI4#V8T,1
M)#''1 <2\*Q\>LG<]T/1PZ*8*]^WMN84)CM,H^."#N97^&UKM=\%@R&T'' #
M?@"9IFX Y :Q--AY@#2D#RX*^-$'UG;1A**0P_@\)\J$KBG3H*)+;!5P"MJ4
ME>C0,6HZ6 >;HY#-M,GNRRJ&SYZM*.UX+*S PY64*))]'CJ+4J9Y>L./&=J:
M\^GD"Z49.\.OO&-/R//K)"*][5,)/I,EL8Z-81^E""8EEM..^=IZ-U\_V]=T
MPNP8NLF='!_B/Z L_<*Q+%OW2HF"G8F:KTM%\+-!<,'O0EL^QXQCU?FF@!P=
MNVK%@7#%6,=QPH7O%Z[Q5950K32&9'?$T<]T'(VHAW\YWDFC"OO('LF(YQ?J
MOUQ0>U%T_+YB+J+2H+\1[#86FQJ3RB5L&_63F%=(LW%L JN%*Z/!\'K[Q8J.
M[Z%*\T>I<EW'IE&3=)?V>;RZ#RI0V(DK\)7#E7:TTQMQJI^!6_V+KIV >^5W
MF8$Z0&K.JOB+XTKOY%8!3+NIG;)V@ZB_!7TK;.V1;Z')6'4:P&/N3/;"9,9-
MUJ=#SO%PPEYHZU(7Y3J H!,?JJL4^<1XC#16FSPV?<.]$)S#PW/.K\/;&HLT
MO0JZ%\..YRYZ"[GE#WC#1#$SFNT&G*,;I9,:X^Z%\+)LCJ/:&87=R/0N<=9D
M\@8\O=EW.!N)1'9 *U94IIB_[YCVIU0[H([$4C8.F'MD?YRQNCK6ZSZ7\:3V
MMU_I?Q05Z$7?*LI-LMSX3M[R?M%6I^50<WALW/$J:]DQNJBQ^GQ9^%^C!4:Z
M!)TW]&>2%W*,J\]7ALW5*YTB>$S J 7E!,\JT;Z>DY@U'TK8%[P68,R7F.:X
MX9*HS0-K 2PKFOE; R/V15Y&E[Z06DQK/@-^?509Z0'I-+X-$YIJ?98.22F"
M),=$G#\+[5%1SZ\!<'U=*@VLR?2FXK2])8B:LW.)]/8DRC=9]A4^%=QLF%6'
MGUYA4P -)IP.$?8NX?"I0:'JZ*=.-_0+0 W(7JPJ*HMK5<.U!EQ? (,PIG9O
M+59Q9A86!C,=Z;!A+4_,:3$QE<>3D-4S%Q $Z/-WMR-CACNZ5(6%QDJH@U.H
M( $HE#I=[MK("NDE/B0U0?J,TO&*_!.A<Y")"&U2&TNZ;WW5GJ56D%2#BK[,
MW/R((X2U8, 44Z,#U^R_K=RUJ]Y'\O=%I-)"._ T'%<VCF;4W1ERC677(.P,
M_P2$_+^-V8?*9=\"8AG$&55&/JGW@#L-VCVL&*9T5[&)+IWXARW]"]B)N1J]
M%(<-='9R?SFQ>;$Q8S5X;<T0^=N;D8"&V%6Y7D?T)PRUJ%/]TD>/5[ )V0=D
M78^'S-<]%'*\7EZ)Q$BU9\7B+<RK/,B-"?63"T7LPXV(Z/<RY<GL6YFEQUTK
M+1B!:=6I[)?/:T=BEMPS3T1BNT]PXXG+>*83<MJ* <TV_8+HAQT5@)+C4_I@
MQR:Y[@SWN'K$EF_,W3Y>[\YPAK4'QC6DU,KU\$Q_9W5EY9,+:TJ35V;^\0-?
M3&TPXBJ&L/-YSR!ANMC@>>8DV^G->)<65PJ894G3!M+X"L"O>;%TKC%=6@G8
M<Z%K FU,IZ;!98E<&](!ON;T(9J?D3R"!-HTD@MK<VD0^>00'12W?\<$T@S9
M)RRM1DG8?9 @L#2F_RZ2JPG3 TR?<G4F,)(?2O7'Z$@Y!'\O2RJ_)K1HO)Y8
M"V"&SZ=;<=:,O;N:S=N<"_Z<X%]WN/'(2:43C> ("17,WX,9PLKR]W#=/V',
M^>-8F4W2-(D,,P.PS(:+0 OK@BW+*[%1.@EC^<DHQOD"/;B$7@L1"V7[2B=N
MK&39K??Z8KD:D*FBA7[2L<\(E?[JT+30%G?I(KLS'B?.VDK$A(XDGZGYY):;
M&4IYGE.BETUH7=,2K^YWC'(9:ORP-#EXN,&R::GU8Y,OI5O;+L+6T2/<#9GS
M0@&20,FDZ[SAG#%-. RU$!*?!->;1\"88L@90KK[DR5DXCB;=E;YO 9PH?\5
M*K=/9:L7?+ 2WVMP=[!O@G_6_];, ?"EUR/H<\CC^;0#D!X"Q\9H7W=H9-T)
MI/DL+A,=Q_PUCR?C 1WXZC9-6IBMA0-PH0Y;96'7SD+ZB3-^%T?0M@PU?;8_
MH,79^UFKLFF=O Y&JR78PY@AB;&JV/WVBKFT6I8!,;5I#<;N9U]:C43&S*[@
M9DA3+6PM(($C <#[Y_8 KBRE>:,,#!C5,F YD+T!W8UV8\$*&=#]7*-.UMZZ
M:L3='SCFQ.!E)C_I>$;9BE"QF;*KU9_9U&&Q<?+F7N8_K]UY[?#3JT?8N1/O
M\<6XP2RD,,]3P,W#:YRG*!P#VF< 85#[ZO8.,K;NK:*U67%PRN8[T^X*M-U+
M2I>B;[BE4++49V[Y7MPQ8E=V1'UOB?;Q=;IQT6T@[Z7WP(/WWQV?+$^0WX-]
MZC;YOGGC9_K>5YXQW^=9[95O)UM#T).O]- 9JW-;\9X_F:'\>#+KDGLES'BG
MTZ@:5F)OX7B*X*;K$A/@5/(^JHJNLEGNT'H^WPKL@IG&-\$SA#&JQ'\W,U:J
MP.RJ9DK/@]<.E'-% ?J\LV]$,/@@6A>9.I$5Q&SIO^L^ [M0?OP>WS"I$:GX
MKGYF[I'ZLXJ!*M7XZM]O<\>  :&JJ&0MDJ'W2')=UDMX,;1T-0K9#VZ>3,<&
M4J?ZV=LVFLLJR*P8:O(K*ID%GK?OFX6(^*'*^^+X*LWC,25>+DQJ"D8)A082
MK[12B$]1VAQK8UB"D#9%W0$P:Y']E/<('<6Q0(L!7LP!AEDUJ\@)>P!(\0$*
M65K\P]/<HTT-;Q+]/G7IH6+E+HUKLH([Z=B#8>Q;,\!=Y1N&CJUM#Q I*:NC
M?N/"&O58 -IE[<!118ORLC>=+_3;''K)*SG&U$ZU44+# ==ZT@.,'DJ.L968
M#OO"A3&]4BL;28HPG<FFVJS@'7Y"B/-8P;:I5_&5I@2[0X9'9A4.CU9I*$#%
M/:\N#1R0R NQZ#^%*GJ4I7U>[LGAH'V4I,M0XS9":O6^H9_U'MDJ/A'6-HJH
M&M=J-^\T]]I]#N^=I,7T:CKHRM5VMYXLT;=C8D]N+.IH:7_@RS#%N(KZ#%(F
M]CH^':\:"TT4@,0ZQ%DD.DFH6KG@ABZ@FH%- XN0@O&'I@"&52?T$E!.K\5E
MJH@][#)>\=5*?AR00/#G6HTT'A"*N%>,?4><E9SBG<;]L"I,(E<)S$YB05<S
M6&+S4H^8DC12JHTIUX;7;*.,>1>%BH=V @-T:#+&LADH5J@H<B%5+%%E-J@2
MW*O,X!<M2H_"AI#SSH9RD1_:LKZE'#Q0A1O!RV.[-;MV Q2:#9X)[X,K8\/7
M95"UEX'M"@QE@M0H/(')9R"#G94QGYW$?FZ"5_5#U<)&FHPDEGY.+<7E+GD6
MN1339L^JSYBI/%$\M9+(<7FU,2S,JM5Y H#LQRBW P2.(ZH4D@II+.R!S ST
MS0A 69ACW[N,6+=;602Z<K*W*<^I=V?]8?VF\WGIP[">0K[Y@QU$&N'-+FM(
M]%,_S9O:)L^C]L2,]FHI).:?>>?Y+"XU)](X:J<=-OJDU:LQ(^]XTTUHD5&5
MZ4_-&O.4B ZW)QJKM=.N&0[=3K.$U67#D-6O>;0-MQ9]N YF&LQTQP(ZYJN!
M1+0F$"%4$M*KN*<H2A]F%PN*LT:P J]-DD('>(78QA<='K$5J'BZ_<,NK3",
M:BY?!JMRKM(VT#P#[<>ZN]Z#E3YAF@ ;-5J+,'?"K4U"WN!%;32[63C:EK"/
MS%"<*')^")?I.$ ?/I20>(X%2YOOE.V/0+@D+R\/7&(1DZOP_V#!2D)B*'Z^
MB)F+=4'/^V2'57H_, =^$M;N"$ BFT*R@Z-Z%@?:"@? ,RDT\[3-81$X^C1K
M@]0PT%?%Q"2RG.A#"[V33C1JJLT!EGH&8UUL127VQ:17J<=:5TK0BR$%BM]<
MN-?)<^%_)+@RA8>1UZ?GZ=)D_'VL1,R=&.ED 4B":Q1$!XN%R<U]7O8R*W)^
MDOO9V']9B:@UOK:VMOGEV[/X:.."HA\_XCRR3S\BE"=5XBHS^^+#&VH3H]+)
MEDUA'\O"^M FWRGA+/=8+==?CA&^!O&#P[WC;\=Z CJS=$;[JAT8"I:Q1_<6
MY0($W[+;Q0\(*HC\<V9?*S[#GX_8*BRIW_3ZYXOJ__U%]CAN:A1V\Y>X %1]
MR@;W4 #Z>B=) "*BB#S[1X-<5P'H494T1P$M5%K/)TI@<; TECW?[D_(J@<3
MR2_WC;WS)>ZF ,1-.SW,$<'QG]1'A5!_GOE 6CT.W[$]6):N/VG]1UFZ#N@_
MC]W9E8KE-O@[4H^>5^766.\WX3DZZ<0>BC"</+"_4%%)Q/9.^(<RJ]I@U PB
M)/]8D;CCY5(%< _RT(7Y:8P!N1I]&*Q 8*["U/$#*;2NU"[==N;V&SEPLE*I
M47H,*X8D;O+.GEV547G &U$.$X]_#O_L6]V(?/J=:*R6%V"LDK=\73L[<\F^
M #]N?(*\1W[[R=CGDW^F7UWP-.#D!XF[G'(4?R.L$YDI&0VPPV3&R:G]VE+7
MPZ[7U#21F@%HBL6#6MY8F&.6M5WTO;[K.@'AY\R]),\W61I76^;#M;PD\FP,
MF(NK 4Q.=QL7=IR90A;V8BEDF&8SRX.48< ->H89!$O$&*D8I0<Z_<3+9[^J
M"%,LM>_[LF^YK20E:7/051VWMS A@5<7D!#_W-_%<A\V6,WL )C,!R?^@U>R
M&F,D":P*F:8_A<#_:".*LV-B^U0EJ6NJX-32@Q3-^W4F.!54N>L>=]96NMLI
MAFA'G(WT6*.=]R+8QQ5VEWZY1-\V. H^>/B7A:M#XVI.?T2%1_V7<M5W;ZI+
M?[&@Z4$O7CY1.!/Z>8$^O-LQT@&2T/)(Z\."[E#3OH'2BNTP.UGVJ>TN*BV[
M*1A_T!G/U1D35NB&.U'U7 \*E>:57.@$5-<M3V"G+:OP+(/?0G]P@^AKQHZ\
MR11D[.-ZKD^43KJ1S/).00FH(?<1<VNUF([?A[9@@;NQXJ@0]AWF</?PH<]#
MX(PNM5!P@SW90*X'=B)[U7LP>EY:#F7N1(GH4*OCVF9M#)F[-!5>&:E':\8,
M67Z,KY.-<-19R%A9UA6 :J:=QCO&VUW,[_RXQ9O):GLD "7 UOP&9VPM^@G6
MV[FW.KRXMH;:#L]I*'7SJ)P%)O7>>*6SEF/X]N'"L^K>\<H.SI28:K_'=JZU
M@\ %QTD39ZG9RY/(#=76&VZJ:F:4GCGUC![^X5$3Q+YCKRDF7XPN92.2[\O.
MB!313+[M"\E?W0 B-E;\O%-<;15^!'R_<.!\@7IQK8[K@X=!L*9KMF%:">%>
M1-WQ6O.$$#<7EW>AY?)=JB<'/#^PIEZ09:!B=LV&C;57*PMI-Q\'[\VK>-I9
M*F?TEE*9V/TI_>%5G8"EFJB.DD7=C[=TRM*GYB7^W0U')C'([?W?26SE4>S&
M?(0;@OH3/"D K5J]$("6/BZ7CY"^&I<)0%,A#@(0):O)@8C]"PL7=K@_&@0@
M@E4-F7]= /KA+@#=?M3")6,_#_-7C/72=>H^G$_7>;K[7PRIT@'^10%(1C@]
MD@S9@=9/GO(_B^.F\36$)Z F8S?P_O777SYC,;!_$T*(5(0?_>_K(];8C1]'
MA#@^]PHWH/^9H3]KLQ];QX)PVL#\A97>E7_:_?:FG7_1@K2S+62QL3_Q]CW8
MG];"8C'9X<4O_VM#<E@<D(1UQ9/DP3*20"-.W*^/EQN]WZQ_!*U1=JEXXM+O
M@2<+'%K4IJ87[NT2^1-+OX96WV2U\,5\!:"?IOYO!"#<.\BJ MV(=]'$,@@]
MX>^E<%A*X8):-D'4X1:%D/:5(#KD_N5APL-6SYWHLWZ3[DNG-FZ^[F=<8UKH
MY<;"398#MA?-!Z$^@[/VC]>(>B,&)GH"4,\;X.S*/)(KU20DWG#(/Y_3MZP]
MH=F8G^Q3R%<0@+9:WZV>Q&X8#@I S$(!J$N"Q*RWD;X+S I >^JPVRHXP LL
MUHF.$(#N3Y"X67 58(#=B^O!,Z] [D->_@X_@(S-NC ?M_J+I3V_ 9$SX%Y\
M=8'>CDV!:6&E!NEWK-7;U'IW7A25'VE7Z5F9$+]>_[+$YON/?,P5X+Y0<OZ&
MZ_9MX<K;7\B@%29'K$-^,\HD-5![](?L&= U43KR(48!*!6 U&]\[<)=PRJB
M&GI(T^J@-\S5J&TS2U%N&V\XPT@S>;3G9_\=!81XX(K=TK?6]/!;B7#?.+>'
M=[[6;2*F[6'(I-6*N>1:T93\NH*@'ZS,2<YI(,1\'VDKN\'9+[;=<XPG+-U)
M4<SXR7XJH(80@/X:P_ZS!;>QC,6U$<XAS/"<$86OQD7QJOFB7'4@J1IU'JY^
MCH97Y_YC- 9R$"SA%^8U,S3WYD;5K7>$/L+2W9*AA@\!>+?D?GM*7;WOI<#<
MKR0E;#<<&T1-(365$-XB4V'& ((&O]_6LAI+Q\YLD4E-U'0;O25+*!DGNV1C
M#."0S"VRS?Y/&U9UZE8E+HM^YKIU845#R4W16N-OS.8OV'JUVY^("/5W,ANH
M=; 5@)JU![7C=?VDMF_?;=>:6SMJ+Y92\.H]T^!6J_;FF?#\^OF[<^R52[_,
M1T*'QZ'_[%Q[KCXN<:[+3 !ZNP+GV]7'O[6Q9MK__2^@%P-"-E)"Q0O;#VEN
M=-D4@.ON,F&65D>\ )"],U*5!XL&/$<VK;Q0AA&&&F<.Y.=H>Z6C&$5G-."%
M:\(^0$@4+[6HV3_X2C[\:4A#YV)O!CBU#=RC3]PSS;4;C>1>PLNCG6-KO4/5
M]V1 6TZ;4E-CG=;$?%X_F!NJ/Y*]#BV:^<80+_URO/7ZJU.NMX9.+;E\KIN7
M=6MSOB4 -:S$4$8Y99Y*$K-.)]ZV@--.'"[.*H86C9<T.2,BW%?7V-+_C*N<
MKS#0O0Y7Q=)BB0*0AM>[(@A77I)]B"7=6X*@S:5P_+A[Q_@G4)&< 5]D*E_=
M#_6#S)?%2U/1)U_AW8$LJ5;"7X^R=*T5"+Y?YH#DY1WO$ZMUJ^O@-=F$G*^V
M[4QC]BPOFQ0VB%2>PWP4@!H%H&Y(Y@1)*N;[)@X\3(,>#FO+01G;Y1M6XGQ8
M2C,'GE$:$]7R9\VJ=3C[K\^Y&O0<W.6DE!IA&_R&/9OC$.@QF]);^,,<!_MB
MQ_SS]^([,''-W A:18X;X!?9E).@MKIS;<?OGR$)]97$/&V+F$5B6@I)^U'M
MS\%+ M"#-OX'B!SD!F0:SG;G%5L',N?9?U)(H2OP[,!>L )?D>M*B3UK1>.W
M,/UZ=I32"\]/=IR22HN-?>',6#&X=8HPAT6$3C0OB5!\F^L6/@\@V$H]Q%ES
MMAVPPM+OQ^_E2V)&A3F-T4-[ S$SKU'S=.K]CMB*E2Y=)OU3;. S1%8<8?:2
M[6=?NY>0ADWEC58DK?%)=8%MVJC=G_.(8?K0JQ\_;\+7\/)Y5XNRF/Q?KCF8
MM:WF^0)I:7"&_EMB'/Z:ZJBAB^[@UMSR+6?#2+^-D?+OI/\P@HG[ 0&(X\'_
M0'V=G?04*&87 ;^8))K-?4:)9X0TV9?0.RSO"]Q5PWJU-.;POY$O)9\S^++1
MW!S5U#?VAU]39XV)4Y2)VS6_BE:L#.0&=MJ(#NZ!BG$3 #S'@:O"-.H&ISI7
M:=_#Z &)_3O^I <=B.,-06:55?;T!%^Q-RJ4+TOL7W,/7Z4'M[0D>[4K<O8I
MLKS_;-4NFJ<\<"M"]3ZYSA;&;\B(C9!X]=_WT.'Z/L&BU69E$U+0QW5C$3Z_
M3,?UF\;!%_X%H:/QC&$A7;-5F& R,9FDU!$FC&!1YD /*;.Y5+,3@+*DO5C?
M\&(/^<?\4&:CJNN*YDE-'C['2,7D@A;%G^$3-XYV-L>G&F2U^SO+&Y74"^/5
MEO0;7'(.K4?I<.+\CAFV 9. A:= ?!]$;+4)EUH$P\>R),DPPS8G(XF5&7ES
M5?6SVKUQ;@/J&?$U669JYS2=,F['>\H]1LVLH&?5V-AOEI#PSZ2?\VO^?IT#
MFY>M9O6[STYR\K9PO:2,CAO;A2[--MW_BH+)\X5KE9PC_ ^ENDR\L':$$F<0
M-$(W1!FU_,60"Z9C4[LL1QO5D+V*I^'V57W/?:;^^CFH6'R66XU 5L,3<GH8
MYXX^^':)_GC^ S#,N<WO@S>4MH*3,6?YX]@]-@>!9.S>,(A,G0GR,+#N/(IL
MD@:M['18[DV95],[NEA/I//\O$OU#6P$(*?XWM;/D7^H'EIH.S>O7X_X-K4P
M&*0_'_CCBS]\2\4?Z_5)46G_V@VBR'9N5+,$]+&!:E9M>.Z7VLJ)@3'X?UQ<
MS='6O"92X' &7OX8H,VL93\#E%@:C V^8@.KDT3&B7 O?NJP9=3B]U&7[MYN
M#2'Z>8=-RFD-/6DS(U:%9\G+.<2+9FUV;)G]46LV@Q'GM6(#P6EPE5CX-)F^
MON;,M.K'@V.<AJ)=QC$'4=$#OI'E\\7.]N3]@XRS5AS#TQIM8R9F#G:5@4%1
MT;$17Z_]R%"<5'??F3LZ,UU_]I=#CUE_WQS"2X&3Y;L*]B#K"\,2)GGI%X2M
M&Z;4B%]OQ&V5%)9F4UW^5;@.T8QFL6Q3H)J%\^>58E0P8]@]W#NL2;+L2O/.
M5@]2$O7+<1R-(%Q#P:(0#*?HJAZ^_T)_RDUTG<L!2\9/OV ?25WOBJ"=[!J+
M)U<I-X>,Q34_^V6?,BFZ'38KM0F-T4[NL7OO$[G;H&*T0*:OD1UFN;RT$6^S
M /\/N:+VJD?\C1#>_@8CKA#9^JV$9&E^TC26+RO42&^]N=: K<)FYDNP\C8+
M-CTH]CC^1N"O^=8T^B]0B\C MQHD*+/>+BQ6.@6_[]N8J7B]="9_Q)2W.JGN
MO_82MR;[Q4F3[VWV-94[D7 OYSQ-SO,$:9X]P"?=$( VJO1N/Q. CAZXP">M
M8S=J?(=G&+PZ8=F(5N7HPU=\9V?F)G>Z)B<FJ'X;1E._\4I(#4Q%=F'+>"/I
M==.:D" +NV;\JO/_&\9__M^DTWAX.F4V$/(]Z#&6+I3I\8_^9T2?Y_/R?__;
ME)?"9/W4;B3T,YP/_&NYB8O(%(">%00)EX3E_5 GBPE YU=) I XED.K_=?K
M/OOOQ.J;^/U@GN1K 8BK)?31 ^)_6-@]:G384\,[RL%"QPM <_3_ _E_';)!
M-TTZ2;QLV?,Y.I"MN][XKCX.YJ?,Y:#6)R;?!T2"<#<FU6\>R4&7[>M^0?SG
M>?V8V+]4KPA Q"]6 I#MW(1'B,2;WF73/[_I;:K>[O-=SREJ%Q;!\9GW.Z$Y
MS46?O_\V0T"30&O.6FC3U=;E4!+F!3$N(A;I?Z/F7YJ]\=^#__K_"</]_S!6
M_@_D_S<AU]YU2:1CI>!P>_J>FC\C5S>FD=CF2H>*7X%XCVR97>D6;YV+,Q;/
M:$5EJC@60P4@'&=XAT4A;1 \B49G:M,*X#Y7^^?U+Q1E+4WTQCM&<#Q"=.(/
M^?>M@._XK-0/5.:-DNW!MI1NNLYP05V-Z[/59<TEJTHCA)6N ;CM1R,EJA#,
MVM;F/>@0KNUY<LIEPF?LP%<\6X)9R"]343O=)+3VYY>DS27LDL=^%G7]3_S.
MCK &%@78RGL%O,?LXU/!3.@!??:8L%VIP;Q3-P3&F8M]ZEJ\7*XHYRC:G]F"
MLPZAXS-\AWL"Z>OIOH6X^DV2:*C7W<7[7"0=#$XSE12?68MX\7#&X*O[Q9;Z
M;Z=?8>!__]_\P)L;#B"8QGQ)?:8V.Q*08\Q2=Z$#>=78 +P2YGV;627+W9Y5
MW\+2H M 9*?9OV_&:26@6AC2O6?M>]OR24F1/Q8+^'#E</9.6OJEM8WO/\K3
MCN%VFH TCCY&B$J)ZZ"=R3? ? 3OMM%!]2#T#<R0"MP+@#,-KHS*\;=RSOB+
M\D)S@GONV;)*[K3W.4ZQ?G#KR9D^SAM7N70ZEGZ?% #9.3T\+53[,K_HPO \
M/=[MOD<E^U;C58)E;K0;>J):RAY,;WI?4(VH7RM_76IX)5/CCD6/R6A2;M;2
M6.S5NH^=WZCZ=^/;-3<ACXP '>E^:A)V%RD,#Q@2NTE*:"M FG,>(+'+>:7<
M/0PC::XK*Z17 $JVD9\0@();/MF('B^,H/G;NP!/"TJU6/9I&T,N'P>%1TBA
MSS#%.P)J$+#CK<S.DIXE9_16$?)[X:HNYP@*WP=O@J_&<?[!O0+HT]?EN!(C
M6%H22:)+)A1FSOH*VS.!/EN%CAHW_;XIQGQBN;>]^O-R<ZE..U.](<ZBL_A<
M]KN8.CMOBIM#Y:G)'P^%J0A%3DDL7RQ:9ROS<(;?,A_D^O.'(&*&56X6HL'X
M[M%+^P[O5CUR\Z3^(GS&B8[CRJFRKT$?3'19\U(A(77QO?A&Z7[27NXNH=UQ
MNS ?!*"]FS@%5/& ^LD[16=^HQ WZA1'J63,H=$ZP\UA^? L%*3!)-Y!96*4
MO;:VNC#TVX+XQSJ?D9N+[J[A#D94QS*W2-E%E]B(FDAN\VM/$U2EA5V^Q9C[
MUYNW.ORP;9FJZ>Z.BEE6ZPCM!+^08F'CI,H7Y3KS2B"T?)*TL*I1L\W S J,
MWO<ASN5S"4\1ZL>8XQ-UM"&K?JP\7PO1)3?NVG@@WN.UMQ)Y9J*P;JJ;0'70
M]'QM*SN@T/.GTK8UK[3+@GN*Y=6]#F@LKI;0J(FD/<4# E #CJM@_Y:M,KEF
M2H.D"D#[-^$*7'1#*PO7:S4$[<6H,'?[A<'!$1W@FN[HLF7U,RQ[H2.E47$7
MFSI'T)(1%5UU9N7'EK"?Y>&O"KERZ8M>_KL'V==YR4UJMYUFU\S4Y*" !U-]
MRZ>51!%7R<_JPNW-WJF8+$)M-TF:-IA[ZD3?V;_'(CB%(XGM-M]<;!]#ZW/4
M,3W\(SD]V-?+*K@DC AWUP35I<TC##/\'/X=H]H>8;,0:%_XKJU(O,#DCEF2
MW6_+ 4%N%JCSE9K/^]PG2V\]N;[D2)5PS8D9_^P6SF[SE8/*[7-L7)#(B?U]
MD7#B:I#.> ;'*Z?)*^CX1+%Y#5?(X)Q#F$\V(%X&EM9<_13S$;XO%CQ#9#_B
MO22%&2GQAW>\^JT@#_FZ&?-*W7 9;?(B\Z_[F\[NGJ/K'6?KEH21]@K<TR7#
M\I\KK@CO.IYC!9==.M^_.8%,L=F'[;; 1B#54+5L .<'^+/B:8W@)F&L&7)H
M<?>L_3GGT0Z\)Y=]H?UG]_A12(TVAX?*,,,#%YB3/=(II89Y,&TR5"1L9F\#
MDKXN^EB*2'0VECS%LPO%OH)RY=K[]&/X"KP\ >@Z7J$RDSD+AR1AI+G2++VI
M:Y_3G)N:.*%WM8#7;UH/7E-%&6:Z?318/*61&C3% [,UA31V!TA;/\:DKN(Y
MBD"!O]G"C2:=#G,FDE:8JD4Q\B^1'7;#V7U:AT/;'\WGF#1W>&O'95_T'K2C
MVR<^["QVSRI7KLC[4O%UY<R[F:*XIK#CZV69L"QSS5>1-A3[.^]/1W3#K&MR
M'+2M?#>NKXZ.OPLO<MJF +&<DYAQL+( ).02[?J7$%K)"+];7857B@T@S<#9
M+L!C%I8O![\_6DGMA:I@ALW!TERU^3 :$$&\P!!C!N$R-L5CB?L0E@_@J/1?
M<)921N\C[P%"?7G"^[]OZ?W[1@%LHU(W9 ;+/C?998'6X%5V@6'\?KXZ0 QB
MX-(%(%D28OA^T>3J;&WXW4;+Q423(55V,.!%(Z;$J5NRX _X1\-\DUI28Q%0
M,$ FCWX/0ZKMP.8Z%-GN I"]D$M?>W'EG)Q'K>'$:W\_,/ER90DNO5'G[L<:
M&DKI@=XO*@><+H\\;7TS5F]]#E'UO<7+U\E/JV0,9KMQ\II3G*3/!;DO##D&
MO,'\ 826(P UX5<Y=.@,E@Y=)7..S*+!K)*MU!,Q_G$#\-U\,939LO8GM$<]
MREFJ):@F+)$OL]0T6[)[Q>.3R5 XPB!\Z^*;UYW%SDTY80:,/^FZ/3%".2&F
M<^:JH_L76XKSF_XG'N5Z-[=ROG6.4QT+]-P>CCXL%]=R;E+<OI;O66A"./ZY
MW.UVQNVFHIGA!1QP8G*5,@_.[K+DY76=X!H#"JSX><,ZYEWIC)D3X(.0(&D<
M58RKS)JGQV[AN"8%[.8MO 3?_/O=@9YAH5WW=;A&5_GXH!@3*[Z?FE90>4NG
M_F);=A<8?:3*8H3.8;K60J;-^>)X&E61_X%_8.P;4VMKS=9\P&@_9F!':366
MN<[^ ] 7ZU/S_?:+?M5FUUC'G: :M JP!UNWU)8U--Q'DN?J?EHG;G#HAH]$
MNFY07(2=+56%JRL B=0!TBPGMBO@REB?&F3?&-^$SH+[8?I,: ]2'K!GWP7D
MZE 2[SG=I6!<;]''5_/2\@[(H(@JU,VP'^_VUE7TU1]M3698I=;-)RU(\9Y;
M"^-(I)Z7VW4($&.L9PM @9#IVGZ8!)#+(M!);['[E\$2V)#A>WQC'W08R]X?
M3VX3'=O"V)54E.PENS<7&=S].>S6WO7R5..5I<DXO8B^J\_$Q^I<)Q[Z92;4
M9):4*ZQ6%'>:?5F#^LV--DUDZRE4'G*MJG[O^#/F<UEQ/N^%+[S#T2RWF/(B
M-BOW&_<2[Y$PK)_ &UM2K&6$"_,!8EE4=ESRHC,O%QN)G(UGF*_)$%#$7NI^
M=! ==P#EU3=AHS*.D4%?' M6^34%U)YG::?' $@3_5GG8PX_8IW5XP?7Y%R2
MZG*0-38G^,,0Y:Z]?S^3RW2%R,QBNTUM5+#=#EU*F#DD4U%HZX9J8)+6G,%<
MH=N5T R4T5K57#W@G5*V5G&OC3C3/B7R0!>IRI\+H9CN4X52(H*SW\GL]Z0V
MQ<%?*7'E/@Y>:V+V+:X^XRCZ J5\F2@"$+Q(6^Q61<J&F_4%Q;92.B!1SP9>
M4/U>^WVV'$8$GKA<\.OU*^_?]7^*,(49K6,B ,EAIDH/3) "!*!$2Z]T4L (
MW=EI'I(2R'MDHP(D^G<RO;([U*TCZ."T+M&1#ETZ+\YMLDMM1>5R'&N0H;\2
MH1;CEP7V*.Q5G/$L"3?ZBJ^F$*2@88=:S,8^$XUNX?0)=4I[\TV^KBMIO2@/
MB8&\>%_Q>5M+:S!$I A'\KGJ[EE3@6^*<NB;KK5SF8!8"T"AP].%[$< G'.%
M3^TR?R44J*(<% !E<WE_\E6XVH!/+<J/8=_SCGN*HX]*Z<%+KF)4$7#)#CN,
M;KCO;5(9^D@B_(YU0!60T5V4T%6=$!*./$I9(Q9$_ D1_YO X"H8-70"8%R!
M]F&:/^1;H@)I!.[!#(;V*A'!"EZ_RH2D6ZL:K7E4 RF]7BIB]SITK)V%NA^A
MAKC,W$K58@ZD6%\P>Q1"$)8%/PW[ZNF!,TDVXV^ OQ^@0S0"SAQC=&@;+P6C
M/@MHLU^S($GHH\PJ-G0**>Q"@HOA+/^DSLVJQUBB41+TX?JFSO$VG'W&)28^
M%>W\ I4"3W0?X6H0@ >_[,9S!J?1YA78;CUK=XX[ O_J6PE'DGNB$7A'7Q<)
MM8&,U6T.3^'(*E(IBO<9DEF^DGXM;>-HN8CJV:6"C$J-91O]CE&##J6(Z#I4
MO+VZ1J[_^%IC3U>=(Q3XA![-RL'[M'AH<4I#/L[F?(NH>%'D*SWKD=ZB.7GB
M]^*O#C-%6=K:G(GROW(>MKHY-W\MCH/HD7X7EI3) 4BB$H3Y#__P2?9MYN)]
MM!?'".7$KLM@UTR4=P*(2B@-(LNU8RZFPGN$$=_8% 'NU?9DR:OKL@P6&I1O
M:+)49WF5F0_>[='C]G&.\<FDEA^/.*'8;JLN8VX KY ;P-RA"/EDGO5Z=CZ%
M+9U&"L**8@9M5"B88Z'\DY0.HWFC>UBQ+F&B!J%FJ#V&D754!J$/K+)2>IR%
MS_@VUOBN;J/J34/I'6PM%/@-.07E9S:PKPA O6C 0P#ZT 1FOJ6^Q/.40U:?
M"4"IVTRA8Q^'C]#DOC8XN-_,<\MU>/\DM,^<4TEZE7'[RWM_2F8"<KXMXJ/I
ML=GT-@\M3V>CN;.=C3G0H$,K;=@AH]7'G .82;@H*9(T/0,'\0<MA3DUG 21
M@H0ATTDRF)/A M!A&QW,$+P1N4JF@\40A7SM#J@\IH^DJ,6<3,:&X5.Z-%@)
MV:0H-?;]J,!%5*YKU^O$:^.CD^0%0]++^<8<=RUQ+?$C.81\S6PI.RE[L>>,
M+B=A*["7)U3@WP>%58-K/YP$YPYZ3<@,'#YE*W*JXDJW_)5S^\-E=7Y+-DT_
M=-UV5V"ZSB.-=--=;J97K\B#+$^.J8F:#GVHH&R$^53D7<]9B8A=;3Q%])MU
M/-W@<FHA;J7N!]6D.&[C]8KV\QV=LK;+DF9P%B=0 ((W8W?<%:R$UOPC66@]
M^!9IQ\/ ;) /N8%=80\+0([7">'@GP?'("O\+>%>9;4 5(C?$HKK6\=("U2>
M4-9^OE']7QY5D[_Z".1_#I18*NV24H<]R1?GU?&-$-B]7?++,%E>%1:)E,7,
M091MS %APT[=TZ4(S-/[^O"K=UC1WD \YQR03H8SK3':$S9B* 2]<XL\)$VK
M2HLVSR VXC+*_2DW;I@:7#B/O\IRSO.]"GC6K=XY.VD8S [S,?0GLAQ:M0[5
M_5_DO7=44UO;+YIM0T5$NH(0%9 .(DUJ5 0$!!00E):MB! 0V#0)$I*M@'11
MZA:$J)2 -)4$E!;I(AOI($$("0+2LP3#DJPD)W[E?;?[WN,[OG/&O>-\]_ZQ
M,@9)UC/G?.KO-U?F@VN_Y&#A@I+VP S*-W?"<H)$M$\*3J^S=BI_R#:X@,S@
M#0['V-:RFW#>7%B,I. RGN6-#J3A.WIC<"3G=K@HVO,D^) Q2QFW'C610,=-
MD<AWUE?Y)I 8J2$= ?Y6)_%\$T",N'ENU"4C^WF>5F^C]W,JX@..A%\60[&4
M,=N T794@])TK\Q"OAA#+^DK4A"5+P&& /QTX\:5>AIB%]7OICUT^A48^'AA
M(U^0T?3$.!E5 79>3+7L7SXW>IR_._Q\_/1%LN\<W\X!?]U/19'JWD_K[3+;
MOX(5D034;R,Y2?9APBBY06=_N6_EM7:5663'*#TS=.?2(D"P8C_F31I!OYA]
M%Q-&TZS\S('7#6OCX)@3P$:KU >2C;7I8)CKZI*- ET\[LEB7>==<;_9:"M
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M?<^1[>?" JE"G%$NK"8NCGQ=(\&@]ZZ1*8\Q>;ZYE=<FXKL/VCU,ZHY2-I0
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M'&';Y+V?;1A\BSQZ[KYLX[;;M?>/'X^\YEU2WOM7=SOGS=]+C0/@XZE?'#A
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M8.;Q,UL^FXM;:^7"MJ9R87)VJN0T'+B-"_NV)44L\F]N^T,4W$/CC!",$[P
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M0JN2L9+@]L@JWQ>0/1#>VBN*<>@+/?-\^.CS.H9==!A;H57FT)#7J*?YP'+
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MD<Z!R.?).3,.&8$WQVW#9^QG&C)3AR.7L0)J_DC'T0HBL:FI9E 5Z3 \-3C
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M?X^@;9GL\D#H<!B.@$0_ZZ5YM["]'0>+]MD10#UZ58?&%@P"J":^%CCHS)$
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M HT%."=PT JD"4Z)WE91FES]N58/E% 'P72>$D;X0L_$'OXP;#\)[\)(::R
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M*QM#5:1XTD?B)42"49P2R*$_G.0' 8'A=+(AIQH-'_49H$BC/>G?XNN08"^
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M.Y,-F^EQ7,MK!4/#:3NS*RT(Q;U_.I[I;A4HD_+W.Y/0!#J[:HS#A"\FOZX
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MF7.T8<UY/LFKSYK91$43]/[DLS6?Y,X,](Y93KMAB#E#V%D $WA\2T=5JFY
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MNQ+VZFN HLN9B(U%)=$WPY054UE9I9#>V*D*PSF+SU@_?#=Y8+:CPR]YF\,
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MK95+QV>34;ASN^P='N1?O&5K,YWH[/*N8_@L\F[5P+PK_:5X^+\ 4$L#!!0
M   ( /B(.58?M!.K+,T! -O< 0 /    9F]R;7,M,5\P,#8N:G!GO+H'5%-A
MGR=\%; !!I'>8D&*-.F*0%0$! 2D-R$" @)"4%J$0!2D@U$04*H(2#-$Z361
MKB(@O4E)0.F04"\0DHWO.[L[,SM[SLRWWVYR;N[)>9[GW]OOW$L?H4\#'/HZ
M>CK H4.'@'N,+T ?![3^_OL_^OPE\G]*XQ#]"W#JV*',P[>8#IT##I\ZQ'3J
M$+T5@ + (99_;@#^Y7/H,!,SRY&CQXZ?8&5LJ.0 #A]B8CK,S,3"PLS,6 UA
MK /,IU@XS\I?/W+:Q/'HN4=<"L]>Y1P[?^-S$[=I+UE4T>EQV/$3/+Q\_ (7
MQ,0E)"\J*:NH7KZBIG536T?WEIZ^F;F%I96UC:WS?1=7MP?N'KY^_@&!R"=!
MX<\C(J.B8V(3DUXGIZ2^>9OV/C<O_T-!85%Q67E%955U36U=<TMK6WO'UV_?
M^_H'!H>&1T;'B*29V=]_YN87%BGK&YM;VSO@[MY?O0X!3/]#]?]0KU,,O0XS
M,S,Q'_VKUZ'#@7\WG&)F.2M_A/.ZR5''1Z?/*3P[QG7C5<[GIN/G%4W)W$Z/
M>T_PB"H1+U#^JO8/S?YSBH7]?]+L?RCV/_4: ]B8#C&<QW0*@ $TFL3[6. _
M>TDF#-"!&G2FYIL)X_VHW;Y@F.[NI;-)E]/#$S!?.XYZ;B3M^K;[>(+&8'A(
MJ.99ZLW#V\N'**P=UR":+M/(<NOE1!:AN7=MZ "O'3$ZX$](LB)'45AI^N*M
MQOL2#FIT8*#<"O=G*N]J6C-Y2LK@(!<:XD4'9,ET8)AZNKT[] 24A-[3ZPJI
MHP,T="D=((O-T($7O=M+=&"75D\'OJ1C:%<M"G&_)SVF?N#I "C^U&;?GPY0
MZ8 ]'9@V[* #PKDKPW1@XR"0#CQ3A5(#2DQHZ()=)5]+FLL.'6@ZW#.. Z'>
M]=^F(16_'H<<77O"V,\X7F!/&3X0F\'@UI"E:T1T,SR:(( RD NG\8+>""[P
M!;O8AEWMY]C5[N:K]N=:=6372M>4CZ]\Q+Z+[N)<K7U[W9W7XW/W1=0MT&4&
M_5SD//H82KO7B:%7-+'?2]FR'UVIU&7!:]S(V?@Q<D.GH;[BB;!3BG;"!9O#
M['VZ%44::+,?EIR7%QPIIYJ,\HIT>1;,K6W,X_3-9^Q;1O4?>4EJ&WY32;J%
M*JM6E:Y%>'MJVFTW8M'G,:IU3P43MD;XN@V[VN67LE7Y=A:NXPG"B-*.H3\S
MX]E;C5?X-<JD%@Y8MR4.\AKTB+B3R$XC<F#4V9_JSKEV(*8EL([0"CD"ALY9
M]Y8Z!U8/.)<-*K/:#51>BN$KBM[-29%D>R@H B7U1(:JD,4C4=PS$*[YW@4'
M03"!IU8NW%]NA54RR=:8?5$FS_-$V*152J\,+NG[CV7G#(7.8_(<@WAQB:Y/
M%8.W'5CY=3@_%..\(K#&.XC1RJO=:3LN*X4UG<34RKQ^%/E/D5D1]Q.S# O<
MFHZ!H?*@5_%P5^ 52+4']'\Z$E,-IP,]6U,TYE]HREC!'QW^EW5';G+6\6@_
MZ'UZKSL';W'VF:F/D$OJ&2%Y[S,^;:XQ81*!9P>*<X2N"A&=O6-GG[N>/21]
M3=,CV<V%-QCG+S51(O[>8-<V-$$C[0SAWX:8[CB.#LSMK=&!P]XP<,5D_Z:@
M>H^:3(8+M75,P>?0E2_2URV.,I>5/=7_=+B']=S7LG:3[@&?I<JIC/=5/MWR
MB4]3@3#S(Z;N!TXJ=1[[]GIP+^Z^88L/V^YCW42WT8,>:MR4-X$.9"\1J,=K
MZ,!,Q;^+^$&5%.4-5;7P4Q8OW5Y+Y[R^M*@J=;@@9_:P_B>V?6T\TQ-R\CT;
M:_WXC^^FRSXYG0AOG[[5?>2QMNB2GF';QD6OBPGVA2JEK],,M2OZ]<86IAQ'
MM]&^<@?X?_#8IP.=71W7&8F.G;^:%=X(]2;,':BM/=6C WHUTR<+#A#7KO3<
M]C5W0#HW?U/0)GQ8Y_7IGF2]!P@"M/M/%1URB?!P @?5MP T,R%7)7WP> 5.
M=53!V!KD/90/SDV9X2GY*_7VMNYS!C7U!ON>DC(#V2O!<?#E6M&#KQFW<@,V
M)9SEE362CYD7F87:^F3JH>Y$U#KS;&7:^M@_*;XAZ6LD&:.RG(0H,\1G\C1:
M3=9G(1'^AX;VED.\_[H"^F_L5AD(_[EES+HT-A>I/&[\R3-4:!"WJ>'4\>.%
MLTN1>S7$ZXE'?VL/VPK;_+QK1#PBOE1*['-ZB5'>@M[EP0+)&QYZ[2:OA0N.
MB[OQ:R](5*0%*3]2&DJPV7;)_C>QICF!I@.P831X^A$=Z/"HY%8?)+P-8?CJ
M6BU/0;%=)]?V7E8.2RMGAT8%>7*B1;GQA^R%ZIK(!Q\X6Y1.GS/@ZBW[QA5=
MIM,T>(L6 YO.AI%-1QI"_1#/Z$"%#@[A-K.L^P$4)VEL?AJS1A)S382K,"3^
M*FVO C />&4[^<G /J2*^FDJA>&@C#V52#[O2Q;/F*,L+;]7>/.C:KFF/[X]
MHIAJ5FL._4@\J= %7E78VSYQI_5.$=]'5QN+<0@F5U_?2#FO=*!(;.[&HYT%
MB_*PQ(S>_HBVP69ST_ =X=<SBSL!PT:8@FDZ@'^3FOADH4+DUOE(43> 4V_B
M6>0996-X)I1L@(C)4@,+]L61P39@.,X>F6K;JVY(,CX^MB3PC-/#=[Y.M*HH
M;WS1"KFAS)HNZ![Q?LJ8EJ3<<.<@/R_3P>J %[>F'J><DW5_-^!15(&:>;GT
M!:'[[@/5ZL(/)N\D.2QGN/#KILD427RHK(/;&(7VG<K6*W699]3E VM&8]J*
M.R'Q_NG_E<O9'[8*G3/^\"K1N)B4-$H'[.:9$3OBC.X%4@4(SV'1\'43S7-T
M8/0&99B6']2(#O3^(OT6]D0(@V+ZLK4T/N)_&4?L9#0>2.C93@H3B>TS2IU"
M[36861/LY/J,%&_CU)8V1198)5YQ>N7W/E%;^KZ>4/2/TGA^/>;3U-^;82U.
M\I<=A/<:3PSN/N*CN>@DZY>J1C"7%C4;2K655'J6.&P3,!EBQ!O?"$$&-Z=&
M=5_UVC\#_2E"Z*[+8-04[3Z":_LR;./$5BZ->[CUH1N-NZ,51CV+LJ)VO\+D
M+*S!?Z!'WZ8>L%*F0+T8.O!;/"Q'M<)E![9^>>_XEX6,:8YCIH]U=6 7LP-F
M<"@K1SIP8HD$0T=!.3H.ODY*[FSV&><P*$^U/L2 U3 .2O8;Z"'PXVS@7>$S
M][*>OKA^5.@%9/E')RT"7*.*MM*!]9=WT@=UC&=[BM%.7K[M=9I82FD'\15X
MH1"YUCK%FD^FI1,A"?T'20:4_/#%H=2@E!CB>%S]@9Q6"NUF=56*%\QA0(:(
MKS!X)A1_VG$3-@;1/XBO@">D5F5=JJ2X9I]'R9%#>N*5Y$:S[_Q4AC+/0P5*
MSS8FM0<YI**Q*OFN=>HJ*_D7K^?=U:C$CM95&Q8_ASZ_ "(HG/='Y5HPT4;
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M&#:OL5YUI^Q:W.E).%]N^$KJ[:>"<:^8Y6^(O:Z(XS)I_\C-=;SI(M]))N?
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M"=U'@7F32%];QL0EIF%GMH^(N5^54!GB&OSM0MHDRE".=GRT%'+"0T2 HIJ
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M-AU(,R,:(_9<QL5INYJYXE28%NV$+AW0MOMRP*#P&C2;HKT-_$('\%$Y372
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MX/\NSS8=J( <ISV-IH:/A_%EW9.VWO=/5^,0Z*%2>]!E]G.(XA'/;JQP-%^
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M)RTY_F14/*2H<3DJQ]X*+LMI+J(02'P4U9[UQ )%X'@5^C3[[38L6E::F)Z
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M%YIO_C;5>+Q@C5[(J.<.Q_(Y0BRA,N5#P.\4>(C3VG>A)5W?!K.\?ORIF1$
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MW@4N/VHA-4QL:S=@14O9UK-8US KLUYZ15E#]H*TKDN/?!J9]D5PX6L)_KL
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M<$_)04]DK9_7T,R) ?$H 3>.PQJM_6?X[JY,Z3\DK1:\QKR[L@B?A F&IWM
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MQ0R3;?0H\MZ/@S_<O#NSG'?TBW]_$G3(L?+L%M;=A!PGG!U[G#$R_,95Q/^
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M3GL$2#\F(6-CGGW>[K[XLT>Y5 /:!P; &S/-@G,CBI"E<9$P*PKH4 ;JUE[
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MEM3]H+=@<']= (,\D(-PA"%^;."PB /$:@\$70(D,8U9/40[BXX!41PI(9-
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M%TK_VXQ5(&;)@KFYD=;C /ZOZ!!';FM20F;HR(. R=5UR#?;G+,Z^# WCX/
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MVG0GUYWX0?85>_DT6\^IC<:F^O)]J9CB7%B35_T^=]JTH61:X[??U'3P=T-
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M43Q"(AJ9[^N\-K9T7V :]*SS&_KNCUK-7I:>*[I$W5<UZ/ZL*HL6:/0B,-E
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MIE'!#?/*'/*7%97B(\#(6N-DHZ&/U?BH>6I3AE6K8"_R#I#&K=C5=@10M3@
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M=_@CWO3)_G-E:+17VVOEU:\;KS*7O?JS^EKG)E5'/NN49"]FNUVY/O.<\SK
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MZGSF"/ 66:>DU:GS.>CF9Z4(Z&GQ)QTUA". FU-"?1"0=*HSD^ $,SP"M'V
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M7;<#VAEBRO"QE:YH_4$8SZQ+R/(ZH(U1*H%A[.NY-M$MPNPT 3Z,ML=XQK;
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M9#V[HUQ1GS+Y*JRD,?B8EQI19() SC!;@DMCO:T".7I)P38B4QB348RBMJ:
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M4$5/29OE2SA2TW.5Z)O<XG^TY=;0)\(+QQN>LF<$7FR]BFKX=/K'T3];&U7
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MGTX_K,$,FGKX*:4T..?.$^=;/Z[2B\YMD?X$6T\M?T;0";N@2E'36*,\IZW
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MQ"Q]'&HAI]#:%J@+3O;.Z!=S@&''[ASME?.*/,2HF<XV5?,UNC&X\$N"?'I
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ML*=_S_X4P?,&@SK2E:5'=;O_X9 #QO(^3$72A7^1[=NK1R\SU5UIAD_)M'?
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M-9,!)R]]]\G03G*7/<?N@OZ58X@(.$ N#$Z!J81X*#<:1T9$M\@2EBV_TCG
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MF&#RL6$8'VF7,3_SZEI\:NURP[D_Y<%PPOKS0B?@^9WJ#P"2\D5'\>HKRL4
M4R"&DJ0%_M6P#>9@F@]'</]0C<[V"/$K$S8UL1]1\-F:,5,4^6 H>A YX'!F
MA_B<"&FY2/^XUE77QE--%\V%16XK5"&F@8R!WG9ZRW1VGTV3T"T[\U*O@>J)
M'S5C^UVY:2SKEW?*9'Z47*25O.CN%GS0OR9#6TR4+1G@)>C8\OG*:9",O@;(
M;&G:I%VI+"]\W)NA<,XR)&;'%'*__XSQ\T2/FUGME!5U018C2[K)LF,T *>=
ML[AM\A(X!'4B:NK7V7R0E*#A:UO2M<YJ<YWL[Y>%ZCL@ I,]-%<&?_>3?7 ,
M=53'2"38%JK51!^/_AEN.QMFG]'=O6B^CGS.\?SD9_B^PKHK/14QSH053$Y.
M)EFBSC E1_% 4#BMK/-)FSA]IB=)]4C%+N<IM3WO?%)ON<SZBU03KMR1D2<U
M+*]0AY^)XRY-"&MX ;N+,0%BZ-D=6+X( 0#<KH8XNTB;ZRS#<4[#5Z%7L[O6
MRI?7_S6YVH3B[+7Q=OB]&ZE";$2N *U2W/+]^Z9=S@L]04H+)^,^\Q@=$5<K
MV\_5YU#5,K:IHUKHC*8L=:P@"U>G%'86>J("3;$68WS^4]CHK? PR]>C=K8,
MB1E\T0?1_!V#ZJ8&19I-DKZS)<8DMI!JR[-@_+Y,W_1F:L*"?T+4SZRTG$/0
MD\QFMY-]HE-*!=?$ES@NXN&*"5UAW@IYUE3;EG2-D01?IU)KI)4Q3C5$JC2N
M:7AG&Q.("3UXJX**R82/SE0-O:T?C1!&"_]=E7JD0[:S&29$+O3-GLZF0U!<
M[8RCS4A1HZ,UL:'ANX][:UW&[,#&[?5-R;"52U'0^H/<""DDC*>-!Q!SH>-?
M0"% >AC95,&!3GQ!,AM1B:N1+3?8M*JI"5&9,9:J>/2@S53)@5J3*N?US8P7
M\XZIF[F>0*N_2T=U;)XIRJ6><P=2B[VRS*-5D0?*IM'=80=!M?PT9C <NY.3
MQ>33FB=Y--2-%%:EF#TU<1.I%GQX*=SXY4W)K!6QA'7^,T).SE&WFAHOG+H@
M]XV."J'6S5WI.->8K!I0>T-2M,[&=*#VD;[(HOVJ=?$!''^FESF<;F/+RV61
MA#^55=V4I MIE:H>Z#'M3M>R\4??*QTII5N7=<LK3/[6DL]N*<2;^?NGOJ[!
M.UPM%VAH!CW_<BGY\8TO&AKSR:>_K&KH%A<0!"53_W"_]O<WNZZ6F'/R^'$1
M"Y>=C#],L(K4NWB0--B\"_L/_LB6\+(>Q+3"C.?V;QEA>2*PKU99_WLWD42S
M8T9BUU>I^W9NB,(%[&_YS]@)7=A77+8[;'.B<O\ UG^2Q\)YZ<+_.];A01NV
MX1"4DHW;!W*P/^TJWPIK0/^!Y(6PTO\<?.WO']IN/'IY: "&Q_1P34^2>;?]
M<3(L+QF?;O65)Z^))CB3#HY115/9O@P9Q=  EU++YA6WS9"IF3NQJDFBJ_N;
M)K6C6V7EEI\MMMGEYRP_XBQ)PU:Q<(9YO$=+-??%6?.I>[&W>=+<3WA\;OO7
M.#T8+;4;>VX[)?:)BW0K?2S?A\I0B.$$E-M=KM*36U2 7RK3.-$6."+F2NYP
MMZZ:G-QFA>^]=%M%X>G;#P/@T#,'V5!NIBY HEOM1-+J4DH<,!; D%?!RMP%
M5<>D,/M6TG:8\S%74QEA7:'%15.(<1Y/(D39/'IRX8;D/YW/\X*I,;_ZR9LI
MB M0=G19-WS@;9X@8,??*;")4<9[[V]&URIPF5#+1?M,:F[1^6-JP\4LJZJ'
MDPJKG>U3H"0;D_1(-#59@NU/RYT_=I&9#'G1:%5*"4.+ER#TC_E]L[(T6>MR
M\:F2AX2S?B\VIFV?0'=>/ ;SI#N97;&WB2XN,TZ2=[KC/9KO<3-->*'DC-E6
MSI)4"<EIW:HUG:?F(!VJ@O;NZ%*;VHU2O:A-X>FAVKXIAP/M2^UY,BU9<S><
M3_UK)KW6C3(OELP0WV!'J(F7T-2$7(L:S7YV"O'VM?;3R3QAP(]QD6E:3S-,
M;-%AG:0GIU(A9TR1\U*(KG'^*</8%G715X>@TP?=!>_0MKO.UV=7U:9NF1"\
MA4;@C[+ZLPT6?Z-]/[_"(+NP-/.^<%>JQ].68/(</X!HQYZ/N.B$5E,XSU2N
MHEF70%/? MAVJ"0MHXPLL-WL;'DZ*%RL\QS%I-S;I-R_QZK-9,(4]\_8GU[#
MD_,PX.J13M>QH*7:$X%<\EH?+$9(H>. [W>'*:TG3N5,/NP<BJD73.ZW:O?"
M Z4#)*,1IBE?(S=Z0]>2W6"885>;L3,V26[*&HWP?U_=.SJ=>6YAV^EJ@8AA
M75%^0F!)M_6JI9U9KK1QD?QSRQ2E[!>%!:*!82,K#^D=/9-T@_LW+8L6KND\
MWE[8MK'T3S+F;<4UVQ+EKETTLB9(F,(?IZAO3&ZK%;QC?<&=QT@6KX7NQF.$
MO<@SL'51\%C0#(*B.ABW,0_CO4=BBK,@([6:M3/FEG9TB4*A)TE%^)^$7QEU
M=*,BHQ.*1E<"H>+ ,8;*0=G-CW2#5^1<F27+IM8$PZH&>NM23$K\AJJ<N<F8
MKTHZ*;K1/4^1- <?VM*UG&WWW):Z-R)WN;DF65.@!G=Q\!!TXFO-(>B%3$?[
M/BQ91Q)9.H%1!L+(R+*RRF/"Y0J=4'D:6[=7A((#T->9%0A_K[2JMI_^/A7M
M7+7(FAI 3F;\FDZO$1UBV+!Z\L0.\!C3^8LND+A0R<@:\]/+^ZKELZ]U+@>$
M!?F4>T6H?M=Q"JH$>]?!V[)#?%#!HHDJFEOA?\]Z?9@60+E&ATW8BY:Y7^^@
M(.4%/UF7W;B;+'RV[(96J>_KB@7M>C;C7"-C=9,\ZQP;JDI USV)N'PS)Z,D
M@EE]/;K%-=^BU"S1.]Q2L;"0H#&6JWK&!.$A5&IK^=RPQA/"#CT&A'7.7J&#
MHVK[A6_3$=,UN79=P6,03LM=*U)-OVQG@'>/86M]ZU@E.!HC$4XY(U\P&EB\
MOK5^A;(:XK,A9G@VKIP*/ALQ,'=A"R?@!'2C8B*N?F==6\X*[ICCZ2]&E]W.
M-J'[II.3C,DU<^Q=01P?,_JQ^0CO8+FS*Z\-2R;G!D5O.K\_#U/8KIPX3H4V
MTXA4EX)@R(O 0Y#(F@GC[@KK) V:X.;E6HFNA:HR;Y"V90595P#FFH?Q.$:3
ML#SEI-7VK."'P\J?B3FG$/X_YV(%3+<R7Q#G<7!_8+RC31MX7@EHP[5024PW
M:JO))Y8@36E9]/RP*HJ3*3,$%?2L=^$<VJAU-E7Q";X9+@KF6PUM=,2M0WB^
M9:I53?<(*7O$5&:-Q(Q2.P0\[WO#RPA67*W9.64C';V%*RCT<&J9%+Y?HU9
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M2+TS*C'ZZ)'<?#S#K(Z[A9SKY5XC,S]S/N:DUIS-YUZ\,:^7 ?*BB&Y9,;S
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MNXC-7 ,YO ']+SC^G_W(1,'^%U!+ P04    " #XB#E6(,Y.HZM* @"*IP(
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M;4A\&O19ZOCCM!?/RPN/OIMY"$S5R4_EC"5QPE#=VNP(2):IBML,4_A 9/>
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M0G $-;IF[_V#B&M?N<-1)W-$)J3D>>-WWNUG=7MDEGBPDQ(-O;OX #4-PW1
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M)Z,7VGQ J(O;P%+GKL#0[Y0BTW@#W>< ^UE\8#_!AC54Y\[RR;GA:':OM^=
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M$PL ])]S[_#N&;I$>VP)J4#0&_Q*.W_9&DP@F40$ 6QYRMV)T%5!0-<=S9"
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MT(S<(BQR]N92Q1]6#IKFU=4-YB^C+5H9CTJ*2R+/E9:6QJOZF62(QV9$'@,
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MGCH?JZX6;]R%/9%C8,QGMGP27G#OZTKBX-SS"NP2',S&K.2HC<M[@#<&EGL
M@SU ;"PMN9->HK(!QRB=V;AW]0-!>A"#MK]1?PJTL4.U6<>LU3EOH8819QBA
MM!8(F\I\'M@#N/6"6BNIK$,-Y%FO0G>^\0ZT>=(#J0N&J2+/)>Q>IK^6K ]"
MK=13D 3U#E@DLH*K"?C![FWTV$L_<<D'KUMT!5Z;QLB;R'IZ9Z$_?+]WS=6\
M.C7_(4_0)FU93$ZNZ$?7GXC<-FI0-=AD#1V'511H+ICNM E8N$<+&XI57JY
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MA=VE#OH:[.#V -+FC.2ENQDBAN@1+<;LW$X9GG2+=526DNJTO_S'G7=B<IF
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M&#'=2XP#:#*B$2QBY_BW$L$+!R)<\J!)E[&=PI-*KE^KA UDZ7FO6HVUA*4
M"'/?Y1O]'OO;C4/]*AI,*G9^=LF9^X3":%G(F3BR$DF$??/]A76O(L-&D.7>
MR8\H 01<(Y$<V\+2#F\- U(N),\P]7G%)UIX.E,4-%P%0N/N*8[;/>30/&@T
MFY)*6& (T*E,FA[=,)!(!#($L!V(@]YU((J9;;@-)> =2X.FRZ)L1M^^_M$D
M(+?_T7F5G4)!ST>IW"*&/!NB]';#;V]<;:U">'H.77P44YZYVJ;GA^FCUK-F
M-4(&O;88"N.S88=H6@3A%PW\?QL$:/D$II(312@M9\K>9L!/:DC!^X)4_.-*
MZT?\QV=X6F>>Q!NB$O;G+6<7;8P G(BDIM-DW(B@8R79%#1!>AJ#3_VBZ*T=
MJ15DT6NE^/Y%Z2_=OITC)1I.P432UNS#H<B'1,'9G2R<O]MV[D[6R>WS\8NH
M!98K^&6Y,>HX3<60/+?R?N,!Y >VB[( 53YKH7_]VJ_-8J.+N3(]JYU1EH^_
MUQP2-+_SSTF?_Y[_I0;_>XK86&X/ '>*(O2 II"_9O*^1^QF-AY'&JGT&]$,
MJ&AF#0)FHL3B=LM@>PT(Y%POB;\$FL2<L&E]!@7R^Y%,/>](5]M<]RP1.%8I
MU#AN:MC989HP8\805**^(\-(H5FL9A#Y'O -2X0],2,99EF=(3.8TX$2NT&J
MCO#V8X;<!KY?'GZ4^\G=,]%^K6N!^UJ$?XK1$BD[K-@[^4]O@7FB*A9Z.Q5]
M>Q=31Y>+\1W$J+& B":/!C440XBK%5@*8S-ZEM /&I@W&MF<(A/A^:C:^%>%
MDI0A]Y\[&^6>4K/'];\FBJAMNL;2W1AFPYB9PI2.%27%M]]BCRRR59-7G<F)
M;Y5#"'>UV60>D5LRJ7,[]M>;=T+*&([Y R@SOM-&0&_JCOSR^KC<[WQ]"POZ
M5=@\:0=I>I#7Z$"_!X/!=E@4HLD* 3%C3_9-T#&,"^\[)T&*2B"X<3VPA> W
M+551_6D<@H"^F^+4U6NU?R(]$4/: R@>.2-*A\U@VL2YB&[-9CP,)W)=X04D
MP>04]E[%),[?)4H7ER?#]<?*O/CX[2?X >S&2)#[UOJ3D5PY[;HIJSV #"HM
M!:&2MZ!S$?4",?,#1+Z/F\10)6AMY#6\V4H]N:.IX5P5Q3HVW\,NGI8SNF2S
M3KK*_W%'F,_K<7:,/>)&6^B![ZQI!.\6B"93P\()!/$MRL\\'W.K$'B:<,GV
MZLYR;2]S6G,AIN*KCZ6+:=;N+<3R',PB72++[<A6.FZL9WM)?F,/P#IZ8 ]P
MZ#:S$.2M%+4'.*DKP!K"'-<6QT_47<F$[.9\3A=&U\3<$)J>MTSM3[^W(O#H
M3X:&3*Q9@1+"&S-.-*%5ZG+@6(/3)\+;>622M'5W_X#=<5\]V\.H^E<7-(HS
M+92CI!$?' -6[B[V\7^RHP60_FQ%J) <@!W R1!J,#.EO% '1L2U@WAI1F/W
M4KM^ICH,6P!UU@^?%$A:TGRJ I9C=0$K,>VP6! Z@"1)3NDG.B7G!\HTL<2'
M5AD<RN.3:B7I&WJRD*C?[5)IR@6M6AANGX@^JYF"9PJ.66QE*O2\WBA:I.L,
M70$D[+SJ(3\/'@^A1@ZKQHX7FM':Z':L200O(U3.R?'8VOMIH+OG9O4G#>SI
M\Q<M2P$W6CW,,I9"Q?#"I&JZ%"/T]Q:,'WZ:F<&0)]@K'!9.?9!J.!(/+M6/
M$$EKG+W(R>\3 S6P.(8R9J!5YI*]*QF>P=E"E.05&78'9S#305YFT6&*-*!$
M,9YYS&J087(A=>:S,^5L37*;=:? '>\,,]FK+_):\Q1>J*1L@X7#IH _<2_"
M+K:0;=HQY<C7FYA3#H9S+1E.4!_I)MAJHLSK%9_[HN4+1WIUI-%?+'(ME#_9
MC7@'MPFU,CR96;J<87VZIR+;,>)A"NY.@H-NGPQ@H<4>QXX_J_XK+#//4 %?
M8G5CT#*ML3$8LO4>( )\0!48=4KB/,TJBZ$R5('BGH2,5D8+!O!7Y 59SU]K
M+>68QW2M=JDTGLZPC"J4,PY )"9N<9D:1174)S8$0"#;2&]S/:&,+UBXS$)+
M YNWH (QFR)0RC%J$;*;^9WQD"V\/F_ULZ(\F/7_5)>L?4#\5W7)-6;Q?H$;
MCR3Q9!R:$5X2K,14]=B^)KZ^\ !)SNP@Y&VX6():^R1)$ELXN NS,$R= 1^
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M1?XK](D_SPQ1IT]VSP<UCZ#]ILI2S*F8G5G<=F>)IPS/7*!'HLRUC2YO+_2
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M]6/\FL>_?KS#&>3V_YA$J6Q?V@.4*N?*>0V!:TMC$ROI-0=[? _U0S!AC.F
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ME@0#E3+4\8(_C:U?/?ER^QS0@^/\8<]W?69&%-Y_YUQ()O@7<VS%>75RVCH
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M+PC6?NV<KOAB\)L:G554YE_,R3"IG-??(=8@B()D_12Q+EX[H8ON[-BQ)@%
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MO!-^?Z0PX3)%^&E<V$;WNOB(; ])#+$:3@;#.$BN3H3%V9Y0V08TB:5%IYB
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M5G?UO=!E)[5ZU"D:!T4A1+>"%( ?O]VK9U+KWV4IX\S'H(^I= M.LN0N2A8
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M/]A[[[BFLF]O.(X%Q8(T11&BTE0$!ND(Q(8T 5&*HI!11)H8:=)S5$0Z&4!
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M->7_L%[3J2:OMH0*?CW2W!!?&"[AY-ANV)A3EE"6-=VHGA:8=L&T[7&_G>K
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MIFJQVUL)HF!IMVE7_,DJ EVCW2'AELN!T+8]MA)/AA^J3MY9IS1!V BVP)X
M*(V:6:  M(?,1(T#Y"RMG0S!LLZ2LV!( 7AS3K>8NBG#]Y;,]=+"2-JAE\F\
MV\+G;YEM$[C1_?UVYV)ZHXMIMM:-01W)RO)$G^62'KS,\X\5]=JK$L['T6/L
M>I)<?+4DV$38,$2H  ,SF!FU=P=4*8P!\?">#^HLA%W>XLVAUV=S/Q&LIP,W
M1+W;D+ P]U6.%@ K3UZOC%-@/*41VF*88:\.A"LA@U0\4R1+OD"B4Y9ZY<5E
M$8\5FOP=!# EXZ33NU8^(,*C5J^:JICHFQF;Y98#GJJ:Z?YEG1(%'B\;DGJK
M60BYE6^,ZR!NJ%FJ=I#BA'YX>Y%G:ZV#_\;Q1TI"(Z5%6X_ =GJ-GL-3<,_"
MS\;-W8)?85\.UBCV+(3@!+'4J)PB/*PS<YKJ-E00A*D4OJ&U)Z-Z+BC&465P
MI]P+/0VZQ=O0CT.V.W9_< U=?_OHNH*N5\_NIG.G_5IBAO(:'>M;K+S D &^
M/*&_'H/]V[9RXA V@X2_)WR9 C#XN&@\W1J>E.XZ@B2N%MB7,F7ZQ=G]HG>F
M@0/&(R<F[/:VW,+, [O%[P=RW4<;^>T$)RAXB!O6 QNUWC#S43?\>:S?4)"U
M+,2]5>(CAO&PH4&-9Z^&>DJ6FR=_?<9!Z^IM,4H5U=*HCZ<4#LTJK%X];Z?X
M=C>]Q$-JQE9-*]_06TU;>Y 0]C[!A>82;G$F/ON"ZPK&AKHPU!_QE1D,#*5\
MIT7?QI&G]@@T8$]&G(Z9L&ZE[P)WU\83Y-GIFIWVQ@?*W*@@@GE9ELUN2@GQ
M*?WNPA<*X\2.WG\:+'+,$!L1RU5RX(1/E^O5CP85T8MC+@ =0U;]/CQ"AL:E
M6(@R+!>)IP[?:V?.Q $V^*^G:6'%U):'#(4<+W3-P &<00=T\.NDRNJ9%IG<
M\V&';RUFVA$M;%?B)E5#3QT\U'@L$^4+5&\E'&0< *LIGHWH/95(N@&((N\.
MK709ONPQ*%P]E*Q%:V@Z6Q&GJ%T:V7T^\GAFN^,-C<+G,7/7JVQH7? @?!U1
M)7)UJ&U^[J )W1 L(B'KC#=/J"28QY#GMEWJM4:^ZO^P+7ZG9E6OAO.;=T^N
M/1+-2'> ZO&OG''3R5E@#!D9CE4&<61T'<\>_R2OM$91J0<#6^;X-DIO<]K^
M6MSEX ,OQ,B\H=.6!;=R>QAGNY*K%+NOF8<^3FMJZV8 TA.KHNSW&Z;, N)0
MS%Y4B/%T*WPI1@D*.3JWJTNZ8,L4GI*W%%;WYLUCD31#8GO>Z&'7%[_DC^R?
MH2DM&-='& S//2 ._0I/,ZP*U%:!BAAOPR*AUEY42/YMQLFT%JVR#"_E 0@H
MLD+WI18/7+]2K-W0-L3[QDZ5&?I5/OS"M%"]G=%B5V(_2D:$-DLKSU#.*254
MY/CW&W^:ZU.AM8![*+6T$F8""S&409#&UWV@*"]4^]#B49$R#/ZL]Q5^93<W
ME?HFFF!HF1?01P,ECT;K"'T052"[#>/Z_%&89K<A5"U.Z(H>F<@-6@[7JEN_
M)4U%H,YW.1\H=;UK^3'5G?^%$:\(W]EMQ$/?I&F_'%HOE&:_F/I!ZG:;0=/3
MC )?I='G/U<>[5[&C#?U%8+C=!UHD/BZ92:'1.P)>(<N0M7BA:P'O78/9P0>
MH)HM+=>&S1QKKU%H\,MHOUG^]I$$_:2=R>B)&Z2MRH@--#SE? XR!-A$=.(1
MQ-;AM[I+?UULZ3.24?[<>*&==%RQZ<V8KL;)XS_3@^C2[L^6'9D66R-C1T6E
MF+&*^#W8;L(>9JZ&SK!!4Q %")QSQ^\ ;_1EEI8DS'QI\7VK=JS8)?=TY&Y/
MC:ZH^+F#O6WSF**JY"HY >.C:4:MON)I_8J+V.SI1<QFT.(TQ3BP>) +O%DM
MX\Z4;9 V$+;OWBH@_^S,"<V?[DD;")A<+AV9K9$W"35X9J(M("#XUT3Q+7_/
M)C]ABYX+:TVZ'$0O6MDG*&""-O5:]X_YY_^-/RYGR@M^TB#?+T!3)7IU6PF8
M1C=C*(/WL[!?(%G"*TK<<W$^IS))M8TYI* GWR*E:3 4!!\XFB>,)B6+ZW)!
M$;D8(>A][^X0#P>E/6E6;?*:N[LGKGH#.TU)C,\ENK6)3R6J(@J]-=S"MZOJ
M^U7F5>5CM^$#D;!Y\]VH T790ZR)@01UZG)MH)TSIUF(=5<8TLLZD%!,+?$;
MFCZ*JL&!U]$\@ <@SD)P+P-D<3+JNXC_]#S0X8-:6&&^9\C"7J@Q51IZR&F=
MR(!-[4"3WZ__26_&.U@(%V#N,=P?0.4K1"[N(-"0DYK(%08T@MT-U&2"L2S$
MJ;NPX7@O#Q(((NG4%;$0QWY<"]+368AM>J3!63GF/)ZDPY"7"@+>$)<_ H'(
M/SI3^H?.'ON Q^'5Y!WL4G"C2*9^^BS$\]]_8+:B"J6"<)2"D7_9US\2%O,/
MA $U&>!CU)CA&@^)[@ I1.,XLYZ%(%QD\^"1.&5N>3>T8DQ)@PZ:BT'WNP=J
MF3II+ 0*_PU7,P>:LA!\A2S$04YWS9  GI*M!;/X2V(F,"0-!&(G@%H^+T]Z
M& OAEP&:<,8\=Y*%B/QGX]R%>PCW]O:/<:)!,R0?P)&OX&^T:78[0GHPV7_N
MEE<:5G\GIN:N06GP%;YE5H?DR3B""T$M2CDB0>Y!F"M'@#^NT!4H2EV*"$1F
M(08/_WLZNP/"6,A@'.@-@M:KL._A3B/#GT__00)_YI50_!]0";F$6^5"^_(L
MB>(8$."*VDIDRV\?C@LF9AN'-%S(Z8R $A[&1@REH!_Y)VRA2"%^FLS.W^01
M'!O,0CSS6'[%0IA\9R%:QI?%*&\YP(=G,IOI"D"@%+M#=HDE%39U-]G4M?V%
MNM^!',\XDZ3# /]*G<$^H :YUIL<NS=_%&G';U) _2N$9/R)=:T_6&</7J1*
ME;%'MPE#25^;5<0?E__68 \#=7IUP!=U^E<@LP,87Z!'@5;P+1GD\Q-#/^;D
M88!DRC#0]!/Y ;;O;$'Z?@&&_S8+7) +)/]IU.^3'<6M)8%<B5EC^3/&83#^
MCRDA2$\%8*+P)/2'WR?ZFM[X^SP7Y'D$[#P!L_KZ L1(0)$L018".7]T !B,
M0;]2 0J[ L9*=_+ 'IMG]X39#6;DXKH> +:[N.=PHM=M60C9W0.?/:O71K>R
M ROLM9Q%Z1QDKB@&D8B10>CM_<!@&CJ?AX[\KOJ=& WSSCR1=N*+@7\G(YYQ
MI'O?==3X1_I[%L(4%D-+][+8O TDV!(9Q&B*1R]_;V4_IA&]*&<%#!:A<^:A
M]^J;]_02P3G0S!NX8;A95)!#2:M+*6Q=-\4NQT!9UUB(\2DZ[J,;9:$1M=;0
M; FYV2M#K\2I_[1^@E#[W/%\:=A%[!$^=;Y'6P,H@@3GQQD"NTF!^%H<@MS!
M,V"]<8;9N)C_C4OPNOR3]R;NT6-WJSZ?PVQOK2'9F9EB8JV[M%3HIP'LBY(K
MB7T/2TK,O45>95=-!B:Y#7S+2T["B$?O.Y@YA;:$&HF%HP,9FL30RLL.Y2]J
M=03"OO@,1>(AHO[J5:RMCES:S!&_^+M>0OL(I>IEXKMSIO7H!['O+7KS^HFA
M?E=^N?PD1V=;V+L]DVY]*]W]V,T4Y422H;*J\TSL95/7;"Y'?#5V:SM#+J-Q
M8R5WNL4KP5*&[$:L2VB#16.WAR-1NU5L<9\L7R1W:(:A#V$:8W28?[8M1?6%
M\=M+PEOAQ6Y#0)X^WB>5LWNP;1LF%#FOSX GW/44V/-[X=K]!H:G**P5NY4@
M,]@]^M=GX3Y_TA)B(:QVY,I1D1F3VIRT'H[>:YL(5WF/BYO_*?+M=OA?0^'X
MU01'H1)K])2Y!.?KRIF06W^]Y;!@^I1AAD%7XA6^L^Q=@XN<[![%YQZ58?)D
MQ.ZNMK6+'TH-O?"5ZX\Z.OZI_]','M@_E2\B^VYDER]*9!]E,W-8Z"T+0?[E
MJ)OV?^RH&[9XN"MAR7X3)RY.GU/!2$%>1]]L2I>=W /AKZMNZK%_XL+J8[6_
M[A4XAO[MZ%NWEABS"Y!K%C0&6Y>8/&?7*A:9K\7(683PM\?5>Z\%Q9FGKQ4P
M<D^5^&OAHAO_"86+@#_'P<G\&T?<?BM<)/6C<)&)-N(_\O>?;0MF8IN!*27\
M\EI]UY=<Z=[HZ:]8_QOPE"!"'06F'QI.%$1](@YFS#.B%H60RY<"!?H;Z<6W
M4?WY_*\\?OOW,RX3PV_ V[/#S%[$?\>/YXTV.;S%+=M_$(L*1<P+$Y?R71B&
MIG9[-N5;Q8RIT!NR/NEQ):QN%KURY..=RDZ'H):$(OD5'\C#_.:X4J=(^ C[
M *A#16?(DQEZB;5C[Z9CA[\M8I8-_51@U^QJ<3F!<F97W)WB&+VLC1&[RP\M
M+4NT' _2E'X/'6-L;M,Z/%GJN7>T+%DD=K#W8 1AEO)B6_B\EDUCOG3;._*N
MW8+<>>C8;R,-7[R2Q">D*E@(,3+PM9%VM*)#/* ^1:ZP7SRL0G7$FHLK1=M_
M;@CVZQP(NXLNY0UQ ZM+;C78+6T,F1NE-,JAQC(6PKI$7&W&2BC7]I8'QL%L
M53;$6^C:G>([[O[)J,39,YW"BUE[T["Q24;W,_(.^O=NY;'4_H5+Z:Q-9MJ=
M9[P_ H1#C)6.,"?C%(3)08QHXB[@:T8V,+&O9'8G"]&8"RPU [%>0!T+L2*!
M/<I"%!K#5F.;FE,?^99E8R.C"#UJ?9NSB^I.XNRBJOW813WG/UD9T7']S?6[
MN@_6(GTUZGR6L^?+GN5%)06O:;R+[QOI59-;_E$77OSHTE=E\9@*=K5*3)_\
ML:N:<D'3M],[462C,_\>P5%8(>JZ^EQT^[-*/+QV_%=3J[CX/??A8UP;VD*%
M?CL!K"=R\%_J1(*?PC]LISKZ_7'ZU\@QMTJ]N[G1[6OY!DXAMUS=P8\YY[SR
MR'8T74ZH\,5/,%NVGSP@I298?.YCVUJX<!$[>+A,<SN&_UAE+*QXS"7$NG)T
M_:53)6V]*TSMTO4.-Y\UAN]_WV+IM-2LNO2R7"WGA.+: >!C6\B!OU5V4]S)
MI9CM3;XGGL6ECU."%>3'?[:[.F,-;@+(A50B$_CZ;^A'V^N&9D]6N\/XVV_P
MK>VJYNK7XA-R].]X[<E_>"9T[7RS?N$!J3+' OGA=.?U>P39>\2.A8=I<V9V
MMXF<Q$?>:XF/C+3-'W>U*OSZ,?)%YI1]M#Q'03I<'5HP-!>MF@R^#EM1)'WU
M]I,;WV2L__[;/BN/X,$+-A)AJ^P4I'_*<20MZF)E,5W>.+,U>QL+\8F3R73H
M$_';$1]LYB /1.6Y.*%_^&TB9UH7!&G]^E^L3)Z'H.[>8Y^11^P+#UU9H.6^
M B,\J7R?C3=[%6D7ENP]>HW448E2Z@B';I7_,N&Y>;V0\-WHS5)2JLB3?XN:
M\SY3[I*UHA DCU,6+%#T*J.I-+ 0JX=2!%F(&N5Q%B).$;#QP[ 0J2$D-$/L
M-K!B8V4KN 3U6L5_PR73K#%S:JAI3 3,-1,-:1;BH7,+"W'4'FH !UD(;?X:
M(GCV&PLQWU#Q\1"M;9HP(MK4S!R78D90B5"H5"! B2AG(48CD%\'A6&W.]7+
M@H78W(>'+G5?UA9E/R&@QYM8.0)/< *LXEK/4 H@WC(4HS"-+CP,, 6,N5D(
MDK ;;&SNG3J4UF?PFOZKKYS*<A+^WS,& 5^'NVA7'MLQ:"'F;^3B_C8DI]Q4
MG+-LT^S)Z<K! 5?@KP2W_G5('H]-9M)[_-]KQB?2/QO_C5[47T:4_SI4L_BM
M7#G7ZP7 ^P,+\1=R=?XV(J4N$YW2>-OE_?_'1$#\5R+(GYM3!NR87+30ITN8
M:2#4>EN J,Y3&GY=?]-;YDWY"!.7P6Y*@9[H'F:6+^,Z!0D)A[5 5[HPT]U0
M$6S#WH7)<+3(MF@<,[-=FOA>X6X5-3=DG_$HLF#.+@4>C@+] LP)3KO$0>@*
M[&5L;IF!E:%VV#L O(T!5C#6@=IWZ'JPM-29H;,0S7N.(88JD6/NDEL'\[.\
M"B:_"DD)ASJ(BY<JN6#_<6P99M#2=U.3&0FV!/[KVZC\#Z;M_[;Y[VHCQ1!#
ME\@!X5KK68A:%U]8#80NJO/H:[Y@S_M"G.=RT=C;9!Y:P +2LQZYB3G,0AP3
M@>>.S)&D!.3,N@?&=7/PPTA;/>"&ZHM;"Y8B(&JV@KO2XOG<&4I!N>B5--&Y
M.;NMLD'49>3\13_8!W^HV0UK@LG<"JG&9W>P$EXZ\-0**X N=WNLI;',[(HE
M""Z+J9S5'!SXO-=?>/@-.I%L_)!("8'-O]%8BWAM<"(<'SS #\]26;;2,>MK
M7G8L[G>R-X<UCYB*GB?@J_JT&(B\K 9R5)4LK*K,)%NQROPM=<@_E-W,V*1C
M;K]3JA(>;J5F8@4_3681B$CFJ>/9"I"0G'OR9*.HSUQ8B"W+@2P$Y5>V3@J\
MZ^IAF:-B.<!I=_@BNYWV(BYB POQX02E!>)303+PYPD1U&= \ZG?KJW<V'6*
MG/>F&,R>\97H9TZ/? ZC9L":+@A%B<+#KL]$3JJ?P[7&.F '3)\8BH60LKC$
M3CJ3PU&.QJ_9<HB!JL%V6 ,A:XF@;C/\N [@%S_'&:HT^]H0ON[L:N5HWP.^
M0LN KYH99;GA&Y5ZO+86&EDAKJ@G::A1B9Y-5(/:05#'@',_QZB-MX85:M"T
M#4S60D&P)4]#,':?5X+37(CEAJXI4K)N"S=XUM1!C"[^]K%*GU';V3M?]XO>
M\4':AYUF/M/.]0;Q0]/>3CCP^6TF:EKJ*K*>Y\_F[S=8YCC8(YU*8"&.+"AP
MMXV&O:9'M0:F(>V7?#W]/Q]TYJ'=:T'Q5R)A;,APL+%%T1CW!D5UX_S$@<M4
M.7ZU@\]=J79ORXK%M\@/)FR&!,:?!E=2L))>.@7,S<MH1E'VO#U1U**@#K]Y
MB85X+CG%!L>WM3PY91'LA?6@*7N4I)%6Z#@,!MP6YMPJWVWBBNWYIE2&>PN*
MUT\*?J 5>Z7**?VQL<!Y8/BH-AM568JXR-,!5/Z:*N#[.<X"=1H&2.T^QBE*
M 7J5G[.$)_T(9N@"/A)&3J?FO:7W-.BE,6[/4;EJ^H'OQIQF%HFZ8(<13YW<
M5C:A[.+;<8(]:X26< A5B)5PAH&E!@,+0:6NKV$A0%W819ZO27 '(J0RZI"P
M 4@Z "/SPU*G05>B978!S%.M9IA(-?XTAH,X"U%?RP;?;AA\)FPP)L&SI98R
M"/$IP+WX>S3FP;:H??:*7#G_$0.8Q \B_,/&QN E@@C,M%/A+ 0#?_(+I"2*
M(MF GC#^]\!.C7I%Z<Q2>O8/1+)Q;TS?.FS!%,!Q0 M;#E(7@%\8MU +%QB:
M,!\?#C*2K9P%9=<L"+; 'K./66C E'RFS$&\"\"\AYJ?)K42OW)$2Q3^50L-
M&>7GL<,,\*6Q-+3KYE8.[-';&7?$<*%8$?@6=?B67'3P7JX&>_?-+ZK ^&?-
M2%I#,KV8\C@KCG[KN!&VUVO[ YT[\E%).'VCV "J'*2="4RKI<,6OY] FJ71
M%7C$ZO*C/L2JE"#90/K)'41^!FQB/)3@Z+0M[L:]ZXEU@W^HM-F,'[$B'!S@
M;+XVPMRJ^?"<X=?">#S(M0B+3Y2-,P]K*_[A034PGH1D')@EKMA9=; ]H1;!
M2J<FN&$P3;X$5L N_/:#HKL#J-(U:/!,/S#_,0>6S1<J"[%5K 8 M:W@7]ZR
M70??KL)<%B+6_WT3YWEU\%W-P%@J>!'6E6]A,ZC3&T:BVC@9"5M*X1Q$W7V]
MYE-]C[!CY,R>Q=:S\5K:IJ6R# :PE6 ^C,WS>B\8MT2P^T$TW T=[L;"CAW-
M8D[-DX9%JE/(%JFZH=2PSL4UQ.FP+;2:5&>QX9/(^?,:\C";(AIA*7=?4=$/
M7\RS,8-E),8VQ.P.PJ@4IU)Y:E$P3(%Y?_E%3,1QXLAS$/,#.UH5[5T)XR7V
M.=XP_Z?C/9>30EJU%/$KF81]L%3/ I#QB[U2#2D!9%00L*81<_(XT3,Y; ,Z
M2NL#&]GRSQB.C8S'^#_@%K%^^+(JDN\/N/W"+O+-0:C<];?$JJ0,AMB@,#Q-
M)%!LI<=1FB328,1P1CV2!U;R<FQ%>_G"CEBMWC4=R)YT9[P\AT.LM0ZS@;^Y
M!UA1+\9N_ [L0Y$.4Q]<8NA1:MZ7=0$.T5/597Q<J)M7G;=F2G[AVA?W85PL
M'5/P3<EW:#<CTEJ9A7@5B(.B9=S(.7HDN]2)5D_M]C2DLPAZ@+XW^CN^>(LJ
M"Q&('X)GVH';,(/LS&Y^@;2&\2$#/#!#UB U\",EU2XE_#R\E"9ELK%0JY?J
MYP=;X;\#S2R]E: 1T/(GI=?_(W'5]Q_*A+T>J'HK8B(;8ZC(&G_4=_T?:^E9
M< PUEN;U U>7+3"<+%=YSV$+^0@]*CR3+5Q!R2AJG0>\EEH3%R4Y1GN.P0L_
MS!QU:TT_"S%F] _X4\+L;8'%Q9?*YOW5"IV&2K=_A-*S&#VP?;!Q@)UL\M0P
M6^E]Y40CE458P";*9U,+>+I'J^LTQ+ 02ERU8M"H, XRSHS$45\ S:=_7TL]
M="S/%D3#H&!C7&U7*U91%"!=_P-J3Q31$9H$,:\_]-8X)[AI;2T]S3%())B!
MU,Q2@'1C[2YX=8RG<PU;>X&Q)-C4=PUG8\F."@FDY:'6_*LT]J+=?0+L!<9>
M@@#,+LZ*2A !O_GXG:<L0[SS\  ]/$+8VYS)'!_.AOT<2<(^<+2/G!%$I$3$
MLU&=R4Q8Y,&A*55*JL4%H:*[# K ,\-RFN,/;HOCFNAZ*Z<D4Q\J>W^[%.X2
MN713;LK*>!IFK]36;.#K6N&2A2-M4$M6:M_KV8A7'39+P8[+LRVPI_+0CO82
M!D7]$(JAHD)DE*5!O/C>>"AL]SUV6IL!F+:!*NY0$., #T:GS5>0O=8/@F<!
M1_3J46NVY>?&MOQ\4"3870*^%WK!(-S>/ >KQ*DOF6F]'!_V_V-MO/\'T_8_
MO@W7(\#1FH40XC@2Y(4_.1+AOL2JJ)Z\7LNS\0LZXE-[0UZ$'@MMCM2]<"E3
MZMF'QJPI;3WMF[?^:[?>V1OO?_;KWX^AYXI6L+JKVWCHN:="#^7SOSJ4&HKX
M#_]I'GJV^(R'?=[RTN#<WC25TQ;YQ"X5>D-F\Y=N=IK,(O=_?P;^[.:NBNMV
M!W.3S>%_Y>EULMT/^Z<&KKNF3(CZ414=F+:RX$<IQ2'+#L:6CKREF9\\!-:G
M//Z_;^'^76_AV D<CA3_'PCAG6C,4VI1_7VC^3\EO7X_P%VREG:R4C<EJ52Z
M:6VY+I'SR9$:8#BE[VFZ7LP)X.4,JE_:?@\G*VB[V5-VJHJ*@S"(X,'U.[*'
MV._D]?1]9%K6$?4N\? ?"?7=.,DJ.GEE:D$6@MND*V;MZ_X?B3X/ZVZY#I5T
M8IOP\W<J,I@A,( F+N>;<U:<-\#P 8^3+,0%3G!OP#$6XD[6Q&I:VH\MYD.I
MA'VK)YXE>;PLXFTCG.\FWIX+VZO2,-B+(;5Y86KG'5B(C1!RHF+N$7)Z(21_
M5O;H;(9[!>:XTS/[G>OV-IR0B3;:_-0@;NXU9J3LB+QKM$&.P=R7U890T W:
M D_GC08@GNZ _61]J!O2\-I]@C)8C^'Z_FJR-R4HM5%]8CG!?_1Y1?O<,[UT
M;[^G_*[*5Z/$CVV+E'Y('6<(&M"Z.H&A1"0"L"<^2-D.6A,%",I^I]HU9..@
MPX4=L,7W.GKVRI.Z1ZJRV+;L;7HM3T9^&I2^LRDZ/$U*V"D#,O3%GGO2ZS)F
M; AL] 21:3VBQ3<L:@B;F6^(0VG Z\9Z%!?(!7$G4P#2OA0D%2JM.!M %1N*
M3,^*0!EUB"/?E%05=SS^1+BV84LL[<;]\'EL$O,U5AD,HGDP8S4 ZF#-7MOD
ML2R2,;?U9()_?FJ^\VB<4%CV>][8T&BUVO61#TU-HS.,DV?R!ZPT3R$K,Y^5
MW67XI"1'36G[*=&W,-BGJ"?\[#O\UE,#:-&P:C8,(J%#%-^4:%KWO:-A)7%U
M6YR5"J,%@V8N5+WZ];C.6Q?;/N*&I+W++ 0?4,W._X+C<HRKD HE.J$0$]WQ
M"<R&(&<G;[*3UTB,26"I@>.Z6RN9WXXM;<HW<8F7'BPS.6RE7#KKJR3XCN'.
MA+6-';(GIN8\N$Q[" Z2\)N^EVW;2$@GRUR7OF2KX=_EJN(AHJGM!UNA&S68
M%27((#S%H& W]BNZ4*<A0G1RK,M0' 3J+4^4=.3I&V;W]C45Z[X^LQ*I8VTZ
MK":TGQ>O,A:?WE\BRT9$?N-7[_H]]=[&-7)]IVE7P.;AL+F P>U$>SP7&-1@
MN8_;8Y#'07V:?\!2>9/?^Z@0:^,,P07,.WP?AA9&1;[#XX@[-?2H >]VJ0?=
M!QRV8VI2A#NQXB=N+2:*'!R8'5#->^$DH>/]D^YD9%W1<5G:P:R7V:HK:*K!
MPDU'B]#X!+0/9EZG?T_SAN$\;Z .W:< DW"8-F4<@2I6"6"H>*1]_]EI;YU/
M:;D@L2<W_6[D\>A]#P[:Z9C='C5.=Q<5AB<;1:<>MBN[APL>:1VUWQL4<*-(
MQ8D<9G5!I?#G=3%223OZ"2MI-P:OQY4N'.=>QY7NY5G- Q[V9/#3:;'4:=16
ME-U<'P]I+KQ2SV5;=.UST+/NB]752OMCT[Q"2>NZVRJ%H:U6,)N/Q-#D*07W
ML-R,8\R7E<*4ID8\OX:M[4N5T,J+3AN7&6)[CS[ %#NA;)ZV2E[JE0C':%E/
MJ*5:&!T9Y'^]L,]"B1';LVRVX7Y7Y?ISS%>$3=@F%J+(^ '#@6Z+_::UOL+_
MHD$0IDYZ0@;N8F>1[&CYHW72![FNBF36^ZL6G'G#S"#:A6$"E?'[9K44O9S]
MA/W%Y7O@N6LI9J/PD21F%G]<S^[ B19Q<HAO7O[GNOH%<7IR/R*@[0TQ %6,
M?E?0*UEKUHG=P+#\HF'E]'R*S\&ROC%H274V^C/MYUS:O(#XT= ]>A<_"UDX
MO$LS>\/.F_D3^Z_2AA;"0D3U=D/5L&/W_8-TSU0#RAZ_(I('3.]&0N'154=S
MF%0?A;"?86L $'N0&BH]B?MW+_A+/#T%S)M%T SG!3Z79LY'%N)F;8@2GN[)
MR2%^^:J-TC]F$)_A[;CH2AQ0M 4JG1Y.?_$0^%:P'+$'/;=W_<G?_\-^.Y>)
M(=R/5VLL1'VF***M(LT</FM!;[CW7WN_Z&/.!7+@F:+&@^_04A#];-8Y+R77
M*5$;*N-LED&2J-/WZ]ZV#A5F#KAF<XD6&[.7VY,LSMU5B UMAZT9)>-C0["U
MPR=M+_2QWKLB(4?%LDC9K2W;(.5>M^FYD8_S=]DU@_AN+&6W^5PO#8DYR,FE
M+3R0AGV:EWK@Q<C8:S^3W/I4APM6^OUBJ/==!<U35S$-DM*DXP^$H<OX$<<2
MPSU53Q>6IQOI#GE!8;>UA/PL.H%6\8X;AM+F;S!+E]U*U;9 HM4X(X:K5I$>
M;[>/\LGO3O-.5^]"?15WO.D&42O=':A"_,R37HL>K*"?:<>"TWQ]^F0,:C6_
M1D4*]/W)QWT"[9!\9^J2%YG2E.J*ELC6TCG44F!]Z=;IR39 \RE-=^I"P4#F
MM2@)LVCE;7GO]W=\6,XA7UYB_F]87<T_K*ZD_Q];7; )LJA E^#L7'&J_?AV
MM2IP\F-7.7[BU#8J"WEJS8YZRCEFY@"DNY_YE,?>0LJ29 = K;W@;\=9.HTK
M_??%/J6IW6*;A3#XV9G+$].=UQ]>>Z_/CE)HMSAS;L0L,=TB,>\2YQ/#K\;;
M\1\K971XW5J&;S?(:+<I"U&HC&)**WVL9SIE,>-1(Z028SH_#)FVHJM[XNF!
MQL:=(D*<4D;Z)IQ21KS$T^@D2(V%B,E@$H#IL._ ZJT.I\4[$;6;RE<(_ R9
M\HZ29L=A4FF Q'A(;EM[73PFK<:VT[GU\@7IN+ZGK69/3Y7_LG[GIBU9+E4,
M<O?@]>>REZ5Z,I:/XV-]\(^4\#U$:$LM78.%J#8BB#C$7RP+P&[K!3'DAL2,
M&JL2U)8!RWOM M;6!L<?Q&_]=N")9_[!]D;KK10+!N\4;2N(&\8(3E3(!2W.
MX0:$"!TE>=>79)QOS<2-+?4ZI#_.K@NMC+N.$'%!OU;&;X=$)@8VHA_M$EW?
M2J)\NHNZAJM]->$B$]H[TS>R^:>5ZYJ5M_K*]ETOG^.%..M1N);05P8O%3.]
M-.1_L=K'2<P!XNWPD[+3>NIX\?BVNP5[0N3+"TO.'G/I*J,5)%PP\#XL)YY^
M6&GY;7[OTQJ-XC2N5D4&<\ 4,EC4$H;MIWM0)[K(F"$@=0FTH M!#>A]E0I4
ME;IE@%\1S>MD@>99"O8(L^(R:!_G;W;S<'.<$]ASA-<L25[NG=+B'$-P+TH.
M9A0U[B!VKM;_O!W4WUME0)*:9E*$AS;%*P=0Q(;B'_KQV[BH)+K8DI#;>R=>
M-4DB!CY@]DJKK(]6J'=/V4^A!9";^:9JK0^WRBC)**]N>D0W)I9>?OXFY-$>
MD7V"'F(/-N\/K<DU_5[A,MG7_?8U(UHQ0XJ[-9&N;# RMU*T( UM;J7,05N4
M*%URCPC2H!C=[ZM7&)E0-.3E+$X1Z9[AJWCK/7<K^JJV:'0WIJ2]R:;$YM.U
M*_?6%:C!]Q[%MJ!VHJX9]R62@R*QO-\M&X-Q=2W!!CN*LAPF-.M?E?&(:QF\
MD10I6/![,IZ'?>*'8@80KPT^') K @,I130%\"(I&3"\ZX^Z2F$A:JN4/\YW
M/M67C[3_Q>*4V5.]#3?XU/=.%P\&H#<7 SQ36KQM6$'P=K<>5;"YOC%8L<F?
M;T-9IR3L_J,EZJ[]]*D-$%:58"'"E#R(WH?U['O+,BI3\'<NQ!?AI#O=I*9N
M=$]BC;%?4,7G]@95R_7PD.PB&)X4"])L.AEW7^PR2EA+RUZY-Q+_RX3S=?'"
MTLCY2T-.3T,LCG\5R50>2;)H@;@[\CUPX'Z[&0]2'U[$0>OG]EN06E]]QB0D
M0%EYU;ZT^4:G>YF#C(Q82[Q ^/3'$/S_P]B;AT/]O?_C4RI))45V4Y$E(?MN
M6EY9DI0UZR2R30C)8,Q((<2$4,0D).MDCYC)GB1E&\8Z(V099BSCR2Q^X_5Z
M?Z[/Y_UY?Z_/]?MC+M=U+N<\[W.?>WG<Y]SGW$VK<V?P#QN=&=K(7A=#JE$&
MM;\3NA<A5@;W_VL558& E,!=^F8[6K\))W1%F7P/N _:3\SS$K_[?@<4S4U5
M86I]@.O@#@,6#+ M/FG3I@]/DJAE:%#Z5'4MSCMJ=IVI#OCX:/_C1!.=6U&6
M^.I'0/8.:/7>V4U?(-D\''(/V^S?K+$]QOQ! R= IK(G!79 ]S$C6KM7I&'P
MV"]:$RJ_F%>#@\E0P$Z1F_B0LO^^A)^5]>T*:>FO;LX9ITSQ'_;9"4[O@+:,
ML!0D9&$M&,O2NTU8M'AJN!]Q @@GCSMVXO8"!J0(/F?"S)K&.,R8RJJIF7BW
M YKXE*G.I[(9:*Z*BD1Q*34:E,"-YJ8ZG_[N"QZWWW#VOY[:6MLQ>0OO<900
MU%EUOTKM7$7RXT#KXX'[=<Q>3Q)H;^YMAM=NQ:O,Q#N7 49F*YNXWPBQ0@07
MH$/K9?-6/< +XR2]763J?NZ [D7(K)A7#)6=G)W0&;5-AVA]>W#KE91NU*4O
M'AUJ4$U@N_\: &,<8O_$'-57*/"NQ8E0YRA!=VM=P /O'0UX[K-'80$:9:S6
MNWIBW*W<:331F4O"VMB1<$@,YBC'38F:TLYT?G$X;W@FP\Q<TSQ,0NEL4_C9
MB,7[GKRSPE=FGH82^4YYX! L_ YHZ@U;DE5B>*";NDD2,#Q.S2G5=_4GQY$Y
MUN7(4#+YR.5C7V3*?!XC1TZD:/F=36K7G[(-?/DN0WECI<AE_.%/>:O-ICF6
M7.#H[(:A!V>)+J)![ %HK=;S'9 ?^ A3!I"EKO*B]ML#?KU?,(?9TG!4N]:M
M[U6-:%2 X7,'82WY@\6E(B^SQ_>'H*@.O3$[H*-,*,V1?JV)!HU<][6$88EN
M5_N7SPX\_.3A[2O:>].C[NZ"Z;./AV\R\R--BB!W\( TIITO$E^=B*88T^:L
M 96"15U)=,A[;P?P%VAT%RE![-.RIE_*)NSDIWO$1T5B=CJ+4#\ 2\*WKDB,
M>8?D:%,UT67FN3ZF'_ZD+!#=[8X43IRI+/A^X*J,O+7:GC.DR+M[?@_US<SF
M$T:JZGKP'9M,GJB,E1,,TQ)F*8YB8/'#7Q1(I<L#NXF> ;09#%, 8@4$D3!\
MF)B&\Z@#DV3K(=O,\[8^]X22'5@?RQK,9I^.Y1V^Z/1 88Y/Q&L'Q,?D.+Q]
M=-;[8/\HS1=U7[ GD'T.IP 8?1^\U.^MULF !57[ASL@(QA6#7;JH,G=_"08
MW8[<^P7\& I^>!NA12-P))0)*QS]+E/7S[0GC3I?$\[OT"H-X6^(:=9_G.,S
M6T%%D^R>-8KY4Q?;H(<;(2@2 RJ[1!2<3=Q7^V#KNJCBQTH!YZ=[/X'E0<_O
M5A0N=_3VSWPO")DKP)^PJ,Y<13T,?;BZX,'D =2H65/8R"4FA#,@+H'T6=[7
MU;MLW5E3X=[K-I_<R;N)*Y$'9KL,:XANZL/32<)#<FXV-L(VMR*Y"W2K7[XI
M>'1=JEL@*EZN2&XWQE#X7_%*SG^$-'W?\)-">=I5?)N>J]KGY-[A/E#W_E?\
M\W_]<AL;'$U$0_Z4I%K90N.3U,.?HWK5F!^X9B!"',_N@/<"1Z($&BVF>O<#
M5YHW-6_Z^/H?SDS"/%P5GO8X9&KV4N3W7*1!M-T.*':9/21A$8D$<[3D_28'
M=2C,0(@W(C#BS.L\.Z!7C9/;(J7@V)S]-'P[6N0VPH"S[-V)C@Z#,JNE]Q4O
MCDL%+Y@< G6=-P'M-05YX*_GMC"U'+G%KX;Q?X[WK2683Q3.#3]?TRV,2SMG
M<\^=:#8;P0&;?!.L4M2?2[NG*U%9D^SK^1PR5MA#D/533,CN XPK.R 9NV2@
MCLW32=-K7O5Q.++9B7H:(BG7ITYO'&CDA4T/C]I':5CV-(PGAX(\5^[09>IW
MKV!5GEWA.(]6TB2%-XBVU^ RY!E_E7'^^TPWS=O/3+_GN(5F!VS:?I*;>;/G
MV4NI&_R(OAG;V<$1?+ML>:<3[0WTANK+F;/?LD)JXQQV0#F=.([7XS $!MX^
M]M_<\=HE%?F_2&V%^FSF48S%1>F0@=TCK[=>;,AL*'Y1,GP'!/D=T?V?,\YC
M@YL8' #[\PG'MW*42@O/? T]$I&_D4=Q6=\!#4P(_VL4\*(D)X2 Y$=T<0:9
M9)7R,;]"^'9 5"O.T%TO\536"K&3_10<NP,"Y)MV0+^_;56YL%)QLO 0^MT^
M#O%B%+NKAF*#-<H?B<3.$/G&XWZNZ5>$+]9;_>JB%R('P970=KX17ON?U<IQ
MQ-J$8*UGZA@*[XEWX]WG2AUK2<ROTZV>/_E77"+T8Q\OV%J[W5 R_U103@,R
MOLVY5]V02Y2]]<.I2![:]5EVS;,/LDM-Z[]1 R$Q=D UL:R#_TUTVII=,WC$
MCFS7B8UFZP(UI"-N5VO[#<'S>+^AZ8'R@B1OJ=7?B,O'M0X/)^)HMU)T%F.0
MO9C*R38TT>HR#?4,P5WB-?01+GLEPLY6M&:@HNI+\=)?CE(/>I[JJ]SJSPQ6
M/7HPCZ(S?S5<3]Z_4*,,Y?C.>W;LEMW(JG7J7 ,ZNZXN=QW/A(33*U:F_IW0
MR1KTO]%)PG!#7%$23!= 2(LB$DK+(N&?(.3]BW'9F@73V!.&.0FJE*GZZ#Q0
M!NA>I85/#[ #8@@B_%@YB+.%3#."V!6:T--@(^L*6NR3C6!\?\&C?<5;D0I*
M%Z<JH_W:WCQ^JIJT-UV19'V:H@QS7AFM82;BFMKQ=G1F_TS-RN\&S.5_B=]1
M/#7ROV7MUC]B$+0#.L/=N@-B"NR>^-V#HY:R. :6#:PQW(%P:YIQR_B55OJC
M,/.^T2Z9I@AU0T1!R'UT=[QYI^0GK%2_ON"T@6>G K7?E$H9_-$D\_:^6Q_I
M>779 _%<M&3NXU[7^/G"UD9!*W[+I]Y7?^14VH6%+;B>GXS+C4WTMLXXGYVZ
MW%N%^@^&O42U;N+_75L4OFF@ !EL.^;H@@J@UX879_//XU13.BEF5#:C\Y=Q
MF4"S]K'[S=K[J+\#ACY-1J$J\.WX1!?1(02*547"\ !6K:O5NG7/]7W+93#O
M+\EIR\\=&]&9/B4H\IL@'=C+MW K[7:'>,7X^*BS4-FVPZ;NV>?D/];/Q0M#
M[^/!&=^WI7;5S![U\_%_:YG9?RHC-L50#:&8-46(=Z7V(TRHZ'A2?472,L&!
M>J.Q(?KYKXI3OFD7Y\Y=VG=H >\Y.;P#(M=1^$B^,+(2FH,66UV.4]=\A_1=
MIPV\[ZN/>E\0ZU8]UOGHH.S,EZ]=(B+S&7Q4<WWPT,RU<Y@U34IYP@JE/JKG
M4RX95UYLVELYMJWU_S %IO^L,N1_$IEFJ(\X2A/Z CYV^T\#X7FC,IDWPLI"
MJ,&C@B01H+RTG'O>+O#K6\GBL,=.6L2FQ3R^ED:I^'?%OW*%A*H(S.\E<V^N
MQGR8'RB1)EQ9M@"0FQ2.2[[\/V1(^6^EV 'E<I-V0.Q#_J@MU4:N3GSEU97'
M>#<T-YL0"+#UGB&<2\S<)*,:O&UKA]?>KVF]NN+Y]8<F7Q,A"7%GG-YC)!0#
MAPB___,S828U8=+4V"BA+#M 1N+20#%!U=+%>ZFW'O^W18C< ;W^[^^@_XL<
MOO\F!Z%!QX8M(7D1AX#/C+_@27,M*&[],\0?N9YW-S,TR=L'-2_C0S?-S\AW
MA.VUJ/%U?/K)@L]\H.BR2OQ@+=$T8E8=>/+L7,]EP?S17V<'MGO_B\G_0Q(N
M<CC+\3K<;/?_:3[14W;-*S'XX\OZYOXT&#V%BF^% L;K],S!1G-]'PWYU@N:
M-+\TU1V0,G79+3E:8[8+GB('_SU6F.9_:_%V'RF'K\S!VO62SE69S9&%FA%F
MHF=V@(3NN?P2/4V"^="V'WJ7 _\_-(>$K0G_Q6'!P@[("@YE/Y[FF)?7L=M=
M.3N@WMG_\@;<_^8-.*.@8%P[(%6A_\%&+7I>DCF8XY]8YB3T-C=ZFNW*KO3$
MK+$PKAPIVY_,RK]WMX<#$U:#.K)".*/8G$ UN^*].CA?4VO& (J?.5PIWN+E
MN*6(DHD&(5[J-O&IR0[HMEHAAP6O-[I1S5"45_KBU.0!#NDXCHE**4)SQGW$
MRG6::=PMD,44&D>MVB!2.7,Q'%RQ89?^AJR1>!GAVCL@S/?M+OQ4&:;ZQ&$P
M-\"Q<?LWH<S46WBF8"H]$HD[1D6S0<ZH57-$WC^=K3\%G>'TDH..CG0RV9Z#
M%IP>+@"3B3D(<-0:Y(??DLGS!\YA.]_K<$ ^A@T:W^U<]5]?QO[&K,WP,H(T
M.6.4;B?CIXKP$J^"2)!#',J/].Z I*W-.0/^!?QA(11(_LR]'$SQ.W[KR3]3
M1V_LWB[%R$%JU_RWMGL+T4Q!KNED#I<<=[->]G,,<I? )!"ZV<E%:,%Q,, 7
M!0S;!/N*/;AB3&Q:P'\,]-]:CV,3>U!SBX8<6QV;S7S T;6_.W/M=A;,Y@1[
M<ICV'9# _,K[!4E1*KGS#.FY9M"3[1^P.>@_P@#Y&(C:6G_"@&GL3F&@:2!G
M==6L]I!^YWF[GYF)?N-B@74&Q@8*D%V2"R>:GJUV'.)UZ\Y0+_B^:=C"BH?X
M>O2;8UN@\=LYB_>?K2=:>LR"3?(-"(S2L(?SSR->^ZL'%7>?B+$5L;4:PHNG
MT/+N_ '.!?(51$0P^-AC_,-=NU4:APH3'K6%N92IH8H-]@6"EW,>XY]N3"=3
MG:ZVTG&RAQN)K%OTUR=#:\''6&+,UQN]_W%+ZN\T49-_I8E2)^,LI?&'$'9G
M+MSSY_&Y9[+"CE4,?PFAS?_]&A4TRXTM$#$D!*#[-\[\DQBJ_T_!A?*#V2F[
M&X^-]92_-TP=K A)&PUJR?O^R<K\SO&<*Z-J4T)+5ZA=R',(%.TZ7=/.[M?P
MO*UNQ/.,D(;L:59W.%QJ?WX0(+=\L?P*W9EC#I[ 3]#S!H,MCF B44*&XHNB
MMCG^,[_8YQ 0C'%FN-/CN;]&\Y.N=G5P+=,[-:P7+M5B:W= BJC3U]YL6=7.
MU?^3UXD[SHE]ITC0$6A;V-E-=!G>0YEX",(UKUN=B:R@B2,T3-<E#$V&%:H)
M%YQ-K)5FI'V5N/@R,AEZI,)VOCT(3P"5S[0"7,GASIZMVS.9SO-A:5G+2?!7
M[A>6#9J;N9\\<1;P,2H-?;N,[W7334[3ZE9>Z-A]7^L;*AM>1W%EA"(,62]7
MIJGL7&H0.0.M\?I\S[07_G C5W")V9&/TB(%+^Y':0C_Z8OIU-:077)DP-D_
M,'5SK:9L&7:OBW3#IUB+AI,-0ZDE]EDPBM)4^8H,/.Z4^$-WCRM/8K2U^]),
MK+.>.Q/'?N2?%2[2R#,(=*DF_D;J,P.I%DMK4SPX*8 ^:O^I*FE6S^L^$_)V
M;,$N0^WKJ*5<&27Y]R/945"@"2B3.CE2PC[4R]!B]X'%_2 >"9A]S,M \/2?
M*34B8$&.?3IJVMCT]$@[&:IZZ7E0S+DV]\B+&M4^_<$&V:SEMD"SD;71*_,M
M2!\WUL*6(SV1LW X=B^DRN)9C1B?(%,<:"WQ"I,IE,&0(>)>X"-^^3_7LYZB
M%(<<NYY? ^X_;Y$6L3P [[6GK; /76+H(7A8Z>K041XI0J,;B8\?:N_@Y=8<
M%N8T/M$5G'S,Y'V*4N#!<[<OZ-_)D;M="JD*FOUE#U'X@V-'7TMTN2?F0]_R
M84]/C-8-I3>>H-]E-7)3=*;#T?N5EWQI<Z3-D:7,.0:4C&K%+V6)//@2:JK\
MAI&O\]7I(7>.PL0:Q='HUDOK].]S/GU><MB,W?34_?ZL-/T@AI\+LCE3$1^7
MT?ZHCF"KLF@U_S'QS,+JQ&GI(=H-6541 ?%C;EQ2(C-!&R##]^^SKP47%36/
M&Q;<.%ZHQ:.@\O=6="?3#YBA?J;[ XXE'*'Z148O08]X/8BK,3<9Z0GX??K.
MVZT'4E_'DEN*-#H08:R2#4@LOG(=4HU?8E'-VL!"0C>COLU=I6Y&^\XXEC!@
MZ<Y5YU[E7+4QFKB$/G7TXMPAF]-BM?0:)K9NPOJTO'K*!'W++USW/PJ0E.0<
M)B@SS4@&6FVZ.8\#\L<F;[<'!!1,N/VH#KG8(=M)D]>S^%2,.G%P!_340Q^\
ME>2-VH;N]Q:8UA/^8?>>N!3>."VK8>G6L=\ANZ*OL8X42PEAZ#'O ^W3J$CP
M8>09F2+R2JS:%:'GZ]']?KFZ03V?NR7=*\X'SKFABCVYQ*?CMSXL*MEP0KE@
M-,S%Q>VG^SQ@8__CW/=8=$OQ=_B9NKA]:@^+5S>+?KL^M^O"U%@P!;NG)I?P
M#!-CAAQZ9'I:MLU"U#2WO)SHV;*RO[U$_5'^= "TNE-6W/WI.575P #K!:OW
M?:F3_M]?]1?=TA*LG1L(_"<]EX8?'F4?XF+H(<?##I1]0 @/;, ,'%LSHOK;
M#?EI1NE#HK4) 1,*KX2S\X]]NU:E-./ZB=R48M7SR)AD@7LOIHFY_/G-H#??
M:M'O^W:9S"!6B>$>Y _1R6B$#@W3V?UN CYI[RS;0JW-"@J@C[:H2GU7^81F
MS1_"-L%ZA&M"<#&/4D<'EM_K6YN_";#\:G:88=>-J5%F"EJ0E)<^,RZ-L+^?
M0(" ^ND=D##4"TJD>>,/,Z5.%G?[?HIJ/_(],.!YRK'(@[/E-D6_ZO0F72^_
M*4;(;?LV]#NM0=69NR7@BQ#[ !)ULL-%&?"E$L@VFW&-!XH1%M2"1LE?0/'(
MZY:G)\U/'=?2V7+7EG@ QRK4<?JL,D\U MF09C.+82UZ;FJ'9JU9:!#I+\".
M9R"W[A2_FF-$78_U*?2K<AWQ?GBIOON[F9+!T.TCMTK)X[5CC+?_9.G,-?+0
MCBN+(S3[V6<M2$="+IE1U%UP"61%R%)#]*O13YWZ>NB,4\OUV@:+')=^%SOJ
M3U*FC%,[&.3>YAXIE\K^\\'=B4I>S"N> FKJO_CK(^/M#[3F\)S:?NP89$S4
M#1DBU*514(V=Z3<PND0Z_O72E8)#H?E6[>>2,]U3K)\4&!ULU[_0>2#Y"N$_
MTG\^8,<7[7![P$ IXC['I:OP*K.D'>;:4 V],UOOBG9 HH;XW#_]XD$V]_0'
M7_?BPXI.<\73SH3=CW'9L+T^6_K-"/8- H,0UZ:,EVRHE1;/P=7<\;_['^)K
MSI:]T4P/=!J'.N%Y_/>I1/69=+Z=7[A85B#7G_C[Z\S+['=AY_].(FJ4I>_6
M7HN!"]$K:/<F(TDLC.$%ILY0V3H=7]>/.X<PP!AK#;DF7Z>:-IADAYCD^5%9
M-\:"7"@Z7WH>MI(LZI]7/_K[-*^SYO;K2.;B=]P%Y. DR/  PI3JWV(1CSEV
MPI0FU":V=9XI5:B9%:2"?ZVY[$S[J^NDEK*J*E=.3?4]06F,LQ#VKLX]Q0;8
MJE[]C:N[)VFODG"##E:3@OTG3JKF%9Z<B_<ZM5[F]BGF7Z\)H'O^.5&3_+^?
M$_A?9744_A_E=_[W<P+R_WI.8.1]TH1,IN>AXGH/OY9LI[EVEI ]3;D%>QP>
MTEI9';))%!QO>AG_P-8N.HV/M7[UJJEV?Z S_RVG/E/,:1\(U1I/[)[FCMLP
MN$+?R^&O[P+JI#[76UB(J$O1=!F4?#8C]EU3)C>/@O='"W%T6'S+U8GK/O87
M>+BE?NH;,.XSG0EXW\E][!\.V!:&/Y^WX5E )X3<8V$^]-:?X@NY&4_7WE]E
MDBK\EZO3W.^[-P[>T2Y78!]$TS)(USAAORY"BDJ?ZPBS26JB+D]$\':&F<^0
MKP3D+]BN?I5Q?!DHJBD=&OFQ5>' OB>9N>05 0#6@:+:8_<#><WL4Q6#ZJ.]
M(W6WPPVNW&@PG<I&U;B*)?],<WUA=$DC6/&:4XE->1-KB*4Q?D*(HI,S :6O
MNA3V3X+8FK#)8\BC<%3GI,C#(US-V[,UTA5FN<- RZA-79)-VJ!;_.J%H@?M
M BJ'5//3](O*2V[0=D#1"(L"J ]R'TTIK:P6TR3C>,12GE_&IC=].?]9;WE8
M,+8='#T!XL I5/-I_%T.!G8Y\[DQUF+(T,!I%&J(@=/7A+,L!^J*OSY571:Q
MO,2]C] //@KQ1#T%5W S3THY &"&,F $X0'T.L&5R[EEP)-6W8>]=)T-/6=S
M5[-)Q5>/U8RE%""VPCTZ1CU8FB-['*U%QJX=M<WO&QK=UN$8YF9#.J!,@[5)
MJ@,:GC0]\F9L-?3@A'X@KLC-D_Q!0\%,P]@54VMT4DOLHO24KRQWP<-,9323
MAZS(TWB+-"GJK;7MX-Y59+^@8K9WNMS=5J%S""^*$T?=@4_3(:SX'9 G-+$!
M,X+D QCD]"88C<<#!W-TOGS;<M498O'IQ05):P*([_P;DYO*%=LP^@]@=U.<
MP7JZ W)O"B+Y+VTP#($0VSI:8>*ZLSA3IX\)E<G.+R]X,.-+I.5Y,*3W^7E.
MA68%1'EE!B0@']FNO&?5_3R#4467(#-@ZX8+&>2Z)QN37(N2BD# M(28DZCS
MF[[0S$>Y$M_-SAG=EGKU:OKM]"ERXS2;A\$P 3;II2PT0HJS;)W;1FF^Y3"Z
M:D^PY[M6:<W<(;N+Q\RDG[^-EG BS$*9)V!?H(([H'N3P+F,-LQ(9[O+7@ \
ME64 I?MA;@_H2S @B[K1/Q(E6EQ>QI-GE"]7AQ0(Q[20\E9[PQBC[(.5J&D'
MS.$;J%DQ+?9+TQO6%(M,1CXAH[&?&9<*LUB)F.>$FD7D'=!)R%0QAFH+B49)
MZNM1#RVR#\Z11LLL.D(R:("F!>"U*"#Z7#,OW 3XZ+I'A4/P2%>GM-T(=!].
M%7$=#YPH8)JP/N)$O? 'F:8//$1[8V9H!;@"6&&R6NEMG$V\3D@'/W"K&C=A
MT@,'4SB041["2D<M%L;AU^,49O' ^9"H'9 7E@AA'S*GKM#O4C%/D(?@J:VJ
M"!7<X#J>%Q%&"#8S%[(9N$KL5#%9$LA*>/9N]5O)[_W)PZ"+I0/XX/VP>BTL
MX,CL [?KZ(U<E=TLV*[:T.03@/LL7H8*.,+C.\PU<M>,\B3ZU _H1^R +DA\
MCEB+7X,0K>C]@ 1#E?V=+<LJ1AB3$PP\6W$B?7[*KQ\JWB":*C/SS]^I4SS3
ML?KBJ-"#+FPO^NDDU4*9J+=KZ.%,2]8+Y'EV'X2+*1]0BK"N:*!ZQC1RD1<9
MDWS>49"J<4ALH=9EA5?D3RJ&=RR_%\G?.;@%BP?JJ57TF[0ZYO$L>@D+LZ$\
MC&J%\#%O46--LVX--$)(K#L+#?MT/WSTJ!MXV(6T?&TD77)&-W6-:RC;(B2G
MUQW31>0 *@HGY X8[& Y0K-Q:^O?%ND54&'$62JJO7=D!W3Y)\+.D^QL91ZS
M+=8KZG![!^3A.%;\N4I'J=)"]-,.R-BJ'@W:Q!H/(640>M2I1D,IVFR"*ROG
MEU(NO<=2&/>MCV\\3NO"L&-V?<?R"/8[F"@[!5F:I)Y@\^ 9>O/@*HM(?0Z=
M6DY S90SU#:VM?B=7LD\KA='HJ=FW#E@$> H"EZR8NBR1R:IMU'$?E-6 ?.8
MOMV[/TAAJMEM(.1F0^K2 ;*O[IR6\J$7E=>B3O%GZ:D.=Y@[7^V6/UO),15=
MEJCR&.M[O?MEB1P@NS<-W0]#\P-AO7_Y'Q]?3'\PW\7W9OMIQKF/I? ?J[\I
MHTE;[?<XH<M<"PH,-7P]Y1_'EAPJST,CTK>-:O9W%^^ X*5^)I(;0)]^< 28
M>7R%!&WI%81[MF&.Z2L7L/NVAYX4,=5^_D[QM6HW!/?_Q@>XGIRSR>HV^<7,
M"#[^K(6K/@J3SXDJX\&5D!;4$40X4,%P1YQB16\H/T;RTYQ$'V5-80X!K5<2
M+ AGD@10-=UGB\U.5\>;ZC<:]:2/XG.+Z:C&-_[O\+\S\64[H /6'.B0 +-C
M^T(:" QTW\U N;</Y$J[#\F]B_S[1T,39=G&,"AC/P?9Y$EC/;'"K'>HWX]J
M=D ?G5#;JM?6*[&;[7]^G&]EC3"3#L7+88OU_U5T_O_^E>(YIN2K)&I[%I7F
M8POEV,S??!!6$.1;).0LRGO^,A-.NP!9/YFU [JBL5OV]UAE_]5Z5A[S5K%&
M:9 /W9 O;3WXQ<.[4RJ2.Z"'2,.-U4**5< ,$T53G6/?347]\:AD[V?_Q AP
MY T;U^#? 7[2\-LV;.C5G(^SD7M=0UR,),^+8RZ:$A=/1>W9=^P@RTKD:=&K
M!P,?![(+SGDK.RKWNJUE:N0]Z14,+?GP8V5%!\P/O]O;)LIBUT_##GP:PFK(
M^]7 2MY=[WWTP\'(0W]YX@9L_02]MC\XVXW.Q7JY[G\8N*4QNEB4%]][-3F^
M;"EF'/0T^>MAN'08@0-'C^.GWF(.&TK[;'<F.K)YZJCL[@[1F<:24+(]TSXD
M^+Y,LDEX6O]W,[[7*;=5YD*D4WOL:'Q, 30YO8 Z31)ZK*]#[;_6YV]X9*(S
M)&]1=2$QL.'-L_BWIMSI.9;,QD@*H5:AN>W6=Y67#RH*HQ^.R\LL3WMZ:11D
M4\)#%RLH1K5'$^__-?/,RD9*P6NEQ,*Q!,I$U^$],)%(=2"#8X(%F0*L<D,^
M9.^V1Y9LM#O&G-H;Y5YK>.:7])3"=;O-]@<C:SQ<#USJL5*LV'5LC(L>*R/K
MRPZHZB7XD+^AQA4RCYCM+Z2<=\68Z8<1^:]) Z;]\DP3'JLW26ES;'Z.N6H?
M!93)0Q6[-8VH%M@#\^QSM+-9C@#&*;:#H!@0\>+ G\V+MON_Q;C;Z'UU>O.<
MD(;@8]4@]E#OCEYJ)$!<P0> NK8)(5S*8BM;U?_$V'P=_]?O]N9M 4;=#V_6
M[>^]".(2P1Y(OX4QXW70.*W1\[4OP7;6B= 0.*3G/*Z59V _*Z(/LWKPTO&&
M0S7[9)YO7M[$D+G4/'A$R@BX5PC_/,W=JOP,*0CX3N&3,D2[H-Q_7 RKS1)%
M!U2ZZA[?TY/6RP)Y!EA&!ZI!=9"CR*, =DHY:3/3N ,:+2E!C:D>>E"=;GC"
MN2'BRPBZ^G*3@,X^BC"(]A>TSB6#C!<$T!P_5TU8\I_JC=?%Q.E?U,#4:=8$
MY(UY5^W[Z[94YC[/\.#;!/Z*Q931!-%9B(\R$4\6H@31%-@G0]J.\)KWZ2?(
M+3UL$C*[^W.8V-EB)!'IS2=[_F+7'Q 9ER#?/%L=U.Y2*IH09?FYP?RJ]Q%_
M6)F5@\]RJ$B2E%)1VK<TG9(U%TU;7QWH1-_H_?[5BHW8]M#+'$!TG'FHDQVK
MS"K2V-T-'DKU;)N,GF;G0U@E4'6@D#Y-,XZ'N(T+T=6R2-%O1!\EE*"\C,GW
MANP+LNOT0CTFO^U!<H#V1-C#0C817*<5MP/R[>4'_-N09P&H)\F#.A3'>GU8
M,[/;A540LKQFJF+\D2,N3S9*'X3><#73*W2Y66WC4.FWZ"V=NC4<''18O++>
MTG(S6\ZX?,&\9A.\"W\5T$_>LUY O-6!QT50^S\0:GPAO68HPT>F/F9RB>!(
ME+[+]<F)9 K*_ .9RCF._':<*02P9)>FIS'B/@0N4O;40!X-%4/^:&U1U5O=
M86D\$?1F3AC[ @EBCTI*L[)QO(AK@&P>4[6:H,B6\=H!C6PZ9'=\'.IYKYQV
M'GFWXPQ*C^7WP-YPQ07NO]3.\(*GTNVHA>A&^;<(C2K:7F 'U*KJ13@QMG@$
M1M__,%E_9J_LFLF:6IU"?YG;&_?0=#5^=)%YEWP#HL+<X=&MII7R]&6<QVM;
M[\<M/YLO/_([GI4:TF@5YDB8C> I((XLH*B7*7>)[!&/.)S,D:^++Y!>Y^:6
MN-]+@ZG7\$2Q5K:4T0[HJ<O0)<U8\;;**PC7P]T<_[&B'_.%+2M;A#WQ=X+&
M_CY#84YXS^["\*/<>]3(0C'+&G.#[NF+G5H.9ENQ'D(GJ>E;USSUON@TBUM#
M!%!3[Y 7@.BI;-ZIWB?L_4#(%_P1=0-;":/I+SD2 _F/ALXF79QR=OF:->;.
MM:GJ..O[6^Z$H^+WXFLX274PWL;\QL(WA;3YLF6*>QDAR$&;*:C]LW1A!W3T
M>$),G>^:_:/:NC!,(%,-.,VX@>S%<^$]F]2FC%LES!R2P">4XY"G3&'Z_(\/
MS\^\>I8\4'&LYS37FV/R[&.L''5H-)CJD)5HNVF2>!]QZ]T$;/OHC!ARH(M!
MP5-XM+1J:= L2"V&(E2$'-L!":,[E"7AYPRXNOM=*_K7%23NFI*K8E2><_-*
M+N4@_V#-:02F &-:-E$=$CTY8GBPYB?3AIHSI!"AW!%7IM&Z4)%O)F)*^7YM
M[Z>+M_WOOUF?2M+^K7])R:>O,BW84JV6-C>HN>+ID=(/V] ,K;TEZA/EVY$A
ME?!GS*76%E<74C\-K5:.-8['Z0+3#D!BH49'302Y9%Y#7NE5=92% <XIYZ(P
MZ.@7NS&,X#U6ICX/!_>_ M2$.GJYX'EMNA*S'_L3N5KJ:,2:P=D12*AZDK"K
M4  7MVQ?HQ 9S!0((4VV]0HZ(<QI: X8)[%SIV$E"&=XBK^P"RLI]..E''-M
MHS/)];T_;J=&W9ZRA;9: '+((I)_U"UV+U0,Y0$YS+2D%KPO8Q7F#4_ ZD2O
M9[K/Q"F(O\A+%?K^19;+FQBH73[FP2WQ_!MU72KFI83(I6\_Y+ND^V="YAO\
M.@W$;87X7MNTZ2Y<*\XNQWSNJ=/$R,*R('4K2XE4--UIL%&,[/\X(P-/30 8
MK<F+HL$YA764DZ0T,=C4869YTR<=P5_L3DRMQ=(@:65DTX65L .ZC]WOHR6Y
MGR99KMSOU'?)LS)K$[7(C[Q;_*LD!C3]PIKF(L:XP1Y"G<##L,^2.=&43,9[
M+WI#Q-,P5"Q"X]W<4H--YE$IRXM*G9_O<$6"0'=K# 79 Q@>-ABA'TO:;-L!
M#8>TH/AQ/:BS@^4U6G%*U;"-<?2XF4:EFH5P<TL%R+,P;,/G#@V>)!I]V%?G
M1DC3.X)JE9_2<E=- 2,'-?1Q/6C2]VEF_#6"]VJ=>\'[>0.+#[M/5.Q["RB0
ME$<M2/A8?3WR# $GRKQ843]4Z@X=-P\^TNCB^6*XXXH?^CQ(S^SAF<\K0D#(
M%/J9+TX18<AZJP$=*;E$96/<X(82V"<(L\+.<GNG2XW&$ATB[BE&1"WYKL/7
MIG)@T[UBJ&8SO#=8F!E$Q71"CWI-@*D8I@(#5067;0F[[ZL1G59OF6(LK^?@
MK\)C[%I-Z1C/YS*EV=%G 1N:TIP+32F;0^@8$)X/X-M>?,O,2%#2OQ42(6HF
MQYKY;JLLVB[>EM+\^*M;BNGB6LTJ3J;MVM.%>GNCB15%\E9YUM"Y9<W/=A0W
M8NXK]Y?W;"X940K+E@A*15[CV,J?VYG^(&].I,8!HJ\P5?ZM"8L=,00G(.UL
M?K]\,W_-.""[BC4AL"41_$ 0P\P9<0"(]69H<HPJM^)#CX^?8JUI9Y]+RL=,
M?QVK4UJ]D':[ZW&=U(SOR+0@U;"*$0ZP=T!T-RK?4FL>?"_!#!K;L.:S[9\@
M-?@]9>SZO1P;*_\94*1(!4:EJNYMKP1?&Q20VXPR/ ^D*,?AA2!3;S!\B%O3
MOVM,WM/N$>*QIVL:@IU+SA,#<^.MZJJJ'LU%'H!_3]5_^9M<\&W!YE$B=D6C
M6T'G*F(E>/A"_7OK#_W/,V=O1GUN2LORTZJ*L#.W<*9Z/F4+(;]#/ZXD[8!\
M,""X4*NA-FT?_IB2OA[)K/>XP_M<-]_[J:KGV5 %&9L03YS1484J#LHQ9O>S
MSP%UC*M 40WX"6XO=3[K"]8P=P=T</:9%./J@'YH"69#I>OS;#02F@:;48[<
M =7UQK&/,)5ILLW*DLP#U,DV92[@'77"!7YCSBK+S$PA:K3.T?S0Y[_JN0Z!
MI+@.GR.T3 )R+O54&/UI'4"C8N@^5'1,=;>SP#R8&N6]_;SGR&#ND52#4?D4
M^RX_CWO2E)N7VA^159U:^<5M= =F='K"4P-MS=(<-'&;SF41?D']WS]:LZ*O
M63Z7$@G_968[EE,TZF<W^76;$VU-H]XC!R$G#37AA=.]+<JQFZGS.)XLAE*W
M.36QT3:]0\?I? F_K4W6T*4HF&'K%"%Z!P13!F0*(YF7J/@O#C9USQLUIA4B
M>)WJ^]:'IS/AR_?XI5,%]F R$E9./$YUT:,6L@]=Y6[F P/3G2B.870W.'&E
MBE88LP.J!+<^ /IFO2@BKU\O-VZY>B2_JF!-#(+N[%6Q0;E" 'FA-LBP#,&I
MDKH#:OD,%KF]B/<,51^E/!@N:_PUMUG<(A)R_(+*X\2WLP4SH>V&]XTDLQ*B
M\DDGA\KEB]H7??T@V)G5E ('GVN6Q?E](]?&L'ZQXW:8JKFE7V0L\;,CX/T.
MH4]-K@3 U*&]KK@D,3,8Q=:D56'R*VCB68*8FF' K(H&"5JM@6X!"R';D&<(
M. UX"1U5!^2]6TSN)@4#$#*O^,3PYX[W0E$']@_[(=Y("CHF747,4.O8A_;3
MLDB>E/WD2:(J^.B?[<'.I&4E=(*^6DF51L%,]4KJ??'#'ZZV*-QY+O<MN?TN
MTX[UGGT<OM(2DG,$,&/L!:1(_0MV%;U%\"C(<6>8T(</H[4.KW]=_> 6V:RM
MD)P$G\M-]AQ&W..V#/26TRLQM OOT>NRU]R6#<[]I3\J5Q1;G"M<YI[B7>ZU
M6B"12N@:=;ZQ[_I^Y3<UV;MGY805:/$:)F=5S?B'@_Y,Z4H-XQ<='Z;3FIQI
M&/AK3M$S CN!YK3]$'_^:RT=K0/3HR#7.6U)#WY[H-]4AW;;3\(V\SAM0;%2
MZHB9O!\./QC0)C"G[8V.2-Z<HF3@4 B1]8?3)D[ZV@/6\5I+K\(15HPY;7-'
MC;Q#IS;R_ZW%:ZO;3*+_(OFV<]K+&1,#!?5Q!N$MXB@@3X8DA*T_:/59]*CD
MTS1O*CE\0RGI9$*1#5&.P!==]JRXJ-_N_G8)787UUE */C>%>8[83VY2A75+
M:#4W8(8W0L66^2J^[?L+T]1I<5%A/8PK2[N7I0:=@4H W%,43*M%)$[Z8V7U
ML7> L97VG#0KZ89%4T0<-S/,> ?D1-BR(]<OGTD_][GHAGY1$WI(-5/PPGJ:
M;LJLM__:OY]48T_*EOU=-ND;)'OW(H^WG:Q&@UKRJC)3L(K-LTGCIL\#OJ0C
M%E,9;>&HP\ F"1]/HG$_]=<X^#R]TLG()LJ$V^+UL9AF4)(1#U:1]0P_E;<#
MJA&*9QL L6R>W4N8>P"-0B"(_"B#I*/A#''XJ:3?+>$Q</K 39V1')-M_L=0
M*^00JJJW YM(US7? 7V!$!GMX(/,2^^ZY&-O_EK/,K_Q@^(NG]90^=E*G'%9
M(O:<=86.SJDMS%(/QY/TH:=V0!T&0?3\W02W*S#,2=QY6(,L73]'94@]W%E3
M3.'TFZN^]WSV/4@*_?W[-RW5B59@E>D#X;5L6!Z[G[FT ML2^U9@:*+)FH&%
M*L&J&65LSUD.D+G2CJ\%<XRX3&];[P@O/825Z(\PA4U;B,%J/<E*N61>;?5L
M@T(3R[]23OKKO!;@:GEAA@YCX$G&;;O/PC2?P=_KC4%5=K:!HU$"S/"BVP!*
MRR&C%05R6CSYJ[MQQ0Z.'V1V1H9*96Z@ %F^)1%7SEQ6 *$B!'\_4J:'_&D#
M+ 2%88AJ\V=Z\K3VJLS</]Z5C8-.?/T1=MBNZ1K^Q^>B7VG:A2+A/9>T_)(=
M'RX.S*:9?+.T1'_ND<DHF9QM $/8@] Z0HO_2 C]&I28T>F +/"4+"QH58YE
MJA7;U^ *0D/T7=]5>XG-F@9>#-8O/QIF]PU%->&+G-!C14+<^9Y!:W9 %%[J
M9ILE_ G9ME;_:NC4).^?2I>%D^FA0?L4[F/4KEW_T<Y][M"3KQJ+4.I-9>"L
M9QMTU(T>2PWIG#S"'MYTX4'M;1%KW1:?X*H9*CO5.&;:L+I<P*^VW@&,BETZ
MT 2C.P$B# <F&#]8R"J ^)FA$VHW7W1D.I=R /K#GH/>RZ5FVC"E>V,7+HP=
M#K@J/)!^IL"HWO&&RDB!V"2NC+W'P7KPX"6]DO=#=?[K9C0)A@%[!+F7]0XA
MB(6S)TF]:/T3A?!@-/T)TY3ZAJ@@P+^5>(X'W2/Z0<<O"B?&2E\WMV ?<N-(
MJ ^&?4B(9+ W',SQ#X?ON_]"*)3VB%S!CD?#B;?7AE2:DE#CV!K(5"ZT4CD.
MXJ<\@K5FO:GF2])B[XEU:'BZT%";_3[A?7W-97N*O?XPVU@OQ#7F\E04C^ ,
MIA++/+%([V.]$FO!':O@^-^,KB* N]70R?@+G;/DZWH'E\M>HHJT5#S<98M2
MSW9U2:>8>PL/IFNJO7D8TVON/O@FI^ED=WW6[^WJO)-8Q:$&Q:7JQ;%I_%0=
MOCH[DRFR XHY -B][2+[QTT*Y8HB4]_:EV]65WON69[M'+OT)"J,A+[HXR^^
M&ZH:GH8GL'D2J7-T&:IL&T7Y*DWHB8:SLEVJP^!Y%_)XN>_(3/(CJ;V70J9S
MHCXL0*G&*T0W,U8YTYOASCS/H3QM$HYJEU3^_/(\ <.CWN-@KMN&7RXEA7<Y
MG3%Z[/;MW$G>7BN7F6)D-[0&64^5O4:]@>7P]C!-'W),/>):^%>DE+<D;Q_%
MDN+L;#FQ>'UXJ/^OQ[%@A>.1R]P: G^^%8BFE'#WR KE.5Z=D(?UAX0[#168
M=-Q,U%&Z/1F^<M9C(ON1OL64,J6*0\XY#CE1\SN@CWR4=_I29'FF.6E+ WH8
M^-S<@*CU?C:0*O[BLR;WM[&Y<@/8 I38/5V>S%!G_S!4 >;+3$4[24T'R,L:
MR1\E;[Y*1 F=4^A">5@ ,G\ ,]KR(KV&E8OR<@XBS[7S)FHQ= EM#1VIOH6.
M\_3"TD=#CUJ[GR4WWPF=>YR:TTEGLA)_LQJ0^[2^Z&'BM21/]BMMA#N6W84Y
MJSO54!HMFLHJ9F6^ ,WWWX2)3MQLU\>G;&8UX-TG,I;[=$CG>$5Z_ ,<;] =
MF%D0H6!E8CC]%M5N*8@*F\YX8F@P'X*7U)>E!:)$X*FF23_F_62<+P?07SE<
M.988;RSQ$:*RS^B+I\8V'\./W6>HRRK8 7FOC$S3#0 ]6H@]%?V$K>2UMCAQ
MAL8=XV?>M-&3,MIU9O2*MM@[::,OE:3'4GVXST K0P&A ;0SU!>A59)%A:V>
M>8N2(KY"E&/$(KB42BCLE(B(0O."C@1L3@<RE9@^27W+/@D7,F=]J!E7)LLV
M%^7[[T58]JUKI\/@(W&K'M7IIL?A7[2)3GM5^?85=;DN6OD=<3ET*RT]PS2P
M.HTAU[2A01]8.*M'?)3R>:@'Y[[B1RFKUE]A'VIE"'CC#T*FTL''JK& %R0N
MYU0%E7'UPY^?0$)[BI,)ST.C*+*37\/3]//'KU/NJ/1]0J%S]A @[A#@U$O#
MW1E7D05T\7'JD[P+QWV$)E3KTYT-\L/OP<^/78!Y'90.]0J(9UR##-MQ B]^
M3KPIPNY%U: HE\C0N#I#[9I5#<@QY_E'F3XCD9 0NJ.9.__%/:W@QMO/4X=#
M<64<'<T"4J=[AY5M6-&&2LA1A[JXZLU/_5:MNC.=4;Z*DU<K*A]Z4?YZ\/7]
M5/8KU:[3?CEO>JYK6$P&*KKG>B)[G%'.\7D.& U9K7RG\J9'*,Q$J%$J+8%<
MMS3(40X]0(QL 4;8$?P0>VB?2>JB]]-U:ZO4TVV);9K)'Y.E'@VGZ)V_\U'$
M3><'+!/@IO4[ 8541WH"J]Y0C]V/E*.B(S=6XM(;H$]6SF^(R#A#;E3CHA'=
M<DZJ"@T?[MQ2O1%&&,#4A3"/=[>@ZOB6NJ8PD7:HD_Z-BL7P0PM]OKSM0PZW
M<[R^7P@]KX_75-6*+&N-*HT/;?=@FG(4S XAX0_(=#QA<-4E:,C=?ZC7HVX/
MY'0(QD]!:Q8\UKK/9N@5!'VL$/XRWN%38,%/.;=:DO\[MWS!TISU;=ZIQSIO
M*??[$A&ME1KO';%,J%@#-T.(CZ Q**H5- I_!.\!B9NLWF2>!@M(-WVDI6-H
M+/^G#NAO^EEE&LO;(.GSUQTO&KH$O5!P9/,\88@"BIRP[N,.J'JC#2.$E%%F
M*H!/>(?%9)ZFM;=D.S^O4W(;"-@!@2L2(_<A0=(AV-)U/D *TTZQHS_C0%)S
M]B\\]1;T).(:3:@%-B]F5C.@+U3H33_NH!IY.HGW<HYUK(]_=J9M1-ZI.W:V
M>.IUL  @1&<.[6X81D)KRNNF/H/%S>_N@(XSN<'1][%ES,NU;<FB8Q9KQ -=
M8[^*4-D?6[4E%86O:9S:+K@E.YHYAIX9<>G,/9?\TD>VZN:CY7Y$]VQ924WO
M]R*4+RJ> Y#6F Y )WE2D#WX"SYZE:99Y$HMM !42"7SC1KO(]Y4CG8^4NSH
MCO7DG>79<^I$I\_F"O$SN9<I "-CE_@8.DP'&N:)X3GO!IOO?BBO(\JDGL:&
MD+C&3UV)9TU:XG+Y/GYM!IWZ-"VX[H-J/HM39DH">63T260KGGJS5PAQFMJ;
MI#&O@1:$*T'VSX?]Y@M1\/"L2M_@M4_O?GCTDLYOD$*?H0:R$U^-B6-+ I!6
M#(C#_=P<7:ID$RGB_/ D//7FSW56."/BMLP65K'\A5'_C*F]D%_/$JA3(-<H
M_T'M(GR^H!R+;"@D..(Z4HKX2EVV'9SICRI'C1K\_68MF,=;R75?\ G0RC%=
M[-(.B#;9(:G_Z_Z&:=GS'= Q)5%G-[,7^V6^S;SQ\[P^%^3^8MP<8<.XB7
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M)2Y7B4 >,OXZ[AAPI3-G'^"=#[<@H]KEF;[8$8>E07V;H/SFN]O//\>I1N2
MI!+*]V)!>PAEH3)%C$/SVVBF@)8%"V_1%C<T;4&]CI.4%&)W[Y<^.K+&W &I
M27$!FDB-<8=$G[2IK6I+OT6CU 2SI@VON4++-W)=@8ON94WCA/&!K03VP4$A
MIA**Z#F-I;C2@BS19D!5>-G[:/+*7H=1]0=_ D9)4L3O0=K^RF>N@U"B"5\X
M/KCMFJ3V--MK',-.B,&E !RSO8_5CSR!G)A08=4P>6E&X7I0":\*!R"UV:R
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M>;]#!XK"[=]K?E:-C4:D8MGQSQP+\@;@N%@<++8-UW2 Z^7J=ZHAL(W"<0[
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M,W'U^HL'[0DV;-N?+BL?<YD1C *.3C($Y,<?^[ @Q(0J @<XY(</%[(I0^T
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MW8 (N;5_H1::OSORW8SA>.LN7XR<HWF)OU9\GYP]G^" JGMS:.J:QTA_&F)
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M2_#II%\JKS"]0^_OH;]'4UF0K9S!(NG,]#>)4EZHJ-)WMV\W2K0F/;)]0#^
MMJ80YKSH?N!0@NV>15?,?D!'6(667^(>7[S^(L!6KTWG7'S<#Q/<S]&H[5K6
MHPN,O>&T66:2IMTX'=<W '*)I0#W:DA[RIU]""Y^:#QW:FGYH]:XEVD^>Z\S
M<K.^;Q^(6"HAW@$*P1U)8[Y8.Q@_V(3GQJB.],XB]C ,MA.HLN3M)#O:  NR
MAT_^A?(=P?$=T./;=W)_>+G7$%Y8>RE237CQ0\?W)=>TRHELJ2]A.=K.-I<R
MU-X8L2 />ADM/: *IA6SFXD#!3 #VB+,%$VH%W7R+#"N%LG0'ROS]]B=KO**
M,7:[Q+=J\)+N@;R;47OT&ZSH2)#KWCA^-]@V4@*=0XP-G0,U6H,KCW<GV%Q+
MN]'=4R)FKF?6D^IY]A&3+#L'#\53C&!]X63>N:9L3(OJQLYLN8S<]#%UY6M>
M35B> >YL[Y/WD>[[#[J.CA5^V!]%'#\/[FA(]VVE[:?PSA520\9S5B;#M85'
M_ E5L+WE6AG,J 4CKUCTS:O#EP,^'2PY)5PE2,C/-+I>7&YWRE"J4/]N4:6^
M@6V)4'&&<7M%^M&6$_3LF>172<CS\_D9O>3CEC7T@"=8;YA/ PI>7:G!'E3@
MO<TSL^]X&=0.[/*XJPUICDI7!D<J>:G%2>\Q[=B2"5*DLJ&TN%%X"AI6TF[X
M0PBU?GG8/O+@E.] ;'<I 3BJ.Q?G1?? -%;*,9\?+T=!0VY3E<UGQ0OE0C]:
MWQ.LO6=?>T#-L:EA^( +M7/FUDF3"'-"1C/ZR:>69*C83OVIQ$Y :;RAKK7?
MI-H*.R=!B:6A@=5L7P'?V0NXRUVYQQ-:@F(,3MDMV9?83;100QPB]+BR@R3W
M[_$7HF&H/0VXOGL@UU@.IAISA/E.TXNJ5%5Y!' 9EBI,(!])X9F8#_HYK?;^
M;IV 2SYFCJQB=I'GX:EFOYXH[&C"Z80(M"5=$8C35CSK1BJ<C*,]-PJSIJ/L
MKV9\0;=]MV](/D_Q6+!1K=C(K%O931I-[X91KBA0M8_.SX%04G!K$ M2\-G[
MEKTV%O_C!N^P_]"KTB[3#&.S]!.+F5C*!SKI28IQ8H9C^\D2X!F1P?N5K6FE
M?:J@.'&V>@ST1OL"0Y1)6BMUM::7P4L5L^TLXN&L4JQRYNE.X7F_5S-A\7F_
M]7-+=-$>69WL_.<_Y1KRT7>9Y5AG%!1LQ.?+U[MJD(L+7\]J:P$IZ99 B^'V
MM7DA<UQKE+K$"SL9<361P<>N&CC!%;6Y%^P.%'7"'%"]3>2,N5?WJ/$';L%#
M16GY[W1SCX3=M-[R "5P:)<M\GZ29GGL1Q_'U[DP8S:%BDC1D+D>^FG&;S"H
MJSDBP%:9V..F @=TK^7FY5\N$#:'P5:WSG^ZU1JQK/+2V>QQBB"%8-?S'@.K
MP7[J3G=1D5;7&LAT/:V\AN6O<=/>@38 V+IYVRS0-HK8BFG3/@*@[*1KF"K$
M>>NJX!TKEF.]28<#R=>^[V-!5'>ZE^6=W#%KAMD%]D&)6'8X8$<8.$_S!@*H
MD]>IG&':$ ,OYS'8D_;KS[HD2U!:$HI&SQWB##^B3L:L/8UXNLU?A2H/[D12
MP]B!0 >U9+Z)(D$K2ZK2EJ4>B73.F/9FVXB(]/GW.T6W/;W>(/G\@_FG@SQ!
M\'M&P&TVJQZU@P? >H00UK$)'[$JVA"EK4(<&HFL/(1PMEOM*?Q-+:?TP\#>
M^+O\F+OS2_>N4VO($D'N^H2[+CW#1A:19988AWQ"R'KM;6FL'Z]KC$$B\R>:
MD^[OJ]8 /0"S(_3&CH?40ONER7+U1'(KOU.IT>ML\N4:@9:Y!I,GFG>:,&HW
MC"R#!3$F8>LCM'2J=$,K!/,-P4$:9=N.;>PP!O?$7+7R> &I$WV3:G"M^U Y
M]0)-(4'[LH_A#M.GL0&'WTYL\5=? !6Q50=;ZQ"]&F,6<RFWJ<W+> 'T(5)^
M9[G\N)/G34D'6M\US@<.L<];YN9Y7[Z;S$&B/=@B=T;; //I#'6 2,!T(=B1
M_ %ML2)V@5X[0U; .^&<\3V!8C':\[PS_?OY9YL]6\(CG1<;AKP$$FWL7!-2
MN^;NR829CGL3OK0OQBUCO5_Y\\H TE0AVB-F*&PTJQ3%X)^M)1651( ROMP-
M,-[;U.TA6*HHJ#%OIU\6T5IAV*X3?.'(]NHXR';(KESK)K87%+N.90@HT;J!
MA"RT/14W3R?SP#Z1N,"3B'YLM>BW9B^U)T\-?NBCO-1?*?Q6/Q.=8BGH[OXH
M<WV2QI9DX%W?ID_X(O9?\[%T,_!;#-H02/$88T'F#&'&)=\DVI>9)YKN'2BF
M-;82H\8_Q*M+Y4=T]S#X4;2MY<P 3=YQ+.<PXS*NMJ$.U"JGBEZ_F)Z$*'@_
M\_#<V>A5P;[5 J7DP&312+V6W82^B!R"K2<9_^""UZQQG$@]OM^C\I6Z5:Q-
M[OQDY[J>N\)% 8N;M7XA?XI'X\#FD-7$AO9?MPZ5NHHLB#^^:5'WVPWLT"V!
MJQ?=7P5LK!?]3S]GIR]RID-\F2/K]2R(;Y=(J6B%SQ^6H#=7GLU>;$*VVRCT
M?K$6=* 3K=R(#JBRC0T%)HK1+<!"+?=K)PN?8(1<_/"YG"GOEZ(4:)\TK:L#
ME!W4I_20Y>;,P<,E+]K;)_(RW[V6%IZ3Y,A:G=$(F$$4W6D5"D2%J<+:OD\O
M$YHLO<2&E&KAF<X]<)Y:M8OD>-5#<8_L]^B>1]C5W#?<3X[TN]NN?P3OF+DD
M0G.VD,W1\>C2&/*Q@A*,]\_7F27EH!?HPF!?-T+P^"B HNY=.T3=I4!N_Z'3
M7S+#"49PO%OH]"&\D5+_;A$=5G7KI'"(3D&A;G9075M]FYFSQMMS0RYJT\9J
M5I'KYAZGV?%;Z*HSW.H"G:ASJ^VBP):#F\%SB%6<]LIY#C%R"".&M _;FY&%
MG=Y/_+F'[5B^QZXT8^-\L76\_P7PT+6_;4A9*N0-AO6<S^9FZ$ZO1\,WP^=D
M[.P5_6\]6XT^;P1JOT-B3_T+-/M?EJL/6__YD2\7G?TZG-M7WG;71B<7-= [
MES8#Z1S^0SD#LP9Z0Y5%19^YCKYY5KSEGR$=U.E=C/2E*B"!!3G<":/M9T>X
MRY5<PT9QC]C*\>([[)QZ.CL:10ND4OEA <GSL)&L#O_^PE^7M0_)5;:;NTLV
M%W+]AK5V@9]MW>)L;5=N;7X77?[2_FM=NG!SE3J'[& 1DVW E/D:9X68MN%3
MDMW86B*C7VKJF,Z.MY6Z$YG.#3DJ,]]XM)R%2-W/?@%P.-R*>I;=_=0SW;8(
MLO[4\]W,V?;TE:-W_Q(Q=PG^=<4Z%ZU+?P\B$F7PU-39=?%(>:ML-41UCD%W
M5G,/A;!7.D,N;'$UJ\!_H3['8#CK\RI)=%KG;F^._')6A^?&FOJE'+5+_=N-
M-R$JNAP0LV9O<Y^\:,S>W%?RS]TE[V8N11%#):";1V1>LEF>6 $2+QBX__ZH
MS/G8=+U7,LH;.TR,?]M8GX853#)>GLAD06YM[BV)_^?>$CSMOSXI$_OKI(QH
M X<8<E+.#N2">&+#H5!MX28*X2Z:EW([BL1\7=ISNK5?SDUZ$4V29D)1T268
M:262ALY)3#CZ1L\D+.HL._;Z!\X[LM-%ZH'!%T6L"E+4)"Q.+X/1ACBRHH4'
M=[:R#8DQ975^C7YRE@41LP<,U1YI7AV[%I%\B"+WH^#$]V)]N:"N]]GNAW%?
MPWQ%;.P7&S2"=YI<U\5A1_,QVFRQWT ]8D&*.6MX^W9J7B7C(I(5\RG# 91%
M.%0JPL/&1O^T;MF5F&^Y:N?4G9ZA&=$1^$2&QDWY.3NZT,:NS, 8P%U96ZBK
MDGNZDA.80.["RDX7]H\;=0WNSG&^2U:U:PR>*).[!:C.#,,!*7D&/VU1_5GM
M2)%CD(W]H&H<W6:ZQ5_VK>FX3('!A73A=6UGZ=6TQ!6%#/G!8\0'F2H_/J)0
ML1T_?_J_HH2#7"'4)AV@8HP4B*=<P?=JF -"F;[]*SF:T)P!WYFFVD0Y9J--
MTYW5^,]"T1H/!^SLJQIX8L/6E6AO@ GH7!]=P[=I?#EYO^M-M,380(X%7<ZM
M'$]<4TA89#3G%)ZJG\\0#ZZ\PN[29R"U&L^WS(ZV$04+@6B#F_>IO+50X2(>
M^,4V5[>M">Y]?2W2'\N.OK /M3/>]7A;TY9DY !V]-T7MI';.@9\%H.^P(C-
M/,33O5TF<J17G V=.I#=W3T(:W3DT3H#OAT5)OHDV3*,1O)-NAAF&$\Q@??;
MU0YS=X-2V"II3])O##6J3>)PZW@CR8E'PRSF2[>!=[P(YE.\1],AA\4>-]-<
M!K[THC_2@RH_5O<LNLYK?&B?6N)TSDU+E6NFY3/N;1#K!,ZL*-UTM 6;'APS
M0EL*+0E84\;'+9ZPK? ;Q#[->^DS4%ZYK;#=:/B[:Y6Q#K=+0A.:]%Y;8CVW
M=S8E[VQ!?H>QW;0\Q[E)Z@CM(K, YH0+JQ3\V*UI/08/ V$?*6Z9VNF*>-Y6
M%RNG'X5F-_(:$=M>[BJ&Y&3?[<@\.J"7S0[\]YK/^^NG[C0-45EQE>J?ARW"
M'!@7R2/<OKI&8"\5\81MKWM.L54Y^;RP=M++ -LM[)&LR2S4O$T_ %9ACC.S
M*[?5C W=,VVS[]C^O+3TL]?-TX,SJMTMUG-+.LV/7SP9.+CV4%KB($.7K@,D
MP@>@HR5S!+KV(*89W 9D4I7J85L;PI2H(74^I=A@.=?NX:_7#36]JY(7Q])D
MB:;\PH,-6SZNM>IWHZVA#+$UN@7Z&'5^,CC'%2U$S>*1:>FI\JM=M=).0C$)
M;_6^]<'5E[1;(N;SBD]J*9@<_;($SM+;8\*YE!YG7&)!D%C9NB+,O*]C RA
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M30_W]73&P#C])'SA?EGQ>/+'.F<1G5:;4!<KYX]W?[40.382CN5B.*/[$8_
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M ;CKJMUHVC\?3X1V#NY^'.+ZG-K%_7?8E</L;LSZ V(^*_:?2QI.?ZY=UW!
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MQKS*K#RF$95A#H04H9L5R=:NNR7BS;[08IY2-M7C>04>'TV][ @ZH% O9!.
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M_.,WPP'(4P.;OLL<T#,4_TBEZ\:-%L2!LMWT.N;$1=@^B1MJZHT_+AL+T^,
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M%[>#(QJ9+VH4QY>)GC0,Q;Z O'PT8*1,2X*T5MEHTU?YL3OL4Q)V2=E&0L[
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M2*"),;/+QL+Q!Z4HOX)X<*/'*76]O]HMFD^X.O!>K!74CVTO#_5QR.B#$;"
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MC/--6JR^;7)_X7VSUUZY)/%5F-Y,N<AF5THMO+;(N?\B,T]['=_A3=X''<=
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M:+8F-I%<\8/931VNE0Z[2C(<E:L=MWC;:77',WK3RTR"[=LUICW3WG^ZYW2
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M8>I[NE-9A![&R,U>\[+36GCY':3MC6W/+C02>EN!4ZH.VMN7CHFH6=K=)%I
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M=FI%RJ?$ /%]BF_65 Z*W3QE2 7 ??I$D7A,6=%2,V;(!]J@2?.2"E@.,73
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M.ESG?3 YE3+SPRAL72'K$C==%1>S\E:CLL3MS:72304?O5@\A/8AU* %RW(
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M 7AX>,![W O S@ RP"U"0B)"@EM$1$3$Q+=NDU#>);ESAX2&G(*4DH$6Q,A
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M92L#F8V!!P]*KIL6Q3D,JPRV-G9=T/'T&5?55UR_A90LRL;V>6+_M(O_1-^
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M28IKF:1^V.'Z"ZK@='!J$9J[$X3YT7G5[Z<"OIXWGM#LAZ&8QWU-L "3*Q:
M9Z''X?&X]\FJZ-6FGM+Z?[>_\D='+"3]8KFII]%NA\XO7]94ZXVSXNH#+NKN
MVV(EIX5J_?0'V25/S9WBF:N+YGC\Q\]T#DF")[.A)WT?P *Q6O6B',$(P8D=
M>XXIS)8@7GQNGI1(LF1V%":^9+D$"Y +XZ8)O=IA5MKHJ"*ZSN<R:S<^Q(>>
M35R,XJ\ZDH5Y)FN"C@^QP$"^GJ&2F0_!+(GV.Q;=^Q%M].-!(802FOF1:$_;
M;D1A;K&0_T)&"X9Y^YL;]8DX#]B@@MEB5>EIIQ7(T]]M=D:E2GBXKX%!&G'K
M7++8KZGU#'VS^(?=S)[V8IHB(SWIAE'34EWQ4+>=*KL'WQ 6.-E9VE!81!UE
MGB;DG=0T%!-(%<JXXV#4FO+?V66XDE ,\Q<Q8ZK$1R(3%:X"BK]>'M:T_&29
MH+LA!<N_NW%M]L!E4WSBQX^WOB%A(LE57=LM[2YB,5/T'NT\CI=$S:&Y'3..
M0H&M9@4M8ACH>/V-.M+@1A9&5E3Q[%"EW1YTN+AYJ\([^D04+M4XRMU2)$PK
M.+RND[?]UMG$:.Y2@O2X^ ,6*'EX)+0L] =45GW]I]8O$X2FTC;![/-%"S8R
MC_T#(+=_@#*6_T08\^!>[MU3-RUT%(!QT^D '=Z2Q@+*\B>Y"_R8EM%E(D*=
M ' T)OXH]]W9.+>K]>-2TQ$%<J";?(/>HZ@8K!FXTC[OBY? ]752AH1^Y4K6
MU=L_F>JK"MX1:W2H O.]=TEK%=^71^M5';DY[Y.7WA>S>BZ(QQMZY-FX>=E]
MM:/?#CW$=T1O-@V4NI*3AL 'X4?H<40H>)5PX608F@KX)BY'7M"Z@='GMMW%
MCA18H&LX'PM,M$+%</"!73U',P?JE_T\4&F<IT6Y!<)B5XN2GS"65-TU5OS-
M-.KVU=6NY3531%CXT$2W(60S$F\'?!!U?GM$QWY"S^F2!0.#?L08Z R@GM!<
M/E_.J <M>BP^J4D5M6>>^-353Y6>.>=7J/(F!4=8_E09!F_7"Z15Q/E[>'ER
M*-5E=?^;>E[8[[=E], S9<#D/&+?G,,V]X>4)?KVLJ\9' NT\"R*SZS:5U4M
M;%8V9H&]@H8LJW*C3Y35X@?,[0MWN=H:GYZ'"T&IPI^-'5G $#'?)?[V-*Y0
MCJR379\B#/6NFZG%+CNGG]%&ZK LU5EN&-4?:%DU%HA"G05A 4L$"<+U.A6S
MWG#R]Q.<NQ7'0<R*QF1;&'XPBNN;=P\X7@?)=G%\QVD[ BJMZ=F%!=IJ\7#8
M@<*T  ,E@D[U.S,M34:Y%Q,#J5;&!O*ATO:60NH)_"3^EG7>JT+-=.T)+X[%
MP:FW;L]36OHYRSG6FXI>M3MXEF%>6&%J^8Z*B@E)RSP+_H#^$'6."A4N#U[<
M /U%2L1/W]AES72*;>C)7XXIW5%MDY=B16*!G34LD&JI,ZYQSKP90>/0TD"Z
M>%I;ZQ%*IU3M5UE;Y"_=O?A:5.8"=3Z1]C9*E;6B3>=^B:[IA\W6$J+'F0U4
M>G'YO07T+"LLPR<#0>*ZVZH0/CJ,)N8 GE-_VJJC["([*B'M\$)$_0L3J)7S
MH/6(:E[/@&>LR(5/CN8*LO1!)XMCR:K>*"VH^%LYTA;>]$.(4MWH4Q\.*\!_
M=5!%+]\9?#S8K1F4')EY5FQF8)DEVH2<[5"Z\9()3M)1ERN?(-[[RM4D_VA@
MWR(_OAC"L>1(O"VV$O7D[2&/]#ZS$UJG+^;UD>)A5WNV.W>?3RQR(M?7"G5C
M=D=XGJ'"=\8F]'+6U289L69D;*P:\S[AX>W8N>T!;D-'B-:OS!"N2=&7#:.G
M'EA !P%M>'AH>U![9CRU<*W2@#DV[BX,?8H%/*#_ ,=? +PIO'""HVI.)7U-
M^Y];OX,&64=>+P1C@=MERTJ:WFBWTA.OFE/JU;%^]9>=YB%/"?K>DPXTNNX(
M%L:,$_J:F()G,9:UTZL5CA?T15+Y5_VW[N(Y,*$BDX=4'5ZC(\H;N7'H??1/
M<]H>+Y)(K&C$OW[U'7I&]^6:,S>4]$I!JK2824H>1705YIU^[:> !3)H!XKO
M^J3?WY;'I)EC@:%PJXGQT?.'F<^-EF0IM;Z=DGY&+Z039BT%IR>"(.5$EZW[
M[.@(R)2OB$=;0A%TQGC'^(DG]%UZ*_HZHM!!]8<]NR_ILM$*B@:1._*'I:X2
M633C5M'"T_;*0YL^Y'P7'32&>MHA;Y4E^8:^ 2:J[I^W9YV35?0-GLO9RC2:
M_X. 4OW%?VVH>?XDZ7<^VJUDI5Q6\-<Z9>AW.DM*D6(80ISLA-F5A5TH0B,T
M6T*&QGBGL8":Z0_.>UV=""Q0-!'C:XT"+I5S XJS^[3-^FN9KK=4S8ZI?G_.
M.KEJO8P2*^B=--D;ET\P-.CW\1 ::TU,LGHFSH@SOR$A7/LCE=]0.$'W\\9?
MG(#K)IKF0R^$/ U]1)H#JI,8G*<)+"C*I==V0T2L4'L&ND&7=1>T&N>1=CBI
MH8*T:))H^]A*5(UY<J4*"E H<!Z7P:3I7-#6D2C<Y*"TI;IO\F*7,R$74]F*
M:<3MOF@M&H(KZ6"!Z)[.[?2^"7V#A&(LP)P:.0;^D8&'G'V9^.#PY0KG]EN,
M4/>.AYW$4[,4#'I:G3[]X/YK\#=X2TWD@RU[R3)#F10SBI]_Q$$M2?BKD.[I
M;?3R$N:X5""]#2D$T2CS VO6E$>99$8GGBR.Z:$G9^+?+?D$4*J_94*XGZOC
M)K3S%/9[K#WGEEUY?H1LF6O"-Z(PE&_=)\.Q-O\*%]<$>'-$)-I9G'KFR\4'
M2!!_2Y$*[=NIXML1J;(L?DI+.TUB?<V=/&0KUZ/Z0EW-6&!*K.NBC%@"]%;R
MKMO/57.=KO>V(LJCZ>T,H$WOY]]@O!9E2#WVS+HW-_X6^;\JRH1Z!TLGJ32#
M62]T)CV$<@T<"ETGT,&'ASVYYN]QC_^3ZI+S2#.EN?.T;PNDJFG>NU7LJGDS
MF[22IW5ND9P]S]1545W^FU<[ZUR74R<\+Y?16[V#3H^B)\]8)O*NK%#DP7N^
M7#9/S,JO3Z8TSV"21(M<W86;I=Q$8Q^ZFT+T4K[W8,:S*G_+4NI4.O\%,YT_
MQ4'_1JBO-&&B=>[Z!2R67NY+OM!);N"5N,E2."./N&JPAB!( *^WRAD2> Y:
M@HWX@JZ+N3UKD<F>IJ)D]RC])=([&EXV^H""W=BZ*N6UGNL:!EC9IN^48P'T
M!:AK/-QRF\T_(_<EH7[_,WKWVZ3G$WCY,(.TOW"*_PLG>,SZ*9WN^PCM5I5+
MBAV#@>KEA?8$S=>WI']MH'[>JXW^:,'Y@NE >E])%O"]0.4VA^?V-#[Z%9:L
M_8@-\!N4.=XS$C5VL!5^@,Y)=3+QH(Z97Q:@#_'Y8DSG&2F7V#K_N&G$0A2B
M&T*(.3PA.FSWJ7%G14:6)>P<BMJ.JH_1Q*G+>EM*XU0"T1 &P#$:"X8PJ-]O
M.C#^VY-![<AS?;0_U98WP_YTT4O^OFC?W%EWH<.-5F.*2!+/1F(KQV.ZIF,(
M3%*X2N:<%OUX7"8;0J=;1B:N<"(S--&^'B>5&ZZ5V"J)0]=W+Q\]7E*W@FN5
MQA"BQR%#7?]UVCGZ.V<"&T 2^X(F:6U_RJ[/VHF[B?T?AIHN8J0;<JRXC+H]
MG3-Y'PO0YP909?A]0"=D*M[P8(B.M$4APJ38E/:,0/>F%&I[WV !/>EEA4C-
M<U<$&$]V_3D&6D*Z@[Y@<(.=>-,WV<JGS!L.YAD->CFO*VRXL(3A?+SM;79$
MDP*KN6>&+*4F4"CFEV5L+.O00'W5.>21?]SPV$]%C6+U*RA)XSE(5=.P(34@
M)_U6R#A/UGEJC8=4-LZR)?+810?8HG(?PG/+SE4[Q$AH[P:F\VS/]-_DHM%]
MF]>U\F6DCLZG%Y)-ZNA$6>!-^0$:[[M@!#O8?UE6?[!5\UVA?J#9WKF>Q%LG
M-/QW2YQ?MK'&P;ONL<2RF$UO'LO6RSWO=9FNSZSA?L&KN-EZQ^?][M%Y<<,M
M+U+R=>F\5QB/L0#A0G>AC<NVP%?R?G%"XB'[9JKUO$8=WJ#,U;BXUQ*:CXYH
M)HIK,QC;8J P@7:SP=$B/B*2!:1E;#N(:XX=Y&?*=F2B+2%-P_BP<B4.IZSB
M'X<W\$++M]Q'*7KE!$X*W;K.-?X<J9=45T:X?197D/CU6T3 W*H)OUBDS5U'
M.*%;P%:$@M /]F[1/VY6S]U40]F0@>!/#<RF.;GAY3RWNPTAE+?BZ&%[\!+2
MU\DM?VIM[\E;K40'O/=/(<Y'R5N3A[X=J]>VY27R$LKT>0S4[_/I:<\.OK,/
M^Y[5E2PC^\S7' Q)!3*KW"))%:QJ?=3,J[9U"MG.0UK@1SD486/+.!U$$.!'
ML<@ Q9"GX[=8^$U')(9Z'8UE81X@4@N+SCV68Y=4'T@[<8!-JJ_;1T[9?3 ,
MD('^IY"'@?%2#7</3@PY0UZCDU_67RI'A4>8AZY)K904*Z[RP##=8])W:PD[
MJ%W-<>3;_!F/B.E8Z/ [)_S#*HY_:1:,;C^K=_?.L,X,V7WZ7_('ZS84P5DL
M4!'>Z$74OUM1["2FKU\_0L\9=@T)9[2$Y3UP_^V28#;\UNTJP&LJW(.:\RV&
MP]K-Q":7U\LNS)%\9VL)='MVYV9DI2+) W:?&OJJH=L7< 5&748%ZO*(]A^1
M&C@\)[8-/B"E./\1,Q9Y:O'QJ1["++(>"P3#>1O+V)JY&6GD"V>/2K12]2*D
M9:EX&NHG-+F?RAD.FACE#\Q]*\P8D1 ^VDL[I@S-B\P2F1C2AL<N;=JY]SL%
M.XA#W:325_3?,OKY&D_EGH5%"(8(10C="GE*28*G FNG_KE(WE"WM%:>,'^W
M_.@AH9P-T5 :5UM)!]?T%5Z!X7827LR:R:N J^_:0IT]/W62DXPG"^U=AGMY
M]@S/2ES:$XJEXEB-+TPOOYU*Z'RW3OJ3GP%Q>B?O_;@,$F6N $P%2J0[<(W6
MZ_@)P4)8Y"1CR2.KK2H\TS)<6,=&!;M"=@X9&E &7JZBLYGC">("Q(?LW9(.
MWNG?^(KWX>8^D$FVKW(_OT\RI)R!4UUP]MMM]51]6G^^N2N\HAXVL"A&G[2V
M*X1O8>]UB\B^S<1S5UX&G90)4*\PC]3FK0T'R*T5Z'NE5)01JR2I#S=<15J?
M>UDX.2ZM>+BZ\.P&.GR_</IT5:9GQ/5I;3@4<57ZH7-+2X*T>!:2)- K5/Z4
MA?=1F)PJ$]Z.=KUJGI*%>2&MW([PJOU<->))DTA%HO"9I!Y]8X]$'2,HKV7(
MEB+K9/:=SY=^K<+:U!DC@[7E=W//@HA$"SP1.5G]NQ/"&_UC:Z>1B29<J>,2
MS\L<JDOPS+>'W1US,^"1E*;E5&(Q.?L4?0RT(NS;6G&+GY_*LGK4PD,)LP.:
MQ@:(>ID8_"*+G702-"=53*I?%D^>.CI);P\C: N5>X[590DWFJX$40^O6-)(
M,8.I9[9B+V:ZUU^3RN"85W6(K_[2L:RF+]KU3.]"YG<C:W)+&EOY&'-WL+[Y
MUO7Y( FXV(^-H45W[K>?Y;*2;IP2!7XKLSLB=.#I/D'(N^]7SX;3X ^,IF.S
MS_098)1=,-U,W?MK[\QI_:Q33^3^\_TW57KAPG7@T!ZX$1I/E-OP:H-:=D#_
M40>O2E?7Q/[55F,OG6]T2LV)(Z;":[\-00%MX5^"[NY8S138YDG_7F<73S?U
MUM&VJBRMJ$&>$,U86 ;J?L<"#S.O%1#)]<K+=Q"4GI_WM>O $OV';.;29V_]
M"*RBWZ^%M4E8:&5.+M!H:>3DM:Z;JROBL0'D?H6YP_7L1WO52+S7Z"+#.WY^
M7'O))<L#V>\1S,Q*PW W!2GITOO^-J]7#DZ$9B9M$M"N4@;$G_V/THI/"E'-
MT7(E'9_4Y6[D-5/NQ<&]W$K(\W.Z@NSI;.WCDMEK!F1"^#7MLBP>WJ!_6V)@
M\)*?JJTD\I4S.)ZW1UAM]XRV=M(N5I4//94-/4M)BJ02QNTMJB2<F0VB-(5-
MR?5XW)=U<;JQ%[C\KM. .0JLR+B^AKENZS^)2A)6+\T9WM5:<.8&=82]K6.?
MTG)^72+':1AGE[DH$_+YL./..8D(6:!19VVZNH[P<&5HN'#J\$9M9;!3CJB_
M>15;,+"UZ\?%VZ"UK/,R(B,^\!;S%X.(LB7W4+>.-%ALH<RLGZ1US99:.X=/
MV>PZUXP4F6?BI<[KY)8S#<MM)$V1$J,N.!A\KV+9_/WB26&22KY;YO9X;7QL
M7'5EE!C(P%VJ$^:\\J&D72V>PTWRMA:#:#[S#I34>,_,ZM'B$2-4W9#!ZR0M
ME[ L9PJ"=FH3>2%%=%46Y;<&#G>?=MM>T./."MQ<P8FC]QN<S@D/$.T,]</;
M.B$Q6F9E5[VN."U&])_ZW^<I!M/P;)< ]1A5$P/#M;[:>-0'XEGWCK0O%;:>
M@5B 15?.<^<)6-K .-17,>W>05_B8N0>UR_34AFD=_<QU9K.1L<R\Q=8E69I
MS%N.VI$+>K;V?:JB6/DE0RFU\=/B1A02Q;(PA^;Q@@4$=&0Y_]+O,!S,=731
M\Q8)XKN2%C<0-?_TO3R1="QX)U+3*#)G\S1)Z]?G<<FL\^^'?7X*B-K6D4#:
M&-B]H,'E$O=8G[*'\@?MC4F%W!^5G*Z7GQO#["Z,QEP[]U1"IA6RWRV'ITXN
M<H;%ZKFX6<5S*#KL:P3%R\?O&7*>R^B[SG/3^_ #XW[C\3[F,P[%K-^P0'F]
MO]OM<I;=)&*-%*UI2]7X/=S9>D_UE-S$9&X\C!^@DM>PU9_C/%(QU^^U"DBQ
MD#%+0E@C(-NJ+,4^UN871D@OHS%O<8\$V?"'+B4MD9K:"%?(M2@5@L>(RB6
M)\+:C=S=CI)E;&2HX[ A[_"ZT')0M@FIGC8PMJ[UW+1ZN:#7[J!GN*O.4(7:
MFY;JU5PLW=>8.EE2WDC>BMWRT+E7U6557B%^B]7+WUQ]:D[PWT=A 1C)^C,Y
M9\+7Z*'M=F/#3YJQ997K\HE["FN7.K)8X%9.%19XT8T%5%%9&#)E1\RG6$SZ
MBN;>%A9X=MES*@2.O^X47[M47QO?OV*>#CH-FI2(/$;P]1V6"H19@?1B_^T:
MU9G6BR@?VLC=LK3#S<.=#"SP5=, "_PTQP*YYV,*QZ&]D+72!&Z#7S?EHQ=^
M9FA_F<H0T]0K[XO$W7PEGZL^K@K[N"J8!?!%V*8GOLW)AO]X%AI:)@O&'8=W
M.ASVE'34I4:,,>94@)<H<!:5!KR%$81I\Y^G!M$Z)[; 7>8-V1(-'UX]]MZX
MQF>[!G?D&]MXB-GM$,SZ&\#P]]A8\'=>%A.+/PGBU RI4Z9WKUCZY@:,OKBI
M(]74@@6,4?![V^,0\<#/R\(1LMMW?4");X4,[TWH5!W^H;@GM1IZEE"N43(L
M0[[TI]<TL05$U9F[K7'NHI9H'YC9VF,I(2MB=GZ,L/U5&ZN U!.M?K,7!=6[
M<-0>=G05CV(ELG2A[Q[" I\0G@=6P9UA$IR)Y+_$<M)NZH3.39SC"D1[D8(%
M\+F*+$A#Q--E/[7)*4UU7Q:=_)0&OD1Y$2;\*K\K[^T7H7V!M'SF$ZDX!Q>C
MRM)+2O&.U[B7DO).79:JY#^ER;P]X5HK*;>Y=R>-S$_9 "YO6"U@^^;'Q6.Z
M%V?[!IZ[2JW#SOH-9(V,B>6I:>TLTWL\_:/1).][!<XZS]/BU[W3?H!#ZU^A
MQ\MA/(FK926#Q-1;=3L35)NTNSD+RN7E1B0K W'HHP"JP0E8U/N& %)[OA#O
M-"/'R+B"6K7A5P&F[X;5*3G9F[6H 8W=?&N$]\97V=(Z8SP9TD0?]ML.TK>S
M3^Y$HN!2%<<\8(U:FS^"4[0<C]2[GL^JVK:2U^0+SD6$<:?8YL3W^U2@DF;+
MN/AIGA\J[G6NJ-F*_2E-$JST#L_J%/S*GFQ).(^90FM&():K628/WO1)VA^E
M]]02)*SOMXKP%4O3*Y=4;W4\?[[K8N#LF^ <9IRSX:H#?O8UN]QGU^LTY/OX
M+G2G% N(;5]992ULBP74)R0@GA59O,NGI[],6G<UP0(4R7SHW::!V@6J'1VT
MQ3'9]!LRHV=M5$0IXV,I#?5>(F5/,[I/O%SVW$IZ?R^%FSB86HZN <]9UOS\
M*QI0!,Z5(!U,?#)IR$E0FA D_O=[TC^=Q;;GYQ9V_HAK#A'-F=:T.7<.3F.=
M]+(FY2X,(YQ.#0M\A.JM.&A>\T+1FPM]$Q:+'.H.?*9L]WJ*B/)H!H^*E)5D
MD#R(=4T;@7QGK>$[-P3V=%04GP?/G0KD/^06Y*Y+,B:=H(5M7#N!T%1F<X;]
MN9Y)A]NS ?&641S,S[L?USH2;"6Z>SP4T7DJR%]NHN/Y6V(#YNP=6C2=.IO?
M4]_7?&GY34CL:+OH,VPI*$C>W56*#D58[ ?_[>CB;A[\Q<$P1.#W,>4^)01=
M'%C#V@ ;CF *>;FKV<VX7.;+ E[.KD2+8#[;JM*0G,<8H]?3>W*G6G<>E%:$
MG%9(%?;W[;N(7'JH848QP_/ID,.KADOY'(&('_ O+6A,81ZD9&9NCN8Q>QN\
MG?Y3I[1!PO3\@75G\&,L '>\*M0[7MI=W2M]UCJ6OV<*/[$8)/<,TBZ9<.#9
M@_=]R#,L+%%YSIA9,\6[@:SXQ@M7+(<-D1,*?-$SXJ%!L4X,0X_)=+5#,<E$
MUZ[&&[+4LAH:2OH$WK%N!OHC6"!_S%?&L!^WVOB8^#8[A#2J/;5_1M<O;5ZW
M\L]@0D#)Z$@-:#=<'O/IS/ALK:DEE_AY 8>PMC"YV\QKF'7ZUC@6.!D#?T<H
MH$0GB*::2KZF7O5_@MZK^,V3<IH44&#P:EA<[*DV]?,YPX40N!L$6@:UN)C]
ML[ F7[>5=M<JV'?L$<1MP>P-7YVB1^V,_8#[\D['@X2168->;GXY/.[?HAO4
MU'!WS.F&9C7%7'6,6H:'&<V-*@?>>@4/&YZ*L0;D\&O@T4]F:M&NYB+]4(X]
MF@?+3X)3/0A,OD3"'&593A0Q<E0S$+F]=8TIA=(B^RQ[U]EU#@/=5@]\:2?R
M;HHP*I-V%V^WBK-6+$ N"[?)^..Z7^-&I'T8J2;O-$N[BY-/<<4LRZ>6Y1#%
MV%KQNRC3^4O51+_L[2>5<=Z,"^HC=0QB%WQ[#]1;(QC\[G[PISS,'H67?\QX
MN>[S00S_ZH5V8["[?<5-#7\%?VW&Z\*E'=FU\PGE*XHKFI-RRQ)/"W6'B)80
M=L2;C?\4"[OL]E2NT/G6[P6TCOT[,4S*R/(?JE[VMH\>C!4;ZZZ&>J2);OFC
M7_,R-(UR10JF%?)L?AF\N--K"V.1GK!TIM812MIFCE[^@*K19K@EQ)%&0UU^
M*APKBGD2>1/S]G#^40"M8KSK\7:$G;\2YQB#HJI+3&9MICWI58M=TQ,<\2M7
M2AXGJS97G4\48DK>UY4-8EK:+N@K],J0CH*G<Y /*)<8O,5K6<?=42RP26&/
M!?Q$SH?+5'!]5;GI^GAA1>,\],98*F:I*)+JH>O$O#:CP#C0<4[:E(@%)HKV
M9/200OR5VXNE5N*4)E#.F:D<Z- 3TLN]IH[P)./K&TQ8H''FRI8Y;6W80^E
M,$$S(J8<=IXR5MPZ;2CO1*V!2NVM-K<LVO:N&"_F=C;TLHBR)WA(K_VGGPOS
MZ3X66+!7*E/ W<DKX[,9[?0=0KS>9'TT35$B=59/4DE/QSJ'Q@L\3FF\0%EC
MY$E=OZ&9?A/[A7D\YW>)\?E^-LQ'%'2A(WL*!AUZS'=YCI3  L!TK#>"25>8
MGXUR[$??S*PR1*S_9CA]Z'#<(9>-A$41YT?S@)+9SG[]PV,$^F8G%H#2QO:,
M-&U2II^=Y"7X)*HN3ZP^MZ">].5=$! ^:ILN/GY"PT9,1_(TW'U56]:-424>
M)W4JL$!3L7PT;MJGT(7U7/I+OL_EAHTOTU3#DNM3,98$ <?3]M.S,U^/WMZ_
M W_1+ZZ&9$/^:1S]0-'/Q,%>/<#ELCNM>HT//110/S5D;L2U[:_KD7N[1")"
M)\</3X4%$A-S\_NTBL%JZ6]J'PHO233?_KR38EG5V)N)!8;$C*]N"3:9#X,W
M02*8F[2YZ8LL16OGY*5VYH;C&V"HGS#,?4+@Z]$[0)$$/R20Y@T%2T%!^[T7
M)M%)6_[=F= A*<>K6^"EUW;'9B,M3EC $71M"Y%L9K7@D<1;/>^X2$)^P5!(
MFET.01>:, V@@Q\[H/DOF&L<U6QKFF5A@4%8%Q:HQ +7MJJ[UZ"&!IPBJ6R]
MX@+OV94U+=I<IWX_NWI3N*>WHM84<F@1V1^&U[RXN.JD!_[W YGD6C<LUX-.
MAS2P@*4U=+8!!Z%VS8%GXS'.,UWQ">MD]O!&\W\_]8Z )G)C#$[N\_&SK'*-
M^D?(^RUO/A,?')!YGF[IR5LV@$+&9$1Z3?=I6#C6:K[&PPI.1&<U3&OY=E/9
M,-Y&6&"E?"G;^GJC$71 50RM/  /F%U'AF(TD]NIX7'6:)&KJP7HPAWY4[FP
M;)#4!1:8:@G#"$+M%Z$;BU"S92P0%]2BEKXGRCOP2AC%[[X7\Y3 N$RTZ2,6
M&)6^VC):>C"I-]WR2Q\_]>-JR8G9?+&U>[B;?ZG9F5IJGY_^+T1BY_*X16A(
M=KG\\/M?"QJM%2*%8FCVS(:L__/O",)=VAEYJPXR9[H]K)RX-6,*4%1+0<^9
MHJ=K!L\-O$6N\?>;4(,8SJK !Q6OCUZ*R&D4J_".6&6I&TC]0&FVH@-ZI/G2
MK0?<"]]D.?AUL5&-0I+JO1DCA6$LSY0IF1Z\ZQH00%KFN'*^5'P6GLPI](C5
MM9^3BZ)5BN5+.ZW/_(R^,@D76X+$K,6WG:%TO6&D([CL>":TE4*1*:Q+_=;-
M3]T=?@6LQ'(&X;9"+!//)BMD71JI4'Z(4/)U)27=I8@;!?V\\PH;^#<G9%\M
ML2LE*/8QL[*ZFL]O"I]Q&S&OUNR4?X#>[G>\:QAXP?8QTC<DWP=%V]+;IIS9
M$-]K0/Q5_\N3OI3W&Q)N\($:B$4</%>##O,$B7*IR.*)>'ON<$YZ$@5JPP(!
M(ABR&2SP#KR?A:$J0>PH+%T_49;3][(,?"SRK:N+J.E)]2@J4H[!]7+_R@4+
MA&2F*2@6K >((XS/'W&W?'"/ZT><RSM>X[IS8^2Y.L[D[&&!(O#9,!:XW5MY
MWO!3F5WA??TG550I(?ZAT.STG+0?A*J_J)";'+[J)DK"R;E:GN_K.GU1T@H2
MO7I6TP]M$8=B@3?0?02F G00:8S##M_E=@$$3'Y\3:J3KES[J^Y9RPON.N$H
M;\:*J5;.P9O.B#DW$M'!FQIIRG+$BFHVDA7T3B<LTQJ3:UA@B;$)"^08GXW]
MVU PE'SXKB^7BR/!6/V1X*:!%ZLGL)*2A!P2^GYR_9A!D9HED"-XLI0L!J_#
M4^KGT*$MYVV'>X-]$)!Z;[R2YD,,V0X6>-VT7PM>8D1*XK1/XTY^FNH38M8[
M=:8),U$"D2X&Z4'^3).>L=JT?L6I?<YV5CR/U)Y*!26I=^<I\JJ'EBZH)4AE
MZZGH1^+H#*IV'(JYQ)G!:YG+$NB"V_B8H8QZV4C1_!_T$M,GL;H4?WPDDKN0
M9"[.>+['LZ?0W05Z$+D-FON_793HA(+*A)A&Z1G-LF.$M-2@-URTR_=#&ND;
M/L26G]KY]/TP[K.L!9&V<]4Z[C_337:8W<01\RU,UG77/WF D-":A]=GAC(&
M?)/]?;:&[HYJS[GYTTXV-E8>A(EMG;5BSK' <@'':ES!0LS=F;[\=8J@=BXZ
MT"1MY-G? FR!?PF!_N#\K=\X^(I7\B'&E^^?IZHV_8YG&HCJG:J7H\-!.WT.
M*_E]A68B"=<=+<U'N2H2HU^4D.I]%FS678.8YG^Y!?DK9G30F>G?,=^CULHQ
M[']+="FVQ7<S4)@UUKJY6W00YE:1<NA]OTI0K^F'>N?;A+Y5*"X!<-V_7OVO
M=W1TOCZ_T,ZU=#8*;YP<H'IM/BV]2K\Q$MO.*%YV (?=A<UE'P:;'%$M,R/#
M[CMMO2T54\[+$V_0SJYOL1'I_[5P+G^"LP*XC(;_%BKC&L?E^[6XSP'M6;C.
M<(D%Z'$5R2?M8& -G"S?:7VT)$.%+[4AE(NN;=J8N6R_SL,"/^B,_R[5;.3_
M7JIH7!-WRU\&W6]?FF.W%7DPTG]O$;%&%C^HDFV9NC3G#2;;@N1)VW,_+:-2
M%0RK%$LCAD-W]>A3KN#S.>G&^?V]?GXDZ>?R^UB@#O1/LF=88 XW>G&X8YN>
M<5#Q5W3\2!O='Z:U]$TBO95TW-HQ?+8Y&_AYO7C?ZJ0P-VHT#W%+N$$AP8)=
M7/'UU#_@P^Q"S^9PC\;"RC_)JF==R1U@R@3=48,L#\GO%U*61+U+:P[[8F@A
M^R8AC"'W0:.%#$B4JSW'I1)#Z\XTVT?E4^0'%9NOJ@J9I@JDO!4Z=+L9I1IF
M+\%NWS@!D>B5<O\><B"?QZ*=$US06;SU !VF+J$^4!=O\-DI[1S>\YQ]:>OH
MI; JPH5XF4%73_6MM;J:D<IXI8M*B6".($_):X*2D^6:?1+/\8EV'8I.*PL7
MVF8\C[@\?$E"O$';:<$U]AK6S$?]3S+/K-1E*;]^))8DD'XY;"!5B%)],0I/
MFB>3W.%H%03L!TM8K [RN#&\UB(47A[WYZ8C]\4(01$CD P3KHK^KKZ&!O&9
M[_N;!4GNN1:%>G?J[GQ-N_'Z7BHQ@^W<^U&5OC'Q[<\A[-G_46=/],/7$@M$
MJ>!$H?%=G&#3LN?K3",M'[';^R/88;,<0"YWR9GR"Z!(NQJ+#&N#FMOX8H%>
MG+;?I!H]A[9.LV#H1UEC7_^*D:\(_S$]1VSZUCPVY(0ROY.8U#IY;'?728C-
MR*!RRL'+.*PBE:M=1/NI)U3)<X,@/J2-LCOE_7MOJ-[QPL-V%A#)GXS$:W/W
M;\4GU(2U7,I<JK]8IB;U]6.1[>2(0ZIP%+#2/(VX=L9DEGI^0Z8^E]9E&YO[
M$WJJ0I:2?6)]M(]_?J9T,/YY7"1J5B+',I8_CYF($3-65>"K-<SGFMS[;F\?
MOQ^_(_MGAV*4.!+'];M%?WQ9]B6+R)NF#1P\6QF_C-?Z^2B-KAR<9N^8V195
MED:]4KPEKEIA8^0J]6LTM.$2[46A(N074Z9=919^_I0_9[L5DRR/J]>$U_)=
M(YX[,G5(BXY'+]]"O2(!?[??O@]%1]T<H&OE4/1=D64J)(8%Q9N^Q" EG3IO
MOH?D,@N[)E1=D?4V&J5C.9U#LWQ.N7BZ58RF3YFG:JP],)_G_K$JHF'@E0T=
M?>8%'4R'>0]^JG\A(;.4Q^;>CP37ID#+Q3',21O@)7R4>NDE&>K=I? @7\]A
MQ%QU![_!0@#OQ@%;).OP_NH-XJX0N<U<,$X0&H]7%-HIB[*R3(_I7;H+!&SV
M"Q>E12*/P=^:#A_;0O\@,%^YP@] H;[B69XV]D*BT;RO!B;Y'197Z)?K0-^R
MH2W$^2Y7=[! QNW6<ZLL&QW,?5WX\8Y2L.\9W5J ;DDGS>-?V8N_(M-.U[<V
M(4)LALZG_%<NR^EW(&)<>EM#Q/M3$SW13-.::5[[6R%[4@Q;9]Z.7^R9&N0B
MM"VCF-VTV)C(IJOO0E42EQ;"]DY\GG_9*N/G_&H.^!_Z>(><7$MA9C1_!9Z.
M2+-0L%N8;*E2(JWE!$]"Q_>;')FR/-1K'")I4);13VI08N@6BF CANX_O8PO
MKIP,55NA5!W3! /I^4IKO; ,4X.C-=)M4E"\F@9XR=<-] &'XX*^\^ E2#*8
MHMTI)\O+N\S+1_/3.F.!7Z3Q0"V(YUW+U[D&Y.@5SLQ3]1-Q1O\9#H(K>"V[
MC=6K"Z]6AI@'4DE]761'WU.M01B>NV&!QP\2,2NX4>T--L*.K7W!!W!),6[_
M/^]"J\YFTU0W#$E;*_&;Q4Q8 +)#/RGWHA(MJC?/G*84>X>9%9\Z%<)/D;DH
M 4-[OM8FTRJV/>]/AVI\:DUMT-P5(VC!IDX3Z;Z@I-$32W>U46]B<+#45WI_
M-Y@D3F:WJ=+/S=I,0!P=<TW>IP8N/O5D\HZ-/=>&%Q]@@7;:\"^='LOJGOE'
M1:HT:Q]7MO34/V10C\;%-+55[&!>O=4HF(TYOF ,SUV0R=\Z/:OLHZ49$DLW
M,])<24QO@Y(5^8J-E+OG=57O)=#]:*Q>AONRH?!NK+1.V%>^[HX!.M.:GF&(
MT@=240]?(.V%>J%4-OQE]?IO?A,J4FU._N'_760]^I:?E]1''&P8SJDZK:YA
M#$8>WQ5_.2J8K%596AKX'&GVYX;^;-IZ_C;C_6$ANAE(MYVI[F*<0@TE[Y6[
MHWKZFL%Z,@KRLKI2TS]VV@#OZ*=R;[HI9PX,]6I!@2$]T/4RN3#0C75*'+\+
M?R$'0A74[M) ZX<%%I/$RKV\&<-QX&<LQ0+5T'A/^4_URKF>MFBTH1PQJVX<
MY\T7DTSI>F=\_#FC;Q 4KP8?K(?79G3*&#$L2D+EAA"(U7$*;\4,L^LA?VE1
MM/8D^WR\+&0O4Z!-7.7>Z>R^Z_XWO2<EA5-;XWJ0BRIR>QYNVPPY@73O/R:5
MGV>;8DF<+L)K*MGI(M^D]U13H(B:UU]G'U)+J##0V']XBU[5T5Q:H'AWGD07
M?'R2V!W0XA#M5+TBR95.IJANT'./JV\\;G2X6V35JSW]*I$#NE.' U7M*2W*
M\7Z_R-=&CE3+];GY<?FCMY'+&G4JI'G'\$', T3 53'&K\/I3"(V:8%*#J9%
M+&WH7!R6APP3S6*S<G?1R[U*Y#(^^VLWN9"\@KUT^5>7H:\MXWB;1YA,"5TB
M_"M6YT%ICM2^FK3(!_L,V6Q>IE*;6BVKZ-CIAIBR#B->LNU,N!'CB(8?G839
M<@"LHBJDO'JQ*H3%.JXTDX!HXQ2AC6D=@7UDWJJ$Z7Z NE;@)"T53HM\K5/8
MP.CR8<(0QI'7>M<$$F_2?\$0\A<A,48C5G2H%WB+-LV;K)$7R'02Z*IL&1;P
MP@+'S&_.LZ'+0=58 %Z"!<2@K118@%(H#=R(!=!4;!C<T([^7[# ]\CHUJU*
MLTYC\GU]3=8]^]!T+@E[[>F'6VG*WL=B]N'U-V[9+;[^V"P;AA=R:&\YJ'E
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MZ]P#B9 NE-4W7RH_F (DVX;=T?B&J.G'5_?1J(DMH\*@\D*OT1B_T:%EC;6
M+)8)RTCM [0-:E/8:4N#)4&)^ETJZ3QCD\%XO-/"7<'>.;Z6UXEYP_6EY?ET
M!^HJ_)UV*^!P=Z%5[9!P!99]^(:?B"<;A(!27??!?_1;T%;;M(P_"FJ%KN-$
MN+_<62=9+IJ:FIG4YVDH4J+D.E/WOIT6XCLPWOBYM*&E<'YR>ENXW][KAC(^
M?9Q3E&T[96QEGH4D6/'72);U+H]9E;SX#S/JFVCDF?#0O+Z"HQ-M-\F7>^%#
M(0DA'O:SVMHE,JK#KG,L-:.[&97/S* )U0,<T9Y0A2"U2U_W^SQ3IAWOFX15
M-9-&,M,EJJJ=X;]U==)HA]WN)-34C=JO_RA)=.M^7JS'P?%\^[M@VIIX,6?'
M:3\/;W%6PAQ_I0@-/@/[Z''R74Z1B)9Q<5>7A'<=>$+.(:*IQ7XW>LXX;&GE
MT@L*>*ZS=6X'<;+0 *-%@KT\O \".Z;%/2?_<%$W]^MG1EA!C%^4-O25+<T]
M0O2C1A=%+*HN9OSMYVN*B1]%: 2^TF&?B?HU,+K-J<CN[.A.S%JB@@642L9,
MWR'VLJK#519+23[Z65>-%-ESTW;,CS\OUA?/5 \0W=%AS_HQ/7&':S8CU[K6
M(<9@ZU1MAN8IJ-? BLHS+$QC6,:^[I<"#UDT:<"QN ^L-NA-982K_<YC^"VI
MFF)O]HSNWK]3Q;LM%9.?JCY;42SWD$C@!U21(356N;HV6Z4#(W?<)%^I!PQ.
M4%F&.#C;]@=QJIS2L=APV].%=S47XL]J\UT]:L29L)]"N=>7Q3WL86L,J9_:
M)8>#<'[-(PB\>=<&"_AJ[8G+CQX'1 M>OML;D:D9(\23JO .<<B>+K-3Y-?+
MEG&QL?=Z&._F2(G" NYO2<#,NM"#;YX^_EA@%R(Y-8@NT7^KH1GG;N:DZBIC
M;^-H]3 ><E--#OR9Y3;XD::ZK!+2TAX+!!VGJBRJ^ID0M/VT)WV\^FE+CRRS
MDS:3A#,,;Y,#J>ELKUO"D@!3EOF7HA;_:U'#ADUR=&T^?+>SSZKZEMI^_[UE
M\;"\0 7BIZ[1BN$#6?9MFM>_;YK3=L>VU-Z,N4!D33T\N?\)K=U.B83]2Z*4
M#X;TVAY7!3XW8R 7NDVTR)F6D6'C793/<QTF<N_+[1'>#UQR(8K*XCEWGQ1U
M9'([%5D_+0#PAVX7YMD(TY8^-IZ6_?#-N9"IBQ"N_M)>_*>-),W+!=E1>SN+
MTJJR$'%=ET96:NU!/=B_*Z?_CG,(3 -BV=[[< CG5[Z*MZ8?$Y;CW#:7C,J(
MG>MW(ZX[YE7A,SZ/70>+#3*#-.QU*V_CJFPUOZFGDMF^+[BC.XL%Z-KN^/O9
M5/J#AG?I)>$_;"@B9(ID/EQYC\=3UJSAH+H6OO\^,X13\7_^=S7^OQE@[-3_
M E!+ P04    " #XB#E6K7^5+>H.  "1GP  $0   '-H<&@M,C R,C Y,S N
M>'-D[5WK<^.V$?_<SO1_0-69UIE&EA_WLF,W(S]/4]_)M>Q<IE\R$ E)B"E
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MT".P?C&QO,ZY?2+3H?JL@Q(:JI2EIIZG=N6/6[X(U,RBOC!R.-.AR:V>&-W
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M6[G#OI7++7Y=*$;R9JZ^FR6W<SR9#7*J;;$INA@"FFN^I^/J&LL(8-YU71O
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M6>*]FJ;:TLN"5H_%#/?D<:XR6;#"U2_8O@/[;U'+?+9!76M;*&YP])P@,K]
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MHSS(@+55">A +3*!I!U^U5HK[4TWD!$VK9;0WRQ:"A*;-8LJL66M?9JC/,B
M[:L\6H1E5MP3UU%" @J)E^54ZF *%7W26OOL1S&@M_,0W9TF.SJMM5/#- @:
M=,6[J3$P'H@3E\C2]K%AT/B0GFT((A^"R(<@<A7HAR#R(8A\""+O )O##B(7
M)V%_Q&<H?Y$JFX=]NX>NF@120>,RO+=^XC(YJ8:FA&U])=7@Y773'<YL9E*-
M S0(9?DE]C,:3ZCWB)[! R\I@HR_T8_$]W'*?[+]B7<X75,L7F]G-)V?[A^^
ML>.IYL*(35T7$D?5-FAK.J.L7_*+9(@A(435%=O[A#''WO:,:?N$U#8>QI^2
M<Y;I!_BGXJUF^FHLM@X0YLEIW)&XN=1KR2+_+G0CEHI0F NSDZ_I.9#7(ZMX
M";2'=DTZO]MO129[#W19FJ%O"&LWN@_?1*\(N=UT%:3L<G[ :N+;MS3)WZ!W
M]O 0^A0=.H9:5..=;#<J,LX+TZ*<BE%A[2N:'\(T6.@>BC-SMGP22_^D+#T4
MMW$BL.%^F3E0>]:A1/!\8>N<G#UC6P5V?B4X[L+Y!W_L0&VS"R6!QPU;;:_R
M>*@4MSO;J_G88'O22H)LS]P7AN#Q$!:UHTUIRYS\@%;;B08ADV[Z4M'V.@"'
M9U8-=0 9AKDO $7C8]]'66V-4\6'1 =GD!KT!QESTY>$^HUY<W^LR9+EF1C,
M>&_E039L[6/"0D9V-]ZU^WWG4S^@/393$>C&M-;74Q%4C_]=DH'!1/=2'&BX
M>AU%>[AK8?$A=RVG8I8&9@[4H'4H$33NBB>J_TAC=IB<X9!R$N>/*HH X%L6
M*9T$BW4(W$:(\>>=$.,*H?_ZR^>3XT]_=W*"JYAB9T534W1Q-<'SCIGPLXO?
M&!0#S/@Y6V;<R4?U[G8R)DZ7"PL<>@NIP?A@V@.I$2$#Q=XE(70_PQI*0A@0
MB#J4A!A*0FAZ:-I*30@S'YH>6.:#/98CM40'VIPH0Z(#0]>G(=&!)'B&+E:5
M) &B)6JGZ:3.[$S)@,!E&AQ'VE:D1E4+-;UA;UZVD/?H_+3E1'\M)_LP6==2
MS,,.YG:-/B9)Q>#IO];&3O\Q>62^M/'T.O*#1>"G;@ALN6A;H*D-VRR8>]#\
MM8+PKR"9W:,P\P?'L^#E$5]&"?.(0NMYG8 B(CUOOX08<+"2TT?G&S$#831R
ML]8=U+WFI\JG:\;$-16<H#CY+;]5X"Y;@EZ3XP\]+UU[#"BL*!:XJ'WH=5&[
M" CR*"D0)]IHL\WDI._-\_ZH $* <V'CW30P/,J/QZ/('T^G@8=@A;,.8/O)
M:=^[N7:&A$ @<)IJ>8>GXFA+G^+ #URR?'!7&R>!DPWN8L/.3RP%!).^5QEK
M#MFK^_'TD1[98M=CBA6FKI#HJ\GM)D0 *TMBGO^M6^R,W.QUAJ^A+KKKN['(
M+;1J,CG^J"EF27[T8![KX(;NH[8UK,Q&PE^V-EM9M%+5B6?0^RK9'$IFY-"J
M56:]OLU=4YJIW.2U0AF67H_]C]_QXPRGL1OYEUE4)5I5(?&H5,$",>:X1QT5
M$I,337&M_+1.S<2 1X^V]<+>A)&2*X9D"D@+7UZ:DKQO2 &I?Q6TWXI,7I&'
M%)#=IX \T10X:$P2R!,>V"<:ZURL[^KSO :C-)EA$OS)2P[!Z30Y_:(_1/1&
M5+) Q#\$E FQ47<N&9,L%LS/:E;>(9()(047U-DVV/AR@)X;;<?8C7AD^8'&
M[V<%:#(B@/.B&7BICSBY_A;BUVS<:7LW?(&>DG,<+1!A.\7\)\KZNJ1J;H]Y
MA!KGR:\:'2MP;2*2<=>%!=O!4XCJYIF<^6\OI7Q5YT/=,JE,S JD&\O5M@,>
MBJ6@EK@VNPJW:WZRY 1TKF&>-_>Y;N+-8A*4"9F-WSXR&><)DQ5$, M+D3 ;
MUF;20(":FX?K4)+)V&!,O>H",D6]Z;1^Y/SLUIBH#KU YOI%VU+(HBY1Y,>;
MV[%S-YYQ%C^XDQ7P"_D'G3;Z@@\V."T%N*>'7^Y6M/;@7-_;"N3D!0$AU.9X
M6UE=_0(I,=SJ.UH!G)0,(&;:G&\KMBO^7@F@*JWM0F>'<1 2??GW>)FP;]'W
M[$_<;!4R_:V 3444$$AM#K,Z!Y!457M!1RN@DY(!Q$Q;V.G.;65N?0K7LWD'
M*S#B\@YBH\VKM<.NU&#B];(3)?EAI,]?Q9NXMX(WLG/G+4K&TTIED(;+FPQI
M*T!O24K0,O2YCRH/1K+\W47!\F+NN8XJ#T@X1J! Q0Z\E04"H=7F:JFXU6]Q
M@N([=\E\G.<IW0:L0P*Y=X$U_:R 3T8$,/!"F\]%>"T]FN,T2O:YJR\H6 &B
MFC @G!JS&]:N&5GL2/-SXV9W*X!4D 1$46_=")G;.,LNS"3NM$ZT^5SN"/80
M\N,K*B8S#S?RT#73H!O>I4]AX(VG]#0K.+1+DK ",D5I0$2U.5^*!'0;-ZH7
MR"/(C3D#B]?+"MS$ H!0:?.YU/%\'36!JNQE+52; H!0F>""@8-HQ,-,B8P5
M8#:0"$17F]=&2@CQR%0B<SCH2HY=;9Z7"[I>+[):-#>!^Q2$5+TH%A[.>;VL
MP$XL  B5-D_*E1N0[+0R\O^=Q@D[>XZGQ7K!.<%QNUD!EH0$$%I&Y-(^=U^"
MQ U7;EI$%LB_PN0J94[9<B,M-W5*D;("U892@4CK\[ TC?S<].F.%FX0,O\@
M%3PKK]I!W*W@BU;83;?"@^:ES_7#\5MU<FDF3=D.<VE%2- L]!;D5 BGLSB*
MKDGPW*DV']/E_"7$2X0>Z"I&#P#US-^R4T+, JB9S<6/F"Y_U;^?XSBYQ<G_
M0\D]\O!SQ'^DW-DGK3"/CJ4'+4Q?%CSP#:%:])A%04DB]D&0M#G%-CG.EAM9
M=++&%L)2X1O$HZD;"WBYNHY_'T__Z9* ;>A$C]=81V$_L]6O( *(1,7EU'^U
MY56:.3;;1EX0!MDLS#*BTT;HT7T]0Q']9E*43%[)L5%\^<M.\>6"KH.GSB9E
M]IN<MD.).P7U54GFOU:4T:W ZZ)AX^E%,7HH1Z,X1DG,D_;#.YZT:[+L7R7A
M3-:<=&^BKA#,0])8H@JI4MH?CK?E6^.%*/LEL;_6UM'N"[Y+0C YQX3EWF=O
MXEAN*GJ>(/FI8NV@XD-YPH,R^X13^8;C1KZ3?<7)/^-4OE/!5<LZ=XN^CSR/
MA<"PLQ7!$?W1RQ-[C<GYC!W*KZ-JBX .RI<0[<QMNZMB"Z3UK/U-&1=4,=^3
M;*N+V3YUSELSF:W=2"MJKW_^6$K:5=5T04F98N[+7%E@A;2=1MJRR+8#!(8E
M Z'2! JOI%9-L_YKGT$:K-6Q677-FJK9R(2GS:#H,T^I (T'>N:@APU,3WZ+
M *=QN+Q'+YA%Q/+*78EZ3?JOP 3;.U9BV[2I:+TUY '"Z=![A7E),$0L@T#H
M#;V>Y77J\LSUHZ<X2X\AN).I[3/YI,<AT=5N32 I!*>V"_V1[V>*=L,[-_"O
MH^+26NJ)O+BO+G3E4,!-I.EG9E1 \)X=E"/D7[J$Y:J)J=&F\S3,/133P LX
MXU+<UR8$):4!-X"Z$!S3,XC+9IG+5W9S@V+QA IV.;3YE"\HN'O4!>4->G;#
M*\2+3U@UT065E$HQAV=(Z]HNIW<D4A@X%J%0SSN$AK:+W!6;N:?[!L<R>*P;
M'^P4MB4B!)RVR]TU?^PI%$MZ%T0IY;L0 $?Q&9IB@BIW(9>OU&8IWP$]42XS
M)=SBB/D-J-[#3.2\KC5L !U^]- ,J6M500:I[9'&+4IDYI"-9H<&^JYP$$S:
M7EMLL+B*0'W$E:-3L9,_<^/ DP123.B@H984'S(&;>\YRL-76<%! 'EM\T,#
M%A:2=SNG;3"SW*E4>I9&T#];?HM97HC5)F;D)<$B>U@D/J6JTSHTY!MJP$"O
M;SN!V=K@W0<&J;AM+FP5UU+O46F5&X;Q](IN!*GENN%#^;M8+HSI=#NVIT*6
MA?>L"#MKRK4A35:%KNP,[R&<9PCG&<)YAG">(9Q'<9D>PGF&<!X[ T?LBQLQ
M\9;Z(7V*T7]2RN3E@O[G<;E9%KOF  %U.(P%0R2E<9?4-9P*"[[#77I>7"2U
M+<2FYT5'$SQ&+DKM0MCG8M4<17#)JA>O+ FO*6)'.%RXV%28!T>7MM5+*:SC
MN.]0TXY/K%N20>CH&S3]%)$Y-%A5Q#9O.\FO&<!RU:'\4?U+&/#RB"D2^K&L
M )+?N,WI9LW;,O?D%:42T+4%\8('A%T/#G))B<'=D;[PI#Q6Y1YY*%CPO="[
M;0\.1DA$"#=MT9F;]G;E>B@O+B [)M<]#@Y#OJ 0DMHB.R5*B]^SV]#]:JWG
M) X<:Z'D$/C:HD.EZ\KO!7Y1FOX'!+\J.02^OB)G[81_'!JL/#$A#)N&:0*Y
MHB0L*]_,<VM+,U(-*!T.H'LI ():6Q!F+^61#@9[=:E!?TA3)QB4""Y/],L2
MB"TP)^_;5K/#@0:6#H2@XI."8NV*W[/_/-')F_[F_P-02P,$%     @ ^(@Y
M5O]ML,^W8@  E]0% !4   !S:'!H+3(P,C(P.3,P7VQA8BYX;6SMO7MS)#>2
M)_C_F=UWP*G->B0SLJ6JVMUIJ:=W+?DJ\88B.21+VKZV,UDP DE&*S(BA8AD
MD?WI#T"\ ^_(3,"S^M9L>TI,=\3/@1\<+X?C/_[7ZRI#+YB4:9'_]:MW?_KN
M*X3SN$C2_.FO7WVZ/U[<GUY>?H7**LJ3*"MR_->O\N*K__4__\__ ]'_]Q__
MU_$QNDAQEOR SHKX^#)?%G]!U]$*_X ^XAR3J"K(7]#/4;9A?RDNT@P3=%JL
MUAFN,/VA_O /Z+__Z=V_1^CXV*+<GW&>%.33W657[G-5K<L?OOWV\^?/?\J+
ME^AS07XK_Q07*[L"[ZNHVI1=:=^]?M?\OUK]/[(T_^T']C^/48D1K:^\_.&U
M3/_Z%?MN\]G/'_Y4D*=OWW_WW;MO__=/5_?Q,UY%QVG.ZBW&7[5:K!29WKOO
MO__^6_YK*RI(OCZ2K/W&AV];.%W)]-=4(S] 4J8_E!S>51%'%6]VXV>04H+]
MUW$K=LS^=/SN_?&'=W]Z+9.OVLKG-4B*#-_A)>)F_E"]K2F5RI0QX:OF;\\$
M+^5@,D*^9?K?YO@IJG#"/O0]^]"[_\$^](?FSU?1(\Z^0DR2\D-IU_>CLAJE
M;WV#O<4D+9+S?![JJ78@^+3OD&H+ X;ZWDUX**HHFP5^J.D=]C6>5^.]GO^:
MIGX>SZOI@>9>8%<B9.?JE==KQOYX1?\U@HA?*SJ X:0%R8K0>&#^!3XP-&5W
MI1?QJ-R,>?."B+:SD9&7N8S*1U[PICQ^BJ(U_<#[]]_BK"K;OQRSO_!*:/[P
M*QL;\0KGU6D6E>7-\KXJXM\6KVG9?H<;^=>O+.2_G1K -!>DM2(BL:$J&HEO
MXX(.9.OJ.*LKO59?DF)E!:.IL\)"^-?LL2N_KF0*06'(2(S@LMB0&#NU\= :
MVUIM$*XRJL$F;#@__G3_U?_D8JA8(BZ(_LY$_]__^+8O>@Z7RN?U,R?(=]]_
M^(Z3Y/['VQ]_O:=^')>+TR*GL\@J?<SP+17'A."$?_TGO'K$9&*8DZ8/XLPP
MA5'(02TXF=RQ3FE5*Z,%&JBC3K\E6UW$UG3;G>LZ_WV35F]LT4&7+WE5VK@O
MN4X0%Z:#+W5C,H7@['-!.>5=+8IZV1UYM*TI9N'I]*(^"67R93HY,/1Q\%9P
M'5/M@QW(H]7PZI3,T$<N22T.AE%FC,IA$"S#J*=<%;F95Q(YGVQ2PAQR2! "
MPQP5,F$VSN6@<621)"G;_8NRVRA-+O/3:)U64:;EBT'')W>LX ]YI%4 PRD;
ME%-^]3J(*1VG.6K4=L8VQ=IOT ,>BA-\698;G*@7?%IQ;ZL\"]#=TDXC&YPR
ME@"UWNBA0"<8U5IP7-,=KJ(TQ\EY1/(T?RJU/DDE[-,9Z0$/O9!<,CB7K.!-
MF=0*HU8:#H-N2;'&I'J[I8"K19ZP%>2:K3I/WA[H9S4[ %::?I=MUJ:,5W%&
M-3"LL\<ZI>!5D3\=7Z4OE(0/].]\0VI1EKB"LD-PL:%=H]H03,VZ2%_9O_3N
M3*?@DW9FX$.VJ:7!D,P(<<JM3@%%>8):%3@^CFV';2I,NMYB6NK)I3TO^'20
M)\L^F2@8.NGQ229=7!IUXG!X9,>?H+RQX M4GMCQ R M[G"):9T]4W=YAE]P
M5G!\"T(H[OHLLL@K$L750W&+R;(@JXN"W%3/F)3&2=:.RO8[Q=]A=8Q7!#LH
M& S==VF-N-ZHR^;C\:!T-"C^"+4?0%6!FD\@^C^H_L@18A^!,COL=VXN-CD+
MN5P\$<SM>,!DI9\H6NJ&V9.S,$>^-Z=1!,-Q%[2:O;I&&77:B*O#&0$6GR.2
MG$65SI-/9+RR309OQ*JA !SV2% )+&$RB GM-W;G)L?_M8D(G9AF;[?1&R.A
MW.D8I;WMWIHA=YNW:M'@9+##-Z7%.]3)HU9AWUO\#Y\+!XKHI+U1Q RYHXA:
M% 9%C/BF%'F_3XILOV51'TNE_\3):5%6Y<WR4[XFQ0M.FBW %)?GKW&V27!R
M01MTL2KHW_[);RF<O+7;A#>$_NL?.*XTX])>ON1UJV1_537:9MG]9X+WG/W;
M)H8:<8G]#M:WSU&)+R_5SG<BX,W?2H%U+G;T:W!N*"$)3<IDT.4E'.=YF<?%
M"G?QD^WM+8T3U&KX=&86T(=.22,>G$#V&*>,JC50IX):'2B[$?*]F_/7-<Y+
M;#B#M] ,OULG-<6\%S=2 T- >ZS6^VB-\KZ7%/>;Q[C9I#..:6I9?[="#'#[
M>R *P>"4L4$G!+GVXFB_8V&)XS\]%2_?)CBMO13]1^^<Z'_\>H6?HNP\K]+J
M33+:225\L$,#C7%"\G-P)J@Q"9$53 K58ON=USZ<?OQ(,,Y/G_&*CI&:S06Y
MH+]]!1W0?DM!)A6\X8W0INU/91$71DP:4?&]#PLGEW>:@6#PJS_7+T#JG7WW
M$XRV%? (#IT*P%G,7$0IX?DV3MZZ?_Z88L+F)6]7;$ZB6=?8*GN-EW(R:!0[
M9:49G&6SX HQ552CSK.".AT^#;U>_ QE&=19=9FO-U7)37JGC]G3:00AH1JZ
ME'FB.#RZ*3&J.7:$:J4CQ-70.SC^[Y>(Q2SH0ZXF,CZ))(4WI,Y(  Q99*BF
M]&ADX%!!QO#WSO[F/11_\][-W[P'1B$S1GM_\QXVR3XXD^P#%))]<"/9AP,@
MV8>9)/L AV2+O$J3--M4Z0N^Q_&&I-,CMCH.FN]ZWRS;:T.WF-P_1X1.*.4%
MZ,*/]OE%K\%,^Z^Z46C4_CX'II/MWT8A;&N@@'H-* N;F^4RC;%=N+]"UF>7
MT,(=DEDJ"(:&.G13 M6R>[@DHMARNXH>"YZB]4W/"I.PMPTY(^!N?TXI&9P8
M5O"$[?A.'N(5HCN<\92>$:G>'NCJJHQBYE3+D[?A+]H+(?8%^#U'=C5L?)QL
MJQV<E+,ABX?+7 QQN3U'+W-O2<K[=;%1!"AHY/Q%+&M@]K'*$J'@I# ADP]?
MI$2U[+Y'KR$CFT^K2: 1]L8$(^".#DI)&)PPP=,[A48#SO#%L@A4F*S.\&-E
MN+DH%_4Y).G #@<?F5QP]EB DZ9X8#>C$!.&=7_ONJAP>1N]18\9YO<+FW_K
M;^X9M7S2R=*$(;,,*F!(9H=SRC>NA1K1H_K::/N?>[]MHX1\DVLF.#9:W@8Y
M>Q.ZT<ZL$IQ3;CBUG)I2BBKO>2@L237P9O2_>D]&_^/7.W9Y6C+F37[SP2 I
M',:3T0_!V2!#(\3;L(W%LDKC*$,_X:C<D#KJ>Y]#EZ&A?TKS=+5921V)Y'=?
M#2Z%U3;ZZ$<0#2]#-&W\1B9LO_XI>M4W]_AW;\TM@]4U]_!'&,TM020T=RT3
M;';P\+F8,3L8:(6?'0@FF&<'G4IPGKCA=)H=4.5PM*)J<Z:=(ST U!+-L"!7
MKP2=7@)2-X(Q]6 4NZ 5-(-A0[7P!!.-,/.KUP%.+P&H$[N8=CARI2]SW-=0
M#0"Y!",LR-7I0"?7%*@;N5B<12ARW:>O,[@UT I/+<$$,[,Z%>#$FN)TXA55
MWC>M/N4EBP_BJ2A6:5D6Y(U#4E/*I.&-3G;0.RKIQ6'0R KCE$*=$NJU4,TK
M#S[)N.0+M;K3+^0 KMELEF<^EF&+.*9D2BN<7.8ON*1JZ@96RWIK:Q/<KME5
M@C 88$ GA'AVXJB5AW../7B6D9V5:@\A%;)^LX%KX(YS@4L$@]/'!IV8![Q_
M.),)[]NGT"E-_(SCW^@(56$>R47_]42B%7-J[;Q)=[3H6("_G%-S#.MS4KEH
M!R?:;,A"3JO;6SY!Z>>].SQZW(*!VKF,8P&@&*B>"SEI'PX#37,I@8$>YE7C
M.;W>VZE$_;%*#[;GCUP."%.TX"3)$X>K)R].:010[WY4HH$HH7$I<CF(E#"Z
MB0DEO'L)P\F71C@4+31G7$I)D-0PGF8)Y/!Q@#4&J3^U4LL&(H?F?$HE")$:
MQI.H*3-V>O@T*P3G(:WHM'QYF2?I2YIL(EE6(XV<KY <+<PV-$<J%)PG)F1"
M7C,FBXHEZJ7W>TNIIE_YG*XO\PI3LZL?BRRA?U$[$*.*-S]B";YS)P;YX&QQ
M "G$>'5:J%5#C1Z<'<#[S6.9)FE$WNXCUB7X*[^:ZRP:>9\[@4;8P]U I7!P
M=MDB%$*%H]HE-2_$P[C;<GE[H]U 'OSN-97X%-8H<7C[(Q@J3!$)2<%O;^!X
M#_;^[G6TTCZ//!+Q^@ZR!-SHP>/![V":7P)*F+32_T),9L]9=C\7#\_%IHSR
MY#Q]>JXPSEDB@>KMDM9\SC*6,"#J.8F;OL^W?IS-&K[^8ZT<G%)S$0LO!'WW
M[L^H5D*=%N(L!..(^/MGAINX$QGO+\_I[MZ.!((S1X=*_O(<I#NV=W2B3=*X
MP@F?'GW*TZJ\N_^DG9L8=#R_1&&&/WF#0JT ADLV*"7O3C0ZS4R7:Z&OJ5[Y
M3=A]FK.4X%@5<2,3\+4S(P?6;LF,?PU.#B6D*1-:H7WOVK;?*1=Y8LP0HA'V
M-ITQ N[F+DK)X"RP@J=B1(FHPLXSA%C$=MO%<@>-W;:(U89$ 24N?2PVF$DH
M@V63IELBYSN!AS%=MR 4G"(F9-(HW%WG[E;XA=-BM2IR/D<Q>@>UK#<?88+;
M>0J58' RV* 30RF9>#.3W+7S4)X"XR4FI)GTGK'S(YPG1HY8J7D\&[8V8G!,
M;-2!02)[H.+A<:/94*K5]30PF7*TT+53\VZD*E/+5,);OA8YM"YKR_CGX#11
M8Q+7JR]IR=[G+);HEJ1TN7*+Z?])0J9P&2)/_K$I*V7.7J-T"'XH(,NX,A$%
MQQLY/EL.':&^@+">Y3[&>40A4?_WDA:;,GN[P^N"5#A1TLJLXHM;MN!;@IGD
M0;#,$J1D &O$42L/9S'%CL3Q[QOV0NT+_1_#WKY2VG=0@@;R-"1!(AJ<37;X
M)$^_-M*(BX,Z#IB8HEV9*V0#DDB]0I<*0B60U@\)] GT:O!I\8+)XK'D;QA/
M[)+\[NO%8"FL]KW@T8_!6U^%2%R*O[#-VE;*=T.?%?%FU;@UB07CGWTULPQ4
MV\K#WT TL@20L$'?B/#!P',#+^B'$_;QBRQZDL"?_.ZKB:6PVC8>_0BBD66(
MA./_5@8QH5#-?(;+F*1K=L509\=(S'NC2T *;3^0@44!$9B:"0/90([]#C^E
M;&AA$.[;!;C&C2GD?;M^+>SI6" 5!D$:&X3*T6*HA#JM0#Q:Y/DFRNK%L<;0
ML9AOULA 3LDRE '%$0DP)35JV6:O(A C_FL3D0J3=H=%8YD@Z9L7"JA3:DS$
M0+%#CDU)D$X\+$?X,U@I<V!&DHBBWI<;"K#"TF,B!XHG"G#J)4DG'Y8I]\\X
MR]BCHE%N=B@R8=]L40.>\D64!,48)3PE9[@&:E3@T(;OF)W1:9*EL0/YD.01
M8.OXTPF#I= 4H26+ZNU.IA>(2?79(IUF$Q.'!$G?[%% G?)F(@:*,7)L2JXT
MP0-</CQ)SO/$BB*=7!B"3&#*Z=$( 23'&)F)&E0Z)#$NTC*.LAK+!?W;]'36
M(.N;($JX4Y((@J"(HD*G)$NMT'*&JP0ES-]P1.SH,I ,0Q8!JIPJG1A HDRQ
MF6C"Y(.0Y'1#R BU>L11BWH[E#6 [<YG%7(@B&( )YS:UN(CH@0:@<[S*JW>
M+M(,7V\D\1QR$5_<4(%K.3']'007%*"F'*C%$)-#M6"0EF]/"?**)4)0FC,5
M\\L .<@Q"\8R@)@@!:9@0R_+\U($8<0I]4PDRB[S!+_^)WY3VB7(^>6$ N:8
M%!,A0*R0(U/0HA%&7!I1\2#$N"7IBB562F/#4"$*^J6&"NB8&U,I0.100%.P
MHY%&]Y>G(4>2A^CU,J%$39=IS ^=#2Q1ROLEBP'VF#,*84#4T2-4,(@JH;%6
M2")=YG%!UL4@W.&TV% '^'9:).H9BD'++ZFL3!A32ZL"B& V.!4T&ZD>U3$I
MJ""H*0"Q$H(P;I$DM*+*YO]<I3E^I[1?*NN771JX8TY)! $Q28U.P9]&\JC]
M!V(Z+&D]$-*\=S#U?7C2O+<ES7O0I'D_AS0/GPL@I/G@8.J'\*3Y8$N:#Z!)
M\V$6:5BZ^Y"T.:7_O"$/Q6=9<+92,@AE1*A2PO1B\.@B8#.1A2FP^0Q3"4D3
M/K&Z(;>D>$GS6#UE5HD'(8P"M)0U$UEXU)$#-/&GFQ"W>D%]33TI-W:25BR,
MEQF#E+N86@8>2<; C,ZEE@Y)B=NBK*+L_TG7VH6X7#@(/:2 I2092<*CB@R>
MB3"U#J)*(1;6#5W9@8;T*MGD=W]7@"6P^BO @Q]!D$"&2+P"7.^>U$*^FYEQ
ME.!(X1'&/WMK9 FHKHT'O\%H8A&0T,*\7U.9$!WYJF Q4L]%K@X0$$5\M;0*
M7-O:T]]!M+@"U+35N1CB<H%VXU\KG)=R]SWXS=O(/H73#>3M#R!:=XI&&*;;
MWSVWYB\DK>B76>[&3=Z<\LCB!A5ROEI9"[-M<:D0B-;7(9LRH9%%8V'/M+@O
MLC1.JS1_^HDN/DD:R:R2"?DBA!I@RP91 @05E+"$K#V=(&HE/9/@EF!&0DP;
M@E\"Q'F"R<UR*1WM=<*^2&$&W))#+0F")$9XDE1SQ_%  ]4JB.N$I<UE66XP
M<2*/1"40A93@%402Y"'220722*I:,22W[G&\H>/CV[OWC_S=4)F#%42\C4D*
M<-V(-/D=!#<4H)2OM+Y[__7C-ZC5\MS\U\4#B1(Z)-Z_K1Z+3)%]2BKEBP0:
MB"T/)"(@J*#&)>;^1XTHJF5#9*<:@968,_G=%P&DL-JF'_T(HM%EB(3./VKK
M0"[__#5^IJ"PXD*"7,RWZY>!G+K_H0P("FB "8N21A2ULB$N)/1#UI-Y$O 4
M;!+P9)@$/$&<!#S93@*>@DT"VL_6*4*H7[IYS-*G2)&<4"OMFQ0:R%-^2$1!
M446-3^DS.A74Z_C.:,E3G%WFRX*L^/<OZ#\D5BKDO.6TU,'LDEK*A$!P1(=,
M2&M9)YT;"",F[9L7FR2M<%*#N4CS*(_3*.O2(\IVQ,TJWMAB";XCCD$>!H?L
M0 ITJM7:7(:=8I_JTO=6>AV \0O.LO_,B\_Y/8[*(L=)O9<B.RG2R_N-F#'
M'@?-*(1!T,D&H2)TABD=_\:T4*O6[(0%8=+/1;;)JXCPN^1$YID4<GZ9HX Y
M9LQ$"!!3Y,@4#.F$42T=YH)VG3VBFV0QAR=- :,7]WQ=6PMZ<FM;*@N(,UJ
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M&=J4_)+ X%VA"%!'/<-KBC_E"Q%5<.%(Q&N@I@3<*#IS\#L8(DI "0&8 Y%
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M+UT-G*7ENBBC[",I-FNJP2\4YU6:;W#2G)P7N6K(\POA8+K\S,K=68=W_'Z
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M W-K0GV2[WST#R72PBV\ BB;)!"E@11IIW$$+$9M;(_NMHU4,AR7E#=E)&)
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M?6$WJAOS6##R7J,-)=\!-=N>6TV[[+;"1PYGYCS3,KO!X:A]-I;I?TD]+D!
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MF>&?KNB_Z)_;/]'_80^BT;_\?U!+ P04    " #XB#E6#G.?87E&  "&$04
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M%5K^>9/#&H1Q]/E4VC?E8%0:H26?-Y%]"UOXHE;585<(7TV&EI7>" X(Z^@
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M*(*4E4387J&=<&KCWWP-_9BMH2$[VR1Y6TOP/2,/2O]*2V/TU)P[ 5IF>-1
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MO?ZU -RO-<9C1S4P%*"M>B"T^9;$"?7=)#]-SE\<ZET37C0AHDOB)RGMNA[
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MM4DGXD,T?89SBO3_8M0NKPBJ@=+"_%&T/-*S#PL'^+%NPK1>..9?S"X<1:"
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M(:B,T$_^DD'SAQ;&<089D4WWI!#H(#S9#=99%[#.3,#:RX7K[F"=C0"LMN7
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MT5V,H[[E*KWGSO:WC&'M8S$=';9QVM<R 1+/J#6@>DK-^ .='+2$V*?VO@Z
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M0K&=3^DDE<>RY;_A?SRP?8']Y/\#4$L! A0#%     @ ^(@Y5N. >SA0!@
M,U,   D              ( !     &5X,3 W+FAT;5!+ 0(4 Q0    ( /B(
M.5:VF?C CP,  +$2   *              "  7<&  !E>#(S+3$N:'1M4$L!
M A0#%     @ ^(@Y5F1"Q>;1"@  OD    D              ( !+@H  &5X
M-2TQ+FAT;5!+ 0(4 Q0    ( /B(.5:E3*\,@70$ #.T*P +
M  "  285  !F;W)M<RTQ+FAT;5!+ 0(4 Q0    ( /B(.5:,67J$?QT  ,4A
M   /              "  =")! !F;W)M<RTQ7S P,2YJ<&=02P$"% ,4
M" #XB#E6Q)V3;*)Y 0"Y\0$ #P              @ %\IP0 9F]R;7,M,5\P
M,#(N:G!G4$L! A0#%     @ ^(@Y5D$(]<R_>P$ YJ !  \
M ( !2R$& &9O<FUS+3%?,# S+FIP9U!+ 0(4 Q0    ( /B(.5:V(<$/P+(
M '+<   /              "  3>=!P!F;W)M<RTQ7S P-"YJ<&=02P$"% ,4
M    " #XB#E6>Y^S?1RL  "7S@  #P              @ $D4 @ 9F]R;7,M
M,5\P,#4N:G!G4$L! A0#%     @ ^(@Y5A^T$ZLLS0$ V]P!  \
M     ( !;?P( &9O<FUS+3%?,# V+FIP9U!+ 0(4 Q0    ( /B(.58@SDZC
MJTH" (JG @ /              "  <;)"@!F;W)M<RTQ7S P-RYJ<&=02P$"
M% ,4    " #XB#E69L>#4-<\  !31P  #P              @ &>% T 9F]R
M;7,M,5\P,#@N:G!G4$L! A0#%     @ ^(@Y5JU_E2WJ#@  D9\  !$
M         ( !HE$- '-H<&@M,C R,C Y,S N>'-D4$L! A0#%     @ ^(@Y
M5N^DH:S8$@  %.P  !4              ( !NV - '-H<&@M,C R,C Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( /B(.59BZX&C*#(   >D P 5
M  "  <9S#0!S:'!H+3(P,C(P.3,P7V1E9BYX;6Q02P$"% ,4    " #XB#E6
M_VVPS[=B  "7U 4 %0              @ $AI@T <VAP:"TR,#(R,#DS,%]L
M86(N>&UL4$L! A0#%     @ ^(@Y5@YSGV%Y1@  AA$% !4
M ( !"PD. '-H<&@M,C R,C Y,S!?<')E+GAM;%!+!08     $0 1 !($  "W
%3PX    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
